US20200101000A1 - Methods for generating new hair follicles, treating baldness, and hair removal - Google Patents

Methods for generating new hair follicles, treating baldness, and hair removal Download PDF

Info

Publication number
US20200101000A1
US20200101000A1 US16/222,705 US201816222705A US2020101000A1 US 20200101000 A1 US20200101000 A1 US 20200101000A1 US 201816222705 A US201816222705 A US 201816222705A US 2020101000 A1 US2020101000 A1 US 2020101000A1
Authority
US
United States
Prior art keywords
another embodiment
days
scalp
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/222,705
Inventor
George Cotsarelis
Mayumi Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to US16/222,705 priority Critical patent/US20200101000A1/en
Priority to US16/260,034 priority patent/US20200197488A1/en
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COTSARELIS, GEORGE, ITO, MAYUMI
Publication of US20200101000A1 publication Critical patent/US20200101000A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF PENNSYLVANIA
Assigned to NIH - DEITR reassignment NIH - DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF PENNSYLVANIA
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00743—Type of operation; Specification of treatment sites
    • A61B2017/00747—Dermatology
    • A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Definitions

  • the present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell.
  • the present invention also provides methods for hair removal and inducing hair pigmentation.
  • Follicular neogenesis is defined as the generation of new hair follicles (HF) after birth.
  • Humans are born with a full complement of HF, which can change in size and growth characteristics as in early baldness or can ultimately degenerate and disappear as in late stages of baldness or in permanent scarring (cicatricial) alopecias. Therefore, the generation of new HF is desirable in the treatment of common baldness as well as less common hair loss conditions, such as discoid lupus erythematosis, congenital hypotrichosis, lichen planopilaris and other scarring alopecias.
  • the present invention provides methods of treating baldness in a subject and generating new hair follicles (HF), comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell.
  • HF hair follicles
  • the present invention also provides methods for hair removal and inducing hair pigmentation.
  • the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle (HF) cell, thereby treating baldness in a scalp, eyebrow, or scarred region.
  • HF hair follicle
  • the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell, thereby treating baldness in a scalp, eyebrow, or scarred region.
  • the baldness is an androgenetic alopecia (AGA)-induced baldness.
  • AGA androgenetic alopecia
  • the present invention provides a method for removal of an HF from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing an HF from a skin or scalp of a subject.
  • the present invention provides a method for increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby treating an AGA in a scalp.
  • step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • FIG. 1 Epidermal abrasion results in de novo hair follicle (HF) formation.
  • HF at progressive stages of development are depicted in the left, center, and right panels.
  • the arrow in the left panel indicates a hair germ.
  • the dark stained cells are progeny of HF stem cells in the bulge.
  • FIG. 2 BrdU labeling of HF following epidermal abrasion. HF at progressive stages of development are depicted in the left, center, and right panels.
  • FIG. 3 The wound site did not contain HF immediately after re-epithelialization. Top view (left panel) and tissue section (right panel) of the site 10 days after wound induction.
  • FIG. 4 Appearance of hair germs 12 days after wound induction. Arrow indicates hair germ.
  • FIG. 5 Epidermal Disruption-Induced HF neogenesis (EDIHN)-induced hair germs express K17. Two different hair germs are depicted in the left and right panels.
  • EIHN Epidermal Disruption-Induced HF neogenesis
  • FIG. 6 EDIHN-induced hair germs contain dermal papilla (DP) cells, as evidenced by alkaline phosphatase (AP) staining. Arrows indicate DP cells. Left panel: hair germs. Right panel: HF at a further developmental stage.
  • DP dermal papilla
  • AP alkaline phosphatase
  • FIG. 7 Histological comparison between EDIHN-induced and embryonic HF. Top left, second from left, third from left, and right panels: Progressive stages of EDIHN-induced HF development. Bottom left, center, and right panels: Progressive stages of and embryonic HF development.
  • FIG. 8 Induction of several markers of embryonic HF development, Lef1 (left panel), wingless/int (Wnt) 10b (center panel), and sonic hedgehog (Shh; right panel), by EDIHN. HF structures are indicated by arrowheads.
  • FIG. 9 Proliferative activity during EDIHN, as evidenced by BrdU pulse-labeling. Progressive stages of HF development are depicted in the left, center, and right panels.
  • FIG. 10 Induction of HF markers S100A3 (left panel; tissue section parallel to HF axis) and S100A6 (right panel; cross-sectional view of follicle) by EDIHN.
  • FIG. 11 New hair growth 25 days (left panel) and 45 days (right panel) after wound induction.
  • FIG. 12 Schematic of whole-mount EDIHN assay.
  • FIG. 13 Repopulation of stem cells in the bulge of EDIHN-induced HF, as evidenced by retention of BrdU label following a chase period.
  • Left panel lower magnification: 50 ⁇ .
  • Right panel higher magnification: 400 ⁇ .
  • FIGS. 14A-14B Stem cells in EDIHN-induced HF express K15.
  • Left top panel Top view of wound site.
  • FIG. 14B Neogenesis HF proceed to next hair cycle.
  • FIG. 15 Schematic of creation of new HF by EDIHN.
  • FIG. 16 No new HF are evident 11 days after wound induction in 21-day-old mice.
  • Top panel macroscopic examination; bottom left panel: AP staining of the dermis; bottom right panel: K17 staining of the epidermis.
  • FIG. 17 14 days after wound induction, new HF have begun to form as evidenced by AP staining of the dermis (left panel) and K17 staining of the epidermis (right panel). Main panels: 10 ⁇ magnification. Inserts: 80 ⁇ magnification.
  • FIG. 18 17 days after wound induction, new HF are more developed.
  • Left panel AP staining of the dermis; right panel: K17 staining of the epidermis.
  • FIG. 19 Wounds closed similar in mice subjected to depilation, then wounding (left 3 mice in each panel) vs. wounding alone (right 4 mice in each panel). Left panel: immediately following wounding. Right panel: 10 days following wounding.
  • FIGS. 20A-20B Anagen induction by depilation prior to wounding enhances the efficiency of EDIHN.
  • FIG. 20A Top panel: lower left panel AP staining of the dermis; lower right panel: K17 staining of the epidermis.
  • FIG. 20B Graphical representation of enhancement of EDIHN by depilation.
  • FIGS. 21A-21B EDIHN in human skin grafted to immunodeficient (scid) mice, seven days after induction of an excisional wound. Arrows indicate new HF.
  • FIG. 21B EDIHN in human skin grafted to immunodeficient (scid) mice, seven days after induction of an excisional wound. Arrows indicate new HF.
  • FIG. 21B EDIHN in human skin grafted to immunodeficient (scid) mice, seven days after induction of an excisional wound. Arrows indicate new HF.
  • FIG. 21B EDIHN in human skin grafted to immunodeficient mice, seven days after induction of an excisional wound. Arrows indicate new HF.
  • Dermal abrasion of human skin grafts results in EDIHN.
  • Human adult skin (W) was grafted onto mice, abraded, and examined seven days later, by staining for S100A6 (first, second, and fourth rows) or S100A4 (third row). Hair germs (HG) and dermal papilla (DP) are indicated.
  • Human fetal skin (F) with normal developing hair follicles is shown for comparison.
  • Mouse skin 17 d post wounding was included as a control (top left panel).
  • FIGS. 22A-22C Transcripts up-regulated at least 2-fold in activated HF cells, as assessed by dChip analysis.
  • FIG. 22A Mean values and standard errors of the up-regulated transcripts in non-activated (“bs-line”) and activated (“expt”) samples and fold-changes and differences between non-activated and activated values are depicted.
  • FIG. 22B Raw data for up-regulated transcripts in non-activated and activated cells. “Ctrl” denotes non-activated and “High-dep” denotes activated cells.
  • FIG. 22C Additional information about up-regulated transcripts.
  • FIGS. 23A-23B Pigmented hair follicle neogenesis observed in the skin of Dkk1-expressing mice following EDIHN
  • FIG. 23A 3.2 ⁇ magnification
  • FIG. 23B 8 ⁇ magnification.
  • FIG. 24 Control mice lacked pigmented HF.
  • FIGS. 25A-25D EGF inhibits HF formation by EDIHN.
  • FIG. 25A K17 staining of wounded skin of representative mouse treated with EGF. Magnification is 4 ⁇ .
  • FIG. 25B High magnification view (10 ⁇ ) of skin depicted in ( FIG. 25A ).
  • FIG. 25C K17 staining of wounded skin of representative control mouse that received no EGF after wounding. Magnification is 4 ⁇ .
  • FIG. 25D Higher magnification view (10 ⁇ ) of skin depicted in ( FIG. 25D ).
  • FIGS. 26A-26B Administration of an EGF receptor inhibitor (AG1478) leads to generation of more and larger HF compared with controls.
  • FIG. 26A Top: skin of 2 control mice. Outer dashed line indicates the extent of the wounded area after contraction and healing; inner dashed line indicates the area of neogenesis. Bottom: skin of 2 treated mice, in which the wounded area and area of neogenesis largely coincide, with the exception of a small area on the left side of the encircled area in each panel.
  • FIG. 26B Large hair follicles developed in the wounded area in the AG1478-injected mice. Left panel: epidermis stained for K17, with three large hair follicles next to each other. Right panel: dermis stained for AP with large coalescing DP areas. Scale Bars: 200 ⁇ m.
  • FIGS. 27A-27C show that FIG. 27A . Increased hair follicle formation in K14-Wnt7a mice. Left panel: Wnt7a transgenic mice. Right panel: control (wild-type) mice.
  • FIG. 27B Quantiation of experiment with 4 week old mice.
  • FIG. 27C Quantiation of experiment with 3 week old mice.
  • the present invention provides methods of treating baldness in a subject and generating new HF, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell.
  • the present invention also provides methods for hair removal and inducing hair pigmentation.
  • the present invention provides a method for generating a hair follicle (HF) in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • HF hair follicle
  • the present invention provides a method for generating an HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for generating a new HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a new HF in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for increasing the number of HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby increasing the number of HF in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the compound or factor.
  • the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the compound or factor.
  • the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the compound or factor.
  • the present invention provides a method for increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • the factor is an inhibitor of an EGF protein or an EGFR.
  • the factor is a Hedgehog protein, a nucleotide encoding same or an activator of same.
  • the factor is an androgen antagonist.
  • the factor is any other compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell.
  • the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • the precursor cell of methods and compositions of the present invention is, in another embodiment, a HF stem cell.
  • the precursor cell is an epidermal cell.
  • the precursor cell is a dermal papilla cell.
  • the precursor cell is a connective tissue sheath cell.
  • the precursor cell is any other type of cell known in the art that is capable of differentiation into a hair follicle cell. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a precursor cell that is capable of differentiation into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby treating an AGA in a scalp.
  • step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a precursor cell that is capable of differentiation into a hair follicle cell, thereby treating an AGA in a scalp.
  • the inductive cell is a mesenchymal cell. In another embodiment, the inductive cell is any other type of inductive cell enumerated herein. In another embodiment, the inductive cell is any other type of inductive cell known in the art. Each possibility represents a separate embodiment of the present invention.
  • Contacting refers, in another embodiment, to bringing the scalp, eyebrow, etc, into to contact with the compound, factor, cell, etc.
  • the term refers to embedding the compound, factor, cell, etc into the scalp, eyebrow, etc.
  • the term refers to injecting the compound, factor, cell, etc into the scalp, eyebrow, etc.
  • term refers to any other type of contacting known in the art. Each possibility represents a separate embodiment of the present invention.
  • “Promotes a differentiation” refers, in another embodiment, to the act of increasing the percentage of cells that will differentiate as indicated. In another embodiment, the term refers to increasing the number of cells per unit area of skin that will differentiate. In another embodiment, the promoter of differentiation is active in the milieu of the skin. Each possibility represents a separate embodiment of the present invention.
  • Uncommitted epidermal cell refers, in another embodiment, to an epidermal stem cell.
  • the epidermal cell is a bulge cell.
  • the epidermal cell is a bulge-derived cell.
  • the epidermal cell is any other type of cell known in the art that can be induced to differentiate into an HF cell.
  • the “HF cell” that results from the differentiation is, in another embodiment, an HF stem cell.
  • the HF cell is a dermal papilla cell.
  • the HF cell is a bulb cell.
  • the HF cell is a matrix cell.
  • the HF cell is a hair shaft cell.
  • the HF cell is an inner root sheath cell.
  • the HF cell is an outer root sheath cell.
  • the HF cell is a melanocyte stem cell.
  • the HF cell is a melanocyte.
  • Each type of uncommitted epidermal cell and HF cell represents a separate embodiment of the present invention.
  • the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle (HF) cell, thereby treating baldness in a scalp, eyebrow, or scarred region.
  • the baldness is an androgenetic alopecia (AGA)-induced baldness.
  • AGA androgenetic alopecia
  • the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell, thereby treating baldness in a scalp, eyebrow, or scarred region.
  • the baldness is an androgenetic alopecia (AGA)-induced baldness.
  • AGA androgenetic alopecia
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is administered in a solution.
  • the compound or factor is administered in a cream.
  • the compound or factor is administered in an ointment.
  • the compound or factor is administered in a slow release formulation.
  • the compound or factor is administered in a liposome encapsulated formulation.
  • the compound or factor is directly injected.
  • the compound or factor is administered by any other method known in the art. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is, in another embodiment, an inhibitor of an Epidermal Growth Factor (EGF).
  • the compound or factor is an inhibitor of an EGF receptor.
  • Example 11 activating one or more pathways in which EGF is involved (by injection of EGF) blocks the formation of HF.
  • antagonizing the pathway increases HF formation, as demonstrated in Example 12.
  • the inhibitor of an EGF or an EGF receptor is panitumumab. In another embodiment, the inhibitor is AG1478. In another embodiment, the inhibitor is nimotuzumab. In another embodiment, the inhibitor is an antibody that binds EGF or EGFR. In another embodiment, the inhibitor is HuMax-EGFR® (Genmab, Copenhagen, Denmark). In another embodiment, the inhibitor is cetuximab. In another embodiment, the inhibitor is IMC 11F8. In another embodiment, the inhibitor is matuzumab. In another embodiment, the inhibitor is SC 100. In another embodiment, the inhibitor is ALT 110. In another embodiment, the inhibitor is PX 1032. In another embodiment, the inhibitor is BMS 599626. In another embodiment, the inhibitor is MDX 214. In another embodiment, the inhibitor is PX 1041. In another embodiment, the inhibitor is any other inhibitor of an EGF or an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is an inhibitor of a tyrosine kinase activity of an EGF receptor.
  • the inhibitor is gefitinib.
  • the inhibitor is erlotinib.
  • the inhibitor is canertinib.
  • the inhibitor is leflunomide.
  • the inhibitor is A77 1726.
  • the inhibitor is pelitinib.
  • the inhibitor is ZD 1839.
  • the inhibitor is CL 387785.
  • the inhibitor is EKI 785.
  • the inhibitor is vandetanib.
  • the inhibitor is any other inhibitor of a tyrosine kinase activity of an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
  • the EGF or EGFR antagonist is a carboxypeptidase inhibitor from potato (PCI) protein or a homologue, fragment or mimetic thereof.
  • the EGF or EGFR antagonist is a sprouty protein or a homologue, fragment or mimetic thereof.
  • the EGF or EGFR antagonist is an Argos protein or a homologue, fragment or mimetic thereof.
  • the EGF or EGFR antagonist is a lefty protein or a homologue, fragment or mimetic thereof.
  • the EGF or EGFR antagonist is an antibody that recognizes EGF or EGFR, or a fragment or mimetic thereof.
  • the EGF or EGFR antagonist is small molecule inhibitor that binds and reduces the activity of EGF or EGFR.
  • the EGF or EGFR antagonist is CRM197.
  • the EGF or EGFR antagonist is IMC-C225 (ImClone Systems, New York, N.Y.).
  • the EGF or EGFR antagonist is any other antagonist of EGF or EGFR known in the art. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the inhibitor of an EGF protein or an EGF receptor.
  • the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the inhibitor of an EGF protein or an EGF receptor.
  • the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the inhibitor of an EGF protein or an EGF receptor.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a ⁇ -catenin protein.
  • the compound or factor is a nucleotide that encodes a ⁇ -catenin protein.
  • the compound or factor is an activator of a ⁇ -catenin protein.
  • the compound or factor is an inhibitor of a protein that suppresses an activity of the ⁇ -catenin protein.
  • the present invention provides a use of (a) a ⁇ -catenin protein; (b) a nucleotide encoding a ⁇ -catenin protein; or (c) a compound or factor that activates a ⁇ -catenin protein, for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the ⁇ -catenin protein, nucleotide, compound or factor.
  • the present invention provides a use of (a) a ⁇ -catenin protein; (b) a nucleotide encoding a ⁇ -catenin protein; or (c) a compound or factor that activates a ⁇ -catenin protein, for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the ⁇ -catenin protein, nucleotide, compound or factor.
  • the present invention provides a use of (a) a ⁇ -catenin protein; (b) a nucleotide encoding a ⁇ -catenin protein; or (c) a compound or factor that activates a ⁇ -catenin protein, for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the ⁇ -catenin protein, nucleotide, compound or factor.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a fibroblast growth factor (FGF) protein.
  • FGF fibroblast growth factor
  • the compound or factor is a nucleotide that encodes an FGF protein.
  • the compound or factor is an FGF receptor.
  • the compound or factor is a nucleotide that encodes an FGF receptor.
  • the compound or factor is an activator of an FGF protein.
  • the compound or factor is an activator of FGF receptor.
  • the compound or factor is an inhibitor of a protein that suppresses an activity of the FGF protein or FGF receptor.
  • the protein that is inhibited is an FGF binding protein.
  • the protein that is inhibited is FGF-bp1.
  • FGF and its receptor are upregulated, under the conditions utilized herein, upon HF stem cell differentiation (Example 9). Moreover, FGF-bp1 is downregulated, under the conditions utilized herein, upon HF stem cell differentiation. Thus, FGF and its receptor promote differentiation of uncommitted epidermal cells into HF cells.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is an ectodysplasin protein (referred to, in another embodiment, as “eda”; in another embodiment, as “ectodermodysplasin protein.”)
  • the ectodysplasin protein is Eda-A1.
  • the compound or factor is an ectodysplasin receptor (referred to, in another embodiment, as “edar”).
  • the compound or factor is an activator of an ectodysplasin protein.
  • the compound or factor is an activator of an ectodysplasin receptor.
  • the compound or factor is an inhibitor of a protein that suppresses an activity of the ectodysplasin protein or ectodysplasin receptor.
  • the eda protein of methods and compositions of the present invention has the sequence:
  • the eda protein has a sequence selected from the sequences set forth in GenBank entries NM_001005609, NM_001005610, NM_001005611, NM_001005612, NM_001005613, NM_001005614, NM_001005615, AF040628, AF061194, AF061193, AF061192, AF061191, AF061190, AF061189, and AF060999.
  • the eda protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of an Eda protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the edar protein of methods and compositions of the present invention has the sequence:
  • the edar protein has a sequence selected from the sequences set forth in GenBank entries BC093870; BC034919; NM_021783; NM_022336; AY152724; AF298812; AH008077; AF130996; AF130988.
  • the edar protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of an Edar protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Noggin protein.
  • the compound or factor is a nucleotide encoding a Noggin protein.
  • the compound or factor is an activator of a Noggin protein.
  • the compound or factor is an inhibitor of a protein that suppresses an activity of the Noggin protein.
  • Noggin protein of methods and compositions of the present invention has the sequence:
  • the Noggin protein has a sequence selected from the sequences set forth in GenBank entries BC034027 and U31202.
  • the Noggin protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of a Noggin protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Hedgehog protein.
  • the compound or factor is a nucleotide encoding a Hedgehog protein.
  • the compound or factor is an activator of a Hedgehog protein.
  • the compound or factor is a sonic Hedgehog protein.
  • the compound or factor is a nucleotide encoding a sonic Hedgehog protein.
  • the compound or factor is an activator of a sonic Hedgehog protein.
  • the Hedgehog protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. NM_000193. In another embodiment, the Hedgehog protein has a sequence selected from those set forth in GenBank entries L38518 and NP_000184. In another embodiment, the Hedgehog protein has any other Hedgehog sequence known in the art. In another embodiment, the Hedgehog protein has any other sonic Hedgehog sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Transforming Growth Factor (TGF)-beta1 protein.
  • TGF Transforming Growth Factor
  • the compound or factor is a nucleotide encoding a TGF-beta1 protein.
  • the compound or factor is an activator of a TGF-beta1 protein.
  • the compound or factor is a TGF-beta3 protein.
  • the compound or factor is a nucleotide encoding a TGF-beta3 protein.
  • the compound or factor is an activator of a TGF-beta3 protein.
  • the compound or factor is an antagonist of a TGF-beta1 protein.
  • the compound or factor is an antagonist of a TGF-beta3 protein.
  • the TGF-beta1 protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. BC000125.
  • the Hedgehog protein has a sequence selected from those set forth in GenBank entries BC001180, BC022242, and NM_000660.
  • the TGF-beta1 protein has any other TGF-beta1 sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • the TGF-beta3 protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. J03241.
  • the Hedgehog protein has a sequence selected from those set forth in GenBank entries NM_003239, BC018503, BT007287 and X14149.
  • the TGF-beta3 protein has any other TGF-beta3 sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell acts directly on the uncommitted epidermal cell.
  • the compound or factor acts on the uncommitted epidermal cell via a mesenchymal cell.
  • the mesenchymal cell is a dermal condensate cell. In another embodiment, the mesenchymal cell is a DP cell. In another embodiment, the mesenchymal cell is another cell type or differentiation stage in the dermal condensate-DP lineage. In another embodiment, the mesenchymal cell is any other type of mesenchymal cell known in the art. Each possibility represents a separate embodiment of the present invention.
  • the EGFR of methods and compositions of the present invention has, in another embodiment, the sequence:
  • the EGFR has a sequence selected from the sequences set forth in GenBank entries NM_201282, NM_201283, NM_201284, BC094761, AF288738, AY588246, AY573061, X17054, AF125253, U48722, K03193, and AY698024.
  • the EGFR is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of an EGFR is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the EGF of methods and compositions of the present invention has, in another embodiment, the sequence:
  • the EGF has a sequence selected from the sequences set forth in GenBank entries BC093731, AY548762, and X04571.
  • the EGF is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of an EGF is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • beta-catenin protein of methods and compositions of the present invention has, in another embodiment, the sequence:
  • the beta-catenin protein has a sequence selected from the sequences set forth in GenBank entries BC058926, X87838, AF130085, AB062292, Z19054, and NP_001895.
  • the beta-catenin protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of a beta-catenin protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the Wnt protein of methods and compositions of the present invention has, in another embodiment, the sequence:
  • the Wnt protein has a sequence selected from the sequences set forth in GenBank entries NM_004625, D83175, U53476, and NP_004616.
  • the Wnt protein is a Wnt7 protein.
  • the Wnt protein is a Wnt7a protein.
  • the Wnt protein is Wnt1 protein.
  • the Wnt protein is a Wnt3 protein.
  • the Wnt protein is a Wnt3a protein.
  • the Wnt protein is a Wnt10 protein.
  • the Wnt protein is a Wnt10a protein.
  • the Wnt protein is a Wnt10b protein.
  • the Wnt protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries.
  • a biologically active fragment of a Wnt protein is utilized in a method of the present invention.
  • a biologically active fragment of a Wnt7 protein is utilized in a method of the present invention.
  • a biologically active fragment of a Wnt7a protein is utilized in a method of the present invention.
  • Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a protein encoded by a ribonucleic acid (RNA) molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-232.
  • the compound or factor is an RNA molecule having a sequence selected from SEQ ID No: 1-232.
  • the RNA molecule is homologous to a sequence selected from SEQ ID No: 1-232.
  • the RNA molecule is an isoform of a sequence selected from SEQ ID No: 1-232.
  • the compound or factor increases an activity of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 1-232. In another embodiment, the compound or factor increases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 1-232.
  • the transcripts depicted in Table 3 (Example 8; SEQ ID No: 1-232), the proteins they encode, and the pathways in which the proteins participate contribute significantly to HF stem cell activation. Accordingly, under the conditions utilized herein, anagen can be induced by activation of these transcripts, proteins, and pathways. Activation of the transcripts, proteins, and pathways depicted in Table 3 is thus a method for enhancing EDIHN. In another embodiment, activation of these transcripts, proteins, and pathways represents a method for enhancing hair growth in a subject.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 233-257.
  • the compound or factor is an RNA molecule having a sequence selected from SEQ ID No: 233-257.
  • the RNA molecule is homologous to a sequence selected from SEQ ID No: 233-257.
  • the RNA molecule is an isoform of a sequence selected from SEQ ID No: 233-257.
  • the compound or factor increases an activity of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 233-257.
  • the compound or factor increases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 233-257.
  • the transcripts depicted in Table 4 (Example 9; SEQ ID No: 233-257), the proteins they encode, and the pathways in which the proteins participate, contribute significantly, under the conditions utilized herein, to induction of epidermal cells to differentiate into HF stem cells.
  • Activation of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for enhancing EDIHN.
  • activation of these transcripts, proteins, and pathways represents a method for enhancing hair growth in a subject.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a compound or factor that decreases an activity of a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 258-273. In another embodiment, the compound or factor decreases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 258-273.
  • Each possibility represents a separate embodiment of the present invention.
  • the transcripts depicted in Table 5 (Example 9; SEQ ID No: 258-273), the proteins they encode, and the pathways in which the proteins participate, contribute significantly, under the conditions utilized herein, to preventing induction of epidermal cells to differentiate into HF stem cells.
  • Inhibition of the transcripts, proteins, and pathways depicted in Table 5 is thus a method for enhancing EDIHN.
  • inhibition of these transcripts, proteins, and pathways represents a method for induction of hair growth in a subject.
  • the compound that modulates a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 233-273 or the nucleic acid encoding same is administered before the compound that modulates a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-232 or the nucleic acid encoding same.
  • the two compounds are administered simultaneously. Each possibility represents a separate embodiment of the present invention.
  • a protein encoded by an RNA sequence selected from SEQ ID No: 1-273, or a compound that modulates the protein is administered before other proteins encoded by same or compounds that modulate them, in order to further enhance their effect in generating an HF or stimulating hair growth.
  • the wnt pathway is stimulated before the hedgehog pathway.
  • the two pathways are stimulated in an overlapping fashion.
  • the two pathways are stimulated simultaneously.
  • activating or decreasing expression of an RNA transcript in methods of the present invention occurs via a transcription mechanism (e.g. activation of expression of the RNA).
  • activating or decreasing expression of the RNA transcript occurs via a translational mechanism.
  • activating or decreasing expression of the RNA transcript occurs via a post-translational mechanism.
  • the nucleic acid molecule utilized in methods of the present invention is a deoxyribonucleic acid (DNA) molecule that encodes an RNA molecule having a sequence selected from the sequences set forth in the present invention.
  • DNA deoxyribonucleic acid
  • an RNA molecule of the present invention encodes a protein that plays a role in HF regeneration.
  • the RNA molecule is itself catalytically active, e.g., a ribozyme, etc. Each possibility represents a separate embodiment of the present invention.
  • the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a compound or factor that promotes placodal cell fate.
  • factors that promote placodal cell fate enhance EDIHN, as exemplified in the Examples herein.
  • the compound or factor acts at the placode stage of HF development.
  • the compound or factor inhibits a biological factor that inhibits a differentiation of an uncommitted epithelial cell into an HF cell.
  • compositions comprising one of the above compounds or factors is administered.
  • a composition comprising one of the above compounds or factors is administered.
  • Each of the above types of compounds, factors, and compositions represents a separate embodiment of the present invention.
  • the present invention provides a method for generating an HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with minoxidil, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with minoxidil, thereby treating baldness in a scalp, eyebrow, or scarred region of a subject.
  • the present invention provides a use of minoxidil for the preparation of a pharmaceutical composition for use in a method for an HF in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the minoxidil.
  • the present invention provides a use of minoxidil for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the minoxidil.
  • the present invention provides a method for removal of an HF from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing an HF from a skin or scalp of a subject.
  • the present invention provides a method for hair removal from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing hair from a skin or scalp of a subject.
  • the epidermal disruption is light dermabrasion.
  • the epidermal disruption is a non-scarring method.
  • administering suppresses HF formation.
  • the EGF protein, EGF receptor, nucleotide, compound, or factor is administered within several days of healing.
  • the EGF protein, EGF receptor, nucleotide, compound, or factor is administered within about 1 day of healing.
  • the EGF protein, EGF receptor, nucleotide, compound, or factor is administered according to any of the timing embodiments enumerated herein for Dkk1 protein. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a use of either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, for the preparation of a pharmaceutical composition for use in a method for removal of an HF from a skin or scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the EGF protein, EGF receptor, nucleotide, compound, or factor.
  • a composition or method of the present invention is utilized on human skin.
  • the composition or method is utilized on an area of unwanted hair growth.
  • the area is the face.
  • the area is the bikini area.
  • the area is the legs.
  • the area is the arms.
  • the area is the chest.
  • an “inhibitor” utilized in methods and compositions of the present invention is, in another embodiment, an antibody that binds the protein or biological factor that is the target of the inhibitor.
  • the inhibitor is a pharmacologic inhibitor.
  • the inhibitor is any other type of inhibitor known in the art. Each possibility represents a separate embodiment of the present invention.
  • the step of disrupting the epidermis in methods of the present invention is performed, in another embodiment, by abrading the scalp, eyebrow, or scarred region.
  • the term “abrading” refers to an act of creating an abrasion.
  • abrading refers to rubbing.
  • abrading refers to wearing away by friction.
  • epidermal abrasion causes, under the conditions utilized herein, de novo HF neo-genesis.
  • the epidermal layer is disrupted.
  • “abrasion” has the same meaning as “abrading.” In another embodiment, “abrasion” refers to an area of the scalp or skin from which the epidermis is removed. In another embodiment, “abrasion” refers to an area of the scalp or skin from which the epidermis and dermis are removed. Each definition of “abrading” and “abrasion” represents a separate embodiment of the present invention.
  • epidermal disruption by a method of the present invention converts the skin back, in another embodiment, to an embryonic-like state, in which the follicle regenerates.
  • a subsequent window of opportunity is created, during which the number and size of new HF in the skin can be manipulated.
  • the administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell during this window causes regeneration of larger and more numerous HF.
  • the morphology of HF in abraded skin is similar to that of embryonic HF (Example 1-2 and subsequent Examples), and the markers expressed are similar as well.
  • the present invention provides a method of stimulating hair growth in a scalp, eyebrow, or scarred region of a subject, comprising performing a method of present invention, thereby stimulating hair growth in a scalp, eyebrow, or scarred region of a subject.
  • EDIHN-induced HF are capable of generating hairs.
  • methods of the present invention can be used to stimulate hair growth.
  • EHIHN refers to HF neogenesis induced by disruption of the epithelial layer.
  • the term refers to HF neogenesis induced by abrasion.
  • the term refers to HF neogenesis induced by wounding.
  • the term refers to HF neogenesis induced by disruption of the epithelial layer, followed by administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
  • the present invention provides a method of testing an ability of a compound to modulate HF generation in vivo, comprising (a) disrupting an epithelial layer of a first scalp, eyebrow, or scarred region, whereby the first scalp, eyebrow, or scarred region has been contacted with the compound; (b) measuring a first HF generation in the first scalp, eyebrow, or scarred region; (c) disrupting an epithelial layer of a second scalp, eyebrow, or scarred region, wherein the second scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of the first subject or a second subject, whereby the second scalp, eyebrow, or scarred region has not been contacted with the compound; (d) measuring a second HF generation in the second scalp, eyebrow, or scarred region; and (e) comparing the first HF generation to the second HF generation, whereby a difference between the first HF generation and the second HF generation indicates that the compound modulates an HF generation in vivo (Examples).
  • the present invention provides a method of testing an ability of a compound to stimulate hair growth in vivo, comprising disrupting an epithelial layer of a first scalp, eyebrow, or scarred region, whereby the first scalp, eyebrow, or scarred region has been contacted with the compound; measuring a first HF generation in the first scalp, eyebrow, or scarred region; disrupting an epithelial layer of a second scalp, eyebrow, or scarred region, whereby the second scalp, eyebrow, or scarred region has not been contacted with the compound; measuring a second HF generation in the second scalp, eyebrow, or scarred region; and comparing the first HF generation to the second HF generation, whereby a difference between the first HF generation and the second HF generation indicates that the compound stimulates a hair growth in vivo.
  • the methods of the present invention of testing a compound are repeated using a plurality of subjects, until a statistically significant sample has been tested.
  • the first scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of a first subject.
  • the subject is a subject in need of generation of a new HF.
  • the second scalp, eyebrow, or scarred region in another embodiment, is a scalp, eyebrow, or scarred region of the first subject.
  • the second scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of a second subject.
  • the excisional wounds of methods of the present invention are created using a surgical tool.
  • the surgical tool is a dermal biopsy punch (Example 2).
  • the excisional wounds are induced by freezing or cryoinjury.
  • freezing or cryoinjury is well known in the art, and is used, for example by dermatologists to injure skin.
  • the freezing or cryoinjury results in a blister.
  • the blister is used as a “chamber” to introduce drugs and or cells into the reepithelialized area. Each possibility represents a separate embodiment of the present invention.
  • the excisional wounds of methods of the present invention are not surgically closed.
  • the excisional wounds are not contacted with a bandage or dressing before they heal or during a period of time after wound induction.
  • the excisional wounds are not contacted with an ointment before they heal or during a period of time after wound induction.
  • the excisional wounds are allowed to heal by secondary intention. Each possibility represents a separate embodiment of the present invention.
  • human skin responds to EDIHN in the same manner as mouse skin.
  • the subject is a male.
  • the subject is a female.
  • the subject is any other type of subject known in the art. Each possibility represents a separate embodiment of the present invention.
  • the subject is an adult.
  • “adult” refers to an age greater than about 18 years. In another embodiment, “adult” refers to an age greater than about 20 years. In another embodiment, “adult” refers to an age greater than about 25 years. In another embodiment, “adult” refers to an age greater than about 30 years. In another embodiment, “adult” refers to an age greater than about 35 years. In another embodiment, “adult” refers to an age greater than about 40 years. In another embodiment, “adult” refers to an age greater than about 45 years.
  • the subject is elderly.
  • “elderly” refers to an age greater than about 45 years. In another embodiment, “elderly” refers to an age greater than about 50 years. In another embodiment, “elderly” refers to an age greater than about 55 years. In another embodiment, “elderly” refers to an age greater than about 60 years. In another embodiment, “elderly” refers to an age greater than about 65 years. In another embodiment, “elderly” refers to an age greater than about 70 years.
  • the first subject is a laboratory animal.
  • the subject(s) is/are mice.
  • the subject(s) is/are rats.
  • the subject(s) is/are gerbils.
  • the subject(s) is/are hamsters.
  • the subject(s) is/are guinea pigs.
  • the subject(s) is/are rabbits.
  • the subject(s) is/are pigs.
  • the subject(s) is/are dogs.
  • the subject(s) is/are cats.
  • the subject(s) is/are primates.
  • the subject(s) is/are any other laboratory animal known in the art. Each possibility represents a separate embodiment of the present invention.
  • the subject(s) has a disease or disorder comprising balding. In another embodiment, the subject(s) does not have a disease or disorder comprising balding. In another embodiment, the disease or disorder is androgenetic alopecia (AGA). In another embodiment, the disease or disorder is male pattern baldness. In another embodiment, the disease or disorder is female pattern baldness. In another embodiment, the disease or disorder is a discoid lupus erythematosis. In another embodiment, the disease or disorder is a congenital hypotrichosis. In another embodiment, the disease or disorder is a lichen planopilaris. In another embodiment, the disease or disorder is a scarring alopecia. In another embodiment, the disease or disorder is any other disease or disorder comprising balding known in the art.
  • AGA androgenetic alopecia
  • the scalp, eyebrow, or scarred region(s) has a majority of HF in the telogen stage of the hair cycle.
  • the findings of Examples 5-6 show that (a) EDIHN can restore hair growth to the scalp, eyebrow, or scarred region at the telogen stage; and (b) the efficiency of EDIHN at the telogen stage can be enhanced by depilation prior to abrasion or wound induction.
  • the scalp, eyebrow, or scarred region(s) has more than about 60% of HF in the telogen stage of the hair cycle.
  • the scalp, eyebrow, or scarred region(s) has more than about 70% of HF in the telogen stage of the hair cycle.
  • the scalp, eyebrow, or scarred region(s) has more than about 80% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) has more than about 90% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) does not have a majority of HF in the telogen stage of the hair cycle.
  • the first step e.g. epithelial disruption
  • the second step e.g. addition of an active compound, factor, cell, etc.
  • the interval is 4-12 days. In another embodiment, the interval is 5-12 days. In another embodiment, the interval is 4-11 days. In another embodiment, the interval is 6-11 days. In another embodiment, the interval is 6-10 days. In another embodiment, the interval is 6-9 days. In another embodiment, the interval is 6-8 days. In another embodiment, the interval is 7-8 days. In another embodiment, the interval is 5-11 days. In another embodiment, the interval is 5-10 days. In another embodiment, the interval is 7-10 days. In another embodiment, the interval is about 1 week. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of suppressing an activity or expression of a Wnt protein in the scalp, eyebrow, or scarred region.
  • suppressing Wnt activity induces pigmentation in HF generated by methods of the present invention.
  • the step of suppressing Wnt activity or expression is performed within about 10 days of epidermal disruption.
  • the step of suppressing Wnt activity or expression is performed prior to the second step (e.g prior to addition of a compound or factor that promotes HF cell differentiation.
  • the present invention provides a method for inducing pigmentation of a hair, comprising suppressing expression of a Wnt protein in a follicle of the hair.
  • the Wnt protein is Wnt1.
  • the Wnt protein is a Wnt7.
  • the Wnt protein is a Wnt7a.
  • the Wnt protein is a Wnt3.
  • the Wnt protein is a Wnt3a.
  • the Wnt protein is a Wnt10.
  • the Wnt protein is a Wnt10a.
  • the Wnt protein is any other Wnt protein known in the art. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method for inducing growth of a pigmented scalp hair or eyebrow of a subject, comprising generating a hair follicle in the scalp, eyebrow, or scarred region according to a method of the present invention and suppressing expression of a Wnt protein in the hair follicle, thereby inducing a growth of a pigmented scalp hair or eyebrow of a subject.
  • the step of suppressing expression of a Wnt protein comprises inducing an expression of a Dkk1 protein. In another embodiment, the step of suppressing expression of a Wnt protein comprises inducing an expression of any other Wnt inhibitor known in the art. In another embodiment, the step of suppressing expression of a Wnt protein is performed immediately or shortly after epidermal disruption. In another embodiment, the step of inducing expression of a Dkk1 protein is performed immediately or shortly after epidermal disruption. In another embodiment, the step of suppressing expression of a Wnt protein is performed at the time of epidermal disruption. In another embodiment, the step of inducing expression of a Dkk1 protein is performed at the time of epidermal disruption.
  • the step of suppressing expression of a Wnt protein is performed several days before generation of the follicle.
  • the step of inducing expression of a Dkk1 protein several days before generation of the follicle.
  • the step of suppressing expression of a Wnt protein is performed for about 8 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 8 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 9 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 9 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 10 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 10 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 12 days.
  • the step of inducing expression of a Dkk1 protein is performed for about 12 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed during the period of re-epithelialization. In another embodiment, the step of inducing expression of a Dkk1 protein is performed during the period of re-epithelialization. In another embodiment, expression of a Dkk1 protein is halted after several days. In another embodiment, halting expression of Dkk1 protein after several days induces, or enables induction of Wnt protein expression. In another embodiment, the expression of a Wnt protein is induced about 9 days after the abrating or wounding. In another embodiment, the expression of a Wnt protein is induced following the period of re-epithelialization. In another embodiment, induction of Wnt protein expression is necessary for formation of new HF. Each possibility represents a separate embodiment of the present invention.
  • “several” refers to about 1 day. In another embodiment, “several” refers to about 2 days. In another embodiment, “several” refers to about 3 days. In another embodiment, “several” refers to about 5 days. In another embodiment, “several” refers to about 7 days. In another embodiment, “several” refers to about 10 days. In another embodiment, “several” refers to about 12 days. Each possibility represents a separate embodiment of the present invention.
  • the step of contacting in methods of the present invention comprises directly contacting the scalp, eyebrow, or scarred region with the compound, RNA, protein, etc.
  • the step of contacting comprises indirectly contacting the scalp, eyebrow, or scarred region via contacting another site or tissue of the subject, after which the compound, RNA, or protein is transported to the scalp, eyebrow, or scarred region by a biological process; e.g, diffusion, active transport, or circulation in a fluid such as the blood, lymph, interstitial fluid, etc.
  • a biological process e.g, diffusion, active transport, or circulation in a fluid such as the blood, lymph, interstitial fluid, etc.
  • the epidermal disruption in methods of the present invention further removes dermal tissue from the scalp, eyebrow, or scarred region. In another embodiment, the epidermal disruption does not remove dermal tissue from the scalp, eyebrow, or scarred region.
  • “Disrupting” an epidermis or epidermal layer refers, in another embodiment, to removing part of the epidermis or epidermal layer. In another embodiment, the term refers to disturbing the intactness of the epidermis or epidermal layer. In another embodiment, the term refers to perforating the epidermis or epidermal layer. In another embodiment, only part of the epidermal layer need be removed. In another embodiment, the entire epidermal layer is removed. In another embodiment, the term refers to abrading the epidermis or epidermal layer (Examples). In another embodiment, the term refers to wounding the epidermis or epidermal layer (Examples). Each possibility represents a separate embodiment of the present invention.
  • the epidermal disruption is performed with a tool that comprises sandpaper. In another embodiment, the epidermal disruption is performed with a laser. In another embodiment, the laser is a Fraxel laser. In another embodiment, the laser is a CO 2 laser. In another embodiment, the laser is an excimer laser. In another embodiment, the laser is any other type of laser capable of inducing trans-epithelial injury. In another embodiment, the epidermal disruption is performed with a felt wheel. In another embodiment, the epidermal disruption is performed with a surgical tool. In another embodiment, the epidermal disruption is performed with any other tool known in the art that is capable of epidermal disruption. In another embodiment, the epidermal disruption comprises use of a micro-dermabrasion device. In another embodiment, the epidermal disruption comprises a burn treatment.
  • the epidermal disruption comprises a disruption of a follicle of said epidermis and a disruption of an interfollicular region of said epidermis. In another embodiment, the epidermal disruption comprises a disruption of a follicle of said epidermis and does not comprise a disruption of an interfollicular region of said epidermis.
  • the epidermal disruption comprises a light-based method. In another embodiment, the epidermal disruption comprises irradiation with visible light. In another embodiment, the epidermal disruption comprises irradiation with infrared light. In another embodiment, the epidermal disruption comprises irradiation with ultraviolet radiation. In another embodiment, the epidermal disruption comprises orthovoltage irradiation. In another embodiment, the epidermal disruption comprises X-ray irradiation. In another embodiment, the epidermal disruption comprises any other type of irradiation known in the art.
  • the epidermal disruption is performed by mechanical means.
  • mechanical means refers to abrading.
  • the term refers to wounding.
  • the term refers to ultrasound.
  • the term refers to radio-frequency.
  • the term refers to an electrical process or the use of an electrical current.
  • the term refers to electoporation.
  • the term refers to exision.
  • the term refers to tape-stripping.
  • the term refers to microdermabrasion.
  • the term refers to the use of peels.
  • the term refers to any other type of mechanical means known in the art. Each possibility represents a separate embodiment of the present invention.
  • the epidermal disruption comprises chemical treatment.
  • the chemical is phenol.
  • the chemical is trichloracetic acid.
  • the chemical is ascorbic acid.
  • the chemical is any other chemical capable of epidermal disruption that is known in the art.
  • Each method or type of method of epidermal disruption represents a separate embodiment of the present invention.
  • epidermal trauma is utilized in a method of the present invention.
  • Each type of epidermal abrasion and epidermal trauma represents a separate embodiment of the present invention.
  • the epidermal disruption of methods of the present invention creates an abrasion at least about 1-1.5 centimeters (cm) in width. In another embodiment, the abrasion is at least about 1 cm in width. In another embodiment, the abrasion is at least about 1.5 cm in width. In another embodiment, the abrasion is at least about 2 cm in width. Each type of abrasion represents a separate embodiment of the present invention.
  • the scalp, eyebrow, or scarred region is not contacted with a bandage or dressing following the epidermal disruption. In another embodiment, the scalp, eyebrow, or scarred region is not contacted with an ointment following the epidermal disruption. In another embodiment, the scalp, eyebrow, or scarred region is allowed to heal for a period of time without being contacted by any substance, device, ointment, etc., that is ordinarily administered to an abrasion or wound to facilitate healing. In another embodiment, the scalp, eyebrow, or scarred region is allowed to heal for a period of time without being contacted by any substance, device, ointment, etc., that is ordinarily administered to an abrasion or wound to prevent infection. In another embodiment, the period of time is the time it takes the epidermal disruption to heal. In another embodiment, the period of time is any time or range of times between 2 days and 3 weeks. Each possibility represents a separate embodiment of the present invention.
  • “following” refers to a period of time of about 2 days. In another embodiment, “following” refers to a period of time of about 3 days. In another embodiment, “following” refers to a period of time of about 4 days. In another embodiment, “following” refers to a period of time of about 5 days. In another embodiment, “following” refers to a period of time of about 7 days. In another embodiment, “following” refers to a period of time of about 10 days. In another embodiment, “following” refers to a period of time of about 2 weeks. In another embodiment, “following” refers to a period of time of about 3 weeks. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of depilating the scalp, eyebrow, or scarred region.
  • the findings of Example 6 show that the efficiency of EDIHN can be enhanced by depilation prior to abrasion or wound induction.
  • the depilation is epilation. In another embodiment, the depilation comprises the step of waxing. In another embodiment, the depilation comprises the step of plucking. In another embodiment, the depilation comprises the use of an abrasive material. In another embodiment, the depilation comprises the use of a laser. In another embodiment, the depilation comprises the use of electrolysis. In another embodiment, the depilation comprises the use of a mechanical device. In another embodiment, the depilation comprises the use of thioglycolic acid. In another embodiment, the depilation comprises the use of any other method of depilation or epilation known in the art. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of administering a topical retinoid to the scalp, eyebrow, or scarred region.
  • the topical retinoid induces resting (telogen) HF in the scalp, eyebrow, or scarred region to enter anagen.
  • telogen resting
  • the additional step (depilation or administration of a retinoid) is performed prior to the step of disrupting the epidermis.
  • the additional step is performed following the step of disrupting the epidermis, but prior to the addition of the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
  • the additional step is performed concurrently with the addition of the differentiation-promoting compound or factor.
  • the additional step is performed following the addition of the differentiation-promoting compound or factor.
  • the additional step is performed between about two days and about three weeks before the step of abrading. In another embodiment, the additional step is performed about two days before the step of abrading. In another embodiment, the additional step is performed about three days before the step of abrading. In another embodiment, the additional step is performed about four days before the step of abrading. In another embodiment, the additional step is performed about one week before the step of abrading. In another embodiment, the additional step is performed about ten days before the step of abrading. In another embodiment, the additional step is performed about two weeks before the step of abrading. In another embodiment, the additional step is performed about three weeks before the step of abrading. Each possibility represents a separate embodiment of the present invention.
  • the methods of the present invention further comprise the step of contacting the scalp, eyebrow, or scarred region with an inductive cell capable of inducing an epidermal cell to differentiate into an HF cell.
  • the HF cell is an HF stem cell.
  • the inductive cell is a dermal papilla cell. In another embodiment, the inductive cell is a follicular papilla cell. In another embodiment, the inductive cell is a dermal sheath cell. In another embodiment, the inductive cell is a cell that has been genetically modified; for example, with a gene encoding a factor that activates one of the proteins or pathways shown in the present invention to be up-regulated in HF stem cells. In one embodiment, the factor is hedgehog. In another embodiment, the factor is a DP cell protein. In another embodiment, the factor is wingless/int (wnt). In another embodiment, the factor is a Noggin protein. In another embodiment, the factor is a bone morphogenic protein (BMP).
  • BMP bone morphogenic protein
  • the factor is a fibroblast growth factor (FGF).
  • the factor is a transforming growth factor beta (TGF-beta) protein.
  • the factor is sonic hedgehog protein.
  • the factor is a neurotropin.
  • the factor is any other factor known in the art that can contribute to induction of an epidermal cell to differentiate into an HF cell. Each possibility represents a separate embodiment of the present invention.
  • the inductive cell has been genetically modified with a gene encoding a factor that represses one of the proteins or pathways shown in the present invention to be down-regulated in HF stem cells.
  • the inductive cell has been genetically modified with a gene encoding a factor that activates one of the proteins or pathways shown in the present invention to be up-regulated in HF stem cells upon their activation.
  • the inductive cell is an autologous cell. In another embodiment, the inductive cell is an allogenic cell.
  • the inductive cell is derived from a mesenchymal stem cell. In another embodiment, the inductive cell is derived from a mesodermal progenitor cell. In another embodiment, the inductive cell is derived from a hematopoietic stem cell. In another embodiment, the inductive cell is derived from an embryonic stem cell. In another embodiment, the inductive cell is derived from an embryonic carcinoma cell. In another embodiment, the inductive cell is one of the cell types disclosed in United States Patent Application No. 2003/0201815. In another embodiment, the inductive cell is any other type of cell known in the art with inductive properties for an epidermal cell. Each type of inductive cell represents a separate embodiment of the present invention.
  • the epidermal cell (e.g. the epidermal cell that is induced to differentiate into an HF cell) is an epidermal stem cell.
  • the epidermal cell is a bulge cell.
  • the epidermal cell is any other type of cell known in the art that can be induced to differentiate into an HF stem cell. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an anti-androgen compound.
  • the anti-androgen compound is finasteride.
  • the anti-androgen compound is Fluridil®.
  • the anti-androgen compound is dutasteride.
  • the anti-androgen compound is spironolactone.
  • the anti-androgen compound is cyproterone acetate.
  • the anti-androgen compound is bicalutamide.
  • the anti-androgen compound is flutamide.
  • the anti-androgen compound is nilutamide.
  • the anti-androgen compound is an inhibitor of an androgen receptor.
  • the anti-androgen compound is any other anti-androgen compound known in the art. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen compound. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen receptor agonist. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen analogue.
  • the estrogen analogue is estradiol. In another embodiment, the estrogen analogue is 17 beta-estradiol. In another embodiment, the estrogen analogue is 17 alpha-estradiol. In another embodiment, the estrogen analogue is ZYC3. In another embodiment, the estrogen compound, estrogen receptor agonist, or estrogen analogue is any other estrogen compound, estrogen receptor agonist, or estrogen analogue known in the art. Each possibility represents a separate embodiment of the present invention.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an inhibitor of an EGF protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an inhibitor of an EGFR. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a compound that reduces an expression of an EGF protein or an EGFR.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a Hedgehog protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a nucleotide encoding a Hedgehog protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an activator of a Hedgehog protein.
  • a scalp is treated by a method of the present invention.
  • an eyebrow is treated.
  • any other hair-bearing area or region of the skin is treated.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a lithium compound.
  • the lithium compound contains a lithium ion.
  • the lithium compound contains a lithium atom.
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO).
  • a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with any other compound known in the art that is capable of inducing an epidermal cell to differentiate into an HF stem cell. Each compound represents a separate embodiment of the present invention.
  • the compound administered as part of methods of the present invention is administered systemically. In another embodiment, the compound is administered topically. In another embodiment, the compound is administered to the site of the abrasion. In another embodiment, the compound is administered to the site of the wound induction. In another embodiment, the compound is administered to the site of the depilation. In another embodiment, the compound is administered during wound healing. In another embodiment, the compound is administered prior to HF neo-genesis. In another embodiment, the compound is administered during HF neo-genesis. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method of inducing formation of an HF stem cell, comprising performing a method of the present invention.
  • the present invention provides a method of inducing formation of a DP cell, comprising performing a method of the present invention.
  • homologues and variants of transcripts and proteins of the present invention are administered in methods of the present invention.
  • homologues and variants of transcripts and proteins of the present invention are targeted in methods of the present invention.
  • Each possibility represents a separate embodiment of the present invention.
  • homology when in reference to any protein or peptide, refer in one embodiment, to a percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Methods and computer programs for the alignment are well known in the art.
  • “homology” refers to identity of greater than 70%. In another embodiment, “homology” refers to identity of greater than 75%. In another embodiment, “homology” refers to identity of greater than 80%. In another embodiment, “homology” refers to identity of greater than 82%. In another embodiment, “homology” refers to identity of greater than 85%. In another embodiment, “homology” refers to identity of greater than 87%. In another embodiment, “homology” refers to identity of greater than 90%. In another embodiment, “homology” refers to identity of greater than 92%. In another embodiment, “homology” refers to identity of greater than 95%. In another embodiment, “homology” refers to identity of greater than 97%. In another embodiment, “homology” refers to identity of greater than 98%. In another embodiment, “homology” refers to identity of greater than 99%. In another embodiment, “homology” refers to identity of 100%.
  • Protein and/or peptide homology for any amino acid sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer algorithm analysis of amino acid sequences, utilizing any of a number of software packages available, via established methods. Some of these packages may include the FASTA, BLAST, MPsrch or Scanps packages, and may employ the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example. Each method of determining homology represents a separate embodiment of the present invention.
  • the present invention provides a kit, comprising a tools and/or a compound suitable for performing a method of the present invention.
  • the present invention provides a device, comprising a tool suitable for epidermal disruption and a means of delivering a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
  • the present invention provides a method of treating any disease, disorder, or symptom associated with balding. In other embodiments, the present invention provides a method of treating any disease, disorder, or symptom associated with balding. In other embodiments, the present invention provides a method of treating any disease, disorder, or symptom associated with balding. Each disease, disorder, or symptom represents a separate embodiment of the present invention.
  • methods of the present invention comprise administering a pharmaceutical composition comprising the HF stem cell-inducing or -activating compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising the HF stem cell-inducing or -activating compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
  • compositions containing the HF stem cell-inducing or -activating compound can, in another embodiment, be administered to a subject by any method known to a person skilled in the art, such as topically, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially, intravaginally or intratumorally.
  • a method known to a person skilled in the art such as topically, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially, intravaginally or intratumorally.
  • Each possibility represents a separate embodiment of the present invention.
  • the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation.
  • Suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like.
  • Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
  • the HF stem cell-inducing or -activating compounds are formulated in a capsule.
  • the compositions of the present invention comprise, in addition to the HF stem cell-inducing or -activating compound active compound and the inert carrier or diluent, a hard gelating capsule.
  • the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration.
  • suitable topical formulations include gels, ointments, creams, lotions, drops and the like.
  • the HF stem cell-inducing or -activating compound or its physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.
  • the pharmaceutical compositions are administered by subcutaneous implantation of a pellet.
  • the pellet provides for controlled release of HF stem cell-inducing or -activating compound agent over a period of time.
  • pharmaceutically acceptable carriers are, in another embodiment, aqueous or non-aqueous solutions, suspensions, emulsions or oils.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include, in another embodiment, water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
  • the pharmaceutical compositions are controlled-release compositions, i.e. compositions in which the HF stem cell-inducing or -activating compound is released over a period of time after administration.
  • Controlled- or sustained-release compositions include, in another embodiment, formulation in lipophilic depots (e.g. fatty acids, waxes, oils).
  • the composition is an immediate-release composition, i.e. a composition in which all the HF stem cell-inducing or -activating compound is released immediately after administration.
  • mice were anesthetized with an injection of sodium pentobarbital before the hair on the back was clipped and depilated with Nair (Carter-Wallace, New York, N.Y.), then epidermis was removed using a rotating felt wheel as described by Argyris T, J Invest Dermatol, 75: 360-362, 1980). After scrubbing with 70% ethanol and drying under an incandescent lamp, the basal and supra-basal layers in an area of (1.5 cm) 2 cm of the inter-follicular epidermis were removed by careful abrasion with a felt wheel mounted on a Dremel Moto-tool (Racine, Wis.). After abrasion, the skin was shiny and smooth, and there was no blood.
  • Nair Carter-Wallace, New York, N.Y.
  • FIG. 1 An area of the backs of 50-day old mice was subjected to depilation and removal of the epidermis using a rotating felt wheel. Fifteen days later, HF placodes, hair germs and other signs of follicle neogenesis were present ( FIG. 1 ; arrow indicates a hair germ). Morphology of the follicles was similar to embryonic follicle development. To further characterize proliferation in the new follicles, the skin was labeled with BrdU 60 minutes before sacrifice. As depicted in FIG. 2 , the proliferation pattern was similar to developing follicles in the embryo.
  • mice The backs of 21-day-old mice were depilated as described for Example 1 and sterilized with alcohol, followed by 1% iodine solution.
  • Punch wounds 4 mm in diameter, were induced using a dermal biopsy punch, down to, but not through, the muscle fascia. Excisional wounds were full thickness and 1 cm in diameter; skin and panniculus carnosus was excised using fine surgical scissors.
  • the HF generated by wound induction were further characterized by morphological comparison to embryonic HF, following BrdU staining; a clear correspondence in morphology was observed at various stages ( FIG. 7 ).
  • several markers of embryonic HF development namely Lef1, wingless/int (Wnt) 10b, and sonic hedgehog (Shh) were also induced in the epidermal disruption-induced HF neogenesis (EDIHN) ( FIG. 8 ).
  • Additional BrdU staining ( FIG. 9 ) and staining for HF markers S100A3 and S100A6 FIG. 10 ; left panel: tissue section parallel to HF axis; right panel: cross-sectional view of follicle) provided further verification that the development of the EDIHN follicles closely paralleled embryonic HF development.
  • wound sites contained new hairs ( FIG. 11 , left and right panels, respectively). New hairs appeared to lack pigmentation, except when the wnt pathway was inhibited, using Dkk-1 (Dickkopf-1) during the first nine days after wounding (see Example 10).
  • Dkk-1 Dickkopf-1
  • BrdU bodyweight
  • HF whole mounts were obtained by incubating fresh skin with EDTA (20 mM in PBS) at 37° C. overnight, then separating the epidermis and dermis. Epidermis was then fixed in 10% formalin for 10 min, room temperature (RT). Dermis was fixed in acetone overnight, RT. After rinsing with PBS, whole mounts were stained with antibodies for immunohistochemistry (schematically depicted in FIG. 12 ) and were imaged using a Leica confocal microscope.
  • HF stem cells To determine whether EDIHN-induced HF contain normal levels of HF stem cells, mouse skin was examined for the presence of label-retaining cells at 21 days after wound induction. Retention of BrdU during a long chase period is, under these conditions, one of the hallmarks of HF stem cells. Normal numbers and placement of label-retaining cells (in the bulge of the HF) were observed ( FIG. 13 ). To verify that the label-retaining cells were HF stem cells, K15-eGFP mice were utilized. In these mice, eGFP (enhanced green fluorescent protein) is expressed from the K15 promoter; thus, expression of eGFP identifies HF stem cells. As depicted in FIG.
  • eGFP-expressing cells were observed in tissue sections (right side) of newly formed hair follicles 35 days following wound induction. eGFP-expressing cells were also seen in the epidermis whole mounts (bottom, far left panel) indicating the conversion of epidermal cells into cells with hair follicle stem cell characteristics. (panel is same as panel but viewed under white light) This finding shows that the observed label-retaining cells exhibited HF stem cell properties.
  • mounts were prepared from additional mice at 35, 38 and 45 days after wounding. As depicted in FIG. 14B , the EDIHN-induced HF entered the resting phase, telogen, and then re-entered a new anagen stage.
  • the findings of this Example show that EDIHN-induced HF contain HF stem cells, as do embryonically generated HF.
  • the presence of the HF stem cells shows that EDIHN-induced HF retain the ability to enter into cyclical hair growth in the same manner as embryonically generated HF.
  • the findings also show that wounding induces epidermal cells to assume a hair follicle stem cell state (expressing K15-eGFP). This model is shown schematically in FIG. 15 .
  • the findings of Examples 2, 3, and 4 show that EDIHN-induced HF are fully functional and thus able to restore hair growth to a subject in need.
  • mice wounded at the telogen stage of the hair cycle 21-day-old mice were subjected to EDIHN using a 1-cm excisional wound, as described in Example 2. Skin was then examined by whole-mount assay for indications of new HF. As depicted in FIG. 16 , after 11 days, new HF were not evident by macroscopic examination (top panel), AP staining of the dermis (bottom left panel), or K17 staining of the epidermis (bottom right panel). After 14 days, as depicted in FIG.
  • Example 5 The experiment described in Example 5 was repeated with mice of different ages, and therefore at different stages of the hair cycle. To ensure that wound scarring occurred, larger wounds were in induced in the older mice. As depicted in Table 2, adult mice at telogen, such as 8-week-old mice, exhibited lower efficiencies of HF formation by EDIHN.
  • mice 8-week-old mice were depilated several days prior to wound induction. As depicted in FIG. 19 , the wounds closed similarly whether or not they were preceded by depilation. As depicted in FIG. 20A-B , the depilated mice exhibited enhanced EDIHN relative to the non-depilated mice depicted in the previous Example by a factor of 11-fold.
  • K15-eGFP mice were depliated in order to induce formation of new HF.
  • Activated hair follicle stem cells were isolated from K15-eGFP mice using fluorescence-activated cell sorting (FACS) two days after depilation and 5 ⁇ g (micrograms) total RNA from the cell population was isolated, reverse-transcribed and hybridized to an Affymetrix (Santa Clara, Calif.) array MG_U74v2 chip. Scanned chip images were analyzed using Affymetrix Microarray Suite 5.0 and GeneSpring software (Silicon Genetics) to detect fold-change differences between activated HF stem cells (HFSCs) and non-activated (telogen) HFSCs. Values were normalized before computing fold-changes and differences between non-activated “bs-line” and activated (“expt”) samples.
  • FACS fluorescence-activated cell sorting
  • activated HF stem cells were isolated, and the gene expression patterns of the cells were analyzed to detect up-regulated transcripts.
  • the transcripts depicted in Table 3 were up-regulated at least 2-fold in the activated HF stem cells relative to the cells prior to activation.
  • the sequence in Table 3 is a genomic sequence that contains the sequence of the transcript. Data pertaining to the up-regulation of the transcripts and further information about them is provided in FIG. 22 .
  • transcripts identified in this Example the proteins they encode, and the pathways in which the proteins participate contribute significantly to HF stem cell activation. Accordingly, anagen can be induced by activation of these transcripts, proteins, and pathways.
  • HF stem cells The gene expression pattern of HF stem cells was analyzed as described in Example 8 and compared to non-bulge basal keratinocytes. 157 genes were differentially expressed in the HF stem cells, as assessed by microarray analysis and quantitative polymerase chain reaction (qPCR). A group of selected genes with increased expression in HF stem cells is depicted in Table 4. A group of selected genes with decreased expression in HF stem cells is depicted in Table 5.
  • the transcripts identified in this Example contribute significantly to induction of epidermal cells to differentiate into HF stem cells.
  • Activation of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for enhancing EDIHN.
  • inhibition of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for preventing EDIHN and eliminating hair follicles.
  • inhibition of the transcripts, proteins, and pathways depicted in Table 5 is a method for enhancing EDIHN.
  • activation of the transcripts, proteins, and pathways depicted in Table 5 is thus a method for enhancing EDIHN.
  • a 1 cm 2 wound was induced on the lower back of the doubly transgenic mice at 21 days or 50 days old. Mice were placed on doxycycline-containing chow immediately after wounding to induce Dkk1 expression, and then doxycycline was discontinued after completion of the re-epithelialization at 9 days after wounding. Dkk1 expression inhibits Wnt activity, which in turn induces follicle pigmentation. At 22 days after wounding, pigmented HF were observed in the excised skin after preparing the epidermal sheet ( FIG. 23A-B ). Control mice lacked pigmented HF ( FIG. 24 ).
  • the findings of this Example show that pigmented HF can be produced by suppressing expression of Wnt or by inducing expression of Dkk1 during the period of re-epithelialization, then inducing expression of Wnt1.
  • the findings of this Example show that factors that inhibit neonatal hair follicle formation (e.g. Dkk1) also inhibit EDIHN, thus further supporting the notion that hair follicles formed by EDIHN are similar to normal hair follicles.
  • EGF recombinant EGF (1 microgram (mcg)/microliter (mcl)
  • mcg microgram
  • mcl microliter
  • the inhibitor AG1478 (150 ⁇ M in 10 ⁇ L volume) was administered as a single injection 11 days after incisional wounding (1 cm 2 ) to the middle of the wound near the skin surface. EGF receptor inhibitor administration led to generation of more and larger hair follicles compared with control mice that were wounded only ( FIG. 26A ). As shown in FIG. 26B , large hair follicles developed in the wounded area in the AG1478-injected mice. Left panel: epidermis stained for K17, with three large hair follicles next to each other. Right panel: dermis stained for AP with large coalescing dermal papilla areas.
  • ⁇ -catenin activators leads to an increase in EDIHN.
  • the findings of Examples 11-13 show that new HF can be generated by (a) disrupting the epidermis; and (b) administering a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
  • FGF fibroblast growth factor
  • fibroblast growth factor FGF
  • K14-Eda-A1 transgenic mice which overexpress (ectodysplasin-A1) Eda-A1 in the epidermis, are subjected to EDIHN, then HF formation is measured 19 days after wounding as described in Example 13.
  • the transgenic mice developed significantly larger numbers of HF compared to control, non-transgenic littermate mice, showing that new HF can be generated by (a) disrupting the epidermis; and (b) administering a factor that enhances signaling by ectodysplasin.
  • Minoxidil administration enhances HF formation, showing that new HF can be generated by (a) disrupting the epidermis; and (b) administering a minoxidil.
  • Hair-bearing regions of the epidermis of mice is abraded, as described in Example 1, then administering recombinant EGF, as described in Example 1.
  • This method prevents hair re-growth in the abraded areas, showing that hair can be removed by (a) disrupting the epidermal layer; and (b) administering EGF, a nucleotide encoding EGF, or a factor that increases signaling by EGF.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 14/946,512, filed on Nov. 15, 2015, which is a continuation of U.S. patent application Ser. No. 13/327,611, filed on Dec. 15, 2011, which is a continuation of U.S. patent application Ser. No. 11/887,104, filed Sep. 25, 2007, which is a National Phase Application of PCT International Application PCT/US06/11319, filed Mar. 28, 2006, claiming priority to U.S. Provisional Patent Applications 60/665,857 and 60/683,293, filed 29 Mar., 2005, and 23 May, 2005, respectively. Additionally, this application relates to U.S. patent application Ser. Nos. 12/904,822 and 12/904,981, both filed on Oct. 14, 2010. All of the above-identified applications are incorporated by reference herein in their entirety.
    • FIELD OF INVENTION
  • The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.
    • BACKGROUND OF THE INVENTION
  • Follicular neogenesis is defined as the generation of new hair follicles (HF) after birth. Humans are born with a full complement of HF, which can change in size and growth characteristics as in early baldness or can ultimately degenerate and disappear as in late stages of baldness or in permanent scarring (cicatricial) alopecias. Therefore, the generation of new HF is desirable in the treatment of common baldness as well as less common hair loss conditions, such as discoid lupus erythematosis, congenital hypotrichosis, lichen planopilaris and other scarring alopecias.
    • SUMMARY OF THE INVENTION
  • The present invention provides methods of treating baldness in a subject and generating new hair follicles (HF), comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.
  • In one embodiment, the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle (HF) cell, thereby treating baldness in a scalp, eyebrow, or scarred region.
  • In another embodiment, the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting the epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell, thereby treating baldness in a scalp, eyebrow, or scarred region. In another embodiment, the baldness is an androgenetic alopecia (AGA)-induced baldness. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for removal of an HF from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing an HF from a skin or scalp of a subject.
  • In another embodiment, the present invention provides a method for increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject. In another embodiment, step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby treating an AGA in a scalp. In another embodiment, step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1: Epidermal abrasion results in de novo hair follicle (HF) formation. HF at progressive stages of development are depicted in the left, center, and right panels. The arrow in the left panel indicates a hair germ. The dark stained cells are progeny of HF stem cells in the bulge.
  • FIG. 2: BrdU labeling of HF following epidermal abrasion. HF at progressive stages of development are depicted in the left, center, and right panels.
  • FIG. 3. The wound site did not contain HF immediately after re-epithelialization. Top view (left panel) and tissue section (right panel) of the site 10 days after wound induction.
  • FIG. 4. Appearance of hair germs 12 days after wound induction. Arrow indicates hair germ.
  • FIG. 5. Epidermal Disruption-Induced HF neogenesis (EDIHN)-induced hair germs express K17. Two different hair germs are depicted in the left and right panels.
  • FIG. 6. EDIHN-induced hair germs contain dermal papilla (DP) cells, as evidenced by alkaline phosphatase (AP) staining. Arrows indicate DP cells. Left panel: hair germs. Right panel: HF at a further developmental stage.
  • FIG. 7. Histological comparison between EDIHN-induced and embryonic HF. Top left, second from left, third from left, and right panels: Progressive stages of EDIHN-induced HF development. Bottom left, center, and right panels: Progressive stages of and embryonic HF development.
  • FIG. 8. Induction of several markers of embryonic HF development, Lef1 (left panel), wingless/int (Wnt) 10b (center panel), and sonic hedgehog (Shh; right panel), by EDIHN. HF structures are indicated by arrowheads.
  • FIG. 9. Proliferative activity during EDIHN, as evidenced by BrdU pulse-labeling. Progressive stages of HF development are depicted in the left, center, and right panels.
  • FIG. 10. Induction of HF markers S100A3 (left panel; tissue section parallel to HF axis) and S100A6 (right panel; cross-sectional view of follicle) by EDIHN.
  • FIG. 11. New hair growth 25 days (left panel) and 45 days (right panel) after wound induction.
  • FIG. 12. Schematic of whole-mount EDIHN assay.
  • FIG. 13. Repopulation of stem cells in the bulge of EDIHN-induced HF, as evidenced by retention of BrdU label following a chase period. Left panel: lower magnification: 50×. Right panel: higher magnification: 400×.
  • FIGS. 14A-14B. FIG. 14A. Stem cells in EDIHN-induced HF express K15. Left top panel: Top view of wound site. Bottom, far left panel: epidermis whole mount; bottom, second from left panel: same as panel but viewed under white light; right panel: tissue sections. FIG. 14B. Neogenesis HF proceed to next hair cycle.
  • FIG. 15. Schematic of creation of new HF by EDIHN.
  • FIG. 16. No new HF are evident 11 days after wound induction in 21-day-old mice. Top panel: macroscopic examination; bottom left panel: AP staining of the dermis; bottom right panel: K17 staining of the epidermis.
  • FIG. 17. 14 days after wound induction, new HF have begun to form as evidenced by AP staining of the dermis (left panel) and K17 staining of the epidermis (right panel). Main panels: 10× magnification. Inserts: 80× magnification.
  • FIG. 18. 17 days after wound induction, new HF are more developed. Left panel: AP staining of the dermis; right panel: K17 staining of the epidermis. Main panels: 10× magnification. Inserts: 80× magnification.
  • FIG. 19. Wounds closed similar in mice subjected to depilation, then wounding (left 3 mice in each panel) vs. wounding alone (right 4 mice in each panel). Left panel: immediately following wounding. Right panel: 10 days following wounding.
  • FIGS. 20A-20B. Anagen induction by depilation prior to wounding enhances the efficiency of EDIHN. FIG. 20A. Top panel: lower left panel AP staining of the dermis; lower right panel: K17 staining of the epidermis. FIG. 20B. Graphical representation of enhancement of EDIHN by depilation.
  • FIGS. 21A-21B. FIG. 21A. EDIHN in human skin grafted to immunodeficient (scid) mice, seven days after induction of an excisional wound. Arrows indicate new HF. FIG. 21B.
    •
  • Dermal abrasion of human skin grafts results in EDIHN. Human adult skin (W) was grafted onto mice, abraded, and examined seven days later, by staining for S100A6 (first, second, and fourth rows) or S100A4 (third row). Hair germs (HG) and dermal papilla (DP) are indicated. Human fetal skin (F) with normal developing hair follicles is shown for comparison. Mouse skin 17 d post wounding was included as a control (top left panel).
  • FIGS. 22A-22C. Transcripts up-regulated at least 2-fold in activated HF cells, as assessed by dChip analysis. (FIG. 22A). Mean values and standard errors of the up-regulated transcripts in non-activated (“bs-line”) and activated (“expt”) samples and fold-changes and differences between non-activated and activated values are depicted. (FIG. 22B). Raw data for up-regulated transcripts in non-activated and activated cells. “Ctrl” denotes non-activated and “High-dep” denotes activated cells. (FIG. 22C). Additional information about up-regulated transcripts.
  • FIGS. 23A-23B. Pigmented hair follicle neogenesis observed in the skin of Dkk1-expressing mice following EDIHN FIG. 23A. 3.2× magnification. FIG. 23B. 8× magnification.
  • FIG. 24. Control mice lacked pigmented HF.
  • FIGS. 25A-25D. EGF inhibits HF formation by EDIHN. FIG. 25A. K17 staining of wounded skin of representative mouse treated with EGF. Magnification is 4×. FIG. 25B. High magnification view (10×) of skin depicted in (FIG. 25A). FIG. 25C. K17 staining of wounded skin of representative control mouse that received no EGF after wounding. Magnification is 4×. FIG. 25D. Higher magnification view (10×) of skin depicted in (FIG. 25D).
  • FIGS. 26A-26B. Administration of an EGF receptor inhibitor (AG1478) leads to generation of more and larger HF compared with controls. FIG. 26A. Top: skin of 2 control mice. Outer dashed line indicates the extent of the wounded area after contraction and healing; inner dashed line indicates the area of neogenesis. Bottom: skin of 2 treated mice, in which the wounded area and area of neogenesis largely coincide, with the exception of a small area on the left side of the encircled area in each panel. FIG. 26B. Large hair follicles developed in the wounded area in the AG1478-injected mice. Left panel: epidermis stained for K17, with three large hair follicles next to each other. Right panel: dermis stained for AP with large coalescing DP areas. Scale Bars: 200 μm.
  • FIGS. 27A-27C. FIG. 27A. Increased hair follicle formation in K14-Wnt7a mice. Left panel: Wnt7a transgenic mice. Right panel: control (wild-type) mice. FIG. 27B. Quantiation of experiment with 4 week old mice. FIG. 27C. Quantiation of experiment with 3 week old mice.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides methods of treating baldness in a subject and generating new HF, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.
  • In one embodiment, the present invention provides a method for generating a hair follicle (HF) in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for generating an HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for generating a new HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell, thereby generating a new HF in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for increasing the number of HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby increasing the number of HF in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the compound or factor.
  • In another embodiment, the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the compound or factor.
  • In another embodiment, the present invention provides a use of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the compound or factor.
  • In another embodiment, the present invention provides a method for increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell, thereby increasing a size of a hair follicle in a scalp, eyebrow, or scarred region of a subject. In another embodiment, the factor is an inhibitor of an EGF protein or an EGFR. In another embodiment, the factor is a Hedgehog protein, a nucleotide encoding same or an activator of same. In another embodiment, the factor is an androgen antagonist. In another embodiment, the factor is any other compound or factor that promotes a differentiation of an uncommitted epidermal cell into an HF cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject. In another embodiment, step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • The precursor cell of methods and compositions of the present invention, is, in another embodiment, a HF stem cell. In another embodiment, the precursor cell is an epidermal cell. In another embodiment, the precursor cell is a dermal papilla cell. In another embodiment, the precursor cell is a connective tissue sheath cell. In another embodiment, the precursor cell is any other type of cell known in the art that is capable of differentiation into a hair follicle cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of said scalp, eyebrow, or scarred region; and (b) contacting said scalp, eyebrow, or scarred region with a precursor cell that is capable of differentiation into a hair follicle cell, thereby generating a hair follicle in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a cell selected from (a) a precursor cell that is capable of differentiation into a hair follicle cell; (b) an inductive cell that is capable of inducing differentiation of an uncommitted epidermal cell into a hair follicle cell; or (c) a hair follicle or portion thereof, thereby treating an AGA in a scalp. In another embodiment, step (b) is performed 3-12 days after step (a). Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for treating an AGA in a scalp, comprising the steps of: (a) disrupting an epidermis of said scalp; and (b) contacting said scalp with a precursor cell that is capable of differentiation into a hair follicle cell, thereby treating an AGA in a scalp.
  • In another embodiment, the inductive cell is a mesenchymal cell. In another embodiment, the inductive cell is any other type of inductive cell enumerated herein. In another embodiment, the inductive cell is any other type of inductive cell known in the art. Each possibility represents a separate embodiment of the present invention.
  • “Contacting” as used herein refers, in another embodiment, to bringing the scalp, eyebrow, etc, into to contact with the compound, factor, cell, etc. In another embodiment, the term refers to embedding the compound, factor, cell, etc into the scalp, eyebrow, etc. In another embodiment, the term refers to injecting the compound, factor, cell, etc into the scalp, eyebrow, etc. In another embodiment, term refers to any other type of contacting known in the art. Each possibility represents a separate embodiment of the present invention.
  • “Promotes a differentiation” refers, in another embodiment, to the act of increasing the percentage of cells that will differentiate as indicated. In another embodiment, the term refers to increasing the number of cells per unit area of skin that will differentiate. In another embodiment, the promoter of differentiation is active in the milieu of the skin. Each possibility represents a separate embodiment of the present invention.
  • “Uncommitted epidermal cell” refers, in another embodiment, to an epidermal stem cell. In another embodiment, the epidermal cell is a bulge cell. In another embodiment, the epidermal cell is a bulge-derived cell. In another embodiment, the epidermal cell is any other type of cell known in the art that can be induced to differentiate into an HF cell.
  • The “HF cell” that results from the differentiation is, in another embodiment, an HF stem cell. In another embodiment, the HF cell is a dermal papilla cell. In another embodiment, the HF cell is a bulb cell. In another embodiment, the HF cell is a matrix cell. In another embodiment, the HF cell is a hair shaft cell. In another embodiment, the HF cell is an inner root sheath cell. In another embodiment, the HF cell is an outer root sheath cell. In another embodiment, the HF cell is a melanocyte stem cell. In another embodiment, the HF cell is a melanocyte. Each type of uncommitted epidermal cell and HF cell represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle (HF) cell, thereby treating baldness in a scalp, eyebrow, or scarred region. In another embodiment, the baldness is an androgenetic alopecia (AGA)-induced baldness. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell, thereby treating baldness in a scalp, eyebrow, or scarred region. In another embodiment, the baldness is an androgenetic alopecia (AGA)-induced baldness. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is administered in a solution. In another embodiment, the compound or factor is administered in a cream. In another embodiment, the compound or factor is administered in an ointment. In another embodiment, the compound or factor is administered in a slow release formulation. In another embodiment, the compound or factor is administered in a liposome encapsulated formulation. In another embodiment, the compound or factor is directly injected. In another embodiment, the compound or factor is administered by any other method known in the art. Each possibility represents a separate embodiment of the present invention.
  • The compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is, in another embodiment, an inhibitor of an Epidermal Growth Factor (EGF). In another embodiment, the compound or factor is an inhibitor of an EGF receptor. Each possibility represents a separate embodiment of the present invention.
  • As provided herein (Example 11), activating one or more pathways in which EGF is involved (by injection of EGF) blocks the formation of HF. Thus, antagonizing the pathway increases HF formation, as demonstrated in Example 12.
  • In another embodiment, the inhibitor of an EGF or an EGF receptor is panitumumab. In another embodiment, the inhibitor is AG1478. In another embodiment, the inhibitor is nimotuzumab. In another embodiment, the inhibitor is an antibody that binds EGF or EGFR. In another embodiment, the inhibitor is HuMax-EGFR® (Genmab, Copenhagen, Denmark). In another embodiment, the inhibitor is cetuximab. In another embodiment, the inhibitor is IMC 11F8. In another embodiment, the inhibitor is matuzumab. In another embodiment, the inhibitor is SC 100. In another embodiment, the inhibitor is ALT 110. In another embodiment, the inhibitor is PX 1032. In another embodiment, the inhibitor is BMS 599626. In another embodiment, the inhibitor is MDX 214. In another embodiment, the inhibitor is PX 1041. In another embodiment, the inhibitor is any other inhibitor of an EGF or an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is an inhibitor of a tyrosine kinase activity of an EGF receptor. In another embodiment, the inhibitor is gefitinib. In another embodiment, the inhibitor is erlotinib. In another embodiment, the inhibitor is canertinib. In another embodiment, the inhibitor is leflunomide. In another embodiment, the inhibitor is A77 1726. In another embodiment, the inhibitor is pelitinib. In another embodiment, the inhibitor is ZD 1839. In another embodiment, the inhibitor is CL 387785. In another embodiment, the inhibitor is EKI 785. In another embodiment, the inhibitor is vandetanib. In another embodiment, the inhibitor is any other inhibitor of a tyrosine kinase activity of an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the EGF or EGFR antagonist is a carboxypeptidase inhibitor from potato (PCI) protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is a sprouty protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is an Argos protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is a lefty protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is an antibody that recognizes EGF or EGFR, or a fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is small molecule inhibitor that binds and reduces the activity of EGF or EGFR. In another embodiment, the EGF or EGFR antagonist is CRM197. In another embodiment, the EGF or EGFR antagonist is IMC-C225 (ImClone Systems, New York, N.Y.). In another embodiment, the EGF or EGFR antagonist is any other antagonist of EGF or EGFR known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the inhibitor of an EGF protein or an EGF receptor.
  • In another embodiment, the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the inhibitor of an EGF protein or an EGF receptor.
  • In another embodiment, the present invention provides a use of an inhibitor of an EGF protein or an EGF receptor for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the inhibitor of an EGF protein or an EGF receptor.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a β-catenin protein. In another embodiment, the compound or factor is a nucleotide that encodes a β-catenin protein. In another embodiment, the compound or factor is an activator of a β-catenin protein. In another embodiment, the compound or factor is an inhibitor of a protein that suppresses an activity of the β-catenin protein. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a use of (a) a β-catenin protein; (b) a nucleotide encoding a β-catenin protein; or (c) a compound or factor that activates a β-catenin protein, for the preparation of a pharmaceutical composition for use in a method for generating a hair follicle in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the β-catenin protein, nucleotide, compound or factor.
  • In another embodiment, the present invention provides a use of (a) a β-catenin protein; (b) a nucleotide encoding a β-catenin protein; or (c) a compound or factor that activates a β-catenin protein, for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the β-catenin protein, nucleotide, compound or factor.
  • In another embodiment, the present invention provides a use of (a) a β-catenin protein; (b) a nucleotide encoding a β-catenin protein; or (c) a compound or factor that activates a β-catenin protein, for the preparation of a pharmaceutical composition for use in a method for treating AGA in a scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp with the β-catenin protein, nucleotide, compound or factor.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a fibroblast growth factor (FGF) protein. In another embodiment, the compound or factor is a nucleotide that encodes an FGF protein. In another embodiment, the compound or factor is an FGF receptor. In another embodiment, the compound or factor is a nucleotide that encodes an FGF receptor. In another embodiment, the compound or factor is an activator of an FGF protein. In another embodiment, the compound or factor is an activator of FGF receptor. In another embodiment, the compound or factor is an inhibitor of a protein that suppresses an activity of the FGF protein or FGF receptor. In another embodiment, the protein that is inhibited is an FGF binding protein. In another embodiment, the protein that is inhibited is FGF-bp1. Each possibility represents a separate embodiment of the present invention.
  • Is provided herein, FGF and its receptor are upregulated, under the conditions utilized herein, upon HF stem cell differentiation (Example 9). Moreover, FGF-bp1 is downregulated, under the conditions utilized herein, upon HF stem cell differentiation. Thus, FGF and its receptor promote differentiation of uncommitted epidermal cells into HF cells.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is an ectodysplasin protein (referred to, in another embodiment, as “eda”; in another embodiment, as “ectodermodysplasin protein.”) In another embodiment, the ectodysplasin protein is Eda-A1. In another embodiment, the compound or factor is an ectodysplasin receptor (referred to, in another embodiment, as “edar”). In another embodiment, the compound or factor is an activator of an ectodysplasin protein. In another embodiment, the compound or factor is an activator of an ectodysplasin receptor. In another embodiment, the compound or factor is an inhibitor of a protein that suppresses an activity of the ectodysplasin protein or ectodysplasin receptor. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the eda protein of methods and compositions of the present invention has the sequence:
  • MGYPEVERRELLPAAAPRERGSQGCGCGGAPARAGEGNSCLLFLGFFGLSLALHLLTLCC YLELRSELRRERGAESRLGGSGTPGTSGTLSSLGGLDPDSPITSHLGQPSPKQQPLEPGEAA LHSDSQDGHQMALLNFFFPDEKPYSEEESRRVRRNKRSKSNEGADGPVKNKKKGKKAGP PGPNGPPGPPGPPGPQGPPGIPGIPGIPGTTVMGPPGPPGPPGPQGPPGLQGPSGAADKAGT RENQPAVVHLQGQGSAIQVKNDLSGGVLNDWSRITMNPKVFKLHPRSGELEVLVDGTYFI YSQVEVYYINFTDFASYEVVVDEKPFLQCTRSIETGKTNYNTCYTAGVCLLKARQKIAVK MVHADISINMSKHTTFFGAIRLGEAPAS (GenBank Accession No: NM_001399; SEQ ID No: 274). In another embodiment, the eda protein has a sequence selected from the sequences set forth in GenBank entries NM_001005609, NM_001005610, NM_001005611, NM_001005612, NM_001005613, NM_001005614, NM_001005615, AF040628, AF061194, AF061193, AF061192, AF061191, AF061190, AF061189, and AF060999. In another embodiment, the eda protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of an Eda protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the edar protein of methods and compositions of the present invention has the sequence:
  • MAHVGDCTQTPWLPVLVVSLMCSARAEYSNCGENEYYNQTTGLCQECPPC
    GPGEEPYLSCGYGTKDEDYGCVPCPAEKFSKGGYQICRRHKDCEGFFRAT
    VLTPGDMENDAECGPCLPGYYMLENRPRNIYGMVCYSCLLAPPNTKECVG
    ATSGASANFPGTSGSSTLSPFQHAHKELSGQGHLATALIIAMSTIFIMAI
    AIVLIIMFYILKTKPSAPACCTSHPGKSVEAQVSKDEEKKEAPDNVVMFS
    EKDEFEKLTATPAKPTKSENDASSENEQLLSRSVDSDEEPAPDKQGSPEL
    CLLSLVHLAREKSATSNKSAGIQSRRKKILDVYANVCGVVEGLSPTELPF
    DCLEKTSRMLSSTYNSEKAVVKTWRHLAESFGLKRDEIGGMTDGMQLFDR
    ISTAGYSIPELLTKLVQIERLDAVESLCADILEWAGVVPPASQPHAAS
    (GenBank Accession No: BC093872; SEQ ID No: 275).

    In another embodiment, the edar protein has a sequence selected from the sequences set forth in GenBank entries BC093870; BC034919; NM_021783; NM_022336; AY152724; AF298812; AH008077; AF130996; AF130988. In another embodiment, the edar protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of an Edar protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Noggin protein. In another embodiment, the compound or factor is a nucleotide encoding a Noggin protein. In another embodiment, the compound or factor is an activator of a Noggin protein. In another embodiment, the compound or factor is an inhibitor of a protein that suppresses an activity of the Noggin protein. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the Noggin protein of methods and compositions of the present invention has the sequence:
  • MERCPSLGVTLYALVVVLGLRATPAGGQHYLHIRPAPSDNLPLVDLIEHPDPIFDPKEKDLN ETLLRSLLGGHYDPGFMATSPPEDRPGGGGGAAGGAEDLAELDQLLRQRPSGAMPSEIKGL EFSEGLAQGKKQRLSKKLRRKLQMWLWSQTFCPVLYAWNDLGSRFWPRYVKVGSCFSKR SCSVPEGMVCKPSKSVHLTVLRWRCQRRGGQRCGWIPIQYPIISECKCSC (GenBank Accession No: NM_005450; SEQ ID No: 276). In another embodiment, the Noggin protein has a sequence selected from the sequences set forth in GenBank entries BC034027 and U31202. In another embodiment, the Noggin protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of a Noggin protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Hedgehog protein. In another embodiment, the compound or factor is a nucleotide encoding a Hedgehog protein. In another embodiment, the compound or factor is an activator of a Hedgehog protein. In another embodiment, the compound or factor is a sonic Hedgehog protein. In another embodiment, the compound or factor is a nucleotide encoding a sonic Hedgehog protein. In another embodiment, the compound or factor is an activator of a sonic Hedgehog protein. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the Hedgehog protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. NM_000193. In another embodiment, the Hedgehog protein has a sequence selected from those set forth in GenBank entries L38518 and NP_000184. In another embodiment, the Hedgehog protein has any other Hedgehog sequence known in the art. In another embodiment, the Hedgehog protein has any other sonic Hedgehog sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a Transforming Growth Factor (TGF)-beta1 protein. In another embodiment, the compound or factor is a nucleotide encoding a TGF-beta1 protein. In another embodiment, the compound or factor is an activator of a TGF-beta1 protein. In another embodiment, the compound or factor is a TGF-beta3 protein. In another embodiment, the compound or factor is a nucleotide encoding a TGF-beta3 protein. In another embodiment, the compound or factor is an activator of a TGF-beta3 protein. In another embodiment, the compound or factor is an antagonist of a TGF-beta1 protein. In another embodiment, the compound or factor is an antagonist of a TGF-beta3 protein. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the TGF-beta1 protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. BC000125. In another embodiment, the Hedgehog protein has a sequence selected from those set forth in GenBank entries BC001180, BC022242, and NM_000660. In another embodiment, the TGF-beta1 protein has any other TGF-beta1 sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the TGF-beta3 protein of methods and compositions of the present invention has the sequence set forth in GenBank Accession No. J03241. In another embodiment, the Hedgehog protein has a sequence selected from those set forth in GenBank entries NM_003239, BC018503, BT007287 and X14149. In another embodiment, the TGF-beta3 protein has any other TGF-beta3 sequence known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell acts directly on the uncommitted epidermal cell. In another embodiment, the compound or factor acts on the uncommitted epidermal cell via a mesenchymal cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the mesenchymal cell is a dermal condensate cell. In another embodiment, the mesenchymal cell is a DP cell. In another embodiment, the mesenchymal cell is another cell type or differentiation stage in the dermal condensate-DP lineage. In another embodiment, the mesenchymal cell is any other type of mesenchymal cell known in the art. Each possibility represents a separate embodiment of the present invention.
  • The EGFR of methods and compositions of the present invention has, in another embodiment, the sequence:
  • MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCE VVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAG CTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRN YVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKH FKNCTSIS GDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFE NLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTS GQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEG EPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNT LVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIG LFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVY KGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLI TQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKT PQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWE LMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFS K MARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTS RTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYIN QSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSP AHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA (GenBank Accession No: NM_005228; SEQ ID No: 277). In another embodiment, the EGFR has a sequence selected from the sequences set forth in GenBank entries NM_201282, NM_201283, NM_201284, BC094761, AF288738, AY588246, AY573061, X17054, AF125253, U48722, K03193, and AY698024. In another embodiment, the EGFR is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of an EGFR is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • The EGF of methods and compositions of the present invention has, in another embodiment, the sequence:
  • MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRIDTEGT NYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSGMAIN WINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAGSLYRAD LDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHISKHPTQHN LFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHPLAQPKAEDD TWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNECAFWNHGCT LGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPLCFCPEGSVL ERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASGPQPFLLFANS QDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERANMDGSQRERL IEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQPRGIAVHPMAKR LFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCDAKQSVIEMANLDGS KRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVIRVNKRTGKDRVRLQGSMLKPSSLVV VHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTCLALDGHQLLAGG EVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGCSMYARCISEGEDA TCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCSEGYQGDGIHCLDID ECQLGVHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHLREDDHHYSVRNSDSE CPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELRHAGHGQQQKV IVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRSRRPADTEDGMSSC PQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGMGTEQGCWIPVSS DKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPPHQMELTQ (GenBank Accession No: NM_001963; SEQ ID No: 278). In another embodiment, the EGF has a sequence selected from the sequences set forth in GenBank entries BC093731, AY548762, and X04571. In another embodiment, the EGF is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of an EGF is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • The beta-catenin protein of methods and compositions of the present invention has, in another embodiment, the sequence:
  • MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDT SQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHP TNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQL S KKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPA LVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTD CLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAG GMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCA AGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEM AQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLV RAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQL LYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMS EDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGY GQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL (GenBank Accession No: NM_001904; SEQ ID No: 279). In another embodiment, the beta-catenin protein has a sequence selected from the sequences set forth in GenBank entries BC058926, X87838, AF130085, AB062292, Z19054, and NP_001895. In another embodiment, the beta-catenin protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of a beta-catenin protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • The Wnt protein of methods and compositions of the present invention has, in another embodiment, the sequence:
  • MNRKARRCLGHLFLSLGMVYLRIGGFSSVVALGASIICNKIPGLAPRQRAICQSRPDAIIVIG EGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAITAAC TQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLMNL HNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVR ASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASG CDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK (GenBank Accession No: BC008811; SEQ ID No: 280). In another embodiment, the Wnt protein has a sequence selected from the sequences set forth in GenBank entries NM_004625, D83175, U53476, and NP_004616. In another embodiment, the Wnt protein is a Wnt7 protein. In another embodiment, the Wnt protein is a Wnt7a protein. In another embodiment, the Wnt protein is Wnt1 protein. In another embodiment, the Wnt protein is a Wnt3 protein. In another embodiment, the Wnt protein is a Wnt3a protein. In another embodiment, the Wnt protein is a Wnt10 protein. In another embodiment, the Wnt protein is a Wnt10a protein. In another embodiment, the Wnt protein is a Wnt10b protein. In another embodiment, the Wnt protein is encoded by a nucleic acid molecule having a sequence set forth in the one of the above GenBank entries. In another embodiment, a biologically active fragment of a Wnt protein is utilized in a method of the present invention. In another embodiment, a biologically active fragment of a Wnt7 protein is utilized in a method of the present invention. In another embodiment, a biologically active fragment of a Wnt7a protein is utilized in a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a protein encoded by a ribonucleic acid (RNA) molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-232. In another embodiment, the compound or factor is an RNA molecule having a sequence selected from SEQ ID No: 1-232. In another embodiment, the RNA molecule is homologous to a sequence selected from SEQ ID No: 1-232. In another embodiment, the RNA molecule is an isoform of a sequence selected from SEQ ID No: 1-232. In another embodiment, the compound or factor increases an activity of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 1-232. In another embodiment, the compound or factor increases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 1-232. Each possibility represents a separate embodiment of the present invention.
  • As provided herein, the transcripts depicted in Table 3 (Example 8; SEQ ID No: 1-232), the proteins they encode, and the pathways in which the proteins participate contribute significantly to HF stem cell activation. Accordingly, under the conditions utilized herein, anagen can be induced by activation of these transcripts, proteins, and pathways. Activation of the transcripts, proteins, and pathways depicted in Table 3 is thus a method for enhancing EDIHN. In another embodiment, activation of these transcripts, proteins, and pathways represents a method for enhancing hair growth in a subject.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 233-257. In another embodiment, the compound or factor is an RNA molecule having a sequence selected from SEQ ID No: 233-257. In another embodiment, the RNA molecule is homologous to a sequence selected from SEQ ID No: 233-257. In another embodiment, the RNA molecule is an isoform of a sequence selected from SEQ ID No: 233-257. In another embodiment, the compound or factor increases an activity of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 233-257. In another embodiment, the compound or factor increases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 233-257. Each possibility represents a separate embodiment of the present invention.
  • As provided herein, the transcripts depicted in Table 4 (Example 9; SEQ ID No: 233-257), the proteins they encode, and the pathways in which the proteins participate, contribute significantly, under the conditions utilized herein, to induction of epidermal cells to differentiate into HF stem cells. Activation of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for enhancing EDIHN. In another embodiment, activation of these transcripts, proteins, and pathways represents a method for enhancing hair growth in a subject.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a compound or factor that decreases an activity of a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 258-273. In another embodiment, the compound or factor decreases an expression or level of a protein encoded by an RNA molecule having a sequence selected from SEQ ID No: 258-273. Each possibility represents a separate embodiment of the present invention.
  • As demonstrated by findings of the present invention, the transcripts depicted in Table 5 (Example 9; SEQ ID No: 258-273), the proteins they encode, and the pathways in which the proteins participate, contribute significantly, under the conditions utilized herein, to preventing induction of epidermal cells to differentiate into HF stem cells. Inhibition of the transcripts, proteins, and pathways depicted in Table 5 is thus a method for enhancing EDIHN. In another embodiment, inhibition of these transcripts, proteins, and pathways represents a method for induction of hair growth in a subject.
  • In one embodiment, the compound that modulates a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 233-273 or the nucleic acid encoding same is administered before the compound that modulates a protein encoded by an RNA molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-232 or the nucleic acid encoding same. In another embodiment, the two compounds are administered simultaneously. Each possibility represents a separate embodiment of the present invention.
  • In one embodiment, a protein encoded by an RNA sequence selected from SEQ ID No: 1-273, or a compound that modulates the protein, is administered before other proteins encoded by same or compounds that modulate them, in order to further enhance their effect in generating an HF or stimulating hair growth. In another embodiment, the wnt pathway is stimulated before the hedgehog pathway. In another embodiment, the two pathways are stimulated in an overlapping fashion. In another embodiment, the two pathways are stimulated simultaneously. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, activating or decreasing expression of an RNA transcript in methods of the present invention occurs via a transcription mechanism (e.g. activation of expression of the RNA). In another embodiment, activating or decreasing expression of the RNA transcript occurs via a translational mechanism. In another embodiment, activating or decreasing expression of the RNA transcript occurs via a post-translational mechanism. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the nucleic acid molecule utilized in methods of the present invention is a deoxyribonucleic acid (DNA) molecule that encodes an RNA molecule having a sequence selected from the sequences set forth in the present invention.
  • In one embodiment, an RNA molecule of the present invention encodes a protein that plays a role in HF regeneration. In another embodiment, the RNA molecule is itself catalytically active, e.g., a ribozyme, etc. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is a compound or factor that promotes placodal cell fate. As provided herein, factors that promote placodal cell fate enhance EDIHN, as exemplified in the Examples herein. In another embodiment, the compound or factor acts at the placode stage of HF development.
  • In another embodiment, the compound or factor inhibits a biological factor that inhibits a differentiation of an uncommitted epithelial cell into an HF cell.
  • In another embodiment of methods and compositions of the present invention, a composition comprising one of the above compounds or factors is administered. Each of the above types of compounds, factors, and compositions represents a separate embodiment of the present invention.
  • In one embodiment, the present invention provides a method for generating an HF in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with minoxidil, thereby generating an HF in a scalp, eyebrow, or scarred region of a subject.
  • In one embodiment, the present invention provides a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with minoxidil, thereby treating baldness in a scalp, eyebrow, or scarred region of a subject.
  • In another embodiment, the present invention provides a use of minoxidil for the preparation of a pharmaceutical composition for use in a method for an HF in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the minoxidil.
  • In another embodiment, the present invention provides a use of minoxidil for the preparation of a pharmaceutical composition for use in a method for treating baldness in a scalp, eyebrow, or scarred region of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the minoxidil.
  • In another embodiment, the present invention provides a method for removal of an HF from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing an HF from a skin or scalp of a subject.
  • In another embodiment, the present invention provides a method for hair removal from a skin or scalp of a subject, comprising the steps of: (a) disrupting an epidermis of the skin or scalp; and (b) contacting the skin or scalp with either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, thereby removing hair from a skin or scalp of a subject. In another embodiment, the epidermal disruption is light dermabrasion. In another embodiment, the epidermal disruption is a non-scarring method. In another embodiment, administration of the EGF protein, EGF receptor, nucleotide, compound, or factor suppresses HF formation. In another embodiment, the EGF protein, EGF receptor, nucleotide, compound, or factor is administered within several days of healing. In another embodiment, the EGF protein, EGF receptor, nucleotide, compound, or factor is administered within about 1 day of healing. In another embodiment, the EGF protein, EGF receptor, nucleotide, compound, or factor is administered according to any of the timing embodiments enumerated herein for Dkk1 protein. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a use of either: (i) an EGF protein; (ii) an EGF receptor; (iii) a nucleotide encoding an EGF protein or EGF receptor; or (iv) a compound or factor that activates a EGF protein or EGF receptor, for the preparation of a pharmaceutical composition for use in a method for removal of an HF from a skin or scalp of a subject, the method comprising the steps of: (a) disrupting an epidermis of the scalp, eyebrow, or scarred region; and (b) contacting the scalp, eyebrow, or scarred region with the EGF protein, EGF receptor, nucleotide, compound, or factor.
  • In another embodiment, a composition or method of the present invention is utilized on human skin. In another embodiment, the composition or method is utilized on an area of unwanted hair growth. In another embodiment, the area is the face. In another embodiment, the area is the bikini area. In another embodiment, the area is the legs. In another embodiment, the area is the arms. In another embodiment, the area is the chest.
  • An “inhibitor” utilized in methods and compositions of the present invention is, in another embodiment, an antibody that binds the protein or biological factor that is the target of the inhibitor. In another embodiment, the inhibitor is a pharmacologic inhibitor. In another embodiment, the inhibitor is any other type of inhibitor known in the art. Each possibility represents a separate embodiment of the present invention.
  • The step of disrupting the epidermis in methods of the present invention is performed, in another embodiment, by abrading the scalp, eyebrow, or scarred region. In another embodiment, the term “abrading” refers to an act of creating an abrasion. In another embodiment, “abrading” refers to rubbing. In another embodiment, “abrading” refers to wearing away by friction. As provided herein (Example 1), epidermal abrasion causes, under the conditions utilized herein, de novo HF neo-genesis. In another embodiment, the epidermal layer is disrupted.
  • In one embodiment, “abrasion” has the same meaning as “abrading.” In another embodiment, “abrasion” refers to an area of the scalp or skin from which the epidermis is removed. In another embodiment, “abrasion” refers to an area of the scalp or skin from which the epidermis and dermis are removed. Each definition of “abrading” and “abrasion” represents a separate embodiment of the present invention.
  • As provided herein, under the conditions utilized, epidermal disruption by a method of the present invention converts the skin back, in another embodiment, to an embryonic-like state, in which the follicle regenerates. In another embodiment, a subsequent window of opportunity is created, during which the number and size of new HF in the skin can be manipulated. In another embodiment, the administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell during this window causes regeneration of larger and more numerous HF. The morphology of HF in abraded skin is similar to that of embryonic HF (Example 1-2 and subsequent Examples), and the markers expressed are similar as well.
  • In another embodiment, the present invention provides a method of stimulating hair growth in a scalp, eyebrow, or scarred region of a subject, comprising performing a method of present invention, thereby stimulating hair growth in a scalp, eyebrow, or scarred region of a subject. As demonstrated in Example 3, EDIHN-induced HF are capable of generating hairs. Thus, methods of the present invention can be used to stimulate hair growth.
  • “EDIHN,” in another embodiment, refers to HF neogenesis induced by disruption of the epithelial layer. In another embodiment, the term refers to HF neogenesis induced by abrasion. In another embodiment, the term refers to HF neogenesis induced by wounding. In another embodiment, the term refers to HF neogenesis induced by disruption of the epithelial layer, followed by administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method of testing an ability of a compound to modulate HF generation in vivo, comprising (a) disrupting an epithelial layer of a first scalp, eyebrow, or scarred region, whereby the first scalp, eyebrow, or scarred region has been contacted with the compound; (b) measuring a first HF generation in the first scalp, eyebrow, or scarred region; (c) disrupting an epithelial layer of a second scalp, eyebrow, or scarred region, wherein the second scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of the first subject or a second subject, whereby the second scalp, eyebrow, or scarred region has not been contacted with the compound; (d) measuring a second HF generation in the second scalp, eyebrow, or scarred region; and (e) comparing the first HF generation to the second HF generation, whereby a difference between the first HF generation and the second HF generation indicates that the compound modulates an HF generation in vivo (Examples).
  • In another embodiment, the present invention provides a method of testing an ability of a compound to stimulate hair growth in vivo, comprising disrupting an epithelial layer of a first scalp, eyebrow, or scarred region, whereby the first scalp, eyebrow, or scarred region has been contacted with the compound; measuring a first HF generation in the first scalp, eyebrow, or scarred region; disrupting an epithelial layer of a second scalp, eyebrow, or scarred region, whereby the second scalp, eyebrow, or scarred region has not been contacted with the compound; measuring a second HF generation in the second scalp, eyebrow, or scarred region; and comparing the first HF generation to the second HF generation, whereby a difference between the first HF generation and the second HF generation indicates that the compound stimulates a hair growth in vivo.
  • In one embodiment, the methods of the present invention of testing a compound are repeated using a plurality of subjects, until a statistically significant sample has been tested.
  • In another embodiment of methods for testing compounds of the present invention, the first scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of a first subject. In another embodiment, the subject is a subject in need of generation of a new HF. The second scalp, eyebrow, or scarred region, in another embodiment, is a scalp, eyebrow, or scarred region of the first subject. In another embodiment, the second scalp, eyebrow, or scarred region is a scalp, eyebrow, or scarred region of a second subject. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the excisional wounds of methods of the present invention are created using a surgical tool. In one embodiment, the surgical tool is a dermal biopsy punch (Example 2). In another embodiment, the excisional wounds are induced by freezing or cryoinjury. The use of freezing or cryoinjury is well known in the art, and is used, for example by dermatologists to injure skin. In one embodiment, the freezing or cryoinjury results in a blister. In another embodiment, the blister is used as a “chamber” to introduce drugs and or cells into the reepithelialized area. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the excisional wounds of methods of the present invention are not surgically closed. In another embodiment, the excisional wounds are not contacted with a bandage or dressing before they heal or during a period of time after wound induction. In another embodiment, the excisional wounds are not contacted with an ointment before they heal or during a period of time after wound induction. In another embodiment, the excisional wounds are allowed to heal by secondary intention. Each possibility represents a separate embodiment of the present invention.
  • The subject of methods of the present invention, is, in another embodiment, a human. As provided herein (Example 7) human skin responds to EDIHN in the same manner as mouse skin. In another embodiment, the subject is a male. In another embodiment, the subject is a female. In another embodiment, the subject is any other type of subject known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the subject is an adult. In one embodiment, “adult” refers to an age greater than about 18 years. In another embodiment, “adult” refers to an age greater than about 20 years. In another embodiment, “adult” refers to an age greater than about 25 years. In another embodiment, “adult” refers to an age greater than about 30 years. In another embodiment, “adult” refers to an age greater than about 35 years. In another embodiment, “adult” refers to an age greater than about 40 years. In another embodiment, “adult” refers to an age greater than about 45 years.
  • In another embodiment, the subject is elderly. In one embodiment, “elderly” refers to an age greater than about 45 years. In another embodiment, “elderly” refers to an age greater than about 50 years. In another embodiment, “elderly” refers to an age greater than about 55 years. In another embodiment, “elderly” refers to an age greater than about 60 years. In another embodiment, “elderly” refers to an age greater than about 65 years. In another embodiment, “elderly” refers to an age greater than about 70 years.
  • In another embodiment, the first subject, or, where applicable, both the first subject and the second subject, is a laboratory animal. In another embodiment, the subject(s) is/are mice. In another embodiment, the subject(s) is/are rats. In another embodiment, the subject(s) is/are gerbils. In another embodiment, the subject(s) is/are hamsters. In another embodiment, the subject(s) is/are guinea pigs. In another embodiment, the subject(s) is/are rabbits. In another embodiment, the subject(s) is/are pigs. In another embodiment, the subject(s) is/are dogs. In another embodiment, the subject(s) is/are cats. In another embodiment, the subject(s) is/are primates. In another embodiment, the subject(s) is/are any other laboratory animal known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the subject(s) has a disease or disorder comprising balding. In another embodiment, the subject(s) does not have a disease or disorder comprising balding. In another embodiment, the disease or disorder is androgenetic alopecia (AGA). In another embodiment, the disease or disorder is male pattern baldness. In another embodiment, the disease or disorder is female pattern baldness. In another embodiment, the disease or disorder is a discoid lupus erythematosis. In another embodiment, the disease or disorder is a congenital hypotrichosis. In another embodiment, the disease or disorder is a lichen planopilaris. In another embodiment, the disease or disorder is a scarring alopecia. In another embodiment, the disease or disorder is any other disease or disorder comprising balding known in the art.
  • In another embodiment, the scalp, eyebrow, or scarred region(s) has a majority of HF in the telogen stage of the hair cycle. The findings of Examples 5-6 show that (a) EDIHN can restore hair growth to the scalp, eyebrow, or scarred region at the telogen stage; and (b) the efficiency of EDIHN at the telogen stage can be enhanced by depilation prior to abrasion or wound induction. In another embodiment, the scalp, eyebrow, or scarred region(s) has more than about 60% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) has more than about 70% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) has more than about 80% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) has more than about 90% of HF in the telogen stage of the hair cycle. In another embodiment, the scalp, eyebrow, or scarred region(s) does not have a majority of HF in the telogen stage of the hair cycle. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment of methods and compositions of the present invention, the first step (e.g. epithelial disruption) is performed 3-12 days prior to the second step (e.g. addition of an active compound, factor, cell, etc). In another embodiment, the interval is 4-12 days. In another embodiment, the interval is 5-12 days. In another embodiment, the interval is 4-11 days. In another embodiment, the interval is 6-11 days. In another embodiment, the interval is 6-10 days. In another embodiment, the interval is 6-9 days. In another embodiment, the interval is 6-8 days. In another embodiment, the interval is 7-8 days. In another embodiment, the interval is 5-11 days. In another embodiment, the interval is 5-10 days. In another embodiment, the interval is 7-10 days. In another embodiment, the interval is about 1 week. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of suppressing an activity or expression of a Wnt protein in the scalp, eyebrow, or scarred region. As provided herein, suppressing Wnt activity induces pigmentation in HF generated by methods of the present invention. In another embodiment, the step of suppressing Wnt activity or expression is performed within about 10 days of epidermal disruption. In another embodiment, the step of suppressing Wnt activity or expression is performed prior to the second step (e.g prior to addition of a compound or factor that promotes HF cell differentiation. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for inducing pigmentation of a hair, comprising suppressing expression of a Wnt protein in a follicle of the hair. In another embodiment, the Wnt protein is Wnt1. In another embodiment, the Wnt protein is a Wnt7. In another embodiment, the Wnt protein is a Wnt7a. In another embodiment, the Wnt protein is a Wnt3. In another embodiment, the Wnt protein is a Wnt3a. In another embodiment, the Wnt protein is a Wnt10. In another embodiment, the Wnt protein is a Wnt10a. In another embodiment, the Wnt protein is any other Wnt protein known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method for inducing growth of a pigmented scalp hair or eyebrow of a subject, comprising generating a hair follicle in the scalp, eyebrow, or scarred region according to a method of the present invention and suppressing expression of a Wnt protein in the hair follicle, thereby inducing a growth of a pigmented scalp hair or eyebrow of a subject.
  • In another embodiment, the step of suppressing expression of a Wnt protein comprises inducing an expression of a Dkk1 protein. In another embodiment, the step of suppressing expression of a Wnt protein comprises inducing an expression of any other Wnt inhibitor known in the art. In another embodiment, the step of suppressing expression of a Wnt protein is performed immediately or shortly after epidermal disruption. In another embodiment, the step of inducing expression of a Dkk1 protein is performed immediately or shortly after epidermal disruption. In another embodiment, the step of suppressing expression of a Wnt protein is performed at the time of epidermal disruption. In another embodiment, the step of inducing expression of a Dkk1 protein is performed at the time of epidermal disruption. In another embodiment, the step of suppressing expression of a Wnt protein is performed several days before generation of the follicle. In another embodiment, the step of inducing expression of a Dkk1 protein several days before generation of the follicle. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 8 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 8 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 9 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 9 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 10 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 10 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed for about 12 days. In another embodiment, the step of inducing expression of a Dkk1 protein is performed for about 12 days. In another embodiment, the step of suppressing expression of a Wnt protein is performed during the period of re-epithelialization. In another embodiment, the step of inducing expression of a Dkk1 protein is performed during the period of re-epithelialization. In another embodiment, expression of a Dkk1 protein is halted after several days. In another embodiment, halting expression of Dkk1 protein after several days induces, or enables induction of Wnt protein expression. In another embodiment, the expression of a Wnt protein is induced about 9 days after the abrating or wounding. In another embodiment, the expression of a Wnt protein is induced following the period of re-epithelialization. In another embodiment, induction of Wnt protein expression is necessary for formation of new HF. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, “several” refers to about 1 day. In another embodiment, “several” refers to about 2 days. In another embodiment, “several” refers to about 3 days. In another embodiment, “several” refers to about 5 days. In another embodiment, “several” refers to about 7 days. In another embodiment, “several” refers to about 10 days. In another embodiment, “several” refers to about 12 days. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the step of contacting in methods of the present invention comprises directly contacting the scalp, eyebrow, or scarred region with the compound, RNA, protein, etc. In another embodiment, the step of contacting comprises indirectly contacting the scalp, eyebrow, or scarred region via contacting another site or tissue of the subject, after which the compound, RNA, or protein is transported to the scalp, eyebrow, or scarred region by a biological process; e.g, diffusion, active transport, or circulation in a fluid such as the blood, lymph, interstitial fluid, etc. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal disruption in methods of the present invention further removes dermal tissue from the scalp, eyebrow, or scarred region. In another embodiment, the epidermal disruption does not remove dermal tissue from the scalp, eyebrow, or scarred region. Each possibility represents a separate embodiment of the present invention.
  • “Disrupting” an epidermis or epidermal layer refers, in another embodiment, to removing part of the epidermis or epidermal layer. In another embodiment, the term refers to disturbing the intactness of the epidermis or epidermal layer. In another embodiment, the term refers to perforating the epidermis or epidermal layer. In another embodiment, only part of the epidermal layer need be removed. In another embodiment, the entire epidermal layer is removed. In another embodiment, the term refers to abrading the epidermis or epidermal layer (Examples). In another embodiment, the term refers to wounding the epidermis or epidermal layer (Examples). Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal disruption is performed with a tool that comprises sandpaper. In another embodiment, the epidermal disruption is performed with a laser. In another embodiment, the laser is a Fraxel laser. In another embodiment, the laser is a CO2 laser. In another embodiment, the laser is an excimer laser. In another embodiment, the laser is any other type of laser capable of inducing trans-epithelial injury. In another embodiment, the epidermal disruption is performed with a felt wheel. In another embodiment, the epidermal disruption is performed with a surgical tool. In another embodiment, the epidermal disruption is performed with any other tool known in the art that is capable of epidermal disruption. In another embodiment, the epidermal disruption comprises use of a micro-dermabrasion device. In another embodiment, the epidermal disruption comprises a burn treatment.
  • In another embodiment, the epidermal disruption comprises a disruption of a follicle of said epidermis and a disruption of an interfollicular region of said epidermis. In another embodiment, the epidermal disruption comprises a disruption of a follicle of said epidermis and does not comprise a disruption of an interfollicular region of said epidermis. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal disruption comprises a light-based method. In another embodiment, the epidermal disruption comprises irradiation with visible light. In another embodiment, the epidermal disruption comprises irradiation with infrared light. In another embodiment, the epidermal disruption comprises irradiation with ultraviolet radiation. In another embodiment, the epidermal disruption comprises orthovoltage irradiation. In another embodiment, the epidermal disruption comprises X-ray irradiation. In another embodiment, the epidermal disruption comprises any other type of irradiation known in the art.
  • In another embodiment, the epidermal disruption is performed by mechanical means. In another embodiment, “mechanical means” refers to abrading. In another embodiment, the term refers to wounding. In another embodiment, the term refers to ultrasound. In another embodiment, the term refers to radio-frequency. In another embodiment, the term refers to an electrical process or the use of an electrical current. In another embodiment, the term refers to electoporation. In another embodiment, the term refers to exision. In another embodiment, the term refers to tape-stripping. In another embodiment, the term refers to microdermabrasion. In another embodiment, the term refers to the use of peels. In another embodiment, the term refers to any other type of mechanical means known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal disruption comprises chemical treatment. In another embodiment, the chemical is phenol. In another embodiment, the chemical is trichloracetic acid. In another embodiment, the chemical is ascorbic acid. In another embodiment, the chemical is any other chemical capable of epidermal disruption that is known in the art.
  • Each method or type of method of epidermal disruption represents a separate embodiment of the present invention.
  • In another embodiment, epidermal trauma is utilized in a method of the present invention.
  • Each type of epidermal abrasion and epidermal trauma represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal disruption of methods of the present invention creates an abrasion at least about 1-1.5 centimeters (cm) in width. In another embodiment, the abrasion is at least about 1 cm in width. In another embodiment, the abrasion is at least about 1.5 cm in width. In another embodiment, the abrasion is at least about 2 cm in width. Each type of abrasion represents a separate embodiment of the present invention.
  • In another embodiment, the scalp, eyebrow, or scarred region is not contacted with a bandage or dressing following the epidermal disruption. In another embodiment, the scalp, eyebrow, or scarred region is not contacted with an ointment following the epidermal disruption. In another embodiment, the scalp, eyebrow, or scarred region is allowed to heal for a period of time without being contacted by any substance, device, ointment, etc., that is ordinarily administered to an abrasion or wound to facilitate healing. In another embodiment, the scalp, eyebrow, or scarred region is allowed to heal for a period of time without being contacted by any substance, device, ointment, etc., that is ordinarily administered to an abrasion or wound to prevent infection. In another embodiment, the period of time is the time it takes the epidermal disruption to heal. In another embodiment, the period of time is any time or range of times between 2 days and 3 weeks. Each possibility represents a separate embodiment of the present invention.
  • In one embodiment, “following” refers to a period of time of about 2 days. In another embodiment, “following” refers to a period of time of about 3 days. In another embodiment, “following” refers to a period of time of about 4 days. In another embodiment, “following” refers to a period of time of about 5 days. In another embodiment, “following” refers to a period of time of about 7 days. In another embodiment, “following” refers to a period of time of about 10 days. In another embodiment, “following” refers to a period of time of about 2 weeks. In another embodiment, “following” refers to a period of time of about 3 weeks. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of depilating the scalp, eyebrow, or scarred region. As provided herein, the findings of Example 6 show that the efficiency of EDIHN can be enhanced by depilation prior to abrasion or wound induction.
  • In another embodiment, the depilation is epilation. In another embodiment, the depilation comprises the step of waxing. In another embodiment, the depilation comprises the step of plucking. In another embodiment, the depilation comprises the use of an abrasive material. In another embodiment, the depilation comprises the use of a laser. In another embodiment, the depilation comprises the use of electrolysis. In another embodiment, the depilation comprises the use of a mechanical device. In another embodiment, the depilation comprises the use of thioglycolic acid. In another embodiment, the depilation comprises the use of any other method of depilation or epilation known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of administering a topical retinoid to the scalp, eyebrow, or scarred region. In one embodiment, the topical retinoid induces resting (telogen) HF in the scalp, eyebrow, or scarred region to enter anagen. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the additional step (depilation or administration of a retinoid) is performed prior to the step of disrupting the epidermis. In another embodiment, the additional step is performed following the step of disrupting the epidermis, but prior to the addition of the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell. In another embodiment, the additional step is performed concurrently with the addition of the differentiation-promoting compound or factor. In another embodiment, the additional step is performed following the addition of the differentiation-promoting compound or factor. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the additional step is performed between about two days and about three weeks before the step of abrading. In another embodiment, the additional step is performed about two days before the step of abrading. In another embodiment, the additional step is performed about three days before the step of abrading. In another embodiment, the additional step is performed about four days before the step of abrading. In another embodiment, the additional step is performed about one week before the step of abrading. In another embodiment, the additional step is performed about ten days before the step of abrading. In another embodiment, the additional step is performed about two weeks before the step of abrading. In another embodiment, the additional step is performed about three weeks before the step of abrading. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the methods of the present invention further comprise the step of contacting the scalp, eyebrow, or scarred region with an inductive cell capable of inducing an epidermal cell to differentiate into an HF cell. In another embodiment, the HF cell is an HF stem cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the inductive cell is a dermal papilla cell. In another embodiment, the inductive cell is a follicular papilla cell. In another embodiment, the inductive cell is a dermal sheath cell. In another embodiment, the inductive cell is a cell that has been genetically modified; for example, with a gene encoding a factor that activates one of the proteins or pathways shown in the present invention to be up-regulated in HF stem cells. In one embodiment, the factor is hedgehog. In another embodiment, the factor is a DP cell protein. In another embodiment, the factor is wingless/int (wnt). In another embodiment, the factor is a Noggin protein. In another embodiment, the factor is a bone morphogenic protein (BMP). In another embodiment, the factor is a fibroblast growth factor (FGF). In another embodiment, the factor is a transforming growth factor beta (TGF-beta) protein. In another embodiment, the factor is sonic hedgehog protein. In another embodiment, the factor is a neurotropin. In another embodiment, the factor is any other factor known in the art that can contribute to induction of an epidermal cell to differentiate into an HF cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the inductive cell has been genetically modified with a gene encoding a factor that represses one of the proteins or pathways shown in the present invention to be down-regulated in HF stem cells. In another embodiment, the inductive cell has been genetically modified with a gene encoding a factor that activates one of the proteins or pathways shown in the present invention to be up-regulated in HF stem cells upon their activation.
  • In another embodiment, the inductive cell is an autologous cell. In another embodiment, the inductive cell is an allogenic cell.
  • In another embodiment, the inductive cell is derived from a mesenchymal stem cell. In another embodiment, the inductive cell is derived from a mesodermal progenitor cell. In another embodiment, the inductive cell is derived from a hematopoietic stem cell. In another embodiment, the inductive cell is derived from an embryonic stem cell. In another embodiment, the inductive cell is derived from an embryonic carcinoma cell. In another embodiment, the inductive cell is one of the cell types disclosed in United States Patent Application No. 2003/0201815. In another embodiment, the inductive cell is any other type of cell known in the art with inductive properties for an epidermal cell. Each type of inductive cell represents a separate embodiment of the present invention.
  • In another embodiment, the epidermal cell (e.g. the epidermal cell that is induced to differentiate into an HF cell) is an epidermal stem cell. In another embodiment, the epidermal cell is a bulge cell. In another embodiment, the epidermal cell is any other type of cell known in the art that can be induced to differentiate into an HF stem cell. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an anti-androgen compound. In one embodiment, the anti-androgen compound is finasteride. In another embodiment, the anti-androgen compound is Fluridil®. In another embodiment, the anti-androgen compound is dutasteride. In another embodiment, the anti-androgen compound is spironolactone. In another embodiment, the anti-androgen compound is cyproterone acetate. In another embodiment, the anti-androgen compound is bicalutamide. In another embodiment, the anti-androgen compound is flutamide. In another embodiment, the anti-androgen compound is nilutamide. In another embodiment, the anti-androgen compound is an inhibitor of an androgen receptor. In another embodiment, the anti-androgen compound is any other anti-androgen compound known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen compound. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen receptor agonist. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an estrogen analogue. In one embodiment, the estrogen analogue is estradiol. In another embodiment, the estrogen analogue is 17 beta-estradiol. In another embodiment, the estrogen analogue is 17 alpha-estradiol. In another embodiment, the estrogen analogue is ZYC3. In another embodiment, the estrogen compound, estrogen receptor agonist, or estrogen analogue is any other estrogen compound, estrogen receptor agonist, or estrogen analogue known in the art. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an inhibitor of an EGF protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an inhibitor of an EGFR. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a compound that reduces an expression of an EGF protein or an EGFR. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a Hedgehog protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a nucleotide encoding a Hedgehog protein. In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with an activator of a Hedgehog protein. Each possibility represents a separate embodiment of the present invention.
  • In one embodiment, a scalp is treated by a method of the present invention. In another embodiment, an eyebrow is treated. In another embodiment, any other hair-bearing area or region of the skin is treated. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with a lithium compound. In one embodiment, the lithium compound contains a lithium ion. In another embodiment, the lithium compound contains a lithium atom.
  • In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO). In another embodiment, a method of the present invention further comprises the step of contacting the scalp, eyebrow, or scarred region with any other compound known in the art that is capable of inducing an epidermal cell to differentiate into an HF stem cell. Each compound represents a separate embodiment of the present invention.
  • In one embodiment, the compound administered as part of methods of the present invention is administered systemically. In another embodiment, the compound is administered topically. In another embodiment, the compound is administered to the site of the abrasion. In another embodiment, the compound is administered to the site of the wound induction. In another embodiment, the compound is administered to the site of the depilation. In another embodiment, the compound is administered during wound healing. In another embodiment, the compound is administered prior to HF neo-genesis. In another embodiment, the compound is administered during HF neo-genesis. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a method of inducing formation of an HF stem cell, comprising performing a method of the present invention. In another embodiment, the present invention provides a method of inducing formation of a DP cell, comprising performing a method of the present invention. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, homologues and variants of transcripts and proteins of the present invention are administered in methods of the present invention. In another embodiment, homologues and variants of transcripts and proteins of the present invention are targeted in methods of the present invention. Each possibility represents a separate embodiment of the present invention.
  • The terms “homology,” “homologous,” etc, when in reference to any protein or peptide, refer in one embodiment, to a percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Methods and computer programs for the alignment are well known in the art.
  • In another embodiment, the term “homology,” when in reference to any nucleic acid sequence similarly indicates a percentage of nucleotides in a candidate sequence that are identical with the nucleotides of a corresponding native nucleic acid sequence.
  • In another embodiment, “homology” refers to identity of greater than 70%. In another embodiment, “homology” refers to identity of greater than 75%. In another embodiment, “homology” refers to identity of greater than 80%. In another embodiment, “homology” refers to identity of greater than 82%. In another embodiment, “homology” refers to identity of greater than 85%. In another embodiment, “homology” refers to identity of greater than 87%. In another embodiment, “homology” refers to identity of greater than 90%. In another embodiment, “homology” refers to identity of greater than 92%. In another embodiment, “homology” refers to identity of greater than 95%. In another embodiment, “homology” refers to identity of greater than 97%. In another embodiment, “homology” refers to identity of greater than 98%. In another embodiment, “homology” refers to identity of greater than 99%. In another embodiment, “homology” refers to identity of 100%.
  • Protein and/or peptide homology for any amino acid sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer algorithm analysis of amino acid sequences, utilizing any of a number of software packages available, via established methods. Some of these packages may include the FASTA, BLAST, MPsrch or Scanps packages, and may employ the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example. Each method of determining homology represents a separate embodiment of the present invention.
  • In another embodiment, the present invention provides a kit, comprising a tools and/or a compound suitable for performing a method of the present invention.
  • In another embodiment, the present invention provides a device, comprising a tool suitable for epidermal disruption and a means of delivering a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
  • In other embodiments, the present invention provides a method of treating any disease, disorder, or symptom associated with balding. In other embodiments, the present invention provides a method of treating any disease, disorder, or symptom associated with balding. In other embodiments, the present invention provides a method of treating any disease, disorder, or symptom associated with balding. Each disease, disorder, or symptom represents a separate embodiment of the present invention.
    • Pharmaceutical Compositions
  • In another embodiment, methods of the present invention comprise administering a pharmaceutical composition comprising the HF stem cell-inducing or -activating compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically acceptable carrier. Each possibility represents a separate embodiment of the present invention.
  • The pharmaceutical compositions containing the HF stem cell-inducing or -activating compound can, in another embodiment, be administered to a subject by any method known to a person skilled in the art, such as topically, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially, intravaginally or intratumorally. Each possibility represents a separate embodiment of the present invention.
  • In another embodiment, the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation. Suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like. Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In one embodiment of the present invention, the HF stem cell-inducing or -activating compounds are formulated in a capsule. In another embodiment, the compositions of the present invention comprise, in addition to the HF stem cell-inducing or -activating compound active compound and the inert carrier or diluent, a hard gelating capsule.
  • In another embodiment, the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration. Suitable topical formulations include gels, ointments, creams, lotions, drops and the like. For topical administration, the HF stem cell-inducing or -activating compound or its physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.
  • In another embodiment, the pharmaceutical compositions are administered by subcutaneous implantation of a pellet. In another embodiment, the pellet provides for controlled release of HF stem cell-inducing or -activating compound agent over a period of time.
  • For liquid formulations, pharmaceutically acceptable carriers are, in another embodiment, aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include, in another embodiment, water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
  • In one embodiment, the pharmaceutical compositions are controlled-release compositions, i.e. compositions in which the HF stem cell-inducing or -activating compound is released over a period of time after administration. Controlled- or sustained-release compositions include, in another embodiment, formulation in lipophilic depots (e.g. fatty acids, waxes, oils). In another embodiment, the composition is an immediate-release composition, i.e. a composition in which all the HF stem cell-inducing or -activating compound is released immediately after administration.
    • EXPERIMENTAL DETAILS SECTION Example 1 Depilation and Epidermal Abrasion Causes De Novo Hair Follicle Formation Materials and Experimental Methods Depilation and Epidermal Abrasion
  • Mice were anesthetized with an injection of sodium pentobarbital before the hair on the back was clipped and depilated with Nair (Carter-Wallace, New York, N.Y.), then epidermis was removed using a rotating felt wheel as described by Argyris T, J Invest Dermatol, 75: 360-362, 1980). After scrubbing with 70% ethanol and drying under an incandescent lamp, the basal and supra-basal layers in an area of (1.5 cm)2 cm of the inter-follicular epidermis were removed by careful abrasion with a felt wheel mounted on a Dremel Moto-tool (Racine, Wis.). After abrasion, the skin was shiny and smooth, and there was no blood. One day later, the abraded area was covered by a fibrin crust, which fell off after 3-7 days, exposing the newly regenerated epidermis. A group of control mice was sacrificed immediately after abrasion to confirm microscopically the complete removal of the interfollicular epidermis.
    • Immunohistochemistry
  • Skin samples were fixed in PBS-buffered 10% formalin. Six-micron thick paraffin sections were cut and stained, where applicable, with antibodies.
    • BrdU Labeling
  • The protocol described by Bickenbach and colleagues (Bickenbach et al, Cell Tiss Kinet 19: 325-333, 1986; Bickenbach et al, Exp Cell Res 244, 184-195, 1998) was used. Mice were injected with 50 milligrams per kilogram (mg/kg) bodyweight 5-bromo-2′-deoxyuridine (BrdU) every 12 hours for a total of four injections.
    • Results
  • An area of the backs of 50-day old mice was subjected to depilation and removal of the epidermis using a rotating felt wheel. Fifteen days later, HF placodes, hair germs and other signs of follicle neogenesis were present (FIG. 1; arrow indicates a hair germ). Morphology of the follicles was similar to embryonic follicle development. To further characterize proliferation in the new follicles, the skin was labeled with BrdU 60 minutes before sacrifice. As depicted in FIG. 2, the proliferation pattern was similar to developing follicles in the embryo.
  • These findings demonstrate that (a) disruption of the epidermis causes generation of new HF, and that this generation of new HF can occur (b) in adult subjects and (c) during telogen (50-day-old mice are in the second telogen stage of the hair cycle).
    • Example 2 Induction of a Large Excisional Wound, but not a Small Punch Wound, Causes De Novo Hair Follicle Formation Materials and Experimental Methods Punch Wound and Excisional Wound Induction
  • The backs of 21-day-old mice were depilated as described for Example 1 and sterilized with alcohol, followed by 1% iodine solution. Punch wounds, 4 mm in diameter, were induced using a dermal biopsy punch, down to, but not through, the muscle fascia. Excisional wounds were full thickness and 1 cm in diameter; skin and panniculus carnosus was excised using fine surgical scissors.
    • Results
  • To test whether wounding could induce HF formation, punch wounds or excisional wounds were induced in mice. Both types of wounds exhibited contraction and re-epithelialization following wound induction; however, unlike the mice receiving punch wounds, the mice receiving excisional wounds also exhibited scar formation within 10 days of wound induction (FIG. 3, left panel). No follicles were evident at this time point (FIG. 3, right panel). 12 days after wound induction, hair germs, with similar morphology to fetal hair germs, were observed in the wound site, following BrdU pulse labeling (FIG. 4). Several markers were used to verify that the observed structures were HF. The structures exhibited staining with anti-keratin 17 (K 17), an HF marker (FIG. 5), and staining with anti-alkaline phosphatase at the 12 day time point verified that the structures had dermal papilli containing fibroblasts, as expected for HF (FIG. 6; HF at earlier and later stages are depicted in the left and right panels, respectively).
  • The HF generated by wound induction were further characterized by morphological comparison to embryonic HF, following BrdU staining; a clear correspondence in morphology was observed at various stages (FIG. 7). In addition, several markers of embryonic HF development, namely Lef1, wingless/int (Wnt) 10b, and sonic hedgehog (Shh), were also induced in the epidermal disruption-induced HF neogenesis (EDIHN) (FIG. 8). Additional BrdU staining (FIG. 9) and staining for HF markers S100A3 and S100A6 (FIG. 10; left panel: tissue section parallel to HF axis; right panel: cross-sectional view of follicle) provided further verification that the development of the EDIHN follicles closely paralleled embryonic HF development.
  • These findings provide further evidence that disruption of the epidermis causes generation of new HF, and that this generation of new HF can occur (b) in adult subjects and (c) during telogen (21-day-old mice are in the first telogen stage of the hair cycle).
    • Example 3 EDIHN-Induced Hair Follicles Generate Hairs
  • At 25 and 45 days after wound induction, wound sites contained new hairs (FIG. 11, left and right panels, respectively). New hairs appeared to lack pigmentation, except when the wnt pathway was inhibited, using Dkk-1 (Dickkopf-1) during the first nine days after wounding (see Example 10).
  • These findings indicate that EDIHN-induced HF function normally; i.e. are capable of generating hairs.
    • Example 4 EDIHN Hair Follicles Retain the Ability to Enter into Cyclical Hair Growth Materials and Experimental Methods BrdU Labeling
  • 50 mg/kg bodyweight BrdU (Sigma) was injected twice per day for 3 days beginning 20 days after wounding. BrdU was detected 40 days after wounding (17 day chase).
    • Whole Mounting and Immunofluorescence
  • HF whole mounts were obtained by incubating fresh skin with EDTA (20 mM in PBS) at 37° C. overnight, then separating the epidermis and dermis. Epidermis was then fixed in 10% formalin for 10 min, room temperature (RT). Dermis was fixed in acetone overnight, RT. After rinsing with PBS, whole mounts were stained with antibodies for immunohistochemistry (schematically depicted in FIG. 12) and were imaged using a Leica confocal microscope.
    • Results
  • To determine whether EDIHN-induced HF contain normal levels of HF stem cells, mouse skin was examined for the presence of label-retaining cells at 21 days after wound induction. Retention of BrdU during a long chase period is, under these conditions, one of the hallmarks of HF stem cells. Normal numbers and placement of label-retaining cells (in the bulge of the HF) were observed (FIG. 13). To verify that the label-retaining cells were HF stem cells, K15-eGFP mice were utilized. In these mice, eGFP (enhanced green fluorescent protein) is expressed from the K15 promoter; thus, expression of eGFP identifies HF stem cells. As depicted in FIG. 14A, eGFP-expressing cells were observed in tissue sections (right side) of newly formed hair follicles 35 days following wound induction. eGFP-expressing cells were also seen in the epidermis whole mounts (bottom, far left panel) indicating the conversion of epidermal cells into cells with hair follicle stem cell characteristics. (panel is same as panel but viewed under white light) This finding shows that the observed label-retaining cells exhibited HF stem cell properties.
  • To determine whether EDIHN-induced HF cycle normally, mounts were prepared from additional mice at 35, 38 and 45 days after wounding. As depicted in FIG. 14B, the EDIHN-induced HF entered the resting phase, telogen, and then re-entered a new anagen stage.
  • In summary, the findings of this Example show that EDIHN-induced HF contain HF stem cells, as do embryonically generated HF. The presence of the HF stem cells shows that EDIHN-induced HF retain the ability to enter into cyclical hair growth in the same manner as embryonically generated HF. The findings also show that wounding induces epidermal cells to assume a hair follicle stem cell state (expressing K15-eGFP). This model is shown schematically in FIG. 15. The findings of Examples 2, 3, and 4 show that EDIHN-induced HF are fully functional and thus able to restore hair growth to a subject in need.
    • Example 5 EDIHN-Induces New Hair Follicles in Mice at the Telogen Stage of the Hair Cycle
  • To determine whether EDIHN was induced new hair follicles in mice wounded at the telogen stage of the hair cycle, 21-day-old mice were subjected to EDIHN using a 1-cm excisional wound, as described in Example 2. Skin was then examined by whole-mount assay for indications of new HF. As depicted in FIG. 16, after 11 days, new HF were not evident by macroscopic examination (top panel), AP staining of the dermis (bottom left panel), or K17 staining of the epidermis (bottom right panel). After 14 days, as depicted in FIG. 17, dermal papilla cells were detected in the dermis (left panel) and HF stem cells in the epidermis (right panel), demonstrating that new follicles were being formed. After 17 days, the new follicles were more developed, as shown by examination of the dermis and epidermis (FIG. 18, left and right panels, respectively). This method induced formation of an average of 49 new follicles in the wound, a number that was consistent over three separate experiments, as depicted in Table 1.
  • TABLE 1
    Results of three separate experiments
    performed on 21-day-old mice.
    Sample Expt 1 Expt 2 Expt 3 Avg of expts Std dev of expts
    1 24 70 55
    2 29 52 25
    3 27 85 53
    4 102 25 80
    5 53 27 23
    Average 47 51.8 47.2 48.67 2.71
    Std dev 32.8 26.3 23.7
  • The findings of this Example demonstrate that EDIHN is capable of inducing formation of new HF in mice at the telogen stage of the hair cycle, despite that fact that these mice do not contain HF at the anagen stage during wounding.
    • Example 6 In Adult Mice, Induction of Anagen Increases the Efficiency of EDIHN
  • The experiment described in Example 5 was repeated with mice of different ages, and therefore at different stages of the hair cycle. To ensure that wound scarring occurred, larger wounds were in induced in the older mice. As depicted in Table 2, adult mice at telogen, such as 8-week-old mice, exhibited lower efficiencies of HF formation by EDIHN.
  • TABLE 2
    Efficiency of HF formation by EDIHN in adult
    mice at various stages of the hair cycle.
    Wound Days after Mice exhibiting
    Age size wound EDIHN Hair cycle
    3 wk 1 cm 20 25/25 (100%) Telogen
    4 wk 1 cm 20 5/5 (100%) Early anagen
    5 wk 1 cm 20 1/2 (50%) Anagen
    8 wk 1.5 cm 30 16/35 (46%) Telogen
    14 wk 1.5 cm 30 1/2 (50%) N/A*
    20 wk 1.5 cm 30 2/2 (100%) N/A*
    *The second telogen lasts approximately 40 days in mice. Thus, 14-week-old and 20- week-old mice contained a mixture of telogen and anagen HF.
  • To determine whether experimental induction of anagen increased the efficiency of EDIHN, 8-week-old mice were depilated several days prior to wound induction. As depicted in FIG. 19, the wounds closed similarly whether or not they were preceded by depilation. As depicted in FIG. 20A-B, the depilated mice exhibited enhanced EDIHN relative to the non-depilated mice depicted in the previous Example by a factor of 11-fold.
  • The findings of this Example demonstrate that anagen induction enhances EDIHN. In addition, these findings show that EDIHN is capable of not only forming new HF, but also of activating anagen in pre-existing HF in the telogen stage.
    • Example 7 EDIHN-Induces New Hair Follicles in Human Skin Materials and Experimental Methods Grafting
  • Discarded human adult scalp from the preauricular area obtained from plastic surgery was grafted onto immunodeficient (scid) mice. The graft was bandaged and allowed to heal, then was used in the wound healing study 3 months after grafting.
    • Results
  • To determine whether human skin responded to EDIHN as did mouse skin, human skin was grafted onto SCID (immuno-deficient) mice and subjected to depilation by plucking and wound induction three days later. Seven days following wound induction, formation of new HF was observed in the human skin (FIG. 21A; arrows indicate new HF) by hematoxylin and eosin staining of paraffin embedded tissue sections.
  • In additional experiments, adult human skin was grafted onto mice, abraded, and examined at 7 days post-abrasion. New HF were generated in the human skin, which mimicked normal hair follicle formation during fetal development, as evidenced by staining for S100A6 or S100A4 (FIG. 21B).
  • The results of this Example show that EDIHN can be used to generate hair growth in human skin as for mouse skin.
    • Example 8 Molecular Pathways Activated During HF Stem Cell Activation Materials and Experimental Methods Isolation and Activation of HF Stem Cells
  • K15-eGFP mice were depliated in order to induce formation of new HF. Activated hair follicle stem cells were isolated from K15-eGFP mice using fluorescence-activated cell sorting (FACS) two days after depilation and 5 μg (micrograms) total RNA from the cell population was isolated, reverse-transcribed and hybridized to an Affymetrix (Santa Clara, Calif.) array MG_U74v2 chip. Scanned chip images were analyzed using Affymetrix Microarray Suite 5.0 and GeneSpring software (Silicon Genetics) to detect fold-change differences between activated HF stem cells (HFSCs) and non-activated (telogen) HFSCs. Values were normalized before computing fold-changes and differences between non-activated “bs-line” and activated (“expt”) samples.
    • Results
  • To identify molecular pathways up-regulated during HF stem cell activation, activated HF stem cells were isolated, and the gene expression patterns of the cells were analyzed to detect up-regulated transcripts. The transcripts depicted in Table 3 were up-regulated at least 2-fold in the activated HF stem cells relative to the cells prior to activation. In some cases, the sequence in Table 3 is a genomic sequence that contains the sequence of the transcript. Data pertaining to the up-regulation of the transcripts and further information about them is provided in FIG. 22.
  • TABLE 3 
    RNA transcripts up-regulated during HF stem cell activation.
    SEQ
    ID
    No: Access. # Sequence
    1 AW047343 uuuuuuuuuuuuuuuuucuuaaaaauauaaauguauuugucugcaucaugacguucuucg
    ggcaccuagcuggccagaccacuggccaugggacaaggaggaagucagguguaagucugag
    caaggaacaggacucugcccuggcaggguggagguggccucacagugucccaugcugggcc
    ugguagcgugaaagcacagcacgguagugggacagcuccugccgcacagccaccaccuccu
    gccgcaacagggcguuuuccuucuccaggaaggcagcccgcacagauauccgguucuccuu
    gagucuucuugcaucuc
    2 AF053235 Sequence below.
    caguuccucagcauggccaccugcagccgccaguucaccuccuccagcuccaugaagggcuccuguggcaucggugguggc
    ucuagccgcauguccuccauccuggcuggaggauccugccgggcucccagcaccugcgggggcaugucaguuaccuccucu
    cgcuucuccucugggggagucugugggauuggagguggcuauggugggagcuucagcagcagcaguuuugguggaggac
    uugguaguggauuugguggucgauuugauggauuugguggugguuuuggugcuggucuuggugguggucuuggcggu
    gguauuggugaugggcuccuggugggcagugagaaagugaccaugcagaaccucaaugaccgccuggccaccuaccuggac
    aaggugcgugcccuggaagaggccaacagagaccuggaggugaagauccgggacugguaccagaggcagcggcccacugag
    aucaaagacuacagccccuacuucaagaccauugaggaccugaagagcaagaucauuauugccacccaggagaaugcacagu
    ucacuuugcagauugacaaugccaggcuggcagcugaugacuucaggaccaaguacgagaaugagcuguucuugcggcagu
    ccguggagggugacaucaauggccugcgcaaggugcuagaugagcugacccuguccagagcugaccuggaaaugcagauug
    aaaaccucagagaagagcuggccuuccugaagaagaaccaugaggaggagaugcuugccuugaggggucagacuggugggg
    acgucaauguggagauggacgcagcccccgguguggaccucagccgcauucugaaugagaugagggaccaguaugagcaga
    uggcagagaagaaccgcagagauguggaggccugguuccugagaaagacugaggagcugaacaaagagguggccucuaaca
    gugaucuaauccagagcaaccgcagcgagguggcugagcuccgcaggguguuccagggccuggagauugaacugcaguccc
    agcucagcaugaaagcauccuuggagaacagccuagaagagaccaaaggcagauacuguaugcagcugucccagauccaggg
    uuugaucagcaguguggaggagcagcuggcucagcuucgcugcgagauggagcagcagagccaggaguacaacaucuugu
    uggaugugaagacaaggcuggagcaggagaucgccaccuaccgccgucugcuggauggcgagaauauccacuccuccucac
    agcacuccucuggacaguccuauucuucucgagaagucuucuccucauccucccgccagccccgguccauccucaaggagca
    agguucaaccagcuucagccagagccaaagucagaguuccagggacuaauguuuugccuagagccuccucacccacaacugc
    cucucaagcugagggcuuggggcaggacccuguuuucuuugcgcauuccccaucugucuccccuacccucucaugguggu
    aggcuaauaaagcuuuuugguugaugcaaaaaaaaaaaaaaaaaa
    3 M26005 gcgccaguccuccgauagacugagucgcccggguacccguguucucaauaaagccucuug
    cuguuugcauccgaaucguggucucgcugguccuugagagggucuccucagauugauugac
    uacccacgucgggggucuuucauuuggaggccccagcgagauuuggagaccccugcccagg
    gaccaccgaccccccgucgggagguaagcuggccagcggucguuucgugucugucucuguc
    uucgugcguguuugugccggcauuuaauguuugcgccugcgucuguacuaguuagcuaac
    uagaucuguaucuggcgguuccgcggaagaacugacgaguucguauucccggccgcagccc
    cugggagacgucccagcggccucgggggcccguuuuguggcccauucuguaucaguaacca
    cccgagucggacuuuuuggagcuccgccacuguacguggcuuuguugggggacgagagaca
    gagacacuucccgcccccgucugaauuuuugcuuucgguuuuacgccgaaaccgcgccgcg
    cgucugauuuguuuguuguucuuuuguucuucguuaguuuucuucugucuuuaaguguu
    uuucgagaucaugggacagaccguaacuaccccucugaguuuaaccuugcagcacugggga
    gauguccagcgcauugcauccaaccagucuguggaugucaagaagaggcgcuggauuaccu
    ucuguuccgcugaauggccaacuuucaaugugggauggccucaggaugguacuuucaauuu
    aaguauuaucucucagguuaagucuagaguguuuuguccugguccccacggacacccggau
    caggucccauauaucgucaccugggaggcacuugccuaugaccccccuccgugggucaaacc
    guuugugucuccuaaacuuccucccucgccgacagcucccguccucccgcccgguccuucug
    cgcaaccuccgucccgaucugcccuuuacccugcccuuacccccucuauaaaguccaaaccuc
    cuaagccccagguucucccugauagcggcggaccccucauugaccuucucacagaggaccuc
    ccgccguacggagcacaaccuuccuccucugccagagagaacgauaaagaagaggcggccac
    caccuccgagguuucccccccuucucccauggugucucgacugcggggaaggagagacccuc
    ccgcagcggacuccaucaucucccaggcauucccacuccgcauggggggagauggccagcuu
    caguacuggccguuuuccuccucugauuuaacccuuccuuuucugaagauccagguaaauu
    gacggccuuga
    4 AA681998 gacguagagccccuugcgcccgguuuccugaucccgcuuacuccucugcgcgccggcagga
    uggcccacaagcagaucuacuacucagacaaguacuucgaugagcacuacgaguaccggcau
    gucauguuacccagagaacucucuaaacaaguacccaaaacucaucugauguccgaagagga
    guggaggagacuugguguccaacagagucuaggauggguucauuacaugauucaugagcca
    gaaccgcauauucuucucuuuagacgaccucuuccaaaagaacaacaaaaaugaagugcagc
    ugggaucaucuaaucuuuuucaaauuuaauguauauguguauauaagguaguauucaguga
    auacuugaaaaguguacaaaccuuucauccauaccugugcaugcgcuguauucuucacagca
    acagagcucagucaaaugcaacugcaaguagg
    5 AF057156 atuaaaaagccagcugcccaaugccugcacacagaauccacaccaacagagaaccugcucuuc
    ucugaguauuagguaagucucugcuugcaacugauuugaaauucuugcuuauuuuuuuac
    uaugaaaaacuguucaaagccaacucuauuacagaguugauguggggugcugccuacaguu
    agugaacaguagcauuguuugcuuaaauuauagcacauuuugggucuaggaacuugagagg
    ugauucaguuggucacuguaguagacagccuuggaaucagagauuaaggcaaaaggaaacc
    uccauucaaauauucauggaaguucacagcuggagacagguuaaggcuucaguccagauag
    cuuucagaauuauugcaguucuuacugauaggcauaucaauagcgaaauuuaauuuauuag
    aggaaucuacuaaaguaaauuuuuaggccaauauagaacauaccauacuuguagucuggcag
    agaaggugacauaugaaauugaaaugcgauucauagacagugguagugaaagaaauaaugg
    uggggangggcugugcangggaggcauggcucaaggacagcacuuagugguagcacacacc
    augaacuaugauggaaaagcauuugauaggcagagacagaaauguaggaaauguguaggga
    uccaugagagcauaaacuaaaagggcaaaagcauaugagcauggacuaacaugcagccacuc
    ugcaaguuauacuaugaucuauuucacaaggagguugguaugcugcugucuuugggugac
    accgcuuucccagauguccugguguguagguucacaagccucucagaagccauacuuuauu
    gcuuuuuaagacguauuauuaauauuuuggcuagcauaugguuuagugugagaguuuuau
    augcauaugucauuauacuuugcucauuuaugucuuggaacuucuucaacuagguagaaaa
    caugaccagggagaaugagaguaaggaaagaacccacugagacagacaagagcaaaccauac
    uucugcuaaucauguuuaaaaguccagaaaugaucauaccauauuuuauuuucaagugugg
    aagucagcauggagaggggcucuuuuucucuaaaggggccugaaauuaaauugacuugaug
    uugagguuaccuucucuuucaaugaaucacuaaauugucuuuucuguuucccaggacccaa
    gugcuaucuaaccaugaguucccaccagcagaagcagcccugcacuguaccuccucagcugc
    accagcagcaggugaagcagccuugccagccaccaccccaggaaccuugugcccccaaaacca
    aggaucccugccacccuguuccugagcccugcaaccccaaggggccagagcccugccacccc
    aaggcacccgagcccugccaccccaaggcaccugagcccugcaaccccaaggugccagagccc
    ugccagccuaaggugccagagcccugccagccuaaggugccagagcccugcaaccccaaggu
    gccagagcccugccaaccuaaggcaccagagccuugccaccccaaggcgccugagcccugcca
    cccuguuguucccgagcccugccccucaacugucacuccaucaccauaccagcagaagacaaa
    gcagaaguaauauuguccagagccaugccugaagaccugaucaccagaugcugaggcugcu
    gucuauccugcuuaugagucccauugccuugugcuaccaaugcugugaccuucagucuuaa
    ucccucucuccuugcaccaccuaaaaaguugacucucauccucaucuucaagggcuccugag
    ccucuuaacauugcccaaagucauauugaauggcuacacuuuucauggcucaggauucauc
    ugaagggggugaggagugagacaaguguauggucaauauuuuccccccauuaaaugccauu
    uaacucc
    6 AI845584 uuuuuuuuuuuuuuuuuagccaaaauaguuauuuauuaauaauuuaagguuuuacauucu
    uauaauaaauuccagcucaaaacuuuacaccacgaacaucauggagcaaguuaauucucccu
    uccucucaaccuguugcauccaccaaaugggcgcucauacucgcacacauacacacacuucca
    guuucguauuuuuuuuuaaaaggaaagaaaccaacccaaaguauugcauuugaggugacac
    ucccugaa
    7 AA614971 aagaugcccuuuggauuggauuggauugaucauguuuaacucagcguauuuuauggauga
    aagcuaaauacagauauuuggcaucucuaagguggaaugagcccacuccacacacugauaaa
    auucaugcauaguuu
    8 AV374591 aaccaaaugggaaugggguccccaacnuuncugugguaccagccggguuucucuugcauug
    gaaacaaacaccuuuguaggcauuugcguauucgugaagagacuguuuuaugaaucaccuc
    uuagauuuaunuaauuaaccuaaguuguugaaguuucuguuucuccuuaagagaaauuaca
    aaaauucaacauugaagcauaguuucuuguuuucuguugucaaauaguaauaaugugcugu
    gauguuuaugcuuauucauaaagauguuuuacuuuuuaguguaauguuaguucuuuuuaa
    cauuauuuugcuuaaauuugauaaugcccgacaagaauauauuuugcuuugauuuauacac
    ugauucuuugugacaaauaugacccauuaaaaaugccuuuuaauagacuaacuuaccuuuu
    guagcuagguacucauguucuuuuuuaaaagaugcccuuuggauuggauuggauugauca
    uguuuaacucagcguauuuuauggaugaaagcuaaauacagauauuuggcaucucuaaggu
    ggaaugagcccacuccacacacugauaaaauucaugcauaguuuuaaaugaacauuaauaaa
    cucauguugucuu
    9 U04443 gaauucaaggaggcuuuccagcuguuugaccgaacaggugauggcaagauccuguacagcc
    aguguggggaugugaugcgggcccugggccagaacccuaccaacgccgaggugcucaaggu
    ucuaggaacccccaagagugaugagaugaaugugaagguacuggacuuugagcacuuccug
    cccaugcugcagaccguggcgaagaacaaggcccagggaaccuacgaggauuauguugaagg
    ccuucguguguuugacaaggaaggaaauggcaccgucaugggugcugaaauccgucauguc
    cuagucacacugggcgagaagaugacagaggaagaaguagagaugcuaguggcagggcaug
    aggacagcaaugguugcaucaacuaugaagcauuugugaggcauauccugucggggugacg
    ggcccgauggggcggagcucguccggauggugcugaauggcugagacauucuguaucccga
    gucuguucccugcccagugugauuucuguguggcuccagacgcuccccugucacagcaccu
    ugucccauuugguuucuuuggaugauguuugccuucaccaaauaaaauuugcucucuuugc
    cc
    10 Y07836 caaccaccuccuaccugccugcccaaagcuccagggcuggagcacggagaccugucaggg
    auggauuuugcccacauguaccaaguguacaaguccaggcggggaauaaaacggagcgaa
    gacagcaaggaaacuuacaaacugccgcaccggcugauugagaaaaagagacgugaccgg
    auuaacgagugcauugcccagcugaaggaucuccuacccgaacaucucaaacuuacuacu
    uugggucacuuggaaaaagcagugguucuggagcuuacguugaagcacgugaaagcauuga
    caaaucuaauugaucagcagcagcagaaaaucauugcccugcagagcgguuuacaagcuggu
    gauuugucgggaagaaaucucgaggcagggcaagaaauguucugcucagguuuccagacuu
    gugcccgugagguacuucaguaccuggcgaagcaugagaacacucgggaccugaaaucuuc
    ccagcucgucacucaucuccaucguguggucucggagcugcugcaggguggugcuuccagg
    aaaccauuggacucggcucccaaagccgucgacuugaaagagaagcccagcuuccuagccaa
    gggaucagaaggcccagggaaaaacugugugccagucauccagcggacuuuugcucccucg
    gguggggagcagagcggcagugacacggacacagacaguggcuauggaggugaauuggaga
    aaggggacuugcgcagugaacagccguacuucaaaagcgaccauggacgcagguucgccgu
    gggagaacgugucagcacaauuaagcaagaauccgaagagccccccaccacaaagagccgaau
    gcagcucucagaagaggaaggccacuucgcgggcagugaucugauggguuccccauuucuu
    gggccacacccacaucagccuccuuuuugccuucccuucuaucucaucccaccaucggccac
    ugccuaccugccuaugcuggagaaaugcugguaccccaccucugugccaguguuauaccca
    ggccucaacaccucagcugcagcccucuccagcuucaugaacccagacaagauaccgacuccc
    uugcuucugccccagagacucccuucuccuuuggcacauucgucccuugacucuucggccu
    ugcuccaggcuuugaagcagaucccuccuuuaaacuuagaaaccaaagacuaaacucuggag
    ggaucuccugcugccuugcuuucuuuccucccuaauuccaaaaaccacgaagguuucccuga
    gugcagagagaucagcccacccugcagacccacagagaagauucagagugugugugagagu
    gagugagugugcgugcgugcgugcuuguauguauguuuguauauguaggacaauaaguuc
    cuucugacacaagggagacacgagaaggauagccugacaucagaugacagacuggaggacug
    uagcacaucucugggcguuucccuacccagagaagagcc
    11 M21285 Sequence below.
    uugcaggcgagggcuuccacaacuaccaccacaccuuccccuucgacuacucugccagugaguaccgcuggcacaucaacuu
    caccacguucuucaucgacugcauggcugcccugggccuggcuuacgaccggaagaaaguuucuaaggcuacugucuuagc
    caggauuaagagaacuggagacgggagucacaagaguagcugagcuuugggcuucugaguuccuguuucaaacguuuucu
    ggcagagauuuaauauucuguugauuaacuaacaacuggauauugcuaucgggguguuaaugaugcauuuaaccuauucc
    gguacaguauucuuauaaaaugagaaagcuuugaucacguuuugagguaauaaauauuuuauuuagcuaggauuaaccau
    gccacaagacauuauauauuucuaagcacacaugauaaaugcauauacaauuuugcacaacagcuuuaaauaauaacaauaa
    auuugaacauucuauacagagaggaucaaagccaaggaacaugcuguuuugaugcuagggugagcauggugcucagucccu
    guuuguuugcaugguguccagcuuuguuucuucucugucaucaccaccuucaggcaaauaguugaccaaccacuggccug
    ugucuguccacccuccaaagcccaggccaccuuucuguuuucugaaauacugauccuuccuccugaauacaucccuccuug
    uuccuagcuucaagacugcugccucaaauagggauagagcaaguccccgcugcagguugugcuagaugggauggagaaauu
    aucuucauuugauacagagcaaguagauugucucgagagaaaaguuagcaugcgugguaugauuuguaaguaaagaugga
    agagagagagagagagagagagagagagagagagagagagagagagguagccauaucuaacagccuacuuaccaaagacccc
    aggccucucugcuuggcaugccuccuuucuguccauccucugaaccccagagauuagugagauuugaauaauuaaaucauu
    uucagagugaaggggguuaaugcagggucugugcuaggggaggguuuuagcuuuugguaacugaagauuuuuucaugga
    aaaagucuucguguucaaugugccuagaacugauaacuaaacagcugacauuugucggggacagauauggugugaaacuau
    gaaaauauaagcaaaaucuucacuuggaacaugaaacuauuucacuuagaaaauaaucgaaggacccgagguguugccugg
    guugccaguuucuuucguggcugggcaggaacuagugagguugaggggcagugucuguaaguagcugcuaagaggugca
    uuuccagaugaagcccuuggggaacaucugccagggauccgcaugguguuggcuccauccauugcuuuaguuuccuccuu
    ggauuguguagaaacuuggcuucccaugguuuugaaccuuccaugccuucuuugcuuuguggccacccagccugccuagu
    gcugccuaggaagcucuuacccaccugauuucuucugacauuucuuucuuuggccuuuuuuucuuucuccggacaugcag
    cuaguugccugaguguaucaagagcacccaggacuugcugcuguccaggccuguuccucccccaguauccgugggugugg
    aagagcuguguagcuucaggaagcagagccaggugccaccuuucuguggcuuccagauccucccuaccuccaacucaugug
    ccucugucacagugauuucaggaaagcuugguagacccucuagcaacaucucgguucagaaagucucucugguuugugag
    uuaacagcucagcuaagugcuguuuugucucagugaguuaaccacugaaugcgaggguugguuguugaucugucucggug
    ugugucggaguagacagcauaugcacuucucccugugcgcuuugcaagguaauguggcuuuggcugauccaugcaggcag
    guagugguacagugcugcugaaaggaagaaguuccccauuuuaucuguuaaaacaccagagacaugggcaagugcuaaugg
    accucacuucaggaagagggucugcuuccugaagccagugugugaugaaaagugacugagaccugauaucuaaggugagac
    cugauaccuaacacucugucacacaguccagggccaacagugcuauaggaaagucuagaagaaaacaucacaucaguauuuu
    agaaccaucaaccaucucuugucccuauagcccaauccagaggccugguuuuuagaacuggcuguguaaggugccaaacac
    ucaguucacuuguagaaucagagccuuuuuuccccccuauguuaauugaacacgcgcucugagcuguuuuguugaaguag
    aaaaucucauagaaaaaucacuguagaucuacugaccuauagcccucuggaaaugccuuugagaugguuuuacuuuucuag
    gucauagaugccugauuauaaagaugaacaauaaaaucagcuuucuuucuuucucuucugaucuuauuccccagaucugau
    ucaggccauguuccaaagcaaggcuacauugagguccuggugucuuuaaguaaaggacaucuuucagauccucucaaagaa
    ggauuuauaacaguuuccagaugaauguacuaauagcuuugggugccuuaucucuuuccuaaucuguagugccugugagc
    ucagucucacuccuucccuuagcccggagaccccuuagaucgagugggaauagucaagaggcuggcuggagagucaucagu
    acauugguuugcagaaaucuuuuacaggcuacauuuuggaauuuuuuuuuuuuuaguaagugaucaaauuuggugggaa
    guaauucgaguguauucgauuguauugucguccucguuaucauugucaaacauguuauagacggcaguuggcacuggggc
    ugcuaaucucuggguguagucucugaaacuguagcuccagugagguggugugaaagguuagcaaagccaccaucugcugg
    ugcuccagccaaggugccucuuagccacugaauugcuauguuauccuuucucuuguaacaaacccaccccagagauaaagcc
    uuuaaucaacccaagaaacuccugggcuaaguaucugacagucucacaucucaacagugugaauuaaguguccauagcauca
    gcucaggaggacacucugggagagugcugacaaaaaaggguuauuaauacugaccuacuacuucaagggcaguucugaggu
    gauuagagcuuuuuuuaaaaaccaaguauuuggggauccucagcagagguauucauacagacucccaaagaacuauauaug
    uuccugagaccaucguuuagucuacauugcucuucccagagacugacagauaugaccagucaaagugcaagacuaccuaccc
    acugccaugaaaaccauugcaggaaaccuuucccuuccugaaugagauuuuuuuuuucccuuuuuaugugggguaauuau
    uugugacccaaguguaauuuggaugauuuccauuaauaucaacucuugaagccuacuuguacugauugagauuguauuug
    uuccuaauaaaaguggaucugguuguacuguc
    12 V00756 accacuugcagacaaaugaauuccuucgaaauguauuugagguuggacccccugugaugcu
    ugaugcugcaacacuuaaaaccaugaagauuucucguuuugaaaggcauuuauauaacucu
    gcagcuuucaaagcucgaacaaaagcucgaagcaaaugccgagauaagagagcagauguugg
    agaauucuuguagaugucugaauuugauggcuguuuucuaaucucuuccuuuauuauuau
    uuuugcuacuucuaauguauauaagcuuuuagagacaguuuuuuaucuuggucaacuuaaa
    uaauuuuugauguagggguggguuguauuuuaauuuaauguacaguguuacaaauuaaug
    aguucuuuauucucuguaaaaauaacugguaaccacaaauaaaguguuugugauguuuggu
    cgu
    13 Y14296 auguccgcggccgccuacauggacuucguggcugcccagugucugguuuccaucuccaacc
    gcgccgccgugccggagcacgggggcgcuccggaagccgagcggcugcgacuaccugagcg
    cgaggugaccaaggaacacggugacccgggggacaccuggaaggauuauugcacgcugguc
    acuaucgccaagagcuuguuggaccucaacaaauaccgacccauccagacccccucggugug
    cagcgacagucuggagagucccgaugaggauauaggauccgacagcgacgugaccaccgaau
    cugggucgaguccuucccacagcccggaggagagacaggauucuggcagcgcgcccagccca
    cucucccuccuccacucuggaguggcuucgaaggggaaacacgccuccgaaaagaggcacaa
    gugccccuacaguggcugugggaaagucuauggaaaauccucccaucuuaaagcccauuaca
    gagugcauacaggugaacggcccuuucccugcacguggccagacugccuuaaaaaguucuc
    gcgcucggaugagcugacccgccacuaccggacccacacuggggaaaagcaguuccguugcc
    cacugugugagaagagauucaugaggagugaccaucucaccaagcaugcccggcgucacacc
    guguuccaucccagcaugaucaagagaucaaaaaaggcucuugccugccccuugugaggug
    cuccccauggcagccaggcagagauggguccccggaaggacagagcucccaggaaacagacu
    gacacauggaaaucugccacagcagaggcgcgcuggccacaggaggucacugcuucuuugg
    ccaauauucugauaucucccugcacuguuuccaaaaagcacaugguagcccuaaggucaaag
    ucaacauuugguccccuugcagaggcaacucugaaccgucucugacugaagauucagacug
    gugguguacauacgucunacugggugaguugaccccuggccucccacagugcagaaccacu
    cucuugaaucacauuaacuuuugagauuuaaaaaaaacccaaacccaacccnncaaaacncca
    ganacaccgaaacucuggauccucgaugcuugcugacucucagaauugnuunuucuucuca
    nuuaugcaagcnagagcacaccuacuccagcaugauuugucaucuaaagacuugaaaacaaa
    acaacaacaacanaaaguuacuuauagucaauggauaagcagaguccgaauuuacacuaauc
    aagacagaccuucgaggggucacgauaaguccggaacuuucaaaccuugcuucguaugaau
    uguacuaucugaacauaaacugcacuuuuauuuucuaauaccgagggugaauacgguaaau
    acaugcuuugaggguagaanccgacggucuguuuggcaccacguuauaaucugcunnuuuu
    aacgaguaccaccuuggagggcaggcaaauaaaugcuuuuggguauuuucuccuuuguuuu
    ugacaaaugcugcggaugggggaucgggaucggaggggagugcuuuuaaagauaauaaaaa
    augagguaaauaauuuuaacuuaugaauuuguuugaauuc
    14 X16490 gagauugaaacaauggaagaacuuuccauggcaaacaccauguuugcccucaaucuccuu
    aagcagauagaaaaaucaaacucuacccagaacaucuuuaucucuccauggagcaucuca
    ucaacauuggccauaguucuccucggugcuggggguaacacugaacagcagauggccaaa
    gugcugcaguuuaaugaaauuggcaguuaugguaucaccacaagaaacccagagaacuuc
    aguggcugugauuucgcacaacagauacagaaggaaaauuauccuagugcuauuuuacagg
    cacaagcaggagauaaaauccauucagccuucuccucucucagcucaacaaucaacaca
    ccacagggggauuauuuguuagaaagugcaaacaagcuguuuggagagaagucugcaagau
    ucaaagaagaauacauccaacucucuaagaaauauuacucaacagaaccagaagcagug
    gacuuccuugaaugugcugaagaagcuagggaaaagauuaauucuugggucaagacucaaa
    ccaaaggugaaaucccaaaccugcuacccgaagguucuguagaugaagacaccaagauggug
    cuggugaaugcugucuacuucaaaggaaaguggaaaacuccauuugagaagaaacuuaaug
    ggcuuuauccuuuccgugugaacucgcaugagagcauaccuguccagaugauguuccucca
    ugcaaagcugaacauuggauacauaaaggaccugaagacucagauccuagaacuuccgcaua
    cuggaaacaucagcaugcuccuguugcuucccgaugagauugaggacgcauccacuggcuu
    ggaauugcuggaaagugaaauaaacuuugccaacuucaacaaguggaucagcaaagacacac
    uggaugaagaugauguuguggucuacauucccaaguucaaacuggcacaaagcuacgaacu
    caaguccauucuucaaagcaugggcauggaggaugccuucaacaagggcaaggccaacuucu
    caggaaugucugagaggaaugaccuuuuucuuucugagguguuccaucaagccagcgugga
    ugucaccgaggagggcacuguggcagcuggugggacuggggcaguuaugacaggaagaacu
    ggccaugguggcccacaguuuguggccgaucaucccuuucuuuucuuuaucauggacaaaa
    uuacccacacgauacuauuuguugguagauucuccucacccuaaaaggggaagaccuauuuc
    cacaugagguuuuguagcaugaacuauaagccucagaauugcaucuucaagugccaaaagu
    uuaaauacuuucuuacacauuuuuauacuucugcuauacacuaaauauaaccuaaaagcaau
    uguauagcagucuucagugcuuacaguauaacucuauuaaugauuuuguuuccuaaaguca
    gaugaugucuauuuaguucauccuuauuacugcuuugucuuuauaacuuuaguuuuuaca
    guguuauuuauuguuuauauaaugguuguuuuacaaauuguuguccucuguuuaaugaaa
    cuguaacacuacagaagcagaaaauuagauaauuuucuauuuaaagaaaaucagccauuuaa
    uuuaauaaugaaggaaaaauaugagucuuccauacuuucccaugauauucacccagaaaaaa
    uguacuuaacaaaagacauguuauaucucuaucauuauauaucauauguacguaucugcaac
    ucaucuauaauuaggacuacaucauaaguaagcaugcuuacuuacacacugcuaucuguug
    uauaaaacuuagcaauccuuauuuguuaguuaucuuucuaucacuguaacaaaauaccuga
    gauaauaaaguucaaagauuuauuuugaaaaaaaaaaaa
    15 AW120868 uuuuuuuuuuuuuuunuaagaauuaacuuuuauuuuugcuuaguuuuauuaaaaaaauaa
    auaugucauaaagcuuuuguuuccuuuagggagaaaaaaaaggaacaaguuccauaaaauca
    aacaagcaaugguaacaugucuuaacuugaaaacaacuggggucacugguuuacaaguuaua
    acugaaugaaugacugccacaguugcccauuuccuccugccaauggcagcaaacaacaggau
    caacuagggcaaaauaaauaauuguguggaagcccuga
    16 C78850 aacuaaacuuccuuguaacuuuugagaacucagcucugguacuuuuucaugccuugcaaaa
    uggcguuanugcagcuagcuugcuaanccuuaugguggggucuuucauuccccccucuuuc
    uggaaacugnauaaaaucauuuauucacgugauucuauuucuucuggaucuauugauuuga
    guuggugauacuguugggucanaaccagggccuguu
    17 D67076 Sequence below.
    gcagcuccgagcuaggugcuaucgcaaggccagagcgcacagcccggcggagagagcagauccuugcucagaucgagucaa
    aucgggccaaggcggaggacgaagaguccaggcuccuauucuggacuuguuccccagcuccgggggcgcuucuagguccu
    gcagcagccagcagugcggagccaccaacucggugcuggaaugaaaaaauucccgcgcgccagugcagaaucuuucuaagu
    gacccggagcuucgggugcuagcucugcacgaacuuucccaucaaagugaucgugaauuuuaagcaucaggagcaggccag
    cgaagcucuacgcgucuaaacgucuauccagaccaagaguucucugcggugcagggugcggugccaugcagccaaaagucc
    cuuuuggggucacgcaagcagaagcccugcuccgacaugggggacguccagcgggcagcgagaucucggggcucucugucc
    gcacacaugcuguugcugcuccucgcuuccauaacaaugcugcuaugugcgcggggcgcacacgggcgccccacggaggaa
    gaugaggagcugguccugcccucgcuggagcgcgccccgggccacgauuccaccaccacacgccuucgucuggacgccuuu
    ggccagcagcuacaucugaaguugcagccggacagcgguuucuuggcgccuggcuucacccugcagacuguggggcgcag
    ucccggguccgaggcacaacaucuggaccccaccggggaccuggcucacugcuucuacucuggcacggugaacggugaucc
    cggcucugccgcagcccucagccucugugaaggugugcguggugccuucuaccuacaaggagaggaguucuucauucagcc
    agcgccuggaguggccaccgagcgccuggccccugccgugcccgaggaggagucauccgcacggccgcaguuccacauccu
    gaggcgaaggcggcggggcaguggcggcgccaagugcggcgucauggacgacgagacccugccaaccagcgacucgcgacc
    cgagagccagaacacccggaaccaguggccugugcgggaccccacgccucaggacgcgggaaagccaucaggaccaggaagc
    auaaggaagaagcgauuuguguccagcccccguuauguggaaaccaugcucguagcugaccaguccauggccgacuuccac
    ggcagcggucuaaagcauuaccuucuaacccuguucucgguggcagccagguuuuacaagcaucccagcauuaggaauuca
    auuagccuggugguggugaagaucuuggucauauacgaggagcagaagggaccagaaguuaccuccaaugcagcucucacc
    cuucggaauuucugcagcuggcagaaacaacacaacagccccagugaccgggauccagagcacuaugacacugcaauucugu
    ucaccagacaggauuuauguggcucccacacgugugacacucucggaauggcagauguuggaaccguaugugaccccagca
    ggagcugcucagucauagaagaugaugguuugcaagccgccuucaccacagcccaugaauugggccauguguuuaacaugc
    cgcacgaugaugcuaagcacugugccagcuugaauggugugaguggcgauucucaucugauggccucgaugcucuccagc
    uuagaccauagccagcccuggucaccuugcagugccuacauggucacguccuuccuagauaauggacacggggaauguuug
    auggacaagccccagaauccaaucaagcucccuucugaucuucccgguaccuuguacgaugccaaccgccagugucaguuua
    cauucggagaggaauccaagcacugcccugaugcagccagcacauguacuacccuguggugcacuggcaccuccgguggcu
    uacuggugugccaaacaaaacacuucccuugggcagauggcaccagcuguggagaagggaaguggugugucaguggcaag
    ugcgugaacaagacagacaugaagcauuuugcuacuccuguucauggaagcuggggaccauggggaccguggggagacug
    cucaagaaccuguggugguggaguucaauacacaaugagagaaugugacaacccagucccaaagaacggagggaaguacug
    ugaaggcaaacgaguccgcuacagguccuguaacaucgaggacuguccagacaauaacggaaaaacguucagagaggagcag
    ugcgaggcgcacaaugaguuuuccaaagcuuccuuugggaaugagcccacuguagaguggacacccaaguacgccggcguc
    ucgccaaaggacaggugcaagcucaccugugaagccaaaggcauuggcuacuuuuucgucuuacagcccaagguuguagau
    ggcacucccuguaguccagacucuaccucugucugugugcaagggcagugugugaaagcuggcugugaucgcaucauaga
    cuccaaaaagaaguuugauaaguguggcguuuguggaggaaacgguuccacaugcaagaagaugucaggaauagucacuag
    uacaagaccuggguaucaugacauugucacaauuccugcuggagccaccaacauugaagugaaacaucggaaucaaagggg
    guccagaaacaauggcagcuuucuggcuauuagagccgcugaugguaccuauauucugaauggaaacuucacucuguccac
    acuagagcaagaccucaccuacaaagguacugucuuaagguacagugguuccucggcugcgcuggaaagaauccgcagcuu
    uaguccacucaaagaacccuuaaccauccagguucuuaugguaggccaugcucuccgacccaaaauuaaauucaccuacuuu
    augaagaagaagacagagucauucaacgccauucccacauuuucugagugggugauugaagaguggggggagugcuccaag
    acaugcggcucagguuggcagagaagaguagugcagugcagagacauuaacggacacccugcuuccgaaugugcaaaggaa
    gugaagccagccaguaccagaccuugugcagaccuuccuugcccacacuggcaggugggggauuggucaccauguuccaaa
    acuugcgggaaggguuacaagaagagaaccuugaaaugugugucccacgaugggggcguguuaucaaaugagagcuguga
    uccuuugaagaagccaaagcauuacauugacuuuugcacacugacacagugcaguuaagaggcguuagaggacaagguagc
    guggggaggggcugauacacugagugcaagaguacuggagggauccagugagucaaaccaguaagcagugagguguggca
    aggagguguguguaggggauacauagcaaaggagguagaucaggacacuacccugccaguuacauucugauaagguaguu
    aaugaggcacaguagcaucugaaagaccauacagagcacuaaggagccccaaagcacuauuaguaucucuuuucuuauaucu
    aucgcccaaauaauuuucagagucuggcagaagcccuguugcacuguacuaacuagauacuucuuaucacaaagauuggga
    aaggcaaagcagaaagaugguaagacuggguuucaaacaaggcuugguuucaaucacuggaggcaaggaggaggggacaaa
    caagaucauuauucgaagucgcugguugcugugguuuuacggaagguugaugcaucauuccuaucaacagugaaaaguuc
    agcuuguucaacgugacagaaaggcucaucuccgugaaagagcuccugauuucuucuuacaccaucucaguucuuaacuau
    aguucauguugagguagaaacaauucaucuauuuauaaaauguacauuggaaaaaaaaagugaaguuuaugagguacacau
    aaaaacugaaggaaacaaugagcaacaugccuccugcuuugcuuccuccugagguaaaccugccuggggauugagguuguu
    uaagauuauccauggcucacaagaggcaguaaaauaauacauguugugccagaguuagaaugggguauagagaucaggguc
    ccaugagauggggaacauggugaucacucaucucacaugggaggcugcugcag
    18 M61007 ccgcgggcccgcguucaugcaccgccugcuggccugggacgcagcaugccucccgccgcc
    gcccgccgccuuuagacccauggaaguggccaacuucuacuacgagcccgacugccuggc
    cuacggggccaaggcggcccgcgccgcgccgcgcgcccccgccgccgagccggccauugg
    cgagcacgagcgcgccaucgacuucagccccuaccuggagccgcucgcgcccgccgcgga
    cuucgccgcgcccgcgcccgcgcaccacgacuuccucuccgaccucuucgccgacgacua
    cggcgccaagccgagcaagaagccggccgacuacgguuacgugagccucggccgcgcggg
    cgccaaggccgcgccgcccgccugcuuuccgccgccgccucccgccgcgcucaaggcgga
    gccgggcuucgaacccgcggacugcaagcgcgcggacgacgcgcccgccauggcggccgg
    uuucccguucgcccugcgcgccuaccugggcuaccaggcgacgccgagcggcagcagcgg
    cagccuguccacgucgucgucguccagcccgcccggcacgccgagccccgccgacgccaa
    ggccgcgcccgccgccugcuucgcggggccgccggccgcgcccgccaaggccaaggccaa
    gaagacgguggacaagcugagcgacgaguacaagaugcggcgcgagcgcaacaacaucgc
    ggugcgcaagagccgcgacaaggccaagaugcgcaaccuggagacgcagcacaaggugcu
    ggagcugacggcggagaacgagcggcugcagaagaagguggagcagcugucgcgagagcu
    cagcacccugcggaacuuguucaagcagcugcccgagccgcugcuggccucggcgggcca
    cugcuagcgcggcgcgguggcguggggggcgccgcggccaccgugcgcccugccccgcgc
    gcuccggccccgcgcgcgcgcccggaccaccgugcgugcccugcgcgcaccugcaccugc
    accgaggggacaccgcgggcacaccgcgggcacgcgcggcgcacgcaccugcacagcgca
    ccggguuucgggacuugaugcaauccggaucaaacguggcugagcgcguguggacacggg
    acuacgcaacacacguguaacugucuagccgggcccugaguaaucaccuuaaagauguuc
    cugcgggguuguugauguuuuugguuuuguuuuuguuuuuuguuuuguuuuguuuuuu
    uuuuuggucuuauuauuuuuuuuguauuauauaaaaaaguucuauuucuaugagaaaaga
    gg
    cguauguauauuuugagaaccuuuuccguuucgagcauuaaagugaagacauuuuaauaa
    acuuuuuuggagaauguuuaaaagccaaaaaaaaaa
    19 C85523 aaaauguagaaggcaagauuuaauaaggcagcaacaugaaagcacacagaccagagcucu
    ggggucgaaauaaagcagcaacauggaagcacacagagcucuggggucgaaacucauaca
    ccuuagcacaggguagaggagucucgacggucanccagaauuuuucacaggcuuauauag
    uaaaacucaaagggggagaacugggcagggaaaguacaaguuuacaucacuagggaguuc
    ugccaaaggacaanggguucunucagaggaaucuacguaacuaaggngucauguccuauc
    aaggnaucuacguaacuaaggagucauguccuaucauuuggcaauguacccggnucuuuu
    gagguuguuccggagggncuuauucucaaaauguuuuucagauuggaagggguggguunc
    cgguaaaaaguucuguuuucaaagaggcnguaauuuucuauucuucauuccccauucucc
    uguaaguauucnnaucuuagaauuucagaaguccauauucncuauguggggaauaacugg
    cuuuaacccnaucuuuaaaauggggg
    20 AW122030 uuuuuuuuuuuuuuuuuaugaaacaguuuuguucagcccaugacuuugugcaugacuguc
    guccguucuagucaccugugcucuccaucuacugccuuuuaaagcugcgucaugagaagg
    aucuacacguuccaccaugacucucguuucuugccacaaguagaagaaaugguugauucu
    uugcuuuucgguuaggccguuaaacaaaacucagucacaccccugccuuccacccucaaa
    cugugaucacguggcuguucuuguaguunaaccagggcaacacuauauauuccaggucua
    uacauugcugaggucuuuuucugguuguucauguaucaguguuuucaaccucgugccg
    21 U57524 Sequence below.
    gcggccgcggcuccagaccccggccuugcgcacccuccccccaccuccagcccgcgccucccccccccccacgcauggcucac
    caccccucggguuucccugucaucccucagguuccugcacuuggcaaucauccacgaagagaagccgcugaccauggaagu
    cauuggucaggugaagggagaccuggccuuccucaacuuccagaacaaccugcagcaggugcgcugcuugcuugccccgcg
    gugccccucuuugaccccuugguggagucagauguagcacggucgcccccaaagcguuucuaaauuaauagucacuuaguu
    cuuaucugccuuggcuuuuuugcauucaaaucagccaacgucuuagaaccagaagaaaaaucccuugguuuuagugagguc
    uuuaugacccaccuagggccuccuguuugccugaucuccuaagagacaaaugggaggaucagauuccauagcgggaggugu
    cugggguucaggaaacucaagacuauggguuugcuccauggcuuaucccuuucuguuuccucuuccauuuguagacucca
    cuccacuuggcugugaucaccaaccagccaggaauugcugaggcacuucugaaagcuggcugugauccugagcuccgagac
    uuucgaggaaauaccccucuacaucuugccugugagcagggcugccuggccaguguagcagucuugacgcagaccugcaca
    ccccagcaucuccacuccguccugcaggccaccaacuacaaugguaggucugccaguccauccaaggaugcagaggagggag
    agagauggggccacuugagucuuaaacuccgaacguauacaaaguucagacacugugaucuuuuuaaaaaguuuucuccuc
    gaugccuauaugauauucacucagaacccagauucugaguucuucaaaacugaugauguuugugguuguccucaagacaau
    agacaugaguugugugaggauugaaacacguaguacaguuuuugucuuccuccuccaggccacacgugucugcaccuagcc
    ucuacucacggcuaccuggccaucguggagcacuuggugacuuugggugcugaugucaacgcucaggugaguacaucucc
    cuuccaccuaaucucuguugggcuggcucugauggugagcagguuuccagaugcagccguaaacuaacgccugauugcuu
    uugguuucaggagcccugcaauggccggacagcccuccaccuugcgguggaccugcagaauccugaccugguuucgcucuu
    guugaaauguggggcugaugucaacaggguaaccuaccaaggcuacucccccuaccagcuuaccuggggccgcccaaguac
    ccggauacagcagcagcugggccagcugacccuggaaaaucuccagaugcuacccgagagcgaggaugaggagagcuauga
    cacggagucagaauucacagaggaugaggugaguguuccuccccucagcacgcugacggcuguucuagggcugcuuugga
    ucagagggauuucaguuguuuaacuucucagacucggcuugcaaagcaggaucccaagaauuugucucugguuuguuuua
    agagcuuacccuuuugguugaggaaugagggaauucuagaaauugaacccaggccuuagcacauggugauaagcacacguu
    caaccauuaagcuccacccccucaauagcuuagacuuuuuuuuuuuuuaaggaaagaauagguaagggaaacuccuacagc
    cuggugcccuuguucuauuuggguuaaggagaaaaagagcccaagaauaggaguuauuucagcagcagcucuccccuuauc
    ccaaugucuuggugaaguucuaggaauuuaauaugucuuuuuccccucucuuguuuuagcugcccuaugaugacugugug
    uuuggaggccagcgucugacauuauaaguggaaaguggcaaaaaagaauguggacuuguauauuuguacaaauagaguuu
    uauuuuucuaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaguauacuuagcaccacaccacacagcgccuagacccaggc
    auuuuacuggggugauucggcuguugucuuugugaaauccgggg
    22 U05809 cucucggucacugccggucgcuuccugagccgcugcuggcucugugucucuguccucagc
    guucucuuccucguccucguccuaccacgccauggaagguuaccauaagccagaucagca
    gaagcuccaggcccugaaggacacagccaaucgccugcgcaucagcuccauccaggccac
    caccgcggcaggcucaggccaccccacaucaugcugcagcgcugccgagaucauggcugu
    ccuguuuuuccauaccaugcgcuacaaggcccuggauccccgaaacccucacaaugaucg
    cuuugugcucucuaagggccaugcagcucccauuuuauaugcagucugggcugaagcugg
    cuuccugcccgaggccgagcugcugaaccugaggaagaucagcucugacuuggacgggca
    uccugucccgaaacaagccuucaccgauguggccacuggcucccugggccagggccuggg
    agcugcuugcgggauggcauacacaggcaaauacuuugacaaagccagcuaccgagucua
    uugcaugcugggagacggggaggucuccgagggcuccgucugggaggccauggccuuugc
    uggaauuuacaagcuggacaaccucguugccauuuuugacaucaaccgccugggccagag
    cgacccagccccgcugcagcaccagguggacaucuaccagaagcgcugugaggccuuugg
    cuggcacaccaucaucguggacggacacagcguggaggagcugugcaaggccuuugguca
    ggccaagcaccaaccaacagccaucaucgccaagaccuucaagggccgagggaucacagg
    gauugaagacaaggaggcguggcacgggaagccccuccccaaaaacauggccgagcagau
    uauccaggagauuuacagccagguucagagcaaaaagaagauccuggccacgcccccuca
    ggaggaugccccauccguggacauugcuaacauccgaaugccuacgccacccagcuacaa
    agugggggacaagauagccacccggaaggccuauggacuggcccucgcuaagcugggcca
    cgccagugaccguaucauugcccuggauggagacaccaagaauuccaccuucucggagcu
    cuucaaaaaggagcacccagaccgguucauugagugcuacauugccgagcaaaacauggu
    gagcauugccgugggcugugccacacgugaccggacagugcccuucugcaguacuuucgc
    ggccuucuucacacgggccuucgaccagauucgcauggccgccaucucugagagcaacau
    caaccucuguggcucccacugugguguguccauuggggaagacgggcccucucagauggc
    ccucgaagaccuggccauguuccggucaguccccauguccaccgucuuuuacccaagcga
    uggaguugcaacagagaaggcaguggaguuagcagccaacacaaagggcauuugcuucau
    ccggaccagccgcccagagaaugccauuauuuauagcaacaaugaggauuuccaggucgg
    ccaagccaaggugguccugaagagcaaggaugaccaagugacagugaucggggcuggugu
    aacucugcaugaggccuuggcugcugcagagagucuaaagaaagauaagaucagcauccg
    ggugcuggaucccuucacuaucaagccccuggacaggaaacucauccuagacucugcccg
    agcaaccaaaggcaggauccucaccguggaggaccacuacuacgaagguggcauaggaga
    ggcagugucugcugccguagugggugaaccuggagugacggucacucgccuggcugucag
    ccaaguaccacgaaguggcaagccagcugagcuacugaagauguucgguauugacaagga
    cgccauugugcaagcugugaaaggccuugucaccaagggcuagggagggcaugggaugcu
    gggugggugaacuacacauuccagggagguucuggcagagguggcgaagguguacugagu
    ggggagguaaauauauguuuug
    23 AW212475 uuaacggugucauaaauaaguaauauaacuuuauuaaaaugaaaagacaauauucaaaau
    aaugcaacaaaaugaauaaauccuuuguccaauacuguacacacagugcggagaucagug
    cauuuuucuaaagcauguuuuaaccuucauuuaguucauacuaaaguaagcuuuaaauag
    cucaaauaaugucauucagcaguuuaaacugaacagcuuguugggacaug
    24 V00835 ugaguucucguaaacuccagagcagcgauaggccguaauaucggggaaagcacuauaggg
    acaugauguuccacacgucacaugggucguccuauccgagccagucgugccaaaggggcg
    gucccgcugugcacacuggcgcuccagggagcucugcacuccgcccgaaaagugcgcucg
    gcucugccaggacgcggggcgcgugacuaugcgugggcuggagcaaccgccugcugggug
    caaacccuuugcgcccggacucguccaacgacuauaaagagggcaggcuguccucuaagc
    gucaccacgacuucaacguccugaguaccuucuccucacuuacuccguagcuccagcuuc
    accagaucucggaauggaccccaacugcuccugcuccaccgguaagacucccgauccuug
    gucuuuagaauaccaaguugggaccgcagagcggaauccccgaguuguagaggcuuggcg
    ggaauaggcaccuuuaguuggcgauucauuccgguucuuucuagaauccgcucuugcaaa
    agccuucauuaguuacgaguauugucgaacggguccuuuggcgggguuggggcuaggauu
    uagacgcgcaaauguccgguuccugaucacccaguuaguggggacaucuggguugagucc
    caggcauuacuaaacuuacugugaauugcuugaauuaagaaagaggugaaggaccuuuau
    gucuugggacucaaagacauaaucccugacuuaaccugugaggagaaaaguggggcuagg
    cucccugcagcuccgaggaggacuuagugaacugagccgggacucgugguguuggccacu
    gcuguaaugcugccucccucaugcugucuucuuucuccucccaggcggcuccugcacuug
    caccagcuccugcgccugcaagaacugcaagugcaccuccugcaagaagagugaguuggg
    acaccuuggguggcggcuaaggcuaggggcggggaacuccuacaaaacuggcucugagaa
    auguccuuugcuucccggaggccauuguauugucucggggacagaacuauacagagaacu
    auuuaaaaaaaccgaggucuucucuguuggggacaggaagcagaggucuucagccaggcu
    gccucuuccuccuucuucuaggcugcugcuccugcugucccgugggcugcuccaaaugug
    cccagggcugugucugcaaaggcgccgcggacaagugcacgugcugugccugaugugacg
    aacagcgcugccaccacguguaaauaguaucggaccaacccagcgucuuccuauacaguu
    ccacccuguuuacuaaacccccguuuucuaccgaguacguuaauaauaaaagccuguuug
    agucuaacucugguuucuuggugugguuuggcaauaagaaacuggggugacuugauaguc
    uggggaucugguuuuggacccccucgugccuuuaccuccgcccucuggcccucacagagg
    gguaaugucuuuggguaaagccaagcuauaucccauaagcuuccucauggaaaacagcug
    25 AV374868 gcggcacgaugugucuucggguggcuuuuuuuuuuuuguuuugaauaauguuuacaauuu
    cccucaaucacuuuuauagaaauccaccuccaggccccccccuuuccccacuuaggccuu
    cgaggcugucugaagaugcuugagaaacucaaccaaaucccaguucaauucagacuuugc
    acauauauuuauauuuauaaucagaaaagaaacauuucaguaauuuauaauaaaagagca
    cuauuuuuuaacg
    26 M21285 See above (same Accession Number).
    27 U74683 acugccaucgagugguguuccaguugaacuugcucucucugccaucugcuccgcgggcgc
    cgucagcaugggucccuggacccacuccuugcgcgccguccugcugcuggugcuuuuggg
    agucugcaccgugcgcuccgacacuccugccaacugcaccuacccugaucugcugggcac
    cuggguguuccaggugggcccuagaaguucccgaagcgacauuaacugcucggugaugga
    agcaacagaagaaaagguagugguacaccuuaagaaguuggauacugccuacgacgagcu
    gggcaauuccgggcauuuuacccucauuuacaaccaaggcuucgagauuguguugaauga
    cuacaaaugguuugcguuuuucaaguaugaagucagaggccacacagcuaucaguuacug
    ccaugagaccaugacuggguggguccaugaugugcugggccggaacugggcuugcuuugu
    uggcaagaagguggaaagucacauugagaagguuaauaugaaugcagcacaucuuggagg
    ucuccaggaaagauauucugaaagacucuacacucacaaccacaacuuugugaaggccau
    caauaccguucagaagucuuggacugcaacugcauauaaggaauaugagaaaaugagccu
    gcgagaucugauaaggagaaguggccacagccaaaggaucccaaggcccaaaccugcccc
    gaugacugaugaaauacagcaacaaauuuuaaauuugccagaaucuugggacuggagaaa
    cguccaaggcgucaauuauguuagcccuguucgaaaccaagaaucuuguggaagcugcua
    cucauuugccucuauggguaugcuagaagcaagaauucguauauuaaccaacaauucuca
    gacaccaauccugaguccucaggagguuguaucuugcagccccuaugcccaagguuguga
    ugguggauucccauaccucauugcagggaaguaugcccaagauuuuggggugguggaaga
    aagcugcuuucccuacacagccaaagauucuccaugcaaaccaagggagaauugccuccg
    uuacuauucuucugacuacuacuaugugggugguuucuaugguggcugcaaugaagcccu
    gaugaagcuugagcuggucaaacauggacccauggcaguugccuuugaaguccacgauga
    cuuccuacacuaccacaguggaaucuaucaccacacugggcugagugacccuuucaaccc
    cuucgagcugacaaaucaugcuguuuugcuugugggcuauggaagagauccaguuacugg
    gauagaauacuggauuauaaagaacagcuggggcucuaacuggggggagaguggcuacuu
    ccguauccgcagaggaacugaugaaugugcaauugagaguauagccguggcggccauacc
    gauuccuaaauuauaggacauagcucccaguguuacauacgggucuuuaucacucacaga
    gugauuuagucacaugcugaagacuuuuucagagcaauaucagaagcuuaccacuaagca
    ucuuuaaagaauuuugucuuugaacuuaaaaccauccuugauuuuuuucuuuuaauaucu
    uccccaucaacuacugaacuacuuuucuuuuuaaaguacuugguuaaguaauacuuuuau
    gagcagugguucaguuguccaauauuuuuugcaggucaucuacaaugcaaccagauguuu
    caguucuaaaaaucuauguaaaaguacaagcucguuuuuaaauuauguaagucacaugaa
    aacauggcaaaaaaauuaguuaaauuuuuuacaaagaguuuuaaauaaauguuuauguaa
    ucaguaccauagucuuucuauguguguuuacaagaauuuuugucaccuacuucuucccuu
    agaagcauuuaugcuccauggacguacuucuuuauggagaaaaaaaaaa
    28 X61800 gagcucgaucccuguuccgccuuugcuaugucugaaggcguccugcuuugcgcgugucgg
    ggccaaauccagauuuucauuucgcuccaggcuuggacggcuaaguagguccaaaccgca
    caaacaggaaggagggaaggcaaggagugcgggcagagggcgggucguucccagcagcac
    cccagucccuccccgcuccgucuccgacccacuggggccggggcgggcgugcgcgucagc
    uggggcuagaaaaggcggcgguccggcccggcgaggugacagccaacuuggacgccaggu
    ccggccgacgccgccaugagcgccgcgcuuuucagccuggacagcccggugcgcggcaca
    cccuggcccacagaacccgcggccuucuacgagccaggcaggguggacaagcccggccga
    gggcccgagccaggggaacugggggagcugggcuccacgacuccugccauguacgacgac
    gagagcgccaucgacuucagcgccuacauugacuccauggccgccgugcccacccuagag
    cugugccacgacgaacucuucgccgaccucuucaacagcaaccacaaagcggccggcgcg
    ggcggccuggagcugcugcagggcggcccuacgcgacccccggguguggggucugucgcu
    agggggccgcucaagcgcgaacccgacuggggcgacggcgacgcgccgggcucccugcug
    ccggcgcaaguggcggugugcgcgcagacaguggugagcuuggcggccgcggcucagccc
    acuccacccacuucgccggagccuccucgaggcagcccggggccgagccucgcgcccggc
    acaguccgagaaaagggcgcgggcaagagggguccggaccgcggcagcccggaguaccgg
    cagcggcgcgagcgcaacaacaucgcugugcgcaagagccgcgacaaggccaagcgccgc
    aaccaggagaugcagcagaagcugguggaguugucggccgagaacgagaagcugcaucag
    cgcguggagcagcucacccgggaccuggcuggccuccggcaguucuucaaaaaacugccc
    agcccgccuuuccugccgcccaccggcgccgacugccgguaacgcgcggcgugggccuuu
    gagacucugaacgaccuauaccucagaccccgacagcggggagcagacgccgcccgaauc
    gcuaguuucuuugggaccugcgagcgacaggaagcugcagcuugggcacuggacugcgag
    agaagcuauauuaaucuuuccccuuaaauuauuuuuuauaaugguagcauuuucuacguc
    uuauuaccauugcagcuaagguacauuuguagaaaagacauuuccgacagacuuuuguag
    auaagaggaagagacugcgcaugcuuuuuauauucauuuuuacaguauuuguaagaauaa
    gaauaagaauaaagaagcauuuaaaucgcaaaaaaaaa
    29 U20735 Sequence below.
    uugaggguggccaggccagcguaggaggccagcguaggauccugcugggagcggggaacugagggaagcgacgccgagaa
    agcaggcguaccacggagggagagaaaagcuccggaagcccagcagcgccuuuacgcacagcugccaacuggccgcugccga
    ccgucuccagcucccgaggacgcgcgaccggacaccggguccugccacagccgaggacagcucgccgcucgccgcagcgagc
    ccggggcggcccuucagggggaccuuucccagaucgcccaggccgcccggaugugcacgaaaauggaacagccuuucuauc
    acgacgacucuuacgcagcggcgggauacggucggagcccuggcagccugucucuacacgacuacaaacuccugaaacccac
    cuuggcgcucaaccuggcggaucccuaucggggucucaaggguccuggggcgcgggguccaggcccggagggcagugggg
    caggcagcuacuuuucgggucagggaucagacacaggcgcaucucugaagcuagccuccacggaacuggagcgcuugaucg
    uccccaacagcaacggcgugaucacgacgacgcccacgccuccgggacaguacuuuuacccccguggggguggcagcggug
    gagguacagggggcggcgucaccgaggagcaggagggcuuugcggacgguuuugucaaagcccuggacgaccugcacaag
    augaaccacgugacgccccccaacgugucccugggcgccagcggggguccccaggccggcccagggggcgucuaugcuggu
    ccggagccgccucccgucuacaccaaccucagcaguuacucuccagccucugcacccucuggaggcuccgggaccgccgugc
    ggacugggagcucauacccgacggccaccaucagcuaccucccacaugcaccacccuuugcgggcggccacccggcacagcu
    ggguuugagucguggcgcuuccgccuuuaaagaggaaccgcagaccguaccggaggcacgcagccgcgacgccacgccgcc
    ugugucccccaucaacauggaagaccaggagcgcaucaaaguggagcgaaagcggcugcggaacaggcuggcggccaccaa
    gugccggaagcggaagcuggagcgcaucgcgcgccuggaggacaaggugaagacacucaaggcugagaacgcggggcuguc
    gagugcugccggucuccuaagggagcaaguggcgcagcucaagcagaaggucaugacccaugucagcaacggcugccaguu
    gcugcuaggggucaagggacacgccuucugagagccucccuugccccauacggacacccccagccuugaaggcugggcgcc
    ugccccccacuggggugaggggggcaggcgaugggcacccgccaaaaggccuggggcgcagcucacacacuggacuccggc
    ccgcccgccugcgcccaguccuuccaccucgagguuuacauggcccccuuccagcguauuuuguauguuuuuuuuuucug
    caaagagacugaauucauauugaauauaauauauuuguguauuuaacaggagggagaagggggcugucgcggcggagcug
    gccgccgcuugguacucagcugcggggauacuagggagggaccuccgcccccugcccucccccucugcauaguacugugga
    gaagaaacacgacuucgugucuaaagucuauuuuaagauguguuuguguguguguguuugacuuuuuauugaaucuauu
    uaagua
    30 U19118 Sequence below
    gaauucggcacgagcagcgagacgccgcgcacggugcuuccccaguggagccaaucggcuaacccgcgcuccggcagaguc
    cuuggcgcucgcccgccggcgggacagaccacccgccucuggccgcucucuggacccuggccgccccgagcgaagacugga
    gcaaaaugaugcuucaacauccaggccaggucucugccucagaagucagugcgaccgccauuguccccugccucucaccucc
    ugggucacugguauuugaggauuuugcuaaccugacacccuuugucaaggaagagcugagauucgccauccagaauaaaca
    ccucugccaucggauguccucugcgcuggagucaguuaccgucaacaacagaccccuggagaugucagucaccaagucuga
    ggcggccccugaagaagaugagaggaaaaggaggcggcgagaaagaaauaaaauugcugcugccaagugucgaaacaagaa
    aaaggagaagacagagugccugcagaaagagucagagaaacuggagagugugaaugcugagcugaaggcccagauugagga
    gcugaagaaugagaaacagcauuugauauacaugcucaaccugcaccggcccaccuguaucguccgggcucagaauggacg
    gacaccggaagacgagaggaaccucuuuauccaacagauaaaagaaggaacauugcagagcuaagcagagguggcacggagg
    caauuggggaguucuuacugaauccuccuuuuccaccccacacccugaagccauuggaaaacuggcuuccugugcacuucu
    agaaucccagcagccaagagccguuggggcaggagggccuguggugaccuacugcauugacccacucugcccccgagugaa
    ccguggagcaggcaggagcauccuuugucucaccaauuccaggauuuaggccuuaucaucccggccagucucagaugaccu
    agcuggccccaggcugggguccuaugcaaagcaggaucccacuaaugggauucaggcagaagugucuaccuugauaggugg
    ggugggaccacauccuccacuguggcugacaacgcccuuccaagggaauauggaaugagaacauucauuauugagguuguc
    caauggccaggguaugcuuucuagaaaauaugcuguucugucccagaaugacugugcauaggguauccguuucagagccu
    gguguugugcuauuuagauguuugucuugcacaacauuggcaugauuuuuccgggaguuucaucagaucugauuucuga
    gagucuggggaucugccaugguggaaagugccccucaaaagcauuuguguggccacaugaacuggcuggcaccaggggag
    ugaaacuggcugaugaccagcugagccacuuugugccaacagaggauggacgacaccuuucccuguacccacugcagagga
    agaacccugggcacagcagcuuuguccuuggcuacaaacuguuacaacgucacacaaugaaggcacaaaguccaacuuucaa
    aggguguaggacuccauacucagugacagggcaggaagagccaaagauaaccacagccacagccuguggagaccaggguug
    gaagccaggugcagggccaggcaucugcauugugggauguuaauggcacuuuugucuuguagcuauuuugagauguggu
    ccagagcauuucagcugggagaucucccucuggccaccaggacucuggcuacuguuaaaauccugauguuucuguggaauc
    cucaguguuuaaucccacucaauaguaucauuacaguuuucuguaagagaaaauauuacuuauuuaucccaguauuccuag
    ccugucaacauaauaaauaucggaacaaaaccuggua
    31 AW049031 uuuuuuuuuuuuuuuuugcugauaagaauucuuuuuauguuauucgaauaaaaaauaca
    uucauacagaaauauaacaaucucgcaaaaaacaauuucaaauaaaaucuuguaaaacaaa
    auuuuacaaaaaucuuacaaagauucuuuagauaacagggugcuucaaaaaaaaagaaau
    aaagaaauuucacuaauagaaauuuuuuuuuuuaauuucaagcaaaaguuccugcuugau
    ugaggcucaguugucaccugaccagaauggacugcuuaguauuaaaguuacagcaucgac
    acggacggcacccagccccagccaguccagcaacgucgcuguguuucauaagugagacgc
    gccagcacaaguuuccucucucuucuguuuaccuucuuacuuaauggaauugcuauggau
    aagcacacagcagggccaaaaaaggaguuuuccaaaauccagcaaaucaagug
    32 M93275 uaguggugaucuggaccgugcggacuugcucgucccucagcucuccuguuaggcgucuc
    u
    uuucuccaggaggaaaaaauggcagcagcaguaguggauccgcaacagagcguggugaug
    agaguggccaaccugcccuuggugagcucuaccuacgaccuuguguccuccgcuuauguc
    aguacaaaggaucaguacccguauuugagauccgugugugagauggccgagaagggcgug
    aagaccgugaccucugcggccaugacaagugcccugcccaucauccagaagcuggagcca
    caaauugcgguugccaauaccuaugccugcaaggggcuagacaggauggaggaaagacug
    ccuauucugaaccagccaacguccgagauuguugccagugccagaggugccguaacuggg
    gcgaaggauguggugacgacuaccauggcuggagccaaggauucuguagccagcacaguc
    ucaggggugguggauaagaccaaaggagcagugacuggcagcguggaaaggaccaagucu
    guggucaauggcagcaucaauacaguuuuggggauggugcaguucaugaacaguggagu
    a
    gauaaugccaucaccaagucggagaugcugguagaccaguacuucccucucacucaggag
    gagcuggagauggaagcaaaaaagguggaaggauuugauaugguucagaagccgagcaac
    uaugaacggcuggagucccugucuaccaagcucugcucucgggcuuaucaccaggcucuc
    agcaggguuaaagaggccaaacaaaagagccaggagaccauuucucagcuccacuccacu
    guccaccugauugaauucgccaggaagaauaugcacagugccaaccagaaaauucagggu
    gcucaggauaagcucuaugucucguggguggaguggaagagaagcaucggcuacgacgac
    accgaugagucccacuguguugagcacaucgagucacguacucuggcuaucgcccgcaac
    cugacccagcagcuccagacuacaugccagacuguccuggucaacgcccaaggguuacca
    cagaacauucaagaucaggccaaacacuugggggugauggcaggcgacaucuacuccgua
    uuccgcaaugcugccuccuuuaaggaaguguccgauggcguccucacaucuagcaagggg
    cagcugcagaaaaugaaggaauccuuagaugaaguuauggauuacuuuguuaacaacacg
    ccucucaacuggcugguaggucccuuuuauccucagucuaccgaggugaacaaggccagc
    cugaagguccagcagucugaggucaaagcucaguaaaccccuccuugucaccagagcaug
    auguugcuggccagaugaccccuuuugcuguauugaaauuaacuugguagauggcuuua
    g
    cuuagaaaagcagcuucuuagaaccaagggccucauuauggucacucacagcucaguuau
    ggucuugccccagcuggcccuggcacaggaguucucuuaccuggcuggugaguggccug
    u
    guuagucuugugaggaccuggaggaaccuaaaagcucagaugcacuuacagucuugucug
    uggccuuuguauuguuauuggcuguaaacgucugucuggaccgaauaaagauucacgug
    a
    33 AB000713 ggcacgagggagcugcaguguucgcgcuugguagcuggugcaucggacucagcuggcuu
    u
    gugucccugaggcucaccgaaaaacacuuucucagcccucugacuccagagagagagaga
    gagagguacuuuuuguggucaccgacuuugaccccugcagaggcugagcgauggcgucu
    a
    ugggacuacagguccugggaaucuccuuggcaguccugggcuggcuggggaucauccug
    a
    guugugcgcuccccauguggcgggugaccgccuucaucggcagcaacaucgucacggcac
    agaccagcugggagggccucuggaugaacugcguggugcagagcacaggucagaugcagu
    gcaagauguacgacucgaugcucgcccugccgcaggaccugcaggccgcccgagcccuua
    uggucaucagcaucaucgugggugcucuggggaugcuucucucagugguagggggcaag
    u
    gcaccaacugcauggaggacgagaccgucaaggccaagaucaugaucaccgccggagccg
    uguucaucguggcaagcaugcugauuauggugcccguguccuggaccgcucacaacguca
    uccgcgacuucuacaacccuaugguggcuuccgggcagaagagggaaaugggggccucgc
    uuuacgucggcugggcggccuccgggcugcugcuccugggaggaggccuccucugcugc
    a
    guugcccaccucguagcaacgacaagcccuacucggccaaguacuccgccgcccgcucug
    uccccgccagcaacuauguguaaggugggccacucuguccacauugccuuuguuauuuuu
    uuucggauugagcucauaacagccuguggccccucacauucuccaggaccugcccugcua
    ugggccacuaacugcuugcuggggacaggcaaacccggacugugcaaaguuacuagcccg
    uagcucuugggcugcuccacauggcuccuuacggccggcaagaauggauguaaaaauauc
    uugcugcuuacauccaaauugcgguggauaugggcugaaggcagaagcagcugggaagg
    g
    caguagaggcgcaagcuggguccugcuggccgggguagcucagcugugacuuuggacuc
    g
    gaguggauguccucauguuagcaaacguccacuguccuuucucuaucccccucacucagc
    cuacacguuacuccagcgcuacucuugccauuacgccccguguuuccgagcacagcuggu
    ccuaccccaagucauggugugcugagugacugaugaggggccauugagagccggugggc
    u
    cugccauggaacccuuccguugauuagcaaugacugugcuugacccacccaccuacccua
    cuaaugaauuucuguagaguggauggacggguuugagggaagaaggguggagguggauu
    aaacugguuuggggagggcuggggaccuagaagcagcccaguguguccccaccccuuuuc
    c
    gcacugucuugcuaauguucugaucacugugcgcccccucccucuucagaaggacccugg
    gccucuugaguuggccccucugaguucccucccuuugcccauuucaaggacaccggccag
    ucugcggaaggaagguacggggggggggggggggggugauggcauuguaccagggaguc
    uccuggacuccccugccuucucugugguuucuuguuuuguaauuaaggucuguucacag
    cuguaauuauuauuauuuucuacaauaaauggcaccugcauacag
    34 U20735 See above (same Accession Number).
    35 U83148 augcagcugagaaaaaugcagaccaucaaaaaggagcccgcaccccuagauccuaccagc
    agcucagacaagaugcugcugcugaacucugccuuagcugagguggccgaggaccuagcc
    ucaggugaagauuugcuccugaacgaagggagcauggggaaaaacaaauccucggcgugu
    cggagaaaacgggaauucauuccggacgagaagaaagacgccauguauugggagaaacgg
    cggaaaaacaacgaagcugccaaaagaucucgggagaagcgccgccucaaugaccugguu
    uuggagaacaagcugauugcccugggagaagaaaaugccacuuuaaaagcugagcugcuc
    ucccugaaauuaaaguuugguuuaauuagcuccacggcguaugcccaagaaauccagaaa
    cucaguaauuccacagcugucuacuuucaggacuaccagacauccaaggcugccgugagc
    ucuuuuguggacgagcaugagccugcgaugguagccggaaguugcaucucagucaucaag
    cacucuccccagagcucgcucuccgaugugucagagguguccucgguggagcacacucag
    gaaagccccgcacagggaggcugccggagcccugagaacaaguucccugugaucaagcag
    gagcccguggaguuggagagcuuugccagggaggccagggaggagcggggcacguauuc
    c
    accuccaucuaccagagcuacaugggaagcucuuucuccacuuacucccacuccccaccc
    cucuugcagguccauggguccacuagcaacuccccaagaaccucagaggccgaugagggu
    guagugggcaagucuucugauggggaagacgaacaacaggucccuaagggccccauccau
    ucuccaguggagcugcaacggguucacgccacgguggugaagguuccggaagugaacccu
    ucugccuuaccgcacaagcuucggauuaaagccaaggccaugcaggucaaaguggaggcu
    uuggacagcgaguuugaaggcaugcagaaacucucuucacccgccgaugcgaucgccaaa
    agacauuuugaccuggagaaacauggaaccucggguauggcccauuccucccucccuccu
    uucucagugcaggugacgaacauucaagauuggucccucaaaucggaacacuggcaucac
    aaagaacugagcagcaaaacucagaguagcuucaaaacaggugugguggaagucaaagac
    gguggcuauaagguuuccgaagcugagaauuuguauuugaagcagggaauagcaaacuua
    ucugcagagguggucucgcucaagagauucauagccacacaaccgaucucggcuucggac
    uccagguaa
    36 L10244 gcucccgggaaacgaaugaggaaccaccuccuccugcuguucaaguacaggggccuggug
    cgcaaagggaagaaaagcaaaagacgaaaauggcuaaauuuaagauccguccagccacug
    ccucugacugcagugacauccugcgacugaucaaggaacuggcuaaauaugaauacaugg
    aagaucaagucauuuuaacugagaaagaucuccaagaggauggcuuuggagaacaccccu
    ucuaccacugccugguugcagaagugccuaaagagcacuggaccccugaaggacauagca
    uuguuggguucgccauguacuauuuuaccuaugacccauggauuggcaaguugcuguau
    c
    uugaagacuucuucgugaugagugauuacagaggcuuugguauaggaucagaaauuuug
    a
    agaaucuaagccagguugccaugaagugucgcugcagcaguaugcacuucuugguagcag
    aauggaaugaaccaucuaucaacuucuacaaaagaagaggugcuucggaucuguccagug
    aagagggauggaggcucuucaagauugacaaagaguacuugcuaaaaauggcagcagagg
    agugaggcgugccgguguagacaaugacaaccuccauugugcuuuagaauaauucucagc
    uucccuugcuuucuaucuuguguguagugaaauaauagagcgagcacccauuccaaagcu
    uuauuaccagugacguuguugcauguuugaaauucggucuguuuaaaguggcagucaug
    uaugugguuuggaggcagaauucuugaacaucuuuugaugaagaacaaggugguaugau
    cuuacuauauaagaaaaacaaaacuucauucuugugagucauuuaaauguguacaaugua
    ca
    cacugguacuuagaguuucuguuuugauucuuuuuuuuuaaauaaacucgcucuuugau
    uu
    37 U88328 cgcuggcuccgugcgccauggucacccacagcaaguuucccgccgccgggaugagccgcc
    cccuggacaccagccugcgccucaagaccuucagcuccaaaagcgaguaccagcuggugg
    ugaacgccgugcgcaagcugcaggagagcggauucuacuggagcgccgugaccggcggcg
    aggcgaaccugcugcucagcgccgagcccgcgggcaccuuucuuauccgcgacagcucgg
    accagcgccacuucuucacguugagcgucaagacccagucggggaccaagaaccuacgca
    uccagugugaggggggcagcuuuucgcugcagagugacccccgaagcacgcagccaguuc
    cccgcuucgacuguguacucaagcuggugcaccacuacaugccgccuccagggacccccu
    ccuuuucuuugccacccacggaacccucguccgaaguuccggagcagccaccugcccagg
    cacuccccgggaguacccccaagagagcuuacuacaucuauucugggggcgagaagauuc
    cgcugguacugagccgaccucucuccuccaacguggccacccuccagcaucuuugucgga
    agacugucaacggccaccuggacuccuaugagaaagugacccagcugccuggacccauuc
    gggaguuccuggaucaguaugaugcuccacuuuaaggagcaaaagggucagaggggggcc
    ugggucggucggucgccucuccuccgaggcacauggcacaagcacaaaaauccagcccca
    acggucgguagcucccagugagccaggggcagauuggcuucuuccucaggcccuccacuc
    ccgcagaguagagcuggcaggaccuggaauucgucugaggggagggggagcugccaccug
    cuuuccccccucccccagcuccagcuucuuucaaguggagccagccggccuggccuggug
    ggacaauaccuuugacaagcggacucuccccuccccuuccuccacacccccucugcuucc
    caagggagguggggacaccuccaaguguugaacuuagaacugcaaggggaaucuucaaac
    uuucccgcuggaacuuguuugcgcuuugauuugguuugaucaagagcaggcaccugggg
    g
    aaggauggaagagaaaagggugugugaaggguuuuuaugcuggccaaagaaauaaccacu
    cccacugcccaaccuaggugaggagugguggcuccuggcucuggggagaguggcaaggg
    g
    ugaccugaagagagcuauacuggugccaggcuccucuccauggggcagcuaaugaaaccu
    cgcagaucccuugcaccccagaacccuccccguugugaagaggcaguagcauuuagaagg
    gagacagaugaggcuggugagcuggccgccuuuuccaacaccgaagggaggcagaucaac
    agaugagccaucuuggagcccagguuuccccuggagcagauggaggguucugcuuuguc
    u
    cuccuauguggggcuaggagacucgccuuaaaugcccucugucccagggauggggauug
    g
    cacacaaggagccaaacacagccaauaggcagagaguugagggauucacccagguggcua
    caggccaggggaaguggcugcaggggagagacccagucacuccaggagacuccugaguua
    acacugggaagacauuggccaguccuagucaucucucggucaguagguccgagagcuucc
    aggcccugcacagcccuccuuucucaccuggggggaggcaggaggugauggagaagccuu
    cccaugccgcucacaggggccucacgggaaugcagcagccaugcaauuaccuggaacugg
    uccuguguuggggagaaacaaguuuucugaagucagguauggggcuggguggggcagcu
    guguguugggguggcuuuuuucucucuguuuugaauaauguuuacaauuugccucaauc
    acuuuuauaaaaauccaccuccagcccgccccucuccccacucaggccuucgaggcugucu
    gaagaugcuugaaaaacucaaccaaaucccaguucaacucagacuuugcacauauauuuau
    auuuauacucagaaaagaaacauuucaguaauuuauaauaaaagagcacuauuuuuuaau
    gaaaaaaaaaaaaaaaaaaaaaaaaaa
    38 X82786 Sequence below.
    aaggaaucuucaguacagaaacaagacccaaguguaaguuuaacuggcaggaggaaccaaccaaggacaguuaagga
    gaaaacccaacccuuagaagaacucaccaguuuccaagaggaaacugccaaaagaauaucuuccaaaucuccacaacc
    ggaagagaaggaaaccuuagcagguuuaaagaggcagcucagaauacaacuaaucaacgaugguguaaaagaagagc
    ccacagcacagagaaagcaaccauccagggaaaccaggaacacacucaaagagccuguaggugacaguauaaauguu
    gaagagguuaagaagucuacaaagcagaaaauugauccaguagcaagugugccugucagcaagaggccacggaggg
    uacccaaggaaaaggcacaggcccuagaauuggcuggucucaaaggaccaauccaaacccuaggccacacugaugaa
    ucagcaagugauaaaggacccacacagaugcccuguaauucucuacaaccagagcaaguugacagcuuccaaagcuc
    accaaggcgacccaggacaagacgugggaaaguagaggcagaugaagagccuucagcaguaagaaagacaguaucaa
    caucaaggcaaacuaugcgaucccgcaaggucccugaaauugguaacaaugguacccaaguuucaaaggccuccaua
    aagcagacauuagauacaguagccaaaguaacuggcagcaggaggcagcuaaggacacauaaaggaugggguucaac
    ccucuugaaguuguuaggugacuccaaagaaauaacccaaauaucagaucacucugagaaacuagcacaugacacca
    guauccuuaagagcacucaacagcaaaagccagacucaguaaaaccucugagaacaugcagaagagugcugagggcc
    ucuaaagagguccccaaggaaguguugguggacaccagagaccaugcaacauuacaaagcaaaagcaacccuuugcu
    guccccgaagaggaagucugcaagagauggaagcauugugagaaccagggcuuugcgcucuuuagcaccaaagcag
    gaagcaacagaugagaagccuguaccugagaaaaaaagggcugcuuccagcaagagguauguaucaccugagccugu
    gaagaugaaacaccugaaaaucgugucaaacaaacuugaaucuguggaagagcagguuagcacuguuaugaaaacag
    aagaaauggaagccaaaagagaaaauccugucacuccagaucagaacucuagguaccgaaagaaaaccaauguaaaac
    agccaaggcccaaguuugaugcaucugcagagaaugucgggauaaagaaaaacgagaagacuaugaagacugccucc
    caggagacagagcugcagaauccagaugauggagccaagaaaucuacaucucggggccaagucagugggaaaagaac
    augcuugaggucuagaggaacgacugagaugccccagccuugugaagcagaagagaaaacaagcaaaccagcugcag
    aaaucuugauaaagccucaggaagagaaaggagucucuggagagucugauguuagguguuugagguccagaaaaac
    uagagucgcuuuggacagugaaccuaagccaaggguaacucguggaaccaagaaagaugcaaaaacucugaaggagg
    augaagacauuguaugcaccaagaaguuaagaacaagaaguuaagaacaagaaguuaccagaaaagugaaacuaugu
    agcaaagacauuuaagaaggaaaaguaaauuugacuuagugauaaguuccagugugguuuucaccuccaguguaaa
    gaugaacuguaaauacuacugcuacugccugaguuuaaggaaggaagcuuugagcuuuccuggucauacucucuuc
    agacgccaauggaggucaugaggaagaucaccagggaucucagcgcaauuacaguuuaggggugagcaggcagaaa
    uguggcccucuguccuauccaauaaagcucugaaauucgcugccaaaa
    39 AW122523 uuuuuuuuuuuuuuuuuaaaucaaaaguuaugaugacuuuauuuuaaaucuuaauacac
    c
    aaaaauauuuuucaauguugugagauaagcacuugaaaauaagaauuccaacacugcugu
    gauuucgcugugaggcuugauagugaauuuucccucugaauauggguuuagggccuagg
    a
    agcagaaugccagucauuuuccaaguagcagugagcuaagcccagcccggucaugcucag
    acccacacuuaacugaaauauucacacuaggaggcggcaccaccaggcaacaccuugauc
    aaccaggagaacaaaagucugaagugccaccaagcauuggggaaaugauauuguuuagau
    gcuagugagucagguucuuucaaauguguccuaacuggguugcaaacauaguugcauccu
    uau
    40 AI642048 gucuguaaaaaucuguuuaauaaauauacaucuuagaaguaccaaaauaauuaccaacaa
    aauacaacauauacaacauuuacaagaaggcgacacagaccuuaguugggggcgacuuuu
    aagcacaugccacugaacaccuggcucuuacaugggaggacacacugggcucacuuacua
    ggucuauggugguucaaucaaaagcacaauaaauaaaacgugguccuuucauuagguucu
    ggaaaaucaccucccccccccccaaaaaaaaucccacaaacaugaaccuuaagagacauu
    uucuuugaauuucagugaucuguuuccccggauuucacaaagacaacagccgaaucaccc
    caguaaaaugccugggucuaggcgcugugugguguggugcuaaguauacccuuucucau
    u
    uuuuuucuuuuucu
    41 L07264 cggccgccagaccuucaagggcuggaguggacgcgcggaccgacucugaacagacagacg
    aaccgcggccgcaagguucccagacaggaucucacccagaggcaggcagcggacagugcc
    uuaguggaaccucgcuguccuccaccgccuggccccggugcaggcguccaguggccgccg
    cauccaaagugaucgcugccuccccgucuccgccagcucgggaccaugaagcugcugccg
    ucggugaugcugaagcucuuucuggccgcaguguuguccgcguuggugaccggugagag
    u
    cuggagcggcuucggagaggucuggcggcagcaaccagcaacccugacccucccacugga
    uccacaaaccagcugcuacccacgggaggugaucgugcucaggggguccaggacuuggaa
    gggacagaucugaaccuuuucaaaguugcuuucuccuccaagccacaaggccuggccacc
    ccaagcaaagaaaggaaugggaaaaagaagaagaaaggaaagggguuagggaagaagaga
    gacccaugccucaggaaauacaaggacuacugcauccacggggagugcagauaccugcag
    gaguuccguacucccucuugcaaaugccucccugguuaccacggacacaggugucauggg
    cugacucuaccaguggagaauccccuauacacauaugaccacacuacagucuuggcugug
    guggcuguaguacugucguccgucugucuucuugucaucgugggacuucucauguuuag
    guaccacaggagaggagguuaugacuuggaaagugaagagaaagugaaguugggcgugg
    cuagcucccacugaggaggaccugagcuauaggaaccuucagaggcuacuucugagacag
    ug
    guucguuacacguucuacauagaggagaaauauuucaccagcagccaugaaaacgucuuc
    auucauuuccaguugcuacccugacugggccuccuguaau
    42 M15668 ucgaccucacggucuugccaaaaugucgcuuuccaacaagcugacuuuggacaagcugga
    cgugaaggggaagcgggucgugaugaggguggacuucaacguuccuaugaagaacaacca
    gauaacaaacaaccaaaggaucaaggcugcuguuccaagcaucaaauucugcuuggacaa
    uggagccaacuccguuguccuuaugagccaccugggccggccugaugguguucccaugcc
    ugacaaguacuccuuagagccaguugcugcugaacucaaaucucugcugggcaaggaugu
    ucuguucuugaaggauugugugggcccagaagucgagaaugccugugccaacccagcggc
    ugggacugucauccugcuggaaaaccuccgcuuucauguagaggaagaagggaagggaaa
    agaugcuucugggaacaagguuaaagcugagccggccaaaauugaugcuuuccgagccuc
    acuguccaaacuaggagaugucuaugucaaugaugcuuuugggacugcacaccgagccca
    uagcuccauggugggugugaaucugccacagaaggcugguggauuuuugaugaagaagg
    a
    gcugaacuacuuugccaaggcuuuggagaguccugagcgacccuuccuggcuaucuuggg
    aggcgcuaaaguugcagacaagauccagcugaucaauaauaugcuagacaaagucaauga
    gaugaucauuggugguggaauggccuuuaccuuccuuaagguccucaacaacauggagau
    uggcacaucucuguaugaugaagaaggagccaagauugucaaagaucucauguccaaagc
    ugagaaaaauggugugaagauuaccuugccuguugacuuugucacugcugacaaauuuga
    ugagaaugccaagacuggccaagcuacuguggccucugguauaccugcuggcuggauggg
    cuuggacugugguacugagagcagcaagaaauaugccgaggcugugggucgagcuaagca
    gauuguuuggaaugguccuguugggguauuugaaugggaagccuuugccaggggaacca
    a
    gucacucauggaugagguggugaaagccacuucuagggguugcaucacuaucauaggug
    g
    uggagacacugccacuugcugugccaaauggaacacagaggauaaagucagccaugugag
    cacugggggcggugccagucuagagcuccuggaagguaaaguccuuccugggguggaug
    c
    ucucagcaauguuuaguauuuucuuuccugccuuugguuccugugcuccuaagcuaacc
    u
    gcuguuuuccacaucuccauuugguguuagcgcaagauucagcuaguggcugagaugug
    g
    cacagaccuuaacagugcaagcaucucagcucgucuuacugcaucagaugcugguucuuc
    aagaucccauuuaaauuccuuagugacuaaaaccauugugcauuguagagggcgucuauu
    uauauucugccugagaaaggaagugagcuguaaaggcugagcucucucucugacguaugu
    agccucugguuagcuucgucacucacuguucuugacucagcauggcaaucugaugaaauu
    cccagcuguaagucugcagaaauuuccgaauuc
    43 AI047508 uuuuuuuuuuuuuuuucauguuuaauaguuuauuucuuauuuuguugcuuauaucuuc
    aauaaaucauuuugcagguuuuguuacagauuuuugauaagccaacucaaguacugauuu
    uucauccucucugaaaguuuuaaaccaggaaaggaaaacguuccauggaauccaucuucca
    cauggugaugagucacaugaacuccaacauucugaagccgcuugacauacaugaguccau
    c
    aucucuuaggacaucauacuggcaagugaugauauaggucuuagguaaaugaugcaauau
    auugucauuggccaacagagggcaugccuucacaucuaugaacccuggauacuuuugagc
    cagcucagaacuaccaggagugggauuuuuguaaacgggacuuuucuuguaucucucagg
    gagcaaggaacuccaauucacaaacuguaacaaguggcuagauuccauggguacauguug
    guuga
    44 AJ001418 Sequence below.
    gagcacccgggacccugggaccacaacgcacuugcucccucucgaccgcgcuccugacccgcagcccucgccaacccuacgg
    auccuaaccaccgccagccuaggugggcgucaggaugaaggcagcccgcuucgugaugcgcagcgccagcucgcugagcag
    cgccagccugguccccagggaggucgagcuguucucccgcuacagcccguccccgcuguccaugaagcagcugcuggacuu
    ugguucagaaaaugccugugaaagaacguccuuugcuuuucugcggcaagagcugcccguccgccuggccaauauccugaa
    ggagauugacauccugccugaccgcuuagugaacacuccuucggugcagcuggugaagagcugguauauccagagccugau
    ggauuugguggaguuccaugagaagagcccagaagaccagaaagcccugucagaguuuguagacacgcuggucaaaguucg
    aaacagacaucauaauguggucccuacaauggcucaaggcauccuggaguauaaagacaccugcacaguggaccccguuacc
    aaucaaaaucuucaguauuuuuuagaccgguuuuacaugaaccgcauuucuacucggaugcucaugaaucagcacauccuc
    auauucagugacucaaagacgggaaacccaagccacauuggaaguaucgacccaaacugugaugugguagcaguaguccaa
    gaugccuuugagugugcaaagaugcucugcgaccaguauuaucuaacaucgccagaauuaaaccucacacaagucaaugga
    aaauuuccaggccaaccaauccacauuguguacguuccuucacaccuucaccacaugcucuucgaacucuucaagaaugcca
    ugagggccacggucgagcaucaagaaaaccguccuuccuugaccccaguagaggccacugucgucuugggaaaagaagacc
    uuacaaucaagauuucugaccgaggaggcgguguuccucugaggauuacugaccgccucuuuaguuacacguacuccacug
    cuccaacaccugugauggacaauucccggaaugccccuuuggcugguuuugguuauggcuugccaauuucucgucucuac
    gccaaguauuuucaaggagaucugaaucucuacucuaugucagguuaugggacagacgcuaucaucuacuuaaaggcuuua
    ucuucugagucuguagaaaagcucccagucuuuaacaagucagccuucaaacauuaucagaugagcuccgaagcugaugac
    ugguguaucccaagcagggaaccgaagaaccuggcgaaggagaagcuggcagugugaagcggaugacgccugacauuuuac
    gggaucaaagugggucuguggcauugcugcuucgugaauguguguggacucuaguuuccgcaaaacaacgcaacacaaaac
    caagcaagcaaaacacaaacacgaguacaaaccuugaccugaugagggacagagcuugguuggaugacccgggagaagucag
    ggcagggcuccaggggauaacagguguccugcuucuccuuuggcaaugcaaaaugacuccugacuguuccaaauacugaaa
    agaagucugccucugaguuacagcucuuucucaacaaguacagaguuugaggcuugcaguugcaacagcuggauguuugg
    ugguucuugcugccagccaaauaaauugguguuuagugaacauuuucaguguuuccccgccaugcaaagcuuggcgccuu
    gggagaaauguguguaaauguacauuguauagguauuagugugcucuagaaaggacaggauggaaggaaucaaagcacuu
    uaucgagcuuguggcugagcauugcagccuaugugcaaacccagaggaaaaguaucucugucaagacagcuccaguaucau
    gcagcuuuuuauguuugcacucaaaaagccagugccuucuggcuggugccgaggcuugggugaaauguuaaauaugcacu
    gaccucagaaagucgaguucaaaagggagauaaaauugccaaagugauccaaggauugugcauguugggaaacccauauga
    gagaaaggauucucauacuuagaacuuuccuaugaagaaauggugguaaacuuucucuaccuagaaguaguggaaauuuca
    aggucaucuuaaaaaagaugugcguuguauauuuuaacuacauucucuacacucuaacauuaacauaucuauucaaauuug
    ucuaguugccaauugucuucagagugugaaaauuuaaauccuucuugaaguaucuuucgugagaguaguauggaaguaaa
    acguucucauaucaggaggaugucauuugugaagcauggggacaucaugaacuagugaugugcgugaggcuugggaggcu
    gaaggguaaggaucagcgggaggccauccauguaggagagagaauuaaaacgaggagcgagggaagcaauggagagaggga
    agcaagaaaggaaccagaaggcuggcaucauccuauuucccacaggcuaacccaagggaugcucugugccuuuccugggga
    gggaagggggugaacugguagauuugaaagcaguauggcuucuucugugggucucccucuuacuagacaaggugaaauga
    uaauucgugucaaauuaaugugaaauuuuuuuccugcauuguaauauuaugaggccugagucgcaguugaguuugaaauu
    uguauuuaauuucacagugaccuagagcuaaggugcucccgguuguggcaauaggagccacaaguauuuucuuucuuucu
    uucguucuuucuuucuuucuuucuuucuuucuuucuuucuuucuuucuuuccuuccuuccuuccuuccuuccuuccuuc
    cuuccuuccuuccuucuuccuuuccuuuucuuuucucuucucuucuuuucuuuuuucuguuucuuuuucuuuuuuugca
    uuguagauguuguccuuaaaagaucagggcagugacuuucacagcaggacuuugacucccacauugguugaucacacaaaa
    cugucagcauuuggguaaucugauguauaguuguuuuguugcugauguuuccauugaaauuucagcucugaguuugugc
    acaugaauacuuacuuguguuuaccaaaggucuaaggcauuugguuacuuaacccaaauauccugaacugugcguaaagua
    auagagaaaagcuuuagggucucaauagugucaccuguguaaaucaaaucaaaauagccuucccuauuauuuaugaaccca
    ugggagacuuuaaacucuuguagauagaugcuaaaugcccaggcccacuuaacuuauuaaugugugaauuacauuuaugu
    uuuuaguuuauaugcaaagaauugugauaauuuuauaauaaauauuuuuauuauaauagu
    45 AI838080 uuuucuuuuuuuuuuuucuucucuuuuuucugccaccaacagcacugugcaguuuauua
    accauucauguacaguagccaucuggggagauugggacagaauugggaucgcaaagugga
    uagauauucagcaucuaauggguuggcagaagccgccauauacucuucacaaauaucuuc
    c
    acagucaauacagaacuagccauuaucccagcacaccgauuugugc
    46 AF072127 agccaggagccucgccccgcagcugcacagagagcaaggguauaggcacuaacuuguuug
    cagagaccccaucaccuucgggagcucaggugcgcaccuugcaaacuccacuuucugcau
    cugccacugagcccgcgggagccucggaaagagccauggccaacgcggggcugcagcugc
    uggguuucauccuggcuucucugggauggaucggcuccaucgucagcacugcccugcccc
    aguggaagauuuacuccuaugcuggggacaacaucgugaccgcucaggccaucuacgagg
    gacuguggauguccugcguuucgcaaagcaccgggcagauacagugcaaagucuucgacu
    ccuugcugaaucugaacaguacuuugcaggcaacccgagccuugaugguaauuggcaucc
    ugcuggggcugaucgcaaucuuuguguccaccauuggcaugaagugcaugaggugccug
    g
    aagaugaugaggugcagaagauguggauggcugucauugggggcauaauauuuuuaauu
    u
    caggucuggcgacauuaguggccacagcaugguauggaaacagaauuguucaagaauucu
    augaccccuugacccccaucaaugccagguaugaauuuggccaggcccucuuuacuggcu
    gggccgcugccucccucugccuucugggagguguccuacuuuccugcuccuguccccgga
    aaacaaccucuuacccaacaccacggccuuaucccaagccaacaccuucuagugggaaag
    acuaugugugacagaggcaaaggaagagaucuuccuggagcaaauacaaaauggacauug
    aaccuaggauugacauuaacgccuuagacuguugaugaugguuaucggaacugugguaga
    acagaaggaagcauauuuuuauacauccccauggcuaugcaggccuuggcug
    47 X80417 Sequence below.
    cggcacgagcggccacugaccgagaagugcccccgccuggagucagccugggggcaggccaggguccaccagaccc
    cgggaugaccgcagccagucgggccaaccccuacagcaucguaucaucagaggaggacgggcugcaccugguuacca
    ugucaggcgccaacgguuuuggcaauggcaaggugcauacacggcgccggugccgcaaccgcuucgucaagaagaa
    cggucagugcaacauugaauucgccaacauggacgagaagucacaacgcuaccuggcugacauguuuaccacgugu
    guggacauccgcuggcgcuacaugcugcucaucuucucucuggccuuucuugccuccugguuguuguuuggcauc
    aucuucugggucauugcugucgcccacggggaccuggagccagccgagggccguggccguacacccugugugcugc
    agguccacggcuucauggcagccuuucucuucuccauugagacacagaccaccauuggcuacgggcuacgcugugu
    gacugaagagugcccgguggcugucuucauggugguggcgcaguccauugugggcugcaucauugacuccuucau
    gaauggugccaucauggccaagauggcacggcccaagaagcgcgcacagacucugcuuuucagccauaaugccgug
    guggcucugcgugacggcaagcucugccucauguggcgcgugggcaaccugcguaagagucacaucguggaggccc
    augugcgggcccagcucaucaagcccagggucacagaggagggugaguacaucccacuggaccagauugacaucga
    ugucggcuuugacaagggccuagaccguaucuuccugguaucacccaucaccaucuugcacgagauugaugaggcc
    agcccacuguuuggcauuagccgucaggaccuugagacagacgacuuugagauuguggucauccuggagggcaugg
    uagaggccacagccaugaccacacaggcucgcaguuccuaccuggcuaacgagauccuguggggccaccgcuuugag
    ccagugcucuucgaagagaagaaccaguacaagauugacuauucacacuuccacaagaccuacgaggugccaucuac
    accccgcugcagcgccaaggaccugguggagaacaaguuccuccugcccagcgccaacucuuucugcuaugagaacg
    agcuggccuuccugaucagagaugaggaggacgaggugucuaccgaccgggauguccgcaccccucagcccgagca
    ugacuuugacagacugcaggccagcagcgcugcccuugugcggcccuacagacgggagucggagauuugaaugccc
    uuggcuuagaugcagcaccacccugaccacaauaggucccaugucccuugggggccugcguuugagcagagcaggc
    cgaaagccucgggucacagacucaguagcaucuuagucuuuuucauguuuuuucgcaguagcuugggaaaguugg
    cgggagcguggauggcccaaaugacuggcucacggccucggaggcugauguauacccaugggcaaggaggugacuu
    cuugggguaggguugcucaggaguuagggacucugcuggaggccuuaggugcaggucccaaccccggugggagga
    ggcuguguauguacacuucauugguuuuuaacuugggcaagacuguuuacaaaccaaaacaaacaaacaaacaauc
    caaaaaaaaaaaaaaaaaaaaaaaaaaaa
    48 AI847051 uuuuuuuuuuuuuuguuccuuuuuuggaauucccaaagcugguuuuaauuucaaaaaau
    uaugaggucucuucccacacuggggauaaugggaugggauagcccaaacuauuaucccag
    u
    ucaaccccagccugguccaaacaccauuacugucacugggcccugucauuucacc
    49 U09504 uccucguccucgucuguuccaucuucuccaaauagcucuaacugugaugccaacggcaau
    cccaagaacgcugauaucucuagcaucgaugguguucugaagagugaccgcacagauugu
    ccugugaaaacaggcaaaaccagugcuccuggcaugacuaagagucacaguggaaugaca
    aaauuuaguggcaugguucuacuguguaaagucuguggggauguggcaucaggauucca
    c
    uauggaguucaugcuugugaaggcuguaaggguuucuuucggaggagcauucagcaaaa
    c
    auccaguauaagaagugccugaagaaugagaacuguuccaucaugaggaugaacaggaac
    cggugccagcagugccgcuuuaagaagugucugucuguggggaugucacgagaugcugu
    u
    cgauuuggccgaauuccuaagcgugaaaaacagagaaugcuaauugaaaugcaaagugca
    augaagaccaugaugaacacccaguucaguggccaccugcagaaugacaccuuagcagaa
    cagcaugaucagucagcacuaccagcucaggaacagcugcggcccaagucccagcuggag
    caagaaaacaucaaaaacacuccuucugauuuugcaaaggaggaagugauugguauggug
    accagagcccacaaggauaccuuucuguauaaucaggaacaucgagaaaacucaucugag
    agcaugccaccucagagaggagaacggauucccaggaacauggagcaauauaauuuaaau
    caagaccaucguggcagugggauucacaaccacuuccccuguagugagaggcagcaacau
    cucaguggacaguacaaagggaggaacauaaugcauuacccaaacggccaugccguuugu
    auugcaaauggacacuguaugaacuucuccagugcuuauacucaaagagucugugauaga
    auuccaguagguggauguucucagacugagaacagaaauaguuaccugugcaacacugga
    gggaggaugcaucugguguguccuaugagcaagucuccauauguggacccucagaagucu
    ggacaugaaaucugggaagaauuuucaaugaguuuuaccccagcaguaaaagagguggug
    gaauuugcaaagaggauuccuggcuuccgagaucugucucagcaugaucaggucaaucug
    uuaaaagcugggacuuuugagguuuuaaugguacgauuugcuucauuauuugaugcaaa
    g
    gaacggaccgucaccuuucuaagugguaagaaguacaguguggaugaccugcacucaaug
    ggagcaggggaucugcucagcucuauguuugaguucagugagaagcugaaugcccuccag
    cucagugaugaggaaaugagcuuguucacagcaguuguucugguaucugcagaucgauc
    u
    ggaauugaaaaugucaacucaguggaggcuuugcaggaaacacucauccgugcacuaagg
    accuuaauaaugaaaaaccauccaaaugaggccuccauuuuuacaaaauuacuucuaaag
    uugccagaucuucgaucuuuaaacaacaugcacucugaggaacucuuggccuuuaaaguu
    cauccuuaa
    50 U22033 auggcguuacuggaucugugcggugccgcucgggggcagcggcccgagugggcugcccu
    g
    gaugcgggaagcgggggucgcucggacccgggacacuacaguuucuccgcgcaagcuccg
    gagcucgcacuuccccggggaaugcagcccaccgcauuccugagguccuuugguggugac
    caggaaaggaauguucaaauugagauggcccacggcacaaccacacucgccuucaaguuc
    cagcauggcgucaucguggcuguggacuccagggccacugcagggaguuacauuagcucc
    uuaaggaugaacaaagugaucgagauuaacccuuaccugcuuggcaccaugucugguugu
    gcagccgacugccaguacugggagaggcuguuggccaaggagugcagguuguauuaucu
    u
    cggaauggggaacgcaucuccgugucugcagcauccaagcugcuuuccaacaugaugcug
    caguaccgggggaugggccucuccaugggcagcaugaucuguggcugggacaagaaggga
    ccaggacuuuacuacguagaugacaaugggacucggcucucgggacagauguuuuccacu
    ggcagcgggaacaccuaugccuacggggugauggacagugguuaccggcaggaccucagu
    ccugaagaggccuacgaccuuggccgcagagcuauugcuuaugcuacccacagagacaac
    uauucuggaggagucgucaacauguaccacaugaaggaagacgguugggugaaaguggag
    aguuccgaugucagugaccugcuguacaaguaccgagaggccgcucuguga
    51 AF033034 Sequence below.
    auuccaggaguuccagcugcuggagaggacuguguagaagguaaccuaccccaucucucuuacuucgucucuagaugggag
    cagacaaguacauauagccugcuuggagcgaggacuuugaaaggcugagacuugcguccacucugagggcaacuaguccag
    acucugacaggucagcauuuccugacugggugcacugaaugccaagcaccagaggucugucaccuuccgacauuggaccaa
    gagagucccagagacccucaaagacacaggaacagagguguccuuugggugagagaccugugcccugccaagccucucagc
    cccuagaaaggcggcagggcugaguagcugagugugugcaacuugggagcagccugauuucagugcuugucaccugugag
    ggcaaaggcagcaugcuuaaugccaucaguccuacucuucucacccguggaacagacgcauaacugaccuuuuuucgugac
    cacuauuagggugcauuuaaaaaucaaucucucucuuuucugcuccucuuucuccaccuucccucaugugugugucugug
    uguguguguuucugugugugugugcgugcaccauacagguauaugugccaugacaugugugcaggucaguagacagccu
    ugguugucagucccugccuucuacuuuguucaaggcagggucuauucuuuauuauugacugcuauccagguacaccaaga
    caguuggccugugagguuccagggagucuccugucucuggcccccaucuuauagcaggaguugugagauuucagaaaugu
    gcacccacaucuagcuuuauuuggcaucuuggcacccaaacuuggguucucaugcuuuccaagcaaggacuucacccacug
    aaccaucucaccagcuccacuauggcgguuuucugaaacugaagggaguggggagaaggcgcugagugugaacgggucug
    gaaggcggguauaaccuuuaaggcuggcugguucugagagaggaaagccggcuugugucccauucaggugccaggugcag
    caucaaauguggcuccacccaacggucaguaacuccgcagacagcaccgugguuaacugccucacagagggggcccagggac
    cuaguuccuuaaagcccacuuaguuuugagagacgacauggaggggcaagcccagcccuguccagcugcauucacacgagg
    cccuucuccuccgaggacccuaccuuuguguuuaguggcugaggcuguguggcucugcuugaagcucuggcuaucaggaa
    ggaccuggcccaccggcuggcaggacaaacuggcccagugaaggcacuguccggucuccugguggaucacaaggaaagggg
    cguggcauguccagauuugaacccuggaugccucuucccaggguaggaagucuaagggucaacaugaauaggugagggug
    gugguggaaagaaucugcaugcaaaaucaggcacucaugucugacaucgucaaacacuauauuuauguagauuuauauggg
    ggugaggcuuggggagcacuuguauuuuugugugcaauugcaagagcuuccuccacauugcaguguuaaauaucauaugg
    ugcuggaccaaccaucucuggaacgagggugaggguuugguacccgugacuaugguucucuguguaguagaaacggcuuc
    uugggaagagagaggaagugcuuugaaaugcauccucucuuguuucauucugcaucauggccagguuucucugcacaaag
    augcaauagacauucaggaaaauaagcgcauugcaagaugucaaaagucaugaaaaaugaaaagcaaggucacugcagcugg
    gguguaguguggcuguagaagcacguuuaugauguacagguuccgggagagggaggaagagagagggagggaaggaggaa
    uggaggaagagagggagagggagcaagagaggggggagggagggaggggagaagggagagagagagagaagaaagagagg
    gagggaagaaggaauggaggaagagagagaaagaggggaagaaagagagggagggaaggagggguggaggaagagagagg
    ugugagggauggagggacagagagggagggaaggagaaauggaggaagagagaaacagagagauggaggaagagagaaaa
    gucaccaauuauuuuucuccccagucgcccccugcccucacaccaaggguacccccacuuuucuuucacucaugcacacaca
    cuacacccaauguuuagguaacacauguagggcaggcagagccuuugugaaugugcuugguaguuuucugccuuacuucu
    aaauaaccaaucacacggaugccacaggguuccuuuagacuguccagggcuccggggcucuuagacuguucccaauguggg
    ugucacaugcaaacaguaagcaccuucuuguuuguggugcccaggaugcugcagguacuagaaauuccugcacagaccuuu
    gcuacuucuacacagacuuacccuuuaaaacauuuaauuauauguuuuuuucagcauaaagaucuauuuugauuauuuuua
    guugcguguaugggugugugccugugugugauuguguaauugucuguaugggaguguaagugccuacagaggcaucgga
    uccccuggagcugccguuacaaguaagggacugggacucagaccugagugguuuggaugagcagugaaugagcgugguga
    gccaucccaccaugcccuauaaacacuuucaagaggacuuugcuggguauggucaaguugucccccugcgacagccacccca
    acuugccauccucauuuacuguacuggaagcagcaaccaccucugcaauuuugcacaagaaccugagagucugaaagacuu
    uuguuggcacuggccuguguuccacugggguggacacauuaaucuaaaagcuaagaagcucacuucagcuuugccaggcaa
    ccagcacguuugagcacaacgguguagccaggaagggugugugggaauuuugaugcuaguuuuucuuuaauuagguugag
    agugaaaucauggucuguaugcauccaacaacuuaauccaaaaaguugguugcacggcuccuggaagguuuaccggcaagg
    aaccugucccauuuuguaaguaggugggacuggagaguugccaagaagccccccucccugcccccuuccuccuggcagauu
    cugcuuaaaaugagugugguucacugcagaauagugucaccugucuucagaugucuaaagacauaagaaaggccuagccag
    cuaagucagaaaaggggacuuuccggugggaaugcauuuuccagucucuaggagaagucuuuauccaaauaaaauuagcau
    agugguggagucacugccagggcgcuggugcggaagcacagcccagagccgaggacguggccauccuccuuccucugaugc
    aaaguguucucuauccccaguuaccaugagcaauaucaguagcaucgugaaccgggcccgugaugccuuuaacucaggcaa
    gacucgaccgcugcaguuccggguugagcagcuggaggcguugcagcgcaugauc
    52 AA960603 uuuuuuuuuccaaaaaauuuuauugggggaaacuacaaaacauuuacaguacaauguuua
    cagucacaauuuguagugaacugauuccccaaaauauauuacaacucaaguugacuuaau
    cuuguuacauucaaaaaccuacuucugucaaaguaguccagagugcacacgcggugcucc
    aacuguaccuacauacaaacuaaacaacugcucauuuaucugccauccaggaaagccgga
    gacauuccugccucuuuacauugaaaaauaauaguacaaguuuuuggacugucauugaac
    aaggcauauucauguaccaccaacauuuc
    53 U47737 Sequence below.
    ggugauccuccaggaccuaagguuucgguauuaucuucggggccucuucacccggaggugagucugcugagcccgaccuc
    agguguucacucgucacgcgagggccuggccacggcggggaagcacugggagagagcgggaggccuugaccgcagcgugu
    aggaucuggggucccggcgcucugcucccgggugcagagugguuggagcaugcgaggcccucugcagcgugcucuguucc
    uaccaucaccccacccccaccccaguccuuccugcacguuucuggagaggcaaaggccccugcugagccuucacuggguacc
    ccuaucucgacuccacuugucugcuugggaucuccaaagggggauacacccucguaaacuagagcaggaggcuggggggug
    gggguagggguagggucugaccaguuagauugaggcuggacccuccccagagugaggagcgggaagcucuuugucuuauc
    caggauuuugcauaucaaugcugagguucuggugauuaaguagggucccuggcuagcggggguaaccugaacaaccuucc
    uccgcuggccgcuagccaauagacaccuggcuuccgcggaugagcccuuugaguuuguggagguguuccucaggucccca
    gggcccugccccguugccugcagauguguggacagacaaaacauuggacucguuuuccaaccacuucaccccuuccuucgc
    uaguccuccgguggacgaugggaugccucauugacuuguuuguggcugugcaugccagagcuuccuagcagacagcucag
    ggcuccaucguuccuaaaucccacuguguaacgaaaaaaaaaaaaacaaaaacaacaacaacaacaacaacaaaaacaaaacca
    gaaaugaggacaggcccagcugggcuuggcacugaacuuggccaccuggagcuuuggcuacccacuacaagaugucagcaa
    gucucaggauagaagaggccuaaggccaguccuggaagauaccaaaacuucaccuccucuauaccccguuccucuaggagaa
    cuguaagccaccuuugucucugggacgccccucucccacucaacagauggcaccagucaucuuccuccucaagaggccagug
    guauucaaaauaggauauugaaaccaagcaagcugguccucuccucuacccuaugccaaagacuucugcccaaagggcccag
    aaaagucccauagccaucuggcuggcuagugugcugacugcuacaggugucaguguccccagcgagcagguaguggagug
    gaggugucuucuuguggaaauggguccugagccucuaccuuguacagaaaggaauuagugaagcccagaggccuccagccc
    gugucucugccacaagagagaggggguggggguggggcuguauuugguucccagggcucagggaagguuuucgguucau
    gcaugcucauuuaucugaccacugucuuaaccccaggacaaccacuuaacuguccacuuccauaucagaguucuugguucc
    ccuuuacuucgucuauggagccccugaguuugggaagggguauuaacugaaagguaccauuagaugaacuuggagaaaga
    uuuguaggugccacgggagauuucagguaaaagcucuuuuaauaauuggcuacaauagcagcaggaggaggccaggaauu
    cugagguagagauuugauuagcagcacguggagcaaaggagacuucugacuccuacagguuucagaaaguggggagaggc
    ucucagaugaauggcuuggacugugagguaaguguuaguguagcacgagacuagcuuaaggcuguacaaauuguccgucu
    gauuggugcauugggccagguagacacuagauaagcaauugggccuuaacucgaguugucuuaauggcuacccccagggca
    gcagggagucaauacugcucuccugucuggggccugaaugcugaaaccaucuacaaaggggacauaaggcauauuggggag
    guguagagugggccaggcccagggucugcugguaucuaugccaggauccugaguggugguggcguagccugucuuuuaac
    caacugccucucucacaguaggcuucuuuggcuugcgaaccuucagcagaugucugccacuuccaacaugagagucuuccu
    gccugugcuguuggcagcccuucugggcauggagcaagguauggagcucugagauaacccugcagccugguccuccuccu
    gaucucucauucuuucuccugaguagaugcccagggcuccuccugagccagcccuccuaggaacgucuggccuucccaccu
    ccuacucucuagccaacugaccuaguuccccugaugcugugcuggcccagcuacaccuuugucaccucguguugacuuuag
    ccacuccaguaccaaagucugaagucaguugucauuggcuggcuuuuuucccugacccagggcugagcaugcuguugcuu
    cuugucaguggguuggggaucaagggccccacuggaaagucaccuuacccuggaaggcuuccccaggcaauaggcaggugu
    caccuacagcauugucccuuuugcaguucauucccugaugugcuucucauguaccgaucagaagaacaauauaaacugccu
    guggccaguuucaugccaggagaaagaccauuacuguaucacguuaucugccgcugcgggcuuuggugaguagcugccug
    uuucccuagccagggccagggaccugcggggcuuuccccauuuccugcuacccugucugucuguccccucauccucacuuu
    ccaugcagggaaugucaaccuuggcuacacccugaacaagggcugcuccccgaucugccccagugaaaaugucaaucucaau
    cucgguguggcguccgugaacagcuacugcugccaaagcuccuucugcaacuucagcgcagcuggccucggacuucgugcc
    aguaucccacuacugggccuuggacuccugcuuagcuuguuggcucugcugcagcugagccccugaccaucccccaugugu
    ucuccauauccccccagcucaggaaaagcccagcuccuuuuaggucccaggggacccuaggaaccuucagcuccuccugggu
    gugucuaguucccccuccacacucucucaacgucagggcuaaguaccaaacucacccauaccugcucuguugaagugguac
    uggcuacccuugcuuccagagccaauccuauaaccucccuuggggaaccagcgaaggggugaagaucuccuuggagucuca
    agaguaccagagucagcgccgaaucuuguggacacacugacaaggaugucuaauccaaauagauguauaucugugugcuca
    guguaucccugugugaaugaagccacuuggauucuggggugggcaaagaagaccugaaaagauucuacagcagaaggccug
    ugucgccaccaaaaccccucccccugguaucauuguacccaccuuguacucuguucaggaggcugcccauggaggacugcc
    accccuccagaugaaggcucccacuacccgaugcaguugagucccauccugcccucucugcccacacuggcuuccugcugcu
    auucuagugccucaaauaaaccguucacacccuu
    54 L00039 cuuccucccucuacagaagaagagcaagaagaugaggaagaaauugauguggugucugug
    gagaagaggcaaaccccugccaagaggucggagucgggcucaucuccauuccgaggccac
    agcaagccuccgcacagcccacugguccucaagaggugccacgucuccacucaccagcac
    aacuacgccgcaccccccuccacaaggaaggacuauccagcugccaagagggccaaguug
    gacaguggcaggguccugaagcagaucagcaacaaccgcaagugcuccagccccaggucc
    ucagacacggaggaaaacgacaagaggcggacacacaacgucuuggaacgucagaggagg
    aacgagcugaagcgcagcuuuuuugcccugcgugaccagaucccugaauuggaaaacaac
    gaaaaggcccccaagguagugauccucaaaaaagccaccgccuacauccuguccauucaa
    gcagacgagcacaagcucaccucugaaaaggacuuauugaggaaacgacgagaacaguug
    aaacacaaacucgaacagcuucgaaacucuggugcauaaacugaccuaacucgaggagga
    gcuggaaucucucgugagagcuaaggagaacgguuccuucugacagaacugaugcgcugg
    aauuaaaaugcaugccaaagccuaaccucacaaccuuggcuggggcuuugggacuguaag
    cuucagccauaauuuuaacugcucaacuaaauaguauaaaagaacuuuuuuuuaugcuuc
    ccacucuuuuuucuuuuuccuuuuaacagauuuguauuuaauuguuuuuuuaaaaaauc
    g
    uuaaaaucuauccaauuuuccauguaaauagggccuugaaauguaaacaacuuuaauaaa
    acguuuauaacaguuacaaaagauuuuaagacauguaccauaauuuuuuuu
    55 D21099 gugggacgggccccccucgaggucgacccacgcguccgggaguacccccgaccuuggcug
    cgugcugacucgcuuccuucugccugcccaggcuugcacuccccggggaucugccucugc
    aucucuugccuucgcuguuguuucccucucuguccagcuccccucccgcucucgcccugg
    agaauggcucagaaggagaacgccuacccguggcccuacggcucaaagacgucucagucu
    ggccugaacacguugucccagagaguccuacggaaggagccugccacgacaucugcgcuu
    gcucucgugaacugguccaacagccaguccacagcugccccuggccagaaguuggcugag
    aacaagagucagggcuccacugccucgcaaggaucccagaacaagcagccuuucacuauu
    gacaacuuugagauugggcguccuuugggcaaaggcaaauuuggaaacguguacuuggc
    u
    cgggagaagaagagccguuucaucguggcacucaagauccucuucaagucucagauugag
    aaggaggggguagagcaccagcuucgccgagagaucgaaauccaggcgcaccugaaacau
    cccaacauccuucaacucuacaacuacuucuacgaccagcagaggaucuacuuaauccug
    gaauacgccccucgcggggaacucuacaaggaacugcagaagagucggaccuucgaugag
    cagcggacugccacgaucauggaggaacugucagaugcccugaccuacugccacaagaag
    aagguaauucacagagacauaaagccggagaaccugcuguuaggucugcagggagaacug
    aagauugcagacuuuggcuggucggugcaugccccaucccugaggaggaagaccaugugc
    ggcacgcuggacuaucugcccccagagaugauugaggggcgcaugcauaaugaaauggua
    gaucuauggugcaucggggugcucugcuaugaacugaugguggggaacccccccuucga
    g
    agcccuagccacagugagacguaucgucggauugucaagguggaccugaaguuccccucu
    ucugugccuucgggcgcccaggaccucaucuccaagcugcucaaacauaaccccuggcaa
    cggcugccccuggcggagguugcagcucacccuuggguccgggccaacucaaggaggguu
    cugccucccucugcccuuuagccugcuccuugguuuuuugucccugucauuuuucagug
    u
    ucuuuguaugucuguguauguguucugagaaggggugggaacuggaaacuauuccuagc
    uccaguucuaggggaucugaucucucuucugaccucuacaggcaaaauuaggcaccccug
    u
    ggugcacauauaugcacgccaaacacaugaaguuacaaacaaacaacaaacacacagaua
    gugcuggagagauggcucggcaguuaaaagcacuggcugcucuucccaggaaccuagaac
    ucaauucuagcacuacauggugcucacggccacugucuguaacacccaguccuggggaau
    cuggggccuucgagccucugcaggcacuaggcauggaugugguauacauguaugcaggca
    aaacacccaugcacugacuuuuaagaaacccucuagucugauuccuuucaauuugucaaa
    uguugaauguuauuuuuaaaauauuauaagccauuuaauacaauuuuucuuugaaacaug
    guauagccuagucugucuuaaauucagaaaaauuaugaagaacaacauuuuauaauaaag
    ucuuaaauguuucauguuuuug
    56 AF026481 Sequence below.
    uugccuaggaagggcgcgucgucucucugcucguccggcugugacggggaagggucccgcugcguuuuggucacugugag
    uaccaaguuugggggauccccgagggacucucgagagcucauuuuagggaugcaggggcuacuccccggugguagagagc
    uuucuaguuggcaggagguuucguauguggaggaggccagcuuaggcagaaagcacauguucucagagaugaggacaaga
    cuaagaccgucuaaucccugaucuuuaccuuccggcccgcugaccugggccuggaugcuaaagcccucugcuuucgucuaa
    acagcgcuaaauaguaaacaguauugccuaagauaaaugcggauuauuacccgauucagugucgggaaaaggcagcuagga
    gagagcggcuggcacgugguaagcacacgguaaguuucgguuaaauuaaaacaaccauccguugagcaucucuuagcaagc
    uccuuccacccuucaaacaaucagugauagugcgucuguuucacugauuagggagcuaaggcuccaacagcagcaaaggaa
    cuaauccgccucugaucaacauggcguuucuuacagggcauuccuuauacgcuuucccacgugcguaacaggaaucgggug
    uucccggguuuuguuuuguuguuguuguuuuuguuuuguuuucuuagugaaagaggcagggugggcuccaggccgcug
    aggauuaauaaagagauucuaugaggaggaaauaacaggcaggugguaugaucgaggcaaggcccugaggaaggcuuggg
    uggggugaguagaaccagagccggaaguccacucagcagccuggggcacuuaaagcuucugcuggggcaaaugguaaggcg
    gcguaaggucacauuccuuucauuucuuccagacucaggaggagaccacaccuuccggagaaccaggccugaaccgaggua
    cuauuuuguagcucucagaagccaggacucugcaacacuguuugcugccuguggaucuucuauauucacagugucccagu
    ugcuucugaucuaccacuguuagauacuucugccacccauccuaagaguauaguuguucuuggaaaggagucucagcugcu
    gucagcaggagucccucauucgacuccugugguugcccuuuccaccaugccaaagaauaaaggcaaaggaggcaaaaacagg
    cgcagagguaaaaaugaaaaugaaucugagaaaagagaguugguguuuaaagaggaugggcaggaguaugcucaggugau
    caaaaugcugggaaauggacgguuggaagcaaugugcuuugacggugugaggaggcugugccauauaagagggaagcuga
    gaaagaagguuuggauaaauaccucggacauuauauugauuggucuacgagacuaucaagauaacaaagcugauguaaucu
    uaaaguauaaugcagaugaagcaagaagucugaaggccuauggagaacuuccagaacaugccaaaaucaaugaaacggacac
    auuugguccuggggaugaugaugaaauccaauuugaugauauuggagaugaugaugaagacauugaugacaucuagccug
    accuaagcaugcuaccuuccaaguucucugaagauagcuccacacaguggcaucuugaccuucaucuguuaaguaaaacuu
    cauggcauguguaugacuuguuaaugcaagcuaaugaauuuuauuuuuugaaguacuauauuucuuugaaaaccaaagau
    guugaguuaucaucuuaagugacauguuaacacuuugugcuuuugaauauaauugaaccuagcgcacagcagugagcacu
    guuaagagacugccuuuccauuuguagcuucauuucuggcacgggaguguuuugugucagcaguucugccagguggccau
    cgaugagcugaaguaaguccuaguccagcacaucugcuucaggccuuuguacucuagucaucuggcugcguucgagacuuc
    ucagcagaacuuauagauguguacggcugcacuuggagucagacaagauauggcuacuuuuguacuuauggagccaugcca
    uuuuauacuuucacguuguauacauucguuugacccuuuaaguuguugccacccauaaaaaggcaucuuacagugcaguu
    uuuaaauuacauggguagcaauuuugaguuuuaaaaauuagucauugcagaaauuaaauacuuagaggagauaauccauua
    ucuugauuuuaggaauauaauaguugacaauguuuauauauaauuuuacuucucuaaggcauacccaaaaauagaaaauga
    aaaagagcagugagucuguucugaugcuugcauugcauagagaaguuuuccaacaaagcagcuguuaauaacacauaaaau
    auguuuuacuuugcaaaguagguuguguuaagucauuuucaaaaaguuaccuacuauaucgaggcucuggauaauuacua
    uguguugauuaaaguuaguuacagaauuguacaagcuaaguuuuccuuaaacuaagcuuagguuaaagggagaggagcca
    cagcucaaugaaaacacgguuccuguuuucuaaauggaggcgcccagaaacacaauaaaacauguugguacaaaaaaaaaaa
    aaaa
    57 J04596 caugaucccagccacccgcucgcuucucugugcagcgcugcugcugcuggccaccagccg
    ccuggccacaggggcgccuaucgccaaugagcugcgcugucagugccugcagaccauggc
    ugggauucaccucaagaacauccagagcuugaagguguugcccucagggccccacugcac
    ccaaaccgaagucauagccacacucaagaauggucgcgaggcuugccuugacccugaagc
    ucccuugguucagaaaauuguccaaaagaugcuaaaagguguccccaaguaacggagaaa
    gaagacagacugcucugauggcaccgucuggugaacgcuggcuucugacaacacuauaca
    auuucuuuugaggguccuauuuauuuauguauuuauuuauuccacaaagugugugguuu
    uuauuuuacauuaauauuuaacaguguggauacauuucaucgaugguaguucaguucug
    cuuguucaguuuaaagaugguaggcuuaaaauauuucauuaaaacuaauauuuauuggga
    gaccacuaagugucaaccacugugcuaguagaaggguguugugcgaaaagaagugcagag
    ag
    auagaguuuaguauuauguuuuguauguauuagggugaggacaugugugggaggcugu
    guuuguaugucuugaaaagaaugucaguuauuuauugaaagucgucuuucauauuguau
    ggucaacacgcacguguugacgcuucccuuggacauuuugugucuaguugguagcccaua
    augggcuuuuacauucuuuaacccuguuucuccuggucucgucucgcucgggacagagac
    guucaaaggacuguuacaaaugaaguaaaaauaaaaguuuuauuaag
    58 X81580 cgucucccgcauucgucugggccgugcaccugcccgcuagcucgcugcacuaccguugcc
    cacaagccaacaugcugccgagauugggcggccccgcgcugccgcugcuccugccgucgu
    ugcucuugcugcugcucuugggcgcgggcggcugcggccccggggugcgcgccgaggug
    c
    uguuccgcugcccacccugcacgcccgaggcucuggccgcuugcgggcccccacccgacg
    cgcccugcgccgagcuggugcgagagcccggcugcggcugcugcuccgugugcgcacggc
    aggagggcgaagcaugcggcgucuacaucccgcgcugcgcccagacgcuacgcugcuauc
    ccaacccgggcuccgagcugccccugaaggcgcuugucacaggcgcggguaccugugaaa
    agagacgcgugggcaccaccccacagcagguugcagacagugaugacgaccacucugagg
    gaggccugguggagaaccacguggaugggaccaugaacauguugggaggugguagcagu
    g
    cuggccggaagccccucaagucaggcaugaaggagcuggcuguguuccgggagaagguca
    augaacagcaccggcagaugggcaagggugccaaacaccucagucuggaggagcccaaga
    aguugcgcccgccucccgccaggaccccuugccagcaggaguuggaccagguccuggagc
    ggaucuccaccaugcgccuuccggaugaucggggcccccuggaacaucucuacucccugc
    acauccccaacugugacaagcauggccgguacaaccuuaagcagugcaagaugucucuga
    acggacagcgcggggagugcuggugugugaaccccaauaccgggaagcccauccagggag
    cucccaccauccggggagaccccgagugccaucucuucuacaacgagcagcaggagacug
    guggggcccaugcccaaagugugcaguaaaccccagccagucggugccuggcuuccccau
    cccgaacaccagcagaaauggagggcgucagggugacggguguggaggaguucccaguuu
    ugacacauguauuuauauuggaaagagaccaacacugagcucagaagccccccucugacc
    ccccccagcggcuguuaacugaaccucccuugcuucuguuagagaggggaagggugguau
    ggagggcacuggguacaggccugggaauggggaaagaaauuuuuauuuuugaaucccug
    u
    gucucuuuuacuuaagauuaaaggaaggaaaaauaaaaaaaaaaaaaaaa
    59 AI314958 gaugugaaaaacguuuuuauuauaaucucuuaaacuuucaguguauauuuucauuacaau
    cauugguacaauaaauauggaaaugcugagcagacaauuaucacaguggccuaugggcug
    agggacagggacccaggaauacuguuacccuggauacuuccucagggccaaucaggaggu
    cuucaaagaguauugagagggagagggauagaaauauuauuaagacugucagugcagcaa
    cuuuuagaaugucuauuaaagccauggauacaggauuuacgauaacagaagauggauacu
    aaaaaagaacagagacucaaguucuccuguaagaggcagaagaaacauugcagaagccag
    ugccuuccucggguccccagugugugcccccauccacccacgcauuguguuggucaucuc
    caccugcccugugcccagcccugugcccacccagguucuccuaggcacccaccuugcacc
    ucgcacg
    60 AF058798 gaauucugcgcgguuuugcauuuuuugggucagauuggcuuuuuacaugauuacgaagc
    uccaacgacuagaccacagggaccgucgccuuggcggccgagcagucguauccaacuugg
    a
    gacagccaguucgccgugugucugucuguccuucaucgcagucauggagagagccagucu
    gauccagaaggccaaguuggcugaacaggccgaacgguaugaagacauggcagcuuucau
    gaagagcgccguggaaaagggcgaggagcucuccugcgaggagcgaaaccugcuuuccgu
    agccuacaagaacguggugggcggccagagagcggccuggaggguccuguccagcaucga
    gcagaagagcaacgaggaggggucagaagagaagggccccgaggugaaagaguaccggga
    gaagguagagaccgagcucagaggugugugcgacaccguacucggccugcuggacucgca
    ccucaucaaaggggcuggagaugcagagagccgcgucuucuaccugaagaugaaggguga
    cuacuaccgcuaccuagccgagguggccacuggcgaugacaagaagcgcaucaucgauuc
    ugcccggucagccuaccaggaggccauggacaucagcaagaaggagaugccgccuaccaa
    ccccauccgccugggccuggcccugaacuuuucagucuuccacuacgagauagccaacag
    ccccgaggaggccaucucgcuggccaagaccaccuucgacgaggccauggccgaccugca
    cacccucagugaggacuccuacaaggacagcacccucaucaugcagcuccugagagacaa
    ccugacgcuguggacagccgacagugcuggggaagaggguggugaggcuccggaugaccc
    ccacaucugaagcagcggaaaaacaacccggguuggcuuggccuuccaguccccagccug
    gcauagaggauuaaaagggagugggauuuugccuuucccaaacccugaauguucagcaac
    accuugggaaggucuuucgaagggggcgcagccaagcugaagccaccagggcagggaauu
    uaauuuuucguguagcuguuuggguggguguuucccaaaaccaucccaccccuguuuuu
    u
    gaacccccuccccaauucuucccccugagccucccucgggcaccuguugcuuuuggaucc
    gaauaauccaggagguuccccacccuguggcugagaaauggacuguggcaagggcugugu
    gugugugagagagagggaaacucugugugugugugugugagagagagagagagagugaa
    ugagagggaaaaaguuugcugggugugaccaugguaccaaucaauaaaguugcccuguga
    gacucaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    61 AW046627 uuuuuuuuuuuuuuuuuaaauaccaaaacauuuaauugaaauaccuguauaaaaaauaug
    aucuucagacauuucacacuuuugaacuuauacaaccccaccccugaugcuuagucacac
    cagggucacagaaacacagcugcuaaaauaaauuaagggcuugagacucugucccccaac
    cccagcuuucagagccagcaagcagacuguacaaggucaauaauuuaaaccccuccccag
    cgcagagugcucagggugacagggucuc
    62 AI848050 uuuuuuuuuuuuuuuuuaauguaacgaccggugugcuucaguuuguuuagcagaaccac
    ucucuugaaucacauuaacuuuugagauuuaaaaaaaacaaaacaaaaaaaaaaaaaaaca
    acaaaaaaaaaaccaacccuccauagcacagcugucuuuuaugcaagcaagagcacaccu
    acuccagcaugauuugucaucuaaagacuugaaaacaaaacaacaacaacaaaaaguuac
    uuauagucaauggauaagcagaguccgaauuuacacuaaucaagacagaccuucgagggg
    ucacgauaaguccggaacuuucaaaccuugcuucguaugaauuguacuaucugaacauaa
    acugcacuuuuauuuuc
    63 AF065441 augagacuccacagccucauccugcucuccuuccuucuccuggcuacucaggcguucuca
    gaaaaggucagaaagagagccaagaacgcaccacacagcacagcggaggaggggguagag
    gguucagcucccucguuagggaaggcccagaauaagcagagaagcaggacaucuaaaucu
    cugacgcauggcaaguuugucaccaaagaccaagccacaugcagaugggcugugacugag
    gaggagcagggcaucagccugaagguccagugcacacaagccgaucaggaguuuucuugu
    guuuuugcuggugacccaacugacugccuuaaacacgacaaagaccagaucuacuggaaa
    cagguugcccgcacgcugcgcaaacagaaaaauaucugcaggaacgccaagagugucuug
    aagaccagagugugcagaaagagauuuccagagucuaaccucaagcuggugaaccccaac
    gcacguggaaacacgaagcccaggaaggagaaagcagaggucuccgcaagggagcacaac
    aagguccaagaagcugucuccacggagccaaacagggucaaagaagacaucacacucaau
    ccagcugcgacccagaccauggccauuagagauccagagugucuagaggauccagaugug
    cucaaccagaggaagaccgcccuggaguucuguggggaaucuuggagcuccauuugcaca
    uucuuccucaacauguuacaggcgacaucaugcuaa
    64 AF022992 Sequence below
    cgggucgacccacgcguccgcccacgcguccggcggagcuucuggguugcgggccgaaacggcaagcggauggagggcgcu
    cgaacggccaggugucgugauuaaauuagucagcccucagagacaggcguccuaccuccuuuauccagaccucaaaagcccc
    guugugcacccgugguggcuucuucaccuucccuguuucguccuccacuguauggcccagacaugagugguccccuagaa
    ggggccgaugggggaggagaccccaggcccggagaaccuuuuuguccuggaggagucccauccccuggggccccgcagcac
    cggccuuguccaggccccagccuggcugaugacacugaugcaaacagcaauggcucaaguggcaaugaguccaacggaccc
    gaguccaggggcgcaucucagcggaguucucauaguuccucuucuggcaauggcaaggacucagcucugcuggagaccacu
    gagagcagcaagaguacaaacucacagagcccauccccacccagcagcuccauugccuacagccuccugagugcgagcucag
    agcaggacaacccaucuaccaguggcugcagcagugaacagucagcucgagccaggacccagaaagaacucaugacugcacu
    ucgggagcucaaacuucgacugccaccagagcgucggggcaagggccgcucugggaccuuggccacacugcaguacgcucu
    ggccugugucaagcagguucaggcuaaccaggaauauuaccagcaguggagucuggaggagggugagccuugugccaugg
    acaugucuacuuacacccuggaggaauuggagcauaucacauccgaauacacacuucgaaaccaggacaccuucucuguggc
    uguguccuuccugacaggccggauugucuauauuucggagcaggcagguguccugcugcguugcaaacgggauguguuuc
    ggggugcccgcuucucagagcuccuggcuccccaggaugugggugucuucuauggcucuacuacaccaucucgacugccca
    ccuggggcacuggcaccucugcagguucaggucucaaggacuucacccaggaaaagucugucuucugccgaaucagaggag
    guccugaccgggauccagggccucgguaccagccauuccgccuaaccccauaugugaccaagauucgggucucagauggag
    ccccugcacagccgugcugccuacucauugccgagcgcauccacucugguuaugaagcuccccggaucccuccugacaagag
    gaucuucaccacccgacacacaccaagcugccucuuccaggauguagaugaaagggcugccccacugcuggguuaccuuccc
    caggaucuccugggggcuccaguacuucucuuucuacauccugaggaccgaccccucaugcuggccauucauaagaagaua
    cugcagcuggcaggccagcccuuugaccauuccccuauucgcuucugugcucggaacggggaauaugucaccauggacacc
    agcugggccgguuuugugcaccccuggagccgcaagguggcuuucguguugggucgccauaaagugcgcacggcaccccu
    gaaugaggacgucuucacucccccagcccccagcccagcuccgucccuggacucugauauccaggagcucucagagcagauc
    caucgauugcugcugcagccugugcacagcuccagccccacggggcucuguggaguuggcccucugauguccccugguccu
    cuacacagcccuggcuccuccagugauagcaaugggggggacgcugaggggccugggccuccugcuccagugacuuuccag
    cagaucuguaaggaugugcaucugguaaagcaccagggacaacagcucuucauugaaucucgggccaagcccccaccccggc
    cccgccuccuugcuacagguacauucaaagccaaaguccuucccugccaguccccaaaccccgaacuggagguggccccagu
    uccugaccaagccucguuagccuuggccccugaggagccagagaggaaagaaaccucuggcuguuccuaccagcagaucaac
    ugccuggacagcauccucagguauuuggagagcugcaacauucccaguacaaccaagcguaaaugugccuccuccuccucc
    uacacugccucuucagccucugaugaugacaagcagagggcagguccaguuccugugggggccaagaaagauccgucguca
    gcaaugcugucuggggagggggcaacuccucggaaggagccaguggugggaggcacccugagcccgcucgcccuggccaau
    aaggcagagagcgugguguccgucaccagucaguguagcuucagcuccaccaucguccaugugggagacaagaagcccccg
    gagucggacaucaucaugauggaagaccugccuggccuggccccuggcccagcccccaguccggcccccagccccacaguag
    ccccugacccaaccccagaugcuuaucgcccagugggucugaccaaggccgugcugucccugcacacacagaaggaagagca
    agccuuccucaaccgcuucagagaucuuggcaggcuucguggacuugacaccucuucuguggcccccucagccccuggcug
    ccaccauggccccauucccccuggucgccgacaccacugccgaucuaaagcaaagcguucccgccaccaccaccaccagaccc
    cccggcccgaaacucccugcuaugucucccauccuucaccugugcccucuucuggacccuggccacccccaccagccacgac
    ccccuucccagcaaugguccagcccuacccacucccaguauucuccccucgaggaggaccccagccccuucccccugccccua
    caucuguguccccugcuaccuucccuucucccuuagugaccccaaugguggccuuggugcucccuaacuaucuauucccua
    ccccaccuaguuauccauauggggugucccaggccccuguugaggggccacccacgccugcuucccacucgcccucuccauc
    ccugcccccaccaccucucagccccccccaccgcccagacuccccacuguucaacucgagaugcagcuccccacuccagcuca
    aucugcugcagcuugaggaguccccccgcacggaggggggcgcugcugcaggaggcccaggaagcagugcugggccccugc
    cucccagugaggagacugcugagccagaggccagauugguggagguuacugagucguccaaucaggaugcacuuucaggc
    uccagcgaccugcuggagcuacugcuccaagaagacucucgcucgggcacaggcuccgcagccucaggcucccugggcucu
    ggccugggcucugggucugguucaggaucccacgaagggggaagcaccucagccagcaucacccgcagcagucagagcagc
    cauacaagcaaguacuuuggcagcaucgacucuuccgaggcugaagcuggggcugcucgggccaggacugagccuggggac
    caggucauuaagugugugcuccaggaccccaucuggcugcucauggccaaugccgaccagcgugucaugaugacauaccag
    gugccguccagggaugcagccucugugcugaagcaagaccgggagaggcuccgggccaugcagaaacagcagccacgguuc
    ucagaggaccagaggcgggaacugggugcugugcacuccuggguccggaagggccagcugccucgggcccuugaugugau
    ggcguguguggacuguggcagcagcguucaagauccuggccacucugaugacccgcucuucucagaacuggauggauugg
    ggcuggagcccauggaagaggguggaggcgaggguggugggugugguguuggcgguggugggggugaugguggugagg
    aggcccagacccaaauuggggcuaaggguucaagcucucaggacucugccauggaggaagaagagcaaggugggggcucau
    ccagcccagcuuuaccugcagaagaaaacagcaccagcuagauccauuuuggggccgcuuacagcagucuaaugagaggcu
    uccuuucgaccauguugggguucuuauaacucaagauacagcuggaccaaccaauaggaaacugccccagcuucucccaaca
    uagggggcuggacccccauuaccagcccaggcacaggagcugccucuagcuucuuagcagaguggaaguucucagccccau
    uuggaggauuguccacgcccgucccacugaggagacgggcgggucuucgguuaagguugcugacaagcugcugaaguggu
    cuguccaaaucccagcugagccugagucccagucgcaggguuggggcugcacuuauuuauuugggagagacagcucacucu
    cccaccucaccccaagaugggaggaggggaaccugggaucuguguaggauccagguccgugaaccccuagcugcuccaggg
    ugggggagguugguggaccauggagucccuggugcugccccucaggugggacccagguguucucagcucuacccucuacc
    aaugacauuuguguuuuugauauugugucuguuauuuuuuuuuuaauacaaaaugacaaaaugaaaaaccaaaaa
    65 AF064088 Sequence below.
    gacagcggagcgcgguggcgucgacgucuagugucucagugcucccgucuguggcuaacuaagcagccagcagccaggcag
    cucgcgaccugcggccaggcagccaaccaugcucaacuucggcgcuucucuccagcaagcuucggaggggaaaauggaacu
    aauuucugaaaagcccagagaggggaugcaucccugggacaaagcugagcagagugacuuugaagcgguggaagcgcucau
    guccaugagcugcgacuggaagucucauuucaagaaauaccuugaaaacaggccugucacaccagugucugauaccuccga
    ggaugacagcuugcuuccagggacgccugaccuucagacagucccagcauuuuguuuaacgccaccuuacagccccucuga
    cuucgaacccucccaagggucaaaucugacugcaucagcgccaucuacuggccacuucaaaucuuucuccgaugcugccaag
    ccuccaggcgccacuccuuucaaagaggaggaaaagaauccuuuagcugccccuccucuuccuaaggcucaagccaccagug
    ucauccgucacacagcugaugcccaacugugcaaccaccaguccugccccgugaaagcagcuagcauccucaacuaucagga
    caauucuuuccggagaagaacccacggaaauguugaggcuacucgaaagaacauacccugugcugcagugucaccaaacaga
    uccaagccugagcccagcacaguguccgauggugaugagaaggcgggcgcugcacuauaugacuuugcugugccuuccuca
    gagacaguaauuuguaggucucagccagcuccuucguccccagugcagaagucaguacuggugucuucaccuacaguaucc
    acugggggagugccaccccugccugucaucugccagaugguuccccuuccugccaacaacucucuuguuagcacaguuguc
    cccagcacuccuccuagccagccaccagcugucugcucaccuguguuguucaugggcacucaggugccugagggcaccguc
    guguuugugguaccccagcccguugugcagagcccaaggccuccaguggugagccccaguggcaccagacugucucccauu
    gccccugcuccuggauucucuccuucagcagcaagggucacuccucagauugacucguccagaguaagaagucacaucugu
    agccacccaggguguggcaagacuuacuuuaaaaguucccaucugaaggcccacgugaggacacacacaggggaaaaaccuu
    ucagcugcagcuggaaaggcugugaaaggagguuugcucgcuccgaugaacuguccagacaccggcggacacacacaggug
    agaagaaguuugccugucccaugugugaccgucgguuuaugaggagcgaccauuuaaccaagcaugcccgacgccaccuau
    cagccaagaagcugccaaacuggcaaauggaaguuagcaaguuaaaugacauugcucugccuccgaccccugcuuccgcaca
    gugacggccagaagauggagacgcagaauaaacuuuggucagagucaggagccagugauggugucaagugcuucugcaag
    gcuguggcccuccaaaagggccuaaaguagaagcccuggccugggggaggccccgccugggugaaaugacaagaagugcuu
    cagccacaggcaggucacagaggacagggcucaguucuuaccacagagagagaggagaacccuuuuauuccucccuuauuu
    uagucuggaaaguuucggcugaggugagcgcagcacagguuuugaaucacauacacauuggggacuuuguuuuugccauu
    uauacuugagaccagcuuugcagugugauucuuucaaaggauugguuucaagaauauagaggcuggaaauuacgguacag
    aaauggagcuagaaaaugaguuuguguuacacagagaugucaucuucuccuagaguuaucuuguuucuuauuccuagucu
    uuccagucaaauccguggauguagcuaaguauaucuaaaacucauuuuuccacuauuguugguauuugaaguugaacagc
    uguacauugcugugggggagccaaaggauuggaacccucauuaauuuaauugcuuggaaaugcagcuaaaauucuucuuu
    ggcauuuuguuuugaaaguuuaggcauuuuacucuacuuuagauuuuaguuugcuugcaguuuuuuguguagauuugaa
    aauuguauaccaauguguuuucuguaggcuuaaaauacacugcacuuuguuuagaaaaaaaucuggagaugaaaauaugua
    uuauaaagaagagaugucaagaauuugagauaacuccuugagaaaguuggcuuuaugucaucagcaaaggacacuuaacgu
    caagcauacacugugguuuuuuuguuuuuuuguuuuuuuuuuucaaauuagaaaguuuaaugaccguuacagauggacag
    ugucuuuuuauuuauaggaguuuuucaggaugucagaguagauagguaggaaaauuguuauuagaacauucgcuucuacc
    uugaaaaggauguuaauguggucauguucuuagcaccacagugucugggcaucugggaaacuccgagacuuuuuuaaagu
    gucaugaugugaucacaccugcaguuuggggcaucgaauccagggccuugcaugucuucuguaagagcucucaucgcuga
    ccuguaucccccgcaagagcaaugacuuuugcuaacaguauuucuuuucuguuguaaaguggacagaugauacacuugguc
    gcaaagguaaauuauucaaaauccacagugaaaaccucaccacacuuucccauuuaaacuauuuccauaucucagagguuuc
    ugacaugcaaacuugaacccuugaaagaagaguuuucuuaaaaauuauaaaaaaucacgaguuacaauuugcacaauauuu
    uuuguugaacuuuauaccuuguuuacaauaaagacuuuucuuug
    66 AI787713 uugucanuugcacgacagaaacugcaggaagaugagaugcgccgggcugcggaggagcgc
    aggaggguaaaggcugaagaguuagcugccagacaaaggguucuagaaaaaauugaaagg
    gacaaagcagagagagccaagaaguauggugguaguguggguucucggucauccccacca
    gcaacagacccagguccuguuccuucuucucccagccaggagcccccuacuaagcgggag
    uaugaccagugucguauacagguuaggcugccugaugggacuucacugacccagacuuuc
    cgggcccgggaacagcuggcagcugugaggcucuacguggagcuucaccguggggagga
    g
    ccuggacaggaccaggacccugugcaguugcucaguggcuuccccagacgggcuuucuca
    gaggcugauauggaacggccucugcaggaacugggacucgugccuucugcuguccucauu
    guggccaagaagugucccagcugaggguucuccaucccaccaucuc
    67 AI853531 uuuuuuuuuuuuuuuuucacaaauaaguaauauaacuuuauuaaaaugaaaagacaauau
    ucaaaauaaugcaacaaaaugaauaaauccuuuguccaauacuguacacacagugcggag
    aucagugcauuuuucuaaagcauguuuuaaccuucauuuaguucauacuaaaguaagcuu
    uaaauagcucaaauaaugucauucagcaguuuaaacugaacagcuuguugggacauggca
    gcagugucccugcuagcaagcaccuucucuuuguguuuaucugcacaagauaaacaauca
    gaggauguaaaaacugaacacaaacugcgugucucacugaaucucagggcagugaagcag
    ccagcgugaguuuucaaagcaggaagaugcugaagugaccucuggcauuaagacguucug
    ugcua
    68 X14678 Sequence below.
    uucauuggaaagcacauugcucuucucaguaauuucuuuaguaucuucaugaauuuuuuccuuuugcgucguuauuucag
    caauucuaucugcagaucauaaagguaguauugacagaugugauucuuuuucuuaaacauuucauuuccaggguaaggaac
    ucaauggcuauguuuuucucucccucuagugcauccuucuccuuuucuaccauuuucacucuauuuaacuucaucauguu
    cagucuggccuuuggguuucaucauagcaaucuguucaacuucacccugcaagauuaaaaaucgauuauggucuaagucaa
    ugccauggcuucuaaggagauuuccaacaucuuuaaacgucuucuucuucccacuuaugugguagacagaagugcuaucuc
    uguaggcgguucuggauacauagaaguugcuguuaggaaggacuucguaaucaucuccuuccuuaucaauuaucuuuuga
    aaaugaacuucuacaguacaacucugaauauccuuguguucaucagaauuauguaucaguaccgauagcuuuuuagaccuu
    auuuuuugugcucgauagccaaacacaaaaagcauggaaucaauaacauuggauuuuccacugccauuugguccaauaaua
    caggaaaagcgcuuauggaaaggucccacaaguuucucuccagcauaggacuugaaguuuugguuuacaauaugaguuauc
    augagacgaggagcuccagcuucacuggccauggcuggagguggggguggagggauacuauucaaaaucuccucuaaacu
    ucuguuauccagcuccucaccuggaggcuuugcgggugcagcgcuccccucaccuacuucgccuacugcaacucccaccacc
    uccucucgauacaagaccgagcucugucggaccuacucagaaagcgggcguugucgcuacggggccaagugccaguuugcu
    cacggccugggugaacuucgccaagccaaucgccaccccaaguacaaaacggaacucugccacaaguucuaccuccagggcc
    gcugccccuauggcucucgaugccacuucauccacaaccccaccgaggaccuagcucucccuggccagccccaugugcugcg
    acaaagcaucagcuucuccggcuugccucaggccgcagaagcucgccgccaccuccaggcuuuucuggcccuucccugucc
    ucuuguuccuuuucgccuuccagcuccccaccgcccccuggggaucuuccacuuuccccuucugccuucucugcugccccu
    gggaccccugugacucgaagagacccuaaccaggccuguugccccuccugccgaaggucuacuacccccagcaccaucuggg
    ggcccuuggguggccuggcucggagcccaucugcccacucucugggauccgauccugaugacuacgccagcagcggcagca
    gccugggggggucagacucaccugucuuugaggcagggguguuugggccuccccagaccccugcacccccaaggcgucucc
    ccaucuucaaucguaucucugucucugagugacaagugccuaccuacccaguauggaucagcuagaucucaaagagagggc
    agggacugcucauugcuguggggaccuggggcacuccucuaaguuaauaagucccaucuucuggacauuccaagaugcaau
    aacccauuucccuggugcugggcuggggcaggucccuaguuugcaaauucaguguuuggguggauccguuccuaggguac
    cuaagauguuugagggagacaguugacaguuggucuuccaggccccaagucuucuguuguuuuugagauaggagcuuauu
    augguaccccaggcuggcuuugaacucaauauaauccugccuuagccuuuuccaaguucugggguuacagguaugcaccag
    ccccucugcaacucuggucuccuggaaucuuaagugcugugaagagccggcucccacaauacuauccuaauuuuuacuaga
    cccugaaguucaguguccgguggucgaagccucuccugagaauccuggugcucaaauuucccuccuaaagcaaauagccaa
    agccauugccaaaucccuucucccccaaccagugggcccuuuauuuaugacgacuuuauuuauuguauuaagauuuuauag
    uauuuauauauauugggucgucuacuccguuuuucuuuuuguaauguuaaaacugauacuguauuaaguauaugcuauaa
    uauauuaauauauugcu
    69 AI854358 cggacgcugcagaccugaccgacgugcugugcgaguucgacgcggugcuggccgacuucg
    cgucgcccuuccacgagcgcacuuccacuaugaggagcaccuagagcgcaugaagcggcg
    cagcagcgccagcgucagcgacagcagcggcuucagcgacucggagagugcagacucagu
    guacagggacagcuucaccuucagugaugagaagcugaauucuccaaccaacuccucucc
    agcucuccugcccuccgcugucacuccucggaaagccaaauuaggugacacuaaagagcu
    cgaagacuucauugccgaucuggacaggaccuuagcauguaugugaagcaaggaguuugg
    gguc
    70 X67668 ccgggccgaggagaagucugcaaaacaagaggcuggggauugccuuagcgagaaaucagu
    ucucuuaggagguuagggaaggaagucuuucucuggaggucugagggaagcgcucgugu
    c
    agaugccggguugucauggguaagggugaccccaucaagccgcugggcaaaauguccucu
    uacgccuuuuuugugcagaccugccgggaggagcacaagaagaagcaucccaauucgucg
    gucaacuucgccgagaucuccaagaaaugcuccaagagauggaagaccaugucugcaaag
    gaaaacucgaaguuugaagauuuggccaagagcgacaaagcuuguuauuacagggagaug
    aagaacuauguuucucccaaaggugauaagaaaggaaagaaaaaagauccaaaugcuccg
    aagagaccaccgucugccuucugccuguuuugcucugaaaaucgcccaaagaucaaaauu
    gaauacccgggccugucuauuggagauacugcgaagaaacugggugagauguggucuga
    g
    cagucugccaaagagaaacaaccguaugagcagaaagcagcuaaacuaaaggagaaguau
    gaaaaggauuuugcugcauaccgugucaagggcaaaagugaagcaggaaagaaggguccu
    gguaggccagcaggcucaaagaagaaugacucagaagaugaggaagaagaagaggaggaa
    gaugaagagggggaagaagaggaugaagaauaaguggcuauccuaaaguguggaguauau
    gugcucaggcaguuauuuugcuaagaauguaaauucaagcgcagcucaacauuagcucca
    guaggaa
    71 K02236 aucacgcuccuagaacucuucaaaccgaucucucgucgaucuucaa
    ccgccgccuccacucgccauggaccccaacugcuccugugccuccgguaagggggacugc
    ugacgggauuucugggagagcuagacaggcuuuuuggccccuccuuuaguaauuacuuu
    a
    aggguacgaccggcuaccccuuccgaaugaauucugaagcacuccugcuccuuuaaacua
    guccuugagauaguggcucgccuacccgggugauuugccucaccuuccuaggagaacagc
    guucagguacucccgggucccacucaaccgcgcucacugacugccuucuacuuuuagaug
    gauccugcuccugcgcuggcgccugcaaaugcaaacaaugcaaauguacuuccugcaaga
    aaaguaaguuggaucuucucugccauuuccccgucacucuccuggggucccuagcccgcc
    gcgccgcgccuucccucccgggagcguucagguggugugccucugacaagguuucucgcu
    cacguucaacucuucucuccccacaggcugcugcuccugcugccccgugggcugugcgaa
    gugcucccagggcugcaucugcaaagaggcuuccgacaagugcagcugcugugccugaag
    gggggcggagggguccccacaucuguguaaauagaccauguagaagccuagccuuuuuug
    uacaacccugacucguucuccauaacuuuuucuauaaagcauguaacugacaauaaaagc
    cguugacuugauu
    72 X51829 Sequence below.
    gcucugaguuuguggaagauuacaugcgauaucccgcgcgaccccgcaucccuuugccggccgggacagccuuugcuacag
    ccugugaaacauugcguccccgagccccacgccugagggcgacaugaacccgcuggcuucgcgagcaguccggacccacgau
    cgcuuuuggcaaccagaaccggcgcuucagcccccggggugacgugcagcccgccgcccagacacauggccccgagcccaag
    accccagcauguccugcacuggagggacgcccacaacuucuaucuccuguccccacugaugggcuugcucagucgggccug
    gagccgccugaggggcccagaagucccagaggcauggcuggcaaaaacaguaacaggagcagaucagauagaagcugcggc
    ucugcugacaccuaccccugucucugguaaccuccucccucauggggagacugaagaaaguggaucuccugaacagaguca
    agcagcccagaggcucugccuuguggaagcugaaaguuccccuccugaaacuuggggacuuucaaauguugaugaguacaa
    ugcaaagccaggacaagaugaccuuagagagaaggaaauggaacgcacagcuggcaaggccacacuacagcccgcuggccug
    caaggggcugauaagaggcuuggggaggugguggcuagagaagagggaguggcugagcccgcuuaucccacaucacagcu
    ggagggugguccagcugagaaugaagaggauggagaaacagugaagacuuaccaagcuucugcugcuuccauagcuccggg
    auacaaacccagcaccccugugccuuucuugggggaggcagaacaucaagccacggaagaaaaaggaacagaaaacaaggcu
    gaccccuccaacucuccuucuucaggcucccacuccagagccugggaguacuacucuagagagaagccuaagcaggagggag
    aagccaagguagaggcacacagggcagggcagggucacccuugucggaaugcugaggcugaggaaggaggaccugagacaa
    cuuuugucuguacuggaaaugccuuccugaaggccuggguguaucgcccaggagaggacacagaggaagaagacaacagcg
    auucggauucagcugaggaagacacagcucagaccggugccaccccccauacaagugccuuccugaaggccuggguguauc
    gcccaggagaggacacagaggaagaagacagcgauucggauucagcugaggaagacacagcucagaccggugccacccccca
    uacaagugccuuccugaaggccuggguguaucgcccaggagaggacacagaggaagaaaacagcgauuuggauucagcuga
    ggaagacacagcucagaccggugccaccccccauacaagugccuuccugaaggccuggguguaucgcccaggagaggacaca
    gaggaagaaaacagcgauuuggauucagcugaggaagacacagcucagaccggugccaccccacauacaagucccuuccuga
    aggccuggguguaucgcccaggagaggacacagaagaugacacagaagaggaagaggacagugagaauguggccccaggug
    acucagaaacagcugacucaagccagagucccugccuucagccccagcguugucuaccaggagagaagaccaagggacgugg
    ggaagagcccccucucuuccagguggccuucuauuuacccggagagaagccagaaucaccuugggcugcaccuaagcugcc
    ccuucgacugcagaggcggcucagauuguucaaagcccccacccgggaucaggaccccgagauuccucuaaaagcucggaag
    guacacuucgcugagaaagucacaguccauuuccuugcugucugggcaggaccagcccaagcugcccgucgaggucccugg
    gagcaguuugcacgagaucgaagccgcuuugcucgacgcauugcccaggcagaggagaagcugggucccuaccuuaccccu
    gauuccagggccagagcaugggcacgccuuagaaacccaucucuuccacaguccgagccucgcucuuccucugaggccacuc
    ccuugacccaagaugugaccacacccucuccccuucccagugaaaccccuucgcccagccuguacuugggagggaggcggg
    gcuaagccugaguaguuuccuauuauuuauuuauuuauuuauuugaauaagaaauaaagccuuuuaauuuguagugau
    73 AW048937 uuuuuuuuuuuuuuuuuaaucaucgagaaguauuuauugagcaccagcuuuggggucgg
    gugugaggacucgggacaaugcagggugcugucccuucucgugagacgcuuacaaucuga
    guggagacagggagggagccacaauacauguucuuggggugcgggcuaaggguagacag
    uccagaccaggauguuacagaaacagggauguuuggggcuggagucagacccacuaagug
    cu
    uugacacccacgguauucaacacugagaaaggaucagccauugcucaguguccugugagc
    ucccuuagcccccaagacaccaucuuggccuggcuccuuguacaacugcuacuaa
    74 AV139913 cccaaaacccauucagcaaaguucccaaccucgacgggcuagcaguauuuaaccagugau
    ggguucacuguuguauuuggugaauacuguauuuuguuucaguucuuucucccagauaa
    uuugaaaacguuccaggagaaggcagcuuccuauaugcagcgugugcuuucuuauucuu
    uuuuuuaauauaugacaguuauuugagaacccauuucuacuuugaauucauuuucguug
    aaagugauguuucuucaccuaccauuuuccuauuaaaguucuguauucaaau
    75 M32490 Sequence below.
    agaccgugagcgagagcgccccagagaagcgccugcaaucucugcgccuccuccgccagcaccucgagagaaggacacccgc
    cgccucggcccucgccucaccgcacuccgggcgcauuugaucccgcugcucgccggcuuguugguucugugucgccgcgcu
    cgccccgguuccuccugcgcgccacaaugagcuccagcaccuucaggacgcucgcugucgccgucacccuucuccacuugac
    cagacuggcgcucuccaccugccccgccgccugccacugcccucuggaggcacccaagugcgccccgggagucggguuggu
    ccgggacggcugcggcugcuguaaggucugcgcuaaacaacucaacgaggacugcagcaaaacucagcccugcgaccacacc
    aagggguuggaaugcaauuucggcgccagcuccaccgcucugaaagggaucugcagagcucagucagaaggcagacccugu
    gaauauaacuccagaaucuaccaaaacggggaaagcuuccagcccaacuguaaacaccagugcacauguauugauggcgccg
    ugggcugcauuccucuguguccccaagaacugucucuccccaaucugggcugucccaacccccggcuggugaaagucagcg
    ggcagugcugugaagaguggguuugugaugaagacagcauuaaggacucccuggacgaccaggaugaccuccucggacuc
    gaugccucggagguggaguuaacgagaaacaaugaguuaaucgcaauuggaaaaggcagcucacugaagaggcuuccuguc
    uuuggcaccgaaccgcgaguucuuuucaacccucugcacgcccauggccagaaaugcaucguucagaccacgucuuggucc
    cagugcuccaagagcugcggaacuggcaucuccacacgaguuaccaaugacaacccagagugccgccuggugaaagagaccc
    ggaucugugaagugcguccuuguggacaaccaguguacagcagccuaaaaaagggcaagaaaugcagcaagaccaagaaauc
    cccagaaccagucagauuuacuuaugcaggaugcuccagugucaagaaauaccggcccaaauacugcggcuccugcguaga
    uggccggugcugcacaccucugcagaccagaacugugaagaugcgguuccgaugcgaagauggagagauguuuuccaagaa
    ugucaugaugauccaguccugcaaauguaacuacaacugcccgcaucccaacgaggcaucguuccgacuguacagccuauuc
    aaugacauccacaaguucagggacuaagugccuccaggguuccuagugugggcuggacagaggagaagcgcaagcaucaug
    gagacgugggugggcggaggaugaauggugccuugcucauucuugaguagcauuaggguauuucaaaacugccaaggggc
    ugauguggacggacagcagcgcagccgcaguuggagaaugccaaggggcugauguggacggacagcagcgcagccgcaguu
    ggagaagacuucgcuucauaguacuggagcgggcauuauugcuccauauuggagcauguuuacggaugacguucuguuuu
    cuguuuguaaauuauuugcuaaguguauuuuuuugcuccagacccccccccccuuucuugguucuacaauuguaauagag
    acaaaauaagauuaguugggccaagugaaagcccugcuuguccuuugacagaaguaaaugaaagcgccucucauuccuucc
    cgagcggagggggacacucugugaguguccuuggggcagcuaccugcacucuaaaacugcaaacagaaaccagguguuuua
    agauugaauguuuuuuuauuuaucaaaguguagcuuuuggggagggaggggaaauguaauacuggaauaauuuguaaau
    gauuuuaauuuuauaucagugaagagaauuuauuuauaaaauuaaucauuuaauaaagaaauauuuaccuaaa
    76 AI121305 ccaauaccacagccgugaccacagccaagaccacagccaaaagccuggccauccgcacuc
    ucggcagcccccuggcagugcccuccauauccugcuuguuuuucucauuaguaaacuccu
    cuucuaaagaaaacuggggaagcagaucuccaaccuccaggucauccucccgagcucauu
    ucaggccagugcuuaaacauacccgaaugaagguuuuauguccucaguccgcagcuccac
    caccuuggaccacagaccugcaacacuagugcacuugagggauacaaaugcuugccugga
    ucuuucagggcacaaauuccgcuucuuguaaauacuuaguccauccauccugcgugua
    77 U35374 auggagaacgaguucacauacgaagauuaugagaccacugccaaguggcuucugcaacac
    acugaauaucgaccucaaguggcagugaucugugguuccggcuuaggagggcugacugc
    u
    cacuuaaaggaggcucagaucuuugacuacaaugagauacccaacuuuccccaaagcaca
    gugcaaggucacgcaggccgacugguguuuggauugcugaauggcagaugcugugugau
    g
    augcaaggccgguuccauauguaugaaggauacucacugucaaaggugacauucccagug
    agaguuuuccaucuucuggguguggaaacuuugguggucaccaaugcugcuggaggacu
    c
    aaccccaauuuugaaguuggagauauuaugcugauccgugaucacaucaaccuaccuggu
    uucuguggccagaacccucuccggggccccaacgaugaaagguuuggaguucguuuuccu
    gccaugucugaugcuuaugaccgggauaugaggcagaaggcuuucagugccuggaaacaa
    augggggagcaacgaaagcuacaagaaggcaccuacgugauguuggcaggccccaacuuu
    gagacuguggcagagagucgucugcuaaagaugcugggggcagaugcuguuggcaugag
    c
    acagucccagaaguuaucgucgcaaggcacugugggcuccgugucuuugguuucucacuc
    auuacgaacaagguugucauggauuaugagaacuuggagaaggccaaucacauggaaguu
    cuggaugccgggaaagcagcugcacagacauuggaaagguuugucuccauucuuauggag
    agcauuccacucccggaucguggcagcuga
    78 X15643 Sequence below.
    uuccaggacagcuggggcuccacgagagaaacccugccucccccccaaaaauggcccaaaguucacugacaaacucacauuu
    gucugauauuuagcuauguaacagcacuuacgguagcaauagaauuugauucucacucaucacaaugaaaauggcuggcgc
    ucucucucucccucucuccccauuucaaaucugcaagcacaccccuuagagauggagagaauuugauccauuggagaaucg
    agcuaaaaauaccaccauggaauugugggaaggauuaaaugcaauaaugcacaaaaggcacauagcagaaugugcccuaaau
    gucagccauuguuaugguauuauguaaucuacaaaguauguuugcuuacuccgugugaaagacuuucagucuaucaaaca
    uaauacaugugaaaucaaaccuugaaaauuaauuuuuuucccaacagucaagacauuugccagcugcagagauuagcauuu
    caugaaucuuagucuugucugauuuuuuuaaugggaaggaacaacuauccucaacuauccuuuuuuuuuuucuguaguuu
    uaaaaugaacuccacaaaacauguuuuuaauauagggaauuauaugaaauuguggggugggcagcgagguuaaaggcagaa
    auagcccaaugguggcacauucacugacacagccuaaaagauuagcaaauuacccagccaacacauacaauuaauacaauuaa
    uauuuuuauaguuaaaacagaguuacuaaagaaauuguuugaaaagaaaauuaugaagacuggaaagacggcucagugcuu
    aagagcuuuggcuagucuuccagagaaccagggucauccagcacucacaaggcagcuugugagcugauacuaucuguauau
    ucaguccuagggaaucugaugcuuuguccugaccuccaaaacaggcacaaauguggugcacaggcaaauguagagauaaga
    cucccaugcacagaacauaaauaacguaguuuaauuuuuuaaauuguaaaacugaaaaugguugcacuugcauuuuuauuu
    ucagcacauccccagauauccgccauauaacaagaaaaugaugccacacucccaagaauuaagaauuacaccucccaacccua
    cccaaauguguauacucuaggucuaaagaaaugcaaaggaugaaguuacugccuugugcgguucucaaggagggaggaugc
    caaaaaaauauuuuuucacaaagugugcugagaaacucuguagcuguuggagucaucuccugugcucuugccaaauaacug
    aaaggggauacacuggaugucugugaauggggugucacuuaugagugcuagaagcggguaccuggauguggacacggugu
    cugagugguccgcacuccaugucuccacaggagcgcuuauguguguuucuuuccuccugcuucuggguguuccuggguuu
    guuuacagccaccucucuguuggaccaggagacagcugucgucuccagaaugagcgggcacgggugugucucgguggcug
    uggcugugguucggcauaagucugagcauguccuggucgucagggugcguuugugcugugugugcguguccgggugagc
    uugcucuuucuguuccuaaaagaaaaugcacccugcgcuaccggcguccagagacucucagcccgcagaggugaccugaac
    ggacagguagcaccuccagacagcgccugguuggcggguugcacagcagccccagauuucucucucuggugccccagcuag
    gguagcuggaagggagcgguggccuggccuccggggagccgcugggccccgccgggcuaacccaggaggaggccggcuag
    gcugggaggguuagcccuuggugcccuacgccugcccgggccagucgcggccgccggccauuggcccaaagaauuguugca
    cgucacuggcaauuccccuagaagucugugcacauaacgggcagggcgcacugcaaggcugcuucucccgcauuuaggcug
    cggcugcaggcaccgcgagcccggagcacccacgagcuuagugugcaggacgcaccccagcacagccaccuacggccgcuga
    augaagcuuccaggaguccgcccccggccgucgccccgucggaggugcacccgcugagagcgccuggaccgaaaggccggu
    gcgcucaccugcuaaccugccagccauggggccacacgggaacgacagcgacuucuugcuggcacccaacggaagccgagcg
    ccacaccacgacgucacucaggaacgggacgaagcguggguugugggcauggccauccucaugucgguuaucguccuggcc
    aucguguuuggcaacgugcuggucaucacagccauugccaaguucgagcgacuacaaaccgucaccaacuacuucauaauc
    uccuuggcgugugcugaucuagucaugggccuagcgguggugccguuuggggccagucacaccucuaugaaaauguggaa
    uuuuggcaacuucuggugcgaguucuggacuuccauugauguguugugcgucacagccagcaucgagacccugugcguga
    uugcaguggaucgcuauguugcuaucacaucgcccuucaaguaccagagccugcugaccaagaauaaggcccgagugguca
    uccugaugguauggauuguaucuggccuuaccuccuuuuugccuauccagaugcacugguaccgugccacccacaagaaag
    cuaucgauuguuacaccgaggagacuugcugugacuucuucacgaaccaggccuacgccaucgcguccucgauugugucuu
    ucuacgugccccugguggugauggucuuugucuauucccgggucuuccagguggccaaaaggcagcugcagaagauagac
    aaaucugaaggaagauuccacgcccaaaaccucagccagguggagcaggaugggcggacgggccacggacuccgaaggucc
    uccaaguucugcuugaaagagcacaaagcccucaagacuuuaggcaucaucaugggcacauucacccucugcuggcugccc
    uucuucauugucaauaucgugcacguuaucagggacaaccucaucccuaaggaaguuuacauucuccuuaacugguugggc
    uacgucaacucugccuucaauccucuuaucuacugucggaguccagauuucaggauugccuuucaagagcuucugugccuu
    cgcaggucuuccuucgaaaccuaugggaacggcuacucuagcaauagcaacggcagaacggacuacacaggggagccaaaca
    cuugucagcuggggcaggagagagaacaggaacugcugugugaggaucccccaggcauggaaggcuuugugaacugucaa
    gguacugugccuagccuuagcguugacucccaaggaaggaacuguaguacaaaugacucgccacuguaauacaggcuuucu
    acucucuaagaccccuccuugacaggacacuaaccagacuauuuaacuugaguguaauaacuuuagaauaaaauuguauaga
    gauuugcagaagggggggcacauccuucucgccuuuuuuuaauuuuuauuuuauuuuuuagcugcaaacaagagagagaa
    cuguauuugagugcuuauuguucuuguauaguucaguuccucuuguauggaacuuaaagguuucugucugaagaguguu
    gguucugaggacugagucugucugucugucugucugucugucugucuggaugauguuuucauguaucuaccucacuggu
    caaguauuaagaaugauauauauugcugcuggaaauccauaucuaaaggagagaguuuucuuccuguacccuuggacuuga
    aauauccugugucuuggaccuuucugcugugacaaugggcccuuucucucucacuccacuuauuuacucaaauggauucga
    ggcagggauuugagggacaacacuaguuguuuuguuuuuguuuuuguuuuuuuguuuguuugguucguuuuugguuug
    uuguuguuuuuugggguuuguuuuuguuuuuguuuuuuuggguuuuuuuuuuuugcugagaaaagucuaaaguuuaca
    guaaauaaauuguuuaaccaugacuucauugcacccguuucuucaaaaccucuugacucuggaguguccuugucucuccca
    cuggaaaccacagguaaacuaugugucgugaccgaugaguggcuuaauguguaagaguaccagaauggcaugcuugcaugc
    accgugccuagcccuuccgugugugucuucagagcuccagaugcaaaccugugccuucccuaacuucacucgugucccaaa
    gcaguccugccuguucacagcauaacccaguauguccuacaguugcucuucugugcugucacuccagaaacccugacucac
    ggaaacagaguuauggacauauguuuuuguccccauaugcucugacaccaccuucagccuuacuugcuuaauaacugugua
    uauuuacaucacugcgucucuuacaguagugccuuuguacugcaucagggcuugguguguucaggaugaggaagauguuc
    uguguaauagcuguucaagcaucuagaaauucugagggaaaucaaaggccucggucagagagagagagagagagcaaagcu
    uuaaaaaacauagcuggugaaugcuucacgcccuucagccucuccucgcuccgucugcugucccgugucuucuguucccaa
    uucucugcacuucuguguaaaccaggcuucccaugucuggcauuccgugcauuauaugauauuuggcggcacgucuguac
    caguaaauucugguagcacccccuaguuacaauaauugcagacacucagcgcguacgacccccuaguuacauaugcagacac
    u
    79 AI849109 uuuuuuuuuuuuuuuuuaagcguccaggcuguacuuuauuuuacacaagugguggcccc
    agaaccacagggacaugaccuggagaguaggcacagugccugaggcugcaagagccaaaua
    cagggauucaugccuucuccuugguccccaugaccaaauuaaaaaaaaaaaaaacaacaa
    aucacacagcacacaucgccacacccauccccuccuuccuuucagcaacagccaauucag
    cuuucuagccaaagacaguggcuacaacugaauuuacagagaaccaugcagccaagaaac
    cagagccacggaggggagaggcuugcguugacuucccacaugugcugucccauagcagcu
    gagugaccccacca
    80 U70132 agaaagauaagggccagcaaggaaagaaugaggaugugggcgccgaggacccguccaaga
    agaagcggcaacgccggcagaggacucauuucacuagccagcagcugcaggagcuggaag
    ccacuuuccagagaaaccgcuacccagacauguccacucgcgaagaaaucgccgugugga
    ccaaccuuacggaagcccgaguccggguuugguucaagaaucgccgggccaaauggagaa
    agcgggaacgcaaccagcaggccgagcugugcaagaauggcuuugggccgcaguucaacg
    ggcucaugcagcccuacgaugacauguaccccggcuauucguacaacaauugggcugcca
    agggccucacgucagcgucucuguccaccaagagcuuccccuucuucaacuccaugaacg
    ucaauccccuguccucucagaguauguuuuccccgcccaacuccaucucaucuaugagua
    ugucguccagcauggugcccuccgcggugaccggcgucccgggcuccagccucaauagcc
    ugaauaacuugaacaaccugagcagcccgucgcugaauuccgcggugcccacgcccgccu
    guccuuacgcgccgccgacuccuccguacguuuauagggacacauguaacucgagccugg
    ccagccugagacugaaagcaaagcagcacuccagcuucggcuacgccagcgugcagaacc
    cggccuccaaccugagugcuugccaguaugcagucgaccggccggugugaaccgcgccca
    gggcgcggggauccgaggacugucggagugggcaacucugccccagaaagacugagaauu
    gugcuagaaguucgugcgcacuaugggaaggaagaggggggaaaaaagaucagaggaaaa
    gaaaccacugaauucaaagagagagcgccuuugauuucaaaggaauguccccaagugucu
    acgucuuucgcuaagaguauucccaacaguuggaggacgcguacgcccacaaauguuuga
    cuggauaugacauuuuaacauuacuauaagcuuguuauuuuuuaaguuuagcauuguua
    a
    cauuaaaaugacugaaaggauguauauauaucgaaaugucaaauuaauuuuauaaaagca
    guuguuaguacuaucacuacaguguuuuuaaaggcuaggcuuuaaaauaaagcauguuau
    acagaaucaguuaggauuuuucgcuugcgagcaaaggaauguauauacuaaaugccacac
    uguauguuucuaacauauuauuauu
    81 M13805 cugagaggccaggugggcggcgaaaucaacguggagauggaugccgcucccgguguggac
    cugagccgcauccugucagagaugcgugaucaguacgagaagauggcggagaagaaccgc
    aaggaugccgaagacugguucuucagcaagaccgaggagcugaaccgcgagguggccacc
    aacagcgagcuggugcagagcggcaagagcgagaucuccgagcucaggcgcaccaugcag
    gcccuggagauugagcugcagucccagcucagcaugaaagcaucucuggagggcagccug
    gcagagacagagaaccgcuacugcgugcagcugucucagauccaggggcugaucggcagu
    guggaggagcagcuggcucagcugcgcugcgagauggagcagcagaaccaggaguacaag
    auccugcuggaugugaagacaaggcuggagcaggagaucgccaccuaccgccgucugcug
    gagggagaggaugcccaccugacucaguacaagccaaaagaaccugugaccacccgccag
    gugcgcaccauuguggaagaaguucaggauggcaaggucaucucaucccgggaacaggug
    caccagaccacccguuaaggacucagcuccuuccgcccaguuccccgaggcugcagagag
    gcagcuucccucuccgcuccggcaucacccuccugcuacagccucuccccagcauuccua
    ugcuugagaccauuaaagcuugcugaccugaagugaacuguggccuuuguucugaacacu
    gaaauaaaugaccauggugac
    82 AV138783 ccccaggggugaaaugaggauucccccacccugcggaacagugaaauguguauaauuaag
    aggagggcgacgacccuugccgcgggacccgggacucgagcccgggacuucgcagcuaca
    gcaaaucuauuuuuaauauugugcugagcaagacagaucgcuugcauauuuuuaaaaauu
    uuuacuacagagacauuccaauaaauucguuaagcc
    83 K02927 Sequence below.
    cugacagucgucucugucccuucuucgccucggagcugcuaacuggucucgaaccucucagcacuucagcuucuagcggcg
    augcaugugaucaagcgagauggccgccaagagcgaguuauguuugacaaaauuacaucacgaauccagaaacucuguuau
    ggacucaacauggacuuuguugauccugcucagaucaccaugaaaguaauccaaggccuauauaguggggucaccacagug
    gaacuggacacccuggcugcugagacagccgcgaccuugaccacgaagcacccugacuaugccauccuggcagcaaggauag
    ccgucucuaacuugcacaaagaaacaaagaaaguguucagugaugugauggaggaucucuacaacuacauaaauccgcacaa
    cggcagacacucucccaugguggccagcucaacacucgacauuguuauggccaauaaggaucgccugaauucugccauuau
    cuaugaccgagauuucucuuauaacuacuuuggcuuuaagacacuggaacggucauauuuguugaagaucaaugguaaag
    uggcugaaagaccacagcauauguugaugaggguuucuguggggauucacaaagaagauauugaugcugcaauugaaacc
    uacaaccuacuuucugagaagugguucacucaugccccuccuacucucuucaaugcugggaccaaccgcccacagcugucua
    gcuguuuccucuugaguaugaaagaugacagcauugaaggaauuuaugauacucugaagcagugugccuugauuucuaag
    uccgcugggggaauugguguugcugugaguuguauucgggccacugguagcuacaucgcugggacuaauggcaauucuaa
    uggccuugugccaaugcugagaguauauaacaacacagcucgcuauguggaucaagguggaaacaagcgcccaggcgcguu
    ugcuauuuaccuggagccuuggcacuuagacaucuuugaguuccuugacuugaagaagaacacaggcaaggaagaacagcg
    agcacgcgaucucuucuuugcacuuuggaucccagaucucuucaugaagcgaguggagacuaaccaggacuggucauugau
    gugucccaaugaguguccuggucuggacgaggucuggggagaggaguuugagaaguuauaugaaaguuacgagaagcagg
    gucguguccgaaaaguuguaaaagcucagcagcuuugguaugccaucauugagucccagacggagaccgguaccccauaca
    ugcucuacaaagauuccuguaaccggaagagcaaccagcagaaccugggaaccaucaaaugcagcaaccuguguacagaaau
    aguagaguacaccaguaaagaugagguugcaguuuguaacuuggcuucucuggcucugaauauguaugucacaccggaaca
    uacguaugacuuugagaaacuggcagaagucacuaaagucauuguccgaaaucugaauaaaauaauugauauaaacuacua
    cccuauuccagaggcacacuuaucaaacaaacgccaucggcccauuggaauugggguacaagguuuagcagaugcuuucau
    ccugaugagauaccccuuugagagcccagaagcccaguuauuaaauaagcagaucuuugaaaccauuuacuauggagcccu
    ggaagccagcugugaacuagccaaggaguauggccccuaugaaacguaugagggaucuccagucagcaaggguauucuuca
    guaugacauguggaauguugcuccuacagaccugugggacuggaagccucucaaggagaagauugcaaaguaugguauaa
    ggaacaguuuacuuauugccccaaugccuacugcuucaacugcccagauucuggggaauaaugaguccauugagccuuaua
    ccaguaacaucuacacucgaagagucuugucaggggaauuucagauugugaauccucacuuacugaaagaucuuacugagc
    ggggcuuguggaaugagagaugaaaaaucagauuauugcaugcaauggcuccauucagagcauaccagaaauuccugauga
    ccugaagcaacucuauaagaccgugugggaaaucucucagaagacuguucucaagauggcagccgagagaggugcuuucau
    cgaucagagccagucuuuaaacauccauauugcugagcccaacuauggcaaacucacuaguaugcacuucuacgguuggaa
    gcaggguuuaaagacuggaauguauuacuuaaggacgaggccugccgcuaauccaauccaguucacucugaacaaggaaaa
    acugaaagauaaggaaaaggcacugaaggaggaggaggagaaggagaggaacacagcagccauggugugcucuuuggagaa
    cagagaggagugccugauguguggauccugagaaaagcggggccugggagacgcagcgggcucuccugcccgagaggcag
    acgauuugagcauagauaggauaguggguuugcuugguuaucagcagcucugcuuggacgugccugccaggacagggagc
    cacgacuuacaguacuguuucuacacaguguaaauaucauuuuuaacaaacagaaaaccaaagccagcuuugauauuaggaa
    ucaagguagaggcuuugggaauacuaaagagccuuccugcaaauagugaggagacuuaggaagucucgucucuccagcuuu
    cccugccuggccauucucaguuugggcaaagagauuuaguuugauuugacugauugccuagaaguaaaaucaagcaauuac
    ucaucagcuaaagaccuuugucuagacaaacuucuauaagucauuuugaaauaaacauuucuaagugau
    84 X07699 Sequence below.
    uugccucagacgcuagcuguagcuggcaggcgguuguacgugcuccagagucgucgguacccgcuacugcagucgcuuuc
    guguggcuuccgcugagcucuuccgagcugcucgcucuccacacgcgccgccgccguaauccgccaccauggugaagcucg
    caaagguaagaggccuuggcgcgccgacgcggacgacuaggccccugcuuucggagggacgcgcgcgcgcccgcccguccg
    ucgcggaggggaggagggcuugcgcgcaaucccgggcgcguucgagggcgccaugcugggggggaaagucucgcgcgacu
    agcgggaggucucgcggugcuugcccucugacuuagggggaugagaagagcggaggcagguuuccgggagggcgauaucg
    aggguucggauguagcgggcgggaggggacggugugaggagagaucggaggagcugagagcggauaggggcacggcgug
    ggaagagagggccaaccuuaggcggcgagcggucccggggccccgccuccccgcgcacgugcucuggugcgcgcccgccac
    gugcucugcggagccccgcacgugucgcgcgacccggggcagugggggagugucuguaguaccccggaaagggggacggc
    agcguggggauggauggguggcccggcgaucugcugucucugccggugaccgggauggacacgugguggaccccugaggu
    ggcggcguggugacuccacgugguggggcuggaagcgagagaaagugggaagcaguuggguuacguggugcugcuuuaa
    gaggugauuucgagauacccccuuccccagcaaauaacuuaaagggaucccuuuaacuggguuuuuuuuuuuuuuuuuuu
    uuuuuuuuuuguggaagaugccagaaaauagauggccaggauuaggagacuuuauaaccuguggcuguuucuuggugua
    gaguucugucugcucaguuaucugugagaaggaaaaaaaaauuaugcgcgguucgcagaaaaaacugccaggagaaugcca
    ugccuggccaagaagaagucuuuaugcuuguguccuuuaguaagaaaaaggugguggccaaaggcaaagugacugaaaaug
    cgugcaauuuuugugugcguuuguaggcuggcaaaacccacggugaggccaagaaaauggcuccuccuccaaaggaggug
    gaagaggauagugaagaugaagaaaugucagaagaugaagaugacagcaguggagaagaggagguaagaagcuauuugcag
    cgaauuaaaccgguggaauugaaugucuggaagucuuagaaauacaggauauguaguaaaugguugaauggcaagccccuu
    ccucccucccucccucccucccucccucccucccucccucccuuccuuccuuccuuccuuccuuccuuccuuccuucugcaa
    gacagucggcaaaacaggggacagaaacaggcagaauuuugaguuccaggcaagcagggaguaguacauagugaaaccuug
    ucucaagaccguuguuauggucaugcucaaucagauuucuuagaaaagcucaggugcugaguccaguuuuuuuuuuuuua
    aaguauugaaagccaugucuccuuauuucaggguuuaauguuuaucuuugugugugcgcgcacccauuaagcaugcuugg
    uacccucauacuagaauguacuuggauccccuggaacuggaguuaaagccacaugugaauguuacauguuacaagaguaac
    acaugugcuuaacuuuugagucaucucuccaguucuugguuguuuguuuuuuuuuuuuuaagccuaucuaauguccauu
    uucuugugcucaaaguuagucucuuaauguagcauuggguauaaaggaaugcuuaugauuuguuugcuuucaagguugu
    caucccucagaaaaaaggcaaaaaggcuaccacaaccccagcaaagaaggugguuguuucacaaacaaaaaaggcugcaguu
    cccacaccagcuaagaaagcagcugugaccccaggcaaaaaggcaguagccacaccagcuaagaaaaacauuacaccagccaa
    agucauuccaacaccggguaagaagggagcugcacaagcaaaagcguugguaccaacuccugguaaaaagggagcugccacu
    ccagcuaagggggcuaagaacgguaagaaugccaagaaggaagacagugaugaggaugaagaugaagaggaugaagaugau
    agcgaugaggaugaagaugaugaggaagaggaugaguuugagccaccaauaguaaaaggagugaagccagcaaaagcagcu
    ccugcugcuccugccucagaggaugaggaagaugaugaggaugaagaugaugaggaagaugaugaugaagaggaggaaga
    uggugaguuagaucuuaggauauuuaggguacugcauguacauucccucacuguuucauuagauuaaaaacucauuuugu
    gcucuuaguucuuuccauaacuuaauagguuuucauuugcuaaguaguuuuuguuuuuuuuaaguauuuguagcauuua
    ucuugucuggauugguagguagcaaauacauuugccugauuugccaucuuucuuccagacucugaggaagaaguuaugga
    gaucacaacagccaaaggaaagaaaacuccugcaaaaguuguuccuaugaaagccaagaguguggcugaggaggaggauga
    ugaggaagaggaugaagaugacgaggaugaggaugaugaggaagaggaugacgaagaugaugaugaggaagaagaggagg
    aagguaaccauauuaacuuuuaaaguaugcugaccuaaguaaggcuuacuggcuaugcuaaagugucugcuuacucaugaa
    uggcauuuuaaaacaucuagaaccuguuaaagcagcaccuggaaaacggaagaaggagaugaccaagcagaaagaagccccu
    gaagccaagaaacagaaaguagaagguaagccugcaaaacuggggaaacagaucagaguagcacuagcacaagugaugagug
    acaaagggacuuaauacugaaccaugggguugaaaugaaauaugcugaugugcuuuauaguuuaugaugaaauuuguugu
    gugcuuaagugggcugaaaguucauuuuuugugugugcaggcucagaaccaacuacaccuuucaaucuguucauuggaaa
    ccuuaauccaaacaagucuguuaaugaauuaaaauuugccaucagugaacuuuuugcuaaaaaugaucuugcuguugugga
    ugucagaacugguacaaauagguaaguuuuaauugaauguuacauguguaucagcuagaauuuuuaguuuccaguuguau
    ucuucccugccuuuaaacauggggcuauaucuaacuauguuaguaaaagucaguugucuccucucguggccuuaaguacag
    uuaaggagcugcaguaagaaagacuauaguauugaacuaaaugaucgagucauagggccugcaauuugaaguuccugugu
    uugacuugauaaagauaaaauaaaauuuaaagaagaaaagauauuaaacacauaaaauuuugugcaguaucuacaacuaugg
    aucugcauagucauaugcuuuuagcuaaaaguauucucuguacuuuuagcgggguccaugcuagcuacugcuguuaguua
    caauauacugaaugaagaaaucgaggugaauuuguuguaaugucuugguacauggacuuguuuuguuuuuuguuuuuuu
    uucuuuaagauuuguuuauguauaugagcacacuguagcuguccagaugguuuugagccuucaugugguuguugggaau
    ugaauuuuuaggaucucagcucgcucugcucucaguccuugcuugcucuggcccaaagauuuauuuguuguuauacauaa
    guacacuguagcugacuuaagaugcaucagaagagggcauuaggucucauuaugggugguggugagccaccaugugguug
    cugggauuugaacucaggaccuucagaagagcagucaaugugcuuacccgcugagccaucucuccagccuuuggacuuggu
    uuuauggaagauaagggugaucuaguuuuauuuuuguuagugcuguagaugcucugugugugugccacaugguauaagu
    gcagaucaccuucucauaccuguaaucuuguuuuuuccaucuucaaggaaauuugguuauguggacuuugagucugcuga
    agaccuagaaaaggccuuggagcucacugguuuaaaaguguuuggcaaugaaauuaaacuagaaaaaccaaaaggaagaga
    uaguaagaaagguauguaagggggucugggugacuggauacuaacagacuuaggcagucuggugccucuuccuuaguuuc
    auccucauugugaaccaaugagaugucauaggucaugugcuuguugacagguuugauuccugggauauauaaugucaggg
    cugacaggaggaauagcuuagugaguaaagaugcuugcugcaaaauguuugaucucuagaagccacaugaagagagaagaa
    ccuuuaaucccagcauuugggagacagaggcaggcagauuucagaguucgaggccagccuggucuacagagugaguuccag
    gacauccagggcuacacagagaaacccugucucggaaaaaaaguuuuagcuuauccucugaccacauguguaucgugacau
    gcuugaagcuuaccuaucucuuaaaugaauucuugaucccuauauuuugaguuucagaauuuggauuuuaaguguuuguu
    ucuuaguugugcugaaaauugaacgugggcuuuucacaugcuaggcaaauuuguuggguuuuuuuguuuguuuuuuucu
    caagacaggguuuuucuguguagcccuggcuguccuggagaccaagcuagccuugaacucagaaaucugccugccucccaa
    gugcugggauuaaaggcgugagucaccacugcccugcuaggcaaucacucuuaaaacugcuacauauccucuguccccuuu
    ugcucauuuuacaagguugcugugugcucaaucugcagucuauguuauaugcuuacuggaucuaggcuuuugauguagaa
    ugaaccauaugagugaugagguaucuuagagauggaaacuaagucuaaauagacuuguuccauauacaacuuaauacauau
    ggucuaaggaacaugauauacauguaaacaaguaggaaggagauaagucugguguccagggaagccaggagagccucaucu
    gaaacuggacagggguuugugagucaucaggugacaauugaacauggguacucuucaugcaaaugguuaguaaccauuga
    gccaccucuccaucccuuuauaccauuuuuuuuuuuagcauauauccuuguacuuuauaggaauuauuugcuuuauucuc
    uugugacuuguaaauugauguacuuaauuaaaucuuuuuccaacauaguucgagcugcaagaacacuucuagccaaaaacc
    ucucuuucaacaucacugaggaugaauuaaaggaaguguuugaagacgccauggagaucagauuagucagccaggauggga
    aaaguaaaggguaguuuugugucuuugaguguuaaaguuuuauuaaguuuagugucuucuuccccucuccuuguccuug
    acagucucuagucugcugcuucaaacuuaacuucauaaccagaaaauugaauaucugguccucuggccucuaccucccaag
    uucugacauuaaaaaugcucaacugauggguuuugaaggugugaucaauuuuacaggcucaauccaaauuggcaucuuuu
    gccacaaguacuauccuucccuauuuuaugagagaaaugugauucuaggcaguucagucuauuguguuggcucuuuuucc
    uccucaccaguuuaaaggaugaagaugagcuaauacauaguaaaagaacaguaaaagcacaugugacuaaguccuucauguc
    ugaugcuugaguaauauuuucucuaacguaguaacugaauugucuuguacucuuucaggauugcuuauauugaauuuaag
    ucugaagcugaugcagagaaaaauuuggaagaaaagcagggggcagaaauugauggacgaucuguuucacucuacuauacu
    ggagagaaaggucaaaggcaagagagaacuggaaagaccagcacuuggagugguaaguuaaaggguuuauuguguagugg
    gaacaggaaucauuuguaucuuuguauuuuaaguaauugguuaccuacaauuaguucaccuuuguucauauagcugaugu
    uuagucuucaugagugaaagcuauuugaaaucauuuccuuuggaguauaguaggcaaauaaagcuuuuuguuggguaugu
    uuuguacuuuaaauggcuuaaacuauuuuagaaaauaguguaagacaacaaagaacaguuaucuaauuagaaugaaaauga
    aaggagcaaagaaggcauuacuguauauaauggauauacacuggugguucuagaauuaugguauaugguacaugguugaa
    gugccauuguuucaguuaacauuccaguaaccuuguggauuagguuggagacaugcuuuauaggugacccacuuacugag
    uguuuaaauauacacagacauacucuaacauaccuugcuaauguguuaucuuuguauuugcaggugaaucaaagacuuugg
    uuuuaaguaaccuuuccuacagugcaacaaaagaaacucuugaggaaguauuugagaaagcaacuuuuaucaaagugcccc
    agaacccacauggcaaaccuaaaggguaaaauaauuuuuacguuagaugugggcuggacauacauacucuuacguauaaga
    guaagacuguccuguuagcuuaaaaaaaaacuaaaguuuuagcuauacaaagggcaguaaauauugauaguaaauuacaug
    cugaugccaaguguuucuaagcuuuauucugagaacugacuuucaaccuucagguaugcauuuauagaauuugcuucauu
    ugaagaugcuaaagaagcuuuaaauuccuguaauaaaauggaaauugagggcagaacaaucaggcuggaguugcaaggauc
    caauucgagaagucguaaguccuuugacaugauaugacuugguugggugauuuuuuuuuuuauuuuuaugugccuauau
    gcucauuuggggcugucuuuauguuguugcugagaaaaugacaacuggauaugaugacugauuaccugagaaauaauuga
    ugaaaucucaagaaaauuccucuagauagucaaguucugauccagcuaugucaacucaaagcagcaaccuugauugcccucu
    gaguacgcuuuuuuuuugauccaguguagucuuuuuuuuuuuaaccuuaauuucuuguguuaauugcuuuuucugguaa
    aagggggaaaaaaagacauaacaaaaucaguguaagggaaggcucagugguugagcacugagaggaccuggguucaaaucc
    cagcacucacauggcaccuaucgagacaggauuucucuguguaguccugccugucguggaacucacucuguagaccaggcu
    ggccucaaacucagaaaucugccugccucugccuccuaggugcugggauuaaaggugugcgccaccacugcccaacccugu
    cuguaacucuuaagaucugacauagauugcagacaaaacacuaaugcacauaaaaaaauuuuuuuuuuuaaaaaaggaaucu
    acuucagcugaauguggcaguauggcaguauucaccaaggguucauagugaaacaggaauuuuucucuuccagaaccaucc
    aaaacucuguuugucaaaggucugucugaggauaccacugaagagaccuuaaaagaaucauuugagggcucuguucgugca
    agaauagucacugaucgggaaacugguucuuccaaaggguaagaaggcguaguaguguugcugcuuuuuagugaauucug
    cauggagaacuugggucugcaguaucuucucauugagcuccuuucuguccaucagugauagauuauggauucgcacgaga
    agaagagagaauucacagaacuggcacuuaucuucuguuuuugcagaaguauauuuggcuguugugugagacauuaugag
    auacuggcgauuuucucgaccugaagaguacuuuggucacucuacuugggugacuugguacuuauuguguuacuuuaaaa
    uguguuuacuuaaugggugagguuuuuuuguuuuucuuuucuguuuuagguuugguuuuguagacuuuaauagugagg
    aagaugccaaagcugccaaggaggccauggaagauggagaaauugacggaaacaaaguuaccuuggacugggccaaaccuaa
    gggugaagguggcuuugguggucgagguggaggcagaggagguuucggaggcagagguggaggcagagguggaagaggu
    ggauuuggaggaagaggccggggaggcuuuggagguaaggaagggaaaggaacuggaaacggauuccuaaaccugugucc
    uaaccaaccaccuuaaaugggaaggucaguccuaauuguaucacccuuugauguuuuuccuuccuauagguagaggaggcu
    uccgaggcggcagaggaggagggggagacuucaagccacaaggaaagaagacgaaguuugaauag
    85 X57800 Sequence below.
    uuagacgguugcgcgcgcagaggguugguaguugucgcuguaggccuucgcugccgcuucugcaucgugaaucgggggac
    cuuggcagccagaccucguuccucuuagaguagcucucaucuagucgccacaacuccgccaccauguuugaggcacgccug
    auccagggcuccauccugaagaaggugcuggaggcucucaaagaccucaucaaugaggccugcugggacgucagcucgggc
    ggcgugaaccugcagagcauggacucgucucacgucuccuugguacagcuuacucugcgcuccgaaggcuucgacacauac
    cgcugcgaccgcaaccuagccaugggcgugaaccucaccaggugagcggguggcgggagcggggccccacucuucccgcuu
    ccgcucuuggcggggcugugacucugcacgcucauuggcuggcuuggccauccgcgcuuucugauuggucuauggugucg
    ggggcagcccucaccaaagcgcgcgguuccgaaaagcccgcgcuggcaguggcgcccacucuguuuccgcgccaaagccaca
    aagcgggaguccgcgggaaaaugagugcuccggagcugugcucauuaaaugccugcagcuuugaguggcuggucuuagcg
    ccuaauaaacgagucuuagugcaaauguaaugucgacuuagagugacaauagaccuuuucuugacuuccagagucucacug
    cgcaucauggauuugaggggaaaucugucaguuuuagcuuuuaacuuugcuacagcuaccuagguuagugccuccuguau
    acguguucaaggacagugugugacuuauuuuaguacagauacauggauuagugccacuuguauacauuuugaaagauuua
    cgaaaaggccagacgugauggggcacauucuccaguacacuagaaaccaaggacaccccgcucaaaaagaugcuuucucgaa
    uguuggcuuuuagugcauuuuacuaagucgguuuuaagaaucacauauacccgguaauuugcuucaccccugagagaguu
    ugggguacccuuagccccuuuaacaguucuccaaccgugagugugaaaugguacaacuuguaauugcuuuuuaaaauauag
    auguggauuacauguugauaaagccugucuuuuuuuuuuugggggguagcauguccaaaauucuaaaaugugcugguaau
    gaagacaucauuacauuaagggcugaagauaaugcagacaccuuagcacuaguauucgaagcaccaaguaaguuaaacaccu
    uuaaaacucggaguuacguguuguuucuguuucucaaaaccaaaaaaaauauuaacaauauuguaaauuccaucauagaua
    ggaccguguggugugcuugguaacauuuuccuucuuuugguagaucaagagaaaguuucagacuaugaaaugaaguuaau
    ggacuuagauguggagcaacuuggaaucccagugaguuaccuuguuucugauuguguguuacccugcugugauaccagcu
    gaugcguguucugaguggaguggugguauuggggaugaauggcacacugccauuucacuaaaccacagcagucuaaaguu
    gauugaguuuuaaagaaaccagaagucuugcauucugaguucugguuaagaugcuaaaucuugagaacaugaagcugagcc
    uucccccuuuucuagacugaccuuuaacuuguggguuuacaggaacaggaguacagcuguguaauaaagaugccgucggg
    ugaauuugcacguauaugccgagaccuuagccacauuggagaugcuguugugauauccugugcaaagaauggggugaagu
    uuucugcaaguggagagcuuggcaaugggaacauuaaguugucacaaacaaguaauguggauaaagaagaggaggcggug
    aguaguaagggggcguccaguuaggugucugaagcagggauggagccucggcuuuuguuuuuauuuauucauucauuuu
    gagauggagucuugaguagaccaagcuaucuuagagcucagagacgacuccauaagcuuuuacagguagcauuuggaaagc
    uaaguguacagccuuuugcuuccuggaaauacucuuggcaaauaagugaggguuggcaagugagcaaaagaaaaugguug
    gggguguauguagcuuuauguguugcagguucaagaguauuugcagucccaagggaaauaagaaagacuucacaaaaugu
    ggaaagaguuguauuaaaugcucuugacaguuacauccauagagaaagcugggcaugaugucucaaacccacaacugaugu
    acucaaagcuacagcaggaagauucucagcuuaaagucaaccuggcagaaaaucuagcucaaaaagaaugaggaagaaauug
    ggaaggcaaaggaagauguucuccgaguccuccucauucaaguagaacauacuaggccucuuuaauuucuaaguaucccug
    aaucgaggcuuuuucucaggaauccaauguauauuucauggcuacacuuuuuuuuuucuuuuuuaaguuuugcuagcuag
    ccugagcaucagaauuacacacagaagucugaacuaaauaggauuuuuaggguuuaguauagugaaauucagagugcuucu
    gcaaguauuuaagguaaauauaagguguuacuuggccucugcaugaauuuaaaguaaaugaaaguguaagaauucgaacau
    agauaaacacacaacccaagaacuaguucuuaaccuuaaucugcugaauuauuucuacuuccauaucaacuucagcuccuca
    guucucaaauacugacauguaauucaucaguauuugucugaugugcaagcauuuccacaacaaaagaaauuaaggaauuuu
    ucaguauccacauguucaaggauugggaauugaauaaaauugauaaucauacaaugaagacugguuuacugucccuuagcu
    ugcauucagcuguugguucuuguuuuuggaagugguuauguguuaucuuccucucuucaugcauucuuugcaagagaag
    uauguacaaucugaauaggaacaacuuucuccuuuguuuugauugcuugggguguggcucuacaggaugggcaagcuaga
    cuuuuuucuucuuuagucaagguuuucaucaacccuuccaaaaugauaacuauuuguuuugcuuugugguauaauaccgu
    gaucuaauagugugaguuucugaugucuacagugagccuguuuucuccucuagguaaccauagagaugaaugagccuguu
    caccuaacguuugcucugagguaccugaacuuuuucacaaaagccacuccacugucuccuacaguaacacucaguaugucu
    gcagaugugccccuugguaagaugauaaguuugaacauuguuuuguaaugugguauuuauaguauucggugguuuaauu
    uuuccugucuuucaguuguagaguauaaaauugcugacaugggacacuuaaaguauuauuuggcucccaagauugaagau
    gaggaagcaucuuaggcauugcuagaaauugagaaaacuaaaccuuugaagauugcuccugagaugccagcguguccugag
    gucuuuucugucaccaaguuuguaccugaguauucuuaaauauuaaaauaaaauauguagauaucuucuguaaauaaccua
    cuuucuuuucucuccauucuccauaauuugcuuaaagaauaagcuccaaaguaaaaacuaguuuuguuaacaugaauguuu
    cugcuuuacaaauacuggugauuuuccaucaaugaucuugacgcuaaaugcaguuuuaagaaauauuguucaauuuaaaua
    aaguuaacaauuugaaaaguca
    86 M35247 Sequence below.
    ggugcaggauguaggccugcagaauugucagacccaguggcggcuuuugccacuggaagaauuuccaacauaaaacaga
    ugaucaguuugggacaaucgauucugcgaccagagguagugucauuugguuacuuuuaaaauucagauugucuggug
    uuuuccaaucacucgcgacuguaauuugaaguuggguucugagauaauacaaucgcugucgcucuaguuuauaaagcu
    guccaagaucugcccagucccagauguccuggguccucagggccgcuguggucugccaacuucugcagcuggaugcca
    gaccauccuggacucggaucccuuuggguauuucuacaccgcugugucccggccuggccuuggggagcccugguucau
    aaucgucggcuauguggacgacaugcagguccugcgcuucagcagcaaggaggagacuccgaggauggcacccuggcu
    ggagcaggaggaagcaggugacugggagcagcagacucguauagucacaauucaaggacagcugucugaaaggaaucug
    augacccugguucauuuuuacaacaagagcauggacgacucucacacacuacaguggcugcaaggcugcgauguggagc
    cagaucggcaccugugucucugguacaaccagcucgccuaugauagcgaggaucuccccacccugaacgaaaacccaagu
    uccuguacagugggaaacagcacuguaccucacaucucucaggaccugaagagccacugcucagaucugcugcagaaau
    accuggaaaaagggaaggagaggcugcugcguucagacccuccaaaggcacaugugacccgucaccccagaccugaagg
    ugaugucacccugagguguugggcccugggcuucuacccugcugacaucacccugaccuggcaguugaauggggagga
    gcugacccaggacauggagcuuguggagaccaggccugcaggggauggaaccuuccagaagugggcagcugugguggu
    gccucuugggaaagagcagaguuacacaugccauguguaccaugaggggcugccugagccccucauccugagauggga
    gccugcaugguaccaaaagccuuggauuuggauuguugccaugguuuucauuuuguucaucauuugucucugugugg
    uuugcauaugcaugaagaagaaugcaggugggagaggaaggcgugacacccaagaagcaggcagagacaguccccaaga
    cucuagcaagacuguuguggaugaugaggagauggggguuugcuuuuggaagauuaaguccuguaaaacuugucuag
    gccacuccccaggaacuucaguuggcgagucuuuacugucaccuugacuggauuuaggaucaucugggagaugccccu
    uugaguggcugggcugugaggacagcaggccaguucuugccacccuggacagaaacacaucucaccuuucuggcucaag
    gaucugaacaccugucucuugccuacucggcuucuagucaggcauuuugucaccuugucaagggucccagggacacaaa
    gcucccuccucucacccacagcacucuggguccuacccucagugcuucagggacauuuaaucaggucaaauugggauca
    auggcuuugaugcagaaaagaacuguggacuaauagagauaggguuuaauuaaaaaauauaucuuuuuaauuuu
    87 AI553024 cuggcacggacauggcugucuucugucugcugugugggaaacgcuuucaggcacaaagcg
    cacuccagcagcacauggagguccacgcaggcgugcgcagcuauauuugcagugagugca
    accgcaccuuccccagccacacggcucucaagcgccaccuucgcucacauacagguuuuu
    uucuccaugugucaccaagugaaguuugugccuucuauagcaaagagaauauuuuuuaca
    uccuacuaacaguagauuuuuuuguagugaacauuuuuuguauuuuuauuuauaagucuc
    auaagaaaaauagcgauguucaguuguauaccuugaaucugcaguuagaagagaauaaag
    uuaacuc
    88 X16995 Sequence below.
    ggagccccagugcaggaggcugcgaaaguugggggagugugcuagaaggacugcggagcggagcgcacgcgggaccaggc
    ugcgacugggucgcuggucccggccacagggagugggagccggcuggguagguaccccgcagggagcguguuucuguuuc
    uagggacagugcaugaaagagaugggguguacgcgcgggcgaaaaggaaggguguuuucgggucggcuuacgaggagggg
    uguguagggugcauuuuugguauuaaaggauagcucuuggaguagggugagccagggcuugaaguuuaggaagcgggcg
    aagggucugcaaggugcuugguuuugguagguagugggcgcuuguuuaggagguuuccccgcuaggaucuccaguguga
    ggcacucuguacucuggguuuggguguugauugccggguaggggguugucugagcauggacugggaaaagguacucaga
    gcuucggcguugcuggggauccauccaaguacaaguaagauuggauuuccacgggucuccuucccggcucucagcccccuu
    ucccaguguuuacuuaauacuucauaggcuguacuuagauuuucugauucccuuaccgaacuuucuuucugaaccgugcu
    ggaagaccuggggguugcugaaggaaauggccagcuagguuggcuggguaaugguuguguuagacuaaguugucagagu
    aucuagaaaccuaggagcuguagccuggugcagcuacugaaagccgcacguggagccuggguggaaguugcucacgauaga
    gucucgauguaguacugacuaggggggagaccccuucugucaucagacagacuuguauaccccaguggucuuuugaaucu
    guuagguagggugcagccugcgggcuuggucaccuaacagguguugccaggaccugccccaagccggauucucccacuccc
    ucuuucaaccccgccucuuccuccuccuugagacacccccacccccucaggaggcuagaugcagaucuguaucuuguguug
    cugacuaucggccugaagcuggguagauugguggggguugauccggauguaggauguccaaguggagaaacaggauuuga
    auggagcuggaacaaacgcccaguccugacugcugccacccuucuuccuccacccccaacccaucccuucccaggcuucuug
    caaacagaggcagaaguggccauauuucuuucuuucucccaggugcuguaugcccuagggacuugacacggggcaggcgg
    ggugggaacugguuggggggggacgugcuguuuuaugggaagucguaugccuagccagcgguggagcuguccuggcuag
    gcacccaggggugguguggggaaugggagaaauacugggacuagagggucucaagggccagcagguggugauagucuuuu
    ucuccaccccacccucugcuccaccaccccucugccucagcaccccucugcccucagcaccccucugccucagcacccucugc
    cuccagccacccucugccucagcacccucugccucagcacccucugccucagcacccucugccucagcacccucugccucag
    uguuccugugugaccugucuuuucaacuagaaagucuagaacuguacagaccccagaguuggagguggaaagggacacuag
    guccuggagccuccucugugggcuuuuuugaccagaugagaacguaagggccuccuccagcuaucccuggucauucaggu
    gcuucagguuugugaccuuugcugagacccuggaugcugcagcaaacagacaucugcuuuagcagagggacagcuugucu
    cugugcauccgcugguaggauccuccacucuguccaauuagcuugcgcugcugcuggguucugaguguucucuuacaaaa
    ugacaagguuagggggcuggagagauggcucaggggcuaagagcacccauguggcaguuugcaacugucuguaacuccug
    uuccaggggggaucugacacccucacacggacaaacaugcaggcaaaacaccuauuggcauggaaaaugaaaauaaaugacc
    ggguuagcugagaaauuccuuuugagaguugucuuuucuccaguccaggacugcucucuggaucuuccugcucaguuccu
    cgccucccuuccauauaugguauuuaagguuuuacuuuuuuuugcguuuucaauuguuuuuaauuguauuuauaugugu
    cucugugugugcacaugagcauggguguccuacaaggcuagagacaucagauguccuggagcuagaguuacagaugguug
    ugagccaccugauguaguugcugggaacuggauuuaguuccuguggaagagcagugcaugcucuuaaccacugagcaacu
    ucuccacgcggcccccccccaguauacgguauuuaaaacucuauagcaaugcuacccaacccauuguggagcuggggaugg
    ugagguggccuaguuccccccaacuccuggaaacaugucagaaaguacagagugggugccugugggaucagcaugcgggg
    gguggugguggugagguguggggcugcuuucucccgaggcuaccgugauagacaguuguaccuugcuggcagccucuacc
    ccauuuccaggaugucagucucugcagacguaugggggacgguggggaagggguauacagagccaugggugugccuggga
    auguacucccaggaagugacugguugaaaagucagcagaucuccugggggauagaggggugggcugaagcucuguggguu
    gccucucucagcccugaccugugaacagggaggcuggggguuggaggaacacagcuucccccuguuccuggggggacaug
    cuggacagccuuuccuagcucccccggcccacugggguguggcuggucgucggacugagcucuuuuggaccuggucucug
    ccugugagcuuugugacucguugagauagcauuugggcugagggauugggagucuucuguucuuugguccugacacccg
    cuuccuugucuaggccugccaccuggcuccccccaccccccuccccggccuaccaaguuucuugcuucccuuacugaccccu
    ccuccucccuccuuugugucuccucccucuccagagaugcccuguauucaagcucaauauggaacaccagcaacgagcccag
    gaccgcgugaccaccugaccggugauccccuggcccuugaguucggcaagccuaccauggaccuggccagccccgagacagc
    accugccgcaccugcuacacugcccagcuucagcaccuucauggacggguacaccggagaguuugacaccuuccucuaccag
    cugccggggacgacccagccgugcuccucagcuuguuccucugccuccuccacgucuucuuccucauccucggccaccucc
    cccgcuucggcguccuucaaguuugaggacuuccagguguacggcugcuacccgggcacccugagcggcccauuagaugag
    acccuauccuccagcggcucugaguacuauggcagucccugcucagcccccucgccaucuacacccaacuuccagccguccc
    agcuuucucccugggacggcucauuuggccacuucuccccgagccagacuuaugaaggccucugggcauggacagagcagu
    ugccuaaggcuucuucagggccuccgccaccuccaaccuucuucuccuucaguccucccacuggccccagccccagccuggc
    ccagaguucucugaaauuguucccaccaccagccacccaccagcuuggggagggggagagcuauuccaugccagcagcuuu
    ccccggcuuggcacccaccucuccgaaccgugacacuuccggcauucuggacgcacccgugaccuccaccaagucccggagc
    ggggcuucagguggcagcgagggccgcugugcagucuguggugacaaugcuucgugucagcacuaugggguccgcaccug
    ugagggcugcaagggcuucuucaagguauuuuguugguucugggggacgaugauaucauguuggagguggggguggagu
    gggucauccguugggaucuguagugaccucuccugagguuucuucccagcugguucuguccugcaggacgagggacaggu
    gugugccaucuuagaggcugggacuuuuuauucagcagggcacacaucucucuagggcugcagaaagcuggggaaggggg
    cagaagguguguguguguguggccugcaguggugcucagaaacagaaaaccuagugggcagccucugguucuccacagaa
    cuuguguuucuggcacuggaugaaaggacacaggcagaggguuugguucuugcuggggguggacuugggaacaggcugu
    guguuugucccagugcugggugccugcuuggcnnnncccaccuccanccccuuaguccucuccucugcgccaggaaaagg
    gcagguggacacaugcagacaccuguuagaacaggugucuggacggccgugggaguuccuagacccuggucuuggguucu
    gggaucuucccugugagguugaaaccuucuccaguaucucccagacuccucucugcgcucuggcccuccguuucucccucc
    cccuacauccaaauguuaggaaaauagcuaugaacagagggcgcuuuugucugcgucggccacaggaucuggacggucccc
    uccccugggcucuccaccccccccccaaaccccaugcucugacagccuguuccguguccccccuuccuccagcgcacaguac
    agaaaagcgccaaguacaucugccuggcaaacaaggauugcccuguggacaagaggcggcggaaccgcugccaguucugcc
    gcuuccagaagugccuggcugugggcauggugaaggaagguggguggcaagauggugcccucggcauaggcgaccugaug
    gggugggacagccgggcucaccaggaucugcaccuaauucccacucccacuucuagauuccagccccuaaaugcaggugua
    gcuuccaccugcuuucuggaaaggguggggugaggagggccuugugggguccccaucauggucugaguucucugucucu
    gacuucucagaagugggguguauagugugcccugaagacccuccuucuccaggucuccuuucucaauacugcccgucucuc
    ugcaguuguacggacagacagccuaaaagggcggcggggccggcuaccuucaaaacccaagcagccuccagaugccuccccu
    accaaucuucucacuucccucauccgggcacacuuggacuccgggccuagcacugccaaauuggacuauuccaaggugagg
    ucuugcccgcccaucugcccugcccugagaacauaugcaaugccuuugugccuguuaggaaaggcucucccuccagggcaa
    caucaggaaacaagcauccucuauguacuggcuaguuggagaaaugcauugggauggguguggggucggggagccaguua
    caaacagcugccguagcccuguuuuccugugggaauugacaagcacaugggcccagaauagggcucuuuugcacgccugga
    ucuggugucccagugcaugagagcucuguaaugcagcuuguguaggcuuugcuguggacccaaugcaggacacagcugug
    ugaugcaggccuugcuguggagccagugcgugacacagcuguguggugcaggcccucauguggaacuuaccugcguuccu
    uucaguuccaggaacuggugcugccccgcuucgggaaggaagaugccggugacgugcaacaauuuuaugacuugcucucu
    gguucccuggacguuauccgaaagugggcagaaaaaaucccuggcuucauugagcuuugcccaggagaccaagaccuguug
    cuagagucugccuuccuggaacucuucauccuccgccuggcauaccgguaagcugcccaccauccuccuagcccuggcccca
    gcccugcggccccggccugccuggacccugaguccugacuguucucugccuucugccagaucuaaacccggugaggggaag
    cucaucuucugcucaggccugguacuacaccagcugcagugugcccguggcuuuggugauuggauugacaacauccuggc
    cuucucacggucccugcacagcuuggguguugauguucccgccuuugccugccuguccgcucugguccucaucacuggug
    aguggcagaaacuagacugggcccaaggguugcaggaccauuggguagguagcaucuaacacuuuggggaccccuagagug
    ccugcaacauugggauguuaggaccugcaaagggacuuagcucuauucgccccuaaagcuuaaaucagccuccgaaugacc
    ccggacuccucagguacgacuguaggcgcugggcaucuagcuuagggauucuguuuguuuaaaaaccuagcugucaaccuc
    acaagacacaggaacgugcacacaugaauuuuucacauucugcgcuuggauagcuaucgccaugguccagaaacaggaccua
    cuucagcucuguugggcucccuccuuauugucucuguaagagguaaccacucugccagccucaguggcauuccugucaug
    gauuuuacugugcguaucacaggguauggacucuaguguuaaauguagagguuucugggucccuucucguuccgcuccca
    uuuccacuuaaauuucuuaggggauccuccugaguagaucaagaccaggagcuggaucuugaaaggguagggagugauau
    cuacacccagcucaguccuuagucuguccugcgagacuccaggauuuuagaacaguguggagccuggaccuccagaaaacc
    uggauuaggcuuuugccuuggccagccauucagugguuucaaauauugaccagucuggacagugggcuccugugggacgu
    gcuagagggcuggggaagcuugucagggagaaggcgucaacugagcggggcugacucuaccuucccugcugcagaucgac
    acgggcuccaggacccucgucggguggaagagcugcagaaucgcauugcuagcugucugaaggagcacauggcuaccgugg
    caggagacccacagccggccagcugccugucacgucugcugggcaaacugccugagcuucggacccugugcacucaaggcc
    ugcagcgcaucuuuugccucaaguuggaggacuugguacccccuccaccuauuguggacaagaucuuuauggacacauugu
    cuuucugaccccugcccugaacaugugugcgcacacgugcgugcucuucugucacccaugugccuuuaagccuauagccca
    cggacccccagaccacccuacccccagccugguuuugagcuaagacugacguaccuccucacuccagaagauggacagagaa
    cucaagaccugggggaggguguguauucacgggggugaccccacuauuugucuuaucccuccagcucaguccuggccuuc
    guguguuuuuguaagauaaaccauuuuuaacacauaccacucuguuguaaauaagcugacgcuacuguaaauacagaaagg
    aagagguugagauggggguugggaggaagggguggggcucccaccagcugggcgagccuccaacucgagaucucuuccgc
    ucuccuuccauguguacauaacugucacucaagaaggugauugacagauucugauuuauauuuguguauuuuccuggauu
    uauaggaugugacuuuucugauuaauauauuuaauauauugaauaaaaaauagacauguaguugaaa
    89 AF038562 ggcacgaggcugugcccgccaugucugcuacccaucacaagaccucccugccucagggcg
    uccgcgugggcacugucaugagaauucgaggcuuggucccugaccaggcuggcagguucc
    auguaaaccugcuaugcggugaggagcaaggagcagaugccgccuugcacuuuaacccga
    ggcuggacacuuccgagguugucuucaacaccaaacaacaaggcaaauggggccgugagg
    agcgaggcaccggcauccccuuccagcgugggcagcccuuugaagugcuccucaucgcca
    cagaggaaggcuucaaggcuguggucggggaugacgaauaucuccacuuccaccaccggc
    ugccgcccgcccgcguucgcuugguggaagugggcggagacgugcagcugcauucauuga
    auaucuucuaagcaaaggacccaagggccuuugcccgguuacggguuggggguuuuuuga
    ucccacaagaaagguuuuggaucggccaauaacauuuuucuguuguucugaaaaauuaaa
    aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    90 Y11666 gccacauuguugcaccaacuccagugcuggagucucaggacaccaca
    ggcuacccggaguuguucugcuuuggagauccgagggcaggagcaucacgccagugacuc
    ugauaggugcgaucgccggauuggaacagaacugucauuuuuuuccgaaguugagccuua
    gugacccagugagugaaguuagcgacgggacgcuaagcagcuagaccggucggcaggagu
    gagacuuaggguaccuucuaguaguugugauuaaaaaaauugaaaaaaagaaaaaaaaaa
    acccuguuucuggaaacuugaggcccucagcuggugagccaucgugguuaagcuucuuug
    uguggcuccuggagucuucgaucccagccggacacccgggccugguuucaaagcggucgg
    acagcgcugccugcuccaucgguagcgcucgagccucgguuucucuauuuggccccgacu
    cgccgcaacaagaugaucgccucgcauaugaucgccugcuuauucacggagcucaaccaa
    aaccaagugcaga
    91 U40930 Sequence below.
    cccagcuguuucguccguaccuagaccgcgguuauggcgucguucacggugaaggccuaucuucugggcaaggaggag
    g
    cgacccgcgagauccgccgcuucagcuucugcuucagcccggagccggaggcggaagcccaagccgcggccggcccggg
    g
    cccugcgagaggcugcugagccgaguggcugugcuguuccccacgcugaggccuggcggcuuccaggcgcacuaccgc
    g
    augaggauggggacuugguugccuuuuccagugaugaggagcugacaauggcuauguccuaugugaaagaugacaucu
    uccgcaucuacauuaaagagaagaaggagugccggcgggaacaucgcccaccaugugcucaggaggcaccccgaaacau
    ggugcaccccaaugugaucugugaugguugcaacgggccuguggugggaacucgcuauaagugcagugugugcccaga
    cuacgaccugugcagcgugugcgaggggaagggccugcacagggaacacagcaagcucaucuuucccaaccccuuuggc
    caccucucugauagcuucucucauagccgcuggcuucggaagcugaaacauggacacuuuggcuggccuggcugggag
    augggcccaccggggaacuggagcccacguccuccucgugcaggggauggccgcccuugcccuacagcugagucagcuu
    cugcuccaccagaagaucccaaugucaauuuccugaagaaugugggggagaguguggcagcugcccucagcccucuagg
    cauugagguugacauugauguggaacauggagggaagagaagccgccugacacccacuaccccagaaaguuccagcaca
    ggcacagaagacaagaguaacacucagccaagcagcugcucuucggaagucagcaaaccugacggggcuggggagggcc
    cugcucagucucugacagagcaaaugaaaaagauagccuuggagucggugggacagccagaggaacagauggagucggg
    aaacugcucaggaggagacgaugacuggacacauuugucuucaaaagaaguggacccaucuacaggugaacuccagucu
    cuacagaugccagaaucggaagggccaagcucucuagaccccucacaggaaggacccacagggcugaaggaagcugcccu
    auacccacaucucccaccagaggcugauccccggcugauugagucccucucccagaugcuguccauggguuucucggau
    gaaggcggcuggcucaccaggcuccuacagaccaagaauuacgacaucggggcugcucuggacacgauccaguauucga
    agcacccuccaccauugugauagugcuguggccaagccccacccccuuugucuuguaguugcaucacguagagcagcag
    ggcuucuauagauaggcccagugucuuggcauucuuguagaaucuucaggugggaaugugugaugccuuuucaggcaa
    uaggaaagugcaugaggagaguuuugaaugugcauaugcugacgccugagaacagacccagguacccguggcugagcu
    gagcuuccucugcuuccccuaggccuggccucugcagggaacugcagcacacacugcacucccaccugcucuugccgcc
    agcauugcaccagcaguccagaauuccugccugacaacccguguuuccuuuauuaaaagugauuaguacaacugcuagu
    uauuuucaacaaauaaagccauuauguuaagaggggacuguccauagugagugaaagguggcaggcaggggccuacag
    cuccuagggaauggagaauucaugugaagccgaaugaaggaucuuaucuuauacugucccccuuucuaauggccacucu
    uuaguguuugugucuaauguuaaugcuuaaagcacaggacccccauguagcuuccucugacuugguuuguaaguaacc
    uguaauaaaaugccauaugcacuuuaacca
    92 D26090 Sequence below.
    gagggaauugcgggaccccgucuggggaagcucccgccgccccggggugcucagcucucugucucccuugacccaggu
    a
    cagucaugucgggcuucgacgacccgggcauuuucuacagcgacagcuucgguggcgaccccggugcggaagagggcc
    a
    ggcccgcaagucgcaacugcagaggcgauucaaggaguuccugagacaguaccgagugggcaccgaucgcacgggcuuc
    a
    ccuucaaguacagagaugaacucaagcggcauuacaaccugggugaauacuggaucgagguggagauggaggaccuggc
    c
    aguuuugacgaggaacuggcugaccacuugcauaaacagccggccgagcacuuacagcugcuugaggaagcugccaagg
    a
    gguggcagaugaggugacccggccccggccagcuggagaugagcugcuccaagacauccaggucaugcucaagucagau
    g
    ccagcccgucgagcauucggauucugaagucagacaugaugucacaccuggugaagaucccuggcaucaucauuucagc
    c
    ucugcaguccgugccaaggcuacucguaucuccauucagugccgcagcugccacaacacccucaccaauaucgccaugcc
    caggccuagagggcuaugccuucccaggaagugcaauauggaucaggcugggcgcccaaagugcccacuggauccauac
    uucaucaugccugacaagugcaaguguguggacuuccagacucugaaacugcaggagcugccugaugcagucccucaug
    gugagaugcccaggcacaugcagcuuuauugugacagguaccugugugacaagguuguuccugggaacagggucacca
    ucaugggcauuuauuccaucaagaaguuuggcuugaaccccagcaagggccgggacaggguaggugugggcauccgga
    gcucguacauccgagugcugggcauccagguggacacagauggcucuggccgaagcuuugcugggucugucagcccac
    aggaagaggaggaauuucgucgccuggcugcccuccccaacauauaugagcucaucuccaagagcauuucccccuccau
    cuuugggggcauggauaugaagaaggccauugccugccugcuuuuuggggguucccggaagaggcucccagauggacu
    cacucgccgaggugauaucaacuugcugauguugggagacccugguacagccaagucucagcuucugaaguuugugga
    gaagugcucucccauugggguguacacaucugggaaagguagcagugcugcaggcuugacugccucagugauacggga
    ccccucaucucgaaacuucaucauggaagguggagccaugguucuggccgauggugggguugucuguauugaugaguu
    ugacaagaugcgggaagaugaccguguugcaauccaugaggcuauggagcagcagaccaucuccauugcuaaagcuggg
    aucacuaccaccuugaacucucgcugcucuguucuggcugcagccaacucaguguuuggccgaugggaugagacaaaag
    gggaggacaauauugacuucaugccuaccaucuugucccgauuugauaugaucuucaucgucaaagaugagcacaauga
    ggagagggacaugaugcuagccaaacaugugaugacucugcaugugagugcacugacacagacacaggcuguggaggg
    ugagaucgaccuggccaagaugaagaaguucauugccuacugccgagcgagguguggaccucggcuaucagcagaggca
    gcagagaagcugaagaaccgcuacaucaucaugcggaguggggcucgucagcaugagagggacagugaccggcguucca
    gcauccccaucacugugcggcagcuggaggcuauugugcgcauugcugaggcccucaguaagaugaaacugcagcccuu
    ugccacugaggcugauguagaggaggcauugagacuguuccagguguccacacuggaugcugcuuugucuggcaaucu
    gucggggguggagggcuucacuacccaggaggaccaggagaugcugagccgcauugagaagcaacucaagcgccguuu
    ugccauuggcucucaggugucugaacacagcauuguccaggacuucaccaaacagaaauauccagagcacgcuauccga
    aaggugcugcagcucaugcuacgcaggggugagauccaacaccguaugcagcgcaaggugcucuaucgccucaagugag
    cccauugcccaucaacccucaagccugaaaugcugccaccacccuaucucccagucagugcuccaaaccuccuuuugccc
    ugccucuccaccucagacugcugucugcagcacaucugcagccccuggaaauguacuuuggucuguuggcucauacug
    uguuugagugucugaggacucucugcucugggugucuauccccugucaugccuucucaacaagaugagucuggagcag
    gaacaggcccuggaauguagaugggucuguauauuggcucccgggccacucacugccaagcuucuuuguauguacaga
    gguaauaaagcaauugagucccuggcugcuaaggucaguggacccagu
    93 AI787627 ggaugcagccggaagugcagcgugcgugcgguuuggugggucgcugugugcgcuccgcgu
    gugcagccgcgugggccauggggcggcgggcgcggggccggcgguuccagcagccgccgc
    agccugagggcgaggaagacgccagcgacggcggcagaaagcgaggccaggcgggcuggg
    aagguggcuaucccgagaucguaaaggagaacaagcucuucgagcacuacuaucaggaac
    ucaagaucgugccagagggagaaugggaccaauucauggagucacuccgagaaccucucc
    cagccacacugagaaucacuggguacaaaagccaugccaaagagauucuccauugcuuga
    agaacaaguacuuuaaggaguuggagganccugaaguagauggacagaaaguugaguucc
    acaaccacuaagcugguacccugaagaacu
    94 M33988 gagcucaaauucuggcuuucuauuggguacgauauauuaaccaaugggagaaacacaaac
    agaauaccuccaguuaguauaaaugcuugcuguucaguugcagaauuuacuauauauucu
    uuuccuuucucugcuuugccuuuacugauacuuaaacgcauacaugucuggacgcggaaa
    gcaagggugcaaggcccgcgcuaaggccaagacccgcuccucccgggccggccugcaguu
    ccccgugggccgcgugcaccggcugcuccgcaagggcaacuacucggagcgcgugggcgc
    cggcgccccgguguaccuggcggcugugcuggaguaccugacggccgagauccuggagcu
    ggcgggcaaugcggcccgcgacaacaagaagacgcgcaucaucccgcgccaccugcagcu
    ggccauccgcaacgacgaggagcucaacaagcugcugggccgcgugaccaucgcgcaggg
    cggcguccugcccaacauccaggccgugcugcugcccaagaagaccgagagccaccacaa
    ggccaaggggaaguaaucuggcgauugucuguacugcccaguugaaaguuaaccaaaaca
    aaggcucuuuucagagccacccacaucuuuccauaaaaugagcugccaccucgugaaacg
    uucuuccacuacaguuuuuauacuacauaugaaaaaguuacgaaguagcuuucaaucuua
    guaaauugauuuuaauacuguuagucccugcgauaaaucuuacgaccuuccuuaguuuga
    gucaaaaguguguaagagaugaaaccuuuagaacauacuauaaauuuuuaguagaaauuu
    ggcacccagguuugucauucacgucacgauugucuagagcauaaugguaguaagggcuaa
    gggccauuaaaucccacuuccauaguuuc
    95 AI845182 uuuuuuuuuuuuuuuuuggaaaugaagguaauuuauugaaacugguuuugggacaggcga
    guggacaacuguugaaaggagcuagcgcacagccgggugggagcgggugcuuagccacag
    auccuaucugaggcccaacuuuuucuuuuccuucugcuucuuacggaccacauccagguu
    ccgguccuuccacaugcuuuugcgaagcuugauggggcgugagcccacauacuucccauu
    caucucucgcauggcgcgcacauagucacuggggucuuugaagcugacaaagccauagcc
    cuugguuuugccugugcgcuuguca
    96 AA619207 uucggauccuugccaauauauguaucccauuuggaauggugaucuuaaaaugugagugca
    ugcauacuaucuuauuuaagauacuugcaccccacccacucccaucucccgaagcuggaa
    cacugccaacuagguccuuaagaaucacgcaauuaacacaagguugggugcugcuaauuc
    uucaugaaaauccaaacacguuaagggaccagggagaugccacugccccccugaauuuuc
    aucaaaaauagacacguuuauguaaacagaacuauuuuccauauucauagugacuuuuua
    aguauuugagccuaaagauuuugaucuccauuuuuauaacuauuuaaauuguucacaauu
    auuacau
    97 AW125783 cggccgccgccgcccccacacugccccgcguugacgagcgccgcgacggcaaggacagcg
    ccucgcuuuucgugguggcucggauccuagcggaccucaaccagcaggcgccggcgcccg
    cccccgcggaacgcagagaaggggccgcugcgcgcaaggcgaggacccccugccgccugc
    cgccugcgcccccugcgccgccacccggcccagagcccgccuccccgggacaagcaggcg
    cgccggccgcgccccccagccccgcguggagcgagccggaggcggcauuggagcaggagc
    ccggccccgcggggagcggcgagccuggccucagacaaaggggucggggaggccggagcc
    gcgcggaccucgaguccccgcagaggaagcacaagugccacuacgcgggcugcgagaa
    98 J04103 Sequence below.
    cgucaguccccgccaccuccccggccccgcgcgcccggaucggcccuacggccucgucucgcccggccuugcgcgccgggac
    cgccgcgaucuccucuccccgccgcccuccggcuggcccugccugcugcggcgcgaugaaugacuuuggaaucaagaacau
    ggaccaaguggccccugucgccaacaguuuucgugggacacucaagcgccagccagccuuugacaccuucgauggcucucu
    guuugcugugcucccuucucucagugaagaucagacacuccaagaagugcccacgggccuggauucugucucccaugacuc
    ggccagcugcgagcugccuuugcucacucccugcagcaaggcagugaugagccaagccuuaaaagccaccuucaguggcuu
    ccaaaaggagcaacgacgucuuggcauccccaaaaaccccuggcuguggagcgagcagcaggugugccaguggcuucucug
    ggccaccaacgaguucagccuggugaaugugaaccugcaccaguuuggcaugaacggccagaugcuguguaaccucggcaa
    ggagcgcuuccuggagcuggcgccugacuuugugggugacauccucugggaacaucuagagcagaugaucaaagagaacca
    agaaaagacagaagaccaauaugaggaaaacucucaccucaacgcgguuccucauuggaucaacagcaauacauuaggcuuc
    agcauggaacaggcuccauauggaaugcaggcaccaaacuaccccaaagacaaucuccuggacagcaugugcccgccaucgg
    ccacgccugcagcucugggcucugagcuccagauguugcccaagucucggcucaacaccgucaaugucaauuacuguucca
    ucagccaggacuuccccagcagcaacgugaauuugcucaacaacaauucuggaaaacccaaggaccacgacucuccagagaa
    cgguggggacagcuucgagagcuccgacucgcugcugagguccuggaacagccagucgucccuacuggauguacagcggg
    uaccuuccuucgagagcuuugaggaggacuguagccagucucugugccucaguaagcugaccauguccuucaaggacuaca
    uccaagagaggagcgacccagucgagcaaggcaaaccaguuauuccugcagcaguacuggcuggcuucacuggaagcggac
    caauccaguuguggcaguuucuucuggagcuacucucugacaaguccugucaaucuuucaucagcuggacgggggaugga
    ugggaguucaagcuugcugaccccgaugagguugcccgccggugggggaagaggaaaaauaaaccaaagaugaacuacgag
    aagcugagccggggcuuacguuacuacuacgacaagaacaucauccacaagacuucgggcaagcgcuacguguaccguuuc
    guaugugaccugcagaacuugcugggcuucacuccggaggaacugcaugccauccugggcguccagccugauacagaagac
    ugagggccuca
    99 D90146 Sequence below.
    auggcucuaacaacgcugcucuuggugguggcggccgcccugacccugaucgagacccgcgcgggugagugcggggucgg
    gagggaaacagccccugugccgcguccccgcuucgcccaccggaccuccgccccuucuccacccgagccccgagcccugcuc
    cacucccggcccgcguacccgaccggggucccgggaggaggucggggucucaccgcgcgccgcccccaggcccacacucgcu
    gcgguauuuccacaccgcugugucccggcccggacucggggagccccgguucaucaucgucggcuacguggacgacacgca
    guucgugcgcuucgacagagacgcggaaaauccgaggauggagccgcgggcgcgguggauggagcaggaggggccggagu
    auugggagcgggagacacagaucgccaagggccaugagcagaguuuccaagggagccugaggacugcacagagcuacuaca
    accagagcaagggcggugagugaccccgggucggaggucacuaccucuccacgucccgaaacagaggccggugaggucccg
    ggugcaaaguccgagguucaggagcagaacugacccaggacuggauucccuuucaguuuggaggaguccgcggugggggg
    guggggggggggcggaggagggacugaccacugggucccgcaggcucucacacacuccaguggauguauggcugugacau
    gggguccgacgggcgccuccuccgcggguaccugcaguucgccuaugaaggccgcgauuacaucgcccugaacgaagaccu
    gaaaacguggacggcggcggacauggaggcacagaucacccgacgcaagugggagcaggcugguauugcagagagagaccg
    ggccuaccuggaggucgcgugaggcuccgcagauaccugcagcucgggaaggagacgcugcugcgcacaggugcaggggcc
    gcgggcagcuccucccucugcccucaggcuggggcucaguccuggggaagaagaaacccucagcugggguggugccccugg
    cucagaggggagagagugacccugggucuccugaucccucaucacagugacugcacugacucucccagggcucagccuucu
    cccuggacagugcccaggcugucucaggagggaaggagagaauuucccugagguaacaacagcugcucccuucaguucccc
    uguagccucugucagccauggccucucccaggccaggguucucagccuacacccacugucuguagacacugacuccugucc
    ugcugagugugucagcccuuacaccucaugaccugaagucuccuuuacccgaugggagacauggacaucuacacuaggcug
    guucccccaguuucuagaacuuuccaaagaauacagucuaccagauccuucccugucugugggguuugcauccuuugacac
    ccaauucuaucuauuccugcaauggugaauagucacaugagccauuauggguuacccuaaacaaauacuuuucuuguguuu
    uuccccucucguuuucuuuuuaucuuuacuuuuuuuuuaaggguauuauguugcuuauaaucgguuuuucuucggcacu
    ggaaugauauugcucucucuccccaccauacccccacccccgccuauaucauuuguaucaguagcccuggcugucguggaa
    cucacucuguagaccaggcuggccuugaacucagaaaucagccugccucugucucugccucugccucccaagugcugggau
    uaaaggcuugggccaccaccacugggcagaagaaagguuccugugagcuuaaaauguuuucuggcagaauuaaccauccag
    aucacuccugauaucccugugccccaccaaguuacagugcucccccuggugaaucagaacuuggacucugagagacagggu
    cuucugcaauccaggccugagugagagggaagaccacacacccugugagcccacuguguuccagugagugcugcacugggg
    uccacagcacauuccagggauccugugugacacaucuguaccuugucccccagagucaggggcugggagucauuuucucug
    gcugagugucagagguucaccacauuucugcuacacacucccugauggcuguuuacuuggacugacaguuaauguugguc
    agcaagaugaccacagugguuuagucucaauggugucacucuuccaguagcauaugguccugauuucuaauuuagauacga
    acucaaacacauaugaaauuucuuauuuuccauuccaucuuccauuauauagcuaccuaucucgugcuauugaacaucaca
    uaaggaugaccauguugacccacuggcucauguggauucccucuuagcuucugaguccccucaggaaaaugugcaguccug
    ugcugagggggccagcucugccugcaggucacuagugccaugacaguuaaaguguucauacagacacauaguucauuguaa
    uuacugauuuagcguugucuuggcaguuuucaguuugcaugcauuuauuuauuuauuuauuuauuuauuuauuuauuua
    augcauggaaguacacuguugcuguacugaugguuguuugccuuugugugguuguugggaauugaauuuuuuuuuuuag
    gaccucucuuugcucuggucgacccugcucacuccggucaacuccuaugggucaacucugcucauucagucccugcuuguu
    cuggcccaaagauuuauuuauuauuuauuauacauaaauacacuguagcugacuucagaugcaccagaagagggcgucaga
    ucucauuacagaugguugugagccaccaugugguugcuggaguuugaacucaggaccuucaaaagagcagucagugcucu
    uacccucugagccaucuccccaguccucaguuugucuucuuaauugugcgauuucuugaaucuuccaaacagaucccccaa
    agacacaugugacccaucaccccauaucuuaugaugcugucacccugaggugcugggcccugggcuucuacccuguugaca
    ucacccugacuuggcaguugaauggggaggagcugacccaggacacggagcuuguggagaccaggccugcaggggaugga
    accuuccagaagugggcagcugugauggugccuuuuggggaggagcagaauuacacaugccaugugcaccaugaggggcu
    gccugagccccucacccugagaugggguaaggagggugugggugcagagcuguggucagggaaagcuggagcauucugca
    gacucugagcuggucagggcugagagcugggaucaugacccucaccuucauuuccuguaccuguccuucccagagccuccu
    ccauacacugucuccaacauggcgaccauugcuauugugguugaccuuggagcuguggccaucauuggagcugugguggc
    uuuugugaugaauaggaggugaaacacagguaggaaagggcagggucugaguucucucucagucuccuuuagaagugugc
    ucuaaucauuaaugggaaacccaucuacaccccacauugcuaccuucuccaacuggguccucugucaguucugggaacuuc
    caagaucuuccuugaacucucacagcuuuccuucucacagguggacaaggaggggacugugcuccagcuccagguuagugu
    ggggacaggauuguccuguggacauugcagugaagcuggagauguuggggagcucugggaacccauaguaacucuuccag
    agaaaucuuccagggccgcaguuguccaauaugaauacauauauguacauaugcauauacauuuuuuacccuuggcaggga
    cagcuccuagagcucugauagaucucucccaggugguaaaggugacacucugggaccugauuggggaggggcaaugugga
    uaugauuggguuucagggacuccacgaauccccucugagugagugguggguuguuggaauguugucuucacagugaugg
    gucgugucccuc
    100 AI563854 uuaaaucuggagggauuuuucacacagccuaucuuuuuaggugugccuuucccauauuuu
    auuaaacucgaguuguuguuuuaaaaaaacagcagcauuaucaaagacacaucuguacaa
    acauuuuacaaaagagaacucucuaggaucagcuacaucaaggacaagcagaaaaauaga
    ugcaguccaacaaagacauugaaaaugacuu
    101 AF017128 Sequence below.
    ggucgcuuucugucuguagaggcggcuugccacccgagcagagggucgugaaguuccgaccggaccgguccacagaggu
    ucaucuggagagguggguccccuccgaggugaaaggcgccgcugagaaacgcccccaccccccgugguucaagugguuca
    gcccaagaacuuuucauucauaaaaaagaccagacuccgagaggcgcgagugagucagaaccgcagccgccaacgcggacc
    cuaccgaacauccagcccagggcauguaccgagacuacggggaaccgggaccgagcuccggggcuggcagcccguacggu
    cgccccgcgcagcccccgcaagcucaggcacagaccgcccagcagcaggugagacuggccgaaucgucgggggggggggg
    accugaguuuggacagcaucagggaugcugggauuagucuaguuugcuccgggauuuggacuggggccccgagcagcau
    cugacucugguggucgcgaccgaggauccugcacguucuguguggucggggaaccuauguacccgguggccaaggggac
    gagcgcagcgggaagcgcgaauaucugcgaauuccccuucucgcucgcccguaucucccuagcugacugucuuucugccc
    cuccgucuccguuacggucuuacauuuccuccuaucugccccuaauacgcugucccucuaaauaccugccccaucccugc
    cuggacaggaucagagguguucuccaucuccaguuaauaacugggaccuggggucugggcacauagagacgggguccau
    cagaacucagccgggacagagaauucuuagcagccuguccgaggcuguccguguguugcucugguuguccgugucccuu
    uauccggucaaguccucaucucuuugugcgcaguauagagcccaugggccccaggcagugguuccgagggguuccugga
    gaccacgaaguguugggaugugcgcggggucaccugcccggccacacucgcgcuccacauucucggcacccgacgucucu
    cacugcuggauaggggcacuugagagguugcagguguccauuuccugucgaggggccgcgagcacgugucgccagggga
    gggaaggagcugcguccguuucgccgagucacagcgggccgagucacugaggcugagucacccugggugccccucccuu
    ccuggccccaaacggccccuaaggaccgacgaccugggagcgagagaugccccuggcagugcuucuagcccagaacgggg
    gucacugagaugcugggucccccaguauugggcuggggacauagcuguccagacuugccuaagcaugugaggugcuucc
    uggacuggagggcccccacauccuuagcucacagagcuugaacccaguuuucucucccagaacgcugagcccccaccccca
    ccgacacucaaucccaacacaugccucagauuucugcaagaaaaggaaggaaaggaugccagaccccuuauaggaggcuuu
    uacucucuucacuuuauuucauggacuuaaaaaaccccaucaauuuugaacuuucaaguuuuuaagucgacagcuaggca
    ugcauuuaaucccagcauucaggaggcagaggcaggcagaucucugggaguuugaagccaauuuggucuacaaagugac
    uuccaggucagcuagagcuacauaauagagauccugucucaaaacuuaaaaaauaaaaaacaaaaacaaaagccgauuaaa
    acucugauuucugagcuaugagagcuggcuucucaacagcaauggaacguugaaugauguuaauaacagggaaacugag
    acuaaauaacaugccccagucucaaagcccaucaauggccaagcuccaagcugaugcuggacucccaagcucuggugcuac
    augucuauagucuuggugccugggagguagaggcagaggaaucgugaguuuaggucuagccugagcuaugugagaucc
    ugcccaccccacccccggcccccaaacaacaaauucucauccugauucucagaauugccuugggagcuagaagcugaaagu
    augcccaucugugaggacugggucucaaaucuuaguuucuacuuacuagcugugggucuaugggcaacugcucuccugu
    cugaaaacaggauuauggcagcugugugagucacuauuuguuaaauaguuggaacaguguuacgcaguccauacuugau
    uuaaaacaaaaaaccaaacuaucucugguggggaaacagacagacgaagagagacauuuugugaccugcccaaaaucacac
    agcuccugaacaaguaaguuucugguugccaaauguugcuccuuguggucucccaaaacugguaucuacacugagguga
    agggagacagaaguccagccucuguccccgggaagccccucaguccacacagaccuuaucauuucccuucuuaucucuca
    gaaguuccaccuugugccaagcaucgacagcagcagccaggaacugcacuggauggugcagccucauuuccugggaccca
    cuggcuauccccgaccucuggccuauccccaguacagucccccucagccccggccaggagucauacgagcccuagggccac
    cuccgggggugcgucgcaggcccugcgagcagguaagaaacagcgauguuucacuuuccauagcccguagggguccuac
    uagacagggacaggaucuugcuacgagggaauuucuuauucagcauugaaguuccugagaggccaagaaggagguaaaa
    ggucaccuuugagucaaggaaggcuuccuggagaaggcuacacguuaaccuaaaccacggauaggauuugcguauggaa
    gcugaaaagaaucuucugggaggaggguuggaggcacagaauugaggugaaggggacagaguguuaagugagcaugucu
    ccacugucugacgugcacaggguggaaggaagccugaugcuggcuuuguaccucggggugacucuucuuuucaacaguc
    acggaaucucagccuauuucuuuuaauuaucacaaaaagugagugggcagugguggcucacaccuuaaauuucagcacug
    gggaggcagaggcagguggaucucuggguucaaggccagccugguuuacagagugaguuccaggacagccaaggcuaca
    gagaaacccugucucaagaaagggaaaaaaaaagugaaugggaaauguauuucaauuuuuccaucuuccaucagaggaag
    ugaagcauagagggguacucacuuguccagauucauacaaaugugaguaaugagacaggacugguccuggccugagguc
    uacucaacucccaaagucagagcuuaaugagccacugucucaaugggagcucacagaagccugcagagggagugagcuga
    gaacuuuugccucccugaaugccuuucuaaaauaaagaaggguguguuuugguugguuuguagagguggggucuugag
    agccuccugccuucccaagugcuaggaguauagguguaugcuagauacccgacagggaugacggaucuuuuaggccaua
    gcacuuucuuuccucucccugaaguacugagacugagucuagugcagggaggccuccauacuaaaaagcuggguguaccc
    guaaucccagaacucggaaaaucaagacaggaggagccauucaagucacgcucagaaacauggagaguuuaaggucagcc
    ugggauauauaaacccuaucuccgauaaccaaacaacaaucaaagcaaaccugacuuaaguguuaaguaggaaagaauaug
    cuguaagucaucagccuggcugggggacugaccgccucugagggacugaagaaccugcuucaagcccggagcccugcacu
    caaccccuaguggaugcacacacagauccuugccaugauggcucgaagagggauggcaagacccugggagauaugugaga
    uuggccagagaagagccagcaacaggcuucccagcaagggaacagcuuaccucugugaucagcuggggcgugagcaagag
    gcaagcccagggugaauccuuccuuuagcccuguccugaggagacaccuuuugaccacggguacuaguggguuggagcu
    gugagcuguggguagguggcuuccccucggugugcucuggaacuugaacaaaucacucauccuuccugagcuuccucac
    augugagugugcagagaucuggaugggugacucagcagcggcucuggcugcuccuuagaggauccggguuccaaucuca
    gcacccacguggcaacucacuguccacaacgucccccaaagguucugaugcccucuucuggccuccaccagcacugaaugc
    acaaggugcucauacaaacacacaggcaaaauacucagagguaaauuuguucuuuuuuuucuuuugagacaggguuucu
    cuguauagcccuggcuguccuagaacucacucuacagaccaggcuggccucaaacucacagaggcaucugccugccuccc
    aaguguugggaccaaagauguaugccaucacuauaagccuuuuuuuuuuuuguaaauuuuauuuaugaaugagugcuuc
    cauguauaccuucaugccaggagagggcaucagauccuauuauaggugguugugagccaccguguguggcugggauuug
    aacucaggaccucugaaagaggagcucuuaacugcuaaaacaucucucuagccccagucuacauauuuuaaaucuuuuuu
    uaagauugauuuauuuauuauacauaaguacauuguagcugucuucagacacuccagaagagggcgucagaucuuguua
    uggaugauugugagccaccaugugguugcugggauuugaacucaggaccuuuggaagaguagucaaugcucuuacccgc
    ugagccaucucaccagccccuuuuuuaaucuuuaaaaaaaaaagggggggggccuggagagauggcucagccguuaagag
    cacugaaugcuuuuccagagguccugaguucaauucccaacaaccacaugguagcucacaaccaucuguaaugggaucca
    augcccucuucugguguaucugaagacagcaagggucuacucacauauguuaaauaaauaaauaaaaauuuaaaagccag
    gugguguugguucagacagcagaucucuguuuaaggccagccuggucugaucuacaaaccaaguuccaggacagccagg
    gcuacacagagaaacccucuaaaaaaccaaucuauguagggggugcuggugaaauggcuccguggguaaagguacuugcu
    gcgaaauuaaugaccugaguucaauccuugaaauccacacaguagaaggagagaaccaaccuccaagggugcuaugacaca
    cacacacacacacacacacacacacacacacacacacacacacacacgacuauauauaugaauauaugacucuagccaggca
    uaguguggcacaugccuuuaaucacaguacuugggaggcagaggcaggugaaguuugaggccagccuacagagugaauu
    ccaugacagcuagaacuaugaagaugaacccugucuuuaaaaacaacagcaacauaaagaaucuauguagggaagcuggaa
    gggaugcugauacagucugcaauccuauuacucuagagguggaagccaaagaaucagggguuucaggccggucuugccu
    auacacugagcuaaaggccagccugggacacaugagacuuugucucuuuuaaaaagacaaaacaaggggguugguuagau
    ggcucaguggguaagagcacccaacugcucuucugcagguccgaaguucaaaucccagcaaccacaugguggcucacaac
    caucuguaacgaaaucugagucccucuucuggagugucugaaaacaacuacaguguacuuacauauaauaaaaauaaaua
    aaucuuaaaaaaaaaaaaaaaagacaaaacaagccagaugaggucugugaguuccaggccagccuggucuauaaaucaagu
    ucaaggccaggcagggcuacucagagauucugucuaaaauacaaagaaacaaaacuacaaaaagcagaaaaaggaaucuac
    gaaagggcuggugaagggguguaacucagugguagagcauuugccgagcuagcauguaccaagccauggguuugauccc
    uagcacuaagcaaaagaaaaguccuacaaagggcuuuguuggcauaguagauugauucccaguagcuuuuggcacucaag
    agcaccuucuacaauucacagcuccugggggaagaaaucccaucuuccacagaugaggaggcugagaguccugugaaaag
    agauaaucaugucucauacacucaggagagaaggcuacuucugccugagaaaugaaaaggcuuccuggggucccaacauc
    uuaguccaguccuaagaugcggaagggaggaagaucaaaguuuacagagagggaaagcauuucaggaaagaaaccagcag
    uaaagcuaggugugugugagcuggaaaugucaccaaugagaugacaagcguccgguacagagaagcaacuguggagugu
    ugggugguggcaccuagacuacagacugaaggaaagcuggaugaccagcucagggcagcugguggcucagagucagccu
    cauugucucccuucuucuaucccaaccuagaucagcccagaggaggaagagcgccgcagggugagacgcgagcggaacaa
    gcuagcagcugcuaagugcagaaaccgaagaaaggagcugacagacuuccugcaggcggugagcaucauccccaggcccg
    gacccacagagccccaagaggggucucggcucccaagaacacaaaagacccaaaauuacuccucaggacucugucauccuc
    ccugccuguggggaaguccuggaaaaaggauaagggaaaguggcuuaaauauuguuugucgggcuucgaggcagagucg
    aagaugguaggcagcaauucuccuaagaugcccccgucugaugggagucauggccauuuucucccagaggcucacggga
    gggaguugcaguccagacuuguuggggaugacaggcacagucccuacuccagccugaggcuuggggaucuuuagccuuc
    auuuuccuaucuuucugcuaauccuguaaaggagaccgacaaauuggaggaugagaaaucggggcugcagcgagagauu
    gaagagcugcagaagcagaaggaacgccuugagcuggugcuggaagcccaucgccccaucugcaaaaucccagaaggaga
    caagaaggacccaggugguucuggcagcaccagcggugcuagcagcccaccagcccccggccgcccagugccuugcaucu
    cccuuucuccaggacccguacuugaaccggaagcacugcauacccccacgcucaugaccacacccucucugacuccuuuua
    cuccgagucugguuuucaccuauccuagcacaccagaaccuugcuccuccgcucaccgaaagaguagcagcagcaguggc
    gaccccuccuccgacccccugggcucuccuacacuccuggcuuugugaggcacccagccacaucccuugcuggugcuacu
    ccaagccauccccuuucucccauugauccagcaggccuggaccauacccuugccccaaaccagcagaucuuuuaucucuuc
    cgacuagaacaaacacauuaugcuuugauguagagccagcuuggaggggauccccaaagcugcucacuguuuuucuagag
    cuggccuaucauaauuugcacaaaauuagaggaaaauauguucccucugccagagaacgccuggcagcccagacuuugua
    gauccccagggguccuuugacacccuuaccccuugcagaccacuuucccacaccacgucacuuucuucauguuauccagc
    cuacucuacaccuagacagaaggugcccuuugacuagccuagaacacuaacucacacagcaucaacagccagcagcaccgg
    acauccugcaggcuccuccugaauggcacaacgcaggaggcgccaggggcuucugugaggagcggagcugcacucccuag
    cucugagaagcgcuuagcuucaggguauccgagccuccaccgcaagggcagcugcuauuuauuuuccuaaagagacuauuuuuaua
    caaaccuuccaaaauggaauaaaaggcuug
    102 X67644 Sequence below.
    ccguggguuccuaauggugcuauugacgacgggcacaaagucucauaauuuuagaaacuucacuuauuuugugacccaccu
    aguauggggcaaaggcaggagcuucggacuuccugucuucccucuaucccuuugaauagcgucucgggagugucccuaag
    uaaccauugcaguuuuguguccgugugcucuguugaaaucucugugauguguguaugguuuucacgugaacggaggcag
    gcagagcccggucuguggguucuaguguguucuuuaucuucuuggaaguuugugcaaugacuucccuccuguuuccugc
    gcauaccuccaaguaaguacgugaauguguuuucuguggucccuugaucuugcuggacuucacuaaggaggguggcugga
    ccaucugcuacgugucugagagccccucucuagcuaccucauguccggacgugagcuuacucccaauguuuuuacccacaa
    gcauucacuacucccaggaaagaacgugcacuggggcaccuagagaauaaccaaucaacgcuccgccuacauuuugcuuccu
    ccuuggaauuuccagccccuugcagccaacugcuccccagcugcgaagggcggaguuccccccggcccggccccuucuuug
    gcucuauaaguagcucugcuuugcgggggauuugcacuccucuacacucucugcacaacgucuaaauuaugugccacucgc
    gcaaccaucuccacaccaugacuggccugagggccccuucuccagcucccuccaccggcccggaacuccggcggggcucugg
    ucccgaaauuuucaccuucgacccucucccggagcgggccgugguguccaccgcgcguuugaacacuucucgcgggcaccg
    aaaacgcagccgaagggugcucuacccucgaguggugaguaucgcccgagugggcaucaggaggucgcgucgcccuggaac
    uuguagguaacaacuaggagcagggaccuucgaucugacguuucccucuuuuaucugcucagguccggcgccagcuaccaa
    ccgaggaacccaacauugccaagaggguccucuuucuccuguucgccaucaucuucugccagauuuugauggcugaagagg
    gugugucgcagccccuggcuccggaggaugcuaccagcgccgugacaccugagcccauuucugcgcccauuacugcgcccc
    cgguccucgagccuuugaaccugaccucggaguccucggacuaugcgcuggaucuuaaagcuuuucucuagcaacauccgg
    cggccuucuaaacgcgaugggucacaguccgaagaaacaaaggcaccauggauggguaccuggugcgagagaacguauccc
    aaacugggauuucuaaggcaacgcuaacucagaacacuaccgccaagagacaccgcggguccuggcuaggcccacuggggac
    ggacagagacuuucuccgugucuaauuaauauuuauguauuuauguauauccuccuaggugaaggagggguguauguaau
    auuuauucuaacuuaugcaggggugcgagauaugccucccugcuguaacacagauauuuauuacgauuuauagggucggu
    aagacagaguugugggagggaggacccgggugguaggacucccagcuuggggauuagucugggggggguguaauaagau
    uagggguaacacuccgucuuccagcacuucaacucuguagucuguuguaaggcuuuggaagacccuugggaauccggccu
    uugaugucuucugguugcuucucaggggcagcugcaggagucuuggguccauggauugucagagggcggcugucugggg
    ucgccuaguauguauguucugugaacacgaauaaacuugauuugccugucauuauuaucugcaguucucgaaguguauca
    uucag
    103 AF064088 See above (same Accession Number).
    104 AI843085 uuuuuuuuuuuuuuuuuaaauugccgaauuaaguucuuuuaauagauugcauauauagau
    guuuagccauacucuagaucaacucuuuaagaguagaauuuuauauccaauuuacaugcu
    ucagauaucaccucuguuuguuacauaaggucuuguauccaaauguccacuuguacacug
    agagcuuuaggaacaaaaaaggacacagagagaguugccauuuuuagcagcaaugaaaca
    ucacuaaccccuuuuuacauaccgaauucaagucacuac
    105 AW124932 cggccgccgguauuuuuuugcaaguauugagaguucuguauguuuugaaaagaguaauuu
    uaacguuugggugccaagaaguggguuuucucagaguccauugccggcaaugggcaagcc
    uggcgguacuccucgugccgaau
    106 X58609 augg
    cgcugggaacgcugcuccugcugcuggcggccgcccuggcccggacccagaaccgagccg
    gugagugcagggucgggagggaaacagaacuuuccaaacagucugcggggaggggcgggu
    gcggcaccggggaagccgcgugcccgcgucgcccaccagacccuccgucucuuuacccgc
    gucccuagccccgcgcccugcuccccuccugucccgcgcauccgcccggggucccgggag
    aaggucggggucucaccgcgcgccgcccccaggcucacacucgaugcgguauuucgagac
    cgucgugucccggccgggccucggggagccccgguacgucucugucggcuacguggacga
    cacggaguucgugcgcuucgacagcgacgcggagaaaccgagguaugagccgcgggcgcg
    guggauggagcaggaggggccggaguauugggagcggaucacgcagaucgccaagggcca
    ugagcagugguuccgagugagccugaggaaacugcuaggcuacuacaaccagagcgcggg
    cggugagugaccccgggucggaggucaggccccuccacuucccgacacagggacgcugac
    guccugguucccaagucugagguucgggaacagaacggacccgggaccgguuucccuuuc
    aguuuggaggaguccgcgggugggcggggcugaccgcggggucccgcagguucucacaca
    cuccaggagauguauggcugugaugugggaucggacgggcgccuccuccgcggguaccgg
    caguccgccuaugauggcugcgauuacauugcccugaacgaagaccugaaaaccuggacu
    gcgaaggauguggcagcgcugaucaccagacgcaagugggagcaggauggugcugcagag
    uauuacaaggcuuacauggagggcgagugcgugcagucgcuccgcagauaccuggagcuc
    gggaaggagacgcugcugcgcacag
    107 M18837 Sequence below.
    auggcgucaacaaugcugcuucugcugguggcagucgcccagacccugaucgagauccgcgcgggugaguaccggguccg
    gagggaaauggccucugaggaaaggggagggggcggcacgggggaagccgcgucccggcgucgcccaccugacccuccgcc
    ccuucuccacccuagccccgcgcccugcuccccucccggcccgcucacccgcgggggucccggaaggaguucggggucucac
    cgcgcccugccuccaggcccacacuugcugaguuauuucuacaccuccgugucccggccgggccuuggggagccccgguuc
    aucucugucgguuacguggacaacacggaguucgugcgcuucgacagcgacgcggagaauccgagauaugagccgcgggca
    ccguggauggagcaggaggggccggaguauugggagcgggaaacacagaaagccaagggcaaugagcagauuuuccgagu
    gaaccugaggacccugcucagcuacuacaaccagagcgcgggcggugagugaccccggaucggaggucacgaccccuccacg
    ucccaaaacaggggcccgagacgucccgggccccaaguucgagguucugagcagaacggacgcgggacugguuucccuuuc
    aguuuggaggagccgcgggugggcggggccggggcgugugggcggggcugaccgcggggucccgcaggcucucacacuau
    ucaggugaucucuggcugugaagugggguccgacgggcgccuccuccgcggguaccagcaguucgccuacgacggccgcg
    auuacaucgcccugaacgaagaccugaaaacguggacggcggcggacauggcggcacagaucacccgacgcaagugggagca
    ggcuggugcuacagagaaaagcaaggccuaccuggagggcgcgugcgugcagucccuccgcagauaccuggagcucgggaa
    ggagacgcugcugcgcacaggugcaggggccgcgggcagcuccucccucugcccucgggcuggggcucaguccuggggaa
    gaagaaacccucagcuggggugaugccccugucucagagggagagagugacccuggucuccugaucccucaucacagugac
    ugcacugacucucccagggcucagccuucucccuggacagugcccaggcugucucaggagggaaggagagaauuucccuga
    gguaacaacagcugcucccuucaguuccccuguagccucugucagccauggccucucccaggccggguucucagcccacug
    ucuguagacacugacuccuguccugcugagugugucagcccuuacaccucaggaccagaagucgccuuuaacugaucggag
    acauggacuacccuacacuaggcugauugccucaguuuccugaauuuucaaaagaauacauucucccagaucccucccuguc
    ugugggguuuccaccccuucgacaaccuaauucucucuauuccuauagugguggucacaucagcccuuaugggguacccug
    gaggaauaucaauaguggaauuucuucuucuucuucuucuucuucuucuucuucuucuucuucuucuucuucuucuucuu
    cuucuucuucuucuucuucuucuucuucuucuuccuucucucucucucucucucucucucucucucucucucucucucuc
    ucucucucucucucucucucuucuucaguuuuugagauaggguuucucuguaugcccuggcuguccuggaacucacuugu
    agaccaggauggccucgaccucagaaauccgccugccucugccucccagugcugggauuaaaggcguguggccaccuugcc
    cagccuuucuuauuuucuuuacuuuuuuuuuuuuuuuuggaggggguaauuuuguuucuagucaucuuuugucuuuug
    ucugcacuggagugauccuguuucucccugcccuuauauuaucauguguaucagucuccacaggugccagggaaguuaag
    acaaguuaaaucaggguucucuuuaaaggagagauuccugugaacuuagacuguuuccugucagaacuaaacauccagaag
    ccuccugcucuuccucugucccacaaguuacagugcuccccccccccccccagugaaucuggacuuggacucugagagacag
    ggucuucugcaauccagggcuggagugagagggaagaccacacacccugugagcccacuguguugcagugagugcugcacu
    gggguccacagcauacuccagggauccugugugacacaccuguaccuugucccccagagucaggggcuggaagucauuuuc
    ucuggcugagugucagagguugacaccauuucugcuacacacucugugauggcugcucacuuggacuggcgguuaugcua
    guuagcaagaugaacacagugguuuacgucucaguugucacacccuuccaguggcauauggcucuaauuucuacuuuuga
    uacgaacucaaacacuuauuaaauuaguuaguuuccauuccaucuuccauucuaguccauucaugcuaaagaacaucacaua
    aggacugccaggaugacccacuggcucauguggauucccucuuagcuucugagucccccagaaaaaugugcagcugaggaa
    accagcucugccugcaggucaccagugccaugacaguugaagugucaaacagacacauuguucagugucaucagugauuua
    acugugccuuguguagauuucagagggucuuguuaauugugguacuuuuuuuuguuuuuuguuuuuuuuuuuuuuugu
    uuuguuuucaagacaggauuuuucuguauagcccuggcuguccuggaacucacauuguggaccaggcugaccacgaacuca
    gaaaucugccugccucugccucccgagugcugggauuaaaggcgugugccaccaccaaccagcuaaucgugagauuucuuu
    cuuuuuucuuuucuuuucuucuuuuuuuuuuuuuuuuuguuguuguuguuuuguuuuuugagacaggguucucugugu
    aucccuggcuguccuugaacucacuuuguagaccaggcuggccuugaacuuagaaauuugccugccucugcuccggagugc
    ugggauuaaaggcaugugccacuaccaaccagcuaauugugggauuucuuaaaucuuccacacagauccuccaaaggcaca
    ugugacaugucaccacagaucugacggugaugucacccugaggugcugggcccugggcuucuacccugcuaacaucauccu
    gaccuggcaguugaauggggaggagcugacccaggacauggagcuuguggagaccaggccuucaggggauggaaccuucc
    agaagugggcaucugugguggugccucuugggaaggagcagaauuacacaugccaugugcaccaugaggggcugccugag
    ccccucacccugagaugggguaaggagggugugggugcagagcuggggucagggaaagcuggagccuuuugcagacccug
    agcugcucagggcugagagcuggggucaugaccucaccuucauuuccuguaccuguccuucccagagccuccuccauccac
    ugucuccaacauggcgaacguagcuguucugguuguccuuggagcuuggccaucauugcagcugugguggcuuuuguga
    ugaagagaaggagacacacagguaggaaagggcagagucugaguuuucucucagccuccuuuagagugugcucugcucauc
    aauggggaacacaggcacaccccacauugcuacugucuguaacugugucugcucucaguucugggaacuuccuagugucaa
    gcucuuccuugaacucucacagcuuuccuucucacagguggacaaggaggggacuaugcucuggcuccagguuagugugg
    gggacagaguuguccugaggucauuggagugaagcuggaguuguugggugcucugggaacccauaauagcuucucuguu
    guaauccucugguggccugugucagaucuugcuauagauauaucuuuguauauauuuuucccuaggcagggacagcuccc
    agagcucugauauguuucucucaagauuguaaaggugacauucuauggccugauugcagaggggcacuguggacaugguu
    guguuucagggacucccacaauccccugugagugguggguuguugggauauugucuucauuguggugguuccugacccu
    cauucucuaucaugaagacagcugccuggaguggacuuagugacagccagugugaccuugggucuucauuuuucuuuaga
    gaacagcgccugauguucccugugagccuaugggcucaaugugaagaauuguggagcccagccuucgccuacacaccagga
    ccugucucuugcauugcccuguguucccuuccaccgccaaccuuccgggucugcag
    108 AW124268 uuuuuuuuuuuuuuuuucagaauaauugcagacaaauuccauuuauuuuucuaaaaaccu
    cauuaucuaaaauuuauacagccucacauuccuaaaccaccucuggcacuuuucuugaau
    uaagucaaggcguacacagcuccgaaagaaaaauagagauccgguuccaggaagauggcc
    augaggacucgcagauaugucuccucggaccuggaagcgugucagccaugggauccacua
    auccaccauccgguacacagggucacccacucucaggcucccaagcuucuccaccgagaa
    auacaucccaaaaaguggagaugacugguauauacucuucacagaaggaucacacaggcg
    auagcucuucagggucuccaguggc
    109 AF090738 Sequence below.
    cucuagaugaauacacucucaugagggccaccuucucugguaguucaggucgccucugcccauccuucccugcguccucuc
    ccaaaguggccuacaacccuuacccagaggacuauggagacauugagauugguucucacaagaguuccagcaguaaccugg
    gggcagaugauggcuacaugcccaugaccccuggggcagcccuuaggagugguggucccaauagcugcaagagcgaugacu
    acaugcccaugagccccacaagcgugucugcucccaagcagauccugcagccacgcuuggcagcggccuugcccccuuccgg
    agcagccgugccagcacccccuucaggggugggcaggaccuucccaguaaacggagguggcuacaaagccagcuccccagcg
    gagagcuccccagaagacaguggguacaugcgaaugugguguggcuccaagcugucuauggagaacccagacccuaagcua
    cuccccaacggggacuaccucaacaugucccccagcgaggcaggcacugcagggaccccaccugacuucucagcagcuuugc
    guggaggcagugaaggccucaaaggcaucccgggccacugcuacagcucuuugccccgcucuuauaaggcucccuguuccu
    gcagcggagacaaugaccaguaugugcucaugagcuccccugugggccggaucuuggaagaggagagacuggagccccagg
    ccaccccaggggcuggcaccuuuggggcagcuggugguagucauacccagccucaucacucagcagugccuuccuccauga
    ggccgagugccaucgguggccgcccugagggcuuccugggccagcgaugucgggcagugcggccuacacgccuaucgcua
    gagggacugcagacccuucccagcaugcaagaguacccucuacccacagagcccaagagcccuggcgaguacaucaacauug
    acuuuggugaggcagguacccgucugucuccgccugcccccccacuacuggcauccgcggccucaucuucuucacugcucu
    cagcuaguaguccugcuucaucccuggguucaggaaccccaggcaccagcagcgacagccggcagcgcucuccacucucuga
    cuauaugaaccuggacuucaguucucccaagucccccaagccuagcacccgcaguggggacacaguaggcuccauggaugg
    ccuucucucuccagaggcuucauccccauacccaccacugcccccacguccuuccacuuccccuuccuccuuacagcagccu
    cugccaccugccccgggagaccuauaccgccugccuccagcaucagcugccacuucccagggucccacugcuggcuccucaa
    uguccuccgagccuggggauaauggugacuauaccgagauggccuuugguguggcugcaaccccgccacaaccuaucgugg
    caccuccaaagccagaaggugcccgaguggccagucccacaucgggcuugaagcggcuaagucucauggaucagguaucug
    ggguggaggcuuuccuucaagucagccagcccccugacccccaccggggugcuaaggucauccgugcagacccacaggggg
    gacgucgucgccacaguucagagaccuuuuccucuaccaccaccgucaccccaguguccccauccuuugcccacaauuccaa
    gcgccacaauucggccucuguggaaaaugucucacucaggaaaagcagugaaggcagcaguacccugggaggaggugauga
    gccgcccacauccccaggacaggcacagcccuugguggcugugcccccagugccacaggcuaggccguggaaccccggucag
    cccggagcuuugauuggcuguccuggaggcagcaguucucccaugcgcagagagaccuccguggguuuccagaacggccuc
    aacuauaucgccaucgaugugagaggcgagcagggguccuuggcgcagucucagccgcagccaggagacaagaacuccugg
    agccggacccguagccuuggggggcuccucggcaccgucggaggcucuggcgccagcggaguguguggggguccaggcac
    uggagcuuugcccucugccagcaccuaugcaagcaucgacuuccugucccaucacuugaaggaagccacagucgugaaagg
    ugaggcccuuugaccuugaggaugggggagggagaguggaguauuggguggcu
    110 AI834950 uuuuuuuuuuuuuuuuucagcugugaacuauuggauuugagacaggaacagaacaaaucg
    acgggccagaggaggguggagagagcacgagugguuuaaauaggggaggaugggagcaug
    gcggugggggugggggaagaguuauuuacaagaaggcucagggggccagaggcucaucuu
    ggaauauuuuauaacaauauauauaagauucugguuugcuuuuccuuuucgucucguaaa
    ggagagagaauugcauaguucgauucuguccaagggggcagcugcauauggucggccggg
    cgggucacuggucgu
    111 AI851365 uuuuuuuuuuuuuuuuuaagugucaccacuugugacagucagcauguuacuaucagcucc
    agccgcagcguuuuuaaggcguuauagauuaggcaggcaauacaaggaacacgauuaaga
    aacugacacguaccacacgagcaauuuccagaggcuccucuucugcggugcacacguaac
    agugcucuuguugacauucagacaguucugagggccacucugagaggcgccuuccuguuc
    ucaccugacaaggauauuguuugguuugguuugguuugguuuugccuuacuauggcuuuu
    cuuucaacuacauuuugugucaugcuuguuagcuaacucaaauuuugucuuuguauauuu
    acuacuguaaaauuagaauaauuuacuguucaucucauccucugucacugauggaaccua
    gagacgccacaagagccacugccgugacauaccucacaagcuacaucccuguccucaaaa
    u
    112 AW047339 cggccgcggccaccggccugcgccaagcugcugcugcggcagccaguaccucggugaagc
    ccauuuucagucgcgaccugaacgaggccaagcggagggugcgcgagcucuaccgcgcuu
    gguaucgggagcgugccgaacaccgugcacuuaaugcagcuggauaucacggugaaacaa
    ggacgggauaaaguccgagaaauguucaugaagaaugcccaugucacagaccccagagug
    guugaucugcuggucauuaagggaaagauggagcuccaggaaaccaucaaaguauggaag
    cagcggacacacguuaugcgguuuuuccaugaaacagaaacaccaaggccaaaggauuuc
    uuauccaaguucuauaugg
    113 U06834 Sequence below.
    gcaccugagcgcgggugccuggcgcgcccgaugggaucguugagaggcccucgacggaaagucccaaacucggaucgcauu
    cagccaaagugaggcggcgccauggagcuccgagcgcugcugugcugggcuucccucgccacugcuuuagaagagacccug
    uugaacacaaaacuggaaacggcggaucugaaaugggugacuuacccucaggcagagggccagugggaggagcuaagcggc
    cuggaugaggaacagcacagcguccgcaccuaugaggugugcgacaugaagcgucca
    gggggccaggcucacuggcugcgcacuggcugggucccaaggcgaggugcuguccacguguaugccacgauacgcuucacc
    augauggaaugccugucccugccgagggccagucgcuccugcaaggagacauucacugucuucuauuacgagagcgaacgu
    gauacggccacggcccauacgcccgccuggauggagaaccccuacaucaagguggacacaguggccgcagaacaucugacuc
    ggaagcgcccuggagcugaagccacagggaaaguuaauaucaagacgcugcgccug
    gguccucucagcaaagcuggcuucuaccuggcuuuccaggaccaaggagccugcauggcucugcucucccugcaucucuuu
    uacaagaagugcuccuggcugaucacgaacuugaccuacuuccccgagacggugccucgggagcucguggugccgguggca
    gguagcugcguggccaacgcggucccuaccgccaaccccagccccagccucuacugccgggaagauggucaaugggcugag
    cagcaggucacgggcugcagcugcgcgccaggguacgaggcugcggaaagcaacaaa
    guaugcagagccuguggccagggaaccuucaagccccaaauaggagacgaguccugccugccgugcccagccaacagccacu
    cgaauaacauugggucuccugucugccugugucgaauuggguauuaccgggcccgcucagacccccggaguucaccuugca
    cuaccccacccucugcuccaagaagcgugguucaccauuugaaugguuccacccugcgccuggaguggagugcuccccuug
    aguccggaaggccgagagaccucacuuaugcuguucgcugccgagagugccguccuggggguuccugcuugcccuguggg
    ggcgacaugaccuucgaccccgguccucgagaccugguugagcgcuggguggcaauccgagggcugcguccugaugucacc
    uauaccuuugagguugcugcuuugaauggugugucuaccuuagccacuggaccaccuccuuuugagccugucaaugucac
    cacugaccgugaggugccuccugcagugucugacauccgagugacucggucgucacccagcagcuugauccugucaugggc
    uauccccagagcacccaguggggccgugcuggacuacgaggucaaguaucaugagaagggcgcagagggccccagcagugu
    ucguuuccugaagacaucagaaaaccgagcugagcuccgggggcugaagcggggagccagcuaucugguccagguacgcgc
    acgguccgaggcuggcuacggucccuucggccaggagcaucacagucagacucaacuggaugagagcgagagcuggcggga
    gcagcuggcccugauugcaggcacugcgguugugggugugguccugguccugguggucgucaucauugcaguucucugc
    cucaggaagcagagcaaugggagggaaguugaguacucggauaagcaugggcaguaucucaucgggcacgguaccaagguc
    uacauugauccuuuuacuuacgaagacccuaaugaggcagugagggaauuugccaaagagaucgaugucuccuaugucaag
    auugaagagguaauuggugcaggugaguucggcgaggugugccggggucggcugaaggcaccagggaaaaaggagagcug
    uguggccaucaagacucugaaggguggcuacaccgagcgccagagggcugaguuccugagcgaggccuccaucaugggcca
    guucgagcaucccaacaucauccgccucgagggcguggucaccaacagugugccgguuaugauccucacggaauucaugga
    gaacggagcccuggacuccuuccugcggcugaacgacgggcaguucacagucauccagcuggugggcaugcugaggggcau
    cgccucgggcaugcgguaccuggcugaaaugagcuauguccaccgagaccuggcugcucggaacaucuuggucaacaguaa
    ccuggucugcaagguguccgacuuuggccucuccagauucuuggaggagaacuccucugaucccaccuacacaaguucccu
    gggaggcaagauucccauccgauggaccgccccugaagccauugccuucaggaaguucaccucugccagugaugccuggcg
    cuaugggaucgucaugugggaggucaugucuuuuggggaacggccauacugggacaugagcaaccaggaugugaucaaug
    ccauugaacaggacuaccggcugccuccuccuccagacugccccaccucccuccaccagcucaugcuggacuguuggcagaa
    ggaccggaaugcccggccccgcuuuccccagguggucagcgcucuggacaagaugauccggaaucccgcuagccucaaaau
    cguggccagggagaauggcggggccucacauccacucuuggaccaacggcagccucacuacucugcuuucgguucuguggu
    cgaguggcuucgagccaucaagaugggaagauacgaggaaaguuuugcagcggcuggauucggcuccuuugagaugguca
    gucagaucucugccgaggaccuucuccgaauuggagucacucuggcaggacaccagaagaaaaucuuggccagugugcagc
    auaugaagugggaagcuaagccaggagccccuggugggacagggggaccagcccagcaguucugaccuccaaggacucacc
    accguggcagauucuucuuuccgggaggcagaguuggguggggacucacaagaugagccccucccccucgucacagccuuc
    ccauuggauugcacuuugaacagagggggucggagacacagauuuggggaaccgugccauaugggaucauacaugugccc
    uccaggcggggaaccccaaacucagagugagucuuucccucaagacugggcaaagaaacaucccuacgucucuaaccuccca
    ucuucccagaggcucucuccccaagcgccuuccaccucaacgggcaugucccugcagaccaaagagaaagggugaccagccu
    gccaacuugggaguggaaaaugccgucccaggaggcaggaaggggcugucaggacccggugauguaaucauuggguuuug
    auguccugacuugcugucaccaccaaaggcaaucauuuuucccuuguaaaugccccuccccucaucugccuucauauugaa
    gguucugaaguuuuacuguuuuuuauuuuguuaauuuuuuccuccuuccccccucccuccccuucuuguccagauuuugu
    guguuaaagggcaccugguuccacuaucuccuguugggaacaaggacccaucgauauguucuagaacagugccuuggaaau
    gcca
    114 AA980204 ggcagcgagacgagcucacggucgaggauacgggugaagcgggacaggagcaggagccgg
    agccgggccaaagcagaaggugcaggucggcgccggcgguugggcangacccagucaagc
    cggacagugaggagcggaugcagacggcacgaccauggccacgauggugcuuccucgaga
    ggagaagcugagucaggacgagauagugcugggcaccaaggcggugauccaggguuuaga
    gacccugagaggggagcaucgugcccugcuagcuccccuagcuucucaugaagcaggcga
    ggcugagcgggcucacaggagcgcugccuccuccugcgccgcucccuggaggccaucgag
    cuggggcuuggggaggcucaggugauccuggcauuaucaagccaucugggggcuguggag
    ucagagaagcagaagcugcgggcucaggugcggcccugguacaagagaacagugguugcg
    ugaggagcuggcagggacacagcagaagcucagcgcagugaacaggcgguggcucagcug
    gagaagagagcagcacaucu
    115 AI843232 ggcagcgagacgagcucacggucgaggauacgggugaagcgggacaggagcaggagccgg
    agccgggccaaagcagaaggugcaggucggcgccggcgguugggcangacccagucaagc
    cggacagugaggagcggaugcagacggcacgaccauggccacgauggugcuuccucgaga
    ggagaagcugagucaggacgagauagugcugggcaccaaggcggugauccaggguuuaga
    gacccugagaggggagcaucgugcccugcuagcuccccuagcuucucaugaagcaggcga
    ggcugagcgggcucacaggagcgcugccuccuccugcgccgcucccuggaggccaucgag
    cuggggcuuggggaggcucaggugauccuggcauuaucaagccaucugggggcuguggag
    ucagagaagcagaagcugcgggcucaggugcggcccugguacaagagaacagugguugcg
    ugaggagcuggcagggacacagcagaagcucagcgcagugaacaggcgguggcucagcug
    gagaagagagcagcacaucu
    116 U59807 Sequence below.
    augauguguggcgcgccaucugccacaaugccagccacggccgagacgcaggaggucgccgaccaggugaggcugggccca
    ggucaggccagucugagccaggccugcggagacccggcggccucagggaccggccugcccagacuggucagguccugcagc
    ggguuuccggggcggccacaagugugacugggagcugggggcucuggaucugguuggaagauucagggccgggaacugg
    ggcgagucuucugccgcuugcauacaagagggccacucaccuauuagggaacuagccccgggaucgguggagggauccggu
    ggucccagagaauucaggaaggcaguguuagaaccuagacggcaccuuuuugacuuacacccaggccuaaacaagagaaagc
    cagacugggcuacugugcuugucuccucaaaagaaagagcuaggacuguuuagcucaguggcaggaauucaacugauacca
    ccaccaccaucaccaacaccgccccucagggaaaaaaaaaaggaucaaaaccagaaguuguagaacuugcuugugccuaguc
    ugaaacgaggggguggaccuugggccugggcugcccuuccugugacuguuagcagagcagagauucaguacaagguaggg
    ggagguucaggguauuagcaagagaagaaaaguuaaacaaauccucucuucagcucuccugccacgccccaagcccaggacc
    cuguccacuaagccuagcugaucuugggagguguuugcucugaacugaaguggccaagaaggaagugagucagcuccaug
    agacccuagaaaugaggaaauguuacagacacacuggccaggcaagggaaccuuggccacgugccacaucagcacucaggag
    gcagagacaggcgagucucucugaauuugaagccagcccaguuugcuuaguuccaugccagccauagcuacauagugagac
    ccugucccccccccccccaaaaaaaaggagcuguguuguucuuuaucaguggggccaacaguuuaccaugucccccggaau
    gaggaguauugaaggcuggcagugugugugugugggggcaccugugcaugaaucuaaguccuuccuucucacccaccauc
    caggugaagucccagcuugaaucgaaagaaaaucagaaguuugaugucuuuaaagccauauccuucaagagacagauagug
    gcuggcaccaaccucuucaucaagguggguacugauaguagcuugccaugaacuggggacauagucucagaguagagcaga
    guguccugcaacuuccugcagagaaccccuuaaggggacauguacauguucugagaggaugaauuugggguguuaggguu
    cccggccuuaaaggaggagacaaggguuaucacuggcuaaguuaguggcugguggccuguucuggcucaguuucuaaggc
    uggguuaagccuggaacuggaaccuuaccuuucacucacaugucugucugucugucuuccuccagguugauguuggugga
    gauaaaugcgugcacuugaggguguuucaaccccucccccaugaaaacaagccuuugacccugucuuccuaucagaccaaca
    aagaaaggcacgaugagcucuccuacuucuga
    117 AI152659 gaaaauguuaagagccaucaaauuucuggauauuuugcuaggaaaaugaaauucuacacu
    uauuuuuuguagacuuuuuuuaaaugcuguuuacaugaauuguauuuuggaaaaaauauu
    auacugugcacccugugaugcaugaagugauuuuauguauggucugcuaugugggcagag
    gucaccuuauuccuaugaucuggaauuguuuacuuucuacaaaguaagcuuuguggggau
    uuugcuuucauuuucuuuguagcugauguuauuuuaccaggugugcagcaggaauuacac
    cacuguguggaauuauaaauacaucccaugugca
    118 AI850090 uuuuuuuuuuuuuuuuuccuggugaauauuuuuauuagaggugacaguuucccaggugac
    aguuuuucccaaggaagcaaaucucugcgucuauaagggaagaccacagaaccuucacuu
    uguaauuuaccuguguaauuuauccaagaacacagcacagcaauugcuuuaugugguacu
    cugaccuuaaguaacaaguuguuaacagaaaacacaucaaacaaaaggauaauucucuaa
    uuaucaagucagccaucagcuuuucuuaggagagagagagagagugugugugugugugug
    ugugugugugugugugugucugucugucugucugucuggguaucccacuuagggccaugu
    gcauguuagguaaaugcuccaccacugagcuguuucuuagccgcacuuuucucagauuuc
    agguuuguuuguuuguuuguuuguuuuuuaacuaggcaugaaaauaaacuucacuucaaa
    u
    119 AF064635 See above sequence (A1850090).
    120 AI843106 uuuuuuuuuuuuuuuuuguggaaauuacucuuuauugaaaaauaccaguaauacugacag
    acuucaaaaucaauuuacgguuccagaauacaaaguacuuaauacauuuuuuuccaaacc
    uguuuguaucucaaaguuagcauuuuuguaaaucaagauacaaauaugauaacuucacua
    aaauauuuuccagcuuuauucuuuaaggagcuguauaaccuucaaagucagggucccgag
    gucagcagggcauggggcagaaugcaccuggcacucccugugcagcagacugcaaccaca
    uu
    121 AF033186 auggccagcuuucccccgaggguuaacgagaaagagaucgugagaucacguacuauaggg
    gaacucuuggcuccagcagcuccuuuugacaagaaaugugguggugagaacuggacgguu
    gcuuuugcuccugaugguuccuacuuugcguggucacaaggauaucgcauagugaagcuu
    gucccguggucccagugccguaagaacuuucuuuugcaugguuccaaaaauguuaccaau
    ucaagcugucuaaaauuggcaagacaaaacaguaaugguggucagaaaaacaagccuccu
    gagcacguuauagacuguggagacauagucuggagucuugcuuuugggucuucaguucca
    gaaaaacagagucguugcguuaauauagaauggcaucgguuccgauuuggacaggaucag
    cuacuccuugccacaggauuaaacaauggucgcaucaaaaucugggauguauauacagga
    aaacuccuccuuaauuugguagaccacauugaaaugguuagagauuuaacuuuugcucca
    gaugggagcuuacuccuuguaucagcuucaagagacaaaacucuaagagugugggaccug
    aaagaugauggaaacauggugaaaguauugcgggcacaucagaauuggguguacaguugu
    gcauucucucccgacuguucuaugcuguguucaguuggcgccaguaaagcaguuuuccuu
    uggaauauggauaaauacaccaugauuaggaagcuggaaggucaucaccaugauguugua
    gcuugugacuuuucuccugauggagcauugcuagcuacugcauccuaugacacucgugug
    uaugucugggauccacacaauggagaccuucugauggaguuugggcaccuguuucccucg
    cccacuccaauauuugcuggaggagcaaaugaccgaugggugagagcugugucuuucagu
    caugauggacugcauguugccagccuugcugaugauaaaauggugagguucuggagaauc
    gaugaggauuguccgguacaaguugcaccuuugagcaauggucuuugcugugccuuuucu
    acugauggcaguguuuuagcugcugggacacaugauggaaguguguauuuuugggccacu
    ccaaggcaagucccuagccuucaacauauaugucgcaugucaauccgaagagugaugucc
    acccaagaaguccaaaaacugccuguuccuuccaaaauauuggcguuucucuccuaccgc
    gguuag
    122 Z50159 auggccagcuuucccccgaggguuaacgagaaagagaucgugagaucacguacuauaggg
    gaacucuuggcuccagcagcuccuuuugacaagaaaugugguggugagaacuggacgguu
    gcuuuugcuccugaugguuccuacuuugcguggucacaaggauaucgcauagugaagcuu
    gucccguggucccagugccguaagaacuuucuuuugcaugguuccaaaaauguuaccaau
    ucaagcugucuaaaauuggcaagacaaaacaguaaugguggucagaaaaacaagccuccu
    gagcacguuauagacuguggagacauagucuggagucuugcuuuugggucuucaguucca
    gaaaaacagagucguugcguuaauauagaauggcaucgguuccgauuuggacaggaucag
    cuacuccuugccacaggauuaaacaauggucgcaucaaaaucugggauguauauacagga
    aaacuccuccuuaauuugguagaccacauugaaaugguuagagauuuaacuuuugcucca
    gaugggagcuuacuccuuguaucagcuucaagagacaaaacucuaagagugugggaccug
    aaagaugauggaaacauggugaaaguauugcgggcacaucagaauuggguguacaguugu
    gcauucucucccgacuguucuaugcuguguucaguuggcgccaguaaagcaguuuuccuu
    uggaauauggauaaauacaccaugauuaggaagcuggaaggucaucaccaugauguugua
    gcuugugacuuuucuccugauggagcauugcuagcuacugcauccuaugacacucgugug
    uaugucugggauccacacaauggagaccuucugauggaguuugggcaccuguuucccucg
    cccacuccaauauuugcuggaggagcaaaugaccgaugggugagagcugugucuuucagu
    caugauggacugcauguugccagccuugcugaugauaaaauggugagguucuggagaauc
    gaugaggauuguccgguacaaguugcaccuuugagcaauggucuuugcugugccuuuucu
    acugauggcaguguuuuagcugcugggacacaugauggaaguguguauuuuugggccacu
    ccaaggcaagucccuagccuucaacauauaugucgcaugucaauccgaagagugaugucc
    acccaagaaguccaaaaacugccuguuccuuccaaaauauuggcguuucucuccuaccgc
    gguuag
    123 X78683 Sequence below.
    gaauuccgugugcaaggcgaggucuguaagcuggagcggggcagaggcuggcgggcaccccuuccugaccgcuggugccg
    ccgccgccgccuucgggaggaucagacauggcccagaacuugaaggacuuagcuggacgccugcccgccgggccucggggc
    augggcacggcgcugaagcugcugcugggggccggggcgguggccuacggcguccgcgaauccguguucaccguggaagg
    cggucauagagccaucuuuuuuaaucguauugguggcgugcagcaggacacgauccuggccgaauuucacuucaggauccc
    cugguuccaguaccccaucaucuaugacauucgggccagaccucggaaaaucuccucccccacaggcuccaaagaccugcag
    auggugaacaucucccugcgugugcugucccgacccaaugcccaggagcuccccagcauguaccagcgucuagggcuggac
    uaugaggagcgagugcugccguccauuguuaaugaggugcucaagagugugguggccaaguucaaugccucgcagcugau
    cacccagcgggcucaggugucccuguugauccgaagagagcugacagagcgcgccaaggacuucagccucauccuggauga
    uguagcuaucacagagcugagcuucagccgagaguacacagcugcuguagaagccaagcaaguggcccagcaggaagccca
    gcgggcccaguuuuugguggagaaagcgaagcaggaacagcgacagaagauugugcaggcugagggggaggcggaggcug
    ccaagaugcuuggagaagcacugagcaagaauccuggcuauaucaagcuccgaaagauccgggccgcccagaacaucucuaa
    aacgaucgccacaucacagaaccgaaucuaucucacagcugacaaccuugugcugaaucuacaggaugaaaguuuuacucgg
    ggaagugacagccucauuaaggguaagaaaugaguguggacaucaagaaccccaccaccagagaaguuggcacacuugucca
    gcuuggaggagccagcucggggucaagcacagcccacccugccccaggcaucaugugauggacuuuucuguaucugcccuc
    uuggauuaaggaagacugagaccagcccuuucagaggcuuuccuccuuccuguguuggcugggaagcgggguggacaaug
    ugauuucuccgugauuuccuacagccuugagccucucccagagugggggagauaaccaccaugccaggaauuc
    124 X68193 acccaccggcuuucggaccauggccaaccucgagcguaccuucauugccaucaagccaga
    uggcgugcagcgcggccuggugggcgagaucaucaaacgguucgagcagaagggguuccg
    ccugguggccaugaaguuccuucgggccucugaagaacaccugaagcagcauuacaucga
    ccugaaagaccguccuuucuucccggggcuggugaaguacaugaacucggggcccguggu
    ggccauggucugggaggggcucaauguggugaaaacgggccgagugaugcugggggagac
    caauccagcugauucaaaaccaggcaccauccguggggauuucugcauucaaguuggcag
    gaacaucauucauggcagugauucaguggagagugcugagaaagagauccaucugugguu
    uaagcccgaagaacugaucgacuacaagucuugugcccaugacuggguguacgaguagac
    augaagaaaccagaauccuuuucagcacuacugauggguuucuggacagagcucuucauc
    ccacugacaggauggaucaucuuuucuaaaacaauaaagacuuuggaacugaaaaaaaaa
    aaaaaaaaaaaa
    125 AA062013 uuuugcuuucaacaugacagaugccgcuguguccuucgccaaggacuucuuggccggugg
    aguggccgcagcaucuccaagacagcggucacaccaucgagagggucaagcugcugcugc
    aggugcacaugccagcaagcaaaucacggcagauaagcaauacaagggcaucauagacug
    cgugguucguauccccaaggaacagggagugcucugguccuuugggcgugggaaccgggc
    caaugucaucagauacuuccccaccaaggcucucaacuuggccuucaaaguuaauuccaa
    gcagaucuuucugggugguguugacaagaggacccaguucuggcgcuacuuuugcaggga
    accuggcaucaggugguugccgcuggggcuacauccuugggcuuuguguacccucuugau
    uuuugccgguaccgucuagcagcugaugugggcaagcuggagcuaaagggaauucaaggg
    ccuugggacugccugguaagacuucaaucugaugggauaagggcuguac
    126 AI465965 auccgggacccccacggccccuuugcagcuugccacaagguucugagccccuuggaauac
    uuccgccaauguguguaugacaugugugcccauaagggugacaaagccuaucucugccgu
    agccuggcugcuuauacugcagccugucaggcagcuggggcagcagugaagcccuggagg
    acagacagcgucugcccucuccaguguccugcccacagccacuacuccaucugcacccgc
    uccugccagggcuuccugugcugcucucucuggccucacuggcugcaccac
    127 U50413 Sequence below.
    ggcacgagccgaguuggaggaagcagcggcagcggcagcggcagcgguagcggugaggacggcugugcagccaaggaaccg
    ggacagcgaagcgacggcaggucgcagcuggaucgcaggagccugggagcugggagcuucagaggccgcugaagcccaggc
    ugggcagaggaaggaagcgagccgacccggaggugaagcugagaguggagcguggcaguaaaaucagacgacagauggaca
    gugugacaggaacgucagagaggauugggccucgcugcgagagucagccuggagucaagguguugacaaguugcugagaa
    ggacacgugggaggacgguggcgcgcggagggagagcccugucuucagucaccccguugauggaggacagauggacagca
    gccggacggccagucaccucucuuaaaccuuuggauagugguccuuugugcucugcuggacaccuguuggggauuuuagc
    ccauucucugaacucacuuucucuuaaaacguaaacucggacggcagugugcgagccagcuccucuguggcagggcacuag
    agcugcagacaugagugcagagggcuaccaguacagagcacuguacgacuacaagaaggagcgagaggaagacauugaccu
    acaccugggggacauacugacugugaauaaaggcuccuuaguggcacuuggauucagugauggccaggaagcccggccuga
    agauauuggcugguuaaauggcuacaaugaaaccacuggggagaggggagacuuuccaggaacuuacguugaauacauug
    gaaggaaaagaauuucacccccuacucccaagccucggcccccucgaccgcuuccuguugcuccggguucuucaaaaacuga
    agcugacacggagcagcaagcguugccccuuccugaccuggccgagcaguuugccccuccugauguugccccgccucuccu
    uauaaagcuccuggaagccauugagaagaaaggacuggaauguucgacucuauacagaacacaaagcuccagcaacccugca
    gaauuacgacagcuucuugauugugaugccgcgucaguggacuuggagaugaucgacguacacgucuuagcagaugcuuu
    caaacgcuaucucgccgacuuaccaaauccugucauuccuguagcuguuuacaaugagaugaugucuuuagcccaagaacu
    acagagcccugaagacugcauccagcuguugaagaagcucauuagauugccuaauauaccucaucaguguuggcuuacgcu
    ucaguauuugcucaagcauuuuuucaagcucucucaagccuccagcaaaaaccuuuugaaugcaagaguccucucugagau
    uuucagccccgugcuuuucagauuuccagccgccagcucugauaauacugaacaccucauaaaagcgauagagauuuuaau
    cucaacggaauggaaugagagacagccagcaccagcacugccccccaaaccacccaagcccacuacuguagccaacaacagca
    ugaacaacaauauguccuugcaggaugcugaaugguacuggggagacaucucaagggaagaagugaaugaaaaacuccgag
    acacugcugaugggaccuuuuugguacgagacgcaucuacuaaaaugcacggcgauuacacucuuacaccuaggaaaggag
    gaaauaacaaauuaaucaaaaucuuucaccgugauggaaaauauggcuucucugauccauuaaccuucaacucugugguug
    aguuaauaaaccacuaccggaaugagucuuuagcucaguacaaccccaagcuggaugugaaguugcucuacccagugucca
    aauaccagcaggaucaaguugucaaagaagauaauauugaagcuguagggaaaaaauuacaugaauauaauacucaauuuca
    agaaaaaagucgggaauaugauagauuauaugaggaguacacccguacuucccaggaaauccaaaugaaaagaacggcuauc
    gaagcauuuaaugaaaccauaaaaauauuugaagaacaaugccaaacccaggagcgguacagcaaagaauacauagagaagu
    uuaaacgcgaaggcaacgagaaagaaauucaaaggauuaugcauaaccaugauaagcugaagucgcguaucagugagauca
    uugacaguaggaggagguuggaagaagacuugaagaagcaggcagcugaguaccgagagaucgacaaacgcaugaacagua
    uuaagccggaccucauccaguugagaaagacaagagaccaauacuugauguggcugacgcagaaaggugugcggcagaaga
    agcugaacgaguggcuggggaaugaaaauaccgaagaucaauacucccugguagaagaugaugaggauuugccccaccaug
    acgagaagacguggaaugucgggagcagcaaccgaaacaaagcggagaaccuauugcgagggaagcgagacggcacuuucc
    uuguccgggagagcaguaagcagggcugcuaugccugcuccguagugguagacggcgaagucaagcauugcgucauuaac
    aagacugccaccggcuauggcuuugccgagcccuacaaccuguacagcucccugaaggagcuggugcuacauuaucaacaca
    ccucccucgugcagcacaaugacucccucaaugucacacuagcauacccaguauaugcacaacagaggcgaugaagcgcugc
    ccucggauccaguuccucaccuucaagccacccaaggccucugagaagcaaagggcuccucuccagcccgaccugugaacug
    agcugcagaaaugaagccggcugucugcacaugggacuagagcuuucuuggacaaaaagaagucggggaagacacgcagcc
    ucggacuguuggaugaccagacguuucuaaccuuauccucuuucuuucuuucuuucuuucuuucuuucuuucuuucuuuc
    uuucuuucuuucuuucuuucuuucuaauuuaaagccacaacacacaaccaacacacagagagaaagaaaugcaaaaaucucu
    ccgugcagggacaaagaggccuuuaaccauggugcuuguuaacgcuuucugaagcuuuaccagcuacaaguugggacuuu
    ggagaccagaagguagacagggccgaagagccugcgccuggggccgcuugguccagccugguguagccugggugucgcug
    gguguggugaacccagacacaucacacuguggauuauuuccuuuuuaaaagagcgaaugauauguaucagagagccgcguc
    ugcucacgcaggacacuuugagagaacauugaugcagucuguucggaggaaaaaugaaacaccagaaaacguuuuuguuua
    aacuuaucaagucagcaaccaacaacccaccaacagaaaaaaaaaaaaaa
    128 AW120502 uuuuuuuuuuuuguuuuaauuuggcuccaaugaucgcauucucaaacuccuuugggaggg
    cauuagaugacccaguauccgacgacuuagauucacacguguuuuucuccucugagcucu
    uuucuccaggcucacngucuuuguuuuucaagcuuucuugggccuuugaacaauuuucuu
    ccuuugaagauucuccugg
    129 X62940 Sequence below.
    agccgaguaggaccgagcugcugcagacgcgccgggucacucgagccagcaccaccguucucacgcccugagcugcagacag
    cuaggcgguuuuaucuaguuugaaccaggcugcuggagcuugcucccucccgcccucucucuuuuuuuuccacggggcug
    uuuuuuuaauuuggcugcaauugcaugaaaucccaaugguguagaccaguggcgauggaucuaggaguuuaccaacugag
    acauuuuuccauuucuuucuugucgucuuugcugggaaccgaaaacgcuuccgugagacuugacaauagcucuggugcaa
    gugugguagcuaucgacaacaaaauagagcaagcuauggaucuggugaaaagccauuugauguaugcggugagggaggaa
    guggaaguucugaaggagcagaucaaagaacuaauagagaaaaacucccagcuggagcaggagaacaaucugcugaagacgc
    uggccaguccggagcagcucgcccaguuucaggcccagcugcagacuggcuccccuccggccaccacgcagccacaggggac
    cacacagcccccugcacagccagcaucccagggcucaggaucaaccgcauagccuccuaggccccaacagaacuggcugcug
    cugcugcugucugaacugaacagaccgaagagaugugcuagagagaagccgccuccacagucacccauuucauugcugucu
    acgaaagagacgugagacucacacgcuguucucgcuuucuccccaguauuaagcacucauaagcuuuuggcuugaagaaau
    guacuaguugagugaauuaaagguuaaucagagagugagcagggaugugcccugugcaacguggcagaugucugaggaau
    gguuuaauugaccccgaggagcucugugccuuuucaacccuccccagccgcccacccugcuucugagagcucgggcggcuc
    gccuucguggggcucgccugcgugggguucgaaagugggcugcuccuggauucugcgcucucuucuccuucccuucaaag
    aacucggagaggccagaaacaagacugcaauggggggcggggggagggaugaugcaguccuuauacaaaaccgacaacugu
    caccaaagcuuauaaaacacgauaguacugucccucuuuucugaaccaucagaagacacaaaacuguuagugacacaacggu
    gacagguagcugggaccuaggcuaucuuauuaugaagguuguuuugcuuguuguauauuuguguauguaguguaacgaa
    uuuguaccauagaggacuguccguaacuacuguuuagcuucuacacauugaaauguagauguuucauuggcugucugaaa
    agguguggcuuguccuuccuagagagaucuacuuaaaaacugcuuuguggcaaaaaccacaccugaagaaauuuuaagaau
    uuggcccaguuagucacucuguguaaucccggaaucuagcugcugaagucuugcgaaguaaacuccccgugaccgauguca
    guuaagcuggugauaccuggagaaguggucaguugcuaaggaaguggauuucccaguagggguuucugcaccucaccugu
    auagucguucugcgcaugucccccacacaguccccaccuguauuuaccuguucuacuugucaccuuucaauaaagcauauc
    aaauguugau
    130 U60020 Sequence below.
    auggcugcgcacgucuggcuggcggccgcccugcuccuucugguggacuggcugcugcugcggcccaugcucccgggaau
    cuucucccuguugguucccgaggugccgcugcuccgggucuggguggugggccugagucgcugggccauccuaggacuag
    ggguccgcgggguccucggggucaccgcaggagcccauggcuggcuggcugcuuugcagccgcugguggccgcacugagu
    uuggcccugccuggacuugccuuguuccgagagcuggccgccuggggaacacuccgggagggugacagcgcuggauuacu
    guacuggaacagucguccagaugccuucgcuaucaguuauguggcagcauugcccgcagccgcccuguggcacaaguuggg
    gagccucugggcgcccagcggcaacagggacgcuggagacaugcugugucggaugcugggcuuccugggcccuaagaaga
    gacgucucuaccugguucugguucucuugauucucucuuggcuuggggaaauggccauucccuucuucacgggccgcauc
    acugacuggauucuucaggauaagacaguuccuagcuucacccgcaacauauggcucauguccauucucaccauagccagca
    cagcgcuggaguuugcaagugauggaaucuacaacaucaccaugggacacaugcacggccgugugcacagagagguguuuc
    gggccguccuucgccaggagacaggguuuuuccugaagaacccagcagguuccaucacaucucgggugacugaggacacag
    ccaacgugugcgaguccauuagugacacgcugagccugcugcugugguaccuggggcgagcccugugucucuugguguuc
    auguuuugggggucaccguaccucacucuggucacccugaucaaucugccccugcuuuuucuuuugccuaagaagcuggg
    aaaagugcaccagucacuggcagugaaggugcaggagucucuagcaaaguccacgcagguggcccuugaggccuuaucggc
    gaugccuaccgugcggagcuuugccaacgaggagggugaggcccagaaguucaggcagaaguuggaagaaaugaagacgcu
    aaacaagaaggaggccuuggcuuacgucgcugaagucuggaccacgagugucucgggaaugcugcugaaggugggaauuc
    uguaccugggcgggcagcuggugaucagagggacugucagcagcggcaaccuugucucauucguucucuaccagcuucag
    uucacccaggcuguucagguccugcucucccucuaccccuccaugcagaaggcugugggcuccucagagaaaauauucgaa
    uacuuggaccggacuccuugcucuccacucaguggcucguuggcacccucaaacaugaaaggccuuguggaguuccaagau
    gucucuuuugccuacccaaaccagcccaaaguccaggugcuucaggggcugacguucacccugcauccuggaacggugaca
    gcguuggugggacccaauggaucagggaagagcaccguggcugcccugcugcagaaccuguaccagcccaccgggggccag
    cugcugcuggauggccagcgccugguccaguaugaucaccauuaccugcacacucagguggccgcagugggacaagagccg
    cugcuauuuggaagaaguuuucgagaaaauauugcguauggccugaaccggacuccaaccauggaggaaaucacagcugug
    gccguggagucuggagcccacgauuucaucucuggguucccucagggcuaugacacagagguaggugagacugggaacca
    gcugucaggaggucagcgacaggcaguggccuuggcccgagccuugauccggaagccacuccugcuuaucuuggaugaug
    ccaccagugcccuggaugcuggcaaccagcuacggguccagcggcuccuguaugagagccccaagcgggcuucucggacgg
    uucuucuuaucacccagcagcucagccuggcagagcaggcccaccacauccucuuucucagagaaggcucugucggcgagc
    agggcacccaccugcagcucaugaagagaggagggugcuaccgggccaugguagaggcucuugcggcuccugcagacuga
    131 L32752 gaauuccggggccgcucucuccggcaggaucgccgcgauggccgcccagggagagccgca
    gguccaguucaaggucguccuggugggcgacggcggcaccggaaagacgacauucaugaa
    gcgccacuugaccggagaguuugagaaggaguauguagccacccugggcguggaggugca
    cacauuagucuuccauaccaacagaggaccuaucaaguucaaugugugggacacagccgg
    ucaggagaaguucggggggcugcgcgauggcuacuacauccaagcccagugugccauuau
    aauguuugacguaacaucaagaguuacuuacaagaaugugccuagcuggcauaaagaucu
    agugcgugugugugaaaacauccccauuguauuguguggcaacaaaguggauguuaaaga
    caugaaagugaaggcaaaaccuauucucuuccaccgaaagaagaaucuucaguacuauga
    cauuucugccagaaguaacuacaacuuugaaaagccuuucuucuggcuugccagaaagcu
    cauuggagauccuaacuuggaguucguugccaugccugcucuugccccaccugagguagu
    cauggacccagcuuuggcagcacaguacgagcaugauuuagagguugcucagacgacugc
    ucucccagaugaggaagaugaccugugagaaagugaagcuggagcccugcgucagaaguc
    uauuuuaggcaacuguccugugaugccagccagcggugcagugugugugccaccuuauuu
    agcuaaaggagaucgugcaauucauugggaugcugaaggagaugaaugggcuucggagug
    aauguggcaguuaaaauacaccuucauuuuuuuggacuugcguauuuagcccccuggaac
    agaguuguucuggauuucaaagauaagacugcuaccguagcaucacaauagucaguggug
    accggaauuc
    132 AI840013 uuuuuuuuuuuuuuuuugauuuaugaaaaguuuuauuuaucaguacugugaagaauucuc
    aucauaauugcuacguuaaucaaggaaaaggcacagagaagcaugugucguuugaguccu
    cgauacuggaccucccagcccaugcucccuaugaggagucuagcugcugugguggucuuc
    acagcuuugguuuucuggagacgaagcucaugauugcguucaugcacuccucugacagcc
    accuugcuugcagaguagugcacucuucagcguugacugcguagagcuuuucuuucucau
    uuuuucugauuaacucuuuggaaauucucauuggguuuggcgggagcuucgcauau
    133 AB020424 ucgggaaucgauugagagaccgcgaaccuguaaacggaugauaccgagucgggcaggcgu
    uaugccagcccaacucgggaccucgcaucauguccgcggcuaccuuagaguguuucggga
    augauuugcgguggaugaacgaaaccccgguacguccugugccaaggagcauaugucagg
    acggacgcucguuaaugccucagugguggggcaacguucgcucucuaucuauacgacucu
    cgacaauggauaucucggcucucgcaucgaugaagaacguagcgaaaugcgauacuuggu
    gugaauugcagaauccugugaaccaucgagucuuugaacgcaaguugcgcccgaggccuu
    ucgguugagggcacgccugccugggcgucacgccuuguuuugcucugugcccgugcucuu
    ucgggggcggucauggaugcggagauuggcccuccgugccucgugugcggcgggcuuaag
    cgcggggugucggcgucgggaagggcacgacgagugguggacggagcaccagcaggaugu
    uguggucccccgucaccuuaaggggcucaagagacccggacuaggcgagccgcgcuucgu
    aagaggagggcgagcugucucgcaau
    134 AI848453 uuuuuuuuuuuuuuuuugaaguugcugccccuuuauuggugacccgggcaaguuuaagga
    gaacaacauuaaagcacacaaaguguauccaugucaccagcucaaccaggaggagugagg
    gucacggcaggguucucccaugguguaagaaaucaacgcaauuucaucacaccccguuac
    uuuccaaguuaacgaaccgauaagaaaagauucucccuuaaacugacaaguacaauguac
    auguacaugauuuuggaauaauuuaauacuuuaaccucaagauacaacuauauucuaaga
    ccauuauuuuaaaggaacggauccuuacaaaaccaaaauaacccauauagcacgagguug
    guuuagccuuucuucuucuuucaacaaacgugcaccacauguuucaguagcaaggccgau
    gccauggauaugagagcugugauuugcagggaccaaccacaucuagaaccggggaggcca
    aucanacgguggguu
    135 AU040563 cccuuggaggauaguuuuauugacaagucgaguuagguuuuagaguaaacuuuuaucacc
    ccagucaggccccuucccaggggaggcucgcugguagcucagauggccuugguggugggc
    agauuguuguaguugucuuccuggcccuccagcaggcuucgggagguggcuaucuccugc
    uccagccuggacuugauguccaguagcugcuuauacuccggguucuggcgcucuaugugc
    ggcacgcaggugcngcg
    136 X89749 Sequence below.
    ggacugacuccuugggcagauugccucuccuccuucucaugccagaggcugcugaugaggaaagguccaggggacugucca
    ugcugucuucauccucagagucacugccugaugcugcaacaagacccuucuuguuuagcaauagugguuggaacacucucu
    uguaaguuaccggagcacuaguauaggaggaggaucaucgacuacccucccgccacuccacggcugcuggcuccuagaaac
    cccagcuucaccucucacugggacucgaguuccagaaugaaaagcaagaagggucuuguugcagcaucaggcagugacucu
    gaggaugaagacagcauggacaguccccuggaccuuuccucaucagcagccucuggcaugagaaggaggagaggcaaucug
    cccaaggagucaguccagauucugcgagacuggcuguaugaacacagauacaacgccuaucccucagagcaagagaaagcac
    ugcugucccagcagacacaccuguccacacuacaggucuguaacugguucaucaacgcccgccgcaggcuccuuccugacau
    gcugagaaaggauggcaaagauccaaaucaguucacgauuucccgccguggggccaagauuucagaagcuagcucuauuga
    agcugcaauggguaucaaaaacuucaugccaacucuagaagagagcccauuucauuccugcguaguuggacccaacccaacc
    cuagggagaccagugucucccaaaccucccuccccaggauccauuuuggcucgcccgucagugaucugccauaccacugug
    acugcauugaaggaugggccuuucucucucugucagccgauuggugugggacagaguacagauguaccgcaaauagcaccc
    agcaacuuuacagacaccucucucguguacccagaggacacuugcaaaucuggacccaguccaaacccucagaguggucuuu
    ucaacacuccucccccuacuccaccagaccucaaccaggauuuuaguggauuccagcuucuaguggauguugcacucaaacg
    agcggcagagauggagcuucaggccaaacucacagcuuaaccguuuuuucaaacaaaacaguucuccaaaauacgguccuga
    uugccgggggugauggcaagagaugcauuauuuuauauauuuuuuc
    137 AW125390 uuuuuuuuuuuuuuuuuggugguuaucaagugcacuuuauugaauccacuguggauagau
    aaaugaguguuacaccugcguguagggaggggcaaggagggacgcagcugcggaggguga
    agcacuucaggaccggaagucggaauccucuauuaagugugaagguuuugagcguuaaga
    acaaugaugaugacacuaacaauggugauaacaaccaucaggaugcugaggaccaaggug
    cugauguucaggcacuuagcaguggaggcguaggccugggcuccagucacaucacccacc
    aucuuccgaucccuagacuucacggaguaggcauaggcuaugaagcccaggcagcagaag
    uucaugaagaguguauugaacagggaccagaccacauggucaggcaccgacaccucucug
    ggcauguugaucacaguaguucugacagaagccga
    138 X05862 Sequence below.
    aagcuucaggauacagugcacacucguaaauaaaaacuacaggcugcugcgaauuauauuucaacugaccggagaggcaaag
    ccugacuguccauuaacccuuaacuuccaaacgcaaacugcuuacugcaucuuuuggcauuuuaccuuaugccuuguuagg
    uccaaggcaagagaagcgucaucaauaaccacgcaugugcaacagcuuuuccagaggaaagguguggguggcucuuaaaag
    agccuuugaguuaggagugugaguuaaacgagcucacuuggagcugguguacuuggugacugccuuggugcccuccgaca
    ccgcgugcuuggccagcuccccgggcagcagcaggcgcacggccgucuggaucucccgggacgugauggucgagcgcuug
    uuguaaugcgccaggcgggaagccucgcucgcgaugcgcucgaagaugucguucacgaacgaguucaugaugcccauggcc
    uuggaggagaugccggugucggggugcacuugcuucagcaccuuguacacguacaccgaguagcucuccuugcggcugcg
    cuugcgcuucuugccguccuucuucugggccuuggugacggccuucuuggagcccuucuucggggcgggagcggacuug
    gcgggcucaggcauacugagaggaugaagugaacuaaguugaaaaaggauaacuaaaaguuaaugacuguucuggcugcaa
    uuuuaaacaaacuuacggcuauggcaaccugaaucaccauacgucauguacuaacaguccaaucaaaacaagggauuuucaa
    accagggcgccauugguaaccaauguguaaccaaugaaaucucuccguuuucgcguccagccuugacuauauauacuaugc
    guauacguuuuugcuucuuacugcggugguuaucuacagcugaguuaugucuggacguggcaagcaaggacguggcaagc
    aaggaggcaaggcccgcgccaaggccaagacgcgcuccucccgggccggccugcaguuccccgugggccgcgugcaccggc
    ugcuccgcaagggcaacuacucggagcgcgugggcgccggcgccccgguguaccuggcggccgugcuggaguaccugacg
    gccgagauccuggagcuggcgggcaacgcggcccgcgacaacaagaagacgcgcaucaucccgcgccaccugcagcuggcca
    uccgcaacgacgaggagcucaacaagcugcugggccgcgugaccaucgcgcagggcggcguccugcccaacauccaggccg
    ugcugcugcccaagaagaccgagagccaccacaaggccaaggggaagugaaaccaaacauuacgaaucaccaaggcucuuuu
    cagagccacucacuuucucaaagagaccuaacacuacugggauagugcauugugggaaauacguguauuaaccuuccuccu
    auuuucccugcuugugguuaguucaaccccuaagccuuaggcuaagaguauauugguuuuuggaaggcaggcacccaacc
    ucggaccuaguacauaaaacagacacaucuugaacuccaggccagccuacucugcaggacgaguuccaggacagaccggacu
    gcacaaagaauugucuugaaauguuccuuuaucagcacauaugcugauaaacaacuaaucacuguacaaucaauccucacuu
    gaauccuguuuauguggcaugauugacaaguccugccauuuggcaaagucaaaaucagcaaaggauguuaaagcauuuggu
    gguaucacagcuaaaac
    139 AW046181 uuuuuuuuuuuuuuuaugcaaauaguuuucaagauuuuauugcaaaccaaaauugguuua
    ucgcacacaaaaaaaguugugugguaaggaggaggaauuguacaggauuauaacccaugu
    uaauuacaguacauuaaaaugaugguuuacaaauaagccuguaaguuuaaauaucuagug
    uuauaacccaauguacagacuuccuuuacacgauacauacaauaaucaggaaugcaaaag
    aauaugaacaaagggaaaaaaaacauaaauaaugcccguuuuauaggugacauuuuaaac
    aauugaaaacaccaaccggcuuugacugacaacuggggcauugguccauaaaaacccuuu
    cuaaaaauagaaauau
    140 U10118 Sequence below.
    gaggcugcucaagagcugcgguugggucaccgcuucauguuucucugccgauucuggggaaagauggcaacgaaugaugc
    uguucugaagaggcuggagcagaagggugcagaggcggaucagaucaucgaauaucucaagcagcagguugcucuucuua
    aggagaaagcaauuuugcaggcaacaaugagagaagaaaagaaacuucgaguugaaaaugcuaaacugaaaaaagaaauaga
    agagcuaaagcaagagcugauucuggcagaaauucauaacggaguggagcaagugcguguucgauugaguacuccacugca
    gacgaacuguacugcuucugaaaguguggugcagucuccaucaguagcaaccaccgccucuccugcuacaaaagagcagau
    caaagcgggagaagaaaagaaggugaaagagaagacugaaaagaaaggagagaaaaaggagaagcagcagucggcagcagca
    aguacugacuccaagccuaucgacgcaucgcgucuggaucuucgaauugguuguauuguuacugccaagaagcacccugau
    gcagauucacuguauguggaggaaguagaugugggagaagcagccccgcgcacggucgucagcgggcuggugaaucaugu
    uccucuagaacagaugcaaaaucguauggugguuuuacucuguaaucugaagccugcaaagaugcggggaguucugucuc
    aagccauggugaugugugccaguucaccagagaaaguggagauucuggccccucccaacggguccguuccuggggacagaa
    uuacuuuugaugcuuuuccuggagagccugacaaggagcuaaacccuaagaagaagaucugggagcagauccagccugacc
    ugcacaccaaugcugaguguguggccacauacaaaggagcucccuuugaggugaaggggaagggaguuugcagagcccaaa
    ccauggccaauaguggaauuaaauaagugcucuguaacugaaagacauuggcgaaaacuuaauaacaauaaagagaagugu
    guuuaucacuuacauau
    141 AW212775 ggccuuguuuuugguuugcaauaaagaguauuucuuuaaaaggcacauuuuguuaaauag
    gcaguuccccuccugccucuuccuuuguagcaguguacugcauccuagaaacauuuagca
    aagcagcccuuagccuccccgacccccuuucccucccucccagca
    142 AI846302 uuuuuuuuuuuuuuuuuaaacaaugacgccguuuauuuaaaauguuuacucccagaaaua
    uagauauaaaaaaaaaaauaagacaauuaacagcacuaaaccaggcaccuucaaccgaau
    cccaccauccucguuaacucccuuccuguuacccuuuguagaugaccagaagauuucagg
    agccccuggacagccagagugguuccugcccagggcuucccgccuuccuccuguccuaga
    gcuucccgugggaaagcuugggugagaauuuuagccuaaagggagggggcuguggccggg
    cacuuugcgcucauccacugcagg
    143 M22998 Sequence below.
    acaggguacaguugugcgucagggcguggaggucuggcgggagacgcauaguuacagcgcguccguucuccgucucgcag
    ccggcacagcuagagcuucgagcgcagcgcggccauggaucccagcagcaagaaggugacgggccgccucauguuggcugu
    gggaggagcagugcucggaucacugcaguucggcuauaacacuggugucaucaacgccccccagaagguuauugaggaguu
    cuacaaucaaacauggaaccaccgcuacggagagcccaucccauccaccacacucaccacgcuuuggucucucuccguggcc
    aucuucucugucgggggcaugauugguuccuucucugucggccucuuuguuaaucgcuuuggcaggcggaacuccaugcu
    gaugaugaaccuguuggccuuuguggcugcugugcuuaugggcuucuccaaacugggcaaguccuuugagaugcugaucc
    ugggccgcuucaucaucgguguguacugcggccugacuacuggcuuugugcccauguaugugggagaggugucaccuaca
    gcucuacguggagcccuaggcacacugcaccagcugggaaucgucguuggcauccuuauugcccagguguuuggcuuaga
    cuccaucaugggcaaugcagacuuguggccucugcugcucagugucaucuucaucccagcccugcuacaguguauccuguu
    gcccuucugccccgagagcccccgcuuccugcucaucaaucguaacgaggagaaccgggccaagagugugcugaagaagcu
    ucgagggacagccgaugugacccgagaccugcaggagaugaaagaagagggucggcagaugaugcgggagaagaaggucac
    caucuuggagcuguuccgcucacccgccuaccgccagcccauccucaucgcuguggugcugcagcugucccagcagcuguc
    ggguaucaaugcuguguucuacuacucaacgagcaucuucgagaaggcaggugugcagcagccuguguacgccaccaucgg
    cuccgguaucgucaacacggccuucacuguggugucgcuguuuguuguagagcgagcuggacgacggacccugcaccuca
    uuggccuggcuggcauggcaggcugugcugugcucaugaccaucgcccuggccuugcuggaacggcugccuuggaugucc
    uaucugagcaucguggccaucuuuggcuuuguggccuucuuugaaguaggcccugguccuauuccaugguucauuguggc
    cgagcuguucagccaggggccccguccugcugcuauugcuguggcuggcuucuccaacuggaccucaaacuucauugugg
    gcaugugcuuccaguauguggagcaacugugcggccccuacgucuucaucaucuucacggugcuccucgugcucuucuuc
    aucuucaccuacuucaaagucccugagaccaaaggccgaaccuucgaugagaucgcuuccggcuuccggcaggggggugcc
    agccaaagugacaagacacccgaggagcucuuccacccucugggggcggacucccaagugugaggagccccacacccagccc
    ggccugcucccugcagcccaaggaucucucuggagcacaggcagcuagaugagaccucuuccgaaccgacagaucucgggc
    aagccgggccugggcgccuuuccucagccagcagugaaguccaggaggauauucaggacuuugauggcuccagaauuuuua
    augaaagcaagacugcugcucagaucuauucagauaagcagcagguuuuauaauuuuuuuauuacugauuuuguuauuuu
    uuuuuuuuaucagccacucuccuaucuccacacuguagucuucaccuugauuggcccagugccugaggguggggaccacgc
    ccuguccagacacuugccuucuuugccaagcuaaucuguagggcuggaccuauggccaaggacacacuaauaccgaacucu
    gagcuaggaggcuuuacgcuggaggcgguagcugccacccacuuccgcaggccuggaccucggcaccauagggguccggac
    uccauuuuaggauucgcccauuccugucucuuccuacccaaccacucaauuaaucuuuccuugccugagaccaguuggaag
    cacuggagugcagggaggagagggaagggccaggcugggcugccagguucuagucuccugugcacugagggccacacaaac
    accaugagaaggaccucggaggcugagaacuuaacugcugaagacacggacacuccugcccugcuguguauagauggaaga
    uauuuauauauuuuuugguugucaauauuaaauacagacacuaaguuauaguauaucuggacaaacccacuuguaaauaca
    ccaacaaacuccuguaacuuuaccuaagcagauauaaau
    ggcugguuuuuag
    144 X64837 Sequence below.
    gcuuucuaaacuagcaagcaucguguggguccuucaggagugggagugcagacagaccugacagcguccgcuaagcgacac
    ugacuguacuuccacuccugaaggacccacacgaugcuuucuaaacuagcaagucugcagaccauugcugcucugcgccga
    ggaguccacaccucagucgccucugccacgucuguugccacaaagaagacagagcaaggcccaccauccuccgaguacauuu
    uugaacgggaaucuaaauauggugcacacaauuaccauccuuugccuguagcccuggagagaggaaaaggcauuuauaugu
    gggauguggaaggcaggcaguacuucgauuuccugagugcuuauggugcugucagccaaggacacugccacccaaagauca
    uagaugccaugaagagucagguggacaagcugacauuaacaucucgggcuuucuauaacaauguccuuggugaauacgagg
    aguacaucaccaagcuuuucaacuacaacaaaguucucccuaugaauacaggaguggaggcuggagagacugcauguaagc
    ucgcucgucguuggggcuacaccgugaaaggcauccagaaauacaaagcaaagauuguuuuugcugaugggaacuuuugg
    ggucgaacacuaucugcaaucuccaguuccacagauccgaccaguuaugauggcuuuggacccuucaugccaggcuuugaa
    accaucccauauaacgaucugcccgcacuggagcgugcucuucaggauccaaauguugcugccuucaugguggagcccauc
    cagggugaagcaggcguuaucguuccggauccaggauaccugacaggaguucgggaacucugcaccaggcaccagguccug
    uuuauugcugaugaaauacagacaggauuggccagaacugguagauggcuggcuguggaucaugagaaugucagaccuga
    uaugguucuucuugggaaggcccuuucuggcgguuuauacccugugucugcagugcugugugacgaugagauaaugcug
    accauuaaaccaggcgagcacggcuccacauacggcggaaacccacuaggcugccgaauugccauugcggcucuugagguu
    uuagaagaggagaaucuugcugagaaugcagacaagaugggcgcuauccugaggaaggagcucaugaagcugcccucugac
    guugugaccucagugagagggaaaggguugcuaaaugccauugucaucagagaaaccaaagacugugaugcuuggaaggu
    gugccugcgacuucgagauaacgggcuucuggccaagccaacccacggugauaucaucaggcuugccccuccccuugugau
    caaggaggaugagauccgggaguccguggagaucaucaacaagacuaucuuguccuucugagaguaggaacucuggggagc
    caucuucagacagggcucuugugaaacucugcuugcaguggccagagccugucuccugaaaggcauauauuucaguugau
    gcauaauagagugacaccuaggaaccugcagguggcugcgugacagaaaagugagagcgagaggcgaggcgucucuuugu
    ugagguuugacugugugggaacuuucuaaggagaaacggacccaucugcguacagccugcagauggaggccugcagucau
    uuacgugcgucuuuacaguuuccuugcugaugugaaugguuuguauuuagaaguuauuucugagauacuacagaacaguu
    aaaucauuauaaucaaugaauguuaaguugauugaagguuaagcauauguaaaauacuaguuuaaaguaaacuuuucauug
    gccaacaccagaauguauuauauagauucugagaauucauuacuaaauuacacuuugcuugauugcaauuuguaaaacauu
    uauuuucaguauuucuuugaauaaagcuuaauguuucuuuuuacgccaacagaguauuuuguauuuccauuuugguaaua
    aucaguguauuauuucauccugaugacuggcauuucaucaccuauugagaucacuggguguguuucaggccuuuuauucu
    aaauaaagcuaugaccaguuucugucugu
    145 AI843119 uuuuuuuuuuuucuuuuccgacgcccacaagaggaauaagagauuuaaugauggaaagua
    uggggaaaucacaguuuucagacaugaguaaucaaaaacuugacauuuuucuugauaucc
    aaaucuagaugucuguaucaaaccagaggugauggccuuggggauggcagugaagacugu
    uaggaccauuagaucagau
    146 A1837786 uuuuuuuuuuuuuuuuuacaguuuuaaaacaauacacagcuuucucgggcugaagcaauu
    gcaagaacguauugguauugguauauuacagcuacauacaagguuuaugaauagcaaugg
    agaaaaauaaguuauuuaaauauugacuucauaaagagaaagugcaauguuguuaguugu
    cauaucacuugcuugacaguuugugggguuucuucccuaucaauuuuaacaaucaagaua
    acauggacucaagacagaauuuuucgggaaccucacucaguccucacacagcagugacuu
    gggaaucuacguguguuccaccgcaguugugaaacacacuacuccguguccaggacucau
    uucucagagaagaaucaauucgaguuccauccacaccuggggucgggacaca
    147 U41465 Sequence below.
    ccgggcucgaauucucuagacucgaguuuagagaauucgagcucucccaguuuuaaagcaaaauuuuggacugugaagcaa
    ggcacugggcaaacacaacauggccuccccggcugacagcuguauccaguuuacccggcacgcuagugauguucuucucaa
    ccuuaaucgccuccggagucgggacaucuugacggacguugucaucguggugagccgugagcaguuuagagcccauaagac
    agugcucauggccugcagcggccuguucuacaguaucuucacugaccaguugaaaugcaaccuuaguguaaucaaucuaga
    uccugaaaucagcccugagggguuuugcauccuccuggacuucauguacacaucuaggcucaaccugagggaaggcaauau
    cauggcggugaugaccacagccauguaccugcagauggagcauguugucgacacaugcaggaaguucaucaaggccaguga
    agcagaaauggccccugcacuuaaaccuccccgugaagaguuccugaacagccggaugcugaugccccaugacaucauggcc
    uaccgaggucgugaggucguggagaacaauaugccacugagaaauacucccgggugugagagcagagcuuuugcuccuccu
    cuguacaguggccugucaacaccaccagccucuuaucccauguacagccaucucccgcucagcaccuuccucuucucugaug
    aggagcuccgagaugccccccgaaugccuguggccaacccuuuucccaaggagcgugcccuccccugcgacagugccaggca
    agucccuaaugaguauagcaggccagccauggaggugucccccaguuugugucacagcaacaucuacucgcccaaggaggc
    agucccagaggaggcucggagugacauacacuacagugugccugagggccccaagccugcugucccuucugcucggaaugc
    uccauacuuccccugugacaaagccagcaaagaagaagagagaccuucuucggaggaugagauugcccugcauuucgagcc
    ccccaaugcacccuugaaccggaagggucugguuaguccccagaguccccagaaauccgacugccagcccaacucacccaca
    gaguccugcagcagcaagaacgccugcauccuucaggccucuggcucuccgccagccaagagccccacugacccgaaagccu
    gcaacuggaagaaguauaaguucaucguucucaacagccucaaucagaaugccaaacccgagggcucugagcaggcagagcu
    gggucgccucuccccucgagccuacccugcaccgcccgcuugccagccgccuauggagcccgcgaaccuugaucuccagucc
    ccgaccaagcucagugccaguggggaggacucuaccaucccccaagccagccggcucaauaaucucgugaacaggucccugg
    gaggcuccccccgaagcagcagugagagucacucaccacucuacaugcaccccccaaagugcacauccugcggcucucaguc
    cccacagcauacagagaugugccuccauacugcugggcccacguucccggaggagaugggggaaacccagucagaguauuc
    ggauucuagcugugagaaugggaccuucuucugcaacgaaugugacugccguuucucugaggaggccucgcucaagaggc
    acacgcugcagacgcacagugacaaaccauacaaaugugaucgcugccaggccuccuuccgcuacaagggcaaccucgccag
    ccacaagacuguccacacgggugagaaacccuaucgcuguaacauuuguggagcgcaguucaaucggccagccaaccugaag
    acccacacucgaauucacucuggagaaaagcccuacaaaugugaaaccuguggggccagguuuguucagguggcccaccuc
    cgugcccacgugcucauccacacuggagagaagccguaccccugugaaaucuguggcacucgcuuccggcaccuucagacu
    cugaagagccaucugcgcauccacacaggagagaaaccuuaccauugugagaaguguaaccugcacuuucgucacaaaagcc
    aacugcgacuucauuugcgccagaagcacggcgccaucaccaacaccaaggugcaauaccgcgugucggccgcugaccugcc
    uccggagcuccccaaagccugcugaaugaagcauggaguguuccucgcccuuuccucuccagccccuucucagaaucuaccc
    aaaggaugcuguaacacuuuauacaaaggucaucccaugauguagugccucucucauccacuagugcaaaucauaguuggg
    guggggguggg
    148 U70494 ucgcgguccgacggaggagugggcgcugggaucucgcugagcguccgccuggccucgucu
    cuuccucgcucgucggagcuucagcacgguccgagauggcuggcgguaaggcuggaaagg
    acuccggaaaggccaagacaaaggcgguuucccgcucgcagcgagccggcuugcaguucc
    cugugggccguauucaucgacaccugaaaucuaggacaaccagccacggacgugugggcg
    cgaccgccgcuguguacagcgcagccauccuggaguaccucaccgcagagguacuugagu
    uggcaggaaaugcgucaaaagacuuaaagguaaagcguaucaccccucgucacuugcagc
    uugcuauacguggagaugaagaauuggauucucugaucaaagcuaccauugcugguggug
    gugucaucccacacauccacaaaucgcugaucgggaagaaaggacaacagaagacuguuu
    aaggaugccuggauuccuuauuaucucaggacucuaaauauuccuaacagcuguccagug
    uuggugauuccaguggacuguaucucugugaaaaacacaauuuugccuuuuuguaauucu
    auuugagcaaguuggaggcuuaauuagccuuccaaccaaccaaauuucugcauucgaguc
    uuaaccauauuuaaguguuacuguggcuucaaagaagcuauugauucugaaguagugggu
    uuugauugaguugacuguuuuuaaaaaacuguuuggauuuuaauugugaugcagaaguua
    uaguaacaagcauuugguuuuguacagacauuguuuccacucugguggauaagcucaaua
    aaggucauaucccaaacuagcuuuaaacuugcuuaauaaucgggucuuaccuuagaucuc
    acucagcaacaaguacauucucugcuuacuaauuaaacagugcaucuguagucauaaaaa
    aaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    149 D17666 Sequence below.
    caccaccgugcacgcagcuccgggcccgugggguguugguucuugcccucguaacccccucuguccagccaccaugauaag
    cgccagcagagccgcggccgcgcgucucgugggcaccgcugcgucccggagccccgcagccgcccguccccaggugagaag
    cugccaugccuuccggugggggcuccaggcccggacucgagugaggcaggccuugccuucgggucagacucuaggaaaaau
    ccggagcgaagggauguaacggaccuucugugggcauuguuggccuucuugcagggcuuuagcuucgaacugugcugagu
    cacaauccuuggcguuccuaagucuuuaccccgcuaauugagacgucuguccccccucuaaccugugcgcuuugaaugugc
    cuggacuuaggcaguggacguaguuuacuggaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnuuuuacauacuaaggacuaaag
    cuugcauguguuccucagaauaugaaaagcccaaguucuuguguaguugauggcugaugcaacuuuuuuccccccaggau
    ggcuggaauggccuuagccaugaggcuuuuagauuuguuucaagaagagauuaugcguaaguacaaccucaguuucucug
    agaaaaaaaaaaaacacuuauugaaccucaaagcuuggauggguugggugcguuauacauuuguacuuguaguuuauucaa
    uaugccacugguaacaccaacauaaaacacaguucuucguauuggagaccacuguucagaugaccauggaauuucauuucu
    uacagaucagaagcaaucaagggugcagugguugguauugauuuggguacuacuaacuccuguguggcuguuauggaggg
    caaacaagcaaaggugagcaugauuggaaaccugaggucacuuagauacccagucuggcauuaaguacauaggaaugcuga
    gucggagcccagguuaguggugggcacuuuaauccuaguaaaggcagagggaucucugaguucaggaccagccuagagua
    caaagugagnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnacuuuaaucagugucuuugggaauuuuagguccuggagaaugcuga
    aggugccagaacuaccccuucugugguugccuuuacagcagauggagaacgacuuguugguaugccagcaaaacggcaagc
    ugucaccaauccaaacaauaccuucuaugcuacuaagcgucuuauuggacgacgauaugaugacccugaaguacagaaagac
    acgugaguaauaggaaaaucaguccagaagacuggugcuuugaucaaaguucuguggauaccuugaguucuguggaucac
    cuuggaucacuuuuucauuauuucugcuugggaagaaaucacaccaccaucagaggcauauagguuuuuuuuuuguuauu
    ucuuuguuguuguuguuuuccuauuuauuuguuuguuuguuuggggggggguuucuuuguguauuuuccuggaacuca
    uucuguagaccaggcuggnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnucaugugauauaugaugaacuuagagugguuaaguuu
    cacagggauaguuuacuuacauaaucuuucugucuuuaaguaagaauguuccuuuuaaaauuguccgugccuccaauggu
    gaugcuuggguugaggcucauggaaaacucuauucuccaagucagauuggagcauuuguguugaugaagaugaaagagac
    ugcagguaaguggauuuauuucacauuuaggaaaauuggaaugugcuguuuauuucucugcauuaauacugauuaacuuc
    auauucuguagauaauggagucugaagcuunnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnngaauucaugcuccuccugcugccucc
    ugggugcuaaguugcaaggugauagcucagguacucacucuagugucuuucuuggggugcucuuuuccaaggccucucua
    cauauuaagccacaaaggagucuguugccccucaagaggaugagauguggaauauuaggcuacaguuuuguugccuuuuu
    uuuauuuuccuaacaugguaccacaauugaauuuuauucuuuguuucccagaaaauuacuugggccacacagcaaaaaaug
    cugugaucacagucccugcuuauuucaaugauucacagcgacagguaaaauuagaucucuuguuugcugggaguggaggu
    gggguaccugaguuaaaggauggaaagauagauuuauuucuacuuucucuaggccacuaaggaugcuggccagauaucug
    ggcuaaaugugcuucgagugaucaaugagccuacagcugcugcucuagcuuacggucuggacaaaucugaagauaaagugu
    aaguuggucagaugacguagcauuaccugcauuuacagggguuguguguguguguguguguguguaauuuuacuacaau
    uuguguggguccguguguugugguacauuuguacauuuguacauggcauggauauggaugucaaagauunnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnaaaccaguaguugguguguuacuaauuuuacuuguuucuguaugacaugcuuauaugauacguua
    acaggcaugccacuuagguugauaacuacauucaguuauuaaguauuucaggaaauaucauaguuaauaauuaaacuuuug
    gucuuuuaauucguuccuuuguuuuguuccuuggaacuuaacuuacuuauuuauuuuuuagcauugcuguguaugauuu
    aggugguggaaccuuugacauuucuauccuggaaauucagaaaggaguguuugaggugaaaucuaccaauggggacacuu
    ucuuaggaggggaagacuuugaccaagcuuuguugcggcacauugucaaggaguucaagagagagguuaguuaccacugc
    uuagucaccacugguuaagguguaggcguuggguuguugagaauuuuuguuuguuugcauugcuuuuagcuuuguuaau
    agcuuuuuuauacuaagguaacuaacuauacuucagauucauggguaaacuaaaccaguuuaguuauauaaucuuagauug
    ggaacaaaagaccaagugacaguguuauaguagggagaagnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnacuacucucucgcagu
    cuauauaugucuccuaauccuauuuauagacagggguugauuugaccaaagacaacauggcgcuucagaggguucgggaag
    cugcugagaaggcuaaaugugaacuuuccucaucugugcaggugagggauggaaaaaucccaguacugagcauauuugaau
    aguguauucuaauuuaccuaaugucaguguagcucuuuacaguuuucuguuggcugaaaacuuggggcaugagcaaagga
    acaacuugaugaucaguucuuuucauuugaaugaaugaaguagauuuauggauguguguaucuuuugccugcaugugug
    ucuguacuacauuugugcuugguuucuguggcggccagaagaggguaucagaacugacaugucaguguuggggannnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnncacacugagucuaaauucugaucaugucuuucagucguguuauguuacuuugagugagua
    ucaaagaucacgucucccaucugacgugugguccugugcagacugacaucaacuugccauaccuuaccauggaugcuucug
    gaccaaagcauuugaauaugaagcugacucgagcucaguuugaaggcauugucacagaucuaaucaagagaacuauugcuc
    cgugucagaaagcuaugcaggaugcagaagucagcaagagugacauaggagaagugauucugguugguggcaugacaagg
    augcccaagguauggacucaugguauuucuccuagaggaaaaaaauaacaaugcauucuugaggcaaauggcuuguguugu
    guguggaaacaaaugugauccauucuucuaguguucuuuaaagaguggugagaccagacucaccaaaaagugcuuuuaguc
    gccugugauggcucauguaggaggauggccuugaguucuggguaagaugcagcuacagaauucuaccuugcacacacacu
    uaaacccagucugguaaagagaaguuguuaagcuunnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnncagauguaaaauugauaauac
    uucuuccuaagauugggcgauuguguagaauaugagaacuguauuuuauaaccccuugucaugugccuucuauuucaaau
    gauauccucugggaagcuagauaauuaaauucuucucucauuuaaguggacaguggaugagaugcucugaaguugucaaa
    uacaaacaagucugcagucuuggauaugaaucucucugacuugcugucuggcaggcguauucuguuuggcuccaucaguc
    gcccuggguguuggcuaacagguucuuucucccugaugcuuagguucagcagacuguacaagaucuuuuuggcagagccc
    cgaguaaagcuguuaauccugaugaggcuguagccaucggagcugccauccagggagguguguuggcuggugacguuaca
    gacgugcugcuccuggaugucacuccccucucucuggguauugagacucugggaggcgucuuuaccaaacuuauuaauag
    gaacaccacuauuccaaccaaaaagagccagguaagagccauucuuuuuuccugccuauuaacagucccaaguuguacaagu
    gcuguuuacaaucacuuuaugaacucuuuaaaacuuuguuucuaagacuauacuaacuggacugggugnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnccuagguguuuucuacugcugcugauggacaaacucaaguagagauuaaagugugucagggggaacga
    gagauggcuggagacaacaaacuucuaggacaguucacuuugguaaguguuuuugagucugaguaucaugcuuuuggggu
    cuauagcuugcaaagcuccaaacugcugacauuacaggcauauuguguuauuuuuuaaaaagaacguuauguacaugaguu
    augaaacccaugauuuuaguuuuuuaccuaaagugcuuuguguuuucagaauuugaaauuuucaaagccugggaaauguu
    cagacucagaagcaaugcuaacucagaaguuaguuuuauccugauuacucauuuuaaaaaacuuaauagcuacugguucug
    gucagcauugcuacaguagagaaguuuauuugcuguaaauucugggcacauauaaccaucaugguuauuaacuucuugaa
    gcccagugauuucagaaagcacuaaaacuaccaccaucacuuaaaaucucaagguuuugaacauucagugaagauacuuguu
    uuaggaaacaagugguuaguuggccugauuuggaaaugagaauacaugggccuuucaaaggagcucacucuggauauuua
    uuuuagauuggaauucccccagccccucguggagugccccagauugaaguuacauuugacauugaugccaaugggauugu
    gcacguuucugccaaagauaaaggcacuggucgugagcaacaga
    150 X14897 Sequence below.
    auaaauucuuauuuugacacucaccaaaauagucaccuggaaaacccgcuuuuugugacaaaguacagaaggcuuggucac
    auuuaaaucacugagaacuagagagaaauacuaucgcaaacuguaauagacauuacauccauaaaaguuuccccaguccuua
    uuguaauauugcacagugcaauugcuacauggcaaacuaguguagcauagaagucaaagcaaaaacaaaccaaagaaaggag
    ccacaagaguaaaacuguucaacaguuaauaguucaaacuaagccauugaaucuaucauugggaucguuaaaaugaaucuu
    ccuacaccuugcaguguaugauuuaacuuuuacagaacacaagccaaguuuaaaaucagcaguagagauauuaaaaugaaaa
    gguuugcuaauagaguaacauuaaauacccugaaggaaaaaaaaccuaaauaucaaaauaacugauuaaaauucacuugcaa
    auuagcacacgaauaugcaacuuggaaaucaugcaguguuuuauuuaagaaaacauaaaacaaaacuauuaaaauaguuuua
    gaggggguaaaauccagguccucugccaggaugcuaaaauuagacuucaggggaauuuugaagucuucaauuuugaaaccu
    auuaaaaagcccaugauuacaguuaauuaagagcagugcacgcaacagugacacgccuuuagagagcauuacuguguauga
    acauguuggcugcuaccagccacagucaauuuaacaaggcugcucagucaugaacuuaauacagagagagcacgccuaggca
    gcaagcacagcuugcugggccacuuuccucccugucgugacacaaucaauccguguacuugguguaucugaagcgcacgcu
    gcaccgcggcacugcccggcggguuucugggcggggagcgauccccgcgucgccccccgugaaaccgacagagccuggacu
    uucaggagguacagcggcggucugaaggggaucugggaucuugcagagggaacuugcaucgaaacuugggcaguucuccg
    aaccggagacuaagcuuccccgagcagcgcacuuuggagacguguccggucuacuccggacucgcaucucauuccacucgg
    ccauagccuuggcuucccggcgaccucagcguggucacaggggccccccugugcccagggaaauguuucaagcuuuucccg
    gagacuacgacuccggcucccgguguagcucaucacccuccgccgagucucaguaccugucuucgguggacuccuucggca
    guccacccaccgccgccgccucccaggagugcgccggucucggggaaaugcccggcuccuucgugccaacggucaccgcaau
    cacaaccagccaggaucuucaguggcucgugcaacccacccucaucucuuccauggcccagucccaggggcagccacuggcc
    ucccagccuccagcuguugacccuuaugacaugccaggaaccagcuacucaaccccaggccugagugccuacagcacuggcg
    gggcaagcggaaguggugggccuucaaccagcacaaccaccaguggaccugugucugcccguccagccagagccaggccua
    gaagaccccgagaagagacacuuaccccagaagaagaagaaaagcgaaggguucgcagagagcggaacaagcuggcugcagc
    uaagugcaggaaccgucggagggagcugacagaucgacuucaggcggaaacugaucagcuugaagaggaaaaggcagagcu
    ggagucggagaucgccgagcugcaaaaagagaaggaacgccuggaguuuguccugguggcccacaaaccgggcugcaagau
    ccccuacgaagaggggccggggccaggcccgcuggccgaggugagagauuugccagggucaacauccgcuaaggaagacgg
    cuucggcuggcugcugccgcccccuccaccacccccccugcccuuccagagcagccgagacgcaccccccaaccugacggcu
    ucucucuuuacacacagugaaguucaaguccucggcgaccccuuccccguuguuagcccuucguacacuuccucguuuguc
    cucaccugcccggaggucuccgcguucgccggcgcccaacgcaccagcggcagcgagcagccguccgacccgcugaacucgc
    ccucccuucuugcucuguaaacucuuuagacaaacaaaacaaacaaacccgcaaggaacaaggaggaggaagaugaggagga
    gaggggaggaagcaguccggggguguguguguggacccuuugacucuucugucugaccaccugccgccucugccaucgga
    caugacggaaggaccuccuuuguguuuugugcuccgucucugguuuucugugccccggcgagaccggagagcuggugacu
    uuggggacaggggguggggcggggauggacaccccuccugcauaucuuuguccuguuacuucaacccaacuucuggggau
    agauggcuggcuggguggguaggguggggugcaacgcccaccuuuggcgucuugcgugaggcuggaggggaaagggugc
    ugaguguggggugcaggguggguugaggucgagcuggcaugcaccuccagagagacccaacgaggaaaugacagcaccgu
    ccuguccuucuuuucccccacccacccauccacccucaagggugcagggugaccaagauagcucuguuuugcucccucggg
    ccuuagcugauuaacuuaacauuuccaagagguuacaaccuccuccuggacgaauugagcccccgacugagggaagucgau
    gcccccuuugggagucugcuaaccccacuucccgcugauuccaaaaugugaaccccuaucugacugcucagucuuucccuc
    cugggaaaacuggcucagguuggauuuuuuuccucgucugcuacagagcccccucccaacucaggcccgcucccaccccug
    ugcaguauuaugcuaugucccucucacccucacccccaccccaggcgcccuuggccguccucguugggccuuacugguuuu
    gggcagcagggggcgcugcgacgcccaucuugcuggagcgcuuuauacugugaaugaguggucggauugcugggugcgcc
    ggaugggauugacccccagcccuccaaaacuuucccugggccuccccuucuuccacuugcuuccucccuccccuugacagg
    gaguuagacucgaaaggaugaccacgacgcaucccgguggccuucuugcucaggccccagacuuuuucucuuuaaguccuu
    cgccuuccccagccuaggacgccaacuucuccccacccugggagccccgcauccucucacagaggucgaggcaauuuucaga
    gaaguuuucagggcugaggcuuuggcuccccuauccucgauauuugaauccccaaauauuuuuggacuagcauacuuaaga
    gggggcugaguucccacuaucccacuccauccaauuccuucagucccaaagacgaguucugucccuucccuccagcuuucac
    cucgugagaaucccacgagucagauuucuauuuuuuaauauuggggagaugggcccuaccgcccgucccccgugcugcaug
    gaacauuccauacccuguccugggcccuagguuccaaaccuaaucccaaaccccacccccagcuauuuaucccuuuccuggu
    ucccaaaaagcacuuauaucuauuauguauaaauaaauauauuauauaugagugugcgugugugugcgugugcgugcgug
    cgugcgugcgugcgagcuuccuuguuuucaagugugcuguggaguucaaaaucgcuucuggggauuugagucagacuuu
    cuggcugucccuuuuugucaccuuuuuguuguugucucggcuccucuggcuguuggagacagucccggccucucccuuua
    uccuuucucaagucugucucgcucagaccacuuccaacaugucuccacucucaaugacucugaucuccggunugucuguua
    auucuggauuugucggggacaugcaauuuuacuucuguaaguaagugugacugggugguagauuuuuuacaaucuauauc
    guugagaauuc
    151 AJ006289 Sequence below.
    caccugauucccggaggcccgagcccuuagucugggcgggguggcgcgggccggaaggacgccaucccggccugggccaug
    gaggcucccgcaccgucccucacggaggaggauuugacugaagugaagaaggacgcuuuagagaauuuacguguuuaccug
    ugugagaaaaucauagcugagagacauuuugaucaucuacgugcaaaaaaaauacuaaguagagaagacacugaagaaauu
    ucuugccgaacuucaaguagaaaacgggcugggaaguuguuagacuacuuacaggagaaccccaggggccuggacacccug
    guggaauccauccgcagggagaaaacacagagcuuccugauucagaagauaacggaugaggugcuaaagcuucggaauaua
    aaacuggagcaccucaaaggccugaagugcagcagcugugagcccuuugcagccggagccaccaacaaccucucuaggugca
    auuccgaugagagcaaucucucugagaaacagagagcauccacugucauguaccacccggagggagaguccagcacggcucc
    cuucuucucuauggcgucgucccugaacuugccaguccuggaaguuggcaggacugaaaacagcagcuucucuucagccac
    ucuuccucgaccuggggacccuggggcucccccuuugcccccagaccuucgguuggaagaggggggaaguuguggaaacu
    caagugagauguuucuccccuuacggucacgggcucuuucacgccaaugauacaucaccgccuaguuguuuuacuagugau
    gcaaaaugcugugaaggaggccaucuuucuauacaaaccacggugacaggucacucacauucgaugcgugccuuuaaaauc
    aguguacacauucucuguaaauaggauuuguuaggguaaagaagcgcucuggggcggcgugguguaaucaugguggucgu
    gacuuuuccauaauguccuuucuuuuuuauuauuuuuagguguuugcguauuuugaacuuuucauaagauuaauuuuau
    cggaauauuucucaauuugagaaaacaacuuguggauugggaauaauguuuuuagcacauuuaugcuacaaauuuucagu
    cugauuguuuuucccacugaucuggcaguauauuuuagcaguaagcuguugugugucaggaaagcuggacacgggaaagc
    ugccgacacacucagcagugucccacuccuuaguucugagaagccgucggguucugaggagacaccugguggcacugagcc
    uggugaccucagugggccaaaauuuguuuuauacucacccugccagcgugagugucuuacuuucacaggccuuguguccu
    cagucuuaucuuaaaggauguuaucuuggcagggcaucacuuguaauuaauggaugauacuuguaauugacuaaaguccu
    cgcucugagccguuuguucuggcuccgagagcgcugacaugugaagcauggugagcagcgagggaacugacaggaugugg
    ccguggccaguguggcuuuaguguuugcaucaggcagccaccagcuccauccguguucuuacugcuuuacaaaguuugac
    uaacuuuacacauuuuaaaaaugcugauugucuucguuuaaauuauaauuuuaccuauuucuugacaucuaacuccuauuu
    auuucuauuauuuaaaaauuaagaaaugaaaauuugcuauuaacaauaaaguuuuuuuaaugu
    152 X12944 Sequence below.
    ggggggggggggucagcgccgacguccccugccgccaccaugcccaaaagaaaggcugaaggggaugcuaaaggagacaaa
    accaaggugaaggacgagccacagagaagaucugcaagguugucugcuaaaccugcuccuccaaagccagagcccaaaccua
    aaaaggccccugcgaagaagggagagaagguacccaaggggaagaaggggaaagcugacgccgggaaggaugcgaauaauc
    cugcagaaaauggagaugccaaaacagaccaggcacagaaagcugaaggugcuggagaugccaagugaugugugugcauuu
    uugauaacuguguacuucuggugacuguacaguuugaaauacuauuuuuuaucaaguuuuauaaaaaugcagaauuucgu
    uuuacuuuuuuuuuuuuuuuaagcuauauuguuagcacacagaacacuucauuacugggugggggaaggaucauguguca
    guaacaaaaucucucccaagcuggauugaggacagaaaaccucuuucccugauaauuuuggaaggcuccuguuggcuccca
    ggagagagauccuggucuugaccuagguggccaccaaggcacaacaaugccuuguggucugggaaaacuauaaauucacuu
    uuauauccucuucccccuguacuaucaacauagacuuaauucccuuaaaaaccagagaccuguuggaaccuggcccccaaaa
    uugguuucccaguccauugagugauggggacuuugcagugacuucauugaguguucucaaaagagcacugguuccuuuua
    uaaaagauuguggaucuucagauugauaauucugccuaaaagucagggucggcuugugaaaaguuguuaaaacaacauccu
    uaaugugaaaugucaacccucacucuaagcuacuucccccuuuucaaagcauugaaugaagacuucauuggguuuuauagu
    ggcuuucugauuuugguagucauaucagaagggaauuuggaaguucuuguauauuguugcauugucugcccauguccug
    ccugaauaccaugauuguuuaugaaagaaucuuaauaaagcugguuacaguuaggcuggaaaa
    153 AW061302 uuuuuuuuuuuuuuuuuggaaguccauaaguaguuuauugucuucaagacuacagugugg
    auuccucucccagagaagggucuuucagaggcaggggacugucacccaggugcaggccgu
    cuacuugucauuuucauacauggcuggauucuuccuuuucgacugcucaaacuccugguu
    gccccauguguagaucagguagaccacuacaaacggcggcgccacgcgcaggaugcgcuc
    gcgagugcggcgcaacacguuggggaugccuuugcugaaauagcuugggaaggcgcgcug
    cucaaagggcgacaagcugua
    154 U67328 Sequence below.
    caugaagccagagauguggaagaugugucuagacugcaucaaugaacugauggauacguuggaugcacauuccaacaucuc
    ugucggagagaacauuuuggcagagagugagaacuuacacaacuuugaucaguucacuccguguacgacgcugcauccuaa
    cuuugguggagcgaauggaugaagaauuuaccaaaauaaugcaaaauacugauccucacucccaagaguauguggagcacc
    ugaaggaugaggcacaagugugugcaucauugagcgagugcagcgcuaccuggaggagaaagguaccacugaggagaucu
    gccagaucuacuuaaggcgcauccugcacacguacuacaaguuugacuacaaggcccaucagcggcacguuacuccuccuga
    aggauccucaaagucugagcaagaccaggcagaaaaugagggugaggacucagcugugcuaauggaaagacugugcaagua
    caucuaugccaaggaccguacagaccggauccguaccugugccauccucugccauaucuaccaucaugcgcuccacucccgc
    ugguaucaggcccgugaccucaugcucaugagccaccuacaggacaacauucagcacgcagacccgccggugcagauccugu
    auaaccguacuauggugcaacugggcaucugugcuuuccgccaaggccugacaaaggaugcacacaauggcacuucuggau
    auucagucaagugguggugccaaggagcuucuaggucaggguuugcugcugcgcgcuugcaggagcgaaaucaggaacag
    gaaaagguagagcgacgccggcaggugcccuuucaccugcacaucaaccuggagcugcuggagugugucuaucugguguca
    gcuaugcuccuggagauccccuacauggcugcccaugagagcgaugcccgccgacgcaunaucagcaagcaguuccaccacc
    aacugcgggugggcgagcggcacgcccugcuagguccucccgagucaaugagggagcauguggucgcugccuccaaggcca
    ugaagaugggcgacuggaagaccugccacaguuucaucauuaaugaaaagaugaaugggaaagugugggaccuuuucccug
    aggcugacaaaguucgcaccaugcuaguucggaagauccaggaagagucucugaggaccuaccuuuuuaccuacagcagug
    ucuaugacucaaucaguauggagacacuaucagauauguuugagcuggaucuacccacuguucacuccaucaucagcaaga
    ugaucauuaacgaagaauugauggcuucccuggaccagccgacacagacuguggugaugcaccguacugagcccucugccc
    agcaagaaacuuggcucugcaagcuggcugagaaaacuuggcacccuaguggagaauaauggacggguguuugaccaaaaa
    cagggaaccuaugguggcuauuuccgagaccccaaggguggcuaccggaaaaauggaggcuaaaugccccgugguggcuac
    ccccagcaacagucucagacaaccuccugaguuccccacuucagucacccuguggacagaccaucuaaccuuuuucuccuaa
    cucaccccaaucauuaaagaucuuuugaggaauuaaaaaaaaagaaagaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    aaaaaaaaaaaaa
    155 AI604314 uuauuaauuaaaaaacaauuuauugaaaaagaguagugcuuuguacaaauucccauugca
    gcccccagauaucaacugaucucuuuccagcuuugguaguaggguauaaaaauaucaaaa
    cuagguaaguucugauguaagauuucuaugggauuauuuuagaauauauagauuugugua
    guuuggcaaguaucauuucuaugcauuuacauuacauauuaagcacagauucuguggcaa
    aacaucuuugcaugauuacuuuacacacacaaauauaguaaaacuuacauaguacaaauu
    cacauaagacuccauucugucuauaacuucauccaugugguuuuaccaugaauuauaauu
    cuuaaccucuccuauaacugucagcuuccauuuaauuuugaaaguaucacuucacaaaga
    gcacuucauuugcuuuuagaguauacauagacu
    156 AI845121 cggccgccaagaaguauaacaugcgaguggaagacuacgagccauaccccgaugauggca
    ugggguauggcgacuacccgaugcuccccaaccgaucacagcaugagagggauccguggu
    aucagugggaccacucagaacucaggaugaacuggggugaaccgauacacugggaccuag
    acauguacaucaggaaucguguggacacgucaccuaccccuguguccugngaugucaugu
    guaaacaucucuucggcuuuguggcuuucaugguuuucauguucuggguagggcacgugu
    ucccuuccuaccagccuguggguccgaagcaguacccuuacaaaaaucuguaccuggagc
    g
    157 AW047756 uuuuuuuuuuuuuuuuugaugcaaaugucuuuauuuuccacuuaaacaaguuucccuuuu
    gcacuggccuguggcacaaaacagauggcuggguggugacauuaacugucaaguuaguga
    gaugcagagauggugagacacugcauuugagugcauaauacuuuuauuccagaggaacgc
    caugcagcccaguuacaccuuuaggucagaaaggcugaugcgugaccagccucuauugcc
    ucccuugguaagaaggacccacaagugcagaguccaacagaugcuggcucugagcugaac
    ucagggcauuccaauuaccacuuucuucuucaccuacacagggccugcucagauguccuu
    uuuacaacuccauaagcccuuuggccaaagucccugcaguguuuggggaggaccuuccca
    cccuucaccagucagugucugaucugguggag
    158 AI838021 uuuuuuuuuuuuuuuuuaauaucuguaauaguuuauuucaaagauuugacauuuacaagu
    agaggcaccacaugcuaucugacaguaaaauacugcagggacugaaggccaaggagagag
    auccacagaagacaggccuguagugcaggcauugcaucgaccuugcccacagugcuuugu
    ucccaacucaggacaguacuuuagugcuugcuucauuuacuggaaaaguucacuggacau
    aguuuccacuucuucccccacagcuuccagcucagcaaacuuaagcuacuacuccucgau
    gcucucauagaggcucuugauuugugucuggaagaacuuggcaagcucuacucguuuggc
    uuucagugucggugucagaaguccguuuucaa
    159 AW122893 uuuuuuuuuuuuuuuuucugagguauuaaaauaucuagacugaauuuugccaaauguaag
    agggagaaaguuccugaagacucugacuacuugcuuauuuuugauugaccuucuaugcuu
    augucauuacugccucacaacguguuugauguccuuuaaugauacaaagugagccugugc
    cuucauuuucuugcccauuuugguaccccucgugccg
    160 M59821 Sequence below.
    gcgcccgaacgucuagcagaguaccugcugcuguaagcuugucgucugggcugcaccgcccgucuuaacccauucucgacu
    uaacuacucucgucgaacaagcauggaaguacagaaagaagcgcagcgcaucaugacucugucgguauggaagauguacca
    cucucgcaugcagcgagguggcuugcgacuccaccggagucugcagcuaucccucguuaugcgcagcgcucgagagcucua
    ccucucagccaagguagaagcccaccagcccgaguucccgccaucccgcagggcucuugacccucgccugcacccgccgcgg
    gaagccgaaguugcaguggaaguagcgucccccgaagccgugcagccuccggagcccauggauacgcaagaggaagugcug
    cgaguccaggagaccccugcgcucugugacccgccccccgcuagagucagccgcaagcgccggagcagcagcgauuugagc
    gacaguagugaugccggacugguaccaagcaagaaggcccgucuagaagagguggagggggaggcgacgucggagguucc
    cgaucgccugcagcuuccuccggcacaaagcgaaggugccuucccuaaccucgcccgcguccuccaaaggcgcuucuccagu
    cuccugaacuguggacccgccgugcccccgccgacgccccccacgugcgaggccaagccagccugccgcccggccgacaaua
    ugcucaacgugcuggugcgagcugugguggccuucugagagcucugguggcuucuuucgagcggcgccaccggagcggag
    aacgcacacccgaggcgaaggccggcgggggccgugaagaagagccgcggcccgagcugccgagaggccagggcaaggacu
    gaggagcgaggggcgcgggcgccuucucccagacgugcguccauaggugcuauuaaaggacugucccuuccuuggcuugg
    agaagggacaccuagaucuugaaucucagggucgaacucucuaggggccaggcugcccuuucaaggccguuucacuaccau
    ucgcguuucggccccuacaagugggcacgcuugugcaagcggucagaguugcgucaugggacagacgcgggugcuuccug
    uugccuugcguggguguggggccugggaggaggccaggguguggacccgcccuagggacugggaagugacuugagucacc
    ucgcccccacaggcugcugugggugagccugaacugaaccaaucaaaucugcgcagaguugaaguggcuggagaccccggg
    acuggucaaccuagaugaucgccuggcguggaccaccgcgggacgggugggccgcuggucguaguugcugccguagacac
    agcuucuucgggcaggaaagaaaauuuuuuuuuuaccagcguguuuaagaaagucuguuuacuuuucccacgguggguug
    uuuaauuagcaacuaccuggaguuuuacaaugucagcuaggaaaauaaagaccaucggugu
    161 M13805 See above (same Accession Number).
    162 AI845886 uuuuuuuuuuuuuuuuugguuccacuuaaguugcauguuuuauuucucccaaucccagca
    auagcacagaagcccaucauguccaucccagacugguuucuaguaggcugagaugacagg
    gagccucaguaacgcuaauggcacagagggcucccaaaugccaggcacaacugugccucc
    acacuggugacugcccagagugcccuggccccaguguguuggcacucagucugacuuuac
    aacgcaaccugcaccuuugaaagggacagucugggaguggggagugugagggagugaagc
    ucaaacugccuccugucagcucacccuuucaacauuaaacagagaccaagagagaaacag
    uuccaauauuucacauauauuucuucuugugcagucuaagccgagaaugccauguaaaug
    ggucacugcgaaaugcagcaauuuagu
    163 X53157 gucucgggcgagauggcuucaagguuacuucgcggagugggcgcuuuggcggcgcaggcc
    cugaggcgcacggcccguggcgcggccgugacccgcuccauggcuucuggaggugguguc
    cccacugaugaggagcaggcuacugggcuggagagggagaucaugauagcagcacagaag
    ggacuggacccauacaauaugcuaccuccaaaggcagcuucaggcaccaaggaagacccu
    aaucuagucccguccaucagcaacaagagaauagugggcugcaucugugaagaggacaac
    uguacugucaucugguuuuggcugcacaaaggcgagagucagcgaugccccaacugugga
    acccauuacaagcuggugccccaccaaauggcccacugagccccuguguuaucuuuucag
    aauguaaagaaaaacuucucucuaauaaagacuagccauugcaccugcuccuccc
    164 U19118 See above (same Accession Number).
    165 AF062071 Sequence below.
    gcgcaccgccygyguygcgcgscagcgucgucuaggugcaucgcgggcccccgcagrwagaaaaauauggcucaggagacu
    aaccagaccccagggcccaugcuguguaguacaggauguggcuuuuaugggaauccuaggacaaauggaauguguucugu
    uugcuacaaagaacaucuucagagacagcagaauaguggcagaaugagcccaauggggacagcuagugguuccaacagucc
    uaccucagauucugcaucuguacagagagcagaugcugguuuaaacaacugugaaggugcugcuggcagcacaucugaaaa
    aucaagaaaugugccuguggcugccuugccuguaacucaacaaaugacagaaaugagcauuucaagagaggacaaaauaacu
    accccgaaaacagaggugucagagccaguugucacucagcccaguccaucaguuucucagcccaguucuucucaaagugaag
    aaaaagcuccugaguugcccaaaccaaagaagaacagauguuuuauguguagaaagaaaguuggccuuacaggguuugacu
    gccgauguggaaauuuguuuuguggacuucaccguuacucugacaagcacaacuguccauaugauuacaaagcagaagcug
    cagcaaaaaucagaaaagaaaauccaguuguuguggcugaaaaaauccagagaauauaaaauuacuacaugugaagagacug
    aaacuuuguuuuuauuuuaauauaucguaggaaaacauuaaagagcagaugcauggccauuuuccuuugauguucuccag
    aguuuugcuuuauacuugucugucauauaauugaucuuuuaggauguuuggguguuuguuacaggcagaauuggauaga
    uacagcccuacaaauguauaugcccuccccucaguaaaauuggacaaaaauaugcacaacaaauugaaauacacauauacua
    ggaacaaaauuuaguuccacgugccaaacuaaaggaaugaaaucucugcauguuugcagcauaucugccuuuugggaaugu
    aaucaagguauaaucuuuggcuaguguuaugugccuguacuuaaaaaaaaaaaaaugguacaccagaaaaggacuggcagu
    cuacuaccauagucaaacuucaccuuaauuucgacaugacuuuuggaagcaggaagaaagcuacaaaacugguauuuggua
    ccaugugugagccugguuaaauuggucuucuaaaagcugucaauuaggacauucugcgaaagguaacaucacaacugguuc
    uaagucaaaccaucaagucaacagcagggugccugagauaaucuuggaagcuuauugugcuggccugcaccagaagauauc
    ugcauucucauuacuaaaauuguagcacagaacugcacuaggauuuguuuacaaggagaaauuaaacucuguuugguuuuc
    acauauagcagcucuguuaaauaacaugcaucugaauuuuaaguugcaaagguaucugaacaguuaauuuuucaugugcau
    cuuuuguugaauguuuugguucaagaaagaauguuuaaagcuuuuuaaagacuucaguucuuaauguaacuguacccuuc
    ugcauggaaaaucauaaccaacauggcugcaguagacuucuuuagugguauccagcaccacuugcagagggcugcuuuauc
    auauuguacuuggguguaggacucuaguguucuuggguguauugcaugggcugcauuaucuacagcauuguacaauaaca
    acuagaaaaggcgguauacuucacugaugcuugucugguaauaucacuucuguguuaaaauggaagguuuuuugugaugu
    augaaacuuguguuuuuuauauauaaaugaguauaguuagauuaguguugugguaaugccuguuuucaucuguaaauag
    uuaaguauguacacaacaaggcacuacuucugauuuuugcaguguucaguccuaguuuuucuuuauuaaaacauugaguu
    uugcuucaauuuuauguaccuuaguucuaaguuagauuugcagauguguacagauaguucauauuuauguauugcacaua
    aucaugcuauucagcauugaugcuauauuguauuauguaaauaauaaaagcaguguacagagggaaaa
    166 U10404 augacagaugccgcuguguccuucgccaaggacuucuuggccgguggaguggccgcagcc
    aucuccaagacagcgguagcacccaucgagagggucaagcugcugcugcaggugcagcau
    gccagcaagcaaaucacggcagauaagcaauacaagggcaucauagacugcgugguucgu
    auccccaaggaacagggaguccuguccuucuggcgugggaaccuggccaaugucaucaga
    uacuuccccacccaggcucucaacuuugccuucaaagauaaauacaagcagaucuuucug
    ggugguguggacaagaggacccaguucuggcgcuacuuugcagggaaccuggcaucaggu
    ggugccgcuggggcuacauccuugugcuuuguguacccucuugauuuugcccguacccgu
    cuagcagcugaugugggcaaagcuggagcugaaagggaauucaaaggccuuggugacugc
    cugguuaagaucuacaaaucugaugggauuaagggccuguaccaaggcuuuaauguguca
    guacagggcauuaucaucuaccgagcugccuacuuugguaucuaugacacugcaaaggga
    augcucccagaucccaagaauacucacaucuucaucagcuggaugauugcacagucuguc
    acugcugucgcuggccugacuuccuauccuuuugacacgguucgccgucguaugaugaug
    cagucuggacgcaaaggaacugauaucauguacacaggcacgcuugacugcuggcggaag
    aucgcgcgcgaugaagggagcaaggcuuuuuucaagggcgcaugguccaacguucucaga
    ggcauggguggcgccuuugugcuugucuuguaugaugagaucaagaaauacacauaa
    167 U07634 Sequence below.
    cguagaaguugucucugucggcgggcgggcgggcaggauuggggcaccgagaccggcgugcggacagcagggaucgcggg
    gagcgaggggugcggcauggagcuccgggcagucgguuucugccuggcgcugcugugggguugcgcgcuggcggccgcg
    gcggcacagggaaaggaaguuguuuuguuggacuucgcagcaaugaagggagagcucggcuggcucacgcaccccuaugg
    caaagggugggaccugaugcagaacaucauggacgacaugccuaucuacauguacucggugugcaacgugguauccggcga
    ccaggacaacuggcuccgcaccaacuggguguaccgggaggaggccgagcgcaucuuuauugagcucaaguucacggugcg
    agacuguaacagcuucccggguggcgcccaugccugcaaagagaccuucaaccucuacuaugcagagucagauguggacua
    uggcaccaacuuccagaagcgccaguucaccaagauugacaccaucgccccugacgagaucacggucagcagugacuucgag
    gcucgcaacgucaagcugaacguagaggagcgcaugguggggccccuuacccggaagggcuucuaccuggccuuccaggac
    aucggcgccugcgugcggcugcucuccguucgcgucuacuacaagaagugucccgagaugcugcagagcuuggccugcuu
    ccccgagaccauugcugucgcuguuuccgauacacaaccccuggccacgguggccgguaccugcguggaccaugccguggu
    gccuuaugggggcgagggggcucucaugcacugcacgguggauggcgaguggcuggugccauccgagugccugugccagg
    aaggcuacgagaaggucgaggaugccugccgagccuguucuccaggauucuucaagucugaggcaucugagagcccuuccc
    uggaguguccagagcauacccugccauccacagagggugccaccuccugccagugugaagaaggcuauuucagggcaccug
    aggacccacuguccaugucuugcacacguccacccucugccccuaacuaccucacggcaugcaugggugccaaaguagaacu
    gcguuggacagcucccaaggacacugguggccgccaggacauugucuacagugucacuugugaacagugcugcgcagaguc
    uggcgagugugggcccugugaggccacggugcgcuauucagaaccuccucacgcccugacccgcacgagugugacagucag
    ugaccuggagccccacaugaacuauaccuucgcugucgaagcacgcaauggcgucucaggccuggugacuagccgaagcuu
    ccggacugccagcgucaguauuaaccaaacagagccccccaaagugaggcuggaggaccgaagcaccaccucccugaguguc
    accaggagcaucccggugucacagcagagccguguguggaaguacgaagucaccuaccgcaagaagggggaugccaacagc
    uauaauggccgccgcacggaaggcuucuccgugacccuggaugaccuugcuccggauaccacguaccuggugcaggugcag
    gcauggacgcaggagggccaaggagccggcagcaaagugcacgaguuccagacgcuguccacggaaggaucucgcaacaug
    gcggugaucggcgguguggcuguagguguuguuuugcuucugguacuggcaggaguuggccucuucauccaucgaagga
    ggaggaaccugcgggcucgccaguccucugaggauguccguuuuuccaagucagaacaacuaaagccccugaagaccuaug
    uggauccucacacuuacgaagaccccaaccaggcuguacucaaguuuaccaccgagauccacccauccuguguggcaaggca
    gaaggucauuggagcaggagaguuuggagaggucuauaaagggacgcugaaggcauccucggggaagaaggagauaccgg
    uggccaucaagacacugaaagcgggcuacacugagaagcagcggguggacuuccugagcgaggccagcaucaugggccagu
    uuagccaccacaauaucauccgccuggaggcgguggucucuaaauacaaacccaugaugauuaucacagaguacauggagaa
    uggagcgcuagacaaguuccuuagggagaaggauggugaguucagcguacuucaguuggugggcaugcugagggguaucg
    cauccggcaugaaguaccuggccaacaugaacuacgugcacagagaccuggcugcccgcaacauccucgucaacagcaaccu
    ggugugcaagguguccgauuuuggccugucgcgugugcuggaggaugaccccgaggccaccuacaccacaaguggcggca
    agaucccuauucgauggacagccccagaggccauuuccuaccgcaaguucaccucagccagcgauguguggagcuacggca
    uugucaugugggaagugaugacuuauggcgaacggcccuuacuggaacugucaaaccacgaggucaugaaagccaucaacg
    acggcuuccggcuccccacgcccauggacugcccuucagccauuuaccagcucaugaugcagugcuggcagcaagagcgcu
    cccgccggcccaaguuugccgacaucguuagcauccuggacaagcucauccgacgccccgacucccucaagacgcuggcuga
    cuucgauccccgaguguccauccggcugcccagcaccagcggcucggagggaguccccuuccguacgguguccgaguggcu
    ggagagcaucaagaucgaacaguacacggaacacuucaugguggcuggcuacacggccaucgagaaggugguacagauguc
    caacgaagacaucaaaaggaucggagugcgucuuccuggccaccagaagcgcauugccuacagccugcugggacucaaggac
    caggucaacacaguggggauuccuaucugaguccauuggggcugucacacaauacuugaagagccacaguggucucccugc
    cgaucuggugcuggcccacuggaacuuuauuuauuucuguuuccucgucuaugccucccuaggacucugcaggggcuuuu
    ugaaugacaccugccugagccugggaaacuuggauugcuggucagggcucucuuuccccugaaaaggacccagcuaagaac
    uuagcaguuugccauggccuucccagcauccccugaggcuaaaguuccaccaagagucgauaucgacgagggacauuucca
    aacggaccuccccaucuucauuuggccuccugagaagccacucuggagcugaggcuaagcacuaagcccaggaccauaugac
    uagcacuguaccgcccgccccuaguuagaggguagguuuuggacuuggcuggguuguggucacaagcaaucucccagugc
    cuuuuacagaccccagucugcccucccgucgagggccagcuucuugcuuuccuagggcccucucaggaugcuuggcugugc
    ugagguuuuuauuaaauauauauuuuauacuugcggaaagaaugaguguguggcagggacuugccagggcuggagacaga
    ggauccccugcaacaagacauucccgggcugggggcuggcggaccugcaggagacuuuccgccaccaccccgucuccagccc
    cuuuggacaaaugucgcugucaguguuacagauuucuuuuauuggguuguuuuuuuguuguauuuuuuugaaccuuaac
    uuauuauuuuuuuuauauuuauuguuagaaaaugacuuauuucugcucuggaauaaaguugcagaugguuca
    168 X04663 Sequence below.
    ccaaaaaccuuaauuuucuuucuuguucgguaccuacauuggaaccaccaaaaacaauuauuucaguaaaccguagccauga
    gggaaaucgugcacauccaggccggacaguguggcaaccagaucggugcuaaguucugggaggucauaagcgaugaacaug
    gcaucgaccccaccgguaccuaccacggugacagcgaccugcagcuggaccgaaucucuguguacuauaaugaagccacagg
    uggcaaguaugucccucgagcuaucuugguggaucuagaaccugggacuauggacuccguucgcucagguccuuuuggcc
    agaucuucagaccagacaacuucguuuucggucagucuggggcaggcaacaacugggcuaaaggccacuacacagagggag
    cugaguugguugacucugucuuggauguggugcggaaggaggcggagagcugugauugccugcaaggcuuucagcugac
    ccacucacuggguggaggcacuggcucuggcaugggcacccugcucaucagcaagauccgggaagaauauccugaccguau
    caugaauaccuucaguguggugcccucgcccaaagucucugauaccguggucgagcccuacaaugccacccugucugucca
    ucaguugguugagaacacggaugagaccuacugcaucgacaacgaggcccucuacgacaucugcuuccguacccucaagcu
    caccacgccaaccuacggagaccugaaccaucucgucucggccaccaugagcggcgucaccaccugccuccguuucccgggc
    cagcuuaaugcugaccuucgaaagcuggcugucaacauggugccauucccacgucuccacuucuucaugccuggcuuugcc
    ccucucaccagccguggaagccagcaguaccgggcccucacugugccugaacuuacccagcaggucuucgaugccaagaaca
    ugauggccgccugcgacccgcgccacggccgguaccucacaguugccgccgucuuccguggacggauguccaugaaggagg
    uggaugagcagaugcucaacgugcagaacaagaauagcagcuacuucguggaauggauccccaacaaugucaagacagcug
    ucugugacaucccaccgcguggccucaagauggcagucaccuucauuggaaacagcacagccauccaggagcuguucaagc
    gcaucucugagcaguuuacggcuauguuccgccggaaggcuuuccuccacugguacacgggugagggcauggacgagaug
    gaguucaccgaggcugagagcaacaugaacgaccuggugucugaguaccagcaguaccaggaugccaccgcggaagaggaa
    gaggauuucggagaggaggcagaagaggaggccuaacggcagagagcccugcaucagcucaggcugcuuagaucccucagc
    cuuucuccaacugcccuuuguccuccaguuucuuucugcugccucugucuuguauuuguuuugcuucuguuuucucauu
    ggggguaaauggugccuggcacauggcaggcacucaauaaauauuuguuugugg
    169 X61232 Sequence below.
    ggcagacaaaagaggccggcagugcagcucgcgggacgcauggccgggcgcggaggacgggugcugcuggcgcugugugc
    cgcgcugguggccggcggguggcugcugacgcgugaagcccaggagcccggggcgccagcggcuggcaugaggcgccgcc
    ggcggcuccagcaagaggacggcaucuccuucgaguaccaccgcuauccagagcugcgcgaggcgcuggugucgguauggc
    ugcagugcaccgccaucagcagaaucuacacagugggcgccagcuucgagggccgggagcuccuggucaucgagcugucug
    acaaccccgggguccaugagccgggugaaccugaauuuaaauacaucgggaacaugcauggcaaugaggcgguuggacggg
    aauugcucauuuucuuggcccaguaccuguguaacgaguaccagaaaggcaaugagacaauugucaaccugauccacagca
    cccgaauucauaucaugcccuccuugaaccccgacggcuuugagaaagccgcauggcagcccgggcagcugaaggacuggu
    uugugggccgcagcaacgcccagggaauagaucugaaccguaacuucccagaccuggacaggaucguauauguuaaugaga
    aagaaggcggucccaacaaccaccugcugaagaaucugaagaaaauuguggaccaaaauucaaagcuugcccccgagaccaa
    ggcugucauucacuggaucauggacauuccauuugugcuuucugccaaucugcacggaggagaccuuguggcuaauuacc
    cauaugaugagacacggagcgguacugcucacgaauacaguuccugcccugaugacgcaauuuuccaaagcuuggcucgcg
    cguacucuucuuucaacccagucaugucugaccccaaucgaccucccugcugcaagaaugacgaugacagcagcuuugaug
    auggaacgaccaaugguggugcaugguacagcguccccgguggaaugcaagacuucaauuaccugagcagcagcaacugcu
    uugagaucacuguggagcuuacgugugagaaguucccaccugaagagacucucaaaagcuacugggaagauaacaaaaacu
    cccucaucaacuaccuggagcagauacaccgagguguuaaaggguuuguccgugaccuucaggguaacccgaaugccaacg
    caaccaucucuguggaugggauagaccaugaugucaccucggcuaaggauggggauuacuggcgauugcuugcuccugga
    aacuauaaacuuacagccuccgauccuggcuaccuggcaaucacaaagaaaguggcaguuccuuuuagcccugcuguuggg
    guggacuuugagcuugagucuuucucugaaaggaaggaggaggagaaggaagaauugauggagugguggaaaaugauguc
    agaaacuuugaauuuuuaagaaaggcuucuaacuaauugcuuucaucuaucuauagacuguaguaagaugcaauguggcuc
    uuuucuuuuagguugugugcaguugauauuuaacauugauuuauuuuugaucauuaaguaauaguuacuaaucacguaaa
    uacacccggacagaaauauaaugcuggacaucuucauucuacaucaacauucgcuuaaaucauucgaagccucuuuuaacgu
    aaugggugacaaugucacuugacagaugcaugagagucacgauauagcugacugugacccugcacugcaaucacauaguuc
    cauauaaguuguccuuagucucuugugcugauucacuguauaagcaugauccugguaaugcacuuuggaugggaagaaaa
    uguacgugcuuuucagaggggcucugaacagaaugaaaaccuaguucuugcguguacuuugaagaauggaauuguauuag
    ucagcuguuaaugccacuucagaaguuugggguuuugucuugauuguagauugg
    170 X14309 Sequence below.
    gccacggacgccucucugaacggggauccaggcaggauuagagcugccucacugacuacaggccgugucgugucaccguuu
    cugcaggcaccaugagccaggacaccgaaguggacaugaaagauguggagcugaacgagcuagaaccggagaagcagcccau
    gaaugcagcggacggggcggcggccggggagaagaacggucuggugaagaucaagguggcggaggacgagacggaggccg
    gggucaaguucaccggcuuauccaaggaggagcuacugaagguagcgggcagcccuggcugggugcgcacccgcugggcg
    cugcugcugcucuucuggcucgguuggcugggcaugcuggcgggcgccgugguuaucaucguucgggcgccgcgcugcc
    gugagcugccuguacagaggugguggcacaagggcgcccucuaccgcaucggcgaccuucaggccuuuguaggccgggau
    gcgggaggcauagcuggucugaagagccaucuggaguacuugagcacccugaaggugaagggccugguguuaggcccaau
    ucacaagaaccagaaggaugaaaucaaugaaaccgaccugaaacagauuaaucccacuuugggcucccaggaagauuuuaaa
    gaccuucuacaaagugccaagaaaaagagcauucacaucauuuuggaccucacucccaacuaccagggccagaaugcguggu
    uccucccugcucaggcugacauuguagccaccaaaaugaaggaagcucugaguucuuggcugcaggacgguguggauggu
    uuccaauuccgggaugugggaaagcugaugaaugcacccuuguacuuggcugaguggcagaauaucaccaagaacuuaagu
    gaggacaggcuuuugauugcagggacugaguccucugaccugcagcaaauugucaacauacuugaauccaccagcgaccug
    cuguugaccagcuccuaccugucaaauuccacuuucacuggggagcguacugaaucccuagucacuagguuuuugaaugcc
    acuggcagccaauggugcagcuggagugugucgcaagcaggacuccucgcagacuuuauaccggaccaucuucuccgacuc
    uaccagcugcugcucuucacucugccagggacuccuguuuuuagcuacggggaugagcuuggccuucagggugcccuucc
    uggacagccugcgaaggccccacucaugccguggaaugaguccagcaucuuucacaucccaagaccuguaagccucaacaug
    acagugaagggccagaaugaagacccuggcucccuccuuacccaguuccggcggcugagugaccuucgggguaaggagcgc
    ucucuguugcacggugacuuccaugcacugucuuccucaccugaccucuucuccuacauacgacacugggaccagaaugag
    cguuaccugguggugcucaacuuccgagauucgggccggucagccaggcuaggggccuccaaccucccugcuggcauaagc
    cugccagccagcgcuaaacuuuugcuuaguaccgacagugcccggcaaagccgugaggaggacaccucccugaagcuggaa
    aaccugagccugaauccuuaugagggcuugcuguuacaguuccccuuuguggccugauccuuccuaugcagaaccuaccac
    ccuccuuuguucuccccaggccuuuuggauucuagucuuccucuccuuguuuuuaaacuuuugcagauuacauacgaauu
    cuuauacuggguguuuuugucuucaaauaaaaacaucaccccugccucaug
    171 U42386 Sequence below.
    gncuuaagccncguuuauuuugaugnccuguuggcucagunaugnccaagaugccnauuguuuuugcccnaaauaaauuu
    acugaacuugggcuaaaaccaaaccuuggcacacaggugugauacaacuuaacaggaaucaucgauucauccauaaauaaua
    uaaggaaaaacucaagugguagccugucuuaaggcuuuugauacuugcagauuggggaaaaacaaacaacaaacgucuuga
    agcauauuaauggaauuaguuucuaauguggcaaacuguauuaaguuaaaaguucugauuugcucacucuauccuggaua
    gguauuuagaaccugauaauagucuuuaaacaagccauuccagucaugaugaggugauguauggauacaugcauacauuca
    aagcacuguucucaaaguuaaugcaaguaaauacagcaauuccucuuucaauguuuaggcagaucguuaacuaugagcuag
    ccaaaugugggcauguuauuacagggaaaguuuaaaggucugauaacuugaaauagguuuaggagaauucaucuacuuag
    acuuuuuaaaugccugccauaaaaaauugaaaugguagaauggcugaccacagcaaugaccagcccucaccuagggcucug
    gaugauuuuuggucuaauaacgcaugcuaguguugauguuuuuuggucaagaugggaaugaacaggaagaauuaugcagc
    aggcuuuauuuuaaaugccgauucacauuacucuguucaagcugcguugagauguuaaacuggcuuacuauagacuuugu
    aaaaaaaaaaaaaaccaaacaaauggcuccagaagaguaacaaacugaaaucugagaucacacagguuggaaauauguacaua
    acugaacaaggugucaauucugcucuacagugcaguuuagucaguuuuaguugcauagguuuccauuguuuuuauagucu
    guuuaugcuaaaucuggccaaagaugagcauuguccaccacuaaaaugccuaugccacugggaauucuggguuaauuuugu
    gaccagaaugcagugaucaaaauguucaaucuuuuuacaguggcauaggaagauggcaaaaauuuccuaaagugcaauaga
    uuuucaaguguauugugccuuguucuaaaacuuuuauuaaguaggugcacuugacaguauugaggucauuuguuauggu
    gcuauuucaauuagucuagguuuaggcccuuguacauuuggcccauaacuuuuuacaaaguacuucuuuuauugcacauu
    cagagaauuuuauauauaugucuugugugcguguccuuaaacuuccaaucuuauuuugucucuuggagauuguugaacgc
    agcuugucuaggaaagggaugggacuagauucuaaaauuuauuugggaccaugggaaugauaguugggaagaaacuuugc
    acacgacagauuucuagauacuuuuugcugcuaguuuuauguaauauuuauugaacauuuugacaaauauuuauuuuugu
    aagccuaaaagugauucuuugaaaguuuaaagaaacuugaccaaaagacaguacaaaaacacuggcacuugaauguugaaug
    ucaccguaugcgugaaauuauauauuucgggguagugugagcuuuuaauguuaagucauaauaaacucuuaagucaaauu
    aagcagacccggcauuggcguguagccauaacuuucugauguuaguaaaaacaaaauuggcgacuugaaacuaaaucaugc
    caagguuugauacacuugucuugagauauuaacgaaacacuuccaaacacugauacaaaguguccagauucucagauguuu
    guugugugaguuuuguuuaguuguauuuuuuuuucagugaaugucuggcacauugcaauccucaaacaugugguuaucu
    uuguuguauuggcauauucagugacuuguacauucagcaauagcauuugagcaaguuuuaucagcaagcaauauuuucag
    uuauguuuccaaauuaagaauggguuuaaacuugcugaauguaaagauugacccucaagucacuguagcuuuaguaguug
    cuuauuguauuaguuuagaugcuagcacugcaugugcugugcauauucugguuuuauuaaaauaaaaaguugaacugcac
    agucuccuuuguuguugucaauugugguuuacuuuuagaggugaaaauaaaguugugcucuugccucgugccaauaugua
    cauaacugnacaaggugucaauncugcucuacagngnaguuuagncaguuuuagungnauagguucccaunguuuuuaun
    gncuguuuaugcuaaaucuggccaaagaugagcauugcccaccacuaaaaugccuaugccacugggaauccuggguuanuu
    uggngaccagaaugaagugancaaaauguccanucuuuuuacaguggnauaggaagauggnaaaaauunccuaaagugnaa
    uagauuuccaaguguuungugccugguncuaaaacuuuunuuaaguagggugcacunganaguauugaggncauugguu
    auggugcuauuuccanuuagucuagguuuaggcccu
    172 U51126 Sequence below.
    cucggucuccaagaugguggcuaacaaaacgugaggccuagagguugauccuaggucacuggaagcauguccuugaagagg
    acuaugggcaucuggguucuuccucuucuacuuggccacgagguaaccggcuucuuguaccacgugugcucaccucuacaa
    ucugugcggauucagacuccaagcaacuaggcuacccagugacaggcuaaaaacuacagcucuaacgucuuggaaggcgau
    uccauggaccaggauguggaaagcccaguggccauucaccagccaaaguugccuaagcaggccagggacgaccugccgagac
    acaucagccgagacaggaccaaaaggaaaauccagagguacgugaggaaggaugggaagugcaacguucaccacggcaaugu
    gcgggagacguaccgauaccugacggacaucuucaccacccugguggaccugaaguggagauucaaccuguugaucuuugu
    cauggucuacacagugacguggcuuuucuuugggaugaucugguggcugauugcguacauccggggagauauggaccaca
    uagaggaccccucguggacuccuugugucaccaaccucaacggguuugucucugcuuuuuuauucuccauagagacagaaa
    ccaccaucgguuauggcuaccgggucaucacggacaagugcccugaggggauuauucuccucuuaauccaguccguguugg
    gguccauugucaacgccuucaugguaggauguauguuugugaaaauaucccaacccaagaagagggcagagacccuggucu
    uuuccacccacgcggugaucuccaugcgggaugggaaacugugcuugauguuccgggugggggacuugaggaauucucac
    auuguggaggcauccaucagagccaaguugaucaaguccaaacagacuucagagggggaguuuauuccccucaaccagacu
    gauaucaacgugggguacuacacaggggacgaccggcucuuucuggugucaccauugauuauuagccaugaaauuaaccaa
    cagagucccuucugggagaucuccaaagcgcagcugccuaaagaggaacuggagauuguggucauccuggagggaauggu
    ggaagccacagggcaguucugaaaucgaaaucaagcagaggucuauaagaacacccuggagacccccaugcugcuggaucu
    uggguccaugaacugcuuuuauuugcugcaaucaaaaaugcuagucgcugaucugauaggagaggaaacgagacucagagc
    cugaaggauaacacgcugagggcugauuucauacacucuucccggcuggaucaucccagcccccacagcguccaggcuuag
    uuucuuccuuuguuuuaacaaucuauacuuccuccagccugggcgagcuaguauacccagaguuugguuuuguuucuuuu
    cagagcuguaagcccagugcccagugaccucaucugggaggagaguuaagcaauaagaccugaaaugcuaaacucuggggu
    agaaaaccucugcagagacagcgucucugggaagucucuacagagacagaguagggaagucucacgaaggucagagucuua
    cuuccauaccuggagaaauccgcccguccguucagugccgguuucaacuccucugccaaagacuucuuuccaagacacugg
    uaucagcuaucccagcaguaacuuuggcaguauauaaaucaauggcacugccccauaaaaccccguugaguaaaaccuaugg
    ucuucaacagcuggggagccuguagcccagcuccugugugaggcuaaggcuguggagaccaugccugcucaccuccucguu
    gaaaagcaaaacacuguaagaaaccuaacaugacuuuuuccaacauuucucaggcuggggagaagacuugguccacaaagag
    cuugaggucuugaucuggaucccuagcauccauggaagaaggugggcaugaucacccacacuccucaucccauagcucuga
    augagguaggcagauuccuggggcucaccagcucauccuaacagccaggucccaaugagggacugucuacaaaagaacaaga
    gguggauccugagaagcgacacccaagcuugaccucuagccccuguacacaccuguuaagcaccugggcaucgggacacaca
    cucgcaauuugcaaacaaggcaaauucucacacuucagaaggcacugagagaaucccauaagcucaaaaaguuaggagccaa
    gauugaccauuaaugacuuggguugaaaagacuaaaccacuggauagaauguuucauuacuaaaacaccuuaccugaaaag
    uauuacugcucuucuuucugcaacuggaccaugcagagauccacaaagagaugcccagagauuauuagugauggucauaug
    auauacacaauguggacucuaagccaaggccccaucaacucagauccagaggcugacagugugcuuaucuuagagauaccac
    aguggcugccuaaucaccacguccuuaagucaggggaguuugauuauuuccuaugaacaccgaguggggacagcggauuac
    caaugaagcaauccaaccugacaauccuaaccacccagaagaggaucgcugggggaaagcaugaauuauuuacgugucaaca
    ugugcacacuccggccacgcagcucaacagccaggagugcuucuccacuuagcccugcccuggcauccauuuaugaucucg
    ucuguuguguuaauuacccagcuagcuuuuuucucaaaaauaauaucucccagccauagaccuacucaucuguguccucuu
    uaauuucaacccacaguuacaucauucacuggcuugcucaguuucuucaacucugaaaugggaaugaugaugaugaugccu
    cuucccccaagccaccauccucccccgugaccuuccuagguacagacucaaaccagggaagauuauuuccuucucauaggcc
    acagggugaaaugcaauaaagaacaaagccuuguagggaggcagagggaaagaccaguccucacaagaggcuccauuguuu
    ccagggacuuugaagcuuggacagaaugucagaugauccccuuugaaggugcuccaaagagucaaugugaaaaauauugac
    ugaugugugcccguccacaagccaaggugccucugcccuggucaccuaccaugaauuauaaacugaugauauuugaaauaa
    uaaggaacacuggagccggccagaaaggauucugcagucccauaaauagcaacauucaucacuacaaugccugccaacggug
    gccgugaauguagauuacccccggcucuucugaggccacugaggacagggcaaacuaccucugagaauggaggcucacugu
    ucugcaucccacuucuaaauguuccaugaauuuuuugagacaucucccauaucccuguuagaaagauucaaccuugugcua
    uuaaccaaaucauuuugaauuccauaaaccucuacucuaaaguauacacuuaauucuacaauacagacaacaaauaugacuu
    uuuccuaugaaagagugauaaagauacuguaucagucugcuuugacucaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    aa
    173 AF093853 Sequence below.
    uggaaugggugcuaggugaaggcuuuguugaaucaggaugcugagcugguguuuuuacagguccagauaugaugagcug
    gaguuuugguaggcccagguaccuccuccaaaauugaccacauaauuggucacaaaucaggccuccacagauacaaaaauau
    ugaaauuaucccaugcauccugucugaucaccacagacuaaggcugaucuucaauaacaacauaaaaauagaaagccagguu
    cacugcugcggcugcgccuccuuguucucagcgucaccacugccgccaugcccggaggguugcuucucggggacgaagccc
    ccaacuuugaggccaauaccaccaucggccgcauccgcuuccacgauuuccugggagauucauggggcauucucuuuuccc
    acccacgggacuuuaccccagugugcaccacagaacuuggcagagcugcaaagcuggcgccagaguucgccaagaggaaug
    uuaaguugauugcucuuucaauagacaguguugaggaucaucuugccuggagcaaggacaucaaugcuuacaauggugaa
    acacccacggaaaaguugccauuucccaucauugaugauaagggcagggaccuugccauccuuuugggcauguuggaucca
    gucgagaaggacgauaacaacaugccugugacggcccgugugguguucauuuuuggcccugacaagaaacugaagcugucu
    auccucuacccugccaccacgagcaggaacuuugaugagauucucagagugguugacucucuccagcugacaggcacaaag
    ccgguugccaccccaguugacuggaagaagggagagagcgugaugguaguccccacccucuccgaagaggaagccaaacaa
    uguuucccuaaaggagucuucaccaaagagcucccgucuggcaaaaaauaccuccguuauacaccccagccuuaagucuuug
    cggaaauuggggcugcaucugcacguccagcacuggggccugaggacgucagccggcagccguggguccuugcagcaggu
    ccguagaaagaucguggcaugaucacagccgguccuguagaucgcucgcuauacuacugggucauuaaauggaaauggcac
    caaaaccuucucgggauucuuuacucugugccuucgccagcauucugccccucugccugucacagugcccuacugacuggc
    ucucuuugaaacgaauuauguauugaagauuccuuaggucucugcagggucuuugaucagcaagcaagguagugucagug
    ugggcucugugcuagaaugaugaaacaccuuuuguagcuuuccgaacggaaucuucuguuacccauuuuggagagcacug
    acauggggagaagcuuucaauucuguauuuuuaguaaauaaaguggggacagccgggagaauucuuacagggaaucuauu
    guaaguuucuaucgaagugggcucagaaagccuuucgccucccaagagugcgcauguaccuccuagaguuuccacaucugc
    ucucuggugaugucugccugugaacgcaccuuauaaaagacgggcggugacaguguuuuaccacucaguguccuaguagu
    ggguggccauuucugaauucugcuuuuugagguucaacaaauaaaauccugaucagaaaaaaaaaaaaauagaaagccaaca
    uucauguggaaacugaacaacacuacucaaugauuccuuggucagagaugaaauaaagaaagaaauuaaagacuuuuuaga
    guuuaaugaaaaugaagccacaacauacccaaacuuaugggacacaaugaaggcauuucuaagaggaaaacucauagcccug
    agugcauccaaaggaaaaaaaaaaaaaccuagagagaguguacacuagcagccugacugcacacuuagaagcucugcaaaaa
    aaggaaucaaauucacccaagaggaauagacagcaggaaauaaucaaacuuagggcugaaaucaaccaaauggaaacaaaaag
    aacuauucaaagagugggccaaaccaggagcuaguucuuugagaaaaucaacaagauagauaaacccuuagccagacucacu
    agagggcacagggacagcauccuaauuaacaaaaucagaacugaaaagggagacauaacaacagauccugaagaaauccaaaa
    caccaccagauccucuacaaaaggcuauacucaacaaaacuggaaaaccuggaugaaaggaaaagcuucuagacaga
    174 Z19521 Sequence below.
    augagcaccgcggaucugaugcgucgcugggucaucgcccugcuccuugcugcugccggaguugcaguagaagacucagg
    cagcaggaacgaguuccaguguagagacggaaaaugcaucgcuagcaagugggugugcgauggcagccccgagugcccgga
    uggcuccgaugaguccccaaagacaugcaugucugucaccugucaguccaaucaauucagcuguggaggccgugucagccg
    augcauuccugacuccuggagaugugauggacagguagacugugaaaaugacucagacgaacaaggcuguccccccaagac
    gugcucccaggaugacuuccgaugccaggauggcaagugcaucuccccgcaguuugugugugauggagaccgagauugcc
    uagauggcucugaugaggcccacugcccagccaccacuuguggccccgcccacuuccgcugcaaaucauccauaugcauccc
    cagucuuugggccugcgacggggaugucgacuguguugacggcucccaugaguggccacagaacugccaggccgaagacac
    ggccuccaaaggcguuagcagccccugcuccucccuggaguuccacugugguagcagugaguguauccaucgcagcugggu
    cugugacggcgaggcagacugcaaggacaagucagaugaggagcacugcgcgguggccaccugccgaccugaugaauucca
    gugugcagauggcuccugcauucacgguagccgccagugugaccgugaacaugacugcaaggacaugagcgacgagcucgg
    cugcgucaaugugacacagugugauggccccaacaaguucaagugucacaguggggagugcaucagcuuggacaaggugu
    gcgacuccgcccgcgacugccaggacuggucggaugagcccaucaaggagugcaagaccaacgaguguuuggacaacaaug
    guggcuguucccacaucugcaaggaccucaagauuggcucugagugccugugucccagcggcuuccgguugguggaccuc
    cacaggugugaagauauugacgagugucaggagccagacaccugcagccagcucugugugaaccuggaaggcagcuacaag
    ugugagugccaggccggcuuccacauggacccacacaccagggucugcaaggcugugggcuccauaggcuaucugcucuuc
    accaaccgccacgagguccggaagaugacccuggaccgcagcgaguacaccagucugcuccccaaccugaagaauguggugg
    cucucgacacggaggugaccaacaauagaaucuacugguccgaccugucccaaaaaaagaucuacagcgcccugauggacca
    ggccccuaacuuguccuacgacaccaucaucagugaggaccugcaugccccugacgggcuggcgguagacuggauccaccg
    caacaucuacuggacagauucagucccaggcagcguaucuguggcugacaccaagggcguaaagaggaggacacuguucca
    agaggcaggguccagacccagagccaucguaguggacccugugcauggcuucauguacuggacagauuggggaacacccgc
    caagaucaagaaaggggguuugaaugguguggacauccacucacuggugaccgaaaacauccaguggccaaauggcaucac
    acuagaucuuuccaguggccgucucuauuggguugauuccaaacuccacucuaucuccagcaucgaugucaaugggggcaa
    ucggaaaaccauuuuggaggaugagaaccggcuggcccaccccuucuccuuggccaucuaugaggacaaaguguauuggac
    agaugucauaaacgaagccauuuucagugccaaucgacucacggguucagaugugaauuugguggcugaaaaccucuuguc
    cccggaggacauuguccuguuccacaaggucacacagccuagaggggugaacuggugugagacaacagcccuccuccccaa
    uggugguugccaguaccugugccugcccgccccacagaucgguccccacucgcccaaauucaccugcgccugcccugaugg
    caugcugcuggccaaggacaugcggagcugccucacagaagucgacacuguacugaccacccaggggacauccgccguccg
    gccuguggucaccgcaucagcuaccaggccaccgaagcacagugaggaucucucagcucccaguacuccuaggcagccugu
    ggacaccccagggcucagcacaguggcgucagugacagugucccaccaaguccagggugacauggcuggcagagggaauga
    ggagcagccacaugguaugagguuccuguccaucuucuucccuauugcacugguugcccuccuuguccuuggggccgucc
    ugcuguggaggaacuggcggcugaagaacaucacaaucaacagcauaaacuuugacaacccagucuaccagaagaccacaga
    ggacgagcuccacauuugccgaagccaggauggcuauaccuaccccucaagacagauggucagccuggaggacgauguggc
    augagcagccgggagagccgucucuuuccgggauccauugccaagcuuaggcagaaaagacacucucuccagaccuccccau
    ccagcacugguccugccaccucccugggucuguguugcucaaagcaagauagagcaaagcugggcuggggggccaagcuca
    gcuuccugucugccccagguucuguuuuauauauuuauugucugggacagaaaaggcuacuggcugugcuugaaauucga
    175 U04354 Sequence below.
    accggucaucgggcucuuccuugggcucagggcacggaucaaguccucggcucgcucggccagcaccgcggcaccauggcg
    caggagcugcagcaccccgaguucgcgcgcgcaggccagcaggcugggcugcagguguggagggucgagaagcuggaacu
    gguaccggugccccagggugccuauggugacuuuuacgucggagagcccuaccuggugcugcacaccaccaaguccagcag
    gggcuucuccuaccgccugcauuucuggcugggaaaggaguguucccaggaugagagcacagcggcugccaucuuuacgg
    uccagauggacgacuauuuggguggcaagccaguccagagcagagagcuucaaggcuaugagucgacugauuuugugggc
    uauuucaaaggcggucugaaguacaaggcuggagguguggcuucuggacuaaaccauguccucaccaaugaucugacugcg
    aaaagacuucugcacgugaagggucggagaguggucagagccacugaaguuccccucagcugggagagcuucaacaagggc
    gacugcuucaucauugaccuuggcaccgaaauuuaccaguggugugguuccuccugcaacaaauaugagcgucugaaagca
    agccagguggccauuggcauccgggacaaugagaggaaaggaagaucucaacucauugugguggaagaaggaagugaacca
    ucagagcucaugaagguuuuagggagaaagccugagcuuccagauggggacaaugaugacgaugucguagcagacauaagu
    aacaggaagauggcgaagcucuacaugguuucagaugcaaguggguccaugaaaguaacacugguggcugaagaaaacccg
    uucuccaugggaauguugcuuucugaagaaugcuucauuuuggaccauggugcugcaaaacaaauuuuuguauggaaagg
    uaaaaaugcuaacccacaggagaggaagacugccaugaagacagcugaggaguuuuuacagaaaaugaaguauucuacuaa
    uacucaaauucagguucuuccggaaggcggugaaacaccaauuuucaaacaguucuuuaaggacuggaaggauaaagacca
    gagugauggcuuugggaagguguacaucacggagaaaguggcucagauaaagcagauuccguuugaugccucaaaacugca
    caguucuccgcagauggcagcccagcacaacaugguggacgauggcucuggcgggguggagaucuggcguguagagaaca
    gugguagaguccagauugacccaagcuccuauggcgaguucuauggcggugacugcuacauuauccucuacacuuauccca
    gaggacagaucaucuacacauggcaaggagcaaaugcuaccagagaugaacugaccauguccgcguuucugacuguccagu
    uggaccggucccuuggagggcaggcugugcagguccgugucucucaaggcaaagagccugcucaccugcugaguuuguuc
    aaagacaaaccacucauuauuuauaagaaugggacauccaagaaagaagggcaggcaccggcucccccuacacgccuuuuuc
    aaguccggaggaaccuggcaucuaucaccagaauuguggagguugacguugaugcaaauucauuaaauucuaaugacacuu
    uuguccuaaaacugccacgaaacaauggcuucaucuggauaggaaaaggugcuagccaggaggaggagaaaggagcagagu
    auguggcugauguccucaagugcaaagcuucaagaauucaagaaggcaaggaaccagaggaauucuggaacucucuuggag
    ggaggggagacuaccagacuucaccauugcuagaaacucgggcugaagaccauccaccucggcuuuaugguugcuccaaca
    aaacuggaagauucauuauugaagaaguuccgggagaguucacccaggaugaccuggcagaagaugaugucaugcuacuug
    augcgugggaacagaucuuuauuuggauuggcaaagaugccaaugaaguugagaaaaaggaaucagugaagucugccaaaa
    uguaccuggagacagacccuucuggaagagacaagaggacaccgauugucaucaucaagcaagggcacgagccccccacauu
    cacaggcugguuucugggcugggacuccagcaggugguaaaaccagcaacuauccuggcugcauuggggcagcugccacuu
    uguuguuggggaauuguuuacuuuuuguuauuggcuuuugaagauaaacuccugccaaauggauauauaucuauaucuau
    aucuauaucuauaucuauaucuauaucuauaucuauaucuauaucuaucuauaucuaaucuauaucuaucuaucuaucuau
    cuaucuaucuaucuaucuaucuaucuaucuauaugcuccucuuuuccuucucuuucaaagggaauugcuguauguuacua
    uacugaaauaaccuaaagcaaccauuuguuuucgagcaauuuugcaaucuggggaccucugaggaaguaauuuugucauuc
    agccacugcuagccaaacuugucuuuucccauagagaggaaggagagccacagugcuucuaagcauuuccccgucugcuac
    ucuguuugcagugagcuuuacuuuauguauggcuuuaacaaugccuugcuguuucccaucucaagucaaugccacuugga
    ugccauucacucccaaguguccuuacauaggaugaacuucuuuagcuuuuuuagaaaacuaaaaucaugucuuuuaugaua
    aaacacauuuuauuucuauaaguuuaacuuuauauauuugauagcacaugcucaauagcauaaagaauaugcauugaauga
    uguuuuucauaauuaaaauauauccuuuugg
    176 M35244 Sequence below.
    caggguugagagcaagaaggugcaggauguaggccagcagaauuaucagacccaguggcggcuucugccacuggaagaauu
    uccaacauaaaacagaugaucaguuugggacaaucgauucugcgaccagagguagugucaucugguuacuuuuaaaauuca
    gauugucugguguuuuccaaucacucgcgacuguaauuugaaguuggauucugagauaauacaaucgcugucgcucuagu
    uuauaaagcuguccaagaucugcccagucccagauguccuggguccucagggcggcuguggucugcgcccuucuccugcag
    cuggaugccagaccauccuggacucggaucccuuuggguucacacucgcuuagguauuucuacaccgcugugucccggccu
    ggccuuggggagcccugguucauaaucgucggcuauguggacgacaugcagguccugcgcuucagcagcaaggaggagac
    uccgaggauggcacccuggcuggagcaggaggaagcagaugacugggaacagcagacucauauagucacaauucaaggaca
    gcugucugaaaggaaucugaugacccugguucauuuuuacaacaagagcauggacgacucucacacacuacaguggcugca
    ggacugcgauguggagccagaucggcaccugugucucugguacaaccagcucgccuaugauagcgaggaucuccccacccu
    gagcgaaaacccaaguuccuguacagugggaaacagcacuguaccucagaucucucagcaccuggagggccacugcucagau
    gugcugcagaaauaccuggaaaaagggaaggagaggcugcugcguucagaccccccaaaggcacaugugacccgucacccca
    gaccugaaggugaugucacccugaggugcugggcccuggguuucuacccugcugacaucacccugaccuggcagaaggaug
    gggaggagcugacccaagauguggaguuuguggagaccaggccugcaggggauggaaccuuccagaagugggcagcugug
    guggugccucuuggaaaggugcagaguuacacgugccauguggaccaugaggggcugccugagccccucacccugagaug
    ggagccugcaugguaccaaaagccuuggauuuggauuguugccacgguuuuuuccauuuugcucauuugucucugugug
    gcucgcagacccaugaagaagaaugcaggugggagaggaaggcgugacacccaagaagcaggcagagacaguccccaagacu
    cuagcaagacuguuguggaugaugaggagauggggguuugcuuuuggaagauuaaguccuguaaaacuugucuaggccac
    uccccaggaacuucaggaucaucugggagaugccccuuugaguggcugggcugugaggacagcaggccaguucuugccacc
    cuggacagaaacacaucucaccuuucuggcucgaggaucugaacaccugucucuugccuacucggcuucuagucaggcauu
    uugucaccuugucaagggucccagggacacaaagcucccuccucucacccacagcacucuggguccuacccccaaugcuuca
    gggacauuuaaucaggucaaauugggaucaauggcuuugaugcagaaaagaacuguggacuaauagagauaggguuuaau
    aaaaaaaauaucuuuuu
    177 AW121930 uuuuuuuuuuuuuuuuucaacuuuaaagacuggauuugagguucagucugggucucuggg
    ggggaccucugucaucacgccuauaaucaucccgagaguagucaucccuggagcuccacg
    accgaucaucccgucugucauagcggucuucauagcgguccccaccuccucuguagucau
    caucucuccgguacccacuuccaaaugcccuucugccacugccuauccuggagucauagc
    cucggucauagucucugcugccucggucaucauagcgaucccggcccccauagcggucca
    ugucucugcgugggccgucccgauauccgucccuauacccaucccgauaccggucugaau
    cguaacgaucucgauacuugucuccaaagcuaucaucgccucuucuagguggguagucau
    cacaacugucuguggugggacgggcccuccagucugugucuguuuug
    178 AI852632 uuuuuuuuuuuuuuuuuggcccccaggcucugucucaaggaugggaauagaucaagccaa
    acagugaaaaauaaggcaaaucguggcuucgggguuugagacuggcaccaauggcaaauc
    agcagaggagaugcaaaugggguaacaaucacaguuagugggguaacaugagcaggcagg
    aaacccuugagacaacacccaagguccacgucuucgcaugugcagggcacaacuccagca
    gcaguuucugggcuuggaggcuuguuacucuuccuaccuuucccacccccuaaaagacac
    caagauggagcccacgaagagauuacaucaagcucuucuggcuggg
    179 U70475 Sequence below.
    ucuaggacagccagggcuacacagagaaacccugucucaacuaaaacaaagcaaaccccccgaauauuguuuuuuauuugcg
    gaugucuguuuauugagacgggguucauggcagacaugagugucucagugcauuugcuauccucucuucuaaaggggcgg
    gggggggggugcgcuggagagguggcucagcaguuaagagcacugacuucucuuccagagguccugaguucaauucccag
    caaccacaugguggcuuauaaccaucuauagugagaucugaugccuucuucuugccuguaggcagaccacuguauacauaa
    uaaauaaaucuuaaaaggggggggaagguguggagcuaaaaguauggcaauaugcauaaguuuagcuauuucuguuguuu
    ugcagucaucagugagccaaacuaauucgaauggguagcuagaucuuguugcuuuuagcgaauauauauugagugaaugg
    aauugacagucuucuguauucucauucaguuuguuuguguucuuccccaucagugauaacauguagugaacuaacccgug
    uggaccaucuuaaccauggcuucuccuuccuuuucuguuuuaaacauaggacauggauuugauugacauccuuuggaggc
    aagacauagaucuuggaguaagucgagaaguguuugacuuuagucagcgacagaaggacuaugagcuggaaaaacagaaaa
    aacucgaaaaggaaagacaagagcaacuccagaaggaacaggagaaggccuuuuucgcucaguuucaacuggaugaagaaac
    aggagaauuccucccaauucagccggcccagcauauccagacagacaccaguggauccgccagcuacucccagguacacucg
    ucguggugggagcuaaggaaaacucuagugagaaagcagacucucuggaguugaguucuuggucugccauuuacuguguc
    uuuugugaggaggagaaguucucaaacuucgcuucuugauaaucaggacacagaucacagggaggacuuugugaguucag
    aaacauccucuguggugaugaaacagcggcagaaauacuguugggaguaaaagaaguaggcauugcucauugugguaggca
    gggcccugauuguauggguaacugacuuaacuguguuaaguaugauucccauuuuauauucccaugucuaaacaacuaaag
    cauuugcccagaacacucagaaagaaaugaagggagguuauugccuagcacagagcccugguucagucccccacgcuguuc
    guuaaaggggagggacuaauaauuugaacacaaucugguuugaaucuaugcaaaucgauuucugaaaugagaccauagguu
    auuuuaugaacaagucuuauugcucguugugacccugugcuuagaacauuucauaaaugaugcucucugugccuuucccc
    uuccuccagguugcccacauucccaaacaagaugccuuguacuuugaagacuguaugcagcuuuuggcagagacauuccca
    uuuguagaugaccaugagguauaaaaauguuuguuuaacagcaaaacucccuuaucugauauuaguuccuuucauguguc
    uccaauuaagagaagaaaagaaaauuuuagaaggaaaaaauugaucaaagaaauugucaaguaaacuguaugagagcuauau
    aaugcuuaaaaauaagaccuguaugggcuggugagauggcucaguugguaagaguacccgacugcucuuccgaagguccag
    aguucaaaucccagcaaccacaagguggcucacaacauccauaacaagaucugacucccucuucuggagugucugaagacag
    cuacaguguacuuacauauaauaaauaaauaaaucuuuaaaaaaaaaaaauaaggccuguaaacuacaaguccauuuuacug
    uauagcuggaaacaggaaucagaauaauuuucccuggaaacuggauauagauauauaaaauauuuugacuaguaaagaaca
    acuauuaaucagcauuuggauuaaaaaaucuuaaucuguuguuugaagcauucugcuagauauuauggguacagauuaag
    uccuaaugaauguuuuuauccauuuugaagucugccuuuaaauacauggagugaaauaaccuaggaguguauuaauaugg
    agucacugggaggaggaaauguuucauuuuauaaaagcagccugagagcuguaggcccugcugcugucuguucuucaugc
    cuuggcucucacucacaugaaucaaugucacgucaaucuuggcuuucuucacuugcauuucagucgcuugcccuggauauc
    cccagccacgcugaaaguucagucuucacugccccucaucaggcccagucccucaauagcucucuggaggcagccaugacug
    auuuaagcagcauagagcaggacauggagcaaguuuggcaggagcuauuuuccauucccgaauuacagguaagagagcucu
    aggagugugcuguuuucugcgggcccuuuuaaauuagucauccuaguuauuuauuauuuacaugcuaccuccucaaagga
    agaaauugaugguguauuuaaauuacucaugagagcuucccagacucacuuaacacacauaguuuuuagguaaucagacug
    aauauuucuggauaaauucauucaaagacugaaagcuaauuuagaguucugacaaagauaaaauacuuaucuauugaaaaa
    ugggaguugaaggaauuauugaaaagaacaccuuggauuuggggguagggaauugaucuaaaaugcacuuagccucugcu
    cauacaaugugaccuucuuuccuagugucuuaauaccgaaaacaagcagcuggcugauacuaccgcuguucccagcccagaa
    gccacacugacagaaauggacagcaauuaccauuuuuacucaucgaucuccucgcuggaaaaagaagugggcaacuguggu
    ccacauuuccuucaugguuuugaggauucuuucagcagcauccucuccacugaugaugccagccagcugaccuccuuagac
    ucaaaucccaccuuaaacacagauuuuggcgaugaauuuuauucugcuuucauagcagagcccagugacgguggcagcaug
    ccuuccuccgcugccaucagucagucacucucugaacuccuggacgggacuauugaaggcugugaccugucacuguguaaa
    gcuuucaacccgaagcacgcugaaggcacaauggaauucaaugacucugacucuggcauuucacugaacacaagucccagcc
    gagcguccccagagcacuccguggagucuuccauuuacggagacccaccgccuggguucagugacucggaaauggaggagc
    uagauagugccccuggaagugucaaacagaacggcccuaaagcacagccagcacauucuccuggagacacaguacagccucu
    gucaccagcucaagggcacagugcuccuaugcgugaaucccaaugugaaaauacaacaaaaaaagaaguucccgugaguccu
    ggucaucaaaaagccccauucacaaaagacaaacauucaagccgcuuagaggcucaucucacacgagaugagcuuagggcaa
    aagcucuccauauuccauucccugucgaaaaaaucauuaaccucccuguugaugacuucaaugaaaugauguccaaggagca
    auucaaugaagcucagcucgcauugauccgagauauacgcaggagagguaagaauaaagucgccgcccagaacuguaggaa
    aaggaagcuggagaacauugucgagcuggagcaagacuugggccacuuaaaagacgagagagaaaaacuacucagagaaaag
    ggagaaaacgacagaaaccuccaucuacugaaaaggcggcucagcaccuuguaucuugaagucuucagcauguuacgugau
    gaggauggaaagccuuacucucccagugaauacucucugcagcaaaccagagauggcaauguguuccuuguucccaaaagc
    aagaagccagauacaaagaaaaacuagguucgggaggauggagccuuuucugagcuaguguuuguuuuguacugcuaaaac
    uuccuacugugaugugaaaugcagaaacacuuuauaaguaacuaugcagaauuauagccaaagcuaguauagcaauaauau
    gaaacuuuacaaagcauuaaagucucaauguugaaucaguuucauuuuaacucucaaguuaauuucuuaggcaccauuugg
    gagaguuucuguuuaaguguaaauacuacagaacuuauuuauacuauucucacuuguuacagucauagacuuauaugacau
    cuggcuaaaagcaaacuauugaaaacuaaccagaccacuauacuuuuuuauauacuguaugaacaggaaaugacauuuuua
    uauuaaauuguuuagcucauaaaaauuaaaaggagcuagcacuaauaaaagaauaucaugacuuaaacuacuuuggacuuu
    uugaauuuauucacacuauuuuccauaggacaaucacucauuuaccacauuugguuauuuuacauuuucaaaauggguuu
    gaaaauacagaggcauuuuauagccauguguggcaguccaugauuuuuuauucccgacauucaggaggcagaagcaggcag
    aucccugggcuccaggacggccaaggcuacaugagagccugucucaagaaagacaaacccuuucuauacuaaacguuagcua
    ggauugucaaggagaugguauauauccacaaugguaugccugcuguacaguacuguggcacagagaacaaaaccuguaacc
    uccuguguucuuagaaguggcauucuaagaagggcuaggaaga
    180 U09659 ggccagcaggacucuccuugcagcagcggcccgaguucagaguccggagcugcgguggug
    gcggcgaaggcgagagucauggcuggacaagcuuuuaggaaguuucuuccgcucuuugac
    agaguauugguugaaaggagugccgccgaaacuguaaccaaagguggcauuaugcuucca
    gaaaagucucaaggaaaaguguugcaagcaacggucguggcuguggggucaggagggaaa
    ggaaagaguggagagauugaaccugucagugugaaaguuggagauaaaguucuucuccca
    gaauauggaggcaccaaaguaguucuagaugacaaggauuauuucuuauuuagagauagu
    gacauucuuggaaaguaugucgacugaaaucacuguugaaauggugucacgugaagcugc
    cauuccacugaugucugaacuauuucaucauguaaauaauuu
    181 AW124785 uuuuuuuuuuuuuuuuucaggucucauuuucguuuauuugaaauucggugcucguguaag
    uuuuuucucuuccccucaaauuuuauuucaguaaaaggagacuugggcgagguggauacc
    ccacagccggauucuucccccccugccccccaggguggcuaaugcuaucuggggaagucg
    ucauagggaagagaacuaugggugggcuccugccugaggccuccaaucucagcccagugg
    acauaucacaggcagcuuaaaaaaaaaacccuaaaaaaaacaccccaaaacacacauuua
    aauagguauucaagacagcuuuaaaaaaugcacccacucacaccccccucccuuuucuuu
    uuggaaaaaaaaauaggaaaaaaaaaaaaaccaaaccgaauucucgcuuggccucua
    182 AF071315 Sequence below.
    auuuggcuccgaggccaagaauucggauccaaggcgggcgcggggaaaauggcggcggcagcugcggcgggggcgaaugg
    gagcggaggcagcagcggcauggaaguggaugcagcaguccccagcgugauggccuccggagugacugggaguguuuccg
    ucgcucuucauccccuugucauccuuaacaucucagaccauuggauccgcaugcgcucccaggaggggcggccuaugcagg
    ugauuggggcucugaucgggaagcaggaggggcgaaauaucgaagugaugaacuccuuugagcugcugucccacaccgug
    gaagagaagauuaucauugacaaagaauauuauuacaccaaggaggagcaguuuaaacagguuuucaaggagcuggaguuu
    cuggguugguauaccacaggggggccaccugaccccucagacauccacguccauaagcaggugugugagauaauugagagu
    ccgcucuuucugaaguugaacccuaugaccaagcacacagaucuuccugucagcguuuuugagucugucaucgauauaauc
    aauggagaggccacaaugcuguuugcugagcucacuuacacucuggccacugaggaagcugaacggaucgguguagaccac
    guggcccggaugacagcaacaggcaguggggagaacuccacuguggcugaacaccugauagcucagcauagugccaucaag
    augcugcacagccgugugaagcucauuuuagaauaugucaaggccucugaagcaggagagguucccuucaaccaugagauc
    cugcgggaggccuaugcccuaugucacugucucccaguucucagcacugacaaguucaagacagacuuuuaugaucaaugc
    aaugacguggggcucauggccuaccucggcaccaucaccaaaacgugcaacacaaugaaccaguuugugaacaaguucaacg
    uccucuacgaccgacaaggcauuggccggcgaaugcggggacuguuuuucugaugaugguucuggaagggauggugugug
    gggcucagacagcuguuccauggaccugaguaccacauucccuuuagagaaacucauuaauaaaagagcagccccuuaaaaa
    aaaaaaaaaaaaaaaaaaaaaaaaaaaa
    183 D49733 Sequence below.
    aaaacccaauguuugguuuuaaagccaaaaauauaagggaagugcauagguuuggguuuuguuuuuuguuuuuucccgag
    guccuugaucuuugcccccaaauuugagggcauaaaguaaucccucaguuaccuaaaaacacagccauuccuuugccauucc
    acucuccuggauuggccgcuucugugcgcgggggagaggugacucacuauuacuacugaggaaaggggagccaguggugg
    aaguggggugagucacugaugggcagcagcuucagcccuccccccaacuuccuuggcucucuggggaugccugauccucuc
    ccucacuuugcaccuacuuccccuggucccucaccacuacccuuugcccacccacucaaauucuuuggcucugcucuuuacu
    ccagaaggccaaaggcaagcuuagaguugaguaggcaggaaccaacauugugaagccccaggccagaaagggguguucugc
    agagugaggguuggcaugcuggcuccuccucaccauaccugcccccgccccuuuggguacaggauggcuccuuuaagagca
    guggauccacccccuguagaggagggccuauuagagccucugccuggcugucagugacucaguguucgcgggaacgcugc
    cucagccucaacaccagccaacccagaucccgaggugcgccagcgcccagcccagaucuccacgccugccaggagcgagcuu
    cgccggcucgcugucccccugagcagccucuguccuucuguccaagucccgcgcccuucucgggaccccugcccagcgggc
    agcacugucacccugccggccauggagaccccgucacagcggcgcgccacccgcaguggggcgcaggccagcucuaccccac
    ugucgcccacucggaucacccggcugcaggagaaggaggaccugcaggagcucaaugaccgccuggccguguacaucgauc
    gcgugcguucccuggagaccgagaacgcggggcugcgccuucgcaucacugagucugaagagguggucagccgagaggug
    uccggcaucaaggcggccuacgaggccgagcugggggaugcccgcaagacccuugauucuguggccaaggagcgcgcccgc
    cuccagcuagagcugagcaaagugcgugaggaguucaaggagcugaaggcucggugagugaggcccggccggccggcacca
    gggaggcagcagucgccuguaacuggccaucuaguccccucccuccccggaacugccucccgcgggugacuggcagugcca
    annnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnngcuaggccagauauagaaagcuuucuguauuuaauacacaguacaugcaucauuc
    augucuacauaauuaagauaaaggaagcugcauuguuaaugggaaaaaaaauagggucugggaauguagugugccuagcau
    uuacgaacuucgggguuuggguuugaucccagcaucucacaaaccacguguaaucccagcacuuggaagguagaggccgga
    ggauccgaaguuuaaggucauucuugacuacuuagcaaauucggggcacccuaggauaccugagacccugucaugaauaaa
    aauaaauaauaaauaaaccaauaugggucuagguugagcagcagcuugggcaggguagggccggaaguuagccagguagag
    gguugcagucccaggaggacccuggcugggagcagcaccucaguccccugcccaaccacagggggccaccgggucuuuccg
    gaacuccugagggcgcaaggccuugcucucucuggcccagccauggggaacgcggagggccggugaggcaggcggcaggc
    gggcgggcggggcgcgggccgucauccccuccugcuccuuauuuuuagcccaguguagagucugggccgccugucccucc
    cccaggacagggggaggaaauunnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnngaugccaacaauccuaauguaaugaugcccucuuc
    ugacagcugcggggaccgcagagaggucccaucccagaugcacuccugaaaccugcuuuucuuuuucuagcaacaccaaga
    aggagggggacuuguuggcugcgcaggcccggcucaaggaccucgaggcucuucucaacuccaaggaagcugcccugagca
    cugcucucagugagaagcgcacauuggagggcgagcuccaugaccugcgggggcagguagccaagguaggccgcuguccu
    gugaccccagugaccccaccugguccgacauaucauucggucccauuugccugcucaccuucacuucuccagucuagannn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnucuagauggggacagccaucaccucuccuuuggcauuuccugaacccccucccaccucu
    ccaugaacuuggcuuucucccucucagcuugaggcggcccugggagaggcuaagaagcagcuucaggaugagaugcugag
    gcgaguggaugcugagaacaggcuacagacgcugaaggaggagcuugacuuccagaagaacauuuacagcgagguaagcgu
    cccgcuguacaggucuuucuuacuguggacagcugggaggggucaccuaauaaugccaggcuaagcgagggcugcccgug
    ccuggccgguggaguuacgacuucuggucucagcuucuaaggaaccauugcgauguucuaaucuaagugucuccccuuaac
    cuuucaggaacugcgugagaccaagcgccggcaugagacgcggcuuguggagaucgauaacgggaagcagcgagaguuuga
    gagccggcuggcagaugcccugcaggagcugcgggcucagcaugaggaccagguggaacaguauaagaaggagcuagaaaa
    gacauacuccgccaaggugcuggccucauccuguccucucccuggugcugcccuggggacgggugggugguggcaggggg
    ccagggaugccuuccucaggcccccagcuccagguuccugcucucauaacugugugcucccugcagcuggauaaugccagg
    cagucugcugagaggaacagcaaccucgugggggcugcccaugaggaacugcagcagucucgaauccgcauugacagccuc
    ucggcccagcucagccagcuccaaaagcaggugacccucaguuuaccccucccaccuuggcucuggucuaagcagauacugc
    agaagcccacugagaagggggugggggagggacuccaggaccacaugcuaugguucugaaucugaugccugucuggcuuu
    ccagggcucuccuuuagcuagcccugauccucagagccucuauuuuacugugcaugaaggguuuuucauguuucuucugu
    gccugccggagacugaaccagaggccucuugcuugguagauaggugcuuucucacugaguuacaaacccagccgcauuccc
    uacuuggagauagagcuucccuuggacuggacauguagcucaguugguacagugcuugcuuauuauacacgauggccugg
    cuucuauccccaggaccnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
    nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnucuagagagagccuacagauccugagugucccucugccug
    ccccugugccccucccucuucaucgacaucagcccuugggagcucaucagacccuuugucuuccccgccccaguuggcagcc
    aaggaggcaaagcugcgugaccuggaggacucgcuggcccgugagcgcgauaccagccggcgccugcuggcugagaaagag
    cgagagauggcggagaugcgggcgaggaugcagcagcagcuggacgaguaccaggagcugcuggacaucaagcuggcccug
    gacauggagauccaugccuaucgaaagcugcuggagggcgaggaggagaggugaacuaggaggggucuacagaacuuguc
    aggggccucuggccgcaacuaccaugacuaaccccgcaccgugucuccaccuuccccaggcugcgccugucccccagcccua
    ccucgcagcgcagccguggccgcgccuccucccacucaucccagucucaggguggaggcagcgucaccaaaaagcgcaagcu
    ggagucuuccgagagccggagcagcuucucgcagcaugcucgcacuagcgggcguguggcgguagaggaagucgaugaag
    agggaaaguucgugcggcugcgcaacaaguccaacgaggugggccugugaaccaggguggucuuuucaguggcugggagu
    ucuugguucucguggagcaucugucucccuaucugagaauuuggagugugugguaguccugucaucuuuaaauuguugg
    gaagaugcaugauauagggaugggugacccuugagccaauagucuagguuugaugccagagguagugguggaagccuguc
    uuucuuuucuuuuucuuuuucuuuuucuuuuucuuuuucucuuucuucucucuuuuuuuuuuuuccgauggggucuug
    cccagguuggcuuugaucucccuaguuaagcuguuccccugccucagccuccauaguagcuggaacugcaggngcacacug
    gcgnccagccuaccuaagcuccugagugagauaauccaagagucgguugaacucccuguccuccuuccuccuuccuccuuc
    cuccacccuacuucaggaccaguccaugggcaacuggcagaucaggcgucagaauggugacgauccuuugaugaccuaucg
    cuucccaccgaaguucacccuaaaggcugggcagguggugacggugaguggaagggcacuugggacucuggcuggagugg
    agaaguuggccucaggacaggagcauuaaaaauaagcacaucucuuaaaccaucuuuucccagaucugggcuucaggagcu
    ggggccacccauagccccccuacugacuugguguggaaggcgcagaacaccuggggcugugggagcagccuucgcaccgcu
    cucaucaacuccacuggagaagugaguauguugcagccgguagcuugcuggacaaggcucccccgggugaccauaauggga
    acuagcuaccuccaacccaagggaaccugccuuggguuuaggaucgcuuuccugagcccaagucccacccaguaagcaagcc
    agaagucuccccaguagaauaauggguggaagucagccagugaguguuaauagcagacuccagcuuacagagcaccgagcu
    cucaguuguguccuuuuugcgcgugcgugcgcgcgugugcacaugugcauguguuuauccuuaguccccagcaucagagg
    uuggacaagguuguauaaaggcccgggacaguucuaagugguuacuauggguagacaggcugcacagcccucacccccuga
    cucuugggccugggcuuauguccccacaggaaguggccaugcgcaagcuggugcgcucacugaccaugguugaggacaau
    gaggaugacgacgaggauggagaagagcuccuccaucaccaccgugugaguggcagccgccgcugaggcccagcccacaag
    gguagcccugccagccuagggcagcucucccaccuccaugccaaagucuuuucauuaaagaauguuuuggaaugccacuug
    cugcccuggccuuucuucucucuccucccucuaccuugaacagggaacccaggugucugguaaggaagggaguggggacu
    ugcugaugccauggauacuccacgguggcaguggacaggguucuggauuuguguccugggaaggggcugggaggacagag
    guggccccagcccugccucucuuccucacucccauugcaugcacacuucucuccucucuccuuccacccuauugcaugcuuc
    uccucagauuucccugcaacaauguucucuuuccuuccuguccccucacaaauuaagucucuccaucuuugcucuuccucu
    ugauugccccauaagugucuaagauucaggagagaguuaaagccacagcucuuuauuucgaaggcuuccuggcuauuuccc
    ccaucaugcccuuccucccagccacaggucucccaaguccccaucacuugguugucuggguacagacagaggucaccuuccu
    gcccaauggccaggaagcuccaagagcccacagccuaggugccgguccuaagaagucagucccaaacucgcugucccuccug
    agccuugucucccuucccaggguucccacugcagcggcucgggggaccccgcugaguacaaccugcgcucacgcaccgugc
    ugugcgggacgugugggcagccugcugacaaggcugccgguggagcgggagcccaggugggcggauccaucuccucuggc
    ucuucugccuccagugucacagucacucgaagcuuccgcaguguggggggcaguggggguggcagcuucggggacaaccu
    agucacccgcuccuaccuccugggcaacuccaguccccggagccaggugagucaucucugcccuacagcaggacacugcuca
    cugagcagcagggcagggcagcccaagggaguggggucccccuccuugcagucccucuugcauccugccccuccugucuga
    accccagacucgaggucagggcaaggcccagagugugaggguuggggagacaaccccuuuggggucagggagggagagga
    agggccagccacugcugcucacaccucugccuucucuucucucuuagagcucccagaacugcagcaucauguaaucuggga
    ccugccaggcagggcugggggcagaggccaccugcuccccccucaccacaugccaccuccugucugcuccuuaggagagca
    ggccugaagccaaagaaaaauuuauccccugccuuugguuuuuuuuuuucuucuauuuuuuuuucuuuuucuaagagaag
    uuauuuucuacagugguuuuauacugaaggaaaaacucaagcaaaaaaaaaaaucuuuaucucaauccuaaguccuuccccu
    uucuuuccuuguaucugccuuaaaaccaaagggcuucucuaggagcccagggaaaggacugcuuuuuauagagucuagau
    uuuuguccugcugccuuggcuuuacccucaucccaggacccugugacaauggugccugagaggcaggcauggaguucucu
    ucaccagccuccuccaacagcuggcccacugccacgccagcugcagagaaauggggcgcagagaggaugacugagaagguca
    agccccuccccggcacuacacgaggccgaggcuccucugccugccuuaccuucuuccugcccuucccuagccuggggcgag
    uggauucccagaggcaaaucugccgugcuugcuuuuucuauauuuuauuuagacaagagaugggaaugacggggaaggag
    aagggaagaucaguuugagccuaccuuuucccagcuucugagccuggugggcucugucucaaugauggagggcaauguca
    agugggauacagggaagagugggggacgaaggcucccagagauggggagaaccugcuggggcuggugagaagucuagagg
    ugcggcgauugguggcuacagcaaacacuaaggaacccuucaccccauuucccaucugcaccucugcucuccccuccaaauc
    aauacacuaguuguuuccaucccagaugcuguggugucucuuuguugggugugauguguguuuucaggggcagacacau
    gcacacagaggugccacacauucacuauauauucacuacccagcuauaaagguguguaugagggagacuucuagaaagguc
    agcauauguggggugagcgagggguguccuuccuaucccucauccauccagcaccuuuuaaaaggggccagcaauccacau
    gugcaucagacacaggagcacagagagacggaggguagaguagggcagaguagcagagcuuccuugcugcccuguagucgc
    aggcucuugaucgugugaucgcu
    184 X80899 Sequence below.
    gcggugcgaagcgggccuccgccaacauguacuacaaguuuagcaguuucacgcagaaguuggcuggagcuugggcuucg
    gaagccuacaccccgcagggguuaaagccaguuuccacagaagcaccaccuaucauauuugccacaccaaccaaacugaccuc
    cagugugacagcauaugauuauucugggaagaacaaaguuccagagcugcagaaguuuuuccagaaggcugaugguuucca
    ccugaaacgaggccuuccagaccaaaugcuuuaccggaccaccauggcucugacacugggagggaccaucuacugccugauc
    gcccucuacauggccucgcagcccagaaacaaaugagcuugccuguggaggacugguucacuuuguggcacaaacccuuug
    aauccucacguuucauguuuuccacuuggauagucuacuuaacauuuugcaaacaaaggaaaagauaagaauacauuguuu
    ugauuuguuuauggugugcagauggccugucagaugucagagcugguuugacaguuaaaacuauuguuuaaggaaauguc
    acugagccaucacugagcugugcuucugcuccugauuucccuggaguucugcaggaaaguugcucuccagcucauucgug
    gccagccgugcucagggccucgggacucaggcggugucugagcgggaagcgaacgcggaagccuuuuggaguguaggugu
    gauugaggaaggaaaacaaaagccagcggacagguggugaagugagggcugaguuagccacccuagggauucguccgccuu
    gcagaaaacauugagaggaaugauagcaaccugccucuauuugugggcaguugguuucaaaggguugugugucucgccca
    gaaccuagggaaauggguguuuguuccaucgugggaggagcaccugucagugcugcacauuagacagcugugucaggacu
    ucuccuuuaauaaugcuguggcuuuacguuaugauugaccggacugcggaauaaacacuggaaucaaaaaaaaaaaaaaaaa
    aaa
    185 D83203 Sequence below.
    cugagacagaacgaaacguccgcagauaacuacccguucuggcucuuguuaguucuauguguauggauaaugucuuggga
    gguuuugaaaugccacaagccuugcuggcccagggugcagcugccucugccguucagaccucagauuauaaggacagaaca
    cagcacggaaguggggggaucagaaccaugggagauccaggacgaaggguccugugcgcaggugcggcaccgaauccuaua
    uuugacauugaagcugucgucagcccaacuaguguguuauuaacauggaagcacaaugacucaggcgcuucagaauguaga
    auagagaauaagauggagagcaaucugacguuuccuguuaaaaaccagacaucauguaacauuacaggcuuaagcccaggu
    acuucguauacauucuccaucaucucuguaacaaccaaugagaccuugaacaaaacuaucacaacagagcccuggccagugu
    cugaucuccaugucaccucugugggugugacacaggcucgucucaccuggagcaaugcaaauggcacugccuccuaccgga
    ugcugauugaagaguugaccacacauuccucagucaauauuucaggucugaagccggggaccaauaauacguucgcuuucc
    cagaaucaaaugagacacaggcugacuuugcaguugcagaggaggucccggaugccaaugguaccaagagaaucccaguga
    ccaaccuaucccaaccacacaagaauucucuugccucuguggacccacccucuggccaggaucccucccucacagagaucuu
    gcuuacugaccuaaagccugauacucaguacaaugccaccaucuauucucaagcagcaaauggcacugaaggacagcccagg
    aacaaaguguuuaaaacaaauuccacccagguuucugacguccgagcuaugaacaucagugccucaagcaugacccugaccu
    ggaaaagcaauuacgaugggucccguacuucaauugucuacaaaauacacguggcugggggggaccacuccgucaaccaaa
    cugucaauaagacugaggccaucauccucggacucagcuccagcaccuuguacaacaucacaguucauccuuuccuggguca
    gacggagggcacaccaggcuuccuccaaguguacacuucccccgaucaggucucugacuuccgagugacaaaugucagcaca
    agggcaauugguuuggcuuggaggagcaaugacuccaaguccuucgagauuuucaucaagcaggacggaggugagaagca
    ucgaaaugcuucgacgggaaaccagagcuauaugguugaagauuuaaagccuggaaccaguuaccauuuugagauaauucc
    acgaggaccagacgggacagaagggcuguccaguacagugaaugggagcacugaccccagugccgugacugacauccgggu
    ggucaacauuagcaccacugaaaugcaguuggaguggcagaauacggacgaugccucuggauacacuuaccauuuaguucu
    agagucuaaaaguggcuccaucaucaggaccaacaguucucagaaguggaucacaguagggagccucaccccaggcaccuua
    uacaaugucacaaucuuuccagaaguggaccagauccagggaaucuccaacuccauuacccaguacacacggcccagcagug
    ugucccacauugaaguaaacaccaccaccaccacggcagccauccgauggaagaacgaggacacagccucugcuuccuaugc
    cuacuccguccuuaucuugaagacuggagauggcagcaauguaaccagcaacuucacaaaagacccuucuauucuaaucccu
    gaguuaaucccuggcgucucuuacacagugaagauccuuacacaaguuggggaugguacaacaucacugguaccugguugg
    aagcuguucuguacggaaccugaaucagugaccuccuuccacugugaaguggucccuaaggagccagcauugguucucaag
    ugggccugccccuuuggcauguacacaggcuucgagcugggggucaggagugauuccugggacaauaugacacgccuaga
    gaacugcacaucggaugaugacacagagugcaggacggaagucgccuauuugaauuuuucuaccucguacaacaucagcau
    cgccaccuugucaugugggaagauggcgcuucccgcccagaacaucugcaccacuggcaucacagacccaccuacuccggau
    ggauccccuaauauuacaucggucagucacaauucaguaaagguuaaguucagcggguuugaagccagccacggaccuauc
    aaagccuaugcugucauccucaccaccggggaagcugcccaaccuucugcagauguuuugaaguacacguaugaggauuuc
    aaaaggggagccucggauacuuaugucacauaccucauaagaauagaagagaagggacagucucagggcuugucugaaguc
    uugaacuaugaaauugauguggggaaccaauccacuacccucggcuacuacaacgggaggcuggagccucugggcuccuac
    cgggauuguguugcuggcuuuaccaauauuaccuacaaccuucagaaugacggccucaucaauggggaugagagcuaugu
    gucuuucaguccauauucagaggccguguucuugccccaggauccaggugucaucugcggagcaguguuuggauguaucu
    uuggugcccuggccaucacagcugugggaggcuucaucuucuggagaaagaaaaggacagaugccaagaauaaugaagugu
    ccuuuucucaaauuaaaccuaaaaaauccaaguuaauccgaguggagaauuuugaggccuacuuuaagaaacagcaagcuga
    cucuaacuguggguuugcagaggaauaugaggaccugaagcugauugggauaaguuuaccuaaauacacagcugagauagc
    cgagaacagagggaagaaccgcuacaacaauguucugcccuaugauauuucucgagucaaacuuucaguccagacccauucg
    acagaugacuacaucaaugccaacuauaugccuggcuaccauuccaagaaagauuucauugccacacaaggaccuuuaccca
    acacuuugaaagauuucuggcguaugguuugggagaaaaacguauaugccauuguuauguugaccaaaugcguggagcag
    ggaaggaccaaaugugaggaguacuggccuuccaagcaggcucaggacuacggggacauaacuguggcgaugacaucagaa
    gucguucuuccagaauggaccaucagagauuuuguggugaaaaauaugcagaauagcgagagccauccucugcggcaguuc
    cauuucaccuccuggccugaccacgguguuccugacaccacugaccugcucaucaacuuucgguaccugguccgggauuac
    augaagcagauaccccccgagucaccaauucuggugcauugcagugcugggguuggaaggacgggcacuuucaucgccauc
    gaucgccugaucuaucagauagagaaugagaacaccguggacguguaugggauugucuaugaccuucggaugcacaggccu
    cugauggugcagacagaggaccaguauguuuuccucaaucaguguguuuuggauauuaucagagcccagaaagacucaaaa
    guugaucucaucuaucagaacacaacggcaaugacaaucuaugaaaaccucgagccaaguuccuugaaugugacuauguug
    cuucauccacagcugaacgauuuuggauguuggguucuagguccuggcuguugcuggucugcuaggauccagggccuugu
    ugacaucugggaagauguaaauugucccgcugaaggccgcaguuuuagauguggccacuagauggagccagagcacuggu
    augaaggagcaccagggccguguaaggcaaaagaggacccagaaaaagaaacuuaacuuguucacuccugagaaaccugcaa
    gucaacaagccaaggaagugccuuugcaugcauuugguagccuuuccaaucccgcuuauuacauaauauguucauguucau
    ggcaaaaaaaaaaaaaauaaaauaaaauaaauaaaaaaggaaaacaaaauaaaaaaaaucuuagaacauu
    186 Z20410 gcccccucaagggcauccugggcuacacugagcaccagguggucuccucugacuucaac
    a
    gcgacacccacuccuccaccugacgcuggggcuggcauugcccucaacgaccacuuugu
    c
    aagcucauuuccugguaugacaacgaauuugcuacagcaacaggguguggaccucaugg
    cccacauggccuccaagguaagccccuggaccaccagccccagcaaggcacaagaggaag
    g
    agagacccu
    187 AI839906 uuuuuuuuuuuuuuuuucauauuaaacuuguaguuuuauucagguuugauuuuuaac
    aaaugugucagggagagagcccacaggaaaggguaaagcccgugggggcaaggccuucc
    cagaugccugaggagggaucguguccccucccccccuccucuucucaccaccccuacagg
    gguuugggaagagacacaggcagggaaggggcugguccccagucuguacaguggugcu
    ugggggugaaggacuauggagaacaggggaccagaucggggaugaguaggauaaaggg
    cacaagaccauuuaccagaauccagcuuucugauuccaaauugaauuaaaaagaaaaaaa
    ggagaggggaaccuaaaccacaagcaguacccaacucccuuucccccaucagggcugc
    188 AI843448 uuuuuuuuuuuuuuuuuagggaagaggcugaugccagauaaguuuuuauuauauuaa
    aaaaaaaaaaaaaaccagugcaacuggaaaucagggugagucgcuggaggugagugaga
    gucggaaggcccuccacaccucagugguggcaggaucuggacccguagccuaagccugg
    ucugauccagccgagaugcuggaaagcagagcacacgguggugcccaucagggcaaaga
    gggcaagagagcccacggcuccuccauaccgcuugcuagggucuccuguguaguagcca
    uaugcguaaaggacucgcccaauaauccaggccaggcccaggccagaagcuaugcgcgg
    gugguaaacaccucccaccguuaggaaaaa
    189 AW125336 cggccgcgugaguuuugacugagcuucugcangaaguucanaugcaacuccauacauca
    guucauuuucuagcauuaccacuggguuauuaucacgaauggccgauuuaauaagucc
    uuuugcauccucggaauuccaggggcugaccacuuuuaaaccugggcagugcccauacc
    augcagcaaagcauugcgagugcugagcagcuacaccugcugaggcgccauugggcccc
    cugaauacuaugggcaca
    190 AW123802 uuuuuuuuuuuuuuuuugaagggccauuggaguuuauuuacagacaaccuuagguga
    ggccuuuuccucuaggaucuacaugcuuuugaaguuacuugguuucaggcuucuuguc
    uccagcuucgagcuugagacucucaggaggcuggcgauaggcagggaaagccucccagg
    ggcuguucaggucaaacuugcggaauucuugugccagcuccacugguucagccacuacc
    cgcuuuaccucaucgucguaacgaagcucaacauagccagugaggggaaagucuuuccg
    gaaaggaugucccucgaagccauaaucugucaggauccuucuuaaaucagggugguuaa
    aaaaaaaaaaaaaaaaaaaa
    191 AI835771 uuuuuuuuuuuuuuuuuggggggcagcgaacuuuauugaugguauucaaaaaaauag
    ggagggcucccuaggcccccccuguuauuaugggggucugggauggaaauuuugaggg
    aaaugcucaauuuugggggcccauuugggaaaaggccccccuugcccaauguccuugcu
    ggggugggugguccaagguuucuuacuccuuggaggccauuuuggccaagagguccac
    cacccuguugcuguagccguauucauugucaaaccaagaaaugagcuugacaaauuugu
    cauugaaaaaaaugccaaccccggaaucaaagg
    192 X53584 Sequence below.
    gcuccucaucucacucgggccuaugccaaagauguaaaauuuggugcggaugcucgagccuuaaugcuucaagguguagac
    cuuuuagccgaugcuguagcuguuacaauggggccaaagggaagaacagugauuauugaacagaguuggggaagucccaaa
    guaacaaaagauggggucacuguugcaaagucaauugauuuaaaggauaaauacaaaaauaucggagcuaagcuuguucag
    gauguugccaauaacacaaaugaagaggcuggggauggcaccaccacugccacuguucuggcacggucuauugccaaggag
    ggcuuugagaagaucagcaaaggggcuaauccaguggaaauccggagaggugugauguuggcuguggaugcuguaauugc
    ugaacuuaagaaacagucuaaaccugugacaaccccugaagaaauugcucagguugcuacaauuucugcaaacggagacaaa
    gacauugggaacaucauuucugaugcaaugaagaagguuggaagaaagggugucaucacagugaaggauggaaaaacccug
    aaugaugagcuagaaauuauugaaggcaugaaguuugauagaggauauauuuccccauauuuuauuaacacaucaaaaggu
    caaaaaugugaauuccaagaugccuauguuuuguugagugaaaagaaauuuuccaguguucaguccauugucccugcucu
    ugaaauugcuaaugcucaucggaagccauuggucauaaucgccgaagauguugacggagaagcucuaagcacgcugguuuu
    gaacaggcuaaaaguuggucuucagguuguagcagucaaagcuccaggguuuggggacaacaggaagaaccagcuuaaaga
    uauggcuaucgcuacugguggugcgguguuuggagaagaggguuugaaucuaaaucuugaagauguucaagcucaugauu
    uagggaaaguuggagaggucaucgucaccaaagaugaugccaugcuuuugaaaggaaaaggugacaaagcucacauugaaa
    aacguauucaagaaaucacugagcagcuagacaucacaacuagugaauaugaaaaagaaaagcugaacgagcgacuugcuaa
    acuuucagauggaguagcuguguugaagguuggaggaacaagugauguugaagugaaugagaagaaagacagaguuacug
    augcucucaaugcuacaagagcagcuguugaagaaggcauuguucuaggagggggcugcgcucugcuucggugcauccca
    gccuuggauucauuaaagccugcuaaugaagaccagaaaauagguauagaaauuauuaaaagagcacuuaaaauuccugcaa
    ugacgauugcuaagaaugcagguguugaaggaucuuugauaguugagaaaauucugcagaguuccucagaaguugguuau
    gacgccaugcuuggagauuuugugaacaugguggaaaaagggaucauugauccaacaaagguugugagaacugccuuacu
    ggaugcugcugggguggccuccuugcuaacuacagccgaagcuguagugacagaaauuccuaaagaagagaaggacccugg
    aaugggugcaauggguggcaugggaggggguaugggaggcggcauguucuaacuccuagaguagugcuuugcccuuauca
    augaacugugacaggaagcucaaggcagguuccucaccaauaacuucagagaagucaccuggagaaaaugacugaagagaag
    gcuggcugaccacuguaaucaucaguuacugguuuccuuugacgauauauaaugguuuacugcugucauuguccaugccu
    acagauaauuuauuuuguauuuuugaauaaagaacauuuguacauuccugaugcugguugcaagagccauauaccagugu
    ccugcuuucaacuuaaaucacugaggcaucucuacucuucugugagucaucaggacuguagcgcugugucaacaaaacaua
    gagaguucagaagacagccuuucuguggaagggugggaaugauuguguacaaaguagagaaguauccaauuaugugacaa
    ccuuuguguaa
    193 M32599
    acagccgcaucuucuugugcagugccagccucgucccguagacaaaauggugaaggucggugugaacggauuuggccgua
    uugggcgccuggucaccagggcugccauuugcaguggcaaaguggagauuguugccaucaacgaccccuucauugaccuca
    acuacauggucuacauguuccaguaugacuccacucacggcaaauucaacggcacagucaaggccgagaaugggaagcuug
    ucaucaacgggaagcccaucaccaucuuccaggagcgagaccccacuaacaucaaauggggugaggccggugcugaguaug
    ucguggagucuacuggugucuucaccaccauggagaaggccggggcccacuugaaggguggagccaaacgggucaucaucu
    ccgccccuucugccgaugcccccauguuugugaugggugugaaccacgagaaauaugacaacucacucaagauugucagca
    augcauccugcaccaccaacugcuuagccccccuggccaaggucauccaugacaacuuuggcauuguggaagggcucauga
    ccacaguccaugccaucacugccacccagaagacuguggauggccccucuggaaagcuguggcgugauggccguggggcug
    cccagaacaucaucccugcauccacuggugcugccaaggcugugggcaaggucaucccagagcugaacgggaagcucacug
    gcauggccuuccguguuccuacccccaauguguccgucguggaucugacgugccgccuggagaaaccugccaaguaugaug
    acaucaagaagguggugaagcaggcaucugagggcccacugaagggcaucuugggcuacacugaggaccagguugucuccu
    gcgacuucaacagcaacucccacucuuccaccuucgaugccggggcuggcauugcucucaaugacaacuuugucaagcuca
    uuuccugguaugacaaugaauacggcuacagcaacagggugguggaccucauggccuacauggccuccaaggaguaagaaa
    cccuggaccacccaccccagcaaggacacugagcaagagaggcccuaucccaacucggcccccaacacugagcaucucccuca
    caauuuccaucccagacccccauaauaacaggaggggccuagggagcccucccuacucucuugaauaccaucaauaaaguuc
    gcugcacccac
    194 AF035644 agaagcuuccuaaggaacaagcaaguugaauagagaaaauagugaucaauaauaggcauu
    uuaguggucuuuuuaauguuuucugcugcggaacauuucaagauuuauugauuuccucc
    uccccccauuuuuuucccaccacacucacacacgcacgcucacacuuuuuauuugccauaa
    ugaaccguccagccccuguggagaucucuuaugagaacaugcguuuucugauaacucaca
    accccaccaaugcgacucucaacaaguucacagaggaacuuaagaaguacggagugacaa
    cuuugguucgaguuugugaugcuacauaugauaaagcuccaguugaaaaagaaggaaucc
    acguucuagauuggccguuugaugauggagcuccacccccuaaucagauaguagaugauu
    ggcuaaaccuguuaaaaaccaaauuucgugaagagccaggcuguuguguugcagugcauu
    guguugcaggauugggaagggcuccugugcuaguugcgcuugcauugauugaaugcgga
    a
    ugaaguaugaagaugcuguucaauuuauaagacaaaaaagaagaggagcauucaauucca
    aacagcugcuuuacuuggagaaguaccgaccuaagaugcgguuacgcuucagagauacca
    augggcacugcuguguucaguagaaguagaagcaggcuggcuggaucguggcauuagag
    g
    gaa
    195 Y00629 Sequence below.
    auucagguuccucacagacccagggggugaggauguugcuuuuugcccacuugcuucagcugcuggucagcgccacaguc
    ccgacccagaguaguaagugaggggaggggugaggggagggguugggagcgaaaaagacucugugaggaaaagcgggagg
    guggugguggcggaggugcagcaccccaaguuccgccgcccuguccuagucccucccccgccuuuaccugggaccuugagc
    cugggggaggucggggucucaccgcgcgccgcccccaggcccacacucgcugcgguauuucaccaccgccgugucccggcc
    cggccucggggagccccgguucaucauugucggcuacguggacgacacgcaguucgugcgcuucgacagcgacgcggaaaa
    uccgaggauggagccucgggcgcgguggauugagcaggaggggccggaguauugggagcgggagacuuggaaagccaggg
    acauggggaggaacuucagaguaaaccugaggacccugcucggcuacuacaaucagaguaacgacggugagugcggcuggg
    aucacagcuaugaucacuccauguccccugagacgggccugggucaucuugacccgcugagacaaaguuucauccaaacgcc
    uacccagaaccucagacaaaaaagcccccgcagaguucugcuuagguuugggguuguacuuuuguuucucuuuuguuuug
    agauaucuacuaacauugggcaaaguggccacagguggcgcucaucagcguaucccuuccagaaucucacacgcugcagug
    gauguacggcugcgacguggggcccgaugggcgccugcuccgcggguauugucaggaggccuacgauggccaggauuaca
    ucucccugaacgaggaccugcguuccuggaccgcgaaugacauagccucacagaucucuaagcacaagucagaggcagucga
    ugaggcccaccaacagagggcauaccugcaagguccuugcguggaguggcuccauagauaccuacggcugggaaaugagac
    acugcagcgcucaggugcccuggagagcucuccucacuuuuccucugcgguuugggggaaauccuugagguauaaccuca
    ggggcagaacgcuguucagcgggcacagcgcggaggaggagggagagggacucccaaaacugcuuuuccccuguagggau
    ucuaauccuuaacaaaagcagaucaggcucgacaauggcccuggacccauggggggagggggcucuuucucaggccucccu
    ccuugcccuacucagugucucuauagucagacuccagcuuuucucaaucucuuggcccucauccagcucaggaccagaagc
    ccuucccaugagucugcagagaccuggagccuccuguccauguuguccugcucacauccuaaggcaucccuaagagcagau
    ccucccaggugcaggugcucuagcuggugucuagaugauggacaccauaaucccaccgcaguccuccuguccaccccagga
    cggucacaugaacacugcugaguccccagaagaaagcaagaugccucauccuuucaacucucucccucagacccuccaaagg
    cacaugugacccaucacccuagaucugaagaugaagucacccugaggugcugggcccugggcuucuacccugcugacauca
    cccugaccuggcaguugaauggggaggagcugacccaggacauggagcuuguggagaccaggccugcaggggauggaacc
    uuccagaagugggcagcugucguggugccucuugggaaggagcaguauuacacaugccauguguaccaugaggggcugcc
    ugagccccucacccugagaugggguaaggagggugugggugcugaacuggggucagggaaagcuggagccuucugcagac
    ccugaguuggucauggcucagagcugggaucauaacccucaccuucauuuccuguaccuguccuucccagagccuccucca
    uccacugucuccaacaugguaaucauagcuguucugguuguccuuggagcugugaucauccuuggagcugugguggcuuu
    ugugaugaagaggaggagacacauagguaggaaagggcagggucugaguuuucucucagccuccuuuugcagugugcucu
    gcuccuuaaugggaaacauagccacacccacauugcugcagucuccaacugggucagcugucaguuccgggaacucccuag
    ggcugguguuucucuggucucucauggcuuuucuucucacagguguaaaaggaugcuaugcucauguucuagguaagugc
    gagagaggggcaggggacacccuugucccugaggcucucaggauggagcugggauuuguuccagcccauaaucuccucuu
    gccacauccucucugucuccucugugugccuuguuaucucuucuacugcaggcagcaagagcuuccagaccucugacuggc
    cucagaaggcaugaaaaucccugggggggcuggugagauggcucaguggguaagagcacugacugcucuucugaaggucc
    agaguucaaaucccagcaaccacaugguggcucacaaccauccguaacgagaucugacucccucuucuggagugucugaaga
    cagcuacaauguacuuacauauaauaaa
    196 AW125380 uuuuuuuuuuuguucccuugaaagccagauguuccaaaaaguagccugcuccauuguucu
    ucucagucucauagcgacugccagcgucaauccacacucccaccgugcagguagcaugcg
    aggacugcuccgaggccacacgcagcccguuguccaagaugcugaccugggucuccggca
    cgcucuggagggccugggcgaagguugcgguaccccgcaaggcagguaaccucagcaggg
    ccggcgagcggcgggugcgccucgugccg
    197 U68564 Sequence below.
    ggugcuuaauguuuugaccuguagagguccucacuuuucgucauggcgcugaagguggcgauagcugcuggcggugcug
    caaaggcaaugcucaagccaacucuccucugccguccuugggagguucuggcugcccauguggccccccgaaggagcauuu
    ccucacaacaaacaauuccuccaucugcuaaguauggugggcggcauacagugacuaugaucccaggggauggcaucggcc
    cagagcucauguugcauguuaagucuguauucaggcaugcaugugugccgguggacuuugaagaggugcauguaagcucc
    aacgcugaugaggaggacauccgcaaugccaucauggccauccgccggaaccguguggcccugaagggcaacauugaaacaa
    aucauaaccugccaccaucccacaaaucucgaaacaacauccuucgcaccagccuagaccucuaugccaacgucauccacugu
    aagagccugccaggaguggugacccggcacaaggacauagacauccucauuguacgggaaaacacagaaggcgaguacagca
    gccuggagcaugagagcguagcaggagugguggagagcuugaagauuaucaccaaagccaagucccugcgcauugcugaau
    augcuuucaagcuggcccaggagagugggcguaagaaagugacggcugugcacaaggccaacaucaugaaacugggugaug
    gacucuuccuccagugcugcagggaaguagcagcccacuacccucagaucaccuuugacagcaugauuguagacaacacaac
    aaugcagcugguaucccggccucagcaguuugaugucauggugaugccuaaucucuaugguaacauugucaacaacgucug
    ugcagggcuaguuggaggcccaggccuuguggcuggggccaacuauggccauguguaugcaguauucgagacagcuacaa
    ggaacacaggcaaaaguauugccaauaagaacauugcuaacccgacugccacacugcuagcaagcugcaugaugcuagacca
    ccucaagcuccacuccuaugccacuuccauccgcaaagcugucuuagcauccauggacaaugaaaauaugcauaccccagau
    auuggaggccagggcaccacaucccaagccauccaggacaucauucgucauauccgcaucauuaauggacgggcuguggag
    gcuuagcuaucccuacaguuuugcucagcuugucuguaggacucucuucucacuuuagcacuccagcuagcuugggggac
    aggacccagaauaaagccacuucuguuccagaaaaaa
    198 AW125346 uuuuuuuuuuuuuuuuuguucuuaauagaaaacuuuauuuucacugauaaugucacugua
    acauaauuucauagcagaccugugcaaaagaucccacaucaccaaugucuccaagagauu
    ucacacacuucugggcaggacgcacagcucugcccccacccccguguugacagucaacau
    uuuacccccgcuaugaguacagaaaggcgaggcaucauaacgaagccgccugaaggcagc
    gugagcugaagucggacgcuugccaccucugaaugaauggucaccacagcaacagcacau
    gguugccucagugugcucagggugggucuuugaaaaaacgucccacuauguaaauaugcu
    gcacuuaucccuucaacauugu
    199 X61232 See above (same Accession Number).
    200 D20333 gauccuguauauguguguuuugggggagcuaugauaaguuuuauggcaaacgguugguau
    uguuaacuuuuuauugucaucaaaaguucauaaaaguccuauuaauccccauauucunnn
    ncugcccuuaacucugguauacaccaaaaagaaaucuuuacuuuccuuguuuuaucauua
    uaaaaauaaaguauuuugcuaguauggaaa
    201 AB025218 aguccgcgucccggcgucggcccgucccgcaccauggugacgcucgccgagcugcuggcg
    cugcuggccgcgcugcuggccacggccucgggcuacuuugucagcaucgacgcgcacgcc
    gaggagugcuucuucgagcgggucaccuccggcaccaagaugggccucaucuucgaggug
    gcggagggcggcuuccuggacaucgacguggagaucacaggaccagauaauaaaggaauc
    uauaaaggagaccgggaguccagcgggaaguacacauuugcagcccacauggaugggaca
    uacaaguucugcuuuagcaauaggauguccacuaugacuccaaagauaguaauguucacc
    auugacauuggggaggcucccaaaggacaagacauggagacagaagcucaucagaacaag
    cuagaagaaaugauuaaugagcuggcaguggcaaugacagccguaaagcacgaacaggag
    uacauggaaguccgggagagaauacacagagccaucaaugacaacacaaacagcagagug
    guccuuugguccuucuucgaagcucuuguucuaguugccaugacauugggacagaucuac
    uaccugaagagauuuuuugaaguccggaggguuguuuaaaaggccuuuuccuguugaucc
    caaauucaugauuuacu
    202 U84411 Sequence below.
    gcauuggcucugggcugcggccggcucggcgacgcuccucgggcagcucacugcauggucgucuggugcccccgccgccu
    gcauccccgccgccgccccgcgacgcccaccgccgccugcccugccgccgccgccugcgccgccucgggaccggcuguauga
    uuaggccacaaucuucaaugaguagacauauuccucaguucugugguguucucggucacacauuuauggaguuucugaag
    ggcaguggagauuacugccaggcacagcacgaccucuaugcagacaagugaacuguagaaauucauuacuacuccaccaaga
    aacccccauaagaguggauaaccuggacacaggcguguugaauugaaaucugcacagcauuugagaagagcucagaccugg
    augggguaaaccucagugccacuuccuuuguauugccucuaguauuacugggauugaagagucacugcuucuuguuuagg
    agguucauuucauuggcccguuucucccaauuucauacucaagcacugagaauuucaaguggaguauaucgaauaucgaag
    uagacuucagguuguuuuuugguuuuguuuuguuuuuuuuuuguuuugguuuuuuuuuuuuuuuucuguuuugguuu
    aaaucauuucuguauucaauuuuuuaauucuuucauaacccuauuggguguuuuuuuaaacuaaauuaacauggcucgaa
    ugaaccgcccugcuccuguggaagucacauacaagaacaugcgauuucuuauuacacacaauccaaccaaugcgaccuuaaa
    caaauuuauagaggaacuuaagaaguauggaguuaccacaauaguaagaguaugugaagcaacuuacgacacuacucuugu
    ggagaaagaaggcauucauguucuugacuggccuuuugaugauggugcaccaccauccaaccagauugucgaugacuggcu
    aagucuugugaagauuaaguuucgugaagaaccugguugcuguauugcuguccauugugucgcaggccuuggcagagcuc
    cggugcuuguugcccuagcauuaauugaagguggaaugaaauaugaagaugcaguacaauucauaagacaaaagcggcgug
    gagcuuuuaacagcaagcaacuuuuguaucuggagaaguaccguccgaaaaugcggcuccgcuucaaggauuccaaugguc
    auagaaacaacuguuguauucaauaaaacuggggugccugaugccauugccuuggaaguggaacuucagaugggaccugau
    uugucaugcauauuacccaaugugucggcuuacugaauaagucuacugcagcuccacaggaauacugaaaaaccagucuua
    ccaggccacaaguuugacagaauugcaaccucuauauuugggcuaugaucaacauguuuggacacuuagcaaaagauuuuu
    gcuguucagcauuuaaaaugugcuuauuauuuguaccaauugaccuuuccuaaaauaagguauugaguuaugucauuaaa
    uguacuccugugccagaauauuauuagucuauaaggaauuuagaaggauuaggugccaaaauacccagcacaauacuugua
    uauuuuuagcaucauacagaaccaaaauugcaggaacugagaacucucagaccauccaugguguauuccuucagucauuuc
    aaacacugcagggcuccucucguuaucugccugcucacucuguuuacaucucccacacuuaugccagaauacgucagguuu
    gcuuagccauccuuuauuuuuuuuauuuuuuuuuuuaacuaagucuugcgcugauuauuuaauaugucugucucauuuu
    guuuuguuuugggaaaccucugucugaaaaaucaacuuuguuacagaagcacauaucuucaacaaugucuccagacaaaaa
    gccuuauaguuaauuuaauguuugcacucagaagugcaaccuaacagggagggccugaaaaagaaacgagaggaggcuauu
    aaauauuuuuaguaauauguugccuuugucaugugcagaacauguagaguaugcucuuaauuuaguaaauauuuuuaaga
    cauagagauacauguguagcuaacccauucuuauucaaaauucuggaauuuuguguuuuccnauaccuaucaggaaguuuc
    cagcuuguuugaauuauggcuuuccucuucccaaucucuugcaaaaaagacaaagugggaugaaucugcuagugaacugag
    cagaaauguuuuauaacgccuuuugagcuauguaacuuaauaauuggauacuugaucauuuguuuuauuauguaaucgga
    uaaaauggugauguguauuaaaguuaguucaaccauauauuuauacugucugggaaugugugguuauaguucuguggga
    gaaauaguuugucaguguucaccagcuuguaaaaacuuaguaugagagcuucaacauuuaaauaaaugaugaaccgcauuc
    gucacugaggacacuuuugccuaaaauuaacuuaauuuguagaaaacaauggauucaguuaauaucauuucaauuuaugga
    aaaaauuguuaggguugccaagugcuuuuuauuaaaaguuucucuuuaaaggucuagauaauugugaaucaguugaaugu
    ugggcaccgaggggaaacaguuuguaauagaugaucuagauuuuucaguucaguuccaucagucacuuguagcucugcaa
    uuuccagaccaguuuucucauuuuuaaguucauuacaugccuguauauauuuugaaauuaacuugaaccugaguauuugg
    cacaugauggcuuaauaaauuuuaacuuuc
    203 M62362 Sequence below.
    acgcuccccaaccuccaccuccccucgcucggccucuauaugcucccgggcucccuaguguuggcuggaagugggugacuu
    agaggcuuaaaggaggggcgccuaaccacggaccacgugugugcgggggcgacagcgccgccgggguggggcugagcgcu
    gcaagccggguucgccuugcagcgcaggagucagugggcguugcgccacgaucucucuccacuagcacuaugcucccgccc
    cacucaccgccuuggaaagucacaggagaaggcgggcucuaagacccagcaggcaccauccuacuggcgccuucgauccgag
    acccguuuggacaccagggggcgaugccgacccucuauaaaagcgguccccgcgcgggccuggccauucgcgacccgaagc
    ugcgcgggcgcgagccaguuggggcacugggugggcggcggcgacagcggcgccacgcgcaggcuggaggccgccgaggc
    ucgccaugccgggagaacucuaacucccccauggagucggccgacuucuacgagguggagccgcggcccccgaugagcagu
    caccuccagagccccccgcacgcgcccagcaacgcccgccuuuggcuuuccccggggcgcgggccccgcgccgcccccagcc
    ccaccugccgccccggagccgcugggcggaucugcgagcacgagacgucuauagacaucagcgccuacaucgacccggccgc
    cuucaacgacgaguuccuggccgaccucuuccagcacagccgacagcaggagaaggccaaggcggcggcgggccccgcggg
    uggcggcggugacuuugacuacccgggagccccggcgggccccggcggcgcggucauguccgcgggggcgcacgggcccc
    cucccggcuacggcugugcggcggccggcuaccuggacggcaggcuggagccccuguacgagcgcgucggggcgcccgcgc
    uacggccgcuggugaucaaacaagagccccgcgaggaggacgaggcgaagcagcuggcgcuggccggccucuuccccuacc
    agccaccgccgccaccgccaccgccgcacccgcacgcgucucccgcgcaccuggccgccccccacuugcaguuccagaucgcg
    cacugcggccagaccaccaugcaccuacagccuggccaccccacaccgccgcccacgcccgugcccagcccgcacgcugcgcc
    cgccuugggugcugcgggccugccuggccccgggagcgcgcucaagggcuuggccggugcgcaccccgaccuccgcacggg
    aggcggcggcgguggcagcggugccggugcgggcaaagccaagaagucgguggacaagaacagcaacgaguaccggguacg
    gcgggaacgcaacaacaucgcggugcgcaagagccgagauaaagccaaacaacgcaacguggagacgcaacagaaggugcug
    gaguugaccagugacaaugaccgccugcgcaagcggguggaacagcugagccgugaacuggacacgcugcggggcaucuuc
    cgccagcugccugagagcuccuuggucaaggccauggcaacugcgcgugaggcgcgcggcugcgggaccgccuugggccg
    gcccccuggcuggagacccagaggaugguuucgggucgcuggaucucuaggcugcccgggccgcgcaagccaggacuagga
    gauuccgguguggccugaaagccuggccugcuccgcguguccccucccuuccucugagccggacucggugcgucuaagau
    gagggagucaggccguggugguuucuccuugagaccgagagacuuuuccgcggagcugagcugggggcccggcaguacua
    guauuaaggaaguaaccuugugccuuggauacucaaaacucgcuccuuuuccuaccgaguagggggagcaaaaaugugccu
    ugauauuuuauuuggaggauuccugcuuccucucgggccucagcuggcccccgugagaaaaaugaagggugcaggcccag
    ggcaggaggaagauacaggaagcugagaucccggcagugcccugagcugccccucagucccugucuuuagaggggagggac
    uuagguguuggggauuugagucuguguccucacccccagcuacagggagguggagggcuccuaaucccuugcuuuuugca
    ccuccaccuacauccccccccccccacucagcuuacaacaggccagguuuccugggugaguucauggagaaugggggcacca
    cccccagucagacagaaagcugaguugugaguuagccaugugguaggagacagagaccuagguuucugggcuuugugggg
    ugggggauaggaggacacggggaccauuagccuuguguguacuguaugucgccagccgcuguugcugaaggaacuugaag
    cacaaucgauccaucccagagggacuggaguuaugacaagcuucccaaauauuuugcuuuaucauccgauaucaacacuug
    uaucuggucucugugucccagcggugccuugugcaauggcagugugcacgucuaugcuaaaccaccauuuuauuuggucu
    uuuguuuuguuuugguuuugcucugauucuugccaaacugagacucuucacuaacggcugggggaaggagcugagugag
    gcucucauucuuuuugguuuagggauguuuggguuuuuucgucugccucccagaggaccaaugaaaugaagugggcuucc
    cccucuccccuaguuguccaaggguguauguaguagugggucuuagcuuccuccggcuaagacuuaggcuuccccacccac
    ccaaccccauccccaacggcccuggcucugggucuggaaagaaggccaccuccagccaguucauacacacaccccuguggcu
    gggagcagggcuggaccgcuuccuucucuucuuuuuuuggggggggggacacaaaguuucaugcuagaugucguaugua
    uuauaucuauaauauaaacauaucaaacucaa
    204 AA032310 gaagcucagugucgugaaauggaaaccaaaccuuggagccaucgcugaguauaaaaaaaa
    ggaagauuuauauucngcaaagaguagccgaacuggacaaaauuacuucugaaagagaua
    auuuuagacaagcauaugaagaucuucgaaaacaaaggcugaaugaauuuauggcugguu
    uuuacguaauaacaaauaaacuaaaagaaaacuaccagaugcucacauugggaggagaug
    cugaacuggagcuuguggacaguuuagauccuuuuucugaaggaaucauguucaguguuc
    ggccaccuaagaaaaguuggaagaagaucuuuaaccucucaggaggcgagaaaacccuua
    guuccuggccuuaguguuug
    205 M94087 Sequence below.
    gccgguuugaguugugcgcucgggugucccuuuccucuuccccucccgcagggcuugcggccaccauggcguauuagagg
    cagcagugccugcggcagcguuggccuuugcagcggcggcagcagcaccaggcucugcagcggcaacccccaccggccuaa
    gccauggcgcucuucacgaaauccagcagcaguguugcuguaacggacaaagauaccuucgaguuaagcacauuccuggaa
    uccagcaaagccccacaacaugaccgagaugagcuuccugaacagcgaaguguuggcgggggacuugaugucccccuucga
    ccagucggguuugggggcugaagaaagccuaggucucuuagaugacuaucuggagguggccaagcacuugaaaccucaug
    gguucuccagcgacaaggcgggcuccucggaauggccggcuauggaugauggcuuggccagugccucagacaccggcaagg
    aggaugccuuuuccgggacagauuggauguuggagaaaauggaucugaaagaguuugacuucgaugcucuguuucgaaug
    gaugaccuggaaaccaugccagaugagcucuugaccacguuggaugacacaugugaucuuuuugccccucuaguccaagag
    acuaauaaggagcccccucagacagugaacccaauuggccaucucccagaaaguuuaauaaaagucgaccagguugcccccu
    uuacauucuugcagccuuuccccuguuccccagggguucugucuuccacuccagagcauuccuuuaguuuagagcuaggca
    gugaaguugauaucucugaaggagacaggaagccugacucugcugcuuacauuacucuaaucccuccauguguaaaggagg
    aagacacucccucugacaaugacaguggcaucuguaugagcccggaguccuaccugggcucuccccagcauagccccuccac
    cuccagggccccaccagacaaucugccuucuccaggugguucccgugggucuccucggcccaaaccuuaugacccaccugga
    guuaguuugacagcuaaagugaagacugagaaauuggauaagaagcugaaaaagauggagcaaaacaagacagcagccacua
    gguaccgccagaagaagcgggcugagcaggaggcccucacuggcgaguguaaggagcuagaaaaaaagaaugaggcucuga
    aagagaaggcagauucucuggccaaggagauccaguaucugaaagaccugauagaagagguccguaaggcaagggggaaga
    agagaguuccguaauaggguagucaggugcuuugugcuuguacauagucuuguguugcuguguuugcuguaauaaauua
    uuuuguagugaaagu
    206 AI847609 uuuuuuuuuuuuuuuauguagggaaguucauauuuuauuuguccagugacauuuuuua
    caguugaauacaaguuaaaggccugcuugcacaccaaagccagguccuuugggugguuca
    gucaaagaaguaaggccuccagcuggcucacaacagaagcggccacuccuuggcccuggu
    uu
    gggaacuuuuccagcuuugaguucaucaauaaucucuucaauauccuugggugucagauc
    cucauaguaguugucauuuauuugaaccaucggugcauuuacacaggccccuaaacauuc
    cacuucuauaagagugaaaaguuugucagguguagucucuccaaccuuuauuccaa
    207 AI853294 uuuuuuuuuuuuuuuuuggggugaauauagccaaguauuccauuuauuaacaaaauagu
    cuuagcaagggagagcucuguucaccccacaagaggccccgcagccgaggccggcccgaag
    ccccagcgcugcugcguaagaccgggagggagggaagguguuggggagaagacuuguau
    u
    aagucuuuaauccuagccaccgcaggaacccacggaaaccuaaugccagcuuuggcgauu
    gcuggcucaggucugggacauggcgaagggagugcucugauccuagggcucccugaguc
    c
    ccagccugcccccaacagagcuccuaaaguugucuggucugcugacuugaggacugguaa
    gcuuuggagggauccaucaaggauuccccgaccccaccccuaucgccagggga
    208 M33934 Sequence below.
    ccucugcggcgcgguccucggagcggcgcgguucucggagccacgcgucugucuuccuccguggucauggcggacuaccu
    gauuagcggaggcaccucuuacgugccggacgacgggcucacagcgcagcagcucuucaacugcggggacggccucaccua
    caaugauuuucucauucuuccuggguauaucgacuucacugcagaucagguggacuugacgucugcucuaacuaagaagau
    uacacuaaagaccccauugguuuccucacccauggacacugucacagaggcuggaauggccaucgcgauggcgcuuacagg
    agguauugguuucauccaccacaacugcacaccugaauuccaggccaaugaaguucggaaagugaagaaauacgaacaggga
    uucaucacugaccccgugguccuuagccccaaggaucguguacgcgauguuuuugaggccaaagccaggcauggcuucugu
    gguauccccaucacagauacaggccggauggggagucgauuggugggcaucaucuccucaagggacauugauuuccucaag
    gaggaagagcaugaccgguucuuggaagagaucaugacuaagagggaagauuugguggucgccccugccggcgucacucu
    gaaagaggcaaaugagauucugcagcgaaguaaaaagggaaaguugcccauugugaaugaaaaugaugagcugguagccau
    cauugcccggacagaccuaaagaagaaucgugauuacccccuggccuccaaagaugccaagaagcaacugcuguguggggca
    gccauuggcacucaugaggaugacaaguauaggcuggacuuacuggcccuugcugguguggauguagugguuuuggacuc
    uucccagggaaacuccaucuuccaaaucaauaugaucaaauacaucaaggagaaguaucccagucuacaggucauuggaggc
    aauguagucacugcugcgcaagccaagaaccucauagaugcagguguagaugcuuugcgagucggcaugggaagugguuc
    caucugcaucacccaggaaguguuggccugugggcggccccaagccacagcaguguacaaggucucugaguaugcccgucg
    cuuugguguuccuguuauugcugauggaggaauccaaaaugugggucauauugccaaagcuuuggcucuuggggcuucca
    cagucaugaugggcucccuccuggcugccaccacugaggccccuggcgaguacuucuucucagaugggauccggcugaaga
    aauaccgagguauggguucucuugaugccauggacaaacaucucagcagccagaaccgauacuucagugaagcugacaaaa
    ucaaaguggcccaaggaguuucaggggcagugcaggacaaggggucuauccacaaguucguuccuuaccugauugcuggca
    uccagcauuccugucaagacauuggugccaagaguuuaacccaagucagagccaugacguacucgggggagcuuaaauuug
    agaagaggacauccucugcucagguggaagguggcguccacagccuccauucguacgagaaacggcuuuucugaaaacaga
    uccaguauaugccuugaauuuuucaauaaaaguuugggaaaaaaaaagugaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    aaaaaa
    209 X16202 gugugggugcagagcuggggucagggaaagcuggagccuuuugcagacccugagcugcuc
    acggcugagagcuggggucauuacccucaccuucauuuccuguaccuguccuucccagag
    ccuccuccauccacugucuccaacauggcgaacguagcuguucugguuguccuuggagcu
    uggccaucauugcagcugugguggcuuuugugaugaagagaaggagacacacagguagga
    aagggcagagucugaguuuuu
    210 AI661431 acaggaggggaaggccaaagcaagaaugaaagucccccgccccguaucaccacgggcacu
    cggggucacccucaggaacaugcagucucugcacgugaggaaagaaacacgcagagaugg
    acgagcacuuuuacacccuaauaaaauuagaugcacuaaccacagaccccccu
    211 AI839109 uuuuuuuuuuuuuuuuuaaaaaaaaaaauggcaucuuuuauucaucaaucccuguuacac
    acugaaauacaugcaucuuucuuauguuacuuagcaacguccuuucuauccuuucaccca
    uaaaucagucugaugaauucaucuuuaaauucaagaaguuuuucuuuuugaaacgcuacu
    uacauuuuauugucucaauaucaaagccaaucuagagauuuauucuuccuacaggugaaa
    uagauguuaauacgggaacagucaguacauguucaagaugacaucaaaguuaugcccuaa
    gcagauauuucaaggcaauaucaugccacuagcucugagacucuaaguaucacugauagu
    acuaaaagguagaagucagcuucaaaaacacacucuugcaauggacacugcucaugaugu
    cuaagauuguucacucccacagucaugauuucagaugcacaguuuuuuuugcuuuccuga
    gcauucgguuugac
    212 AI849135 uuuuuuuuuuuuuuuuuaagagugucaccaaagcuuuauuuacaugcgucaucaucucuu
    uuacaaacuagauuaugguuuuaaauggaauacacaggcaauaucuacaaacgccacggg
    aaguacgcaccuccauuccaccgggaaggggcagauucccaaaucaaacugguuuugauc
    cuugagaagaaaggcggcagagcuaacucacggcagcguaugguuagacaagguccucag
    uacccagaaugcagcaggauugcgucugccucaaaccagacgaccaacugcugcaggugu
    uuaaacauggccacgcgccacacgaaauucuaguuugugugggguagaagcaagaaaaaa
    aaaaaaccauggcgccucgugccg
    213 M32459 gguccggauaguaaacugcucccuuacaucuccuuaaauauaaaguaaggaaaaagaaaa
    aacucaguucggguaaccaaguucaacaaguaauccuuggggccgcugugguaucgccaa
    aaucuacauaguaucucuuauuaaaauguuuugacgaaaauguaacaauuacgguacuua
    augguaacaauguggcugaggaagcaauaguuaacaaagaggagcuaagcuaugcaacaa
    accagauuucuauuggucacaaauuugaaguugagaccuguuauccaauuaccaaguacu
    uccgcauacaucaucauaggcauuugaagauuucaaccaaucaggagcauguuccuucua
    uaaaggaacccagaaccuaaccucugcauuuccuauuucuuuguagaaauggcucguacg
    aagcagaccgcucgcaaguccacuggcggcaaggccccgcgcaagcagcuggccaccaag
    gccgcccgcaagagcgccccggccaccggcggcgugaagaaaccucaccgcuaccguccc
    ggcaccguggcgcugcgcgagauccggcgcuaccagaagucgaccgagcugcugauccgc
    aagcugccguuccagcgccuggugcgcgagaucgcgcaggacuucaagaccgaccugcgc
    uuccagagcucggccgucauggcucugcaggaggcgagcgaggccuaccuugugggucug
    uuugaggacaccaaccugugcgccauccacgccaagcgugucaccaucaugcccaaggac
    auccagcuggcccgccguauccgcggcgagcgggcuuaauaggcacgcuuucuacacugg
    cacguaaaccaaaacggcucuuuuaagagccaccuccauuauccaccaaagaugcuugaa
    guacaaguugugagaguuuucuaggguuuccuauuauagccuuucuugacaaugugagca
    ccacccgacgaagcagucugag
    214 AI841389 uuuuuuuuuuuuuuuuuggacuucugcggcuuuuauuuuugcauguaaaccacugggggg
    agggggaucuugauggugggcacccuagagauuacacuggaguuccgagggcuccagaca
    cuagcugggaagucaggugacagaaacaaugauucagaccaaucacaugauugcaaaacu
    gggucuccagcagggauucugguggucagguguggaugccuaaggaagcagugacauggg
    aggggcacgcacugggcuggccuugagcugcugggaugacaucagggauagaggaccuag
    cagcugguggcuccagggaucuccgguccaugcuuuauuuggccaggggguuccugaagg
    accugccagcaaacuuggcuuugcugcccagcucuuccucaauucugaggaucugauugu
    acuu
    215 X03039 Sequence below.
    auucuaaggaucaugucugcgagucaggauucucgauccagagacaauggccccgacgggauggagccggaaggcgucauc
    gagaguaacuggaacgagauuguggauagcuuugaugacaugaaucucucagagucccuccuccgugguauuuaugccua
    ugguuuugagaagcccucugccauccagcagcgagcuauucuuccuuguaucaaggguuaugaugugauugcucaagccc
    agucugggacugggaaaacagcuacauuugccauaucaauucugcagcagauugaauuagaucuaaaggccacucaggcuu
    ugguucuggcacccacacgugaauuggcucagcagauacaaaaggugguuauggcauuaggagacuacaugggugccucu
    ugucaugccugcauugggggcaccaaugugcgugcugaggugcagaagcugcagauggaagcuccccauaucaucguggg
    uaccccuggccggguguuugacaugcuuaaccggagauaccugucccccaaauacaucaagauguucguacuggaugaagc
    agaugaaauguuaagccgaggguucaaggaucagaucuaugacauauuccagaagcucaacagcaacacacagguaguuuu
    guugucugcuacaaugccuucugauguccuugaggugaccaagaaauuuaugagagacccuauucggauucuugucaaga
    aggaagaauugacccuggaggguauccgccaauucuacaucaauguggaacgagaggaguggaagcuugacacauugugug
    acuuguaugagacgcugaccaucacccaggcagucaucuuuaucaacaccagaaggaagguggacuggcucaccgagaaga
    ugcaugcccgagauuucacuguuucugccaugcacggagauauggaccaaaaggaacgagaugugaucaugagggaguucc
    ggucuggcucuagcagaguauuaauuaccacugaccuguuggccagaggcauugaugugcagcaggucuccuuagucauc
    aacuaugaccuucccaccaacagggaaaacuacauccacagaaucggucgagguggucgguuuggucguaaggguguggcu
    auuaacauggugaccgaagaagacaagaggacucuucgagacauugagacuuucuacaacaccuccauugaagagaugcccc
    ucaacguugcugaccucauuugaggggcuguccugcgaccuggcccuagcccaggguucaguccugggguggggcuaagg
    aagagcuggaggggggaggggagggagccaagggauggacaucuuguuuuuguuuuggcuuuuuuuuuuuuuuguuuca
    guuuuuuuucucuaugaauaaaugucacuuuuugaggc
    216 AW049795 uuuuuuuuuuuuuuuuugccaggauauauuuauuacugaaaguacaagcaacugagguuu
    acccugggaacacccacaaugaaacguguaucuucccuguuucucagaugcugccuccuu
    ccacagagugaguuuucguuuaaaacucauaaugaggagaaggcagggggcuccaccccu
    uuccuguucaaucugaagacugaauugggcuacacugggauggagauuucaggugcugca
    ggucagugucaaccaaggguucgugugucaggaacucuggcugguaagaugacacaaagg
    cuucaugcugaagcucagggagguccagggagccuggcagaauggaaucaucauggucau
    caucaaacgucugugucuggaaggcuucaaggcucauaauugcaucauucucuggcaguu
    ccugagagagcugccccuuccuggguuugcacgcaucaaauuucacccacugguaauuga
    cacaguuuugagcuucgggacaacucuuaaucagguuguggaugguuggaugagaaaacc
    caaagaagucggcaccgcauga
    217 D87691 Sequence below.
    auuguaacagaagaaggaaaggaaaagaaaguuaacauugacuuugaaccuuucaaaccaauuaauacaucauuguauuug
    ugcgacaauaaguuucauacagaggcucuuacagcguuacuuucagaugacagcaaguuugguuuuauuguaauagacgg
    aaguggugcucuuuuuggcacgcuccaaggaaacaccagagaaguccugcacaaauucacuguggaucucccaaagaaacac
    ggcagaggaggucaaucagccuugcguuuugcccguuuaagaauggaaaagagacauaacuauguucggaaaguagccgag
    acugcugugcagcuguuuauuucuggagaccaagugaauguggcugguuugguuuuagcuggaucagcugacuuuaaaac
    ugaacuaagucaaucugacauguuugaccagagguugcaaucuaaaguuuuaaaauuaguugauauauccuaugguggug
    aaaauggauucaaccaagcuauugaauuaucuacugaaguucucuccaacgugaaguucauucaagagaagaaauuaauag
    gacgauauuuugaugaaauuagccaggacacaggcaaguacuguuuuggaguugaagauacacuaaaggcuuuggaaaug
    ggagcuguacaaauucuaauagucuaugaaaaucuggauauaaugagauacguucuucauugccaaggcacagaagaggag
    aaaauucucuauuuaacuccagaacaagagaaggauaaaucucacuucacagacaaagagacuggacaggaacacgaacuga
    uagaaagcaugccucucuuggaaugguuugcuaacaacuauaaaaaauuuggagcuacacuagaaauugucacagauaagu
    cacaagaaggaucacaguuugugaaaggauuugguggaauuggagguaucuugcgguaccgaguagauuuccagggaaug
    gaguaccaaggaggagaugaugaauuuuuugaccuugaugacuacuagguagucgacauggguccggcaaccgugccucac
    ccuccagcauucaacccaaggagcauacccgugguggaguccaacagaucccugccuuacaauuggagcauuuccagaacuu
    aauccgugagcauuggauacugaaaagaaaagugaaacaaaaccagacccaacccuacacuuugguuugucguggugucag
    cgcagcagccgacaacuaagucucu
    218 AI117211 cagaggagucauuguugcugugguggcuuuugugaugaagaggaggagaaacacagcgua
    agccagcugccuggaguggacuaagugacagacaaugucuucacacaucuccugugacau
    ccagagcccucaguuuucuuuagucaaguaucugauguucccugugagccuaugggucaa
    agugaagaacugugcagcccagccugcccugcacacagaacccugucccugcacugcccu
    ggguucccuuccacagccaaccuugcugcuccagccaaacacugggcgacaucugcaucc
    ugccagcuccaugcugcccugagcugcagcuccucacuuccacacugagaguaagaaucu
    gaaugggaccuugauucuuaacauccugaccgaggguugauuucuuguuaauuucaugga
    uugagaauacuuagaguuuugguuugucuugauuuuuuuucaag
    219 Y00520 ugaauaaaaacgaggagccgaagauucuagggggcuacagcugcgcuuuugcagcacuga
    acaugguuccggguacucaagauauugcguuuguguuuggagagguguagauuguagauu
    ccagccgagaagaccaggaaaagauaaggauaaagaaugucauauaucucaggagcuaga
    ucacuucccgaugaacaaguaagaauugccucaacaaaaauggauggaauuggaccgaaa
    aaagccauucagcuucguuaucgauuagguaucagugggaacaucaagaugaaugaguua
    acuaaguaucagaucgaccaaauugaacaaaugauagcucaagaucauguuguucauugg
    gaauugaagaggggagaacgagcagacaucgaacgauuaauuucuauuucucguuaucgu
    ggaauucgucaucaagauggaucgcccuuacgcggucaacgaacucauacuaaugcaagg
    acugcucgcaagcaaauucggaaaugaaagaaggcuaccgaaagaacaagcaacggauuu
    cgcgcucaucccuugcuaaagcgcauacguuuucuugcuccuugguacuugucugaucaa
    ucacacuguucauuaguucacuugauuuuucguucgaugucuugaaccgcuuacuaauca
    cguauacguauaguaggcccccuucgccacuccacgucuggcccgucuuggucucgcuca
    cuucgcccgccuaucguaucggcucggcuucguccgucaagcgacagcuucugccucuga
    cggcuucacuaucgcucaugacugguaguacucuauguaguagucggccuuuguuaagcu
    u
    220 AA638002 uauaaccauguuagaagcggaaguuggccugaaaaccugaggcuuaggcuucauagcugg
    gcuguagauuggauuuaaacccaguuggagugcaaagucauggugugcucaaggugauga
    cagugaacagaguaug
    221 Z22661 caugggccuccugagaga
    uccuuagauccagguuagugcauaggaaaguguccccccacuaccuacagcuaagggauu
    gggguggugggaucaugguggagggccguggugaauacuagcgaugucccccgcuacccg
    ugcgucugccuccagggugccccuccaaccaggaugaggcucuucaucgcucuuccuguc
    cugauuguggucguagccaugaccuuggaagguaagaaagagccuuggaagguaagaaag
    augcuuggaagugugaaguuggccuugugccugcggcccaggcuuagaagacccucgagg
    agggcucugaggucccuuucugugucaucauuccacuaccgcccucccaucgucccccau
    cccaccugccaggugccuuauuuuugugucaaagugggugcugaaggaggcaacucuguc
    cagaaaagacgcaguaaccaaugaccuaggauaccacccuuuggaauuggcuaaucuucc
    uagaaggggcggacgguaaaaacaaggaggugagaggugcaguaaaaucaaguguccaau
    acccucccccaugcuaaugaguuugcucgcaacccucucgcggcaggcccagcccccgcc
    caggcggccccggauuuguccggaacauuggagagcauaccggauaaacugaaggaguuu
    gggaacacuuuggaagacaaggcccgggcagccauugaacauaucaaacagaaggaaauu
    uugaccaagacccg
    222 X99644 Sequence below.
    cagcgccuggggcgcggcgggcgucggcccaggagacgcguggcggcgcucggccucgcggcaucggcggcugccuggcc
    guuggcggcgagcgcacuugcgccugcgcagcgggguccgugccccuccuccccugggcggcccccccacccccccggcgg
    cgugugaauggcggccucggcggcagcgacugcagcggccucggccgcgacggccgccucggcggccucugguagcccagg
    gucgggcgagggcucggcgggcggugagaagcguccggcugcuuccucagccgcggcggccucugcagccgcgucguccc
    cugcggggggcgguggcgaggcgcaggagcuucuggagcacugcggcgugugucgcgagcgccugcggcccgagcgggau
    ccucggcugcugcccugucuacauucggccugcagugccugccugggccccgcuacacccgccgcagcgaauaauucgggg
    gauggcggcucggcgggcgacggcgcuaugguggauuguccagugugcaaacagcagugcuacuccaaagacaucgugga
    gaauuauuuuaugcgugauaguggcaguaaggccucuucugauucccaggaugcuaaccagugcugcacuagcugugaag
    auaaugccccagccacuagcuauuguguggagugcucugaaccacuuugugagaccuguguggaggcucaccagcgggug
    aaauacaccaaggaccacacugugcgcuccacaggaccugcuaagacucgagauggagagcgaacagucuacuguaaugugc
    acaagcaugagccccucgugcuguucugugagagcugugacacacucaccugccgcgacugccagcucaacgcucacaagga
    ccaucaguaccaguuuuuggaagaugcagugaggaaccaacguaaacucuuggcuucacuggugaaacgucuuggggacaa
    acaugccacacuucagaaaaacaccaaggagguucgaagcucgauccgccaggugucugaugugcagaagcgagugcaggu
    ugaugucaagauggccauucugcagaucaugaaggagcugaauaagcggggucgaguucuggucaaugaugcccagaagg
    ugaccgagggucagcaggaacgucuggagcgccagcacuggaccaugaccaaaauucagaagcaccaggaacacauuuugcg
    uuuugccucuugggcucuggagagugauaacaauacagcucucuugcucucuaagaagcugaucuauuuccagcugcauc
    gggcccucaaaaugauuguggauccuguggagccucauggugagaugaaguuucagugggaucucaaugccuggaccaag
    agugcugaagccuuuggcaagauuguggcugagcguccugguacgaacuccacagguccugggcccauggcuccuccaaga
    gccccaggcccucuaagcaagcaagguucuggcaguagccagcccauggaaguacaagagggauauggcuuugggucagau
    gaucccuauucaagugcagagccgcauguaucaggcaugaagcggucccgcucuggugagggagagguaaguggccucuu
    aaggaaggugccacgugugagccuugaacgccuggaucuggaccucaccucugacagccagccaccagucuucaaggucuu
    uccuggaagcacuacugaggacuacaaucugauuguuauugagcguggugcugcugcagcagcugcuggucaggcuggga
    cugugccaccaggagccccuggugccccaccccuuccuggcauggccauugucaaggaagaagagacagaagcugcuauug
    gagcucccccggcugcccccgaggguccugaaaccaagccuguguugaugccucugacugaagguccuggugccgagggac
    cucgucuagcuucaccuaguggcaguaccagcucaggcuuggaggugguggcuccugagguuacuucagccccaguaagu
    gggccagguauccuggaugacagugccacuaucugccgagucugccagaaaccaggugaccuggucauguguaaccagugc
    gaauuuugcuuccaccuggauugccaccucccugcccugcaggauguuccaggggaggaauggaguugcucacucugccac
    gugcucccugaccuaaaggaggaagauggaagccucagccuggauggagcagauagcacuggugugguagcuaaacucuca
    ccagccaaccagcggaaaugugagcguguucuccuggcccuguucugccaugaaccaugccgucccuugcaucagcuggcu
    accgacucuacauucuccauggagcagccuggugguacccuagaccugaccuugauucgugcucgccuccaagagaagcug
    ucaccuccuuauagcuccccccaggaguuugcucaagaugugggccgcauguucaaacaguucaacaagcugacugaggac
    aaggcagauguucaguccaucaucggcuugcagcgcuucuuugagacacgcaugaaugaugccuuuggugacaccaaguuu
    ucugcugugcugguagaaccaccaccauugaaccuucccagugcuggccuaaguucucaggagcucucuggcccuggugau
    ggccccugaagcuggggcucuuguggucagcccaguccagcucuggucucuguauuuucaccccauacccuguccuuugg
    uggccugacuccuguucuugcuggccccaucguccccucagucccucuucacaaaaugguuuuuacuucuguggauuuaa
    uaaaaacuucacugagucaguuaaaaaaaaaaaa
    223 AI843895 uuuuuuuuuuuuuuuuuaaaaauaauuucauuuuuuaauauucuguacaaaauuucucaa
    ccuaugaaaauaaaguuugcaaaagucaaaguaguacaugggccugcccuggagccaggc
    ccagccggaucuacacuauguacaggucucccagggugagccucagcuagggaaaagcca
    cuaaggugccuacagagcaagagggugccaucgggccagugcagccucugcaauuuccag
    aucugccacuagaggucggcaugguccugauugcuugucaggcucacccucuggaagacc
    acagccaaugacaaagguccucaagggaaagcuuuggggucuagcuggaagugacggugg
    guccgccgcccaggcgcaggagcaucugcuggcaguccagcaguaaccggugaucgccaa
    224 M38724 uccgucguaaccuguugaguaacuauggaagacuauaucaaaauagagaaaauuggagaa
    gguacuuacggugugguguauaaggguagacacagagucacuggccagauaguggccaug
    aagaagaucagacuugaaagcgaggaagaaggagugcccaguacugcaauucgggaaauc
    ucucuauuaaaagaacuucgacauccaaauauagucagccugcaggaugugcucaugcag
    gacuccaggcuguaucucaucuuugaguuccuguccauggaccucaagaaguaccuggac
    uccaucccuccugggcaguucauggauucuucacucguuaagaguuacuuacaccaaauc
    cuccagggaauuguguuuugccacucccggcgaguucuucacagagacuugaaaccucaa
    aaucuauugauugaugacaaaggaacaaucaaacuggcugauuucggccuugccagagcg
    uuuggaauaccgauacgaguguacacacacgagguagugacgcugugguaccgaucucca
    gaaguguugcugggcucggcucguuacuccacuccgguugacaucuggaguauagggacc
    auauuugcagaacuggccaccaagaagccgcuuuuccacggcgacucagagauugaccag
    cucuucaggaucuucagagcucugggcacuccuaacaacgaaguguggccagaagucgag
    ucccugcaggacuacaagaacaccuuucccaaguggaagccggggagccucgcaucccac
    gucaagaaccuggacgagaacggcuuggauuugcucucaaaaaugcuagucuaugauccu
    gccaaacgaaucucuggcaaaauggcccugaagcacccguacuuugaugacuuggacaau
    cagauuaagaagauguagcccucuggauggaugucccugucugcuggucguaggggaaga
    ucg
    225 AW122989 uuuuuuuuuuuuuuuuuacuaggcaaagaauuuuauuaacccuuuccaaacuuuauuccc
    aggcuucuucagcuuuauuugccgcaaagaaugaauuagguauagcgaaaacugaaaaga
    gcugcaguguccgggggcuugggcuuaaaaauauuagagaucuagauuuuaucagaucca
    uaauaaacaaaaaaauuuuaaaaagcagucaugauauaaaauagcagcuccuguaauuuc
    ugcaaguaucaccuucuucagaaguugcuucaauucaguuugccucauucuuagaagccu
    caucaaaauucuccaccagaucuggaacuucaucaucaucauccucuccaguagcaaggg
    gugcuuuuccauccacagauuguuugggcagagcuucagccagucuccuuaaacuaguca
    ggcugucugcaccaagcugguugaggaugcugggaagcauuucugucagcugcuuuguc
    226 AI844810 uuuuuuuuuuuuuuuuuauucaugcuugccuagggauggggaauagaucauucaauaaaa
    acauacaguaaaaacaggggguggggagggggaaggcuuaucauguacaauguuuaaacu
    acaauagugauguaccuuaauuacuuccaugcacacaagucuaacauuacaaguuuuuaa
    aaaauaaacaccauuaagacuucuaggagcauuuuauaauaaauuccuaauuuuuucuuu
    guagauagaucaagcaccuccaaaauacagauuccuauacacagugagcacuuuacuuaa
    cguacauggacagccucaggacgagcugacgucucggaucagcucggcaggcaacaaacc
    auagugccaaauggaaagaagggcaguugcaaauaaacuuaaaacuaaguuaacuuuuau
    aauuaaauacagaaaauauacugauuugcuaaaaauaaauaagaugugauguauuuaaca
    cuucacuauaaagaaugaacaccaugacauccucgugccg
    227 AA940430 agaagaaggaggagugggaccgcaagcaugaggaugcuaguagggaguaugagaaaggca
    ugaaagaguaugaaggaggaagaggggacucaucuaaaagggacaagucuaagaagaaaa
    agaaaguaaaagcaaagauggaaaaaaaguccacuccuucccggggcucgucauccaagu
    cuucauccaggcaguugagugacagcuucaagagcaaagaguuuguguccagugaugaga
    gcucuucaggcgagaacaagagcaaaaagaagaggaggcggacgaggacucugaagagga
    gcuagccaguaccccuccaagcucagaggacucugccucgggaucugaugaauaaaggag
    ggaauucccaccccgucacagcuccagucucucacauaguccuuggauucugugccaucu
    gaguaacugcucuugguggcuuccacugcccugaggcuuugagggaag
    228 M38381 Sequence below.
    aucgucguaaucguuugcagacuucucgccgucgccuuguaagcuuugucuucgccuugcaagcuuugucuucaggguug
    gaaagaugagacauucaaagagaacuuacuguccugacugggaugaaagagacugggauuauggaacauggagaagcagca
    gcagucacaaaagaaagaagagaucacauagcagcgcccgugagcaaaagcgcugcagguacgaucacuccaaaacgacaga
    cagcuauuaucuggaaagcagauccauaaaugagaaagcuuaucauagucgacgcuauguugaugaauacaggaaugacua
    caugggcuacgagccagggcaucccuauggagaaccuggaagcagauaccagaugcauaguagcaaguccucugguaggag
    uggaagaagcaguuacaaaaguaaacacaggagucgccaccacacaucgcagcaccauucacacgggaagagucaccgaagg
    aaaagaucgaggaguguagaggaugaugaggagggucaccugaucugucagaguggagacguacuaagugcaagauauga
    aauuguugauacuuuaggugaaggugcuuucggaaaagugguggaaugcaucgaucauaaagugggagguagacguguag
    caguaaaaauaguuaaaaauguggauagauacugugaagcugcucaaucggaaauacaaguuuuggaacacuugaauacaa
    cagacccccauaguacuuuccguuguguccagauguuggagugguuugagcaucgaggucacauuugcauuguguuugaa
    cuucuggggcuuaguacuuaugauuucauuaaggaaaacaguuuucugccguuucgaauggaucauaucaggaagauggc
    auaucaaauaugcaaaucuguaaacuuuuugcauaguaauaaauugacucauacagacuugaagccugaaaacaucuuauu
    ugugaagucugacuacacagaggcuuauaaucccaaaaugaaacgugaugaacguacuauaguaaauccagauauuaaagu
    gguggacuuuggaagugcaacauaugaugaugaacaccacagcacauugguaucuacaagacauuauagagcaccggaagu
    uauuuuagcccucggguggucacagccaugugaugucuggagcauaggauguauucuuaucgaguauuaucuuggauuua
    caguuuuuucgacucaugauagcagggaacauuuagcaaugauggaaaggauucuuggaccacuaccaaagcacaugauac
    agaaaaccaggaaacgcagauauuuccaucaugaucgauuagauugggaugaacacaguucugcuggcagauauguuucuc
    ggcgcuguaaaccucugaaggaguuuaugcuaucucaggaugccgaacaugagcuucucuuugaccucauugggaaaaug
    uuggaguaugaucccgccaaaagaauuacucucaaagaagcccuaaagcauccuuucuuuuacccacuuaaaaagcauacgu
    gauuuauaaacacagugcucugaaaggaaucuuacagacuguaucagucuagcuuuuaauuaaguuauuuuguauagcuu
    aauuuguaaaacauuuuauguuuuuuagaugcuuuauuaaauacauggccaaaccaaauaacaucuuucaguaauuauaga
    augauuuauuuggaauaaaauuugugcuuaugaauguaaaaaaa
    229 AF014371 ggacucgcgacaagcguccucagcgcgaagaggcggacucggaguccucgccuugagccu
    ugcaucugagaaguuccagguacuuuguacaacugcaucccagaaccuguguguuuucag
    caccuuuauaagugauggcugccaucaggaagaaacuggugauuguuggugauggagcuu
    gugguaagacaugcuugcucauagucuucagcaaggaccaguucccagaggucuaugugc
    ccacgguguuugaaaacuauguggcggauaucgagguggaugggaagcagguagaguugg
    cuuuaugggacacagcuggacaggaagauuaugacugccugaggccucucucuuauccag
    acaccgauguuauauugauguguuuuuccauugacagcccugauaguuuagaaaacaucc
    cagaaaaauggacuccagaagucaagcauuucuguccaaaugugcccaucauccugguug
    ggaacaagaaggaccuucggaaugacgagcacacgagacgggaguuggccaaaaugaagc
    aggagccgguaaaaccugaagaaggcagagauauggcaaacaggauuggcgcuuuugggu
    acauggaguguucagcaaagaccaaagauggagugagagagguuuuugagauggccacga
    gagcugcucugcaagcuagacgugggaagaaaaagucugggugccucaucuugugaagcc
    uugugaacgcagccucaugcgguuaauuugaagugcuguuuauuaaucuuaguguaugau
    uacuggccuuucauuuaucuauaauuuaccuaaga
    230 Z30939 uucaagaccgaccugcgcuuccagagcucggccgucauggcucugcaggaggcgagcgag
    gccuaccucgugggucuguuugaggacaccaaccugugcgccauccacgccaagcguguc
    accaucaugcccaaggacauccagcuggcccgucgcauucguggggagagggcguaaauu
    aggguagugagugaauuuggaccccaaaggcucuuuucagagccacccacauuuucuaua
    aaaggcuguauaucgauaagcuuuuauaaaccccacucagcaacucc
    231 U28208 uuaugugauaaaaaaauucaacuugguauuaacuuaacuaagggccuuggugcuggugcu
    uugccugauguugguaaaggugcagcagaagaaucaauugaugaaauuauggagcauaua
    aaagauagccauaugcucuuuaucacagcagggauggguggugguacuggaacaggugcu
    gcaccgguaauugcaaaagcagccagagaagcaagagcgguaguuaaagauaaaggagca
    aaagaaaaaaagauacugacuguuggaguuguaacuaagccguucgguuuugaaggugug
    cgacguaugcgcauugcagagcuuggacuugaagaguugcaaaaauacguagauacacuu
    auugucauucccaaucaaaauuuauuuagaauugcuaacgagaaaacuacauuugcugac
    gcauuucaacucgccgauaauguucugcauauuggcauaagaggaguaacugauuugaug
    aucaugccaggacugauuaaucuugauuuugcugauauagaaacaguaaugagugagaug
    gguaaggcaaugauugguacuggagaagcagaaggagaagauagggcaauuagugcugca
    gaggcugcgauaucuaauccauugcuugacaauguaucaaugaaaggugcgcaaggaaua
    uugauuaauauuacuggugguggagacaugacucuauuugaaguugauucugcagccaau
    agagugcgugaagaaguggaugaaaaugcaaauauaauauuuggugccacuuuugaucag
    gcgauggagggaagaguuagaguuucuguucuugcaacuggcauugauagcuguaacgac
    aauucaucuguuaaucaaaacaagaucccagcagaggaaaaaaauuuuaaauggccuuau
    aaucaaauuccaacauuagaaacaaaagaauaugcuucaacugag
    232 AV218217 ugaucaggucacauuccggugccuuccacccccuauggcacgggcgccccgccuugccau
    accacagcucccuccaggcuuagaccuggcuucaccgcauuucaggugcuauaccccccc
    cugcuuuuccccccauugcccuuaaaugccccucggccccuccauccccccggaacaggg
    uggcacuugccacucucaggaccaccuugccaaggagaauaaaccgaauccuguugcu
  • Thus, the transcripts identified in this Example, the proteins they encode, and the pathways in which the proteins participate contribute significantly to HF stem cell activation. Accordingly, anagen can be induced by activation of these transcripts, proteins, and pathways.
    • Example 9 Molecular Pathways Activated During Induction of Epidermal Cells to Differentiate into HF Stem Cells
  • The gene expression pattern of HF stem cells was analyzed as described in Example 8 and compared to non-bulge basal keratinocytes. 157 genes were differentially expressed in the HF stem cells, as assessed by microarray analysis and quantitative polymerase chain reaction (qPCR). A group of selected genes with increased expression in HF stem cells is depicted in Table 4. A group of selected genes with decreased expression in HF stem cells is depicted in Table 5.
  • TABLE 4
    Genes up-regulated in HF stem cells. Numbers in parentheses are the fold increase
    as determined by quantitative real time PCR.
    Gene Name/
    Protein
    name/ SEQ
    GenBk Fold ID
    Acces #. Incr. Sequence No.
    Cell surface proteins
    Cd34/Cd 34  43 uuuuuuuuuuuuuuuuucacucaucacguuuauucagaagagaauaca 233
    antigen (189) cccaauccucucaucucuggaaaguuuuguuccuagccaucauuaagau
    AI847784, caggaccccuguucuccccuuaaccccaggagaggaagcuuauagucuu
    AI173145 uguagauauucugaaccucugaucacaaaggguuauaaaauagugaagg
    gguuuggacuaggaaaggcacagacugaaaggaaucugccaggggacug
    aggccacagcucccccaggagucagaggaagggggaagucacguauuuu
    auagaaggccaagggccucagagcaagaguauuccuuugaagagcuca
    Calcium-related
    S100a4/  35 ugguggagcaggucucaggaaucucuucgcuucagcuucaaucauggcc 234
    S100A4 (144) uguggucuggucgccagcaaccugaaucucaaaccuggggaaugucuca
    (mts) aaguucggggagagguggccucggacgccaagagcuuugugcugaacc
    X15986 ugggaaaagacagcaacaaccugugccuacacuucaauccucgcuucaau
    gcccauggagacgccaacaccauuguguguaacaccaaggaagauggga
    ccuggggaaccgaacaccgggaaccugccuuccccuuccagcccgggag
    caucacagaggugugcaucaccuuugaccaggcugaccugaccaucaag
    cugccagacggacaugaauucaaguuccccaaccgccucaacauggaggc
    caucaacuacauggcggcggauggagacuucaagauuaagugcguggcc
    uuugagugaagccagccagccuguagcccucaauaaaggcagcugccuc
    ugcu
    Transcription Factors and related genes
    Id2 helix-  11 (25) gugguucuucggcgccagguucgcccgcuucugcccuuagguaacauu 235
    loop-helix cucuaaacugcguuucucucccaaucuuuugcaggcauuuggggacuu
    protein uuucuuuucuuuuuacuuucucuuuuucuuuugcacaagaagaagucu
    AF077861 acaagaucuuuuaagacuuuuguuaucagccauuucaccaggagaacac
    guugaauggaccuuuuuaaaaagaaagcggaaggaaaacuaaggaugau
    cgucuugcccaggugucuuguucuccggccuggacugugauaccguua
    uuuaugagagacuuucagugcccuuucuacaguuggaagguuuucuuu
    auauacuauucccaccauggggagcgaaaagguuaaaaaaaagaaaaaaa
    ucacaaggaauugcccaauguaagcagacuuugccuuuucacaaaggug
    gagcgugaauuccaggaggacccaguauucgguuacuuaaaugaagucu
    ucggucagaaauggccuuuuugacacgagccuacugaaugcuguguaua
    uauuuauauauaaauauauauauauugagugaaccuuguggacucuuu
    aauuagaguuuucuuguauaguggcagaaauaaccuauuucugcauuaa
    aauguaaugacguacuuaugcuaaacuuuuuauaaaaguuuaguuguaa
    acuuaacccuuuuauacaaaauaaaucaaguguguuuauugaauguuga
    uugcuugcuuuauuucagacaaccagugcuuugauuuuuuuuuaugcu
    auguuauaacugaacccaaauaaauaccaguucaaauuuauguagacug
    uauuaagauuauaauaaaaugugucugacaucaa
    Id4   4 (12) cgaugaaggcggugagcccggugcgccccucgggccgcaaggcgccguc 236
    AJ001972 gggcugcggcggcggggagcuggcgcuacgcugccuggcggagcacgg
    ccacagccuggguggcucggcagccgccgccgccgcugcggcggccgcg
    cgcugcaaggcggccgaggcggcggccgaugagccggcgcugugccugc
    agugcgauaugaacgacugcuacagucgccugcggaggcucgugccuac
    caucccgcccaacaagaaagucagcaaaguggagauccugcagcacguua
    ucgacuacauccuggaccugcagcuggcgcuggagacucacccugcuuu
    gcugagacagccgccaccgcccgcgccaccucuccacccggccggggcuu
    guccggucgcgccgccgcggaccccacucaccgcgcucaacacugacccg
    gugagaagccuuggcgggcacccugggcaucgcgggaaagguggcggg
    gcggcgagauacggguggucuugcuccucucagggaaugacagccgcu
    ucucccgucuccaccgagagccgccugcugggcuuggugauccacuggu
    cccugagccgagggcgguugggcuuggagcccugcgucuccggagugu
    cccuugcaucacaggaggcuuccccagcuucgggcucggguggggacuc
    ugcucaccugccuaguuuuccaggacgucuccugggugguggcgacac
    ugugauaugcgcacucuaaccgcuuuuccccuugguguuggguugcug
    uuccaggccggcgccgugaacaagcagggugacagcauucucugccgcu
    Peg3/  12 Sequence below. 237
    Paternally
    expressed
    gene 3 zinc
    finger
    protein
    AF038939
    acuagucucgaccauguaccaucacggagacgacaccaacagugacaugaacagugacgacgacaugagccgaagugggaga
    gaaaccccacccccucgaccaucucaugcuuuuggcagugagcgagaccuggagcgcaggggcagaagcagagauguggag
    ccucgagaccgcuggccauacaccaggaaucccagaagcaggcugccucaacgggaucuuucucuuccugugaugucaaga
    ccacauuuuggacuggacagagaugaugacagacguuccauggauuaugagucucgaucccaggaugccgagucauaccag
    aauguuguggaacucaaagaggacaagaagccucagaauccaauucaggacaaccuggagaacuacagaaagcugcucucgc
    ugggaguccagcuugccgaagaugaccgacacucucacaugacacaaggccacucaucgagguccaagagagcugccuaccc
    aagcaccagccgaggucucaaacccaugccugaggccaaaaagccaucccacaggcgugggaucugugaggacgagucuucu
    cauggagugauaauggaaaaauucaucaaggauguggcucgcaaccccaaauccggaagagcaagggagcugaacgagcgu
    ccuccuccaagguuccccaggccuaaugauaacuggaaggacaguuccuccagcagaagagagucagugauccaggagagg
    gguuaugaagggagcgcauuuaggggcggcuuccgguucaacgcagaccuggcuuccagaagcagagcucuagaaaggaag
    aggcguuaccacuuugauucugaugagcgggguucgggccaugagcauaaaagcugugugaggaagaagccuuuugagug
    uggugcugagaugagacaggcuaugagcaugggcaaccugaacagcccuuccuucucugagucgcagucaaucgauuuug
    gggccaacccauacgugugugaugagugcgggaggcaguucagugucaucucugaguuuguugagcaccagaucaugcac
    acuagggagaaccucuaugaauauggagaguccuuuauucauagcguggcugucaaugaggugcaaagaagucagggugg
    ggggaaacgcuuugaguguaaggaauguggagaaaccuucaguaggagugcugcccuggcagagcaccgccaaauccaugc
    uagagaauaucuugcagaauguagagaucaggaggaugaggagaccaucaugccuagcccgaccuuuagugagcugcagaa
    gauguauggcaaagauaaguucuaugagugcaaggugugcaaggagaccuuucugcacaguuccgcccugauugagcacca
    gaaaauccaugguagaggcaacucagaugacagagauaaugagcgugaacgcgaacgugaucgucuacgugcacgugcacg
    agagcagcgugagcgcgaacgugaacgggagcgugagcgugagcuuggggaacccuuucugaccuguccaaacuucaauga
    guuucggaagauguacaggaaagacaaaaucuaugagugcaaaguguguggggagagcuuucuucaucucucaucccuga
    gggagcaucagaaaauccauacuagaggaaacccauuugaaaauaagagcaggaugugcgaggagaccuuugucccuaguc
    agucucuccgacggcgccagaaaacuuacagagagaagcuguucgacuuuaacaaugccagggaugcacugaugggaaacu
    cagacuccagcgagcaucagaaaaaccguucccgaaggaacuucuuugagggcagaggauuugagaaacccuucguugaau
    cucagaagagucauacuauaacaagaccaccugaaaacaaagacgaugacaagccguucacaaucagugucaacccuaaugac
    aagcugaaacuccccaucauggaaaauggcucccagggcaaauccugugagaggucuguuauucauagcuugggcuccgca
    gaagcucagaagagucaugguggacugggguucaguaaaccaagaccaguggcagagucuagcacccagagcucaagcagc
    auuuacuaccccagagcacacucuggaggcaacaccuaugaaggaaaagaauacaaggacucuaucauccauagcuugccag
    cuccucgaccucugaaacgucauagagcaaaugaccauauucaaugugaugaggggggagaauccuccauuuauaucccag
    auauuauuaauaagggaaggaagauuccugccagagaagaugcuuaugaaggaaguagcagcagcaacuaccacacaccaaa
    uguaucccgugcugagccuccaagucuuucuggagagucccaugacucuaagcaggaugucacguuuucaguucccagcuc
    aaguguucgugaacaccagaaagcucgugccaaaaagaaguacauugagcccaggaacaacgagaccucuguuauccacucc
    cuaccuuuuggugaguugcuugcaggucaccguagggcaaaguucuuugagugucaggaaugcggggaggccuuugcucg
    uaggucugagcucauugagcaccagaagauucaugauagagaaagaccuucuggaagccgacauuaugagcgcucugucau
    ccgcagccuugcgcccagugacccucagaccaguuaugcccaagaacguuucauccaagaacaagugcguaaauucagagcg
    uuuggacaacgcucaacuaccagcaacaaccucaguguacagaaaaucuaugcccaagagacauuuaaugccgaggagcccc
    augauaaagaaacucauggucaaaaaauucaugacaaagagccauaugguaaggagcccaguggcaaggagccccaugguga
    ugagccccaggacaaagaaccccuuguucaggagaugcgcagugaagagccccaugaugauaagccccauggccaggagccc
    caugaugauaagccccauggccaggagccccaugaugauaagccccauggccaggagccccacggugaugagccccauggcc
    aggagccccacggugaugagccccaugacaaggaacccauugaucaggagaugcgcagugaagagccccacagugaagaguc
    ucauggugaugagccccauggugaagagucccauggccaggagaaaguugaagaugcuaccauucaggccucaguuucuga
    agagcaucagaaagaugacgcuggugaugcaaucuaugaaugccaggacugugggcugggcuuuacugaucucaaugaccu
    cacaagccaccaggacacccauagcagaaaggcucugguugacagucgugaauaugcacauucugaaguucaugcccacucc
    gucagcgaauuugagaaaaaaugcucuggagagaaacuauaugaauguccaaaauguggggagucuuucauucacagcucg
    uuacuuuucgagcaccagagaguucacgaacaagaccagcuguauuccguaaaggccuguuaugacgcuuucaucgcucug
    uugcccguuagaccaaggagaaauugcacuguugaaaggaauccugccguuucugggucagccauucgaugccgucagug
    uggacaaggcuucauucacaguucugcccuaaaugagcacaugagacagcacagagauaaugaaauaauggaacagaguga
    gcuuucagaugagauuuucauucaaggccuagcccucacugaguaucaggggagugaaacagaagagaagcuuuucgagug
    cacaaucuguggggaaugcuucuucacugccaaacagcucggggaccaccacaccaaaguucacaaggaugagcccuaugag
    uaugggcccuccuacacccaugccuccuuucucaccgagccccucaggaagcacaucccacuguacgaaugcaaagauugcg
    gccaguccuuccuagacgacacugucaucgcugagcgcaugguguuucauccugagcgagaaggugggucagaaauaguag
    cugccacugcccaagaggucgaagccaauguccucaucccacaagaaguacugcgaauccaggggucaaaugcagaagcugc
    ugagcccgaaguggaggcugcagagcccgagguggaggcugcagagccugagguggaggcugcagagccuauuggagagg
    cugaagggccagauggagaagcugcugagccugauggcgaggcugagcagcccaauggagaggcugaacagccaaacggug
    augcugacgagccagacggagccgggaucgaagacccagaagagagagcugacgagccugaggaagacgucgaagagccag
    agggagaugcagaugagcccgauggugcagacauugaagacccagaagaggaaggagaagaucaagagauugagguugaag
    aaccauacuacaacugucaugaaugcgcagaaacguucgcuuccagcucagccuuuggcgagcaucugaaaagucacgccag
    ugugaucaucuucgagccggccaaugcuccuggagagugcucuggcuacauugaacgggccagcaccagugcagguggug
    cggagcaggcagacgacaaguacuucaaaugugaugugugcgggcaacucuucaacgaccgccucucccuugccagacacca
    gaauucucacacugguugaguaaccaggcugaagaaaagaagagcaaagccaaaccuucuucccagaaccagacccuuaaua
    aaucacaaagagagccuaaaccaacccauaaugucuauaagaaauucaccuuccuguauacauaccggacuucacaucaaaga
    cuuucacucucaucacagacugaaaaaagaaaagacauugaacgcagggacucuuucaguuuuagcuguucccuauggaac
    aucaguguauauuugggaaagcuagagugaacaucuacaucuuccauuucaucuaaguaacuagauugagggaaaccuagu
    gacaauuccagaccacagagguugccccagucgacuguaaaugauaccccuuucauacccuauacauaaugauuccugccau
    guauauaaaugagcaaaucagugauacauauauuuggauuuagugugcuauagaauuuacaguuuacucuacagagcuacc
    uagccugguacucugauuuuuucccugaggaggaagagagcaacaauuuagcauauauuuguaaguauuguccaugcaga
    agcuuuucugugcaucauuugaaccccauuaguauccuuuccaguaauggaguguucuguccccuaccucuuagauagucc
    ugugaaggugugggugugaaagaucgugugucuuugaauccuggcuguguggaaacaggcauuuuagcuucuacagccau
    uuggugugcacccagaccccuugagacugauuguguaacccuuuacaauauauggauuugucucugugacccaaaucaacc
    caucccuacauuuauauaccuuacagugguuuucuugc
    Growth Factors, Receptors and Related genes
    Fz2/   9 (17) uuuuuuuuuuuuuuuuuaccguucuuuauuuaaaaaaauaaaauagga 238
    Frizzled 2 guccguagggugcacccuccccccuccugagugaaggagggcacggugc
    AW123618 aguccggaccugggagaggggaaagcccggcaggcaggcgagaccgcuu
    cacacaguggucucgccaugccggcuguuggugagacgaguguagaacu
    uccuccacgagugcagugucuugccggaccagauccagaagcccgacgu
    gaugcccacgaugagcgucaugagguauuugaucauguagacugugaa
    gucgggcgacaugcggggcguguagugggccgggcaggggauggcuag
    gcucuugcagugcuggcuuacccaggagcgcucccagugcucgcggaag
    gccugcucauagaaguagcaggcgaug
    Dkk3/   6 (22) Sequence below. 239
    Dickkopf 3
    AJ243964
    ggccgcgucgacgccucuccagcugcucuguggcagcccagcuaccggucgugaccagauccagcuugcagcucagcuuug
    uucauucgaauugggcggcggccagcgcggaacaaacaugcagcggcucggggguauuuugcuguguacacugcuggcgg
    cggcgguccccacugcuccugcuccuuccccgacggucacuuggacuccggcggagccgggcccagcucucaacuacccuca
    ggaggaagcuacgcucaaugagauguuucgagagguggaggagcugauggaagacacucagcacaaacugcgcagugccgu
    ggaggagauggaggcggaagaagcagcugcuaaaacguccucugaggugaaccuggcaagcuuaccucccaacuaucacaa
    ugagaccagcacggagaccagggugggaaauaacacaguccaugugcaccaggaaguucacaagauaaccaacaaccagagu
    ggacagguggucuuuucugagacagucauuacaucuguaggggaugaagaaggcaagaggagccaugaauguaucauuga
    ugaagacugugggcccaccagguacugccaguucuccagcuucaaguacaccugccagccaugccgggaccagcagaugcu
    augcacccgagacagugagugcuguggagaccagcugugugccuggggucacugcacccaaaaggccaccaaagguggcaa
    ugggaccaucugugacaaccagagggauugccagccuggccuguguugugccuuccaaagaggccugcuguuccccgugu
    gcacaccccugcccguggagggagagcucugccaugaccccaccagccagcugcuggaucucaucaccugggaacuggagcc
    ugaaggagcuuuggaccgaugccccugcgccaguggccuccuaugccagccacacagccacagucugguguacaugugcaa
    gccagccuucgugggcagccaugaccacagugaggagagccagcugcccagggaggccccggaugaguacgaagauguugg
    cuucauaggggaagugcgccaggagcuggaagaccuggagcggagccuagcccaggagauggcauuugaggggccugcccc
    uguggagucacuaggcggagaggaggagauuuaggcccagacccagcugagucacugguagaugugcaauagaaauggcu
    aauuuauuuucccaggaguguccccaaguguggaauggccgcagcuccuucccaguagcuuuuccucuggcuugacaagg
    uacagugcaguacauuucuuccagccgcccugcuucucuggcuugggaaagacaggcauggcggguaagggcagcgguga
    gucgucccucgcuguugcuagaaacgcugucuuguucuucauggauggaagauuuguuugaagggagaggaugggaagg
    ggugaagucugcucaugauggauuugggggauacagggaggaggaugccugccuugcagacguggacuuggcaaaaugua
    accuuugcuuuugucuugcgccgcucccaugggcugaggcaguggcuacacaagagcuaugcugcucuguggccucccaca
    uauucaucccuguguuucagcuccuaccucacugucagcacagcccuucauagccacgcccccucuugcucaccacagccua
    ggaggggaccagaggggacuucucucagagccccaugcucucucucucaaccccauaccagccucugugccagcgacagccc
    uuccaaauggagggagugaaauccuuugguuuuauuauuuucuccuucaaggcacgccugccacuaaggucaggcugacu
    ugcaugucccucuaacguucguagcagugugguggacacugucuuccaccgacugcuucaauaccucugaaagccagugcu
    cggagugcaguucguguaaauuaauuugcaggaaguauacuuggcuaauuguagggcuaggauugugaaugaaauuugca
    aagucgcuuagcaacaauggaaagccuuucucagucacaccgagaagucacaaccaagccagguuguguagaguacagcug
    ugacauacagacagaagaaggcugggcuggaugucaggccucagaugacgguuucaggugccaggaacuauuaccauucug
    uaucuauccagaguuauuaaaauugaaaguugcacacauuuguauaagcaugccuuucuccugaguuuuaaauuauaugua
    uacacaaacauguggcccucaaagaucaugcacaaaccacuacucuuugcuaauucuuggacuuuucucuuugauuuucaa
    uaaauacaaauccccuucaugcaaaaaaaaaaaaaaa
    Sfrp 1/   6 Sequence below. 240
    Secreted
    frizzled-
    related
    protein
     1
    U88566
    gcacgagcagcccgcagcccgccgcgccugugcgagccgggacagcacucggccccgcgcgcuccccgccccgcgccagccc
    cgccgcggcgaccugcugcagcggaggaccccaucgaucggagacccggggagcagcgcgcagcccgcgagccgacgggcc
    ccgacugcgucuuuguccccggaggcuccgggaaguuugcagcgggacgcgcgcgugaaggcagcgugggcagccccgac
    gucgccgagcaacaugggcgucgggcgcagcgcgcggggucgcggcggggccgccucgggagugcugcuggcguuggccg
    ccgcucugcuggccgcggguucggccagcgaguacgacuacgugagcuuccaguccgacaucggcucguaucagagcgggc
    gcuucuacaccaagcccccgcagugcguggacaucccgguggaccugaggcugugccacaacgugggcuacaagaagaugg
    ugcugcccaaccugcuggagcacgagaccauggcagaggugaagcagcaggccagcagcugggugccgcugcucaacaaga
    acugccacaugggcacccaggucuuccucuguucgcucuucgcgcccgucugucuggaccggcccaucuacccgugucgcu
    ggcucugcgaggccgugcgcgacucgugcgagccggucaugcaguucuucggcuucuacuggcccgagaugcucaaaugu
    gacaaguuccccgagggcgacgucugcaucgccaugaccccgcccaauaccacggaagccucuaagccccaagguacaaccg
    uguguccuccaugcgacaacgaguugaagucagaggccaucauugaacaucucugugcaagcgaguuugcacugaggauga
    aaaucaaagaagugaagaaggaaaacggugacaagaagauuguccccaagaagaagaaacccuugaagcuggggcccaucaa
    gaagaaggagcugaaggcgcuugugcuguuccugaagaacggugccgacugucccugccaccagcuggacaaccucagcca
    caacuuucucaucaugggccgcaaggugaagagccaguaccugcugacagccauucacaagugggacaagaaaaacaaggag
    uucaaaaacuucaugaagagaaugaaaaaccacgagugucccaccuuccagucuguuuuuaagugauacuggggcggacug
    gggaaggggaguguggcuuggggugagggugggggcgcguggaugacccuggcucuunggggcucacauauugcucuca
    cccauacaguuguggcuuuugcauugcaccuggcucuguuccuacagcgaacccucucccuunccuccauagccacaucca
    gcuaaggccacggccuuuagauuaggaaggcuuuuuuuuuuuuaagggcugcagcagggccagcagcgacgugcaaaagg
    agaggcagaauccuuucacugagccuggggcacaaaaaacagaaaauguunnccgguuuggaaaaacaaaacaaaacggauu
    guaaagaacugcagacggacagcugcucagcucaacguuguucgggacaucauuaccaauugcuuguggagucuaagccuc
    uacagguagaagagucugaucauugccaagccaggcugcuuucaguuuauuauuaaucccccucuuucugccuuagauaga
    ccaucgccaccuucaaaacacacacacacacacacacacacacacacacacacacacacacacacacacacacuucugaaaguag
    ccaggguaucccaguauagaacgggauagcuaaggguuugggugggaggccacugcuacucuaccuucagcuuuugaacu
    ggccaccuuugauaggaaacugaggucucagauggacacuucuaccaguccaucgggauacaaggaugccaggcaaggguc
    ugcuuuugucugaaggagguacgugggcaugaagagacaugaggcauuucaggcugagaagcaacagcuacuaguuuuca
    acaauagaguggaagaaaugagcaaagguagaaaugucaagcaggucacaagucagggugauugggggaauccugugccaa
    cagccucacuuuguaauuccaucugucacuuucaaaagaacagcagcauaagacagggauaaaagcccacauacccuccaag
    gcuugaguaaaaguccacacucagcauuucaaagacuaacgucguugacugcccaaggcugcccucuuaauacaccgccuau
    gcaugugcuguggaaggcaacucugugcaugugcuguggaggagaugggccucauggcugugcuggcugcccggaaucag
    uauagcguggaaggagacaguauccauagacucugcuuuucugcaaggaaagcccuuuuccuuauacaugauugccuauaa
    uucagacaaauuuaaaaucgcugccugccugagcccuccaccuuuacuuuugcauucuccggucauauucuuuugaggcua
    aagugcccuauccgaggagaugguuucaaaggcuaacuaaucugcagcuuucccaagugcccagagguauuucucaaaguu
    gguaugcuuaauaagugauguaaauauuccaguucucuuaggcagccuuacuccuguugucccug
    Dab2/  15 Sequence below. 241
    Disabled
    homolog 2
    U18869
    aauuccgaguggccgcgcggcuauuuaaguggcguuacuccgcguccucggcgcugcagccuugaggcuucgggcgcggg
    ggaagucaugcuggcuccacagaagcacuagcuaguccguguacuuuguggguucuguccuuuugagaccugcccgccgg
    ggauuggcugguaucagugacugucuacugcuggauuuucugcuugccuucccgucaugucuaacgaaguagaaacaagc
    acaaccaauggccagccugaccaacaggcugccccgaaagcgccaucaaagaaggagaagaagaaagguucugaaaagacag
    acgaguacuuguuggccagguucaaaggugaugguguuaaauacaaggccaagcuaaucgguauugaugaugugccugau
    gcucgaggagacaaaaugagucaggauucuaugaugaaacucaagggaauggcagcagcuggucgcucucagggacaacac
    aagcaaagaaucugggucaacauuuccuugucuggcauaaaaaucauugaugagaaaacugggguaauugaacaugaacau
    ccaguaaauaagauuuccuucauugcucgugaugugacagacaacagagcauuugguuauguguguggaggugaaggcca
    gcaucaauuuuuugcuauaaaaacagggcaacaggcugagccauuagucgucgaucuuaaagaccuuuuucaaguuaucua
    uaauguaaagaaaaaggaagaagauaagaaaaagguugaagaagccaacaaagcagaagagaauggaagugaggcccuaaug
    acccuugaugaucaagcuaacaaauugaagcuggguguugaccagauggauuuguuuggggacaugucuacaccuccugac
    cuaaauaguccaacagaaagcaaagauauccuguuaguggaucuaaacucugaaaucgacaccaaucagaacucuuuaagag
    aaaauccauucuuaacaaauggagucaccuccuguucucucccucgaccaaagccucaggcauccuucuugccugagaacgc
    cuuuucugccaaucucaacuucuuucccaccccuaacccugauccuuuccgugaugaucccuuugcacagccagaccaaucg
    gcacccucuucguucgauucucucacaucuccagaucagaagaaagcgagucugaguagcucgucuacuccacagaguaaa
    gggccccugaacgucgauacugauuacuuuggucagcaauuugaccagcucucuaaccggacuggcaaaccggaagcucag
    ggaggcccguggcccuacccaaguucgcagacccagcaagcagugagaacucaaaaugggguaucugaaagagaacagaacg
    gcuuccauaucaaaucuuccccgaacccuuuugugggaagcccucccaaaggacuaucgguaccgaauggcguaaagcagg
    acuuggaaaguucuguccaguccucagcacaugacuccauagccauuaucccaccuccacaaaguaccaaaccaggaagagg
    cagaaggacugcuaagucuucagcaaacgacuugccugcuucagacaucuuugccucagaaccuccaggccagauguccccc
    acaggacaaccugcagucccgcagucgaacuuccuggaucucuucaaaggcaaugcuccucccccaguggggccccuugua
    ggucuagguacggucccaguaacacccccccaagcaggacccuggacgccuguugucuacaguccuucgacaacugugguc
    ccaggagccauaauaaguggccagccucccaguuuucgccagccacucguuuuugguacaaccccagcaguacaagucugg
    aaucagucuccaucauuugcaaccccagcuuccccuccaccccccacaguuugguguccuaccacaucuguggcgcccaacg
    cuuggucauccacaagcccucuggggaauccuuuucagaguaauaauaucuuuccaccucccaccauguccacucaguccuc
    uccucagccuaugauguccucuguucuggccacaccgccucaaccaccuccccgaaauggcccacuaaaggacauucccagu
    gacgcuuucacuggcuuagacccccuuggggauaaagaggucaaggaagugaaagaaauguuuaaggacuuccagcugcgg
    cagccaccucuuguucccucaaggaagggggagacgccucccucugggacuucaagcgccuucuccaguuacuucaacaau
    aaaguuggcauuccucaggagcauguagaccaugaugauuuugaugccaaucaacuguugaacaagauuaaugaaccacca
    aagccagccccgagacaagguguccucuuggguaccaagucugcugacaauucacucgagaacccuuucuccaaaggguuc
    agcucaucaaaccccucugugguuucucagccugcaucuucugauccccacaggagcccuuucggaaauccuuuugccuag
    cuucugaaguuguaaugaugacuauccagaugagcaaaagacuggcuuuggucaagaaugaagcagacagccagaaacaug
    uugaccucuguccucgcuccagcuuugacguauuaucuguuacccuauuuguuuuggccucuuguacuuguaaaaugccu
    uucauuuuccugucuaggcuaaagcuaaacuuaaacuauggcuuuacguaaauuaagcuccuaaacucucuagcuccaaua
    uaaaugaaguagcuucccuaucaaaucccugucuguugugcccccuugaaacuuccagaauauucuccauucuacccucca
    uuugggaggagcggcuaccuuuacccuuaauaucacacugccuugagucaauguccaaauacucauagcucucaaagucau
    uugggguuccuggugugcggccuaaaccuaaagcauccuauuaauagggaaguaagacaccuugcuuccuauguccacuca
    gggagaauuuuauuuaauaaaaugaaagcaagacuaacuucucaaauccacccaaggaccauuuugagauggucguuucuc
    agcuaacugcaccauuuaccaauccugccccaaguggugcuuacauuugacuugaagaagagaaagagcuaacucaaaacac
    aaggcauuauucaaagcuaauaaaacaauuucucccuggggccccacauuguuuucauuccagauacguugcagcuguuug
    acccugaugacauuaugcccuacauuuuccuugaagauccugauuuuauuucaugugauuuuuguuucucaauaaagaug
    auuauugugugcacggaauuc
    Cktsf1b1/  12 (12) Augaaucgcaccgcauacacugugggagcguugcuucuccuccugggg 242
    Gremlin, acccuacugccaacagcugaggggaaaaagaaagguucccaaggagccau
    Cysteine uccgccuccugacaaggcucagcacaaugacucugagcagacccaguccc
    knot caccacaaccuggcuccaggacccgggggcggggccaggggcggggcac
    superfamily cgccaugccuggagaggaggugcuugaguccagccaagaggcccugcac
    1, BMP gugacagagcgcaaguaucugaagcgagauuggugcaaaacucagcccc
    antagonist 1 ugaagcagaccauccacgaggagggcugcaacagccgcacuaucaucaac
    AF045801 cgcuucuguuauggccagugcaacuccuucuacauccccaggcacaucc
    gaaaggaggaaggguccuuucagucuugcuccuucugcaagcccaagaa
    guucaccaccaugauggucacacucaacuguccugagcuacagccaccca
    ccaagaagaaaagggucacacgcgugaagcagugccguugcauauccau
    cgacuuggauuaa
    Fgfr1/  10 Sequence below. 243
    Fibroblast
    growth
    factor
    receptor
     1
    U22324
    guggaauauccauggagguacggagccuuguuaccaaccuuuaaccgcagaacugggauguggggcuggaagugccuccu
    cuucugggcugugcuggucacagccacucucugcacugccaggccagccccaaccuugcccgaacaagcucagcccugggg
    agucccuguggaaguggagucucuccugguccacccuggcgaccugcuacagcuucgcugucggcuucgcgaugaugugc
    agagcaucaacuggcugcgggauggggugcagcugguggagagcaaccguacccgcaucacaggggaggagguggaggug
    cgggacuccauccccgcugacucuggccucuacgcuugcgugaccagcagccccucuggcagcgauaccaccuacuucuccg
    ucaaugucucagaugcacucccauccucggaagaugaugacgacgacgaugacuccuccucggaggagaaagagacggacaa
    caccaaaccaaaccguaggccuguagcucccuacuggacauccccagagaaaauggagaagaaacugcaugcggugcccgcu
    gccaagacggugaaguucaagugcccgucgagugggacacccaaccccacucugcgcugguugaaaaauggcaaagaguuu
    aagccugaccaccgaauuggaggcuacaagguucgcuaugccaccuggagcaucauaauggauucuguggugccuucugac
    aagggcaacuacaccugcaucguggagaaugaguaugggagcaucaaccacaccuaccagcuugacgucguggaacgaucu
    ccgcaccgacccauccuucaggcagggcugccugccaacgagacaguggcccugggcagcaauguggaguucauguguaag
    guguacagcgauccgcagccucacauucaguggcugaagcacaucgaggugaacgggaguaagaucgggccagacaacuug
    ccguauguccagauccugaagacugcuggaguuaauaccaccgacaaggaaauggaggugcuucaucuacggaaugucucc
    uuugaggaugcgggggaguauacgugcuuggcggguaacucuaucggacucucccaucacucugcaugguugaccguucu
    ggaagcccuggaagagagaccagcugugaugaccucaccgcucuaccuggagaucauuaucuacugcaccggggccuuccu
    gaucuccugcauguugggcucugucaucaucuauaagaugaagagcggcaccaagaagagcgacuuccauagccagauggc
    ugugcacaagcuggccaagagcaucccucugcgcagacagguaacagugucagcugacuccagugcauccaugaacucugg
    gguucuccugguucggcccucacggcucuccuccagcgggacccccaugccggcuggagucuccgaauaugagcucccuga
    ggauccccgcugggagcugccacgagacagacuggucuuaggcaaaccacuuggcgagggcugcuucgggcagguggugu
    uggcugaggccaucgggcuggauaaggacaaacccaaccgugugaccaaaguggccgugaagauguugaaguccgacgcaa
    cggagaaggaccugucggaucugaucucggagauggagaugaugaaaaugauugggaagcacaagaauaucaucaaccuuc
    ugggagcgugcacacaggaugguccucuuuaugucauuguggaguacgccuccaaaggcaaccuccgggaguaucuacagg
    cccggaggccuccugggcuggaguacugcuauaaccccagccacaaccccgaggaacagcugucuuccaaagaucugguauc
    cugugccuaucagguggcucggggcauggaguaucuugccucuaagaaguguauacaccgagaccuggcugcuaggaacg
    uccuggugaccgaggauaacguaaugaagaucgcagacuuuggcuuagcucgagacauucaucauaucgacuacuacaaga
    aaaccaccaacggccggcugccugugaaguggauggccccugaggcguuguuugaccggaucuacacacaccagagcgaug
    uguggucuuuuggagugcucuugugggagaucuucacucuggguggcuccccauaccccggugugccuguggaggaacu
    uuucaagcugcugaaggagggucaucgaauggacaagcccaguaacuguaccaaugagcuguacaugaugaugcgggacug
    cuggcaugcagugcccucucagagaccuacguucaagcaguugguggaagaccuggaccgcauuguggccuugaccuccag
    ccaggaguaucuggaccuguccauaccgcuggaccaguacucacccagcuuucccgacacacggagcuccaccugcuccuca
    ggggaggacucugucuucucucaugagccguuaccugaggagcccugucugccucgacaccccacccagcuugccaacagu
    ggacucaaacggcgcuga
    Fgf1/  10 auggcugaaggggagaucacaaccuucgcagcccugaccgagagguuca 244
    Fibroblast accugccucuaggaaacuacaaaaagcccaaacugcucuacugcagcaac
    growth gggggccacuucuugaggauccuuccugauggcaccguggaugggaca
    factor 1 agggacaggagcgaccagcacauucagcugcagcucagugcggaaagug
    M30641 cgggcgaaguguauauaaaggguacggagaccggccaguacuuggccau
    ggacaccgaagggcuuuuauacggcucgcagacaccaaaugaggaaugu
    cuguuccuggaaaggcuggaagaaaaccauuauaacacuuacaccuccaa
    gaagcaugcggagaagaacugguuugugggccucaagaagaacgggagc
    uguaagcgcgguccucggacucacuauggccagaaagccaucuuguuuc
    ugccccucccggugucuucugacuag
    Gpr49/  64 Sequence below. 245
    G protein- (377)
    coupled
    receptor 49
    FEX
    AF110818
    auggacaccuccugcguccacaugcuccuguccuugcuggcgcugcugcaguugguggccgccggcagcucaccgggacca
    gaugcgauaccgcggggcugcccaucacacugucacugugagcuggauggcaggaugcugcucaggguggacugcucgga
    ccuggggcucucggagcugcccuccaaccucagcgucuucaccuccuaccuggaccucaguaugaacaacaucagucagcua
    cccgccagucuccuacaucgccucugcuuccuagaagaguuacgucuugcuggaaaugcuuugacacacauucccaaggga
    gcguucacgggccuucacagccucaaagugcuuaugcugcagaacaaccagcugagaaagguuccggaggaagcgcuacag
    aauuugagaagccuucaaucccugcgccuagaugccaaccacaucagcuacgugccacccagcuguuucagcggccugcacu
    cccugaggcaccuguggcuagaugacaaugcucucacagacgucccuguccaggcuuucagaaguuuaucagcccugcaag
    ccaugaccuuggcccugaacaaaauacaccacauagcagacuacgccuuuggaaaccucuccagccucgugguucugcaucu
    ccauaauaauagaauccacucccugggaaagaaaugcuuugauggacuccacagccuggagacuuuagauuuaaauuauaa
    uaaccuugaugaauuccccacugcaaucaagacacucuccaaccuuaaggaacuaggauuccacagcaacaacaucagguca
    auaccggagcgagcguucguaggcaacccuucucuuaucacaauacacuucuaugacaaccccauccaauuuguuggagua
    ucugcuuuucagcauuugccugaacuaagaacacugacuuugaauggugccucgcacauuacugaauuuccucacuugaca
    ggaacugccacccuggagagucugacuuuaacuggagcaaagaucucaucucuuccccaggccgucugugaucaguuaccu
    aaucuccaagugcuagauuugucuuacaaccuacucgaagacuuacccaguuugucaggcugccaaaaacuucagaaaauu
    gaccugaggcauaacgagaucuaugaaauuaagggcagcacuuuucagcaguuguuuaaccuccgaucucugaacuuagca
    uggaauaaaauugcuaucauucaccccaaugcguuuucuacguugccgucucuaauaaaguuggaccuaucauccaaucuc
    cugucguccuucccugugacuggguuacaugguuuaacucacuuaaaauuaacagggaaccgagccuuacagagccugaua
    ccaucugcaaacuucccagagcucaagauuauagaaaugccaucugcuuaccaguguugugcauuuggggggugugagaau
    gucuauaaaauuucuaaccaauggaauaaagacgacggcaacaguguggacgaccuucauaagaaagacgcuggguuauuu
    caaguucaagaugagcgggaccuugaagauuuccuacuugacuuugaggaagaccugaaugcccuucacucggugcagugc
    ucgccuuccccaggucccuucaagcccugugagcaccuauuugguagcuggcugauccgaaucgggguguggaccacggca
    guacugacgcuuuccugcaaugccuugguggcuuugaccguguucagaacuccccuguacaucucuuccauaaagcugcua
    auugggguaaucgcgguaguggacauucucaugggggucuccagugcugugcuggcugccguggaugcauucacuuuug
    gccguuuugcucagcacggugcguggugggaagacggaaucggcugccaaaucguuggcuuccuguccauuuuugcuucc
    gaaucgucgaucuuccugcucacucuggcagcgcuggaacgagguuuuucugucaagugcucuucgaaguuugaagugaa
    agcuccccuuuuuagccugagagcgaucguuuugcuauguguccuguuggcccugaccauugccacaauccccuugcuag
    gaggcaguaaguacaaugccucuccccucugccugcccuugcccuuuggggagcccagcaccacgggcuacaugguggcuc
    ucguguugcucaacucucucuguuuccucauaaugaccauugccuacacaaagcucuacugcaguuuggagaaaggagagc
    uggagaaucuuugggauuguucgauggugaagcacauugcucuguugcucuucgccaacugcauccuuuacugccccgug
    gcuuucuuauccuucuccucuuugcuaaaccucaccuuuaucaguccugacgucauuaaauuuauacuucucgugaucguc
    ccacuuccuuccugucucaacccacuucucuacauugucuucaauccccauuuuaaggaggauaugggcagccugggaaag
    cauacccguuucuggaugagaucaaaacacgcgagucugcuguccauuaacucggacgauguugagaaacgguccugugag
    ucaacccaagccuuaguauccuuuacccacgccagcauagccuaugacuugccuuccacuuccggggcaucaccagcuuacc
    ccaugacugaaagcugucaucucucuucaguugcauuugucccaugucucuagugacuaugagagaggaacguuuuuaag
    aguuggaaaccugaaaagugauuucuaucagagcaguagcuaagaaaagcugagcuaaaaaccuaccuuaaaacccaagcaa
    acaucucuaaauugguguggaaacaguggugccuuagagcaggagagcaucauuaaacaccgcuuguaucauuuguucagc
    uaagaaggaaagccaucaagucacuuaggugaacccagaugagaaaagcagccugaaaugcucuucgcauuguagucucuu
    cugacucaccagcauagucucccauagugagaagacucguuggaugacucaauggguguauuuaaauccacaaauuccuug
    uuuaaaagguuagaguuuuaagaaaaaaaaaaaaaaaaa
    Igfbp5/  37 Sequence below. 246
    insulin-like
    growth
    factor
    binding
    protein
     5
    L12447
    uuuuuuuucuucaccuccucccuuuucaaggccuccaagcuaauuauuucuguugcuuuggagugagcaauucugugguu
    cucuccaccaccacccccaauucugacccgaucccgccuggggguuucuacggucuccgcucacucugcgugcaccuggcgc
    gccucuuuuuuucacccccaaccuguugcaagucuuuaauccucgcaauugggacuugcgugcaggcaccugaauccuccu
    ugccucauauuuugcaaguguuugggggagagcaccugcucuaccugcaagagauuuaaaaggaaaaaaaucuccaggcuc
    ccucuuucuccacacacucucgcucuccugccccgccccgagguaaagccagacuccgagaaaauggugaucagcguggucc
    uccugcugcuggccgccuaugccguaccggcucaaggccuggguucuuucgugcauugugaacccugcgacgagaaagcuc
    uguccauguguccccccagcccucugggcugugagcuggucaaagagcccggcuguggcugcugcaugacuugcgcccug
    gcggagggacagucguguggugucuacacagagcgcugcgcccaggguuugcgcugccucccccggcaggaugaggagaa
    gccgcugcacgcccugcugcacggccgcgggguuugccucaacgaaaagagcuacggcgagcaaaccaagauagagagagac
    ucucgggaacacgaggaacccaccaccuccgagauggcugaagagaccuacucccccaaggucuuccggcccaagcacacuc
    gcauuuccgagcugaaggcugaggcugugaagaaggaccgcagaaagaagcugacccaguccaaguuuguggggggugca
    gagaacacugcccaccccagagucaucccugcaccugagaugagacaggaauccgaacaaggccccugccgcagacacaugg
    aagcuucccuccaggaguucaaagccagcccacgcauggugccccgugcuguguaccugcccaacugugaccgcaaaggau
    ucuacaagagaaagcaguguaagcccucccguggccgcaaacguggcaucugcugguguguggacaaguacggaaugaagc
    ugccgggcauggaguacguggauggggacuuucagugccacgccuucgacagcaguaacguugagugacgcguccccuccc
    uuccucccccuauccuacccccccagccccaacuccagccagcgccucccuccaccccaggacgucacucauuucaucucauu
    uaggggaaauauauauacauauauauuugaggaaacugaggaccucggaaucucuagcaagggcuaaggagacacucccca
    ccaugaccccggaaauguauuccuuuuugaagcaaguugaacggacagagaagggaaggagagaagaagcaagagggagcg
    agagauggaaagaaagcaaagcguuggaauagaggaaaagagggaaggacagauaggauuagagagagaagagagaaacag
    caaggcagaaaggacuccacaaccaaggcugaaucugcccuuuugcuuucagcucuagccuggggucagaaaaaguguggc
    auucagugacacccaguuuagauuggucaaggggagaaaagaaacaaggugugucagugccucucgggucuguccccuccu
    gcagccagcaguguggauggcuagaccccucacccuccucuccucuuacccaagugcagggugauuucauccccaaauuua
    caaagacuaaaaugcauuccaucccucugaaaauaaacaaaagugagugauugaagauagguuuucccccagcagacaagug
    aacucagaaugugugcaaauuuuacucuuguuaaagauuuuuuuaagaagucaguacgcacccccaacacuggaaagacuu
    gauucuccagggugacaagcaauucagaagcgcguggcuucggcccuugauuucacuagacucaaagcuggcccggcagcc
    ucuguggaggaggaugagagguggagaaaaccaaggggcuuguacucacccacaagacuccauguagacuuuauaggcaua
    uaaaucuauuuucuuuaccuuuuuuucccuuucccuuucuuucgaaguuuugcauuaccucuuuaaaguaguuuuuuuua
    ggacacugaagaucuuccucauucugggaaaaauccauauuucacaaauacaacccagaacgccagcuuggccugcguccag
    gcagccuuucucgugagcuacaaguguggcucuuuuguggggcaccgauuuggaucuucucaugauuccaaacguguguu
    gaagugaauccaccaagccagguaacugccagcacccaagggugcaucaagugcauagcccaggucaccccauuucagccuu
    ccaacccgcagaaaguaacugucucacaccacaccacauaaaccugccagauccaucuguaacccacuggccugcccagaccu
    uuuuuucccaucugcauuuuuuuuuuugaacugcauuuugaaagccucccucagaugccaggcugacagaucagagagaaa
    cuaacaugagagaugacagaggaggaggaaguggagggugggggcagagacuuccacagagagacauagaagauggagcag
    aggucuggggguggggaggacaagaaagagacagagagaggaaaauaccaauagaauuuuccuuggugucucccaucuaau
    caacucucugagauuugagaggaaaaagaaggcaggggaagaacuugagguagaaaugaggucaguucaagucacagggcc
    cagaugguggguaacugaggcaggauccagacuugagacacacgguuggaaacaaggcugguuagccugacuggguauug
    aagggugaagaggaugccuuggaaagacagcacaacuucaguucaacuucaggcccccaaggaggaacugaggccaaagaau
    ccuucaagugcuucaugagucuccucugcccgacucaaacauccuucccugugauggaggaugguagaaagcccaggacaa
    cucaggcccggaucuucacgacuguugucauuugccagccugauuuugauccaagagaagcaucucauugcccacuggcuu
    cuucaacaaagaggugcuuaacaaaaggcucaggacuaucuuugaagacugaagauaaccuuccaggagaggagacucgga
    cauugguacaggaggccccuuuuggcgggggacacagcucuuugcgcucucuugauggcauggcauaguagaggcccccu
    ccaacccggaacauggagcaacacaaagggagagcaaagaaacugacgugcgucgacucauaggacauggguggcugcggg
    cacagaaagggaugccuccuguugccuggacaggacaguuggcugggaaggaaagagaaaauugaucuucauaagacaaag
    ggccugaugggauggcaauagaaggacuuaccagaccugcagggucaguauacccaucaccccgcacaacauccccagcccc
    caacucaaacuucaauauaucuuaggccaguauccuagaccuaagucucuccuuucugccauuauuucuccgcaucuugag
    cagucaucugacugagauuugccaaguggauacugggguaccacugccccccaagaaaagacugagccaggaacugccuac
    ucgcucccccucccgagccuggagcuaacuccugugaggggugcucucuucaccccacaacuuacuagaccuugagugagc
    cucugucccuuaugugggcucuucgcugugagccacagauggaggucauuguauagacaguuagccuuccccaggucagc
    cuaccucccccaaacuugugagucuccccgcugcucauauggagaggcaugucuaagacagcaagucuucuagaggaagcu
    ugccuuuaacagacagauggaacuaaaccuuccaaaugggagaucuggcugaacccaggauacagagaccauggacaugga
    uggggucaucaagagaagagggauguccuucuccagguuagggagagagaaggcaaguuugcaacgaucccaucaugcccu
    gagcaagaagcuuuuggcccaggcuagccuuuaacuccauuagaggccucucuguuggguuuauccacagcaguaggccca
    aguauggccuguccccaccucuacuaucccguggaagguuucuucccaccccuuuuugacaaaugccucacucgagcagug
    gaaagauagcucucuucccccucuucugccagguaacaaagagaccuaaccaggaccuauucuccaccccagccagucuuga
    ccagccagaacaaagcagggaaccuggagaauaaaagacucuacguuccucugacaaagacucuacguuucucugacggcca
    ggccuaaacagacaaggcuugggaacaucugccccacaggauacggaggaggucagcugugcucacuccucuucuccuucc
    aagacccucuuccgaccaugacuuaucuccaugguaacauccucaccaucauucucccacuaccaaggguugccauggcaac
    cucccaaccaccugcccaucccaggcaggcagcuguccuucugcucagaacccuagaggacucuaggugaaauuuuacagcu
    uaagagaggagugagccaaggagaagagacccuguaguccucuggcuuucaagagaaagaaggcuaugauuuaaaacacag
    uagaagggaaagaggucucgucgaggucgaccucucccggggagcuuagggguuguacugucuuuauuuuuuaaaccacu
    aaagugcaaunuuuccugcacucuuguuaccccgccucucuucccuguuagguuuucauuuccuugagcagacuuucuug
    guuuuuuaauggaguauagacuuucaccacuucacagacucuggccuccucuccaagucucucuggauggggaaaaggaag
    guagagggucagaggggaaggggucccucgucaccccgcauccauucacccccacuucucuggucccuagucaccggcuuc
    accccnaucuccgacaccaucacugucacacaguagccugucacacggauaguacaguucagacaagacuccuucagauucc
    gagacgccuaccgguuguuuuugguuuuuguuuuguuuucuuuuguuuguuuguuuguuuguuuuuuacaacagcaau
    aaccacaucacauauuacuguagcucucuauaguguuacguucagacaccguagcucuguccucucuuauuuuguugguu
    uugacuuaaaaaaaaauacuuaugcuuuuuacuggugaaacagauugaaaaaaaaauugaacaacaaaccaguuugugaaaa
    aaaaaaaaaaugugaaaaaaaaucaccccgauguggaagagcucggcuccucuuuagcauuuuguacuuaaggaaauaaaaa
    agaaaaaccuggaagaucucacauuuuauuacaaagugaaaaaaaaa
    Myoc/ 111 Sequence below. 247
    trabecular
    meshwork
    induced
    gluco-
    corticoid
    protein
    AF041335
    guccagucugcagucuguauucggaagacauagauacuaaauacauggcaacucuuuuuuuuguuuguuuuaauucauca
    ggauguggagcgcuagucuggguaggagagccagucacccugaggacagcugaaacaaucgcuggcaaguauggagugug
    gaugagagaccccaagcccacccaccccuacacccaggaaagcacauggaggauugacacgguuggcacagagauccgccag
    guguuugaguacagucagauaagccaguucgagcagggcuauccuuccaagguccaugugcucccucgggcacuggagagc
    acgggugcugugguguaugcggggagccucuauuuccagggggcugaguccagaacuguggucagguaugagcuagacac
    ggagaccgugaaggcagagaaggaaauuccuggagcuggcuaccacggacacuucccguacgcgugggguggcuacacaga
    cauugacuuagcuguggaugagagcggccucugggucaucuacagcacggaggaagccaagggggccauaguccucuccaa
    auugaacccagcgaaccuggaacuugagcguaccugggagacuaacauccguaagcagucuguggccaaugccuuuguuau
    cuguggcaucuuguacacggugagcagcuacucuucagcccaugcaaccgucaacuucgccuacgacacuaaaacggggacc
    aguaagacccugaccaucccauucacgaaucgcuacaaguacagcaguaugauugacuacaacccccuggagaggaagcugu
    uugccugggacaacuucaacauggucaccuaugauaucaagcucuuggagaugugaggagccucuaugccuaccagcaaag
    gccagaaaaggugaaguuccgggcucccgggugaagcagcugucagcagaggcagccagaugcauggaguuucuccuccug
    cuaaagauuuuguuuauccgggucaauguacagcuagcuccccucugacugacacguccuccaggcuuguauagucgcaua
    gacucuguucucuucugucagcuuucaaagggcuguuccucuuuuaaaaaucacauagug
    Itm2a/E25  30 Sequence below. 248
    putative
    Integral
    membrane
    protein 2A
    L38971
    gggagaccugagcucgcugcugccuguggaagacugggagaggagacacuaagugcugcucaagcaagcgcgauccucucc
    ucuuucaaccugcagcccaagauacugauucgagccgcgccuuaccgcgcagcccgaagauucaccauggugaagaucgccu
    ucaacaccccuacggcggugcaaaaggaggaggcgcggcaagauauagaggcgcucgucagucgcacuguccgagcucaaa
    uccugacuggcaaggagcucagaguugucccgcaggagaaagauggcucaucugggagaugcaugcuuacucuccuaggcc
    ucucauucaucuuggcaggacugauuguugguggagccugcauuuacaaguacuucaugcccaagagcaccauuuaccaug
    gugagaugugcuucuuugauucugaggauccugucaauuccauuccuggaggagagccauacuuucugccugugacugag
    gaggcugauauccgugaggaugacaacauugccaucauugaugugccugugcccaguuucucugauagcgauccggcggc
    aauuauucacgacuuugagaagggaaugacugcuuaccuggacuugcuuuugggaaacuguuaucugaugccccucaauac
    uuccauuguuaugacuccaaagaaucugguggaacuuuuuggaaaacuggcaaguggcaaguauuugccucauacuuaug
    ugguucgugaagaccugguugcuguggaagaaauucgugauguuaguaaccuugguauuuuuauuuaccaacuuugcaac
    aaccgaaaauccuuccgccuuagacgcagagaccuucugcuggguuucaacaagcgugccauugacaaaugcuggaagauu
    agacacuuccccaaugaauuuaucguugaaaccaagaucugucaggagugaaaugugacagauaaagaguauccuugauaa
    uaagaagucaggaacuuaccgucugacuuggaaaauugaaauugaugggauacucaugcuauuuacucauacauuuacucu
    auugcuuauacuggaaaaggaaagggaaaggggggagaaaacuacuaaccacugcaagcgauuguccaauucuacuuuaau
    ugacauugcuugcuguuuucaacaagucaaaugauuaucuuuucucuugaauuuauaggguuuagauuucugaaagcagc
    augaaugugucaucuuaccauccugacaauaaagcccauccucugguuuuauuuaaagcaagcucuuuccaacaucacuug
    gcuagagcaugcuuuaaauuuaaaauauuugaaauuuguuuuugacauuuuuuugugugaaacaugucaaaucucuuacc
    auucuuugguuuucuucuuuauuauguucaacucuccugauuucagaaguuacauuuuugcauuucuaucaggugcugu
    guaacgaaucugacugauaugugaacaaucuucaugaggaagcaauuuuuuacucauguaaugauucuuucucacugauau
    cuguauugugaaauccacagaacuguacaggugcugaaugcuguaaggaguucugguuguaugaauucuacaacccuauaa
    uaaaguuuaccguauucaauca
    Eps8/  15 Sequence below. 249
    epidermal
    growth
    factor
    receptor
    pathway
    substrate
     8
    L21671
    ggccauuaccaaucgcgacccgcgcacacacggcccgggcggcgggcgaagcgggcucccggggcgcugggcgcagggcgc
    ggggcaagccccagcagcgugucugcaacggggcgcggcgggcgcuccagcuccgggaucuuucucccucggucaccuccc
    ucgcgucuagggaggucguggcacucccugaggagcgcggcugcucggagggcggauccuagaacagaggcgugagagcc
    ggcaugaauggucauaugucuaaccgcuccaguggguauggagucuacccuucucaacugaaugguuacggaucuucacca
    cccuauucccagauggacagagaacacagcucaagaacaagugcaaaggcccuuuaugaacaaaggaagaacuaugcccgag
    acagugucagcagugugucggacgugucccaguaccgcguggaacacuugaccaccuucgugcuggaucggaaagaugcaa
    ugaucacugucgaggacggaauaagaaagcugaaguugcuggaugccaagggcaaaguguggacucaagauaugauucucc
    aaguggaugaccgagcugugagccugauugacuuagagucaaagaaugaauuggagaauuuuccucuaaacacaaucucgc
    auugucaagcaguggugcaugcaugcagcuaugacuccauucucgccuugguaugcaaagagccaacgcagagcaagccag
    accuucaccuuuuccagugugaugagguuaaggcaaaccuaauuagugaagauaucgaaagugcaaucagugacaguaaag
    gugggaaacagaagaggcggccggaggcccugaggaugauugccaaagcagauccuggcaucccuccuccucccagagcuc
    cugccccugugccaccggggacugucacacagguggacguuaggagucgcguagcagccuggucugccugggcagcugacc
    agggugacuucgagaagccccggcaguaccacgagcaagaagagacgcccgagaugauggcagcccggaucgacagggaug
    ugcaaaucuuaaaccauauuuuggaugacauugaauuuuuuaucaccaaacuccaaaaagccgccgaagcguuuucugagc
    uuucuaaaaggaagaaaaguaagaaaaguaaaaggaaaggaccuggagagggcguuuuaacacugagggcaaaaccgccacc
    uccugacgaguuuguugacuguuuccagaaguuuaaacauggauucaaccuucuggccaaguugaagucccauauccagaa
    cccgagugcuucagaucugguucauuuuuuguuuacuccacuaaauauggugguccaggcaacagguggcccugaacugg
    ccaguucgguacucagcccacuguugacaaaagacacaguugauuucuuaaacuacacagccacugcggaggaacggaagcu
    guggaugucacugggagauaguugggugaaagugagagcagaguggccgaaagaacaguucaucccaccuuacgucccgag
    guuccgcaacggcugggagcccccgaugcugaacuucaugggcgcgcccacagagcaagacauguaucaacuggccgaguc
    cguggccaacgcagaacaccagcgcaaacaggacagcaagaggcuguccacagagcauuccaauguguccgacuauccucca
    gccgacggauaugcguacaguagcagcauguaccacagaggaccacaugcagaccacggggaggcugccaugccuuucaag
    ucaacuccuaaucaccaaguagauaggaauuaugacgcagucaaaacacaacccaagaaauacgccaaauccaaguacgacuu
    uguggcgaggaacagcagcgagcucucgguuaugaaagaugaugucuuagagauacucgacgaucgaaggcaguggugga
    aaguccggaaugccaguggagacucuggguuugugccaaauaacauucuggauaucaugagaacuccagaaucuggagugg
    ggcgcgcugaccccccauacacacauaccauacagaaacaaaggacggaauacggccugagaucagcugacacuccuucugc
    cccaucacccccuccaacgccagcacccguuccggucccccuuccaccuucuguaccagcacccguuucugugcccaagguu
    ccagcagaugucacccgccagaacagcagcuccagugacagugggggcagcauugugcgggacagccagagauacaaacaac
    ucccaguggaccgaaggaagucccagauggaagagguucaggaugagcucuuccagaggcugaccaucgggcgcagugcug
    cgcagaggaaguuccacgugccacggcagaacguuccagugaucaauaucacuuaugacuccucaccggaagaaguaaagac
    uuggcugcagucaaagggauucaaucccgugacugucaauagccucgggguguugaacggagcacaacucuuuucucucaa
    caaagacgaacugaggucugucugcccggaaggugccagagucuuuaaccaaaucacuguucagaaagcugcuuuggagga
    caguaauggaagcuccgaguuacaagagaucaugcggagacggcaggagaagaucagcgccgcugcgagcgacucgggagu
    ggagucuuuugaugaagggagcagccacugaguccaugaacuuccuuauucuugguguggucguugaacagugauggaca
    ugcuuuguuuuaagaagccuugaagggaaugucaaagcugucgucuugguauauguaauuuaucgccauauaaggaaaca
    guauaugccugaguaagcagaggacccgcugcuucugugcacauuaguuugauuaaaacugagaagcggguaggugagau
    ggcucagcaaguaaaggugcuugcugccaagcccaaugacccaaguucgagucccugggucuacaugguaggagagagcug
    gcuucugcaaguuguccucugaccaccacacauaaauaaauaacaaauguaauuuacaaacuuuuaaaagaaaauguaauuu
    aaaaaaccagacguucuagacuguucugggcuugggaaauauuuuuuucacuuuccuaagguguacuuuccuuugcuaca
    uuaauuauugcagccuuguucgaugaucuaaguggggauauuugacaauggcagauuuauucauugcaacaaggaaagac
    acagccauugaugaaaaaaaaaagaaagucucagcuuucagugacugggauaccugcuguccagggaggaggcucaguuag
    acuacccucugcuuacuugaggucugacaugcccaaugagaguguauuuagcuuuauuuaaaguucuuaaugccaacaguu
    uuaaaaaucacauuuaaaugaacuguacaagguagccagaccuugaauguaugaauagacuauauaauaugucccgagaaac
    uuuguuacucucagcucuguugauugcgaaaucuugcauagauuaugcuuugauuuaguuucu
    Fyn/Fyn  10 Sequence below. 250
    proto-
    oncogene
    M27266
    ccugggccccgccgcggacgcgcggagccgccugggccgcgccggaggagggcggggagaggaccaugugaaugugcucc
    ggagcugagcgccaagccaagcaguguuugaaaggaacaggaugcugaucuaaucguggcaaaaagucaguccgaccgcug
    guuucgaagacaugugguguauauaaaguuugugauaguugguggaaauuugggagcuuggauaaugggcugugugcaa
    uguaaggauaaagaagcagcgaaacugacagaggagagggacggcagccugaaccagagcucuggguaccgcuauggcaca
    gaccccaccccucagcacuaccccagcuucggcgugaccuccaucccgaacuacaacaacuuccacgcagcugggggccagg
    gacucaccgucuuugggggugugaacuccuccucucacacugggacccuacgcacgagaggagggacaggagugacacugu
    uuguggcgcuuuaugacuaugaagcacggacggaagaugaccugaguuuucacaaaggagaaaaauuucaaauauugaaca
    gcucggaaggagauuggugggaagcccgcuccuugacaaccggggaaacugguuacauucccagcaauuacguggcuccag
    uugacuccauccaggcagaagagugguacuuuggaaaacuuggccgcaaagaugcugagagacagcuccuguccuuuggaa
    acccaagagguaccuuucuuauccgcgagagccaaaccaccaaaggugccuacucacuuuccauccgugauugggaugaua
    ugaaaggggaccacgucaaacauuauaaaauccgcaagcuugacaaugguggauacuauaucacaacgcgggcccaguuug
    aaacacuucagcaacugguacagcauuacucagagaaagcugaugguuuguguuuuaacuuaacugugguuucaucaaguu
    guaccccacaaacuucuggauuggcuaaagaugcuugggaaguugcacgugacucguuguuucuggagaagaagcugggg
    cagggguguuucgcugaaguguggcuugguaccuggaauggaaauacaaaaguagccauaaagacccuuaagccaggcacc
    augucuccggaguccuuccuggaggaggcgcagaucaugaagaagcugaagcaugacaagcuggugcagcucuacgcgguc
    gugucugaggagcccauuuacaucgucacggaguacaugagcaaaggaaguuugcuugacuucuuaaaagauggugaagg
    aagagcucugaaguugccaaaccuuguggacauggcggcacagguugcugcaggaauggcuuacaucgagcgcaugaauua
    uauccacagagaucugcgaucagcaaacauucuaguggggaauggacuaauuugcaagauugcugacuuuggauuggcuc
    gguugauugaagacaaugaauacacagcaagacaaggugcgaaguuucccauuaaguggacagcccccgaagcggcccugu
    auggaagguucacaaucaagucugacguauggucuuuuggaaucuuacucacagagcuggucaccaaaggaagagugccau
    acccaggcaugaacaaccgggaggugcuggagcagguggagagaggcuauaggaugcccugcccacaggacugcccgaucu
    cccugcacgagcucaugauccacugcuggaaaaaggauccggaagagcgcccgaccuucgaguacuugcagggcuuccugg
    aggacuacuuuacggccacagagccccaguaucagcccggugaaaaccugugagagccugcgcuucagacgccucuucccga
    ggccucccuaccccuccccauuagcuuccaauucuguagccagcugccccagagcaggagaaccguccaggaucagauugca
    ugugacucuugaagcugaacuuccacggcccucauuaaugacacuugucccccaguccgaaccuccucugugaaccaucug
    agacagaagcguguuauuucucagacuuggaaaugcauuguaucgauguuaugucaaaggccaaaccucuguucaguguaa
    auagcugcuccugugccaacaaucccagugcuuuccuuuuuuaaaaaagaaaaagcaaauccuaugugauuuuaacucuga
    uuucaccugauucaacuaaaaaaaaaaaaguauuauuuuccaaaaguggccucuuugucuaaaacaauaaaauuuuuuuuc
    auguuuuaacaaaaaaaaaaaaaaaaaaaaaaaa
    Structurally-related
    Col6a1/  36 Sequence below. 251
    Procol-
    lagen, type
    VI, alpha 1
    X66405
    cccucccuggcucucuccucagcucugggcucugacugcagcaagcagagacaaccucucacucugccuuucccagcgccca
    cccugacccuggcccacauuugacggugacucgcaggccagccagaaacaugaggcuggcccacgcucugcugccccugcu
    gcuacaagccugcuggguggccacacaggacauccagggcuccaaagcgauugccuuccaagacugcccuguggaucuauu
    cuucgugcucgacaccucggagaguguggccuugaggcugaaaccuuauggggccuugguggacaaggugaaguccuuca
    cuaagcgcuucauugacaaccugagagacagguacuaccggugugaccgcaaccugguuuggaaugcgggugcgcugcacu
    acagugacgagguggagaucauccgagggcucacgcgcaugcccaguggccgcgaugagcucaaggccagcguggaugcgg
    ucaaguacuucgggaaaggcaccuacaccgacugcgccauuaagaaggggcuggaggagcugcucauagggggcucccacc
    ugaaggagaacaaguacuugaucguggugaccgacgggcauccucuagagggcuacaaggaaccaugcgggggucuggaag
    augcaguaaaugaggccaaacaccugggcaucaaggucuuuucuguggccaucacaccugaccaccuggagccacgucuaa
    guaucauugccacagaccacacauaccggcgcaauuucacggcagcugacugggggcauagccgcgaugcagaagagguca
    ucagccagaccauugacaccauuguggacaugauuaaaaauaacguggaacaaguguguuguucuuuugagugccaggcug
    ccagaggaccuccagggccccgaggcgacccuggguaugagggggagcgaggaaagccaggucuuccgggagagaagggag
    aagcuggagacccuggacgaccuggggaucuuggaccagucggguaccaggguaugaagggagaaaaggggagccgugga
    gagaaggguuccagaggaccgaaagguuacaagggcgagaaaggcaagcgcggaaucgacggggucgacggcaugaaggga
    gagacgggguacccaggacuaccgggcugcaagggcuccccaggauuugauggcauucaaggacccccgggucccaagggu
    gaugcuggugccuuugggaugaagggagaaaagggugaagcuggagcagacggugaggcugggagaccagggaacucagg
    gucaccuggagaugagggugauccuggagagccugguccccccggagaaaaaggagaggccggugaugaaggaaaugcug
    gcccagacggugccccuggagagagggguggcccuggugaaagaggaccucgggggaccccuggugugagaggaccaagg
    ggagacccgggugaagcuggaccacagggugaccaaggaagagaggggcccgucggcaucccuggagacucgggugaggcu
    ggccccauuggaccuaaaggauaccgaggugaugaggguccuccagguccugagggccucagaggagccccaggaccuguu
    gguccuccuggagaccccggacugaugggugagagaggugaggauggaccaccaggaaacggcacggaagguuuccccggc
    uucccuggguauccaggcaacagaggcccuccugggcuaaauggcacaaaaggcuacccuggccucaagggggaugagggu
    gaagugggagacccaggagaggauaacaacgacauuucaccccguggggucaaaggggcaaagggauaccgaggcccagaa
    ggaccccagggaccuccaggacaugugggaccaccugggccagaugagugugagauccuggauaucaucaugaaaaugugc
    uccugcugugagugcacauguggacccauugacauccucuucgugcuggacagcucggagagcauuggccuacagaacuuu
    gagauugccaaggacuucaucaucaaggucauugaccgguugagcaaggaugagcuggucaaauuugagccagggcagucu
    cacgcgggcgugguacaguacagccacaaccagaugcaagagcacguggacaugcggagccccaacguccgcaacgcccagg
    acuucaaagaagcugucaagaagcuacaauggauggcugguggcacauucaccggagaagcgcugcaguacacccgggacc
    ggcuacucccacccacacagaacaaccgaauugcccuggucauuacggauggacguucugacacucaacgggacacgacacc
    ucucagugugcucuguggugcagacauucagguaguuucugugggaaucaaggauguguuuggcuuuguggcgggcucc
    gaccagcucaaugucauuuccugccaaggcuuaucgcaaggucguccagguaucucccuggugaaggagaacuaugcagag
    cuucucgaugacggcuuucugaagaacauaacagcccagaucuguauagauaagaaguguccggauuauaccuguccaauc
    acauucuccuccccggcugacaucaccauccugcuagacagcucagccagugucggcagccacaacuucgaaaccaccaagg
    ucuucgccaagcgccuagcugagcgauuccugucagcaggcagggcggauccuucccaggaugugcggguggccguggua
    caguauaguggccaggggcagcaacagccaggucgggcggcucuucaguucuuacagaauuacacagugcuggccagcucu
    guggacagcauggauuucaucaacgacgccacagacgucaacgaugcucugagcuacgugacucguuucuaccgggaagcc
    ucgucaggugccaccaagaagagagugcuguuguuuucagacggcaacucucagggggccacagcagaggccauugagaag
    gcugugcaggaggcccagcgugcaggcauugagaucuuuguggugguggugggaccccaggugaacgagccccacauccg
    ugugcuugucacuggcaagacugcagaguacgacguggccuuuggcgagcgccaccuauuccguguaccaaacuaccaggc
    ccugcuacguggcguacucuaccagacagucuccaggaagguggcacugggcuagagggccacacacguggcuggacacac
    auggcauggagacacauuucaacaggccuucccgcccuucccacugacaaaacaggaauaggaaaugugacccaacugguca
    acucaacugucuuaaagggaacgcugagaugcacacucuuugcuuuguguaauguccccuguggcucaccugagcuccuau
    cuagaucccgcccuugguuuguacaucaugguggccaucuugcugaccccucccccaucugggacuggauccagccaucuc
    gucuuccuccucacugccccuaaccuauccguggugucuucacaccaucacugcaguuuccgucuguguucugucuuccau
    gcucaacaugaagcagaccuucucaugaguucagcuugcuggauuauggcuuuuaggaaauugaacacaggaggaguucca
    aacacaaacuuggaggagaccccuccucuucaucaggugcuugucagugaccuacaugcaucuuggucugguccuuagugg
    cuaguccuuccacucugaaagcaaaggugcuaucuaucuguaagggcucucucuacacacccagaggcuuagcuuggacag
    uucacacucaaguguccugucagaaucaauccagagcuuucucccucaaaauagugacuugucucccccugguccccaaagg
    cuccccuuuaguuaguuucuucauggcucccccacauuccccguaaucugauccaagccagcuaucucugcuaauaaaggu
    uuccauuuuucaaaaaaaaaaaaaa
    Tnc/  17 accccaugccccacccccaccuucgauguuuugaacauuucuaacaacug 252
    Tenascin C aagccaguaaagucauauucuuuaaauuuccaggacauucauauuauuc
    AV230686 acauaaucauggucauggugaugauggaaacugaggacuuuaaaagaga
    X56304 uuuucccuucccaaacguuucuggacaguaccugauuguauuuuuuuu
    guuuuguuuuguuuuuuaauaaaagcacaguacuuuucc
    Krt2-6a/  10 Sequence below. 253
    Keratin
    complex 2,
    basic, gene
    6a (keratin
    6a)
    K02108
    gucugcccugccguuucucuacuucccagccuucucaucuccaggaaccaugucuaccaaaaccaccaucaaaagucaaacc
    agccaccguggcuacagugccagcucagccagagugcuuggacucaaccgcucgggcuucagcaguguguccgugugccgc
    ucccggggcagcgguggcuccagugcaauguguggaggagcuggcuuuggcagcaggagccucuaugguguggggagcuc
    caagaggaucuccaucggagggggcagcuguggcauuggaggaggcuauggcagccgauucggaggaagcuucggcauug
    gugguggagcugguaguggcuuuggcuucggugguggagcuggcuuuggugguggcuaugggggagcuggcuucccgg
    ugugcccacuuggaggcauccaagaggucaccaucaaccagagccuccucacaccccugaaccugcaaauugaccccaccau
    ccagcgggucaggacugaggagagggagcagaucaagacccucaauaacaaguuugccuccuucaucgacaaggugcgguu
    cauggagcagcagaacaaggucauggacaccaagugggcccugcugcaagagcaggacaccaagaccgugaggcagaacaug
    gagcccauguuugagcaguacaucagcaaccuccgcagacagcuggacagcaucauuggagagaggggucgcaugaacuca
    gagcugaggaacaugcaggaacucguagaagaacuacggaacaaauaugaagaugaaaucaacaagcgcacagacgcagaga
    augaauucgugacccugaagaaggauguagaugcugccuacaugaacaaaguugaacugcaagccaaggcagacagucuaa
    cagaugauaucaacuucuugagagcucucuaugaagcagaacugucucagaugcaaacucacaucucagacacaucugugg
    uccucuccauggucaacaaccguagccucguccuagacagcaucaucgcugaggucaaggcccaguuugaggucauagcuc
    agagaagucgggcugaagcugagucauuguaccagacuaaauaugaggagcugcaggucacagcuggcagacauggggacg
    accugcgcaacaccaagcaggagauugcugagaucaaccgcaugauccagaggcugagaucugagaucgaccacguuaagaa
    gcagugugccaaccugcaagcugcuauugcugaugcugagcaacguggggagauggcccugaaggaugcaaggggcaagc
    uggaagggcuggaggaugcccugcagaaggccaaacaggacauggccaugcugcugaaggaguaccaugaacucaugaaug
    ucaagcuggcccuugauguggaaauugccaccuacaggaagcugcuggaaggagaggagugcagguugaauggugaaggu
    guuggaccagucaacaucucuguggugcaguccaccguguccagcggcuauggcagugccgggggugccagcagcagcuu
    aggcauggguggaggcagcagcuacuccuauagcagcagccauggccuuggagguggcuucagugcuggcaguggcagag
    ccaucggagguggccucagcucuucugguggccucagcucuucuaccaucaaauacaccaccaccuccuccagcaagaagag
    cuacaggcagugaauucugucaccaagagcuugucucuggucccagaugucauggcugcagcugaaccacaugcuuugguu
    cccggaagggaacgaaucccaaccucuggccuccccauggcucaguucuacauuuguguugcacgucagcaccuauacaug
    uucuuuggugacccagaccccaaaauguugcagaauguagaccuccaagacgaaaccccaaacccuacccagaauacccaccu
    aaauucugucaugguucugacuuccuccagagucuguaaaauaaaaugcccccacaacaaac
    Channel-related
    Potassium
     14 uuuuuuuuuuuuuuuuugauuuuaauuacaaacuuuauuuguccuc 254
    channel, caguucacaguuuauacgugguacaucccaccaugucagcuuccaga
    subfamily acggcuauucaggagauggguggagcuuucuuuguaaaggaacccga
    K, member cauuuuaaaauuuugguuagaaucuucauagguuuauaaaaguacuc
    2 ucugcaagcgaacuggauauauuuacauuuauagcuuaaauucaaau
    AI849601 uuuggaaaauaggaaucuuuuuguguuuuuaaacauccuggguuua
    ugucuuaagacuuuacucugaaugccacaugaucacguaagcccaag
    ccucccccagaagggaaaaaucaguuuugc
    Skd3/   4 uuuuuuuuuuuuuuuuugggugccaugccacagcaaggggccuuua 255
    Suppressor uuagauguucagggcacagacagguggaugcuagaugguguagcaca
    of K+ ccuucucaggguggaguggugccuggauguccaguuugcgggucuu
    transport gcuguccuuaucaaugaucuccagucgcaauguagguggacgcuucu
    defect 3 cagccuggggugagggcagcucacggcucuugaggaggugcuuguc
    AI837887 cgaauccuccacagugauacccagggugcaacccccugg
    Clic4/   3 uuuuuuuuuuuuuuucugacacaguaguaauccuuccagacuccuu 256
    Chloride acacaauauuacaacucccccaguacauaaauguuccuauaccaugca
    intracellular cacagcaacaugggguccacugaugucgcaggcgacuuuucuaaugg
    channel 4 uggaacauagcaccucaaguucugccaucuacacagugaagggacgu
    (mito- gauggucggggcuccagagugacagcaaacugccucuugggugacac
    chondrial) gcuuguggcgaagugccucc
    AI845237
    Col18a1/   5 Sequence below. 257
    Endostatin
    (alpha
    1(XVIII)
    collagen)
    L22545
    gagaauguugcugaggagguggggcugcugcagcuccuuggagacccccuaccugagaagaucucacaaaucgaugacccu
    cacgucgggccggccuacaucuuuggaccagacuccaacaguggccagguggcccaguaucauuucccaaaacucuucuuc
    cgggacuuuucgcugcuguuucauguccggccagccacagaggcagcaggggugcuauuugccaucacagaugcugcccag
    gugguagucucacugggcgugaagcucucagagguccgagauggacagcaaaacaucucauugcucuacacggagccuggg
    gccagccagacccagacgggagccagcuuccgccuaccugcauuuguugggcaguggacacacuucgcgcucagcgucgac
    ggaggcucuguggcucucuacguagacugugaagaauuccagagggugccauuugcucgggccucgcagggacuggagcu
    agagcguggcgcuggccucuuugugggucaggcuggaacagcagacccugacaaguuccaggggaugaucucagagcuga
    agguacgcaaaaccccccgggugagcccugugcacugucuggaugaagaagaugaugaugaagaccgggcaucuggagauu
    uuggaaguggcuuugaagaaagcagcaagucacacaaggaggauacaucucuacuaccugggcucccucagccaccuccug
    ucacuuccccaccccuggcuggaggcagcaccacagaagauccuagaacagaagaaacggaggaagacgccgcgguagauuc
    uauaggagcugagacccuuccuggcacagguucaagcggugcaugggaugaggcuauccagaaccccggaaggggcuugau
    aaagggagguaugaaaggacaaaagggagaaccaggugcccagggcccaccuggcccagcuggcccccaggguccugccgg
    uccagugguccagagccccaacucacaaccugucccuggagcacaaggacccccgggaccucaggggccaccagggaaggau
    ggcacuccaggaagggauggugaaccgggugacccuggugaagaugggagaccgggugacacuggaccucaaggcuuucca
    gggaccccaggagaugugggcccuaagggcgagaagggagauccugguauugggccccgaggaccuccagggccuccaggg
    ccaccaggacccuccuucagacaagacaagcugaccuucauugacauggagggauccgguuucagcggagacauagagagcc
    uuagaggcccacgaggcuucccuggccccccggggcccccuggugucccaggacuuccuggugagccaggacgcuuuggga
    ucaaugguuccuaugcaccaggaccugcaggccuuccugguguaccugggaaggaaggaccccccgguuuuccaggucccc
    cgggaccuccagguccuccaggcaaagagggcccaccaggaguggccggccagaaaggcaguguuggugaugugggcaucc
    caggacccaaggggagcaaaggagaccuugggcccaucgguaugccuggcaagucuggcuuggcuggauccccugggccag
    uuggacccccaggaccuccagggccuccagggccaccaggaccaggauuugcugcuggauucgaugauauggaaggcucug
    gaauaccccucuggacaacagcccgaagcucugaugggcugcagggaccucccgggucgccgggacucaagggggauccug
    gaguggcaggccuaccuggagccaagggagaaguuggagcagauggagcccagggcaucccuggucccccaggaagagaag
    gugcagcuggaucuccggggccaaaaggagagaaggggaugccgggagaaaagggaaacccaggaaaagauggagugggcc
    ggccgggccucccugggccuccaggaccuccagggcuggugaucuaugugucaagugaggauaaagcaauagugagcacgc
    caggaccugagggcaagccaggguacgcaggcuuuccuggaccugcuggaccgaagggugaccuggguuccaaaggcgagc
    agggucuuccgggguuuaagggugagaagggagagccaggcacuaucuuuaguccugauggcagacgucugggccauccc
    cagaagggagccaagggagagccaggcuuucgaggacccccggguccuuauggacgaccugggcacaagggugaaauuggc
    uucccuggacggccgggucgaccuggaacgaauggcuuaaagggagagaagggagagccuggagaugccagccuuggguu
    cagcaugaggggauugccuggccccccugggccuccaggacccccagguccuccugggaugcccaucuaugacagcaaugc
    auuuguggagucuggccgaccuggacuaccaggacagcagggugugcaggggccuucaggaccaaagggugacaaaggaga
    gguggggccaccugggccaccagggcaauuccccauugaccucuuccaccuggaagcggaaaugaagggggacaagggaga
    ccgaggggaugcuggacagaaaggagagaggggagaaccuggggcuccuggugguggauucuucagcucaaguguaccug
    gcccacccggcccaccuggauacccuggaauuccggguccaaagggagagagcauccgggggccaccuggcccuccuggccc
    gcagggaccuccuggcauuggcuaugagggucgccagggucccccaggaccuccaggaccuccaggaccucccuccuuccc
    uggcccucacagacagacugucaguguuccugguccuccgggcccaccugguccuccaggucccccaggagccaugggugc
    cucugcugggcaggugaggaucugggccacauaccagaccaugcuggacaagauccgggaggugccggagggcuggcuca
    ucuuuguggccgagagggaagagcucuauguacgcguuagaaauggcuuccggaaggugcugcuggaggcccggacagcc
    cuccugagaggcacgggcaaugagguggcugcuuuccagcccccauugguccagcuucaugagggcaguccauacacccgg
    agggaguacuccuauuccacggcacgacccuggcgagcagaugacauccuggccaacccaccgcgccugccagaccgccagc
    cuuacccuggaguuccacaucaccacaguuccuaugugcaccugccgccagcccgccccacccucucacuugcucauacuca
    ucaggacuuucagccagugcuccaccugguggcacugaacaccccccugucuggaggcaugcgugguauccguggagcaga
    uuuccagugcuuccagcaagcccgagccguggggcugucgggcaccuuccgggcuuuccuguccucuaggcugcaggauc
    ucuauagcaucgugcgccgugcugaccgggggucugugcccaucgucaaccugaaggacgaggugcuaucucccagcugg
    gacucccuguuuucuggcucccagggucaagugcaacccggggcccgcaucuuuucuuuugacggcagagauguccugag
    acacccagccuggccgcagaagagcguauggcacggcucggaccccagugggcggaggcugauggagaguuacugugagac
    auggcgaacugaaacuacuggggcuacaggucaggccuccucccugcugucaggcaggcuccuggaacagaaagcugcgag
    cugccacaacagcuacaucguccugugcauugagaauagcuucaugaccucuuucuccaaauaggccucugccagcuaggg
    uggcagacagaggccaugcagaacuuugacacagcgcagggagcauucagucagcacccagggcucuggcugggauacaac
    uccuguauaguucccauuuuuauguaauccucaagaaauaaaaggaagccaaagaguaaaaaaaaa
  • TABLE 5
    Genes down-regulated in HF stem cells.
    Gene Fold SEQ
    Name/protein Decr Sequence ID No.
    Growth Factors, Receptors and Downstream genes
    GNA- 14 32 Sequence below. 258
    Mouse G
    protein alpha
    subunit (GNA-
    14)
    M80631
    aacugccuucgagaagcguuagccuagagauccgagccucuucuccauaccauaguugguucaggugguuuccucuucaaa
    ccuugcgucugcggauaauccgcgcggccgggcguuaagcuccaggucccugucgcuccgucgagguggcaagccauggcc
    ggcugcugcuguuugucugcggaggagaaagagucucagcgcaucagcgcggagaucgagcggcacguucgccgcgacaa
    gaaggacgcgcgccgggagcucaagcugcuguugcugggaaccggugagagugggaaaagcaccuuuaucaagcagaugag
    gauaauccaugggucuggcuacagugaugaagauagaaagggcuucacgaagcugguuuaccaaaacauauucacggccau
    gcaagccaugaucagagcaauggauacccugaggauacaauacaugugugagcagaauaaggaaaaugcccagaucaucagg
    gaaguggaaguagacaaggucacugcacucucuagagaccagguggcagccaucaagcagcuguggcuggaucccggaauc
    caggaguguuacgacaggaggagggaguaccagcugucagacucugccaaauauuaccugacggacauugagcguaucgcc
    augcccucuuucgugccaacacaacaggaugugcuucguguuagagugcccaccacuggcaucauagaauauccauucgac
    cuggaaaacaucaucuuccgaaugguggauguugguggccagcgaucugaacgacggaaauggauucacugcuuugagag
    ugucaccuccaucauuuucuugguugcucugagugaauaugaccagguucuggcugagugugacaaugagaaccgcaugg
    aggagagcaaagcccuguuuagaaccaucaucaccuaccccugguuucugaacuccuccgugauucuguucuuaaacaaga
    aggaucuucuagaggagaaaaucauguacucucaucuaauuagcuacuucccagaguacacaggaccaaagcaagaugucaa
    agcggccagggacuuuauccugaagcuguaucaagaccagaauccugacaaagagaagguuaucuauucucacuucacuug
    ugcuacagacaccgagaauauccgcuuuguguuugcugcugucaaagacacaauccuacagcuaaaccuacgggaguucaa
    cuugguguaaauggagggccuacuccuccgagacagagggugaucugagcccuuccugccugaucuacaagugcuucugg
    accaggaccuaaggacauuauguagcccacaggacagagauggguagugcaaugugaaaaauacuucaccaacccuuuuaag
    ugucuuuaauucuucacugucuaacucuuuucucgccuuuugguugaacgauuagguaucauuuuugagugguucccccu
    cuccuauuuuuuuaaacuaguguucaacaguuauuaaaaaaucaugc
    Ly6/Lympho- 12 gaauucccugcaaccuugucugagaggaagcaaggacuggugugag 259
    cyte antigen 6 gagggagcugugagguuuuaucugugcagcccuucucugaggaug
    complex gacacuucucacacuacaaaguccuguuugcugauucuucuugugg
    X04653 cccuacugugugcagaaagagcucagggacuggaguguuaccagug
    cuauggagucccauuugagacuucuugcccaucaauuaccugccccu
    acccugauggagucuguguuacucaggaggcagcaguuauuguggg
    uucucaaacaaggaaaguaaagaacaaucuuugcuuacccaucugcc
    cuccuaauauugaaaguauggagauccuggguacuaaggucaaugu
    gaagacuuccuguugccaggaagaccucugcaaugcagcaguuccca
    auggaggcagcaccuggaccauggcaggggugcuucuguucagccu
    gagcucaguccuccugcagaccuugcucugaugguccucccaaugac
    cuccacccuuguccuuuuauccucaugugcaacaauucuuccugga
    gcccucuagugaugaauuaugaguuauagaagcuccaaggugggag
    uagugugugaaauaccauguuuugccuuuauagcccugcuggguag
    guaggugcucuaauccucucuagggcuuucaagucuguacuuccua
    gaaugucauuuuguuguggauugcugcucaugacccuggaggcaca
    cagccagcacagugaagaggcagaauuccaagguauuaugcuaucac
    cauccacacauaaguaucugggguccugcaauguucccacauguauc
    cugaaugucccccuguugaguccaauaaacccuuuguucuccc
    Bmp4/Bone 11 Sequence below. 260
    morphogenetic
    protein
     4
    L47480
    ggaagaaagagagggagggaaaagagaaggaaggaguagaugugagaggguggugcugagggugggaaggcaagagcgcg
    aggccuggcccggaagcuaggugaguucggcauccgagcugagagaccccagccuaagacgccugcgcugcaacccagccu
    gaguaucuggucuccgucccugaugggauucucgucuaaaccgucuuggagccugcagcgauccagucucuggcccucgac
    cagguucauugcagcuuucuagagguccccagaagcagcugcuggcgagcccgcuucugcaggaaccaauggugagcaggg
    caaccuggagaggggcgcuauucugaggauucgaggugcacccguaguagaagcuggggauggggcucaggcuguaaccg
    aggcaaaaguuggccuauuccuccuuccuucuccaacaguguuggaggugggaugauggaggcuaaaaggcaccuccauau
    auguuacugcgucuaucaaccuacuuuagggaggugcgggccaggagaggcgggaaggagagaaggccuuggaagagagg
    ucauugggaagaacugugggguuugguggguuugcuuccacuuagacuauaagagugggagaggagggagucaacucuaa
    guuucaacaccagugggggacugaggacugcuucauuaggagagagaaccuagccagagcuagcuuugcaaaagaggcugu
    aguccugcuuugcucuaaagcgcgacccgggauagagaggcuuccuugagcggggugucaccuaaucuuguccccaacgca
    cccccucccagccccugagagcuagcgaacuguagguacacaacucgcucccaucuccaggagcuauuuucuuagacauggg
    cacccaugauucugccuucugguacucuccccucccugggaaagggguguaagguuccgacggaaccguggccaggaugcc
    gaaaggcuaccugugcgggucuucugccaugcugugucugugcggacaugccagcagggcuaaugaggagcuugcgauac
    uccaaaggguucgggaauugcgggguccuuacacgcaguggaguugggccccuuuuacucagaagguuuccgccacggcu
    uugguugauaguuuuuuuaguauccugguuuaugaacugaagguuuugugagauguugaaucacuagcagggucauauu
    uggcaaaccgaggcuacuauuaaauuuugguuuuagaagaagauucuggggagaaagugaaggguaacugccuccaggag
    cuguaucaaccccauuaagaaaaaaaaaaauaccaggagaugaaaauuuacuuugaucuguauuuuuuaauuaaaaaaaauc
    agggaagaaaggagugauuagaaagggauccugagcgucggcgguuccacggugcccucgcuccgcgugcgccagucgcua
    gcauaucgccaucucuuucccccuuaaaagcaaauaaacaaaucaacaauaagcccuuugcccuuuccagcgcuuucccagu
    uauucccagcggcgacgcgugucggggaauagagaaaucgucucagaaagcugcgcugaugguggugagagcggacuguc
    gcucaggggcgcccgcggucucugcacccagggcagcagugugggauggcgcugggcagccaccgccgccaggaaggacgu
    gacucuccauccuuuacacuucuuucucaaagguuucccgaaagugccccccgccucgaaaacuggggccggugcgggggg
    ggggagagguuagguugaaaaccagcuggacacgucgaguuccuaagugaggcaaagaggcgggguggagcgggcucugg
    agcgggggaguccugggacucgguccucggauggaccccgugcaaagaccuguuggaacaagaguugcgcuuccgagguu
    agaacaggccaggcaucuuaggauagucaggucacccccccccccaaccccacccgaguuguguuggugaauuucuuggag
    gaaucuuagccgcgauucuguagcuggugcaaaaggaggaaaggggugggggaaggaaguggcngngcggggguggcgg
    uggggguggaggugguuuaaaaaguaagccaagccagagggagaggucgagugcaggccgaaagcuguucucggguuugu
    agacgcuugggaucgcgcuuggggucuccuuucgugccggguaggaguuguaaagccuuugcaacucugagaucguaaaa
    aaaaugugaugcgcucuuucuuuggcgacgccuguuuuggaaucuguccggaguuagaagcucagacguccaccccccacc
    ccccgcccacccccucugccuugaauggcaccgccgaccgguuucugaaggaucugcuuggcuggagcggacgcugagguu
    ggcagacacgguguggggacucuggcggggcuacuagacaguacuucagaagccgcuccuucuaacuuucccacaccgcuc
    aaaccccgacacccccgcggcggacugaguuggcgacggggucagagucuucuggcugaaaguuagauccgcuaggggucg
    gcugccugucgcuagaagcauuauuuggccucucggagacccguguggaggaagugcuggagugugcgaguguguuugc
    gugugugugugugugugugugugugugugugugugugugugugugcgcgcgcccuuggagggucccuaugcgcuuucc
    uuuucauggaacgcugucgugaggcuuugguaaacugucuuuucgguuccucucucggcugcacuuaagcuuugucggcg
    cuguaaagagacgcgucuucaagugcacccugauccucaggcuucagauaacccguccccgaaccuggccagaugcauugca
    cugcgcgccgcagguagagacgugccccacguccccugcgugcagcgacuacgaccgagagccgcgccagugugguguccc
    gccgagaguuccucagagcaggcggggacaacucccagacggcuggggcuccagcugcgggcgcggagguuggccucgcuc
    gcaggggcuggacccagccggggugggaggauggaggaggggcgggcgggcucuucggugaguggggcggggccucugg
    guccacgugacuccuaggggcuggaagaaaaacagagccugucugcuccagagucucauuauaucaaauaucauuuuagga
    gccauuccguagugccauucggagcgacgcacugccgcagcuucucugagccuuuccagcaaguuuguucaagauuggcuc
    ccaagaaucauggacuguuauuaugccuuguuuucugucagugaguagacaccucuucuuucccuucuugggauuucacu
    cuguccucccaucccugaccacugucugucccucccgucggacuuccauuucagugccccgcgcccuacucucaggcagcgc
    uaugguucucuuucuggucccugcaaggccagacacucgaaauguacgggcuccuuuuaaagcgcucccacuguuuucucu
    gauccgcugcguugcaagaaagagggagcgcgagggaccaaauagaugaaagguccucagguuggggcugucccuugaag
    ggcuaaccacucccuuaccagucccgauauauccacuagccugggaaggccaguuccuugccucauaaaaaaaaaaaaaaaa
    acaaaaaacaaacagucguuugggaacaagacucuuuagugagcauuuucaacgcagcgaccacaaugaaauaaaucacaaa
    gucacuggggcagccccuugacuccuuuucccagucacuggaccuugcugcccgguccaagcccugccggcacagcucugu
    ucuccccuccuccuguucuuaaccagcuggaaguuguggaaauugggcuggagggcggaggaagggcgggggugggggg
    guggagaaggugggggggggggaggcugaagguccgaagugaagagcgauggcauuuuaauucucccuccnccucccccc
    uuuaccuccucaauguuaacuguuuauccuugaagaagccacgcugagaucauggcucagauagccguugggacaggaugg
    aggcuaucunauuugggguuauuugaguguaaacaaguuagaccaaguaauuacagggcgauucuuacuuucgggccgug
    cauggcugcagcugguguguguguguguagggugugagggagaaaacacaaacuugaucuuucggaccuguuuuacaucu
    ugaccgucgguugcuaccccuauaugcauaugcagagacaucucuauuucucgcuauugaucgguguuuauuuauucuuu
    aaccuuccaccccaacccccuccccagagacaccaugauuccugguaaccgaaugcugauggucguuuuauuaugccaaguc
    cugcuaggaggcgcgagccaugcuaguuugauaccugagaccgggaagaaaaaagucgccgagauucagggccacgcggga
    ggacgccgcucagggcagagccaugagcuccugcgggacuucgaggcgacacuucuacagauguuugggcugcgccgccgu
    ccgcagccuagcaagagcgccgucauuccggauuacaugagggaucuuuaccggcuccagucuggggaggaggaggaggaa
    gagcagagccagggaaccgggcuugaguacccggagcgucccgccagccgagccaacacugugaggaguuuccaucacgaa
    ggucaguuucugcucuuaguccuggcgguguagggugggguagagcrccggggcagaggguggggggugggcagcuggc
    agggcaagcugaagggguuguggaagcccccggggaagaagaguucauguuacaucaaagcuccgaguccuggagacugu
    ggaacagggccucuuaccuucaacuuuccagagcugccucugaggguacuuucuggagaccaaguagugguggugauggg
    ggaggggguuacuuugggagaagcggacugacaccacucagacuncugcuaccncccagnggguguucuuuagcuauacc
    aaagncagggauucugcccguuuuguuccaaagcaccuacugaauuuaauauuacancuguguguuugucagguuuauca
    auaggggccuuguaauacgaucugaauguuuccuagcggauguuucuuuuccaaaguaaaucugaguuauuaauccucca
    gcaucauuacuguguuggaauuuauuuucccuucuguaacaugaucaacaaggcgugcucuguguuucuaggaucgcugg
    ggaaauguuugguaacauacucaaaaguggagagggagagaggguggccccucuuuuucuuuacaaccacuuguaaagaaa
    acuguacacaaagccaagagggggcuuuaaaaggggaguccaagggugguggaguaaaagaguugacacauggaaauuauu
    aggcauauaaaggagguugggagauacuuucugucuuugguguuugacaaaugugagcuaaguuuugcugguuugcuag
    cugcuccacaacucugcuccuucaaauuaaaaggcacaguaauuuccuccccuuagguuucuacuauauaagcagaauucaa
    ccaauucugcuauuuuuuguuuuuguuucuuguuuuuguuuuguuugguuuuuuuuuuuuuuuuuuuuuuuuugucu
    cagaaaagcucaugggccuuuucuuuuccccuuucaacugugccuagaacaucuggagaacaucccagggaccagugagag
    cucugcuuuucguuuccucuucaaccucagcagcaucccagaaaaugaggugaucuccucggcagagcuccggcucuuucg
    ggagcagguggaccagggcccugacugggaacagggcuuccaccguauaaacauuuaugagguuaugaagcccccagcaga
    aaugguuccuggacaccucaucacacgacuacuggacaccagacuaguccaucacaaugugacacggugggaaacuuucgau
    gugagcccugcaguccuucgcuggacccgggaaaagcaacccaauuaugggcuggccauugaggugacucaccuccaccag
    acacggacccaccagggccagcaugucagaaucagccgaucguuaccucaagggaguggagauugggcccaacuccgccccc
    uccuggucacuuuuggccaugauggccggggccauaccuugacccgcaggagggccaaacguagucccaagcaucacccac
    agcgguccaggaagaagaauaagaacugccgucgccauucacuauacguggacuucagugacgugggcuggaaugauugga
    uuguggccccacccggcuaccaggccuucuacugccauggggacugucccuuuccacuggcugaucaccucaacucaaccaa
    ccaugccauugugcagacccuagucaacucuguuaauucuaguaucccuaaggccuguuguguccccacugaacugagugc
    cauuuccauguuguaccuggaugaguaugacaaggugguguugaaaaauuaucaggagauggugguagaggggugugga
    ugccgcugagaucagacaguccggagggcggacacacacacacacacacacacacacacacacacacacacacacacguuccc
    auucaaccaccuacacauaccacacaaacugcuucccuauagcuggacuuuuaucuuaaaaaaaaaaaaaagaaagaaagaaa
    gaaagaaagaaaaaaaaugaaagacagaaaagaaaaaaaaaacccuaaacaacucaccuugaccuuauuuaugacuuuacgug
    caaauguuuugaccauauugaucauauuuugacaaauauauuuauaacuacauauuaaaagaaaauaaaaugag
    IL1r2/Inter- 11 gaaucccacuuacaugcgagcaucucuauauacauccucaaucuauc 261
    leukin 1 cccucgaauccacggacuuaucagucaaucaauacuacagucaaaga
    receptor, type auuuuuuucuacguuauccuggagcauugcgcuggcaccucuuuuu
    II cuaaucaucuugguuguggggccaauauggaugcgcagacggugua
    AV223216 aacgcagggcuggaaagacauauggacugaccaagcuacggacugac
    X59769 aaccaggacuucccuuccagcccaaacuaaauaaaggaaaugaa
    Wnt3a/wing-  4 Sequence below. 262
    less-related
    MMTV
    integration site
    3A
    X56842
    gaauucaugucuuacggucaaggcagagggcccagcgccacugcagccgcgccaccucccagggccgggccagcccaggcg
    uccgcgcucucgggguggacuccccccgcugcgcgcucaagccggcgauggcuccucucggauaccucuuagugcucugca
    gccugaagcaggcucugggcagcuacccgaucuggugguccuuggcugugggaccccaguacuccucucugagcacucagc
    ccauucucugugccagcaucccaggccugguaccgaagcagcugcgcuucugcaggaacuacguggagaucaugcccagcg
    uggcugagggugucaaagcgggcauccaggagugccagcaccaguuccgaggccggcguuggaacugcaccaccgucagca
    acagccuggccaucuuuggcccuguucuggacaaagccacccgggagucagccuuuguccaugccaucgccuccgcuggag
    uagcuuucgcagugacacgcuccugugcagagggaucagcugcuaucugugggugcagcagccgccuccagggcuccccag
    gcgagggcuggaaguggggcggcuguagugaggacauugaauuuggaggaauggucucucgggaguuugccgaugccag
    ggagaaccggccggaugcccgcucugccaugaaccgucacaacaaugaggcugggcgccaggccaucgccagucacaugcac
    cucaagugcaaaugccacgggcuaucuggcagcugugaagugaagaccugcugguggucgcagccggacuuccgcaccauc
    ggggauuuccucaaggacaaguaugacagugccucggagauggugguagagaaacaccgagagucucguggcugggugga
    gacccugaggccacguuacacguacuucaaggugccgacagaacgcgaccuggucuacuacgaggccucacccaacuucugc
    gaaccuaaccccgaaaccggcuccuucgggacgcgugaccgcaccugcaaugugagcucgcauggcauagaugggugcgac
    cuguugugcugcgggcgcgggcauaacgcgcgcacugagcgacggagggagaaaugccacuguguuuuccauuggugcug
    cuacgucagcugccaggagugcacacgugucuaugacgugcacaccugcaaguaggagagcuccuaacacgggagcagggu
    ucauuccgaggggcaagguuccuaccugggggcgggguuccuacuuggaggggucucuuacuuggggacucgguucuuac
    uugagggcggagauccuaccugugagggucucauaccuaaggacccgguuucugccuucagccugggcuccuauuuggga
    ucuggguuccuuuuuaggggagaagcuccugucugggauacggguuucugcccgaggguggggcuccacuuggggaugg
    aauuccaauuugggccggaaguccuaccucaauggcuuggacuccucucuugacccgacagggcucaaauggagacaggua
    agcuacucccucaacuaggugggguucgugcggaugggugggaggggagagauuagggucccuccucccagaggcacugc
    ucuaucuagauacaugagagggugcuucagggugggcccuauuugggcuugaggaucccgugggggcggggcuucacccc
    gacuggguggaacuuuuggagacccccuuccacuggggcaaggcuucacugaagacucaugggauggagcuccacggaagg
    aggaguuccugagcgagccugggcucugagcaggccauccagcucccaucuggccccuuuccaguccugguguaagguuca
    accugcaagccucaucugcgcagagcaggaucuccuggcagaaugaggcauggagaagaacucaggggugauaccaagacc
    uaacaaaccccgugccuggguaccucuuuuaaagcucugcaccccuucuucaagggcuuuccuagucuccuuggcagagcu
    uuccugaggaagauuugcagucccccagaguucaagugaacacccauagaacagaacagacucuauccugaguagagaggg
    uucucuaggaaucucuauggggacugcuaggaaggauccugggcaugacagccucguaugauagccugcauccgcucugac
    acuuaauacucagaucucccgggaaacccagcucauccgguccgugauguccaugccccaaaugccucagagauguugccuc
    acuuugaguuguaugaacuucggagacauggggacacagucaagccgcagagccaggguuguuucaggacccaucugauuc
    cccagagccugcuguugaggcaauggucaccagauccguuggccaccacccugucccgagcuucucuagugucugucuggc
    cuggaagugaggugcuacauacagcccaucugccacaagagcuuccugauugguaccacugugaaccgucccucccccucca
    gacaggggaggggauguggccauacaggagugugcccggagagcgcggaaagaggaagagaggcugcacacgcgugguga
    cugacugucuucugccuggaacuuugcguucgcgcuuguaacuuuauuuucaaugcugcuauauccacccaccacuggau
    uuagacaaaagugauuuucuuuuuuuuuuuuucuuuucuuucuaugaaagaaauuauuuuaguuuauaguauguuuguu
    ucaaauaauggggaaaguaaaaagagagaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
    Il12rb2/  3 Sequence below. 263
    Interleukin 12
    receptor, beta 2
    U64199
    cgcaccggagguccacacugccgcguggacuccagcgauggcgcugcgcuaggcuagcgggugccaggaucccucucugcg
    uccugugcgcgggaagagcucuggagaaccagaguugcauucuggaguugaagacucauggcacagacuguuagagaaug
    cucauuggcacuucuuuuuuuguucauguggcugcugauuaaagcaaauauagaugugugcaagcuuggcacugugaccg
    uccagccugccccugugauuccucuugggucagcugccaauauuuccugcuccuugaaucccaagcaaggcuguucacauu
    aucccaguucuaacgaauuaauccucuuaaaguuugucaaugauguccuuguugaaaaucuccauggcaagaaaguccaug
    accacacuggucacuccuccacuuuucaagucaccaaccugucccuugguaugaccuuguuugucugcaagcuaaacugua
    gcaacucucaaaagaagccaccagucccaguaugugggguggagaucucaguugguguugcuccagagccaccucaaaaca
    uaucauguguccaggaaggagaaaauggaacuguggccuguuccuggaacucuggaaaaguuacuuaucugaaaaccaauu
    acacuuuacaguuaaguggaccaaacaaucugaccugucagaaacaauguuuuucugacaaucgucagaauugcaaucgcc
    uggaucuugggaucaaucuaagcccugauuuagcugaauccagguucauaguccguguuacugccaucaacgaucuuggaa
    auucuucuucacuuccgcauacguucacguucuuggacauagugaucccucuuccuccgugggacaucagaaucaacuuuc
    uaaaugcuucugggagcagagguacacugcagugggaagaugaggggcaagugguacucaaucaacucagauaucagccuc
    uuaacagcacguccuggaacauggucaaugcuacaaaugccaaaggaaaauaugaccugcgagaucugagaccguuuacaga
    auaugaauuucaaaucuccucuaagcuacaucucucuggaggaaguuggaguaauuggagugagucacugagaacacgaac
    accagaggaagagccuguugggauauuagacaucugguacaugaaacaagacaucgacuaugacagacagcagaucucucu
    uuucuggaagagucugaauccaucagaggcaagggggaagauccuccacuaucaggugacguuacaagaggugacaaagaa
    aacaacacugcagaauacuacaagacacaccuccuggaccagggucaucccccgaacuggggcuuggacggcaucagugucu
    gcagccaacucaaaaggcgcuucugcacccacucacauuaacauaguggaccuauguggcacuggguugcuggcuccucac
    caggucucugcaaagucggagaacauggacaacauucuagugaccuggcagccuccuaagaaagcugauucugcuguucgg
    gaguacauaguggaauggagagcucuccaaccagggagcaucacgaaguuucccccacacuggcugcggauccccccggaca
    acaugucugcucugauuucagagaacauaaagcccuauaucuguuaugaaaucagggugcaugcacugucagagagccaag
    gagggugcagcuccauccggggugacuccaagcacaaagcaccagugaguggcccucacauuacugccaucacagagaaaaa
    ggaacgccuuuucauuuccuggacccacauuccauucccggagcaaaggggcugcauccuccauuacagaauauacuggaa
    agaacgagacucgacagcacaaccugagcucugcgaaauucaguaccgacgcucucaaaacucacauccaauaagcagccuac
    agcccagggugacauauguccuauggaugacagcugugacagcugcuggugaaaguccccaaggaaaugaaagggaauuuu
    guccacagggcaaagccaacuggaaagcauucgugauaucaagcauuugcaucgcuaucaucacggugggcacguucucaa
    uucguuacuuccggcaaaaggcauuuacucuccugucuacucucaaaccucaaugguauagcagaaccauuccagauccagc
    aaacagcacuuggguaaagaaguaucccauucuggaggagaagauccagcuaccuacggauaaucuccugauggcauggcc
    cacuccugaagagccugagccccugaucauccaugaaguccucuaccacaugaucccaguugucagacaaccauauuacuuc
    aaaagaggccaaggauuccaaggcuacucuaccuccaagcaagaugcaauguauauugccaauccacaagcuacaggaacuc
    ucacagcugagaccagacaacuagugaaccuauacaaggugcuagaaagcagagacccugacucaaaacuggccaaccugac
    cagccccuugacagucaccccagugaacuaccuuccuagccaugaaggcuauuuacccuccaacauagaagaucugucacca
    caugaggcugacccaacugauucuuuugaccuggagcaucaacauauuucucuuuccauuuuugcaucaaguucucuccgc
    ccacucaucuucgguggugagcggcugacucuagaucgguuaaagaugggcuaugacucccucaugaguaaugaggcuug
    auacuagaaagccaacguaccucauuuuaucugcccaguuccuacuccaaaggucugugacagugaagacaagccagcuguc
    ucuggauaaaguuagcuucaccauagguacuuaagucuuauggauaagguggcaauacaccaacacugauaucauauagaa
    aggaccccaagauagucaugcuc
    Wnt10a/Wing-  3 Sequence below. 264
    less-related
    MMTV
    integration site
    10a
    U61969
    ggcacgaguucacccucugcaugcguuccccuccccccucuccagcaaacacggcgcgccaguccaaagcggacucaguggc
    cucggggacgggagcaugccaccuccuguggugacgucacuugggguagaacccuuagacacuacauggggggggggggu
    acagaacucccgagccaggacagucacucacucuucaggcgguggggcugggccagacaguaccgcccccaccgcgcccgcc
    ucgcacacccucggaagcgcaggcucgcagcgcggcgcuggggugggggguugcgccccagaacuucggccuccagucccc
    agcccgcugcaccuccuuacccucuagaggcccccucccccuuacccucuagaggcaccaggaguugucgcaaggggcccuu
    gggaaauucccuggaccccugugccaggaggugcccgguucgcccgcuccccauccacccccccgagggcggugcccgggg
    gcgcugccccauggagcggggaggcgggcgccgucugcugcgggagcugugaccugaguaggagcugugugucgcagccg
    ccccaccccugccgaucaugcgccggcgacccugguucgccagucccacugggcugugagccccccacuccuggccugucac
    ggcccgcgcgccaugggcagcgcccacccucgccccuggcugcggcucccacaagggccccagccgcggccugaguucugg
    gcgcuccuguucuuccuacugcugcuggcugccgcugugcccaggucagcacccaacgacauccugggccuccgccuaccc
    ccagagcccgugcucaacgccaacacagugugccugacauugcccggccugagccggcggcagauggaggugugugugcgu
    cacccugacguggccgccucugcuauccagggcauccagaucgccauccaugagugccagcaucaguuccgggaccagcgc
    uggaacugcuccagccuggagacucggaacaaaguccccuacgagagccccaucuucagccgagguuuucgagagagugcu
    uucgccuacgccauagcagcugccgggguggugcacgcaguguccaacgcgugcgcucuggguaaacugaaggcuugcgg
    uugcgacgccuccagacguggggacgaagaagcuuuccgucggaagcugcaccgcuugcagcuggacgcgcugcagcgcgg
    aaagggcuugagccacggggucccugaacacccggccauacuuccugccagcccaggucugcaggacuccugggagugggg
    uggcugcaguccggaugugggcuucggagaacgcuucucuaaggacuuucuggacucccgagagccucacagagacaucca
    ugcucgaaugagacuccacaacaaccgugugggccggcaggcggugauggagaacaugcggcguaagugcaaaugccacgg
    caccucaggcagcugccagcucaagaccugcuggcaggugacgccugaguuccgcacaguaggggcgcugcugcgcaaccg
    cuuccaccgcgccacgcucauccggccgcacaaccgcaacgguggccagcuggagcccggccccgcgggagcacccucgcca
    gcaccgggcacuccagggcugcgccgcagggccagccacuccgaccuggucuacuuugagaaaucucccgacuucugugag
    cgcgagccgcgccuggacucggcaggcacugugggccgccugugcaauaagagcagcacgggucccgauggcugcggcagc
    augugcuguggccgcggccacaacauucugcgccagacgcgcagcgagcgcugccacugccgguuccacuggugcugcuuc
    guggucugcgaagaaugccgcaucaccgagugggucagcgucugcaagugagcagacccaagcuccucugggucucaagaa
    ugguuguccucuuggugccuggcuucugccgcuagcggaucugagccaggcagcaagcagcagccuuggcuccugagaga
    ggugguuggcucuuacagccccgagggucuacaaucaccagacaguccagaucugauugacauuccuccgcucaccucugu
    agguuccccucuuucuguuccuagcucagacagcugggggugauaguggagacuguuccacacccuaggacaggucaccaa
    agcagcccagccuggcaugccuaccuccugucaucucuucuucccuuccccaggagugauaggcaaugcacugaagcugau
    gggcaccggggaagaaaacuaaaaggcagaaauggccgucaucgggcugaagugacucuaagggcuccagaccucugcucc
    ugucuuucacuuaacagauauuuauuuuugcgcucucuuugagacacucucuggggaaaaagaagcuccggagucuacag
    gcugauuaagggacauggacaauaaaccaguaaacacacaaaaaaaaaaaaaaaaaa
    Ifngr2/Inter-  3 Sequence below. 265
    feron-gamma
    receptor
    precursor
    M28233
    gaauuccgggccgcuugcacuuggcgacuagucugcggcggacgugacgccaaggccacgggcagcgcggguccccuguca
    gaggugucccucgcgcaggaaugggcccgcaggcggcagcuggcaggaugauucugcuggugguccugaugcugucugcg
    aaggucgggaguggagcuuugacgagcaccgaggauccugagccucccucggugccuguaccgacgaauguucuaauuaag
    ucuuauaacuugaacccugucguaugcugggaauaccagaacaugucacagacuccuauuuuuacuguacagguaaaggug
    uauucggguuccuggacugauuccugcaccaacauuucugaucauuguuguaauaucuaugaacaaauuauguauccuga
    uguaucugccugggccagaguuaaagcuaagguuggacaaaaagaaucugacuaugcacggucaaaagaguuccuuaugug
    ccuaaagggaaaggucgggcccccuggccuggagaucaggaggaagaaggaagaacagcucuccguccucguauuucaccc
    ugaagucguugugaauggagagagccagggaaccauguuuggugacgggagcaccuguuacacauucgacuauacugugu
    auguggagcauaaccggaguggggagauccuacauacgaaacauacggucgaaaaagaagaguguaaugagacucugugug
    aguuaaacaucucaguauccacacuggauuccagauauuguauuucaguagacggaaucucaucuuucuggcaaguuagaa
    cagaaaaaucgaaagacgucuguaucccuccuuuccaugaugacagaaaggauucaauuuggauucuggugguugcuccuc
    uuaccgucuuuacaguaguuauccugguauuugcguauugguauacuaagaagaauucauucaagagaaaaagcauaaugu
    uaccuaaguccuugcucucugugguaaaaagugccacguuagagacaaaaccugaaucgaaguauucacuugucacaccgc
    accagccagcuguccuagagagugagacggugaucugugaagagccccuguccacagugacagcuccagacagccccgaagc
    agcagaacaggaagaacuuucaaaagaaacaaaggcucuggaggcuggaggaagcacgucugccaugaccccagacagcccu
    ccaacuccgacacaaagacgcagcuuuucccuguuaaguaguaaccagucaggcccuuguagccucaccgccuaucacuccc
    gaaacggcucugacaguggccucgugggaucgggcagcuccauaucggacuuggaaucucucccaaacaacaacucagaaac
    aaagauggcagagcacgacccuccacccgugagaaaggcccccauggccuccgguuaugacaaaccgcacauguugguggac
    gugcuuguggauguuggggggaaggagucucucaugggguauagacucacaggagaggcccaggagcuguccuaaggucu
    cccgaggccugcuggugguaaagaaacugaccuuuuaggcaguuuuucugcauugauuucaugaaagaagcuauacauua
    gcuaauacuaaccacauagaauaucagacuuagauacgugaauaaggauccugugggcacugcuggguccacucugcaaau
    gccaagacuaucaaaggaacguauugucgcuucuggcuccuucccaggugggcuagcaucugugaguuugccucggcuag
    ccuugcuuccuacagccgccacugcuccuccacccugaucaucucacaggacaggguggaccggguuuuuuuuuuuuuuuc
    acacaccuuuguauauguaaguucauguauauaauauguuuacauguuucacuuugaacugaaagcuacucaaagccagcc
    guaagucuaugguagaaugugauggaacauguugguggaagcuuguacaauagaacacauuggugggagcuuguacauac
    uuuuuuauggagcauuacuuacgauuuuuuaaguaaaauguuuugaaaccaaaaaaaaaaaaaggaauuc
    Fgfbp1/  3 augagacuccacagccucauccugcucuccuuccuucuccuggcuac 266
    Fibroblast ucaggcguucucagaaaaggucagaaagagagccaagaacgcaccac
    growth factor acagcacagcggaggaggggguagaggguucagcucccucguuagg
    binding protein gaaggcccagaauaagcagagaagcaggacaucuaaaucucugacgc
    1 auggcaaguuugucaccaaagaccaagccacaugcagaugggcugug
    AF065441 acugaggaggagcagggcaucagccugaagguccagugcacacaagc
    cgaucaggaguuuucuuguguuuuugcuggugacccaacugacugc
    cuuaaacacgacaaagaccagaucuacuggaaacagguugcccgcac
    gcugcgcaaacagaaaaauaucugcaggaacgccaagagugucuuga
    agaccagagugugcagaaagagauuuccagagucuaaccucaagcug
    gugaaccccaacgcacguggaaacacgaagcccaggaaggagaaagc
    agaggucuccgcaagggagcacaacaagguccaagaagcugucucca
    cggagccaaacagggucaaagaagacaucacacucaauccagcugcg
    acccagaccauggccauuagagauccagagugucuagaggauccaga
    ugugcucaaccagaggaagaccgcccuggaguucuguggggaaucu
    uggagcuccauuugcacauucuuccucaacauguuacaggcgacauc
    augcuaa
    Transcription Factors and Related Genes
    Klf5/Kruppel-  5 aauucgucgacaugcgccguuccagugcauggugugccaacgcagc 267
    like factor 5 uucucccgcuccgaccaccucgcgcugcacaugaagcgccaccagaa
    AA611766 cugagcgagcgagcgcugccccacccgccugacgccuugcaguccgc
    ucugccauccuuuaaaccgcagaccuaacuucauaaaaaga
    Gata3/GATA  4 Sequence below. 268
    binding protein
    3
    X55123
    gcuaaacuaucccgcaaagauuuuucuuuccucccuaaacccuccuuuuugcucuccuuuucuauacccuuaacugcaaaca
    aaccauuaaacgaccccucuccugggccuccgacggcaggaguccgcggaccucccaggccgacagcccucccucuacccgc
    gagguuccgggccgggcgagagggcgcgagcacagccgaggacauggaggugacugcggaccagccgcgcugggugagcc
    accaucaccccgcgguccucaacggucagcacccagacacgcaccacccgggccucggccauucguacauggaagcucagua
    uccgcugacggaagagguggacguacuuuuuaacaucgauggucaaggcaaccacgucccguccuacuacggaaacuccgu
    cagggcuacggugcagagguauccuccgacccaccacgggagccagguaugccgcccgccucugcugcacggaucucugcc
    cuggcuggauggcggcaaagcccugagcagccaccacaccgccucgcccuggaaccucagccccuucuccaagacguccauc
    caccacggcucuccggggccucuguccguuuacccuccggcuucauccucuucucuggcggccggccacuccaguccucau
    cucuucaccuucccgcccaccccgccgaaagacgucuccccagacccgucgcuguccaccccgggauccgccgggucggcca
    ggcaagaugagaaagagugccucaaguaucaggugcagcugccagauagcaugaagcuggagacgucucacucucgaggca
    gcaugaccacccuggguggggccucauccucagcccaccaccccauuaccaccuauccgcccuaugugcccgaguacagcuc
    uggacucuucccacccagcagccugcugggaggauccccuaccggguucggauguaagucgaggcccaaggcacgauccag
    cacagaaggcagggagugugugaacugcggggcaaccucuaccccacuguggcggcgagaugguaccgggcacuaccuuug
    caaugccugcggacucuaccauaaaaugaaugggcagaaccggccccuuaucaagcccaagcgaaggcugucggcagcaagg
    agagcagggacauccugcgcgaacugucagaccaccaccaccacccucuggaggaggaacgcuaauggggacccggucugca
    augccugugggcuguacuacaagcuucauaauauuaacagaccccugacuaugaagaaagaaggcauccagacccgaaaccg
    gaagaugucuagcaaaucgaaaaagugcaaaaaggugcaugacgcgcuggaggacuuccccaagagcagcuccuucaacccg
    gccgcucucuccagacacaugucaucccugagccacaucucucccuucagccacuccagccacaugcugaccacaccgacgcc
    caugcauccgcccuccggccucuccuucggaccucaccacccuuccagcauggucaccgccauggguuagagaggcagagcc
    cugcuccacaugcgugaggagucuccaagugugcgaagaguuccuccgaccccuucuacuugcguuuuucgcaggagcagu
    aucaugaagcccgaaagcgacagaucuguguuuuugaaggcagaaagcaaaauguuugcuucuuuuuucaaaggagcucga
    gguggugucugcauuccaaccacugaauccggaucccauuugugaauaagccauucagacucauauucccuauuuaacagg
    gucucuagugcugugaaaaaaauauugcugaacauugcauauaacuuauauuguaagaaauacuguacauuugaggaagac
    uuuauuguaccuggauagcuguaagaaaggcaugaaggacgccaagaguuuuaaggaauauaggggnnuuaaaguaugga
    gauacagaagaaaccacuaagucugauguccaaaugggcacacugucaguuuuguuucccuucaguuguuugaugcauuua
    aaaaaaaaaaaaagaaagaa
    Stimulated by  3 Sequence below. 269
    retinoic acid
    14, basic-helix-
    loop-helix
    protein
    Y07836
    caaccaccuccuaccugccugcccaaagcuccagggcuggagcacggagaccugucagggauggauuuugcccacauguacc
    aaguguacaaguccaggcggggaauaaaacggagcgaagacagcaaggaaacuuacaaacugccgcaccggcugauugagaa
    aaagagacgugaccggauuaacgagugcauugcccagcugaaggaucuccuacccgaacaucucaaacuuacuacuuuggg
    ucacuuggaaaaagcagugguucuggagcuuacguugaagcacgugaaagcauugacaaaucuaauugaucagcagcagca
    gaaaaucauugcccugcagagcgguuuacaagcuggugauuugucgggaagaaaucucgaggcagggcaagaaauguucu
    gcucagguuuccagacuugugcccgugagguacuucaguaccuggcgaagcaugagaacacucgggaccugaaaucuuccc
    agcucgucacucaucuccaucguguggucucggagcugcugcaggguggugcuuccaggaaaccauuggacucggcuccca
    aagccgucgacuugaaagagaagcccagcuuccuagccaagggaucagaaggcccagggaaaaacugugugccagucaucca
    gcggacuuuugcucccucggguggggagcagagcggcagugacacggacacagacaguggcuauggaggugaauuggaga
    aaggggacuugcgcagugaacagccguacuucaaaagcgaccauggacgcagguucgccgugggagaacgugucagcacaa
    uuaagcaagaauccgaagagccccccaccacaaagagccgaaugcagcucucagaagaggaaggccacuucgcgggcaguga
    ucugauggguuccccauuucuugggccacacccacaucagccuccuuuuugccuucccuucuaucucaucccaccaucggc
    cacugccuaccugccuaugcuggagaaaugcugguaccccaccucugugccaguguuauacccaggccucaacaccucagcu
    gcagcccucuccagcuucaugaacccagacaagauaccgacucccuugcuucugccccagagacucccuucuccuuuggcac
    auucgucccuugacucuucggccuugcuccaggcuuugaagcagaucccuccuuuaaacuuagaaaccaaagacuaaacuc
    uggagggaucuccugcugccuugcuuucuuuccucccuaauuccaaaaaccacgaagguuucccugagugcagagagauca
    gcccacccugcagacccacagagaagauucagagugugugugagagugagugagugugcgugcgugcgugcuuguaugua
    uguuuguauauguaggacaauaaguuccuucugacacaagggagacacgagaaggauagccugacaucagaugacagacug
    gaggacuguagcacaucucugggcguuucccuacccagagaagagcc
    Cell Cycle Related
    Mki67/antigen  4 Sequence below. 270
    identified by
    monoclonal
    antibody Ki67
    X82786
    agucaccgacguuguauaacgacggccagugaauuguaauacgacucacuauagggcgaauuggguaccggccccccccuc
    gaggucgacgguaucgauaagcuugauaucgaauucucgnccgcgugcgggucuggucggggcggagcgaaggccgcggg
    uggccguggucgguccuccgcggcuaaggagccgagggcuccgacgcgggcugcgcccggugagcggcggccagagcuaa
    cuugcgcugacuggaccagcugaggagcggcccggcggggcgacugcgagcuucaccgagaggcuucuccgcccugguccg
    cagucccgacggccgggcggaccauggcguccucggcucaccuggucaccaucaagcggagcggcgaugacggcgcacacu
    ucccgcugagccucagcuccugccuguuuggaaggaguauugaaugugacauucguauccagcugccuguagugucucaa
    agacauugcccaauuguaguccaagagcaagaggcgauauuauauaauuucaguucuaccaauccaacucaaguaaacggg
    guuacuauagaugagccugugaggcugagacauggagacauaauaaccaucauugaccgcuccuuuagguaugaagaugga
    aaucaugaggauggaagcaaaccaacagaauuuccaggaaagucccuuggaaaggaaccaucaaggcgagccucaagagaua
    gcuucugugcugacccugauggggaaggucaagauaccaaagcuucaaaaaugacugcuucaagaagaucuuuuguguaug
    ccaagggccuuucugcagauagcccugccucagauggcucaaagaacaguguuagccaagacucaucagggcauguagaac
    agcacacuggcagaaacauaguagagcccacuucugggggaucucuuuuaagaaguccaggucuacagggagcaguuacag
    ggaaccgaagucuucuuccuacacagagccuuagcaauagcaacgaaaaggaaucucccuuugagaaacuuuaucaaucaau
    gaaggaagaguuggauguaaaaucccagaaaucuuguaggaaaucagaaccccaaccugaccgugcagcagaggaaucgcg
    ggagacacagcuauuggugucaggcagggcaagagcaaagucuaguggaagcaccccuguuacugcagccucuucacccaa
    aguaggaaagaucuggacugagagauggcgcgguggaauggugccuguccagacuuccacagagacagcuaaaaugaagac
    cccugugcggcauucacagcaacuuaaggaugaagacucucguguuacuggcagacgacauucugugaaucuggaugaagg
    uggaagugcccaggcaguccauaaaacagucacuccugggaaacuggcgacuagaaaccaaacuccgguggaggcugggga
    uguuggcagccccgcugauacaccagaacauuccucuuccccccagagaaguauuccugcaaagguagaggcuccaucugca
    gagacacaaaaucggcucucuuuaacucagcgccuuguuccaggugaaaagaaaacucccaaggguuccuucagcaagccug
    agaaacuggccacagccgccgaacagacuugcucuggccuaccuggucuuaguuccguugauaucagcaacuuuggugauu
    ccauuaacaagagugagggaaugccuaugaagagaagacguguauccuuugguggacaucuaagaccugaauuauuugaug
    aaaacuugccuccuaauacaccacugaaaagaggagaaacgccaaccaagaggaagucucuuggcacucacagcccagcugu
    ccucaagacaaucaucaaggaacggccccagucuccagggaaacaagagucuccugggauaacgccaccgaggacaaaugau
    caaagacgcagaucaggcaggacuuccaguggaagcaauuucuuaugugagacagacauucccaagaaagcaggcaggaaga
    gcgguaaccugccugcgaagagagcauccaucagccggagucagcauggcauucuacagaugauuugcuccaaaaggcgaa
    guggagcuucugaagccaacuugauuguugcaaaaucaugggcugauguuguaaaacuuggcgugaaacaaacacaaacga
    aaguugcgaaacaugucccuccaaagcagacgagcaagagacaaagaagacccagcacuccaaagaaacccacaagcaaucuu
    cacaaucaauuuacuacaggccaugcaaacucucccuguaccauuguaguagguagagcgcagauugaaaaaguaagugug
    ccugcccgacccuacaaaaugcugaauaacuugaugcuaaaccgaaaaguggacuucagugaagaucugucaggacuaacug
    aaauguucaagacuccagugaaggagaagcagcagcagaugagugauacaggcuccguacuuuccaauucagcgaauuugu
    cugaaagacaauugcaaguaacuaauucaggagacauaccugagcccaucaccacagagauuuugggagaaaaagugcuauc
    caguacucggaaugcagcaaagcagcagucugauagauauucugcaaguccuaccuuaagacggcggagcaucaaacaugaa
    aacacagugcaaacuccuaagaauguccauaacauuacugaccuugagaagaagacuccggucucugagacagagccccuga
    agacugcaucgagugugagcaaguuaagaagaucuagagagcucagacauacccuuguggaaacuaugaaugaaaaaacag
    aagcaguccuugcugagaacaccacagcaagacauuuaagggggacauuucgagaacaaaaaguagaucaacaggugcagga
    caaugaaaacgcuccucaaagaugcaaggaaaguggugaauuaagugaagguucagaaaagacaucagcuaggagaucaag
    ugccaggaagcagaagccgacaaaagacuuacuaggaagucagauggucacccaaacagcagacuaugcugaggaacuacuu
    agucaaggacaaggaaccauacaaaaccuagaggaauccaugcacaugcaaaacacaucaauaagugaggaucaaggaauua
    cagaaaagaaagugaacauaauaguauaugcaaccaaagagaagcacucgccaaagaccccuggcaaaaaggcacaaccucua
    gaagggccagcuggucucaaggaacacuuugaaacaccaaaccccaaagauaaaccuauaacggaagacagaacuagagucc
    uuugcaaaucaccacaagucacaacagagaauaucacaacaaacacaaagccacagacuagcacaucugggaagaaaguagac
    augaaggaagaaagcucugccuugacaaaacguauacauaugccaggggaauccaggcauaaucccaaaauuuuaaaacuug
    agugugaggauaucaaagcuuugaagcaaucugaaaaugaaaugcugaccucaacaguaaauggaagcaagaggacuuuag
    gaaaaucuaaaaaaaaggcucagccccuggaagaccugacuuguuuccaggaacucuuuauaucaccaguuccuacuaacau
    aaucaaaaaaauucccagcaaaucuccacacacacaaccagucagaaccccagcgagcacaaagagacucuccaagacagguc
    ucaguaaaguggaugugagacaagaaccuucaacacuugggaaaagaacgaagucaccaggcagagccccaggcacaccagc
    accagugcaggaagaaaaugacugcacagccuacauggaaacuccaaagcagaaacuggagucuauagaaaauuuaacaggg
    cuuaggaaacaguccagaacaccuaaagacaucacugguuuccaggauaguuuccaaauaccagaucaugcuaauggcccau
    uagugguugucaaaaccaaaaaaauguucuuuaauucuccacaaccagaaagugccauaacccgaaagagcagagagagaca
    gucuagggcaaguauaaguaaaauagauguuaaagaagaacuuuuagaaucagaggaacaccuacaauuaggagaaggugu
    agacacauuucagguauccaccaacaaagucauuagaucaucuaggaaaccugcaaagcguaaacuggauucaacagcuggu
    augccuaacagcaagaggaugcgcuguucuucaaaggauaacacaccaugccuagaagaccugaauggcuuccaagagcucu
    uccaaaugccaggcuaugcuaaugacucuuugaccacuggaaucucaacaaugcuugcuagaucaccacaauuaggaccagu
    uagaacccaaaucaacaaaaagagucugcccaagaucaucuugagaaaaauggaugugacagaagaaauuucaggucucugg
    aagcagucacugggcagaguccacaccacacaagagcaggaggauaaugcaaucaaagcaauuauggagauuccaaaggaaa
    cacugcagacugcagcagauggaacuaggcuuaccagacagccacaaacaccuaaggaaaaaguucaaccgcuggaagauca
    cagugucuuccaagaacucuuccaaacaucacgcuacuguucugauccauuaauugguaacaaacaaacaagaauguccuug
    agaucuccacaaccaggauuuguuagaacuccacgaaccucaaagagacuggcuaagacaaguguugggaauauugcugug
    agagaaaagaucucuccagugagucugccacagugugcuacaggggagguuguacacauacccauagggccagaagaugac
    acagagaacaaaggugugaaggaauccacaccucagacacuggacucaucagcaagucgaacugucagcaagaggcagcaag
    gggcacaugaggaaaggccucaguucucaggagacuuauuucauccccaagagcucuuucaaacaccagccaguggcaaaga
    cccaguaacuguugaugaaacuacaaaaauagcucugcagucuccacaaccaggacauaucauaaacccagcaagcaugaag
    agacaguccaacaugagucucaggaaagacaugagagaauuuuccauacuugaaaaacaaacacagucacgaggcagagacg
    caggcacaccagcaccaaugcaggaagaaaauggcaccacagccauuauggaaacaccaaagcagaaacuggauuucauagg
    aaauucaacaggacauaagaggaggccucggacacccaaaaacagggcucagccccuagaagaccuggauggcuuccaagaa
    cucuuucaaacaccagcuggugccagugacccugugaguguugaagaaagugcaaagauaucuuuggcaucuucacaagca
    gaaccagucagaaccccagcaaguacaaagagacgcuccaagacaggucucaguaaaguggaugugagacaagaaccuucaa
    cacuugggaaaagaaugaagucacuaggcagagccccaggcacaccagcaccagugcaggaagaaaaugacagcacagccuu
    cauggaaacuccaaagcagaaacuggauuucacaggaaauucaucaggacauaagaggaggccacagacaccuaagaucagg
    gcucagccccuagaagaccuggauggcuuccaagaacucuuccaaacaccagcuggugccaaugacucagugacuguugag
    gaaaguguaaagaugucuuuggaaucuucacaagcagaaccagucaaaaccccggcaagcacaaagagacucuccaagacag
    gucucaguaagguggaugugagagaagacccuucaauacuugagaaaaaaacaaagucaccaggcacaccagcaccagugca
    ggaagaaaaugacugcacagccuucauggaaacuccaaagcagaaacuggauuucacaggaaauucaucaggacauaagagg
    aggccacggacaccuaagaucagagcucagccccuagaagaccuggauggcuuccaagaacucuuccaaacaccagcuggug
    cuagugacucagugacuguugaggaaagugcaaagaugucuuuggaaucuucacaagcaaaaccagucaaaaccccggcaa
    gcacaaagagacucuccaagacaggucucaguaagguggaugugagagaagacccuucaacacuugggaaaaaaacaaaguc
    accaggcagagccccaggcacaccagcaccagugcaggaagaaaaugacagcacagccuucauggaaacuccaaagcagaaac
    uggauuuugcagagaauucaucagggaguaagagaaggucacgaacaucuaagaacaggucucagccccuagaagaccugg
    auggcuuccaagaacucuuccaaacaccagcuggugccaguaacccugugaguguugaagaaagugcaaagauaucuuugg
    aaucuucacaagcagaaccagucagaacccgggcaagcacaaagagacuuuccaagacaggucucaauaagauggaugugag
    agaagggcacucuccgcucaguaagucaagcugugcaucacagaaagucaugcaaacccucacacuuggagaagaucauggc
    agagagaccaaagaugggaagguauuguuagcucagaaauuggaaccagcaauauauguuacucguggcaagaggcagcaa
    aggucauguaagaaaaggucccaguccccagaagaccucucugguguucaggaggucuuccaaacaucaggccauaacaag
    gauucagugacaguggacaaucuugcaaaacugcccagcucgucuccaccacuagagccaacagacacuucaguaaccucac
    ggagacaggccagaacuggucugaggaaaguucacgugaaaaaugaacuuucaggaggcauaaugcauccacaaauaucag
    gggaaauuguggacuuaccuagagaaccagaaggugaaggcaaagucauuaaaacaaggaagcaaucuguaaaacggaaau
    uggacacagaagucaaugugccucgcaguaagaggcaaagaauuacaagagcagaaaagacccuagaggaucugccuggcu
    uccaagagcucugccaagcuccaagcuugguaauggacucaguuauuguugagaaaaccccaaagaugcccgacaaaucucc
    agaaccuguggauacaacuucagagacacaggcaagaagaagacucaggagacugguuguuacugaagagcccauaccacaa
    agaaagacuacaagaguuguaaggcaaaccagaaacacacagaaagagcccauaagugacaaucaagguauggaagaguuua
    aggaaucuucaguacagaaacaagacccaaguguaaguuuaacuggcaggaggaaccaaccaaggacaguuaaggagaaaac
    ccaacccuuagaagaacucaccaguuuccaagaggaaacugccaaaagaauaucuuccaaaucuccacaaccggaagagaagg
    aaaccuuagcagguuuaaagaggcagcucagaauacaacuaaucaacgaugguguaaaagaagagcccacagcacagagaaa
    gcaaccauccagggaaaccaggaacacacucaaagagccuguaggugacaguauaaauguugaagagguuaagaagucuaca
    aagcagaaaauugauccaguagcaagugugccugucagcaagaggccacggaggguacccaaggaaaaggcacaggcccuag
    aauuggcuggucucaaaggaccaauccaaacccuaggccacacugaugaaucagcaagugauaaaggacccacacagaugcc
    cuguaauucucuacaaccagagcaaguugacagcuuccaaagcucaccaaggcgacccaggacaagacgugggaaaguagag
    gcagaugaagagccuucagcaguaagaaagacaguaucaacaucaaggcaaacuaugcgaucccgcaaggucccugaaauug
    guaacaaugguacccaaguuucaaaggccuccauaaagcagacauuagauacaguagccaaaguaacuggcagcaggaggca
    gcuaaggacacauaaaggaugggguucaacccucuugaaguuguuaggugacuccaaagaaauaacccaaauaucagaucac
    ucugagaaacuagcacaugacaccaguauccuuaagagcacucaacagcaaaagccagacucaguaaaaccucugagaacau
    gcagaagagugcugagggccucuaaagagguccccaaggaaguguugguggacaccagagaccaugcaacauuacaaagca
    aaagcaacccuuugcuguccccgaagaggaagucugcaagagauggaagcauugugagaaccagggcuuugcgcucuuuag
    caccaaagcaggaagcaacagaugagaagccuguaccugagaaaaaaagggcugcuuccagcaagagguauguaucaccuga
    gccugugaagaugaaacaccugaaaaucgugucaaacaaacuugaaucuguggaagagcagguuagcacuguuaugaaaac
    agaagaaauggaagccaaaagagaaaauccugucacuccagaucagaacucuagguaccgaaagaaaaccaauguaaaacagc
    caaggcccaaguuugaugcaucugcagagaaugucgggauaaagaaaaacgagaagacuaugaagacugccucccaggagac
    agagcugcagaauccagaugauggagccaagaaaucuacaucucggggccaagucagugggaaaagaacaugcuugagguc
    uagaggaacgacugagaugccccagccuugugaagcagaagagaaaacaagcaaaccagcugcagaaaucuugauaaagccu
    caggaagagaaaggagucucuggagagucugauguuagguguuugagguccagaaaaacuagagucgcuuuggacaguga
    accuaagccaaggguaacucguggaaccaagaaagaugcaaaaacucugaaggaggaugaagacauuguaugcaccaagaag
    uuaagaacaagaaguuaagaacaagaaguuaccagaaaagugaaacuauguagcaaagacauuuaagaaggaaaaguaaauu
    ugacuuagugauaaguuccagugugguuuucaccuccaguguaaagaugaacuguaaauacuacugcuacugccugaguu
    uaaggaaggaagcuuugagcuuuccuggucauacucucuucagacgccaauggaggucaugaggaagaucaccagggaucu
    cagcgcaauuacaguuuaggggugagcaggcagaaauguggcccucuguccuauccaauaaagcucugaaauucgcugcca
    aaa
    Cks2/CDC28  4 gacguagagccccuugcgcccgguuuccugaucccgcuuacuc 271
    protein kinase cucugcgcgccggcaggauggcccacaagcagaucuacuacuc
    regulatory agacaaguacuucgaugagcacuacgaguaccggcaugucaug
    subunit 2, sim uuacccagagaacucucuaaacaaguacccaaaacucaucugau
    to cdk guccgaagaggaguggaggagacuugguguccaacagagucu
    regulatory aggauggguucauuacaugauucaugagccagaaccgcauauu
    subunit 2 cuucucuuuagacgaccucuuccaaaagaacaacaaaaaugaa
    AA681998 gugcagcugggaucaucuaaucuuuuucaaauuuaauguaua
    uguguauauaagguaguauucagugaauacuugaaaagugua
    caaaccuuucauccauaccugugcaugcgcuguauucuucaca
    gcaacagagcucagucaaaugcaacugcaaguagg
    Ccng2/  3 Sequence below. 272
    Cyclin G2
    U95826
    cuacccuagacaaucacggcuuagccggcgcgcggagucgaucgucucggucgcuagagcuguccugagcucgaacggucc
    gacgcccccgccgcgccgguccgugacgccggggccgacacgaugaaggauuugggggccaagcacuuggcagguggcgaa
    gggguucagcuuuucggauuguugaacuucuaccuggaacaagaacagagauaccaaccucgggaaaaagggcugaucuug
    auggaggcuaccccggagaaugauaacacuuuguguucaagacugagaaaugccaaaguggaagauuuaagaaguuuaacu
    aacuucuuuggaucuggcacugaaacuuucguucuggcugucaauauuuuggauagauucuuggcccuuaugaaggugaa
    accgaaacaccuguccugcauuggcgucugcugcuuuuugcuggccgccaggcuggcggaagaagaaggugacguuccccc
    cacgcacgacgugauccgcaucagucaguguaaaugcacagcgucugacauuaaacgcauggagaaaaucaucucagagaaa
    cugcacuaugagcuggaagcuaccacugccuuaaacuuuuugcacuuguaccacgcgauuguauuuugucacacuucagaa
    aggaaggagauucucagccucgauaaacucgaagcgcagcugaaagcuugcaacugccgaguugucuucuccaaagcaaga
    ccaucuguauuagcucugugccuucucaauuuggaaauagaaacgauaaaauccguggaacugcuggaaauucucuugcuu
    guuaaaaaacauuugaagcucagcgacacugaauucuuuuacuggagggaacugguuucuaaaugucuagcagaguauucu
    ucgccucgcugcugcaagccugaucugaagaagcugguauggauuguuucgcgacgcacugcgcagaaccuccacagcagc
    uacuacaguguuccugagcugcccacuaucccagagggggguugcuuugacggaagugaaagugaggacucuggugaaga
    caugaguuguggagaggagagucucagcagcuccccacccagcgaucaggagugcaccuucuucuuugacuuccaaguggc
    ucagacacugugcuuuccaccauagaggaaucugacauuguucugugucagggaauuuauaaguguguguaccuagguuu
    caaagcaauaaacuuggggguugaauaggguaguuuuccuagguuuccagccccccgucuagucagg
    Prc1/Protein  3 aacuaccuugggcagguucuauuaacugcaccuaacucagacg 273
    regulator of ugaguaggacagaaggaagcugucccgggcgaacugaggucac
    cytokinesis 1 aaagacuugcuuuugauucaagagagaccuuaaaggcuaguua
    DNA segment, ugauaguuaaguacaaguuuuaacaucugguagcuaacuuuu
    Chr 7 uuucucuaccccguaauucuacuaugacugcucuucuagagg
    AA856349 uccugaguucaaaucccagcaaccacaugguggcucacaacca
    ucuauaaugggaucugaugcccucuucuggugugc
  • Thus, the transcripts identified in this Example, the proteins they encode, and the pathways in which the proteins participate, contribute significantly to induction of epidermal cells to differentiate into HF stem cells. Activation of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for enhancing EDIHN. In addition, inhibition of the transcripts, proteins, and pathways depicted in Table 4 is thus a method for preventing EDIHN and eliminating hair follicles. In addition, inhibition of the transcripts, proteins, and pathways depicted in Table 5 is a method for enhancing EDIHN. In addition, activation of the transcripts, proteins, and pathways depicted in Table 5 is thus a method for enhancing EDIHN.
    • Example 10 Expression of Wnt-1 Inhibitors During the First Nine Days after Wounding Causes Pigmentation of New HF Materials and Experimental Methods
  • In this Example, doubly transgenic mice expressing both tetO-Dkk1 and K5-rtTA were utilized. When these mice are fed chow formulated with 1 g/kg doxycycline (BioServ, Laurel, Md.), they express Dkk1, under the control of the K5 promoter, in the basal epidermis. The control mice also received doxycycline, but they were K5-rtTA negative and thus did not express Dkk1.
    • Results
  • A 1 cm2 wound was induced on the lower back of the doubly transgenic mice at 21 days or 50 days old. Mice were placed on doxycycline-containing chow immediately after wounding to induce Dkk1 expression, and then doxycycline was discontinued after completion of the re-epithelialization at 9 days after wounding. Dkk1 expression inhibits Wnt activity, which in turn induces follicle pigmentation. At 22 days after wounding, pigmented HF were observed in the excised skin after preparing the epidermal sheet (FIG. 23A-B). Control mice lacked pigmented HF (FIG. 24).
  • In other experiments, continued expression of Dkk1 after the 9-day period inhibited formation of new HF.
  • The findings of this Example show that pigmented HF can be produced by suppressing expression of Wnt or by inducing expression of Dkk1 during the period of re-epithelialization, then inducing expression of Wnt1. In addition, the findings of this Example show that factors that inhibit neonatal hair follicle formation (e.g. Dkk1) also inhibit EDIHN, thus further supporting the notion that hair follicles formed by EDIHN are similar to normal hair follicles.
    • Example 11 Inhibition of EDIHN by Epidermal Growth Factor Injection
  • 21 day-old mice were wounded as described in previous Examples. Starting from day 11 after wounding, a time point corresponding to the point at which the wound had recently reepithelialized, 10 μL of 1 μg/ml EGF was injected into the wound bed. EGF was injected once per day after this point for a total of 5 days. Three days later, the skin was collected, and whole-mount EDIHN assays were performed. EGF prevented HF formation as assessed by gross morphology. In addition, whole mounts of control and treated skin were analyzed with anti-K17 antibody immunostaining. All mice injected with EGF (n=4) exhibited no new HF formation (FIGS. 25 A-B), while control mice (n=2) had many new HF, as expected. (FIGS. 25 C-D).
  • In an additional experiment, recombinant EGF (1 microgram (mcg)/microliter (mcl)) was injected at days 11, 13 and 15 after wounding. Skin was collected at 18 days after wounding and stained for K17 and alkaline phosphotase. Once again, administration of EGF inhibited EDIHN.
  • The findings of this Example show that EGF inhibits HF formation. Thus, inhibiting EGF, EGFR, or one of the pathways in which they participate increases EDIHN-induced HF formation.
    • Example 12 Enhancement of EDIHN by Inhibition of EGF Receptor
  • To determine the effect of administration of EGF receptor inhibitors on DIHN, the inhibitor AG1478 (150 μM in 10 μL volume) was administered as a single injection 11 days after incisional wounding (1 cm2) to the middle of the wound near the skin surface. EGF receptor inhibitor administration led to generation of more and larger hair follicles compared with control mice that were wounded only (FIG. 26A). As shown in FIG. 26B, large hair follicles developed in the wounded area in the AG1478-injected mice. Left panel: epidermis stained for K17, with three large hair follicles next to each other. Right panel: dermis stained for AP with large coalescing dermal papilla areas.
  • The findings of this Example confirm the results of the previous Example, and show that more and larger HF can be generated when EDIHN comprises, or is followed by, administration of EGFR inhibitors, or with compounds with a similar mechanism of action; e.g. Hedgehog protein and androgen antagonists.
    • Example 13 Enhancement of EDIHN by Expression of a β-Catenin Activator
  • To determine the effect of administration of β-catenin activators on EDIHN, K14-Wnt7 transgenic mice, which overexpress the β-catenin pathway activator, Wnt7, in the epidermis, were subjected to EDIHN, then HF formation was measured 19 days after wounding. In each of 2 separate experiments, with 4 week old and 3 week old mice, the transgenic mice developed significantly larger numbers of HF compared to control, non-transgenic littermate mice (FIG. 27 A-C).
  • Thus, administration of β-catenin activators leads to an increase in EDIHN. The findings of Examples 11-13 show that new HF can be generated by (a) disrupting the epidermis; and (b) administering a factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell.
    • Example 14 Enhancement of EDIHN by Administration of FGF
  • To determine the effect of fibroblast growth factor (FGF) on EDIHN, recombinant FGF is administered 11 days after incisional wounding, as described in Example 11. FGF administration enhances HF formation, showing that new HF can be generated by (a) disrupting the epidermis; and (b) administering FGF, a nucleotide encoding FGF, or a factor that increases signaling by FGF.
    • Example 15 Enhancement of EDIHN by Administration of Edar
  • To determine the effect of fibroblast growth factor (FGF) on EDIHN, K14-Eda-A1 transgenic mice, which overexpress (ectodysplasin-A1) Eda-A1 in the epidermis, are subjected to EDIHN, then HF formation is measured 19 days after wounding as described in Example 13. The transgenic mice developed significantly larger numbers of HF compared to control, non-transgenic littermate mice, showing that new HF can be generated by (a) disrupting the epidermis; and (b) administering a factor that enhances signaling by ectodysplasin.
    • Example 16 Enhancement of EDIHN by Administration of Minoxidil
  • To determine the effect of minoxidil on EDIHN, recombinant FGF is administered 11 days after incisional wounding, as described in Example 11. Minoxidil administration enhances HF formation, showing that new HF can be generated by (a) disrupting the epidermis; and (b) administering a minoxidil.
    • Example 17 Removal of HF by Abrasion and Administration of EGF
  • Hair-bearing regions of the epidermis of mice is abraded, as described in Example 1, then administering recombinant EGF, as described in Example 1. This method prevents hair re-growth in the abraded areas, showing that hair can be removed by (a) disrupting the epidermal layer; and (b) administering EGF, a nucleotide encoding EGF, or a factor that increases signaling by EGF.

Claims (24)

1-37. (canceled)
38. A method for treating baldness or a hair loss condition or for stimulating hair growth in a human subject comprising: (a) wounding an area of the balding scalp of said human subject by disrupting an epidermis or dermis of the area of the balding scalp, thereby creating a wounded area; and (b) contacting the wounded area with a compound or factor that activates a beta-catenin protein or an inhibitor of a protein that suppresses an activity of the beta-catenin protein and minoxidil.
39. The method of claim 38, wherein said wounding is performed with a tool that comprises sandpaper, a laser, a Fraxel laser, a CO2 laser, an excimer laser, a felt wheel, a dermabrasion device, a light-based method, irradiation with visible light, irradiation with infrared light, irradiation with ultraviolet radiation, orthovoltage radiation, xray radiation, a surgical tool, a dermal biopsy punch, or is performed with a burn treatment or chemical treatment.
40. The method of claim 39, wherein said dermabrasion device is a micro-dermabrasion device.
41. The method of claim 38, wherein said wounding is dermabrasion.
42. The method of claim 38, wherein the wounding-step comprises disrupting the epidermis and dermis of the area of the balding scalp.
43. The method of claim 38, in which only part of the epidermis is removed.
44. The method of claim 38, wherein the method further comprises contacting said area of the balding scalp with a precursor cell, an inductive cell, or a hair follicle or a portion thereof.
45. The method of claim 38, wherein the method further comprises contacting said area of the balding scalp with one or more of the following compounds: finasteride, dutasteride, fluridil, spironolactone, cyproterone acetate, bicalutamide, flutamide, nilutamide, an inhibitor of an androgen receptor, an androgen antagonist, or an anti-androgen.
46. The method of claim 45, wherein said wounding-step is performed between 3-12 days, 4-12 days, 5-12 days, 4-11 days, 6-11 days, 6-10 days, 6-9 days, 6-8 days, 7-8 days, 5-11 days, 5-10 days, 7-10 days, or about 1 week prior to said contacting step.
47. The method of claim 38, wherein said area of the balding scalp is subjected to depilation or administration of a retinoid prior to said wounding.
48. The method of claim 47, wherein said depilation is performed by plucking, waxing, abrasion, laser, electrolysis, or administration of thioglycolic acid on said area of the balding scalp.
49. The method of claim 38, wherein said wounded area of the balding scalp is not surgically closed, or not contacted with a bandage, dressing, or ointment that facilitates wound healing for a period of time following said wounding-step.
50. The method of claim 49, wherein said period of time is within about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 7 days, about 10 days, about 11 days, about 14 days, about 17 days, or about 3 weeks.
51. The method of claim 38, wherein said wounded area of the balding scalp is allowed to heal by secondary intention.
52. The method of claim 38, wherein the method is performed on a subject with androgenetic alopecia (AGA), scarring alopecia, male pattern baldness, female pattern baldness, discoid lupus erythematosis, or lichen planopilaris.
53. The method of claim 38, wherein said treatment results in an increase in markers of hair follicle proliferation, hair follicle differentiation or hair follicle embryonic development.
54. The method of claim 38, wherein said treatment results in an increase in the amount of pigmented hair or an increase in hair follicle size.
55. The method of claim 38, wherein said treatment results in differentiation of an uncommitted epidermal cell into a hair follicle cell.
56. The method of claim 38, wherein said treatment results in generation of a hair follicle in the scalp of the subject.
57. The method of claim 38, wherein said wounding does not result in bleeding.
58. A method for treating baldness or a hair loss condition or for stimulating hair growth in a human subject comprising: (a) perforating an area of the balding scalp of said human subject, thereby generating a disrupted epidermis or dermis area of the balding scalp; and (b) contacting the disrupted epidermis or dermis area of the balding scalp with a compound or factor that activates a beta-catenin protein or an inhibitor of a protein that suppresses an activity of the beta-catenin protein and minoxidil.
59. The method of claim 38, wherein said compound or factor is a Wnt7 protein or a nucleic acid molecule encoding said Wnt7 protein.
60. The method of claim 38, wherein the step of disrupting said epidermis comprises the disruption of the basal and suprabasal epidermal layers.
US16/222,705 2005-03-29 2018-12-17 Methods for generating new hair follicles, treating baldness, and hair removal Abandoned US20200101000A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/222,705 US20200101000A1 (en) 2005-03-29 2018-12-17 Methods for generating new hair follicles, treating baldness, and hair removal
US16/260,034 US20200197488A1 (en) 2005-03-29 2019-01-28 Compositions and methods for treating hair loss

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US66585705P 2005-03-29 2005-03-29
US68329305P 2005-05-23 2005-05-23
PCT/US2006/011319 WO2006105109A2 (en) 2005-03-29 2006-03-28 Methods for generating new hair follicles, treating baldness, and hair removal
US88710407A 2007-09-25 2007-09-25
US13/327,611 US9220926B2 (en) 2005-03-29 2011-12-15 Methods for generating new hair follicles, treating baldness, and hair removal
US14/946,512 US20160310395A1 (en) 2005-03-29 2015-11-19 Methods for generating new hair follicles, treating baldness, and hair removal
US16/222,705 US20200101000A1 (en) 2005-03-29 2018-12-17 Methods for generating new hair follicles, treating baldness, and hair removal

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/946,512 Continuation US20160310395A1 (en) 2005-03-29 2015-11-19 Methods for generating new hair follicles, treating baldness, and hair removal

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/129,100 Continuation US8871711B2 (en) 2008-11-12 2009-11-11 Fibroblast growth factor-9 promotes hair follicle regeneration after wounding
PCT/US2009/064049 Continuation WO2010056759A1 (en) 2005-03-29 2009-11-11 Fibroblast growth factor-9 promotes hair follicle regeneration after wounding

Publications (1)

Publication Number Publication Date
US20200101000A1 true US20200101000A1 (en) 2020-04-02

Family

ID=37054023

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/887,104 Abandoned US20090304635A1 (en) 2005-03-29 2006-03-28 Methods for generating new hair follicles, treating baldness, and hair removal
US12/904,822 Active 2026-11-17 US9700502B2 (en) 2005-03-29 2010-10-14 Methods for generating new hair follicles, treating baldness, and hair removal
US12/904,981 Active 2026-09-15 US9642789B2 (en) 2005-03-29 2010-10-14 Methods for generating new hair follicles, treating baldness, and hair removal
US13/327,611 Active 2027-02-14 US9220926B2 (en) 2005-03-29 2011-12-15 Methods for generating new hair follicles, treating baldness, and hair removal
US14/946,512 Abandoned US20160310395A1 (en) 2005-03-29 2015-11-19 Methods for generating new hair follicles, treating baldness, and hair removal
US16/222,705 Abandoned US20200101000A1 (en) 2005-03-29 2018-12-17 Methods for generating new hair follicles, treating baldness, and hair removal

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US11/887,104 Abandoned US20090304635A1 (en) 2005-03-29 2006-03-28 Methods for generating new hair follicles, treating baldness, and hair removal
US12/904,822 Active 2026-11-17 US9700502B2 (en) 2005-03-29 2010-10-14 Methods for generating new hair follicles, treating baldness, and hair removal
US12/904,981 Active 2026-09-15 US9642789B2 (en) 2005-03-29 2010-10-14 Methods for generating new hair follicles, treating baldness, and hair removal
US13/327,611 Active 2027-02-14 US9220926B2 (en) 2005-03-29 2011-12-15 Methods for generating new hair follicles, treating baldness, and hair removal
US14/946,512 Abandoned US20160310395A1 (en) 2005-03-29 2015-11-19 Methods for generating new hair follicles, treating baldness, and hair removal

Country Status (9)

Country Link
US (6) US20090304635A1 (en)
EP (2) EP1874265A4 (en)
JP (5) JP2008537940A (en)
KR (1) KR20070120559A (en)
AU (1) AU2006230187B2 (en)
CA (2) CA2603365C (en)
ES (1) ES2931949T3 (en)
IL (3) IL186242A0 (en)
WO (1) WO2006105109A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232055A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Methods for treating hair loss and compositions for same
WO2023108136A3 (en) * 2021-12-09 2023-07-20 The Trustees Of Indiana University Methods of generating human cochlear hair cells

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056759A1 (en) * 2008-11-12 2010-05-20 The Trustees Of The University Of Pennsylvania Fibroblast growth factor-9 promotes hair follicle regeneration after wounding
CA2603365C (en) 2005-03-29 2017-06-06 The Trustees Of The University Of Pennsylvania Methods for generating new hair follicles, treating baldness, and hair removal
US20060241696A1 (en) * 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
PL2037967T3 (en) 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
EP2077819A4 (en) * 2006-09-28 2011-05-25 Follica Inc Methods, kits, and compositions for generating new hair follicles and growing hair
BRPI0811102A2 (en) * 2007-05-15 2014-09-23 Puretech Ventures METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS
CA2700311C (en) * 2007-09-21 2016-07-05 Intercytex Limited Epidermal stimulation to enhance hair follicle formation
KR101163171B1 (en) * 2009-01-20 2012-07-19 (주)케어젠 Noggin derived Peptides and Uses Thereof
KR101198918B1 (en) 2009-09-01 2012-11-07 (주)케어젠 WNT10 Derived Peptides and Uses Thereof
KR20120113211A (en) * 2009-09-11 2012-10-12 폴리카 인코포레이티드 Intermittent and pulse lithium treatments for modulating hair growth
BR112013014021A8 (en) * 2010-12-06 2017-10-03 Follica Inc METHODS FOR TREATMENT OF BALDNESS AND PROMOTION OF HAIR GROWTH
DK2695947T3 (en) * 2011-04-01 2017-05-08 Chugai Pharmaceutical Co Ltd Process for Preparation of Recombinant Polypeptides
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
KR101285263B1 (en) * 2011-08-04 2013-07-11 (주)케어젠 EDAR Ligand Derived Peptides and Uses Thereof
EP2797604A1 (en) * 2011-12-28 2014-11-05 Université Pierre et Marie Curie (Paris 6) Rna interference to activate stem cells
WO2013149191A1 (en) * 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
KR101393813B1 (en) * 2012-05-31 2014-05-12 주식회사 엘지생활건강 Composition for inhibiting hair growth
KR101586027B1 (en) * 2014-01-22 2016-01-15 주식회사 엘지생활건강 Composition for inhibiting growth of body hair comprising podophyllotoxin as an effective ingredient
KR20170003656A (en) * 2014-05-09 2017-01-09 오큐소프트, 인코포레이티드 Systems, methods and kits for cleansing an ocular region
ES2928817T3 (en) * 2015-09-22 2022-11-23 Johnson & Johnson Consumer Inc Methods to improve the topical application of a beneficial agent
CA3043886A1 (en) * 2016-11-16 2018-05-24 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP7044229B2 (en) * 2017-02-08 2022-03-30 株式会社Ito Pro Cellular β-catenin production promoting composition
WO2019099861A1 (en) * 2017-11-16 2019-05-23 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2487677A1 (en) * 1980-08-04 1982-02-05 Commw Scient Ind Res Org METHOD FOR DEPILATING ANIMALS
GB8604360D0 (en) * 1986-02-21 1986-03-26 Univ Dundee Stimulation of hair growth
PT683659E (en) * 1993-02-09 2003-01-31 Tulsa Forte Pharmacy Entpr Inc A METHOD FOR STIMULATING HAIR GROWTH WITH CATIONIC DERIVATIVES OF MINOXIDIL USING THERAPEUTIC IONTOFORESE
IL107167A (en) 1993-10-03 2000-01-31 Raziel Lurie Compositions containing relaxin for treatment of alopecia and related conditions
US6867179B1 (en) 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US5767152A (en) * 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
WO1999001034A1 (en) * 1997-07-01 1999-01-14 Cooley Jerry E Method for producing new hair growth
US6159950A (en) 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
WO2000031134A1 (en) * 1998-11-20 2000-06-02 Arch Development Corporation Regulation of hair follicle morphogenesis based on beta-catenin
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
WO2000045736A1 (en) 1999-02-08 2000-08-10 Bioamide, Inc. Filamentary means for introducing agents into cells
GB9925964D0 (en) * 1999-11-03 1999-12-29 Jahoda Colin A B Hair transplantation
DE10005329A1 (en) * 2000-02-08 2001-09-20 Albert Scheller Stimulating growth of hair, e.g. on the head, eyebrows or eyelashes, by subcutaneous application of a preparation containing stem cells and/or preformed hair cells
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2290125T3 (en) * 2000-03-31 2008-02-16 The General Hospital Corporation METHODS TO INCREASE CAPILLARY GROWTH THROUGH A WNT POLYPEPTIDE.
DE10061162A1 (en) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituted indirubin derivatives, their preparation and use
WO2002060396A2 (en) * 2001-01-29 2002-08-08 Aderans Research Institute, Inc. Hair follicle neogenesis by injection of follicle progenitor cells
EP2163256B1 (en) * 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
PT1262177E (en) 2001-05-31 2006-12-29 Pfizer Prod Inc Medical use of thyromimetic compounds to treat hair loss and compositions
JP2003081866A (en) * 2001-09-13 2003-03-19 Yasuhiko Tabata Hair-growing hydrogel containing cell growth factor protein
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20030161815A1 (en) * 2002-02-12 2003-08-28 Intercytex Limited Cell delivery system
CA2482940A1 (en) * 2002-04-17 2003-10-23 Taisho Pharmaceuticals Co., Ltd. Hair growth tonic
US6777988B2 (en) 2002-04-30 2004-08-17 John C. Tung 2-level series-gated current mode logic with inductive components for high-speed circuits
DE10224982A1 (en) 2002-06-05 2003-12-24 Rolf Hoffmann Mesenchymal stem cells of the hair follicle and their use
US20040219179A1 (en) * 2002-09-20 2004-11-04 Mcdaniel David H. Skin abrasive agents
US20040142853A1 (en) * 2002-11-07 2004-07-22 Procyte Corporation Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil
US7053091B2 (en) 2002-12-17 2006-05-30 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20040153131A1 (en) * 2003-02-04 2004-08-05 Yorke John A. Apparatus and method for hair retention and regeneration
JP4664814B2 (en) 2003-06-12 2011-04-06 中外製薬株式会社 Imidazolidine derivatives
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
CA2536443A1 (en) * 2003-08-26 2005-03-03 Alza Corporation Device and method for intradermal cell implantation
US20070190075A1 (en) * 2003-10-09 2007-08-16 Advangen, Inc. C/O National Institute Of Advance Science And Tech Hair growth stimulant composition
EP1773414A1 (en) 2004-07-08 2007-04-18 Alltracel Development Services Limited A delivery system for controlling the bleeding of skin wounds
US20060073117A1 (en) 2004-10-01 2006-04-06 Stowers Institute For Medical Research Methods and compositions for controlling hair follicle stem cell fate
WO2010056759A1 (en) 2008-11-12 2010-05-20 The Trustees Of The University Of Pennsylvania Fibroblast growth factor-9 promotes hair follicle regeneration after wounding
CA2603365C (en) 2005-03-29 2017-06-06 The Trustees Of The University Of Pennsylvania Methods for generating new hair follicles, treating baldness, and hair removal
US20060241696A1 (en) 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc Methods, kits, and compositions for generating new hair follicles and growing hair
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
US20080182859A1 (en) 2006-11-02 2008-07-31 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2700311C (en) 2007-09-21 2016-07-05 Intercytex Limited Epidermal stimulation to enhance hair follicle formation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232055A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Methods for treating hair loss and compositions for same
WO2023108136A3 (en) * 2021-12-09 2023-07-20 The Trustees Of Indiana University Methods of generating human cochlear hair cells

Also Published As

Publication number Publication date
US20120121693A1 (en) 2012-05-17
EP2949328B1 (en) 2022-07-20
ES2931949T3 (en) 2023-01-05
IL233146A0 (en) 2014-08-03
US20110092421A1 (en) 2011-04-21
IL186242A0 (en) 2008-01-20
EP2949328A1 (en) 2015-12-02
WO2006105109A2 (en) 2006-10-05
EP1874265A4 (en) 2012-09-26
JP2013049691A (en) 2013-03-14
JP5985954B2 (en) 2016-09-06
CA2964111A1 (en) 2006-10-05
US9700502B2 (en) 2017-07-11
EP1874265A2 (en) 2008-01-09
JP2017114907A (en) 2017-06-29
CA2603365C (en) 2017-06-06
CA2603365A1 (en) 2007-09-28
AU2006230187A1 (en) 2006-10-05
US9220926B2 (en) 2015-12-29
JP6884609B2 (en) 2021-06-09
KR20070120559A (en) 2007-12-24
US20110152746A1 (en) 2011-06-23
US9642789B2 (en) 2017-05-09
AU2006230187B2 (en) 2012-07-26
IL233146A (en) 2017-02-28
US20090304635A1 (en) 2009-12-10
JP2019218409A (en) 2019-12-26
IL250188A0 (en) 2017-03-30
WO2006105109A3 (en) 2009-04-09
US20160310395A1 (en) 2016-10-27
JP2015172074A (en) 2015-10-01
JP2008537940A (en) 2008-10-02

Similar Documents

Publication Publication Date Title
US20200101000A1 (en) Methods for generating new hair follicles, treating baldness, and hair removal
US20200197488A1 (en) Compositions and methods for treating hair loss
Foitzik et al. Control of murine hair follicle regression (catagen) by TGF‐β1 in vivo
Lee et al. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis
WO2006030693A1 (en) Agents for overcoming hair troubles and method of screening the same
CN100444894C (en) Methods and compositions for the promotion of hair growth utilizing actin binding peptides
AU2012204059B2 (en) Methods for generating new hair follicles, treating baldness and hair removal
US20080193403A1 (en) Inducing And Maintaining Hair Color
Aoki et al. μ-Crystallin, thyroid hormone-binding protein, is expressed abundantly in the murine inner root sheath cells
AU2017204081A1 (en) Methods for Generating New Hair Follicles, Treating Baldness, and Hair Removal
JP2023522061A (en) Methods for Determining Hair Follicle Phenotype
JP2005304491A (en) Method for prognosis of hair growth or epilation of the skin using gene group expression advancing in hair follicle in stage of growth as index, and method for screening hair restorer and/or depilatory
JP2002296267A (en) Method of evaluating proposed substance for hair growth tinic, and method of manufacturing skin external remedy for hair growth

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COTSARELIS, GEORGE;ITO, MAYUMI;SIGNING DATES FROM 20160322 TO 20160721;REEL/FRAME:051291/0595

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:061047/0077

Effective date: 20200103

AS Assignment

Owner name: NIH - DEITR, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:061884/0013

Effective date: 20221024